FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Zampieri, FG
   Romano, TG
   Salluh, JIF
   Taniguchi, LU
   Mendes, PV
   Nassar, AP
   Costa, R
   Viana, WN
   Maia, MO
   Lima, MFA
   Cappi, SB
   Carvalho, AGR
   De Marco, FVC
   Santino, MS
   Perecmanis, E
   Miranda, FG
   Ramos, GV
   Silva, AR
   Hoff, PM
   Bozza, FA
   Soares, M
AF Zampieri, Fernando G.
   Romano, Thiago G.
   Salluh, Jorge I. F.
   Taniguchi, Leandro U.
   Mendes, Pedro V.
   Nassar, Antonio P., Jr.
   Costa, Roberto
   Viana, William N.
   Maia, Marcelo O.
   Lima, Mariza F. A.
   Cappi, Sylas B.
   Carvalho, Alexandre G. R.
   De Marco, Fernando V. C.
   Santino, Marcelo S.
   Perecmanis, Eric
   Miranda, Fabio G.
   Ramos, Grazielle V.
   Silva, Aline R.
   Hoff, Paulo M.
   Bozza, Fernando A.
   Soares, Marcio
TI Trends in clinical profiles, organ support use and outcomes of patients
   with cancer requiring unplanned ICU admission: a multicenter cohort
   study (Aug, 10.1007/s00134-020-06184-2, 2020)
SO INTENSIVE CARE MEDICINE
LA English
DT Correction; Early Access
AB The original version of this article unfortunately contained a mistake in Fig. 4.
C1 [Zampieri, Fernando G.; Hoff, Paulo M.] DOr Inst Res & Educ, Dept Crit Care, 30 Botafogo, Rio De Janeiro, Brazil.
   [Zampieri, Fernando G.] HCor, Res Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando G.] Southern Denmark Univ, Ctr Epidemiol & Clin Res, Odense, Denmark.
   [Romano, Thiago G.; Mendes, Pedro V.] Hosp Vila Nova Star, Intens Care Unit, Sao Paulo, Brazil.
   [Romano, Thiago G.] ABC Med Sch, Dept Nephrol, Santo Andre, SP, Brazil.
   [Salluh, Jorge I. F.; Ramos, Grazielle V.; Silva, Aline R.; Bozza, Fernando A.; Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Ramos, Grazielle V.; Silva, Aline R.; Bozza, Fernando A.; Soares, Marcio] DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Taniguchi, Leandro U.] Hosp Sirio Libanes, Res & Educ Inst, Sao Paulo, Brazil.
   [Taniguchi, Leandro U.; Mendes, Pedro V.] Univ Sao Paulo, Emergency Med Discipline, Sao Paulo, Brazil.
   [Romano, Thiago G.; Mendes, Pedro V.] Hosp Sao Luiz, Oncol Intens Care Unit, Unidade Itaim, Sao Paulo, Brazil.
   [Nassar, Antonio P., Jr.] AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil.
   [Costa, Roberto] Hosp Quinta DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Viana, William N.] Hosp Copa DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia Rede DOr Sao Luiz, Intens Care Unit, Brasilia, DF, Brazil.
   [Maia, Marcelo O.] Hosp DF Star Rede DOr Sao Luiz, Intens Care Unit, Brasilia, DF, Brazil.
   [Lima, Mariza F. A.] Hosp Esperanca Recife, Intens Care Unit, Recife, PE, Brazil.
   [Cappi, Sylas B.] Hosp Sao Luiz, Unidade Brasil, Intens Care Unit, Santo Andre, SP, Brazil.
   [Carvalho, Alexandre G. R.] UDI Hosp, Intens Care Unit, Sao Luis, Maranhao, Brazil.
   [De Marco, Fernando V. C.] Hosp ViValle, Intens Care Unit, Sao Jose Dos Campos, Brazil.
   [Santino, Marcelo S.] Hosp Barra DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Perecmanis, Eric] Hosp Caxias DOr, Intens Care Unit, Duque De Caxias, RJ, Brazil.
   [Miranda, Fabio G.] Hosp Copa Star, Intens Care Unit, Rio De Janeiro, Brazil.
   [Hoff, Paulo M.] Oncol DOr, Sao Paulo, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.; Soares, M (corresponding author), DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Bozza, Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088
CR Zampieri FG, 2020, INTENS CARE MED, DOI 10.1007/s00134-020-06184-2
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
DI 10.1007/s00134-020-06252-7
EA OCT 2020
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA NW0VT
UT WOS:000574727800001
PM 33006683
OA Bronze
DA 2020-12-01
ER

PT J
AU Mazeraud, A
   Polito, A
   Sivanandamoorthy, S
   Porcher, R
   Heming, N
   Stoclin, A
   Hissem, T
   Antona, M
   Blot, F
   Gaillard, R
   Chretien, F
   Annane, D
   Bozza, FAB
   Siami, S
   Sharshar, T
AF Mazeraud, Aurelien
   Polito, Andrea
   Sivanandamoorthy, Sivanthiny
   Porcher, Raphael
   Heming, Nicholas
   Stoclin, Annabelle
   Hissem, Tarik
   Antona, Marion
   Blot, Francois
   Gaillard, Raphael
   Chretien, Fabrice
   Annane, Djillali
   Bozza, Fernando A. B.
   Siami, Shidasp
   Sharshar, Tarek
CA Grp Explorations Neurologiques Rea
TI Association Between Anxiety and New Organ Failure, Independently of
   Critical Illness Severity and Respiratory Status: A Prospective
   Multicentric Cohort Study
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE anxiety; intensive care unit; response to stress; sepsis; sickness
   behavior
ID ACUTE PHYSIOLOGY; ILL PATIENTS; RELIABILITY; VALIDITY; SCORE
AB Objectives: Anxiety results from the anticipation of a threat and might be associated with poor outcome in the critically ill. This study aims at showing that anxiety at admission in critically ill patients is associated with new organ failure over the first 7 days of ICU hospitalization independently of baseline organ failure at admission. Design: Prospective multicenter cohort study. Setting: Three mixed ICU from April 2014 to December 2017. Patients: Coma-, delirium-, and invasive mechanical ventilation-free patients admitted to the ICU were included. Interventions: None. Measurements and Main Results: "State anxiety" was assessed using the state component of the State-Trait Anxiety Inventory State. Severity of illness was measured using Simplified Acute Physiology Score II and Sequential Organ Failure Assessment scores. Primary endpoint was a composite of occurrence of death or new organ failure in the first 7 days after admission. Three hundred ninety-one patients were included; 159 of 391 women (40.7%); median age 63 years (49-74 yr); median Simplified Acute Physiology Score II 28 (19-37). Two hundred three out of 391 patients (51.9%) reported moderate to severe anxiety (State-Trait Anxiety Inventory State >= 40). One hundred two out of 391 patients (26.1%) developed a new organ failure. After adjustment to Simplified Acute Physiology Score II and Sequential Organ Failure Assessment, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with the primary endpoint (odds ratio, 1.94; 95% CI, 1.18-3.18;p= 0.009) and respiratory failure. In post hoc analysis, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with new organ failure independently and notably of respiratory status at admission (dyspnea-Visual Analogic Scale and Paco(2)>= 45 mm Hg). Conclusions: Moderate to severe anxiety at ICU admission is associated with early occurrence of new organ failure in critically ill patients, independently of respiratory status and severity of critical illness. The causality link could be addressed in an interventional trial.
C1 [Mazeraud, Aurelien; Polito, Andrea; Heming, Nicholas; Antona, Marion; Annane, Djillali; Sharshar, Tarek] Univ Versailles St Quentin Yvelines, Raymond Poincare Hosp, APHP, Gen Intens Care Unit, Garches, France.
   [Mazeraud, Aurelien; Gaillard, Raphael; Chretien, Fabrice; Sharshar, Tarek] Inst Pasteur, Neurosci Dept, Percept & Memory Lab, Paris, France.
   [Sivanandamoorthy, Sivanthiny; Hissem, Tarik; Siami, Shidasp] Sud Essonne Hosp, Gen Intens Care Unit, Etampes, France.
   [Porcher, Raphael] Univ Paris 05, Hotel Dieu Hosp, Assistance Publ Hop Paris, Ctr Epidemiol Clin, Paris, France.
   [Stoclin, Annabelle; Blot, Francois] Inst Gustave Roussy Hosp, Gen Intens Care Unit, Villejuif, France.
   [Gaillard, Raphael] Paris Descartes Univ, Sainte Anne Hosp, Dept Psychiat, Paris, France.
   [Gaillard, Raphael] Serv Hosp Univ, Fac Med Paris Descartes, Ctr Hosp Sainte Anne, Paris, France.
   [Gaillard, Raphael] Univ Paris 05, Inserm Ctr Psychiat & Neurosci, Lab Physiopathol Malad Psychiat, Paris, France.
   [Gaillard, Raphael] CNRS, GDR 3557, Inst Psychiat, Paris, France.
   [Chretien, Fabrice] Univ Paris, Sainte Anne Hosp, Dept Neuropathol, Paris, France.
   [Bozza, Fernando A. B.] Fundacao Oswaldo Cruz, Minist Hlth, Natl Inst Infect Dis Evandro Chagas, Lab Crit Care, Rio De Janeiro, Brazil.
   [Bozza, Fernando A. B.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
RP Sharshar, T (corresponding author), Univ Versailles St Quentin Yvelines, Raymond Poincare Hosp, APHP, Gen Intens Care Unit, Garches, France.; Sharshar, T (corresponding author), Inst Pasteur, Neurosci Dept, Percept & Memory Lab, Paris, France.
EM t.sharshar@ghu-paris.fr
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU Assistance Publique Hopitaux de Paris
FX This study was supported by the Assistance Publique Hopitaux de Paris.
CR American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Barnes LLB, 2002, EDUC PSYCHOL MEAS, V62, P603, DOI 10.1177/0013164402062004005
   Brame AL, 2010, CRIT CARE MED, V38, pS600, DOI 10.1097/CCM.0b013e3181f23e92
   Castillo MI, 2016, INT J NURS STUD, V60, P225, DOI 10.1016/j.ijnurstu.2016.05.007
   Chlan LL, 2013, JAMA-J AM MED ASSOC, V309, P2335, DOI 10.1001/jama.2013.5670
   Chlan LL, 2004, J ADV NURS, V48, P493, DOI 10.1111/j.1365-2648.2004.03231.x
   Dantzer R, 2018, PHYSIOL REV, V98, P477, DOI 10.1152/physrev.00039.2016
   Del Negro CA, 2018, NAT REV NEUROSCI, V19, P351, DOI 10.1038/s41583-018-0003-6
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Fernandez R, 2006, CRIT CARE, V10, DOI 10.1186/cc5136
   Gutierrez G, 2004, CRIT CARE, V8, P373, DOI 10.1186/cc2851
   KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008
   KNEBEL AR, 1994, AM J RESP CRIT CARE, V149, P14, DOI 10.1164/ajrccm.149.1.8111572
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Mayou RA, 2000, PSYCHOSOM MED, V62, P212, DOI 10.1097/00006842-200003000-00011
   Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Sharshar T, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000893
   Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6, DOI 10.1164/ajrccm.154.1.8680700
   Szekely A, 2007, PSYCHOSOM MED, V69, P625, DOI 10.1097/PSY.0b013e31814b8c0f
   TEASDALE G, 1974, LANCET, V2, P81
   Tovote P, 2015, NAT REV NEUROSCI, V16, P317, DOI 10.1038/nrn3945
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
NR 23
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD OCT
PY 2020
VL 48
IS 10
BP 1471
EP 1479
DI 10.1097/CCM.0000000000004495
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA NU4MF
UT WOS:000573616600039
PM 32931190
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Azevedo-Quintanilha, IG
   Palhinha, L
   Teixeira, L
   Barreto, EA
   Pao, CRR
   Righy, C
   Franco, S
   Souza, TML
   Kurtz, P
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Azevedo-Quintanilha, Isaclaudia G.
   Palhinha, Lohanna
   Teixeira, Livia
   Barreto, Ester A.
   Pao, Camila R. R.
   Righy, Cassia
   Franco, Sergio
   Souza, Thiago M. L.
   Kurtz, Pedro
   Bozza, Fernando A.
   Bozza, Patricia T.
TI Platelet activation and platelet-monocyte aggregate formation trigger
   tissue factor expression in patients with severe COVID-19
SO BLOOD
LA English
DT Article
ID P-SELECTIN; MESSENGER-RNA; CORONAVIRUS; PNEUMONIA
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent pathogen responsible for the coronavirus disease 2019 (COVID-19). Since its emergence, the novel coronavirus has rapidly achieved pandemic proportions causing remarkably increased morbidity and mortality around the world. A hypercoagulability state has been reported as a major pathologic event in COVID-19, and thromboembolic complications listed among life-threatening complications of the disease. Platelets are chief effector cells of hemostasis and pathological thrombosis. However, the participation of platelets in the pathogenesis of COVID-19 remains elusive. This report demonstrates that increased platelet activation and platelet-monocyte aggregate formation are observed in severe COVID-19 patients, but not in patients presenting mild COVID-19 syndrome. In addition, exposure to plasma from severe COVID-19 patients increased the activation of control platelets ex vivo. In our cohort of COVID-19 patients admitted to the intensive care unit, platelet-monocyte interaction was strongly associated with tissue factor (TF) expression by the monocytes. Platelet activation and monocyte TF expression were associated with markers of coagulation exacerbation as fibrinogen and D-dimers, and were increased in patients requiring invasive mechanical ventilation or patients who evolved with in-hospital mortality. Finally, platelets from severe COVID-19 patients were able to induce TF expression ex vivo in monocytes from healthy volunteers, a phenomenon that was inhibited by platelet P-selectin neutralization or integrin alpha(IIb)/beta(3) blocking with the aggregation inhibitor abciximab. Altogether, these data shed light on new pathological mechanisms involving platelet activation and platelet-dependent monocyte TF expression, which were associated with COVID-19 severity and mortality.
C1 [Hottz, Eugenio D.; Azevedo-Quintanilha, Isaclaudia G.; Palhinha, Lohanna; Teixeira, Livia; Barreto, Ester A.; Pao, Camila R. R.; Souza, Thiago M. L.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Immunopharmacol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.] Fed Univ Juiz de Fora UFJF, Dept Biochem, Lab Immunothrombosis, Juiz De Fora, MG, Brazil.
   [Righy, Cassia; Franco, Sergio; Kurtz, Pedro] Paulo Niemeyer State Brain Inst, Rio De Janeiro, Brazil.
   [Righy, Cassia; Bozza, Fernando A.] Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Souza, Thiago M. L.] Fundacao Oswaldo Cruz, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, Brazil.
   [Kurtz, Pedro; Bozza, Fernando A.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Inst Oswaldo Cruz, Av Brasil 4365 Pav 108 Sala 47, BR-21040900 Rio De Janeiro, Brazil.; Hottz, ED (corresponding author), Univ Fed Juiz de Fora, Dept Bioquim ICB, Rua Jose Lourenco Kelmer S-N,Campus Univ, BR-36036330 Juiz De Fora, MG, Brazil.
EM eugenio.hottz@icb.ufjf.br; pbozza@ioc.fiocruz.br
RI Shinotsuka, Cassia Righy/H-9181-2013; Bozza, Fernando A/A-2618-2013
OI Shinotsuka, Cassia Righy/0000-0002-9206-9552; Bozza, Fernando
   A/0000-0003-4878-0256; Hottz, Eugenio/0000-0002-2201-1742; Palhinha,
   Lohanna/0000-0003-0163-3574; /0000-0002-4469-8645; Souza,
   Thiago/0000-0003-2212-3899
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; Inova FIOCRUZ
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), and Inova FIOCRUZ (P.T.B., F.A.B.,
   T.M.L.S., E.D.H.).
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Akhvlediani T, 2020, LANCET INFECT DIS, V20, P770
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14768, 10.1111/jth.14820]
   Boussekey N, 2005, INFECTION, V33, P257, DOI 10.1007/s15010-005-4096-2
   Campbell RA, 2018, J IMMUNOL, V200, P295, DOI 10.4049/jimmunol.1700885
   CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Christersson C, 2008, J THROMB HAEMOST, V6, P986, DOI 10.1111/j.1538-7836.2008.02956.x
   Christersson C, 2010, THROMB RES, V126, pE327, DOI 10.1016/j.thromres.2010.03.019
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Dann R, 2018, J AM COLL CARDIOL, V71, P53, DOI 10.1016/j.jacc.2017.10.072
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Durrant TN, 2017, BLOOD, V130, P1607, DOI [10.1182/blood-2017-03773614, 10.1182/blood-2017-03-773614]
   Franks Z, 2013, THROMB HAEMOSTASIS, V109, P684, DOI 10.1160/TH12-08-0543
   Franks ZG, 2010, ANN NY ACAD SCI, V1207, P11, DOI 10.1111/j.1749-6632.2010.05733.x
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Grover SP, 2018, ARTERIOSCL THROM VAS, V38, P709, DOI 10.1161/ATVBAHA.117.309846
   Guo L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02204
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hottz ED, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43275-7
   Hottz ED, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00121
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Ivanov II, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49635-7
   Jiang SQ, 2020, BRIT J HAEMATOL, V190, pE29, DOI 10.1111/bjh.16817
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kapur R, 2015, J IMMUNOL, V194, P5579, DOI 10.4049/jimmunol.1500259
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Koupenova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09607-x
   Koupenova M, 2018, CIRC RES, V122, P337, DOI 10.1161/CIRCRESAHA.117.310795
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Martinod K, 2014, BLOOD, V123, P2768, DOI 10.1182/blood-2013-10-463646
   Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mesquita EC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33403-0
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Middleton EA, 2018, AM J RESP CELL MOL, V59, P18, DOI 10.1165/rcmb.2017-0420TR
   Muller I, 2003, FASEB J, V17, P476, DOI 10.1096/fj.02-0574fje
   Pan DX, 2015, BLOOD, V125, P1146, DOI 10.1182/blood-2014-07-591040
   Popa M, 2018, P NATL ACAD SCI USA, V115, pE5556, DOI 10.1073/pnas.1801366115
   Quirino-Teixeira AC, 2020, BLOOD ADV, V4, P2018, DOI 10.1182/bloodadvances.2019001169
   Rondina MT, 2011, J THROMB HAEMOST, V9, P748, DOI 10.1111/j.1538-7836.2011.04208.x
   Schechter ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam5441
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Stevens H, 2019, SEMIN THROMB HEMOST, V45, P802, DOI 10.1055/s-0039-1698829
   Sung PS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10360-4
   Swystun LL, 2016, BLOOD, V128, P753, DOI 10.1182/blood-2016-05-718114
   Nguyen T, 2012, CRIT CARE MED, V40, P3246, DOI 10.1097/CCM.0b013e318260c7f8
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Vardakas KZ, 2009, EUR RESPIR J, V34, P1148, DOI 10.1183/09031936.00041009
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   World Health Organization, 122 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 64
TC 7
Z9 7
U1 3
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD SEP 10
PY 2020
VL 136
IS 11
BP 1330
EP 1341
DI 10.1182/blood.2020007252
PG 12
WC Hematology
SC Hematology
GA NS6DL
UT WOS:000572349600016
PM 32678428
OA Other Gold, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, HB
   da Silva, IRF
   Ramos, GV
   Medeiros, DM
   Ho, YL
   de Carvalho, FB
   Bozza, FA
   Japiassu, AM
AF Andrade, H. B.
   da Silva, I. R. F.
   Ramos, G., V
   Medeiros, D. M.
   Ho, Y. L.
   de Carvalho, F. B.
   Bozza, F. A.
   Japiassu, A. M.
TI Short- and medium-term prognosis of HIV-infected patients receiving
   intensive care: a Brazilian multicentre prospective cohort study
SO HIV MEDICINE
LA English
DT Article
DE AIDS; critical care; mortality; outcomes; sepsis
ID SOFA SCORE; SEPSIS; MORTALITY; OUTCOMES; UNIT; ERA; PNEUMONIA;
   ADMISSION; SURVIVORS; THERAPY
AB Objectives The characteristics of critically ill HIV-positive patients and the causes of their admission to intensive care units (ICUs) are only known through retrospective and unicentric studies. This study aims to fill this knowledge gap. Methods This is a prospective, multicentre cohort study of short- and medium-term prognostic factors. The setting consisted of ICUs of three tertiary referral hospitals from the three largest metropolitan areas in Brazil in the period January 2014 to November 2015. In all, 161 HIV patients over 18 years old were included. Results The clinical data of the outcomes (ICU mortality, hospital mortality and 90-day survival) were extracted from medical records using the REDCap((R))web-based form and analysed with the MedCalc((R))application. Median age was 41.7 [interquartile range (IQR): 34-50] years, the Simplified Acute Physiologic Score 3 (SAPS 3) was 64 (IQR: 56-74), and the Sequential Organ Failure Assessment Score (SOFA) was 6 (IQR: 4-9) points. The main causes of admission were sepsis (54.5%) and acute respiratory failure (13.7%). ICU and hospital mortality rates were 32.3% and 40.4%, respectively. In a multivariate analysis, time until ICU admission >= 3 days (P = 0.0013), performance status (Eastern Cooperative Oncology Group score,P = 0.0344), coma (Glasgow Coma Scale <= 8 points,P = 0.0213) and sepsis (P = 0.0003) were associated with increased hospital mortality. Coma (P = 0.0002) and sepsis (P = 0.0008) were independently associated with 90-day survival. Conclusions Delayed ICU admission and the severity of critical illness determine the short- and medium-term mortality rates of HIV-infected patients admitted to the ICU, rather than factors associated with HIV infection. These results suggest that prognostic factors of HIV-infected patients in the ICU are similar to those of non-HIV-infected populations.
C1 [Andrade, H. B.; Medeiros, D. M.; Bozza, F. A.; Japiassu, A. M.] Oswaldo Cruz Fdn Fiocruz, Evandro Chagas Natl Inst Infectol, Intens Care Unit, Rio De Janeiro, RJ, Brazil.
   [Andrade, H. B.] Univ Fed Fluminense UFF, Inst Biomed, Sexually Transmitted Dis Sect, Niteroi, RJ, Brazil.
   [da Silva, I. R. F.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL USA.
   [Ramos, G., V; Bozza, F. A.] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, RJ, Brazil.
   [Ho, Y. L.] Univ Sao Paulo, Sch Med, Infect Dis Intens Care Unit, Hosp Clin, Sao Paulo, SP, Brazil.
   [de Carvalho, F. B.] Hosp Fdn State Minas Gerais, Hosp Eduardo Menezes, Intens Care Unit, Belo Horizonte, MG, Brazil.
RP Japiassu, AM (corresponding author), INI Inst Nacl Infectol Evandro Chagas, Ave Brasil,4365 Manguinhos, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM andre.japiassu@ini.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Boechat Andrade, Hugo/M-6631-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Boechat Andrade,
   Hugo/0000-0001-6781-6125; MACHADO MEDEIROS, DENISE/0000-0001-7921-5941
CR Afessa B, 2000, CHEST, V118, P138, DOI 10.1378/chest.118.1.138
   Alves Gisele Collyer, 2010, Rev. bras. ter. intensiva, V22, P138, DOI 10.1590/S0103-507X2010000200007
   Andrade HB, 2017, DST J BRAS DOENCAS S, V29, P36
   Andrade HB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186968
   Barbier F, 2014, INTENS CARE MED, V40, P1906, DOI 10.1007/s00134-014-3481-7
   Barbier F, 2009, INTENS CARE MED, V35, P1678, DOI 10.1007/s00134-009-1559-4
   Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872
   Blunt MC, 1998, ANAESTHESIA, V53, P755, DOI 10.1046/j.1365-2044.1998.00488.x
   Coquet I, 2010, CRIT CARE, V14, DOI 10.1186/cc9056
   Dickson SJ, 2007, THORAX, V62, P964, DOI 10.1136/thx.2006.072256
   Espinoza R, 2019, J CRIT CARE, V50, P82, DOI 10.1016/j.jcrc.2018.11.024
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Henley SJ, 2014, MMWR-MORBID MORTAL W, V63, P1
   HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Jang RW, 2014, J ONCOL PRACT, V10, pE335, DOI 10.1200/JOP.2014.001457
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Knobel E., 2006, CONDUTAS NO PACIENTE
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Levy MM, 2018, INTENS CARE MED, V44, P925, DOI 10.1007/s00134-018-5085-0
   Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6
   Meybeck A, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-27
   Morquin D, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-25
   Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
   Ntusi NBA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052452
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Pathak V, 2012, CLIN MED RES, V10, P57, DOI 10.3121/cmr.2011.987
   Pierantoni CR., 2008, PHYSIS, V18
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X
   Rosen Mark J, 2005, J Intensive Care Med, V20, P360
   Rosenberg AL, 2001, CRIT CARE MED, V29, P548, DOI 10.1097/00003246-200103000-00013
   Roussos C, 2003, EUR RESPIR J, V22, p3S, DOI 10.1183/09031936.03.00038503
   Silva JM, 2010, REV BRAS ANESTESIOL, V60, P20, DOI 10.1590/S0034-70942010000100003
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Stevenson LW, 2008, CIRC HEART FAIL
   Tan DHS, 2013, CRIT CARE CLIN, V29, P603, DOI 10.1016/j.ccc.2013.03.010
   TEASDALE G, 1974, LANCET, V2, P81
   Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6
   Tien PC, 2010, JAIDS-J ACQ IMM DEF, V55, P316, DOI 10.1097/QAI.0b013e3181e66216
   Vidal-Cortes P, 2020, MED INTENSIVA, V44, P283, DOI 10.1016/j.medin.2019.02.012
   Vincent B, 2004, INTENS CARE MED, V30, P859, DOI 10.1007/s00134-004-2158-z
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wurtz R, 1994, AM REV RESPIR DIS, V3, P132
   Yende S, 2016, CRIT CARE MED, V44, P1461, DOI 10.1097/CCM.0000000000001658
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
NR 48
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD NOV
PY 2020
VL 21
IS 10
BP 650
EP 658
DI 10.1111/hiv.12939
EA SEP 2020
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA NY7XY
UT WOS:000567660700001
PM 32876389
DA 2020-12-01
ER

PT J
AU Martin-Loeches, I
   Dickson, R
   Torres, A
   Hanberger, H
   Lipman, J
   Antonelli, M
   de Pascale, G
   Bozza, F
   Vincent, JL
   Murthy, S
   Bauer, M
   Marshall, J
   Cilloniz, C
   Bos, LD
AF Martin-Loeches, Ignacio
   Dickson, Robert
   Torres, Antoni
   Hanberger, Hakan
   Lipman, Jeffrey
   Antonelli, Massimo
   de Pascale, Gennaro
   Bozza, Fernando
   Vincent, Jean Louis
   Murthy, Srinivas
   Bauer, Michael
   Marshall, John
   Cilloniz, Catia
   Bos, Lieuwe D.
TI The importance of airway and lung microbiome in the critically ill
SO CRITICAL CARE
LA English
DT Review
DE Pneumonia; Microbiome; Infection; Ventilator-associated pneumonia;
   Ventilator-associated tracheobronchitis
ID DIGESTIVE-TRACT; SURFACE-AREA; GUT; DYSBIOSIS; DECONTAMINATION; IMPACT
AB During critical illness, there are a multitude of forces such as antibiotic use, mechanical ventilation, diet changes and inflammatory responses that could bring the microbiome out of balance. This so-called dysbiosis of the microbiome seems to be involved in immunological responses and may influence outcomes even in individuals who are not as vulnerable as a critically ill ICU population. It is therefore probable that dysbiosis of the microbiome is a consequence of critical illness and may, subsequently, shape an inadequate response to these circumstances. Bronchoscopic studies have revealed that the carina represents the densest site of bacterial DNA along healthy airways, with a tapering density with further bifurcations. This likely reflects the influence of micro-aspiration as the primary route of microbial immigration in healthy adults. Though bacterial DNA density grows extremely sparse at smaller airways, bacterial signal is still consistently detectable in bronchoalveolar lavage fluid, likely reflecting the fact that lavage via a wedged bronchoscope samples an enormous surface area of small airways and alveoli. The dogma of lung sterility also violated numerous observations that long predated culture-independent microbiology. The body's resident microbial consortia (gut and/or respiratory microbiota) affect normal host inflammatory and immune response mechanisms. Disruptions in these host-pathogen interactions have been associated with infection and altered innate immunity. In this narrative review, we will focus on the rationale and current evidence for a pathogenic role of the lung microbiome in the exacerbation of complications of critical illness, such as acute respiratory distress syndrome and ventilator-associated pneumonia.
C1 [Martin-Loeches, Ignacio] St James Hosp, Multidisciplinary Intens Care Res Org MICRO, Dept Intens Care Med, Dublin 8, Ireland.
   [Martin-Loeches, Ignacio] CIBERes, Hosp Clin, IDIBAPS, Dept Resp Med, Barcelona, Spain.
   [Martin-Loeches, Ignacio] Trinity Coll Dublin, Dublin, Ireland.
   [Dickson, Robert] Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
   [Dickson, Robert] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.
   [Dickson, Robert] Michigan Ctr Integrat Res Crit Care, Ann Arbor, MI USA.
   [Torres, Antoni; Cilloniz, Catia] Univ Barcelona UB, Ciber Enfermedades Resp Ciberes, Hosp Clin Barcelona,Dept Pneumol,SGR 911, Inst Clin Torax,Inst Invest Biomed August Pi i Su, Barcelona, Spain.
   [Hanberger, Hakan] Linkoping Univ, Dept Infect Dis, Linkoping, Sweden.
   [Hanberger, Hakan] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden.
   [Lipman, Jeffrey] Univ Queensland, Brisbane, Qld, Australia.
   [Lipman, Jeffrey] Univ Montpellier, Nimes Univ Hosp, Nimes, France.
   [Antonelli, Massimo; de Pascale, Gennaro] Fdn Policlin Univ A Gemelli IRCCS, Dept Anesthesiol Intens Care & Emergency Med, Rome, Italy.
   [Antonelli, Massimo; de Pascale, Gennaro] Univ Cattolica Sacro Cuore, Rome, Italy.
   [Bozza, Fernando] Fundacao Oswaldo Cruz, FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Vincent, Jean Louis] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Intens Care, Brussels, Belgium.
   [Murthy, Srinivas] Univ British Columbia, Vancouver, BC V6H 3V4, Canada.
   [Bauer, Michael] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Klinikum 1, D-07747 Jena, Germany.
   [Marshall, John] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.
   [Bos, Lieuwe D.] Univ Amsterdam, Med Ctr, AMC, Dept Resp Med Infect & Immun, Amsterdam, Netherlands.
RP Martin-Loeches, I (corresponding author), St James Hosp, Multidisciplinary Intens Care Res Org MICRO, Dept Intens Care Med, Dublin 8, Ireland.; Martin-Loeches, I (corresponding author), CIBERes, Hosp Clin, IDIBAPS, Dept Resp Med, Barcelona, Spain.
EM drmartinloeches@gmail.com
RI Bos, Lieuwe D.J/H-2578-2018; Bozza, Fernando A/A-2618-2013
OI Bos, Lieuwe D.J/0000-0003-2911-4549; Bozza, Fernando
   A/0000-0003-4878-0256
FU Health Research Board (HRB)/Joint Programming Initiative on
   Antimicrobial Resistance (JPIAMR) [2018-06335]; Deutsche
   Forschungsgemeinschaft (DFG, German Research & Foundation) under
   Germany's Excellence StrategyGerman Research Foundation (DFG) [EXC 2051,
   390713860]
FX Ignacio Martin-Loeches is supported by the Health Research Board
   (HRB)/Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
   (2018-06335). Michael Bauer is supported by Deutsche
   Forschungsgemeinschaft (DFG, German Research & Foundation) under
   Germany's Excellence Strategy-EXC 2051-Project-ID 390713860).
CR Alverdy JC, 2017, CRIT CARE MED, V45, P337, DOI [10.1097/CCM.0000000000002172, 10.1097/ccm.0000000000002172]
   [Anonymous], 2016, INTENS CARE MED, V43, P59
   BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979
   Barfod KK, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-303
   Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15
   Biteen JS, 2016, ACS NANO, V10, P6, DOI 10.1021/acsnano.5b07826
   Buelow E, 2014, J ANTIMICROB CHEMOTH, V69, P2215, DOI 10.1093/jac/dku092
   Cotran RS, 1999, ROBBINS PATHOLOGIC B, P1425
   de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394
   Dickson RP, 2018, AM J RESP CRIT CARE, V198, P497, DOI 10.1164/rccm.201711-2180OC
   Dickson RP, 2018, AM J RESP CRIT CARE, V197, P549, DOI 10.1164/rccm.201710-2096ED
   Dickson RP, 2017, MBIO, V8, DOI 10.1128/mBio.02287-16
   Dickson RP, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.113, 10.1038/NMICROBIOL.2016.113]
   Dickson RP, 2016, ANNU REV PHYSIOL, V78, P481, DOI 10.1146/annurev-physiol-021115-105238
   Dickson RP, 2015, ANN AM THORAC SOC, V12, P821, DOI 10.1513/AnnalsATS.201501-029OC
   Dickson RP, 2014, LANCET, V384, P691, DOI 10.1016/S0140-6736(14)61136-3
   Dickson RP, 2020, AM J RESP CRIT CARE
   Durck H, 1898, CENTR BAKT, V1, P574
   Emonet S, 2019, INTENS CARE MED, V45, P1082, DOI 10.1007/s00134-019-05660-8
   FOX GE, 1977, P NATL ACAD SCI USA, V74, P4537, DOI 10.1073/pnas.74.10.4537
   Freedberg DE, 2018, INTENS CARE MED, V44, P1203, DOI 10.1007/s00134-018-5268-8
   Frisbee AL, 2020, TRENDS MOL MED, V26, P496, DOI 10.1016/j.molmed.2020.01.009
   Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721
   Gaulke CA, 2018, NAT MED, V24, P1495, DOI 10.1038/s41591-018-0210-8
   Goldstein EJC, 2015, CLIN INFECT DIS, V60, pS98, DOI 10.1093/cid/civ072
   Grice EA, 2012, ANNU REV GENOM HUM G, V13, P151, DOI 10.1146/annurev-genom-090711-163814
   HASLETON PS, 1972, J ANAT, V112, P391
   Helander HF, 2014, SCAND J GASTROENTERO, V49, P681, DOI 10.3109/00365521.2014.898326
   Horikoshi K, 1998, WILEY S ECO, P155
   Hranjec T, 2012, LANCET INFECT DIS, V12, P774, DOI 10.1016/S1473-3099(12)70151-2
   Iapichino G, 2008, J MED MICROBIOL, V57, P1007, DOI 10.1099/jmm.0.47387-0
   IKEDAOHTSUBO W, 2018, FRONT NUTR, V5, DOI DOI 10.3389/FNUT.2018.00090/FULL
   Johnstone J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025228
   Kaul R, 1996, J INFECT DIS, V174, P1279, DOI 10.1093/infdis/174.6.1279
   Kitsios GD, 2017, J CRIT CARE, V38, P84, DOI 10.1016/j.jcrc.2016.09.029
   Kristensen NB, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0300-5
   Kyo M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1203-y
   Langelier C, 2018, P NATL ACAD SCI USA, V115, pE12353, DOI 10.1073/pnas.1809700115
   Lax S, 2015, TRENDS MOL MED, V21, P427, DOI 10.1016/j.molmed.2015.03.005
   Lee J, 2016, ANAL CHEM, V88, P10266, DOI 10.1021/acs.analchem.6b03000
   Ma W, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3689
   Madan JC, 2012, ARCH DIS CHILD-FETAL, V97, pF456, DOI 10.1136/fetalneonatal-2011-301373
   Mandell LA, 2019, NEW ENGL J MED, V380, P651, DOI 10.1056/NEJMra1714562
   Marchesi JR, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0094-5
   McDonald D, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00199-16
   Moeller AH, 2013, GUT MICROBES, V4, P403, DOI 10.4161/gmic.26039
   Morrow LE, 2017, CHEST, V151, P492, DOI 10.1016/j.chest.2016.10.006
   Mukherjee S, 2018, YALE J BIOL MED, V91, P143
   Navas-Molina JA, 2013, METHOD ENZYMOL, V531, P371, DOI 10.1016/B978-0-12-407863-5.00019-8
   Ng KM, 2013, NATURE, V502, P96, DOI 10.1038/nature12503
   Otani S, 2019, ACUTE MED SURG, V6, P91, DOI 10.1002/ams2.383
   Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001
   Pasteur L, 1860, CR HEBD ACAD SCI, P303
   Petersen C, 2014, CELL MICROBIOL, V16, P1024, DOI 10.1111/cmi.12308
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Quinn LF, 1929, ARCHIV OTOLARYNGOL, V10, P152
   Ren YJ, 2019, TRANSL LUNG CANCER R, V8, P235, DOI 10.21037/tlcr.2019.06.11
   Rinninella E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7010014
   Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641
   Ruff WE, 2020, NAT REV MICROBIOL, V18, P521, DOI 10.1038/s41579-020-0367-2
   Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z
   Segal LN, 2017, THORAX, V72, P13, DOI 10.1136/thoraxjnl-2016-208599
   Segal LN, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.31, 10.1038/NMICROBIOL.2016.31]
   Souza DG, 2004, J IMMUNOL, V173, P4137, DOI 10.4049/jimmunol.173.6.4137
   Tanner MA, 1998, APPL ENVIRON MICROB, V64, P3110
   Tavoukjian V, 2019, J HOSP INFECT, V102, P174, DOI 10.1016/j.jhin.2019.03.010
   van Oort PMP, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0353-7
   van Ruissen MCE, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0238-1
   Venkataraman A, 2015, MBIO, V6, DOI 10.1128/mBio.02284-14
   Weinstock GM, 2012, NATURE, V489, P250, DOI 10.1038/nature11553
   Weng H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00717
   Wittekamp BH, 2018, JAMA-J AM MED ASSOC, V320, P2087, DOI 10.1001/jama.2018.13765
   Wu H, 2017, NAT MED, V23, P850, DOI 10.1038/nm.4345
   Wypych TP, 2019, NAT IMMUNOL, V20, P1279, DOI 10.1038/s41590-019-0451-9
   Zakharkina T, 2017, THORAX, V72, P803, DOI 10.1136/thoraxjnl-2016-209158
   Zhang YM, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw165
NR 76
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD AUG 31
PY 2020
VL 24
IS 1
AR 537
DI 10.1186/s13054-020-03219-4
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA NM2ES
UT WOS:000567915900004
PM 32867808
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Nassar, AP
   Trevisani, MD
   Bettim, BB
   Zampieri, FG
   Carvalho, JA
   Silva, A
   de Freitas, FGR
   Soares, JED
   Romano, E
   Ramos, SR
   Faria, GBA
   Silva, UVAE
   Santos, RC
   Tommasi, ED
   de Moraes, APP
   da Cruz, BA
   Bozza, FA
   Caruso, P
   Salluh, JIF
   Soares, M
AF Nassar Junior, Antonio Paulo
   Trevisani, Mariane da Silva
   Bettim, Barbara Beltrame
   Zampieri, Fernando Godinho
   Carvalho Jr, Jose Albani
   Silva Jr, Amilton
   Rezende de Freitas, Flavio Geraldo
   da Silva Soares Pinto, Jorge Eduardo
   Romano, Edson
   Ramos, Silvia Regina
   Alves Faria, Guilherme Brenande
   Andrade e Silva, Ulysses, V
   Santos, Robson Correa
   Tommasi, Edmundo de Oliveira
   Pierre de Moraes, Ana Paula
   da Cruz, Bruno Azevedo
   Bozza, Fernando Augusto
   Caruso, Pedro
   Figueira Salluh, Jorge Ibrahin
   Soares, Marcio
TI Elderly patients with cancer admitted to intensive care unit: A
   multicenter study in a middle-income country
SO PLOS ONE
LA English
DT Article
ID MORTALITY; ADMISSION; OUTCOMES; ICU; TRIAGE
AB Background Very elderly critically ill patients (ie, those older than 75 or 80 years) are an increasing population in intensive care units. However, patients with cancer have encompassed only a minority in epidemiological studies of very old critically-ill patients. We aimed to describe clinical characteristics and identify factors associated with hospital mortality in a cohort of patients aged 80 or older with cancer admitted to intensive care units (ICUs). Methods This was a retrospective cohort study in 94 ICUs in Brazil. We included patients aged 80 years or older with active cancer who had an unplanned admission. We performed a mixed effect logistic regression model to identify variables independently associated with hospital mortality. Results Of 4604 included patients, 1807 (39.2%) died in hospital. Solid metastatic (OR = 2.46; CI 95%, 2.01-3.00), hematological cancer (OR = 2.32; CI 95%, 1.75-3.09), moderate/severe performance status impairment (OR = 1.59; CI 95%, 1.33-1.90) and use of vasopressors (OR = 4.74; CI 95%, 3.88-5.79), mechanical ventilation (OR = 1.54; CI 95%, 1.25-1.89) and renal replacement (OR = 1.81; CI 95%, 1.29-2.55) therapy were independently associated with increased hospital mortality. Emergency surgical admissions were associated with lower mortality compared to medical admissions (OR = 0.71; CI 95%, 0.52-0.96). Conclusions Hospital mortality rate in very elderly critically ill patients with cancer with unplanned ICU admissions are lower than expected a priori. Cancer characteristics, performance status impairment and acute organ dysfunctions are associated with increased mortality.
C1 [Nassar Junior, Antonio Paulo; Trevisani, Mariane da Silva; Bettim, Barbara Beltrame; Caruso, Pedro] AC Camargo Canc Ctr, Sao Paulo, Brazil.
   [Zampieri, Fernando Godinho] IDOr Res & Educ Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando Godinho] HCor Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando Godinho] Univ Odense, Ctr Epidemiol & Clin Res, Odense, Denmark.
   [Carvalho Jr, Jose Albani] Hosp Sao Luiz Rede DOr, Sao Paulo, Brazil.
   [Silva Jr, Amilton] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
   [Rezende de Freitas, Flavio Geraldo] Hosp Sepaco, Sao Paulo, Brazil.
   [da Silva Soares Pinto, Jorge Eduardo] Hosp Norte DOr, Rio De Janeiro, Brazil.
   [Romano, Edson] HCor Hosp Coracao, Sao Paulo, Brazil.
   [Ramos, Silvia Regina] Hosp Sao Luiz Unidade Assuncao, Sao Bernardo Do Campo, Brazil.
   [Alves Faria, Guilherme Brenande] Hosp Oeste DOr, Rio De Janeiro, Brazil.
   [Andrade e Silva, Ulysses, V] Fundacao Pio XII Hosp Canc Barretos, Barretos, Brazil.
   [Santos, Robson Correa] Hosp Estadual Adao Pereira Nunes, Duque De Caxias, RJ, Brazil.
   [Tommasi, Edmundo de Oliveira] Hosp Israelita Albert Sabin, Rio De Janeiro, Brazil.
   [Pierre de Moraes, Ana Paula] Hosp Canc Maranhao Tarquinio Lopes Filho, Sao Luis, Maranhao, Brazil.
   [da Cruz, Bruno Azevedo] Inst Nacl Canc HC II, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto; Figueira Salluh, Jorge Ibrahin; Soares, Marcio] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Caruso, Pedro] Univ Sao Paulo, Heart Inst, Discipline Pulmonol, Sao Paulo, Brazil.
RP Nassar, AP (corresponding author), AC Camargo Canc Ctr, Sao Paulo, Brazil.
EM paulo.nassar@accamargo.org.br
RI V.A.Silva, Ulysses/AAZ-3336-2020; Bozza, Fernando A/A-2618-2013; Nassar
   Jr, Antonio Paulo/I-5508-2015
OI V.A.Silva, Ulysses/0000-0002-1284-2016; Bozza, Fernando
   A/0000-0003-4878-0256; Nassar Jr, Antonio Paulo/0000-0002-0522-7445;
   Soares, Marcio/0000-0003-2503-6088
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); D'Or Institute for
   Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq), Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ) and by
   departmental funds from the D'Or Institute for Research and Education.
CR Andersen FH, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0053-0
   [Anonymous], 2017, RUMIYAH, V7, P26
   Bagshaw SM, 2009, CRIT CARE, V13, DOI 10.1186/cc7768
   Becker S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0097-1
   Boddaert J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083795
   Bos ACRK, 2019, EJSO-EUR J SURG ONC, V45, P1575, DOI 10.1016/j.ejso.2019.04.020
   Bos MMEM, 2012, ACTA ONCOL, V51, P897, DOI 10.3109/0284186X.2012.679311
   Darmon M, 2019, INTENS CARE MED, V45, P977, DOI 10.1007/s00134-019-05653-7
   Flaatten H, 2017, INTENS CARE MED, V43, P1319, DOI 10.1007/s00134-017-4718-z
   Flaatten H, 2017, INTENS CARE MED, V43, P1820, DOI 10.1007/s00134-017-4940-8
   Fuchs L, 2012, INTENS CARE MED, V38, P1654, DOI 10.1007/s00134-012-2629-6
   Guidet B, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0458-7
   Guidet B, 2018, INTENS CARE MED, V44, P1027, DOI 10.1007/s00134-018-5196-7
   Guidet B, 2017, JAMA-J AM MED ASSOC, V318, P1450, DOI 10.1001/jama.2017.13889
   Martin-Loeches I, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0495-x
   Ostermann M, 2017, CRIT CARE MED, V45, P1668, DOI 10.1097/CCM.0000000000002589
   Pietilainen L, 2018, INTENS CARE MED, V44, P1221, DOI 10.1007/s00134-018-5273-y
   Puxty K, 2014, INTENS CARE MED, V40, P1409, DOI 10.1007/s00134-014-3471-9
   Soares M, 2016, J CLIN ONCOL, V34, P3315, DOI 10.1200/JCO.2016.66.9549
   Sohn IW, 2017, CANCER RES TREAT, V49, P204, DOI 10.4143/crt.2016.163
   Sprung CL, 2012, CRIT CARE MED, V40, P132, DOI 10.1097/CCM.0b013e318232d6b0
   United Nations DoEaSA Population Division, 2019, STESASERA423 UN DOEA
   Vincent F, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0386-6
   Zampieri FG, 2019, INTENS CARE MED, V45, P1599, DOI 10.1007/s00134-019-05790-z
   Zampieri FG, 2018, INTENS CARE MED, V44, P1512, DOI 10.1007/s00134-018-5342-2
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
   Zampieri FG, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-59
   Zampieri Fernando Godinho, 2017, Rev. bras. ter. intensiva, V29, P418, DOI [10.5935/0103-507x.20170062, 10.5935/0103-507X.20170062]
NR 28
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2020
VL 15
IS 8
AR e0238124
DI 10.1371/journal.pone.0238124
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NG6GN
UT WOS:000564080300053
PM 32822433
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Zampieri, FG
   Romano, TG
   Salluh, JIF
   Taniguchi, LU
   Mendes, PV
   Nassar, AP
   Costa, R
   Viana, WN
   Maia, MO
   Lima, MFA
   Cappi, SB
   Carvalho, AGR
   De Marco, FVC
   Santino, MS
   Perecmanis, E
   Miranda, FG
   Ramos, GV
   Silva, AR
   Hoff, PM
   Bozza, FA
   Soares, M
AF Zampieri, Fernando G.
   Romano, Thiago G.
   Salluh, Jorge I. F.
   Taniguchi, Leandro U.
   Mendes, Pedro, V
   Nassar Jr, Antonio P.
   Costa, Roberto
   Viana, William N.
   Maia, Marcelo O.
   Lima, Mariza F. A.
   Cappi, Sylas B.
   Carvalho, Alexandre G. R.
   De Marco, Fernando V. C.
   Santino, Marcelo S.
   Perecmanis, Eric
   Miranda, Fabio G.
   Ramos, Grazielle, V
   Silva, Aline R.
   Hoff, Paulo M.
   Bozza, Fernando A.
   Soares, Marcio
TI Trends in clinical profiles, organ support use and outcomes of patients
   with cancer requiring unplanned ICU admission: a multicenter cohort
   study
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Early Access
DE Cancer; Mortality trends; Critical care; Multicenter study; Bayesian
   analysis
ID INTENSIVE-CARE-UNIT; LUNG-CANCER
AB Purpose To describe trends in outcomes of cancer patients with unplanned admissions to intensive-care units (ICU) according to cancer type, organ support use, and performance status (PS) over an 8-year period. Methods We retrospectively analyzed prospectively collected data from all cancer patients admitted to 92 medical-surgical ICUs from July/2011 to June/2019. We assessed trends in mortality through a Bayesian hierarchical model adjusted for relevant clinical confounders and whether there was a reduction in ICU length-of-stay (LOS) over time using a competing risk model. Results 32,096 patients (8.7% of all ICU admissions; solid tumors, 90%; hematological malignancies, 10%) were studied. Bed/days use by cancer patients increased up to more than 30% during the period. Overall adjusted mortality decreased by 9.2% [95% credible interval (CI), 13.1-5.6%]. The largest reductions in mortality occurred in patients without need for organ support (9.6%) and in those with need for mechanical ventilation (MV) only (11%). Smallest reductions occurred in patients requiring MV, vasopressors, and dialysis (3.9%) simultaneously. Survival gains over time decreased as PS worsened. Lung cancer patients had the lowest decrease in mortality. Each year was associated with a lower sub-hazard for ICU death [SHR 0.93 (0.91-0.94)] and a higher chance of being discharged alive from the ICU earlier [SHR 1.01 (1-1.01)]. Conclusion Outcomes in critically ill cancer patients improved in the past 8 years, with reductions in both mortality and ICU LOS, suggesting improvements in overall care. However, outcomes remained poor in patients with lung cancer, requiring multiple organ support and compromised PS.
C1 [Zampieri, Fernando G.; Salluh, Jorge I. F.; Ramos, Grazielle, V; Silva, Aline R.; Hoff, Paulo M.; Bozza, Fernando A.; Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, 30 Botafogo, Rio De Janeiro, Brazil.
   [Zampieri, Fernando G.] HCor, Res Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando G.] Southern Denmark Univ, Ctr Epidemiol & Clin Res, Odense, Denmark.
   [Romano, Thiago G.; Mendes, Pedro, V] Hosp Vila Nova Star, Intens Care Unit, Sao Paulo, Brazil.
   [Romano, Thiago G.] ABC Med Sch, Nephrol Dept, Santo Andre, SP, Brazil.
   [Salluh, Jorge I. F.; Ramos, Grazielle, V; Silva, Aline R.; Bozza, Fernando A.; Soares, Marcio] DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Taniguchi, Leandro U.] Hosp Sirio Libanes, Res & Educ Inst, Sao Paulo, Brazil.
   [Taniguchi, Leandro U.; Mendes, Pedro, V] Univ Sao Paulo, Emergency Med Discipline, Sao Paulo, Brazil.
   [Romano, Thiago G.; Mendes, Pedro, V] Hosp Sao Luiz, Oncol Intens Care Unit, Unidade Itaim, Sao Paulo, Brazil.
   [Nassar Jr, Antonio P.] AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil.
   [Costa, Roberto] Hosp Quinta DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Viana, William N.] Hosp Copa DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia Rede DOr Sao Luiz, Intens Care Unit, Brasilia, DF, Brazil.
   [Maia, Marcelo O.] Hosp DF Star Rede DOr Sao Luiz, Intens Care Unit, Brasilia, DF, Brazil.
   [Lima, Mariza F. A.] Hosp Esperanca Recife, Intens Care Unit, Recife, PE, Brazil.
   [Cappi, Sylas B.] Hosp Sao Luiz, Intens Care Unit, Unidade Brasil, Santo Andre, SP, Brazil.
   [Carvalho, Alexandre G. R.] UDI Hosp, Intens Care Unit, Sao Luis, Maranhao, Brazil.
   [De Marco, Fernando V. C.] Hosp ViValle, Intens Care Unit, Sao Jose Dos Campos, Brazil.
   [Santino, Marcelo S.] Hosp Barra DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Perecmanis, Eric] Hosp Caxias DOr, Intens Care Unit, Duque De Caxias, RJ, Brazil.
   [Miranda, Fabio G.] Hosp Copa Star, Intens Care Unit, Rio De Janeiro, Brazil.
   [Hoff, Paulo M.] Oncol DOr, Sao Paulo, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, 30 Botafogo, Rio De Janeiro, Brazil.; Soares, M (corresponding author), DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Taniguchi, Leandro Utino/L-6471-2015; Soares, Marcio/B-3083-2013; Bozza,
   Fernando A/A-2618-2013
OI Taniguchi, Leandro Utino/0000-0003-4384-0408; Soares,
   Marcio/0000-0003-2503-6088; Bozza, Fernando A/0000-0003-4878-0256
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [302188/2018-5]; Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   D'Or Institute for Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq) (Grant No. 302188/2018-5), Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ), and by departmental funds from the D'Or Institute for
   Research and Education.
CR Azevedo LCP, 2014, CHEST, V146, P257, DOI 10.1378/chest.13-1870
   Azoulay E, 2019, AM J RESP CRIT CARE, V200, P20, DOI 10.1164/rccm.201810-1945ED
   Azoulay E, 2019, LANCET RESP MED, V7, P173, DOI 10.1016/S2213-2600(18)30345-X
   Azoulay E, 2017, INTENS CARE MED, V43, P1808, DOI 10.1007/s00134-017-4947-1
   Azoulay E, 2017, INTENS CARE MED, V43, P1366, DOI 10.1007/s00134-017-4884-z
   Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365
   Chaudhuri D, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1711-4
   Darmon M, 2019, INTENS CARE MED, V45, P977, DOI 10.1007/s00134-019-05653-7
   de Vries VA, 2018, BRIT J HAEMATOL, V181, P68, DOI 10.1111/bjh.15140
   Gerds TA, 2020, RISK REGRESSION RISK
   Gutierrez C, 2020, CRIT CARE MED, V48, P10, DOI 10.1097/CCM.0000000000004087
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Ostermann M, 2017, CRIT CARE MED, V45, P1668, DOI 10.1097/CCM.0000000000002589
   Puxty K, 2015, JAMA ONCOL, V1, P1078, DOI 10.1001/jamaoncol.2015.2855
   Shimabukuro-Vornhagen A, 2016, CA-CANCER J CLIN, V66, P497, DOI 10.3322/caac.21351
   Slatore CG, 2012, J CLIN ONCOL, V30, P1686, DOI 10.1200/JCO.2011.40.0846
   Soares M, 2014, ANN ONCOL, V25, P1829, DOI 10.1093/annonc/mdu234
   Soares M, 2016, J CLIN ONCOL, V34, P3315, DOI 10.1200/JCO.2016.66.9549
   Wallace SK, 2016, CRIT CARE MED, V44, P926, DOI 10.1097/CCM.0000000000001568
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
   Zampieri Fernando Godinho, 2017, Rev. bras. ter. intensiva, V29, P418, DOI [10.5935/0103-507x.20170062, 10.5935/0103-507X.20170062]
NR 21
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
DI 10.1007/s00134-020-06184-2
EA AUG 2020
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA MW5XH
UT WOS:000557108800003
PM 32770267
DA 2020-12-01
ER

PT J
AU Kurtz, P
   Bastos, LSL
   Aguilar, S
   Hamacher, S
   Bozza, FA
AF Kurtz, Pedro
   Bastos, Leonardo S. L.
   Aguilar, Soraida
   Hamacher, Silvio
   Bozza, Fernando A.
TI Effect of seasonal and temperature variation on hospitalizations for
   stroke over a 10-year period in Brazil
SO INTERNATIONAL JOURNAL OF STROKE
LA English
DT Article; Early Access
DE Season; temperature; stroke; ischemic stroke; stroke prevalence;
   epidemiology; Brazil
AB Background Seasonal variation in stroke incidence remains controversial. Aims We aimed to describe the pattern of seasonality in hospitalizations for stroke in Brazil. Methods We evaluated age-adjusted hospitalization rates for stroke per month using data from the Brazilian Unified Healthcare System and median monthly temperature data obtained from the National Institute of Meteorology. To detect a seasonality pattern in time series, we used seasonal-trend decomposition using LOESS. We calculated a seasonal strength statistic and used Kruskal-Wallis test to evaluate the presence of seasonality in Brazil and its five regions. We also assessed the association of temperature and stroke hospitalization rates using Spearman's rho correlation. Results We identified 1,422,496 stroke-related hospitalizations between 2009 and 2018. Mean age was 67 years, 51% were male and 77.5% of stroke diagnoses were not specified as ischemic or hemorrhagic. Median temperature was 23.8celcius (IQR 22.3-24.4). Age-adjusted hospitalizations demonstrated significant seasonal variation during all the years analyzed, with increased rates during the winter. When regional differences were analyzed, seasonal behavior was present in the south, southeast and northeast regions of the country. These were also the regions with lower median temperatures during the winter months and greater amplitude of average temperatures between warmer and colder months. Conclusions In this large national cohort of stroke patients in Brazil, we demonstrated the presence of seasonal variation in the age-adjusted hospitalization rate, with peak rates during the winter months. The regional gradient of incidence of stroke was directly associated with colder winters and greater amplitude of temperature.
C1 [Kurtz, Pedro] Inst Estadual Cerebro Paulo Niemeyer, Dept Neurointens Care, Rio De Janeiro, Brazil.
   [Kurtz, Pedro] Hosp Copa Star, Dept Neurointens Care, Rio De Janeiro, Brazil.
   [Bastos, Leonardo S. L.; Aguilar, Soraida; Hamacher, Silvio] Pontifical Catholic Univ Rio de Janeiro PUC Rio, Ind Engn Dept, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; /0000-0002-4469-8645
CR Ahmad O, 2001, AGE STANDARDIZATION
   Cleveland RC, 1990, J OFF STAT, V6, P3, DOI DOI 10.1016/J.SOILBIO.2009.09.001
   Dantas LF, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213837
   Diaz A, 2013, J STROKE CEREBROVASC, V22, pE66, DOI 10.1016/j.jstrokecerebrovasdis.2012.04.007
   Gomes J, 2014, J STROKE CEREBROVASC, V23, P271, DOI 10.1016/j.jstrokecerebrovasdis.2013.02.012
   Han MH, 2015, STROKE, V46, P927, DOI 10.1161/STROKEAHA.114.007950
   Johnson CO, 2019, LANCET NEUROL, V18, P439, DOI 10.1016/S1474-4422(19)30034-1
   KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441
   Kumar N, 2015, INT J CARDIOL, V195, P134, DOI 10.1016/j.ijcard.2015.05.122
   Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028
   Sebastian S, 2019, STROKE, V50, P2216, DOI 10.1161/STROKEAHA.119.025872
   Skajaa N, 2018, EPIDEMIOLOGY, V29, P777, DOI 10.1097/EDE.0000000000000892
   Wang XZ, 2006, DATA MIN KNOWL DISC, V13, P335, DOI 10.1007/s10618-005-0039-x
   Wang Y, 2003, STROKE, V34, P1144, DOI 10.1161/01.STR.0000067703.71251.B6
NR 14
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1747-4930
EI 1747-4949
J9 INT J STROKE
JI Int. J. Stroke
AR 1747493020947333
DI 10.1177/1747493020947333
EA AUG 2020
PG 5
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA MV4HN
UT WOS:000556321100001
PM 32752950
DA 2020-12-01
ER

PT J
AU Marshall, JC
   Murthy, S
   Diaz, J
   Cheng, A
   Denholm, J
   Hodgson, C
   Tong, S
   Webb, S
   Bozza, F
   Adhikari, N
   Foster, N
   Fowler, R
   Turgeon, A
   Feng, X
   Qiu, R
   Shi, L
   Zhang, J
   Kojan, R
   Malvey, D
   Bauer, M
   Brunkhorst, F
   Glueck, T
   Wolf, T
   Gomersall, C
   Kumar, B
   Clarke, M
   Laffey, J
   Martin-Loeches, I
   Piva, S
   Shimizu, N
   de Jong, M
   Derde, L
   Netea, M
   van de Veerdonk, F
   McArthur, C
   McBride, S
   McGuinness, S
   Morpeth, S
   Salisu-Kabara, H
   Sinclair, J
   Arabi, YM
   Kim, Y
   Oh, MD
   Baillie, K
   Dunning, J
   Fletcher, T
   Gobat, N
   Gordon, A
   Horby, P
   McAuley, D
   Merson, L
   Williamson, P
   Blackwood, B
   Berry, S
   Harhay, M
   Needham, D
   Uyeki, T
   Dat, VQ
AF Marshall, J. C.
   Murthy, S.
   Diaz, J.
   Cheng, A.
   Denholm, J.
   Hodgson, C.
   Tong, S.
   Webb, S.
   Bozza, F.
   Adhikari, N.
   Foster, N.
   Fowler, R.
   Turgeon, A.
   Feng, X.
   Qiu, R.
   Shi, L.
   Zhang, J.
   Kojan, R.
   Malvey, D.
   Bauer, M.
   Brunkhorst, F.
   Glueck, T.
   Wolf, T.
   Gomersall, C.
   Kumar, B.
   Clarke, M.
   Laffey, J.
   Martin-Loeches, I
   Piva, S.
   Shimizu, N.
   Jong, M. de
   Derde, L.
   Netea, M.
   van de Veerdonk, F.
   McArthur, C.
   McBride, S.
   McGuinness, S.
   Morpeth, S.
   Salisu-Kabara, H.
   Sinclair, J.
   Arabi, Y. M.
   Kim, Y.
   Oh, M-D
   Baillie, K.
   Dunning, J.
   Fletcher, T.
   Gobat, N.
   Gordon, A.
   Horby, P.
   McAuley, D.
   Merson, L.
   Williamson, P.
   Blackwood, B.
   Berry, S.
   Harhay, M.
   Needham, D.
   Uyeki, T.
   Dat, V. Q.
CA WHO Working Grp Clinical
TI A minimal common outcome measure set for COVID-19 clinical research
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID TRIALS; SCALES
AB Clinical research is necessary for an effective response to an emerging infectious disease outbreak. However, research efforts are often hastily organised and done using various research tools, with the result that pooling data across studies is challenging. In response to the needs of the rapidly evolving COVID-19 outbreak, the Clinical Characterisation and Management Working Group of the WHO Research and Development Blueprint programme, the International Forum for Acute Care Trialists, and the International Severe Acute Respiratory and Emerging Infections Consortium have developed a minimum set of common outcome measures for studies of COVID-19. This set includes three elements: a measure of viral burden (quantitative PCR or cycle threshold), a measure of patient survival (mortality at hospital discharge or at 60 days), and a measure of patient progression through the health-care system by use of the WHO Clinical Progression Scale, which reflects patient trajectory and resource use over the course of clinical illness. We urge investigators to include these key data elements in ongoing and future studies to expedite the pooling of data during this immediate threat, and to hone a tool for future needs.
C1 [Marshall, J. C.] St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.
RP Marshall, JC (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.
EM john.marshall@unityhealth.to
RI van de Veerdonk, Frank L/C-7256-2008; Bozza, Fernando A/A-2618-2013
OI van de Veerdonk, Frank L/0000-0002-1121-4894; Bozza, Fernando
   A/0000-0003-4878-0256; Gobat, Nina/0000-0002-1558-557X; Fletcher,
   Tom/0000-0002-3712-415X; Murthy, Srinivas/0000-0002-9476-839X; Derde,
   Lennie/0000-0002-3577-5629
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR)
FX Supported in part by a grant from the Canadian Institutes of Health
   Research.
CR [Anonymous], 2020, GLOB COVID 19 CLIN P
   Baud D, 2020, LANCET INFECT DIS, DOI DOI 10.1016/51473-3099(20)30195-X
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Clarke M, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0188-6
   Gates B, 2018, NEW ENGL J MED, V378, P2057, DOI 10.1056/NEJMp1806283
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI [10.1001/jama2020.5394, 10.1001/jama.2020.5394]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hobart JC, 2007, LANCET NEUROL, V6, P1094, DOI 10.1016/S1474-4422(07)70290-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   International Severe Acute Respiratory and Emerging Infections Consortium, COVID 19 REP 08 APR
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Johns Hopkins University and Medicine, 2020, COR RES CTR MORT AN
   Keusch GT, 2017, LANCET, V389, P2455, DOI 10.1016/S0140-6736(17)31602-1
   Kirkham JJ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-324
   KNAPP TR, 1990, NURS RES, V39, P121
   Leon AC, 1997, INT J PSYCHIAT MED, V27, P93, DOI 10.2190/T8EM-C8YH-373N-1UWD
   Liu HI, 2019, AGRONOMY-BASEL, V9, DOI 10.3390/agronomy9090565
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Marston HD, 2017, JAMA-J AM MED ASSOC, V318, P1757, DOI 10.1001/jama.2017.15033
   Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Williamson PR, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-132
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Xie XZ, 2020, EUR RADIOL, V30, P4347, DOI 10.1007/s00330-020-06821-w
   Xu Yan, 2020, Zhongguo Fei Ai Za Zhi, V23, P136, DOI 10.3779/j.issn.1009-3419.2020.03.02
NR 29
TC 6
Z9 6
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD AUG
PY 2020
VL 20
IS 8
BP E192
EP E197
DI 10.1016/S1473-3099(20)30483-7
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA NA3ZL
UT WOS:000559753300008
PM 32539990
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Giordani, NE
   Robinson, CC
   Westphal, GA
   Rosa, RG
   Sganzerla, D
   Cavalcanti, AB
   Machado, FR
   Azevedo, LCP
   Bozza, FA
   Teixeira, C
   de Andrade, J
   Franke, CA
   Guterres, CM
   Madalena, IC
   Rohden, AI
   da Silva, SS
   Andrighetto, LV
   Rech, GS
   Gimenes, BD
   Hammes, LS
   Pontes, DFS
   Meade, MO
   Falavigna, M
AF Giordani, Natalia Elis
   Robinson, Caroline Cabral
   Westphal, Glauco Adrieno
   Rosa, Regis Goulart
   Sganzerla, Daniel
   Cavalcanti, Alexandre Biasi
   Machado, Flavia Ribeiro
   Pontes Azevedo, Luciano Cesar
   Bozza, Fernando Augusto
   Teixeira, Cassiano
   de Andrade, Joel
   Franke, Cristiano Augusto
   Guterres, Catia Moreira
   Madalena, Itiana Cardoso
   Rohden, Adriane Isabel
   da Silva, Sabrina Souza
   Andrighetto, Luiza Vitelo
   Rech, Gabriela Soares
   Gimenes, Bruna dos Passos
   Hammes, Luciano Serpa
   Salomao Pontes, Daniela Ferreira
   Meade, Maureen O.
   Falavigna, Maicon
TI Statistical analysis plan for a cluster-randomised trial assessing the
   effectiveness of implementation of a bedside evidence-based checklist
   for clinical management of brain-dead potential organ donors in
   intensive care units: DONORS (Donation Network to Optimise Organ
   Recovery Study)
SO TRIALS
LA English
DT Article
DE Organ donor; Organ transplantation; Donor management; Donor management
   goals; Checklist
ID BLOOD-STREAM INFECTIONS; NUMBER; GOALS; IMPACT; INTERVENTION; MORTALITY
AB Background: The quality of clinical care of brain-dead potential organ donors may help reduce donor losses caused by irreversible or unreversed cardiac arrest and increase the number of organs donated. We sought to determine whether an evidence-based, goal-directed checklist for donor management in intensive care units (ICUs) can reduce donor losses to cardiac arrest.
   Methods/design: The DONORS study is a multicentre, cluster-randomised controlled trial with a 1:1 allocation ratio designed to compare an intervention group (goal-directed checklist for brain-dead potential organ donor management) with a control group (standard ICU care). The primary outcome is loss of potential donors due to cardiac arrest. Secondary outcomes are the number of actual organ donors and the number of solid organs recovered per actual donor. Exploratory outcomes include the achievement of relevant clinical goals during the management of brain-dead potential organ donors. The present statistical analysis plan (SAP) describes all primary statistical procedures that will be used to evaluate the results and perform exploratory and sensitivity analyses of the trial.
   Discussion: The SAP of the DONORS study aims to describe its analytic procedures, enhancing the transparency of the study. At the moment of SAP subsmission, 63 institutions have been randomised and were enrolling study participants. Thus, the analyses reported herein have been defined before the end of the study recruitment and database locking.
C1 [Giordani, Natalia Elis; Robinson, Caroline Cabral; Westphal, Glauco Adrieno; Sganzerla, Daniel; Guterres, Catia Moreira; Madalena, Itiana Cardoso; Rohden, Adriane Isabel; da Silva, Sabrina Souza; Andrighetto, Luiza Vitelo; Rech, Gabriela Soares; Gimenes, Bruna dos Passos; Falavigna, Maicon] Hosp Moinhos de Vento HMV, Res Projects Off, Rua Ramiro Barcelos 910, BR-90035001 Porto Alegre, RS, Brazil.
   [Giordani, Natalia Elis; Falavigna, Maicon] Univ Fed Rio Grande do Sul UFRGS, Postgrad Programme Epidemiol, Porto Alegre, RS, Brazil.
   [Westphal, Glauco Adrieno] Hosp Municipal Sao Jose, Joinville, SC, Brazil.
   [Westphal, Glauco Adrieno] Ctr Hosp Unimed, Joinville, SC, Brazil.
   [Rosa, Regis Goulart] HMV, Adult Intens Care Unit, Porto Alegre, RS, Brazil.
   [Cavalcanti, Alexandre Biasi] Hosp Coracao HCor, Res Inst, Sao Paulo, SP, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo UNIFESP, Dept Anaesthesiol Pain & Intens Care, Sao Paulo, SP, Brazil.
   [Pontes Azevedo, Luciano Cesar] Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, SP, Brazil.
   [Bozza, Fernando Augusto] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando Augusto] DOr Inst Res & Educ, Postgrad Programme Translat Med, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, RJ, Brazil.
   [Teixeira, Cassiano] Univ Fed Ciencias Saude Porto Alegre UFCSPA, Dept Internal Med, Porto Alegre, RS, Brazil.
   [Teixeira, Cassiano] Univ Fed Ciencias Saude Porto Alegre UFCSPA, Postgrad Programme Rehabil Sci, Porto Alegre, RS, Brazil.
   [de Andrade, Joel] Organ Procurement Org Santa Catarina OPO SC, Florianopolis, SC, Brazil.
   [Franke, Cristiano Augusto] Hosp Clin Porto Alegre HCPA, Adult Intens Care Unit, Porto Alegre, RS, Brazil.
   [Franke, Cristiano Augusto] Hosp Pronto Socorro HPS, Trauma Intens Care Unit, Porto Alegre, RS, Brazil.
   [Hammes, Luciano Serpa] HMV, Off Superintendent, Porto Alegre, RS, Brazil.
   [Salomao Pontes, Daniela Ferreira] Minist Saude, Gen Coordinat Off Natl Transplant Syst, Brasilia, DF, Brazil.
   [Meade, Maureen O.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Meade, Maureen O.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
RP Giordani, NE (corresponding author), Hosp Moinhos de Vento HMV, Res Projects Off, Rua Ramiro Barcelos 910, BR-90035001 Porto Alegre, RS, Brazil.; Giordani, NE (corresponding author), Univ Fed Rio Grande do Sul UFRGS, Postgrad Programme Epidemiol, Porto Alegre, RS, Brazil.
EM natigiordani@gmail.com
RI Azevedo, Luciano CP/H-2652-2012; Bozza, Fernando A/A-2618-2013; Rosa,
   Regis Goulart/P-6422-2019
OI Azevedo, Luciano CP/0000-0001-6759-3910; Bozza, Fernando
   A/0000-0003-4878-0256; 
FU Brazilian Ministry of Health through the Brazilian Unified Health System
   Institutional Development Programme (PROADI-SUS)
FX This study was funded by the Brazilian Ministry of Health through the
   Brazilian Unified Health System Institutional Development Programme
   (PROADI-SUS). The funding body has had no role in the design of the
   study; the collection, analysis, or interpretation of data; or the
   writing of the manuscript. Its role is limited to providing supporting
   information for site recruitment.
CR Bion J, 2013, BMJ QUAL SAF, V22, P110, DOI 10.1136/bmjqs-2012-001325
   Caille A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4291
   Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702
   Cavalcanti AB, 2016, JAMA-J AM MED ASSOC, V315, P1480, DOI 10.1001/jama.2016.3463
   Collet D., 2003, MODELLING SURVIVAL D
   DuBose Joseph, 2008, J Intensive Care Med, V23, P367, DOI 10.1177/0885066608324208
   Franklin GA, 2010, AM SURGEON, V76, P587
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Helms AK, 2004, NEUROLOGY, V63, P1955, DOI 10.1212/01.WNL.0000144197.06562.24
   Ko HCH, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-211
   Leyrat C, 2018, INT J EPIDEMIOL, V47, P321, DOI 10.1093/ije/dyx169
   Malinoski DJ, 2012, CRIT CARE MED, V40, P2773, DOI 10.1097/CCM.0b013e31825b252a
   Malinoski DJ, 2011, J TRAUMA, V71, P990, DOI 10.1097/TA.0b013e31822779e5
   Mascia L, 2010, JAMA-J AM MED ASSOC, V304, P2620, DOI 10.1001/jama.2010.1796
   Niemann CU, 2015, NEW ENGL J MED, V373, P405, DOI 10.1056/NEJMoa1501969
   Pandharipande PP, 2009, CRIT CARE MED, V37, P1317, DOI 10.1097/CCM.0b013e31819cefa9
   Patel MS, 2014, JAMA SURG, V149, P969, DOI 10.1001/jamasurg.2014.967
   Pedroza C, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2248-1
   Pedroza C, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0217-0
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   R Core Team, 2018, R LANG ENV STAT COMP
   Salim A, 2005, J TRAUMA, V58, P991, DOI 10.1097/01.TA.0000168708.78049.32
   Twisk JWR., 2003, APPL LONGITUDINAL DA
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Weiss CH, 2011, AM J RESP CRIT CARE, V184, P680, DOI 10.1164/rccm.201101-0037OC
   Westphal GA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1484-1
   Westphal GA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028570
   Westphal Glauco Adrieno, 2012, Rev. bras. ter. intensiva, V24, P334, DOI 10.1590/S0103-507X2012000400007
NR 28
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 17
PY 2020
VL 21
IS 1
AR 540
DI 10.1186/s13063-020-04457-1
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MB8UL
UT WOS:000542871900003
PM 32552839
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Midega, TD
   Bozza, FA
   Machado, FR
   Guimaraes, HP
   Salluh, JI
   Nassar, AP
   Normilio-Silva, K
   Schultz, MJ
   Cavalcanti, AB
   Neto, AS
AF Midega, Thais Dias
   Bozza, Fernando A.
   Machado, Flavia Ribeiro
   Guimaraes, Helio Penna
   Salluh, Jorge, I
   Nassar Jr, Antonio Paulo
   Normilio-Silva, Karina
   Schultz, Marcus J.
   Cavalcanti, Alexandre Biasi
   Serpa Neto, Ary
CA CHECKLIST-ICU Investigators
   Brazilian Res Intensive Care Netwo
TI Organizational factors associated with adherence to low tidal volume
   ventilation: a secondary analysis of the CHECKLIST-ICU database
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Intensive care unit; Invasive ventilation; lung protection; Tidal
   volume; low tidal volume ventilation; Organizational factors
ID RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE UNITS; LUNG-PROTECTIVE
   VENTILATION; MECHANICAL VENTILATION; ADULT PATIENTS; OUTCOMES;
   GUIDELINES; PATIENT; MORTALITY; EVOLUTION
AB Background Survival benefit from low tidal volume (V-T) ventilation (LTVV) has been demonstrated for patients with acute respiratory distress syndrome (ARDS), and patients not having ARDS could also benefit from this strategy. Organizational factors may play a role on adherence to LTVV. The present study aimed to identify organizational factors with an independent association with adherence to LTVV. Methods Secondary analysis of the database of a multicenter two-phase study (prospective cohort followed by a cluster-randomized trial) performed in 118 Brazilian intensive care units. Patients under mechanical ventilation at day 2 were included. LTVV was defined as a V-T <= 8 ml/kg PBW on the second day of ventilation. Data on the type and number of beds of the hospital, teaching status, nursing, respiratory therapists and physician staffing, use of structured checklist, and presence of protocols were tested. A multivariable mixed-effect model was used to assess the association between organizational factors and adherence to LTVV. Results The study included 5719 patients; 3340 (58%) patients received LTVV. A greater number of hospital beds (absolute difference 7.43% [95% confidence interval 0.61-14.24%]; p = 0.038), use of structured checklist during multidisciplinary rounds (5.10% [0.55-9.81%]; p = 0.030), and presence of at least one nurse per 10 patients during all shifts (17.24% [0.85-33.60%]; p = 0.045) were the only three factors that had an independent association with adherence to LTVV. Conclusions Number of hospital beds, use of a structured checklist during multidisciplinary rounds, and nurse staffing are organizational factors associated with adherence to LTVV. These findings shed light on organizational factors that may improve ventilation in critically ill patients.
C1 [Midega, Thais Dias; Guimaraes, Helio Penna; Serpa Neto, Ary] Hosp Israelita Albert Einstein, Dept Crit Care Med, Albert Einstein Ave 700, Sao Paulo, Brazil.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino IDOR, Res Inst, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil.
   [Guimaraes, Helio Penna] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil.
   [Salluh, Jorge, I] Inst DOr Pesquisa & Ensino IDOR, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Salluh, Jorge, I] Inst DOr Pesquisa & Ensino IDOR, Dept Crit Care, Rio De Janeiro, Brazil.
   [Salluh, Jorge, I] Univ Fed Rio de Janeiro, Post Grad Program Internal Med, Rio De Janeiro, Brazil.
   [Nassar Jr, Antonio Paulo] AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil.
   [Nassar Jr, Antonio Paulo] AC Camargo Canc Ctr, Postgrad Program, Sao Paulo, Brazil.
   [Normilio-Silva, Karina; Cavalcanti, Alexandre Biasi] HCor Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   [Schultz, Marcus J.; Serpa Neto, Ary] Acad Med Ctr, Dept Intens Care, Amsterdam, Netherlands.
   [Schultz, Marcus J.; Serpa Neto, Ary] Acad Med Ctr, Lab Expt Intens Care & Anesthesiol LEICA, Amsterdam, Netherlands.
   [Schultz, Marcus J.] Mahidol Univ, Fac Trop Med, MahidolOxford Trop Med Res Unit MORU, Bangkok, Thailand.
RP Neto, AS (corresponding author), Hosp Israelita Albert Einstein, Dept Crit Care Med, Albert Einstein Ave 700, Sao Paulo, Brazil.; Neto, AS (corresponding author), Acad Med Ctr, Dept Intens Care, Amsterdam, Netherlands.; Neto, AS (corresponding author), Acad Med Ctr, Lab Expt Intens Care & Anesthesiol LEICA, Amsterdam, Netherlands.
EM ary.neto2@einstein.br
RI Neto, Ary Serpa/D-1927-2012; Bozza, Fernando A/A-2618-2013; Borges,
   Marcos Carvalho/A-3585-2014
OI Neto, Ary Serpa/0000-0003-1520-9387; Bozza, Fernando
   A/0000-0003-4878-0256; Borges, Marcos Carvalho/0000-0001-6280-0714;
   Reis, AlessanRSS/0000-0001-8486-7469; Betonico,
   Gustavo/0000-0002-6110-0932
FU Brazilian Health Surveillance Agency (ANVISA); PROADI; Brazilian
   Development Bank (BNDES); D'Or Institute for Research and Education
FX This study was conducted as part of the Program to Support Institutional
   Development of Universal Health System (PROADI) from the Brazilian
   Ministry of Health. It was funded mainly by the Brazilian Health
   Surveillance Agency (ANVISA), PROADI, and Brazilian Development Bank
   (BNDES). D'Or Institute for Research and Education also contributed with
   additional funding.
CR Arabi YM, 2016, CRIT CARE MED, V44, pE940, DOI 10.1097/CCM.0000000000001854
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cavalcanti AB, 2016, JAMA-J AM MED ASSOC, V315, P1520, DOI 10.1001/jama.2016.0154
   Cavalcanti AB, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-014-0190-0
   Cooke CR, 2008, CRIT CARE, V12, DOI 10.1186/cc7105
   Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230
   Ellis SM, 2012, J CRIT CARE, V27, P556, DOI 10.1016/j.jcrc.2012.04.021
   Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345
   Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC
   Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC
   Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST
   Fichtner F, 2019, RESPIRATION, V98, P357, DOI 10.1159/000502157
   Lanspa MJ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2698-9
   LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906
   Loux SL, 2005, ADV PATIENT SAFETY R
   Madotto F, 2018, INTENS CARE MED, V44, P564, DOI 10.1007/s00134-018-5152-6
   Nassar AP, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2323-y
   Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247
   Neto AS, 2015, CRIT CARE MED, V43, P2155, DOI 10.1097/CCM.0000000000001189
   Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730
   Rackley CR, 2019, CHEST, V156, P783, DOI 10.1016/j.chest.2019.06.007
   Radosevich MA, 2019, J INTENSIVE CARE MED, V34, P550, DOI 10.1177/0885066617746089
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Sakr Y, 2015, CRIT CARE MED, V43, P519, DOI 10.1097/CCM.0000000000000754
   Sasichay-Akkadechanunt T, 2003, J NURS ADMIN, V33, P478, DOI 10.1097/00005110-200309000-00008
   Schaefer MS, 2019, ANESTH ANALG, V129, P129, DOI 10.1213/ANE.0000000000003758
   Neto AS, 2016, LANCET RESP MED, V4, P882, DOI 10.1016/S2213-2600(16)30305-8
   Neto AS, 2014, INTENS CARE MED, V40, P950, DOI 10.1007/s00134-014-3318-4
   Shrestha GS, 2017, LANCET INFECT DIS, V17, P893, DOI 10.1016/S1473-3099(17)30453-X
   Simonis FD, 2018, JAMA-J AM MED ASSOC, V320, P1872, DOI 10.1001/jama.2018.14280
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Stowell A, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-17
   Taniguchi C, 2016, INTENS CARE MED, V42, P1185, DOI 10.1007/s00134-016-4359-7
   Treggiari MM, 2007, AM J RESP CRIT CARE, V176, P685, DOI 10.1164/rccm.200701-165OC
   Umoh NJ, 2008, CRIT CARE MED, V36, P1463, DOI 10.1097/CCM.0b013e31816fc3d0
   Wallace David J, 2017, Crit Care Med, V45, pe67
   Zampieri FG, 2019, INTENS CARE MED, V45, P1599, DOI 10.1007/s00134-019-05790-z
NR 38
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD JUN 1
PY 2020
VL 10
IS 1
AR 68
DI 10.1186/s13613-020-00687-3
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA LU9JI
UT WOS:000538062500001
PM 32488524
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mazeraud, A
   Righy, C
   Bouchereau, E
   Benghanem, S
   Bozza, FA
   Sharshar, T
AF Mazeraud, Aurelien
   Righy, Cassia
   Bouchereau, Eleonore
   Benghanem, Sarah
   Bozza, Fernando Augusto
   Sharshar, Tarek
TI Septic-Associated Encephalopathy: a Comprehensive Review
SO NEUROTHERAPEUTICS
LA English
DT Review
DE Sepsis; neuroinflammation; sepsis-associated encephalopathy; microglia;
   blood-brain barrier; neuroanatomy
ID INTERNATIONAL CONSENSUS DEFINITIONS; TERM COGNITIVE IMPAIRMENT;
   BRAIN-BARRIER BREAKDOWN; INTENSIVE-CARE; MITOCHONDRIAL DYSFUNCTION;
   SICKNESS BEHAVIOR; SEVERE SEPSIS; DELIRIUM; NEURONS; MICROGLIA
AB Septic-associated encephalopathy (SAE) is a key manifestation of sepsis, ranging from delirium to coma and occurring in up to 70% of patients admitted to the ICU. SAE is associated with higher ICU and hospital mortality, and also with poorer long-term outcomes, including cognitive and functional outcomes. The pathophysiology of SAE is complex, and it may involve neurotransmitter dysfunction, inflammatory and ischemic lesions to the brain, microglial activation, and blood-brain barrier dysfunction. Delirium (which is included in the SAE spectrum) is mostly diagnosed with validated scales in the ICU population. There is no established treatment for SAE; benzodiazepines should generally be avoided in this setting. Nonpharmacological prevention and management is key for treating SAE; it includes avoiding oversedation (mainly with benzodiazepines), early mobilization, and sleep promotion.
C1 [Mazeraud, Aurelien; Righy, Cassia; Bouchereau, Eleonore; Sharshar, Tarek] GHU Paris Psychiat & Neurosci, Neurointens Care & Neuroanesthesia Dept, 1 Rue Cabanis, F-75014 Paris, France.
   [Mazeraud, Aurelien; Bouchereau, Eleonore] Hop Europeen Georges Pompidou, Med Intens Care Unit, 20 Rue Leblanc, F-75015 Paris, France.
   [Mazeraud, Aurelien; Bouchereau, Eleonore; Benghanem, Sarah; Sharshar, Tarek] Univ Paris, F-75006 Paris, France.
   [Righy, Cassia] Inst Estadual Cerebro Paul Niemeyer, Rio De Janeiro, Brazil.
   [Benghanem, Sarah] CHU Cochin, Med Intens & Reanimat, Paris, France.
   [Bozza, Fernando Augusto] Inst DOr Pesquisa & Ensino, Rio De Janeiro, Brazil.
RP Sharshar, T (corresponding author), GHU Paris Psychiat & Neurosci, Neurointens Care & Neuroanesthesia Dept, 1 Rue Cabanis, F-75014 Paris, France.; Sharshar, T (corresponding author), Univ Paris, F-75006 Paris, France.
EM tsharshar@gmail.com
RI Shinotsuka, Cassia Righy/H-9181-2013; Bozza, Fernando A/A-2618-2013
OI Shinotsuka, Cassia Righy/0000-0002-9206-9552; Bozza, Fernando
   A/0000-0003-4878-0256
CR Adam N, 2013, EXPERT REV ANTI-INFE, V11, P211, DOI [10.1586/ERI.12.159, 10.1586/eri.12.159]
   Adler Joseph, 2012, Cardiopulm Phys Ther J, V23, P5
   Andreasson A, 2018, J HEALTH PSYCHOL, V23, P1452, DOI 10.1177/1359105316659917
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Annane D, 1999, AM J RESP CRIT CARE, V160, P458, DOI 10.1164/ajrccm.160.2.9810073
   Azabou E, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2104-z
   Azabou E, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0290-5
   Azabou E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139969
   Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123
   Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490
   Bleck TP, 2018, NEW ENGL J MED, V379, P2569, DOI 10.1056/NEJMe1813382
   Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1
   Branton WG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054673
   Brown LS, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00282
   Cai HJ, 2014, NAT NEUROSCI, V17, P1240, DOI 10.1038/nn.3767
   Cain MD, 2019, NEURON, V103, P771, DOI 10.1016/j.neuron.2019.07.015
   Carlson DE, 2007, EXP NEUROL, V205, P485, DOI 10.1016/j.expneurol.2007.03.015
   Cunningham C, 2013, BRAIN BEHAV IMMUN, V28, P1, DOI 10.1016/j.bbi.2012.07.012
   Danielski LG, 2018, MOL NEUROBIOL, V55, P1045, DOI 10.1007/s12035-016-0356-7
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   Darcy CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021185
   Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x
   Demoule A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1865-0
   Ehler J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211184
   Ehler J, 2019, NEUROSCI LETT, V692, P167, DOI 10.1016/j.neulet.2018.11.014
   Ehler J, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1850-7
   Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Finelli PF, 2004, J NEUROL NEUROSUR PS, V75, P1189, DOI 10.1136/jnnp.2003.030833
   Flierl MA, 2009, CRIT CARE, V13, DOI 10.1186/cc7710
   Foreman B, 2016, CLIN NEUROPHYSIOL, V127, P1073, DOI 10.1016/j.clinph.2015.07.018
   FREUND H, 1979, ANN SURG, V190, P571, DOI 10.1097/00000658-197911000-00003
   Gilmore EJ, 2015, INTENS CARE MED, V41, P686, DOI 10.1007/s00134-015-3709-1
   Girard TD, 2018, NEW ENGL J MED, V379, P2506, DOI 10.1056/NEJMoa1808217
   Hatch R, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2223-6
   Hennessy E, 2017, BRAIN BEHAV IMMUN, V59, P233, DOI 10.1016/j.bbi.2016.09.011
   Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450
   Hofer S, 2008, CRIT CARE MED, V36, P404, DOI 10.1097/01.CCM.0B013E31816208B3
   Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6
   Horti AG, 2019, P NATL ACAD SCI USA, V116, P1686, DOI 10.1073/pnas.1812155116
   Hosokawa K, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0674-y
   Howarth C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00103
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94
   Kadoi Y, 1996, J SURG RES, V61, P496, DOI 10.1006/jsre.1996.0153
   Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5
   Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4
   Lund-Sorensen H, 2016, JAMA PSYCHIAT, V73, P912, DOI 10.1001/jamapsychiatry.2016.1594
   Marra A, 2017, CRIT CARE CLIN, V33, P225, DOI 10.1016/j.ccc.2016.12.005
   Mazeraud A, 2018, AM J RESP CRIT CARE, V197, P698, DOI 10.1164/rccm.201712-2593ED
   Mazeraud A, 2016, CLIN CHEST MED, V37, P333, DOI 10.1016/j.ccm.2016.01.013
   McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285
   McCaffrey G, 2012, J INVEST MED, V60, P1131, DOI 10.2310/JIM.0b013e318276de79
   Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872
   Michels M, 2017, J NEUROIMMUNOL, V303, P90, DOI 10.1016/j.jneuroim.2016.12.015
   Moraes CA, 2015, MOL NEUROBIOL, V52, P653, DOI 10.1007/s12035-014-8868-5
   Murray C, 2012, NEUROBIOL AGING, V33, P603, DOI 10.1016/j.neurobiolaging.2010.04.002
   Muscatell KA, 2015, BRAIN BEHAV IMMUN, V43, P46, DOI 10.1016/j.bbi.2014.06.201
   Needham DM, 2016, LANCET RESP MED, V4, P203, DOI 10.1016/S2213-2600(16)00005-9
   Nikayin S, 2016, GEN HOSP PSYCHIAT, V43, P23, DOI 10.1016/j.genhosppsych.2016.08.005
   Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604
   Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Pandharipande PP, 2010, CRIT CARE, V14, DOI 10.1186/cc8916
   Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38
   Peterson JF, 2006, J AM GERIATR SOC, V54, P479, DOI 10.1111/j.1532-5415.2005.00621.x
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Pontes Azevedo Luciano Cesar, 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P214
   Racchiusa S, 2019, NEUROL SCI, V40, P915, DOI 10.1007/s10072-018-3651-4
   Retamal MA, 2007, J NEUROSCI, V27, P13781, DOI 10.1523/JNEUROSCI.2042-07.2007
   Reyes EP, 2012, ADV EXP MED BIOL, V758, P185, DOI 10.1007/978-94-007-4584-1_26
   Righy C, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2489-3
   Riker RR, 2014, NEUROCRIT CARE, V21, P27, DOI 10.1007/s12028-014-0025-5
   Rohaut B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176012
   Rosengarten B, 2012, CRIT CARE, V16, DOI 10.1186/cc11310
   Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z
   Schelling G, 1999, CRIT CARE MED, V27, P2678, DOI 10.1097/00003246-199912000-00012
   Schweighofer Hanna, 2016, Intensive Care Med Exp, V4, P19, DOI 10.1186/s40635-016-0091-4
   Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883
   Serantes R, 2006, J BIOL CHEM, V281, P14632, DOI 10.1074/jbc.M512489200
   Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288
   Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x
   Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4
   Sharshar T, 2002, CRIT CARE MED, V30, P2371, DOI 10.1097/00003246-200210000-00031
   Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012
   Shehabi Y, 2019, NEW ENGL J MED, V380, P2506, DOI 10.1056/NEJMoa1904710
   Siami S, 2010, CRIT CARE MED, V38, P1962, DOI 10.1097/CCM.0b013e3181eb9acf
   Singer BH, 2018, AM J RESP CRIT CARE, V197, P747, DOI 10.1164/rccm.201708-1559OC
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Skelly DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069123
   Sonneville R, 2010, BRAIN PATHOL, V20, P613, DOI 10.1111/j.1750-3639.2009.00355.x
   SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001
   Stare J, 2015, J NEUROSCI, V35, P12188, DOI 10.1523/JNEUROSCI.5420-13.2015
   Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205
   Taccone FS, 2010, NEUROCRIT CARE, V12, P35, DOI 10.1007/s12028-009-9289-6
   Tovote P, 2015, NAT REV NEUROSCI, V16, P317, DOI 10.1038/nrn3945
   Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566
   van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7
   Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406
   YOUNG GB, 1990, CLIN INVEST MED, V13, P297
   YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016
   Zaghloul N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01673
   Zauner C, 2002, CRIT CARE MED, V30, P1136, DOI 10.1097/00003246-200205000-00030
   Zhang QH, 2014, MILITARY MED RES, V1, DOI 10.1186/2054-9369-1-20
   Zhu FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093966
   Zrzavy T, 2019, NEUROPATH APPL NEURO, V45, P278, DOI 10.1111/nan.12502
NR 108
TC 2
Z9 2
U1 4
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1933-7213
EI 1878-7479
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD APR
PY 2020
VL 17
IS 2
SI SI
BP 392
EP 403
DI 10.1007/s13311-020-00862-1
EA MAY 2020
PG 12
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA LW6SR
UT WOS:000530769200001
PM 32378026
DA 2020-12-01
ER

PT J
AU Souza-Dantas, VC
   Dal-Pizzol, F
   Tomasi, CD
   Spector, N
   Soares, M
   Bozza, FA
   Povoa, P
   Salluh, JIF
AF Souza-Dantas, Vicente Ces
   Dal-Pizzol, Felipe
   Tomasi, Cristiane D.
   Spector, Nelson
   Soares, Marcio
   Bozza, Fernando A.
   Povoa, Pedro
   Salluh, Jorge I. F.
TI Identification of distinct clinical phenotypes in mechanically
   ventilated patients with acute brain dysfunction using cluster analysis
SO MEDICINE
LA English
DT Article
DE acute brain dysfunction; cluster analysis; C-reactive protein;
   critically ill patients
ID C-REACTIVE PROTEIN; INTENSIVE-CARE-UNIT; POSTOPERATIVE DELIRIUM;
   PORTUGUESE VERSIONS; SEDATION; RELIABILITY; VALIDITY; ICU; PREDICTION;
   MORTALITY
AB Acute brain dysfunction (ABD) is a frequent and severe syndrome occurring in critically ill patients and early identification of high-risk patients is paramount. In the present analysis, we propose a clinically applicable model for early phenotype identification of ABD at the bedside in mechanically ventilated patients, improving the recognition of patients with prolonged ABD. Prospective cohort with 629 mechanically ventilated patients in two medical-surgical intensive care units at academic centers. We applied cluster analysis to identify phenotypes using clinical and biological data. We then tested the association of phenotypes and its respective clinical outcomes. We performed a validation on a new cohort of patients select on subsequent patients admitted to the participants intensive care units. A model with 3 phenotypes best described the study population. A 4-variable model including medical admission, sepsis diagnosis, simplified acute physiologic score II and basal serum C-reactive protein (CRP) accurately classified each phenotype (area under curve 0.82; 95% CI, 0.79-0.86). Phenotype A had the shorter duration of ABD (median, 1 day), while phenotypes B and C had progressively longer duration of ABD (median, 3 and 6 days, respectively;P < .0001). There was an association between the duration of ABD and the baseline CRP levels and simplified acute physiology score II score (sensitivity and specificity of 80%). To increase the sensitivity of the model, we added CRP kinetics. By day 1, a CRP < 1.0 times the initial level was associated with a shorter duration of ABD (specificity 0.98). A model based on widely available clinical variables could provide phenotypes associated with the duration of ABD. Phenotypes with longer duration of ABD (phenotypes B and C) are characterized by more severe inflammation and by significantly worse clinical outcomes.
C1 [Souza-Dantas, Vicente Ces; Spector, Nelson] Univ Fed Rio de Janeiro, Sch Med, Rua Prof Paulo Rocco 255,Cidade Univ, Rio De Janeiro, Brazil.
   [Dal-Pizzol, Felipe; Tomasi, Cristiane D.] Univ Extremo Sul Catarinense, Lab Fisiopatol Expt, Programa Posgrad Ciencias Saude, Ave Univ, Criciuma, SC, Brazil.
   [Dal-Pizzol, Felipe; Tomasi, Cristiane D.] Sao Jose Hosp, Intens Care Unit, Criciuma, SC, Brazil.
   [Dal-Pizzol, Felipe; Tomasi, Cristiane D.] Sao Jose Hosp, Res Ctr, Rua Coronel Pedro Benedet, Criciuma, SC, Brazil.
   [Tomasi, Cristiane D.] Nucleo Estudos & Pesquisas Integralidade & Saude, Criciuma, SC, Brazil.
   [Tomasi, Cristiane D.] Univ Extremo Sul Catarinense, Programa Posgrad Saude Colet, Ave Univ 1105, Criciuma, SC, Brazil.
   [Soares, Marcio; Bozza, Fernando A.; Salluh, Jorge I. F.] Dor Inst Res & Educ, Rua Diniz Cordeiro 30, Botafogo, Brazil.
   [Soares, Marcio; Salluh, Jorge I. F.] Inst Nacl Canc, Postgrad Program, Praca Cruz Vermelha 23, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Povoa, Pedro] Sao Francisco Xavier Hosp, Ctr Hosp Lisboa Ocident, Polyvalent Intens Care Unit, Estr Forte Alto Duque, Lisbon, Portugal.
   [Povoa, Pedro] Univ Nova Lisboa, NOVA Med Sch, CEDOC, Campo Martires Patria 130, Lisbon, Portugal.
RP Souza-Dantas, VC (corresponding author), Rua AArao Reis 105, BR-20240090 Rio De Janeiro, RJ, Brazil.
EM vicentecsdantas@gmail.com
RI Soares, Marcio/B-3083-2013; Bozza, Fernando A/A-2618-2013
OI Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); FAPESC
FX DRs Salluh and Soares have research grants from CNPq and FAPERJ. DR
   Dal-Pizzol has grants from CNPq and FAPESC.
CR Almeida ICT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085332
   Cerejeira J, 2010, ACTA NEUROPATHOL, V119, P737, DOI 10.1007/s00401-010-0674-1
   Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983
   Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Everitt B.S, 2011, CLUSTER ANAL
   Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1
   Gofton TE, 2012, NAT REV NEUROL, V8, P557, DOI 10.1038/nrneurol.2012.183
   Gunther ML, 2012, CRIT CARE MED, V40, P2022, DOI 10.1097/CCM.0b013e318250acc0
   Gusmao-Flores D, 2011, CLINICS, V66, P1917, DOI 10.1590/S1807-59322011001100011
   Hagen DR, 2015, MOL BIOSYST, V11, P574, DOI 10.1039/c4mb00276h
   Hopkins RO, 2013, CRIT CARE, V17, DOI 10.1186/cc11913
   Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7
   Klein PMC, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6652
   Lagarto L, 2016, INT PSYCHOGERIATR, V28, P1283, DOI 10.1017/S1041610216000302
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lemstra AW, 2008, INT J GERIATR PSYCH, V23, P943, DOI 10.1002/gps.2015
   Macdonald A, 2007, AGE AGEING, V36, P222, DOI 10.1093/ageing/afl121
   McGrane S, 2011, CRIT CARE, V15, DOI 10.1186/cc10070
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Monti MM, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00028
   Nassar AP, 2008, SAO PAULO MED J, V126, P215, DOI 10.1590/S1516-31802008000400003
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Pol RA, 2014, ANN VASC SURG, V28, P1923, DOI 10.1016/j.avsg.2014.07.004
   Povas P, 2005, CLIN INFECT DIS, V40, P1855, DOI 10.1086/430382
   Povoa P, 2005, EUR RESPIR J, V25, P804, DOI 10.1183/09031936.05.00071704
   Sepulveda E, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0878-6
   Serafim RB, 2015, J CRIT CARE, V30, P799, DOI 10.1016/j.jcrc.2015.04.005
   Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC
   Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04
   van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wassenaar A, 2015, INTENS CARE MED, V41, P1048, DOI 10.1007/s00134-015-3777-2
   Zhang ZH, 2014, J CRIT CARE, V29, P88, DOI 10.1016/j.jcrc.2013.09.002
NR 34
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2020
VL 99
IS 18
AR e20041
DI 10.1097/MD.0000000000020041
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO4MV
UT WOS:000551502900047
PM 32358385
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Torrentes-Carvalho, A
   Sanchez-Arcila, JC
   Azamor, T
   Barbosa, LS
   Hottz, ED
   Gandini, M
   Bozza, FA
   da Cunha, RV
   Pinto, LMD
   Damasco, PV
   de Azeredo, EL
AF Torrentes-Carvalho, Amanda
   Sanchez-Arcila, Juan Camilo
   Azamor, Tamiris
   Barbosa, Luciana Santos
   Hottz, Eugenio Damaceno
   Gandini, Mariana
   Bozza, Fernando Augusto
   da Cunha, Rivaldo Venancio
   de Oliveira Pinto, Luzia Maria
   Damasco, Paulo Vieira
   de Azeredo, Elzinandes Leal
TI Apoptosis characterization in mononuclear blood leukocytes of HIV
   patients during dengue acute disease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VIRUS-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; CELL-DEATH;
   ANTIRETROVIRAL THERAPY; INCREASED EXPRESSION; IMMUNE ACTIVATION;
   T-LYMPHOCYTES; INFECTION; PATHWAYS; INHIBITOR
AB Dengue virus (DENV) co-circulation in Brazil represents a challenge for treatment and vaccine development. Despite public health impact, the occurrence of coinfections with other viruses is a common event. Increased T cell activation and altered inflammatory response are found during DENV coinfection with Human Immunodeficiency Virus (HIV) impacting HIV-pathogenesis. Even with Antiretroviral therapy (ART), HIV- treated patients had chronic immune activation and lymphocyte apoptosis. However, apoptotic mechanisms have not been investigated during coinfection with DENV. Our attention was attracted to apoptotic cell markers expressions in PBMCs from DENV and DENV/HIV coinfected patients. We found CD4/CD8 ratio inversion in most coinfected patients. CD4 T and CD8 T-cell subsets from DENV and DENV/HIV groups expressed low levels of anti-apoptotic protein Bcl-2. Furthermore, CD8 CD95 double positive cells frequency expressing low levels of Bcl-2 were significantly higher in these patients. Additionally, the density of Bcl-2 on classical monocytes (CD14(++)CD16(-)) was significantly lower during DENV infection. Upregulation of pro-apoptotic proteins and anti-apoptotic proteins were found in DENV and DENV/HIV, while catalase, an antioxidant protein, was upregulated mainly in DENV/HIV coinfection. These findings provide evidence of apoptosis triggering during DENV/HIV coinfection, which may contribute to knowledge of immunological response during DENV acute infection in HIV-patients treated with ART.
C1 [Torrentes-Carvalho, Amanda] Univ Fed Fluminense UFF, Dept Imunobiol, Inst Biol, Niteroi, RJ, Brazil.
   [Sanchez-Arcila, Juan Camilo; Barbosa, Luciana Santos; de Oliveira Pinto, Luzia Maria; de Azeredo, Elzinandes Leal] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz IOC, Lab Imunol Viral, Rio De Janeiro, Brazil.
   [Azamor, Tamiris] Fundacao Oswaldo Cruz FIOCRUZ, Lab Tecnol Imunol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio Damaceno] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Gandini, Mariana] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz IOC, Lab Microbiol Celular, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz FIOCRUZ, Intituto Nacl Infectol Evandro Chagas INI, Lab Med Intens, Rio De Janeiro, Brazil.
   [da Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul UFMS, Fac Med, Campo Grande, MS, Brazil.
   [Damasco, Paulo Vieira] Univ Fed Estado Rio de Janeiro UNIRIO, Hosp Univ Gafree & Guinle, Rio De Janeiro, Brazil.
   [Damasco, Paulo Vieira] Univ Estadual Rio de Janeiro UERJ, Hosp Pedro Ernesto, Rio De Janeiro, Brazil.
RP de Azeredo, EL (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz IOC, Lab Imunol Viral, Rio De Janeiro, Brazil.
EM elzinandes@ioc.fiocruz.br
OI Bozza, Fernando Augusto/0000-0003-4878-0256; Gandini,
   Mariana/0000-0003-3603-6921
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX The authors thank all the health professionals from Rio de Janeiro and
   Mato Grosso do Sul, especially those working in dengue surveillance and
   those who provided scientific guidance and tecnical assistence. The
   authors gratefully thank Dr<SUP>a</SUP>. Ana Rita Motta Castro for their
   help and assistance with patient recruitment and sample collection.This
   work was supported by grants from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ).
CR Castillo JA, 2018, APOPTOSIS, V23, P576, DOI 10.1007/s10495-018-1488-1
   Castillo JA, 2019, ARCH IMMUNOL THER EX, V67, P27, DOI 10.1007/s00005-018-0525-7
   Arias J, 2014, VIROLOGY, V452, P42, DOI 10.1016/j.virol.2013.12.027
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Azeredo EL, 2010, IMMUNOLOGY, V130, P202, DOI 10.1111/j.1365-2567.2009.03224.x
   Badley AD, 1998, J CLIN INVEST, V102, P79, DOI 10.1172/JCI2691
   Badley AD, 1999, CELL DEATH DIFFER, V6, P420, DOI 10.1038/sj.cdd.4400509
   Boudet F, 1996, J IMMUNOL, V156, P2282
   Bruno G, 2017, AIDS REV, V19, P81
   Chen P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00272
   Cummins NW, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.77
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Donalisio MR, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006889, 10.1590/s1518-8787.2017051006889]
   Ehrhard S, 2008, INFECTION, V36, P120, DOI 10.1007/s15010-008-7368-9
   Freed EO, 2004, TRENDS MICROBIOL, V12, P170, DOI 10.1016/j.tim.2004.02.001
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Hottz ED, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43275-7
   Khoury Z, 2015, AIDS BEHAV, V19, P679, DOI 10.1007/s10461-014-0885-x
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Liao HW, 2010, J MED VIROL, V82, P1392, DOI 10.1002/jmv.21815
   Limjindaporn T, 2007, BIOCHEM BIOPH RES CO, V362, P334, DOI 10.1016/j.bbrc.2007.07.194
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Limonta D, 2014, J MED VIROL, V86, P1437, DOI 10.1002/jmv.23832
   Massanella M, 2013, CYTOM PART A, V83A, P648, DOI 10.1002/cyto.a.22299
   Matsuda T, 2005, J GEN VIROL, V86, P1055, DOI 10.1099/vir.0.80531-0
   Moenkemeyer M, 2008, J MED VIROL, V80, P1933, DOI 10.1002/jmv.21305
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mongkolsapaya J, 2006, J IMMUNOL, V176, P3821, DOI 10.4049/jimmunol.176.6.3821
   Nagata S, 2017, NAT REV IMMUNOL, V17, P333, DOI 10.1038/nri.2016.153
   Pang JX, 2015, AM J TROP MED HYG, V92, P1156, DOI 10.4269/ajtmh.15-0031
   Pereira MF, 2018, BRAZ J INFECT DIS, V22, P245, DOI 10.1016/j.bjid.2018.05.005
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Rizza SA, 2008, MED CHEM, V4, P75, DOI 10.2174/157340608783331443
   Schimmer AD, 2004, CANCER RES, V64, P7183, DOI 10.1158/0008-5472.CAN-04-1918
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sevilya Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02068
   Simonelli C, 2006, J CLIN ONCOL, V24, P209, DOI 10.1200/JCO.2005.04.1178
   Souza PRB, 2007, CLINICS, V62, P579, DOI 10.1590/S1807-59322007000500008
   Suzuki T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007299
   Team R. C., 2018, LANG ENV STAT COMP
   Tehrani HS, 2018, PROG BIOPHYS MOL BIO, V140, P5, DOI 10.1016/j.pbiomolbio.2018.03.001
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Torrentes-Carvalho A, 2016, CLIN IMMUNOL, V164, P95, DOI 10.1016/j.clim.2016.01.005
   Torrentes-Carvalho A, 2014, IMMUNOBIOLOGY, V219, P329, DOI 10.1016/j.imbio.2013.11.002
   Torrentes-Carvalho A, 2009, MEM I OSWALDO CRUZ, V104, P1091, DOI 10.1590/S0074-02762009000800005
   Vasudevan D, 2015, CURR TOP DEV BIOL, V114, P185, DOI 10.1016/bs.ctdb.2015.07.026
   Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X
   Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200
   Warnes G. R., 2015, VARIOUS R PROGRAMMIN
   WHO/TDR, 2009, DENG GUID DIAGN TREA
   Wong ME, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01435
   Yatim N, 2011, IMMUNITY, V35, P478, DOI 10.1016/j.immuni.2011.10.010
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Younas M, 2016, HIV MED, V17, P89, DOI 10.1111/hiv.12310
   Ziegler-Heitbrock L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00423
NR 57
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 14
PY 2020
VL 10
IS 1
AR 6351
DI 10.1038/s41598-020-62776-4
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ND8OT
UT WOS:000562162800029
PM 32286360
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Silva, AYO
   Amorim, EA
   Barbosa-Silva, MC
   Lima, MN
   Oliveira, HA
   Granja, MG
   Oliveira, KS
   Fagundes, PM
   Neris, RLS
   Campos, RMP
   Moraes, CA
   Vallochi, AL
   Rocco, PRM
   Bozza, FA
   Castro-Faria-Neto, HC
   Maron-Gutierrez, T
AF Silva, Adriano Y. O.
   Amorim, Erica A.
   Barbosa-Silva, Maria C.
   Lima, Maiara N.
   Oliveira, Helena A.
   Granja, Marcelo G.
   Oliveira, Karina S.
   Fagundes, Paula M.
   Neris, Romulo L. S.
   Campos, Raquel M. P.
   Moraes, Carolina A.
   Vallochi, Adriana L.
   Rocco, Patricia R. M.
   Bozza, Fernando A.
   Castro-Faria-Neto, Hugo C.
   Maron-Gutierrez, Tatiana
TI Mesenchymal Stromal Cells Protect the Blood-Brain Barrier, Reduce
   Astrogliosis, and Prevent Cognitive and Behavioral Alterations in
   Surviving Septic Mice
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE anxiety; astrocytes; blood-brain barrier; cognition; mesenchymal stromal
   cells; sepsis
ID ELEVATED PLUS-MAZE; MORRIS WATER MAZE; STEM-CELLS; ALZHEIMERS-DISEASE;
   SEPSIS; IMPAIRMENT; NEUROINFLAMMATION; ANXIETY; INFLAMMATION; ASTROCYTES
AB Objectives:
   Survivors of sepsis are frequently left with significant cognitive and behavioral impairments. These complications derive from nonresolving inflammation that persists following hospital discharge. To date, no study has investigated the effects of mesenchymal stromal cell therapy on the blood-brain barrier, astrocyte activation, neuroinflammation, and cognitive and behavioral alterations in experimental sepsis.
   Design:
   Prospective, randomized, controlled experimental study.
   Setting:
   Government-affiliated research laboratory.
   Subjects:
   Male Swiss Webster mice (n = 309).
   Interventions:
   Sepsis was induced by cecal ligation and puncture; sham-operated animals were used as control. All animals received volume resuscitation (1 mL saline/mouse subcutaneously) and antibiotics (meropenem 10 mg/kg intraperitoneally at 6, 24, and 48 hours). Six hours after surgery, mice were treated with mesenchymal stromal cells IV (1 x 10(5) cells in 0.05 mL of saline/mouse) or saline (0.05 mL IV).
   Measurements and Main Results:
   At day 1, clinical score and plasma levels of inflammatory mediators were increased in cecal ligation and puncture mice. Mesenchymal stromal cells did not alter clinical score or survival rate, but reduced levels of systemic interleukin-1 beta, interleukin-6, and monocyte chemoattractant protein-1. At day 15, survivor mice completed a battery of cognitive and behavioral tasks. Cecal ligation and puncture mice exhibited spatial and aversive memory deficits and anxiety-like behavior. These effects may be related to increased blood-brain barrier permeability, with altered tight-junction messenger RNA expression, increased brain levels of inflammatory mediators, and astrogliosis (induced at day 3). Mesenchymal stromal cells mitigated these cognitive and behavioral alterations, as well as reduced blood-brain barrier dysfunction, astrocyte activation, and interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and interleukin-10 levels in vivo. In cultured primary astrocytes stimulated with lipopolysaccharide, conditioned media from mesenchymal stromal cells reduced astrogliosis, interleukin-1 beta, and monocyte chemoattractant protein-1, suggesting a paracrine mechanism of action.
   Conclusions:
   In mice who survived experimental sepsis, mesenchymal stromal cell therapy protected blood-brain barrier integrity, reduced astrogliosis and neuroinflammation, as well as improved cognition and behavior.
C1 [Silva, Adriano Y. O.; Amorim, Erica A.; Barbosa-Silva, Maria C.; Lima, Maiara N.; Oliveira, Helena A.; Granja, Marcelo G.; Oliveira, Karina S.; Fagundes, Paula M.; Moraes, Carolina A.; Vallochi, Adriana L.; Castro-Faria-Neto, Hugo C.; Maron-Gutierrez, Tatiana] Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Immunopharmacol, FIOCRUZ, Rio De Janeiro, Brazil.
   [Neris, Romulo L. S.] Univ Fed Rio de Janeiro, Microbiol Inst, Rio De Janeiro, Brazil.
   [Campos, Raquel M. P.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Neurochem, Rio De Janeiro, Brazil.
   [Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Pulm Invest, Rio De Janeiro, Brazil.
   [Rocco, Patricia R. M.] Natl Inst Sci & Technol Regenerat Med, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Oswaldo Cruz Fdn, Rio De Janeiro, Brazil.
RP Maron-Gutierrez, T (corresponding author), Fundacao Oswaldo Cruz, Oswaldo Cruz Inst, Lab Immunopharmacol, FIOCRUZ, Rio De Janeiro, Brazil.
EM tati.maron@gmail.com
RI Bozza, Fernando A/A-2618-2013; Vallochi, Adriana/W-6405-2018; Oliveira,
   Helena/AAR-6862-2020
OI Bozza, Fernando A/0000-0003-4878-0256; Barbosa-Silva, Maria
   Carolina/0000-0001-6842-9207
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Rio de Janeiro State Research Supporting Foundation;
   Coordination for the Improvement of Higher Education Personnel; National
   Institute of Science and Technology for Regenerative Medicine/CNPq
FX Supported, in part, by grant from the Brazilian Council for Scientific
   and Technological Development (CNPq), Rio de Janeiro State Research
   Supporting Foundation, Coordination for the Improvement of Higher
   Education Personnel, and National Institute of Science and Technology
   for Regenerative Medicine/CNPq.
CR Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575
   Anderson ST, 2015, BRAIN BEHAV IMMUN, V43, P98, DOI 10.1016/j.bbi.2014.07.007
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Bandera A, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00187
   BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0
   Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96
   Boivin MJ, 2007, PEDIATRICS, V119, pE360, DOI 10.1542/peds.2006-2027
   Cao W, 2015, IMMUNOL LETT, V168, P147, DOI 10.1016/j.imlet.2015.06.003
   Chao YX, 2009, J NEUROIMMUNOL, V216, P39, DOI 10.1016/j.jneuroim.2009.09.003
   Cruz FF, 2015, STEM CELL TRANSL MED, V4, P1302, DOI 10.5966/sctm.2014-0280
   D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4
   Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3
   Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Gharibi T, 2015, CELL IMMUNOL, V293, P113, DOI 10.1016/j.cellimm.2015.01.002
   Greene C, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0123-z
   Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012
   Guha SK, 2014, BRAIN BEHAV IMMUN, V42, P123, DOI 10.1016/j.bbi.2014.06.009
   Heming N, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1643-z
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1
   Jackson JC, 2009, SOUTH MED J, V102, P1150, DOI 10.1097/SMJ.0b013e3181b6a592
   Kihara M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-273
   Kim KS, 2013, NEUROBIOL AGING, V34, P2408, DOI 10.1016/j.neurobiolaging.2013.03.029
   Kuperberg SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00597
   Kwak KA, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6392986
   Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006
   Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23
   Maron-Gutierrez T, 2014, CURR OPIN CRIT CARE, V20, P122, DOI 10.1097/MCC.0000000000000061
   Maron-Gutierrez T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt334
   Maron-Gutierrez T, 2013, CRIT CARE MED, V41, pE319, DOI 10.1097/CCM.0b013e31828a663e
   Mayr FB, 2014, VIRULENCE, V5, P4, DOI 10.4161/viru.27372
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Miyaji T, 2003, KIDNEY INT, V64, P1620, DOI 10.1046/j.1523-1755.2003.00268.x
   Moraes CA, 2015, MOL NEUROBIOL, V52, P653, DOI 10.1007/s12035-014-8868-5
   Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038
   Nakazaki M, 2019, NEUROSCIENCE, V408, P361, DOI 10.1016/j.neuroscience.2019.04.018
   Nishioku T, 2009, CELL MOL NEUROBIOL, V29, P309, DOI 10.1007/s10571-008-9322-x
   Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7
   Plumb J, 2002, BRAIN PATHOL, V12, P154
   Prescott HC, 2018, JAMA-J AM MED ASSOC, V319, P62, DOI 10.1001/jama.2017.17687
   Reis PA, 2017, BRAIN BEHAV IMMUN, V60, P293, DOI 10.1016/j.bbi.2016.11.006
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Romanitan MO, 2007, J CELL MOL MED, V11, P569, DOI 10.1111/j.1582-4934.2007.00047.x
   Schouten J, 2011, AIDS, V25, P561, DOI 10.1097/QAD.0b013e3283437f9a
   Shiotsuki H, 2010, J NEUROSCI METH, V189, P180, DOI 10.1016/j.jneumeth.2010.03.026
   Shoji H, 2014, JOVE-J VIS EXP, DOI 10.3791/50871
   Shulyatnikova T, 2019, NEUROCHEM RES
   Suzuki S, 2015, NEUROSCI LETT, V584, P276, DOI 10.1016/j.neulet.2014.10.039
   Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44
   Weycker D, 2003, CRIT CARE MED, V31, P2316, DOI 10.1097/01.CCM.0000085178.80226.0B
   Yang H, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt227
   Young GB, 2014, ENCY NEUROL SCI, V8, P143
   Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012
   Zhang Y, 2018, EXP THER MED, V16, P2375, DOI 10.3892/etm.2018.6487
NR 56
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD APR
PY 2020
VL 48
IS 4
BP E290
EP E298
DI 10.1097/CCM.0000000000004219
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA LG3UU
UT WOS:000528030700004
PM 32205619
DA 2020-12-01
ER

PT J
AU Pecego, AC
   Amancio, RT
   Costa, DM
   Bozza, FA
   Siqueira, MM
   Oliveira, ML
   Cerbino-Neto, J
   Japiassu, A
AF Pecego, A. C.
   Amancio, R. T.
   Costa, D. M.
   Bozza, F. A.
   Siqueira, M. M.
   Oliveira, M. L.
   Cerbino-Neto, J.
   Japiassu, A.
TI Etiology, clinical, and epidemiological characteristics of severe
   respiratory infection in people living with HIV
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE Human immunodeficiency virus; viral disease; bacterial disease; viral
   disease
ID COMMUNITY-ACQUIRED PNEUMONIA; RIO-DE-JANEIRO; SOUTH-AFRICA; RHINOVIRUS
   INFECTIONS; PANDEMIC INFLUENZA; VIRUSES; HOSPITALIZATION; ILLNESS;
   TUBERCULOSIS; POPULATION
AB People living with HIV (PLWH) are more prone to severe respiratory infections. We used the severe acute respiratory infection (SARI) definition to describe the etiology, clinical, and epidemiological characteristics in this population. This was a prospective observational study including PLWH hospitalized with fever and cough. Those with symptom onset up to 10 days were classified as severe acute respiratory infection and 11-30 days as non-severe acute respiratory infection. Blood, urine samples and nasopharyngeal swabs were collected. Data were extracted from patient charts during their hospital stay. Forty-nine patients were included, median CD4 cell count: 80 cells/mm(3), median time since HIV diagnosis and hospital admission: 84 months and 80% were antiretroviral therapy exposed. Twenty-seven patients were classified as SARI. Etiology was identified in 69%, 47% were polymicrobial. Respiratory virus (9 SARI vs. 13 non-SARI), bacteria (5 SARI vs. 4 non-SARI), Mycobacterium tuberculosis (6 SARI group vs. 7 non-SARI group), Pneumocystis jirovecii (4 SARI vs. 1 non-SARI), Cryptococcus neoformans (1 SARI vs. 3 non-SARI), and influenza A (1 SARI vs. 2 non-SARI). Dyspnea was statistically more prevalent in SARI (78% vs. 36%, p = 0.011) but the risk of death was higher in the non-SARI (4% vs. 36%, p = 0.0067). In the severely immunocompromised PLWH, severe acute respiratory infection can be caused by multiple pathogens and codetection is a common feature.
C1 [Pecego, A. C.; Amancio, R. T.; Costa, D. M.; Bozza, F. A.; Japiassu, A.] Fundacao Oswaldo Cruz Fiocruz, Inst Nacl Infectol, Lab Med Intens, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Inst DOr Pesquisa & Ensino, Rio De Janeiro, Brazil.
   [Siqueira, M. M.; Oliveira, M. L.] Fiocruz MS, Inst Oswaldo Cruz, IOC, Lab Virus Resp, Rio De Janeiro, Brazil.
   [Cerbino-Neto, J.] Lab Pesquisa Imunizacao & Vigilancia Saude, Rio De Janeiro, Brazil.
RP Pecego, AC (corresponding author), Fiocruz MS, INI, Ave Brasil 4365, Rio De Janeiro, RJ, Brazil.
EM anacarlapecego@gmail.com
RI Bozza, Fernando A/A-2618-2013; Cerbino Neto, Jose/P-3713-2018
OI Bozza, Fernando A/0000-0003-4878-0256; Cerbino Neto,
   Jose/0000-0001-9254-917X
CR Almeida A, 2016, INT J STD AIDS, V27, P998, DOI 10.1177/0956462415605232
   Asner SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099392
   Bantar C, NEUMONIA AGUDA ADQUI, P30
   Cebey-Lopez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152481
   Choi SH, 2012, AM J RESP CRIT CARE, V186, P325, DOI 10.1164/rccm.201112-2240OC
   Coelho LE, 2017, BRAZ J INFECT DIS, V21, P190, DOI 10.1016/j.bjid.2016.10.007
   Cohen C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117716
   Cohen C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118884
   Crotty MP, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002332
   Damasio GAC, 2015, J MED VIROL, V87, P1456, DOI 10.1002/jmv.24210
   Fica A, 2015, BRAZ J INFECT DIS, V19, P118, DOI 10.1016/j.bjid.2014.10.003
   Garbino J, 2008, AIDS, V22, P701, DOI 10.1097/QAD.0b013e3282f470ac
   Groome MJ, 2015, J CLIN VIROL, V69, P125, DOI 10.1016/j.jcv.2015.06.089
   Hull MW, 2008, CHEST, V134, P1287, DOI 10.1378/chest.08-0364
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Johansson N, 2010, CLIN INFECT DIS, V50, P202, DOI 10.1086/648678
   Karhu J, 2014, CLIN INFECT DIS, V59, P62, DOI 10.1093/cid/ciu237
   Kim HC, 2016, J MED VIROL, V88, P2092, DOI 10.1002/jmv.24577
   Kwan CK, 2011, CLIN MICROBIOL REV, V24, P351, DOI 10.1128/CMR.00042-10
   Lieberman D, 2010, CHEST, V138, P811, DOI 10.1378/chest.09-2717
   Lopez-Aldeguer J, 2012, ENFERM INFEC MICR CL, V30, P608, DOI 10.1016/j.eimc.2012.02.007
   Lynfield R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101785
   Martinez E, 2011, HIV MED, V12, P236, DOI 10.1111/j.1468-1293.2010.00905.x
   Mayaud C, 2002, EUR RESPIR J, V20, p28S, DOI 10.1183/09031936.02.00400602
   Monto AS, 2002, CLIN THER, V24, P1987, DOI 10.1016/S0149-2918(02)80093-5
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   Njouom R, 2012, J INFECT DIS, V206, pS29, DOI 10.1093/infdis/jis573
   Ormsby CE, 2011, AIDS, V25, P435, DOI 10.1097/QAD.0b013e3283434844
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003132
   Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464
   Peters PJ, 2011, CLIN INFECT DIS, V52, pS183, DOI 10.1093/cid/ciq036
   Pretorius MA, 2016, J CLIN VIROL, V75, P21, DOI 10.1016/j.jcv.2015.12.004
   Qu JX, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0808-0
   Ruuskanen O, 2014, CLIN INFECT DIS, V59, P71, DOI 10.1093/cid/ciu242
   Saraceni V, 2014, JAIDS-J ACQ IMM DEF, V67, P98, DOI 10.1097/QAI.0000000000000247
   Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR
   Sheth AN, 2011, CLIN INFECT DIS, V52, P219, DOI 10.1093/cid/ciq110
   Sogaard OS, 2008, CLIN INFECT DIS, V47, P1345, DOI 10.1086/592692
   Tempia S, 2015, EMERG INFECT DIS, V21, P600, DOI 10.3201/eid2104.141033
   Tempia S, 2014, CLIN INFECT DIS, V58, P1241, DOI 10.1093/cid/ciu095
   Walaza S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0746-x
   Wansaula Z, 2016, INFLUENZA OTHER RESP, V10, P161, DOI 10.1111/irv.12360
   World Health Organization, 2014, WHO GLOB EP SURV STA
   Yone EWP, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-46
NR 44
TC 0
Z9 0
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD FEB
PY 2020
VL 31
IS 2
BP 100
EP 108
AR 0956462419882587
DI 10.1177/0956462419882587
EA JAN 2020
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA KM5XN
UT WOS:000509209700001
PM 31969059
OA Other Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rosa, RG
   Falavigna, M
   Robinson, CC
   Sanchez, EC
   Kochhann, R
   Schneider, D
   Sganzerla, D
   Dietrich, C
   Barbosa, MG
   de Souza, D
   Rech, GS
   dos Santos, RD
   da Silva, AP
   Santos, MM
   Dal Lago, P
   Sharshar, T
   Bozza, FA
   Teixeira, C
AF Rosa, Regis G.
   Falavigna, Maicon
   Robinson, Caroline C.
   Sanchez, Evelin C.
   Kochhann, Renata
   Schneider, Daniel
   Sganzerla, Daniel
   Dietrich, Camila
   Barbosa, Mirceli G.
   de Souza, Denise
   Rech, Gabriela S.
   dos Santos, Rosa da R.
   da Silva, Alice P.
   Santos, Mariana M.
   Dal Lago, Pedro
   Sharshar, Tarek
   Bozza, Fernando A.
   Teixeira, Cassiano
CA Quality Life After ICU Study Grp I
   BRICNet
TI Early and Late Mortality Following Discharge From the ICU: A Multicenter
   Prospective Cohort Study*
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE cause of death; critical care; critical illness; follow-up studies;
   mortality; survivors
ID CAMPAIGN INTERNATIONAL GUIDELINES; LONG-TERM SURVIVAL; INTENSIVE-CARE;
   CRITICAL ILLNESS; SEPSIS; IMMUNOSUPPRESSION; MANAGEMENT; OUTCOMES
AB Objectives: To identify the frequency, causes, and risk factors of early and late mortality among general adult patients discharged from ICUs. Design: Multicenter, prospective cohort study. Setting: ICUs of 10 tertiary hospitals in Brazil. Patients: One-thousand five-hundred fifty-four adult ICU survivors with an ICU stay greater than 72 hours for medical and emergency surgical admissions or greater than 120 hours for elective surgical admissions. Interventions: None. Measurements and Main Results: The main outcomes were early (30 d) and late (31 to 365 d) mortality. Causes of death were extracted from death certificates and medical records. Twelve-month cumulative mortality was 28.2% (439 deaths). The frequency of early mortality was 7.9% (123 deaths), and the frequency of late mortality was 22.3% (316 deaths). Infections were the leading cause of death in both early (47.2%) and late (36.4%) periods. Multivariable analysis identified age greater than or equal to 65 years (hazard ratio, 1.65; p = 0.01), pre-ICU high comorbidity (hazard ratio, 1.59; p = 0.02), pre-ICU physical dependence (hazard ratio, 2.29; p < 0.001), risk of death at ICU admission (hazard ratio per 1% increase, 1.008; p = 0.03), ICU-acquired infections (hazard ratio, 2.25; p < 0.001), and ICU readmission (hazard ratio, 3.76; p < 0.001) as risk factors for early mortality. Age greater than or equal to 65 years (hazard ratio, 1.30; p = 0.03), pre-ICU high comorbidity (hazard ratio, 2.28; p < 0.001), pre-ICU physical dependence (hazard ratio, 2.00; p < 0.001), risk of death at ICU admission (hazard ratio per 1% increase, 1.010; p < 0.001), and ICU readmission (hazard ratios, 4.10, 4.17, and 1.82 for death between 31 and 60 days, 61 and 90 days, and greater than 90 days after ICU discharge, respectively; p < 0.001 for all comparisons) were associated with late mortality. Conclusions: Infections are the main cause of death after ICU discharge. Older age, pre-ICU comorbidities, pre-ICU physical dependence, severity of illness at ICU admission, and ICU readmission are associated with increased risk of early and late mortality, while ICU-acquired infections are associated with increased risk of early mortality.
C1 [Rosa, Regis G.; Teixeira, Cassiano] HMV, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Rosa, Regis G.; Falavigna, Maicon; Robinson, Caroline C.; Sanchez, Evelin C.; Kochhann, Renata; Schneider, Daniel; Sganzerla, Daniel; Dietrich, Camila; Barbosa, Mirceli G.; de Souza, Denise; Rech, Gabriela S.; dos Santos, Rosa da R.; da Silva, Alice P.; Santos, Mariana M.] HMV, Res Projects Off, Porto Alegre, RS, Brazil.
   [Rosa, Regis G.; Dal Lago, Pedro; Teixeira, Cassiano] UFCSPA, Postgrad Program Rehabil Sci, Porto Alegre, RS, Brazil.
   [Falavigna, Maicon] Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Inst Hlth Technol Assessment, Porto Alegre, RS, Brazil.
   [Falavigna, Maicon] Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, Brazil.
   [Sharshar, Tarek] Univ Versailles St Quentin En Yvelines, Raymond Poincare Hosp, AP HP, Gen Intens Care, Paris, France.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, Dept Crit Care, Rio De Janeiro, Brazil.
   Hosp Moinhos de Vento, Crit Care Dept, Porto Alegre, RS, Brazil.
   Hosp Clin Porto Alegre, Crit Care Dept, Porto Alegre, RS, Brazil.
   Hosp Santa Clara, Crit Care Dept, Porto Alegre, RS, Brazil.
   Pavilhao Pereira Filho, Crit Care Dept, Porto Alegre, RS, Brazil.
   Hosp Ernesto Dornelles, Crit Care Dept, Porto Alegre, RS, Brazil.
   Hosp Nossa Senhora Conceicao, Crit Care Dept, Porto Alegre, RS, Brazil.
   Hosp Urgencias Goiania, Crit Care Dept, Goiania, Go, Brazil.
   Hosp Reg Baixo Amazonas, Crit Care Dept, Santarem, Brazil.
   Hosp Geral Cleriston Andrade, Crit Care Dept, Feira De Santana, BA, Brazil.
   Hosp Coracao, Crit Care Dept, Sao Paulo, Brazil.
RP Rosa, RG (corresponding author), HMV, Intens Care Unit, Porto Alegre, RS, Brazil.; Rosa, RG (corresponding author), HMV, Res Projects Off, Porto Alegre, RS, Brazil.; Rosa, RG (corresponding author), UFCSPA, Postgrad Program Rehabil Sci, Porto Alegre, RS, Brazil.
EM regis.rosa@hmv.org.br
RI Rosa, Regis Goulart/P-6422-2019; Bozza, Fernando A/A-2618-2013; Dal
   Lago, Pedro/AAM-9136-2020
OI Bozza, Fernando A/0000-0003-4878-0256; Dal Lago,
   Pedro/0000-0001-9907-7689
FU Brazilian Ministry of Health through the Brazilian Unified Health System
   Institutional Development Program
FX The present study was funded by the Brazilian Ministry of Health through
   the Brazilian Unified Health System Institutional Development Program.
   Drs. Rosa's, Falavigna's, Robinson's, Sanchez's, Kochhann's,
   Schneider's, Sganzerla's, Dietrich's, Barbosa's, de Souza's, Rech's, and
   dos Santos's institutions received funding from Brazilian Ministry of
   Health through the Brazilian Unified Health System Institutional
   Development Program. Dr Falavigna is manager partner of HTAnalyze, a
   consulting and training firm in health technology assessment topics. The
   remaining authors have disclosed that they do not have any potential
   conflicts of interest.
CR Asehnoune K, 2012, ANESTHESIOLOGY, V117, P411, DOI 10.1097/ALN.0b013e31825f018d
   Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829
   BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
   Brazilian Ministry of Health, 2019, INF DEP BRAZ UN HLTH
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Coopersmith CM, 2018, INTENS CARE MED, V44, P1400, DOI 10.1007/s00134-018-5175-z
   Cuthbertson BH, 2016, AM J RESP CRIT CARE, V194, P132, DOI 10.1164/rccm.201602-0257ED
   Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af
   Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012
   European Centre for Disease Prevention and Control, 2015, EUR SURV HEALTHC ASS
   Garland A, 2014, INTENS CARE MED, V40, P1097, DOI 10.1007/s00134-014-3348-y
   Gayat E, 2018, CRIT CARE, V22, DOI 10.1186/s13054-017-1922-8
   Hicks PR, 2010, CRIT CARE RESUSC, V12, P78
   Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552
   Iwashyna TJ, 2016, LANCET RESP MED, V4, P566, DOI 10.1016/S2213-2600(16)30098-4
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lone NI, 2016, AM J RESP CRIT CARE, V194, P198, DOI 10.1164/rccm.201511-2234OC
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Mayr VD, 2006, CRIT CARE, V10, DOI 10.1186/cc5086
   Niskanen M, 1996, CRIT CARE MED, V24, P1962, DOI 10.1097/00003246-199612000-00006
   Pene F, 2016, INTENS CARE MED, V42, P1051, DOI 10.1007/s00134-015-4161-y
   Prescott HC, 2018, JAMA-J AM MED ASSOC, V319, P62, DOI 10.1001/jama.2017.17687
   Prescott HC, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2375
   R Development Core Team, 2016, R LANG ENV STAT COMP
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ranzani OT, 2013, CRIT CARE, V17, DOI 10.1186/cc13024
   Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255
   Robinson Caroline Cabral, 2018, Rev. bras. ter. intensiva, V30, P405, DOI [10.5935/0103-507X.20180063, 10.5935/0103-507x.20180063]
   Rosa RG, 2019, J CRIT CARE, V52, P115, DOI 10.1016/j.jcrc.2019.04.014
   Stelfox HT, 2018, JAMA INTERN MED, V178, P1390, DOI 10.1001/jamainternmed.2018.3675
   Szakmany A, 2019, CRIT CARE MED, V47, P15, DOI 10.1097/CCM.0000000000003424
   Teerawattanapong N, 2017, CLIN INFECT DIS, V64, pS51, DOI 10.1093/cid/cix112
   Timsit JF, 2019, INTENS CARE MED, V45, P172, DOI 10.1007/s00134-019-05520-5
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36
   Vossenberg-Postma SR, 2015, INTENS CARE MED, V41, P2031, DOI 10.1007/s00134-015-4029-1
   Williams TA, 2005, INTENS CARE MED, V31, P1306, DOI 10.1007/s00134-005-2744-8
   Wright JC, 2003, ANAESTHESIA, V58, P637, DOI 10.1046/j.1365-2044.2003.03205.x
   Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216
NR 39
TC 1
Z9 1
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JAN
PY 2020
VL 48
IS 1
BP 64
EP 72
DI 10.1097/CCM.0000000000004024
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA JW0SY
UT WOS:000502770900017
PM 31609775
DA 2020-12-01
ER

PT J
AU Nguyen, YL
   Hejblum, G
   Guidet, B
   Capuzzo, M
   Rowan, K
   Flaaten, H
   Valentin, A
   Kahn, JM
   Ferrer, R
   Rhodes, A
   Moreno, R
   Marshall, J
   Fowler, R
   Tavola, M
   O'Leary, M
   Webb, S
   Perner, A
   Thomspon, T
   Walsh, T
   Gordon, B
   Ferrer, R
   Artigas, A
   Sevransky, J
   Martin, G
   Brochard, L
   Richard, JC
   Mercat, A
   Csomos, A
   Van de Voort, P
   Bozza, F
   Salluh, J
   Bin, D
   Gusmao, D
   Lefrant, JY
   Allaouchiche, B
   Constantin, JM
   Leone, M
   Jaber, S
   Jean-Francois, T
   Wrigge, H
   Reinhart, K
AF Nguyen, Yen-Lan
   Hejblum, Gilles
   Guidet, Bertrand
   Capuzzo, Maurizia
   Rowan, Kathy
   Flaaten, Hans
   Valentin, Andreas
   Kahn, Jeremy M.
   Ferrer, R.
   Rhodes, Andrew
   Moreno, Rui
   Marshall, John
   Fowler, Robert
   Tavola, Mario
   O'Leary, Michael
   Webb, Steve
   Perner, Anders
   Thomspon, Taylor
   Walsh, Timothy
   Gordon, Bernard
   Ferrer, Ricard
   Artigas, Antonio
   Sevransky, Jonathan
   Martin, Greg
   Brochard, Laurent
   Richard, Jean-Christophe
   Mercat, Alain
   Csomos, Akos
   Van de Voort, Peter
   Bozza, Fernando
   Salluh, Jorge
   Bin, Du
   Gusmao, Dimitri
   Lefrant, Jean-Yves
   Allaouchiche, Bernard
   Constantin, Jean-Michel
   Leone, Marc
   Jaber, Samir
   Jean-Francois, Timsit
   Wrigge, Hermann
   Reinhart, Konrad
CA ESICM
TI Structural features shared by ICUs belonging to research networks an
   international survey. "Critical care research network survey"
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Critical care; Health services research; Organizations
ID CLINICAL-RESEARCH; ENROLLMENT; MORTALITY; DELIVERY
AB Purpose: Major acute care research is conducted within critical care research networks (CCRN). Our aims were to describe CCRN and participating ICUs.
   Methods: A cross-sectional survey was conducted among all CCRNs belonging to the International Forum of Acute Care Trialists. A network questionnaire was sent to CCRN directors and an ICU e-questionnaire was sent to participating ICUS.
   Results: Survey was answered by 366 ICUs from 17 CCRNs (median response rate 21% [12-38]). CCRNs have different organizations (ownership, memberships, funding). The number of studies conducted, patients included and publications varied a lot across CCRNs. The collaboration with other research networks or health authorities was very frequent (n=13, 76%). Most ICUs (n=315; 86%) are located in large teaching hospitals in high income countries with a mean volume of 968 (842-1102 (95% CI)) annual admissions. The recognition at the academic level (n=133; 70%), the collaboration with experts (n=284; 85%), and improving practices (n=286; 86%) are incentives reported to belong to a CCRN.
   Conclusions: Despite different organizations, CCRN share similar ventures including the value of improving quality of critical care delivery. Participating ICUs share several structural and managerial patterns. These observations enlighten the importance of CCRN to enhance quality of critical care delivery. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Nguyen, Yen-Lan] Sorbonne Univ, Hop Cochin, AP HP,Inst Pierre Louis Epidemiol & Sante Publ, INSERM UMR S 1138,Serv Anesthesie Reanimat Chirur, Paris, France.
   [Hejblum, Gilles] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM UMR S 1136, Paris, France.
   [Guidet, Bertrand] Sorbonne Univ, Hop St Antoine, AP HP,Inst Pierre Louis Epidemiol & Sante Publ, Serv Reanimat Med,INSERM UMR S 1136, Paris, France.
RP Nguyen, YL (corresponding author), Paris Descartes Univ, Dept Anaesthesia & Intens Care Med, Cochin Univ Hosp, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
EM yen-lan.nguyen@aphp.fr; gilles.hejblum@inserm.fr;
   bertrand.guidet@aphp.fr
RI Bozza, Fernando A/A-2618-2013; Rhodes, Andrew/G-4265-2011; Leone,
   Marc/P-4835-2016
OI Bozza, Fernando A/0000-0003-4878-0256; Rhodes,
   Andrew/0000-0002-8737-574X; Leone, Marc/0000-0002-3097-758X; Hejblum,
   Gilles/0000-0003-0127-1964
CR Arabi YM, 2016, CRIT CARE MED, V44, pE940, DOI 10.1097/CCM.0000000000001854
   Capuzzo M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0551-8
   Cook D, 2002, CRIT CARE MED, V30, P1636, DOI 10.1097/00003246-200207000-00039
   Cook DJ, 2008, CRIT CARE MED, V36, P2100, DOI 10.1097/CCM.0b013e31817c00b0
   Diaz JV, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2413
   Estenssoro E, 2017, CRIT CARE MED, V45, P1325, DOI 10.1097/CCM.0000000000002413
   Jones Daryl A, 2007, Crit Care Resusc, V9, P198
   Kagan Jonathan M, 2009, Health Res Policy Syst, V7, P12, DOI 10.1186/1478-4505-7-12
   Maharaj R, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0973-y
   Marshall JC, 2010, LANCET, V375, P11, DOI 10.1016/S0140-6736(09)61792-X
   Marshall JC, 2009, CRIT CARE MED, V37, pS165, DOI 10.1097/CCM.0b013e3181921079
   Nguyen YL, 2010, AM J RESP CRIT CARE, V181, P1164, DOI 10.1164/rccm.200909-1441CP
   Reade MC, 2017, CRIT CARE RESUSC, V19, P110
   Sakr Y, 2015, CRIT CARE MED, V43, P519, DOI 10.1097/CCM.0000000000000754
   Shih TH, 2008, FIELD METHOD, V20, P249, DOI 10.1177/1525822X08317085
   Simonsen L, 2018, LANCET GLOB HEALTH, V6, pE956, DOI 10.1016/S2214-109X(18)30304-8
   Vukoja M, 2018, CURR OPIN CRIT CARE, V24, P421, DOI 10.1097/MCC.0000000000000528
   Wallace DJ, 2012, NEW ENGL J MED, V366, P2093, DOI 10.1056/NEJMsa1201918
   Wilcox ME, 2013, CRIT CARE MED, V41, P2253, DOI 10.1097/CCM.0b013e318292313a
NR 19
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD DEC
PY 2019
VL 54
BP 99
EP 104
DI 10.1016/j.jcrc.2019.05.018
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA JT4BE
UT WOS:000500935700019
PM 31404722
DA 2020-12-01
ER

PT J
AU Zampieri, FG
   Salluh, JIF
   Azevedo, LCP
   Kahn, JM
   Damiani, LP
   Borges, LP
   Viana, WN
   Costa, R
   Corr?a, TD
   Araya, DES
   Maia, MO
   Ferez, MA
   Carvalho, AGR
   Knibel, MF
   Melo, UO
   Santino, MS
   Lisboa, T
   Caser, EB
   Besen, BAMP
   Bozza, FA
   Angus, DC
   Soares, M
AF Zampieri, Fernando G.
   Salluh, Jorge I. F.
   Azevedo, Luciano C. P.
   Kahn, Jeremy M.
   Damiani, Lucas P.
   Borges, Lunna P.
   Viana, William N.
   Costa, Roberto
   Correa, Thiago D.
   Araya, Dieter E. S.
   Maia, Marcelo O.
   Ferez, Marcus A.
   Carvalho, Alexandre G. R.
   Knibel, Marcos F.
   Melo, Ulisses O.
   Santino, Marcelo S.
   Lisboa, Thiago
   Caser, Eliana B.
   Besen, Bruno A. M. P.
   Bozza, Fernando A.
   Angus, Derek C.
   Soares, Marcio
CA ORCHESTRA Study Investigators
TI ICU staffing feature phenotypes and their relationship with patients'
   outcomes: an unsupervised machine learning analysis
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Intensive care unit; Outcomes; Cluster analysis; Nurse autonomy;
   Staffing features; ICU organization
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; STRUCTURAL EMPOWERMENT;
   HOSPITAL MORTALITY; ORGANIZATIONAL CHARACTERISTICS; MORAL DISTRESS;
   RESOURCE USE; IMPROVEMENT; ADMISSION; NURSES
AB Purpose To study whether ICU staffing features are associated with improved hospital mortality, ICU length of stay (LOS) and duration of mechanical ventilation (MV) using cluster analysis directed by machine learning. Methods The following variables were included in the analysis: average bed to nurse, physiotherapist and physician ratios, presence of 24/7 board-certified intensivists and dedicated pharmacists in the ICU, and nurse and physiotherapist autonomy scores. Clusters were defined using the partition around medoids method. We assessed the association between clusters and hospital mortality using logistic regression and with ICU LOS and MV duration using competing risk regression. Results Analysis included data from 129,680 patients admitted to 93 ICUs (2014-2015). Three clusters were identified. The features distinguishing between the clusters were: the presence of board-certified intensivists in the ICU 24/7 (present in Cluster 3), dedicated pharmacists (present in Clusters 2 and 3) and the extent of nurse autonomy (which increased from Clusters 1 to 3). The patients in Cluster 3 exhibited the best outcomes, with lower adjusted hospital mortality [odds ratio 0.92 (95% confidence interval (CI), 0.87-0.98)], shorter ICU LOS [subhazard ratio (SHR) for patients surviving to ICU discharge 1.24 (95% CI 1.22-1.26)] and shorter durations of MV [SHR for undergoing extubation 1.61(95% CI 1.54-1.69)]. Cluster 1 had the worst outcomes. Conclusion Patients treated in ICUs combining 24/7 expert intensivist coverage, a dedicated pharmacist and nurses with greater autonomy had the best outcomes. All of these features represent achievable targets that should be considered by policy makers with an interest in promoting equal and optimal ICU care.
C1 [Zampieri, Fernando G.; Salluh, Jorge I. F.; Bozza, Fernando A.; Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, Grad Program Translat Med, Rua Diniz Cordeiro,30 Botafogo, BR-22281100 Rio De Janeiro, Brazil.
   [Zampieri, Fernando G.; Damiani, Lucas P.] HCor Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   [Salluh, Jorge I. F.; Borges, Lunna P.] Epimed Solut, Dept Res & Dev, Rio De Janeiro, Brazil.
   [Azevedo, Luciano C. P.] Hosp Sirio Libanes, ICU, Sao Paulo, Brazil.
   [Kahn, Jeremy M.; Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA.
   [Kahn, Jeremy M.; Angus, Derek C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA.
   [Viana, William N.] Hosp Copa DOr, ICU, Rio De Janeiro, Brazil.
   [Costa, Roberto] Hosp Quinta DOr, ICU, Rio De Janeiro, Brazil.
   [Correa, Thiago D.] Hosp Israelita Albert Einstein, Adult ICU, Sao Paulo, Brazil.
   [Araya, Dieter E. S.] Hosp Santa Paula, ICU, Sao Paulo, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia Rede DOr Sao Luiz DF, ICU, Brasilia, DF, Brazil.
   [Ferez, Marcus A.] Hosp Sao Francisco, ICU, Ribeirao Preto, Brazil.
   [Carvalho, Alexandre G. R.] UDI Hosp, ICU, Sao Luis, Brazil.
   [Knibel, Marcos F.] Hosp Sao Lucas, ICU, Rio De Janeiro, Brazil.
   [Melo, Ulisses O.] Hosp Estadual Alberto Torres, ICU, Sao Goncalo, Brazil.
   [Santino, Marcelo S.] Hosp Barra DOr, ICU, Rio De Janeiro, Brazil.
   [Lisboa, Thiago] Hosp Santa Rita, Santa Casa Misericordia Porto Alegre, ICU, Porto Alegre, RS, Brazil.
   [Caser, Eliana B.] Hosp Unimed Vitoria, ICU, Vitoria, ES, Brazil.
   [Besen, Bruno A. M. P.] Hosp Luz, ICU, Vila Mariana, SP, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Grad Program Translat Med, Rua Diniz Cordeiro,30 Botafogo, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Soares, Marcio/B-3083-2013; Angus, Derek C/E-9671-2012; Besen, Bruno
   Adler Maccagnan Pinheiro/I-2241-2019; Bozza, Fernando A/A-2618-2013;
   Lisboa, Thiago/W-2973-2019; Azevedo, Luciano CP/H-2652-2012; Zampieri,
   Fernando/K-3305-2014
OI Soares, Marcio/0000-0003-2503-6088; Besen, Bruno Adler Maccagnan
   Pinheiro/0000-0002-3516-9696; Bozza, Fernando A/0000-0003-4878-0256;
   Lisboa, Thiago/0000-0003-4306-2212; Azevedo, Luciano
   CP/0000-0001-6759-3910; Zampieri, Fernando/0000-0001-9315-6386
CR Al Ashry HS, 2016, J INTENSIVE CARE MED, V31, P252, DOI 10.1177/0885066614533910
   Armellino D, 2010, J NURS MANAGE, V18, P796, DOI 10.1111/j.1365-2834.2010.01130.x
   Cavalcanti AB, 2016, JAMA-J AM MED ASSOC, V315, P1480, DOI 10.1001/jama.2016.3463
   Fagoni N, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0354-1
   Fitzpatrick JJ, 2010, AM J CRIT CARE, V19, P218, DOI 10.4037/ajcc2010442
   Ganz FD, 2013, J ADV NURS, V69, P415, DOI 10.1111/j.1365-2648.2012.06020.x
   Gershengorn HB, 2017, JAMA INTERN MED, V177, P388, DOI 10.1001/jamainternmed.2016.8457
   Gray B., 2014, CMPRSK SUBDISTRIBUTI, V2, P2
   Hauck A, 2011, J NURS MANAGE, V19, P269, DOI 10.1111/j.1365-2834.2011.01205.x
   Hirzallah FM, 2019, NURS CRIT CARE, V24, P89, DOI 10.1111/nicc.12404
   Kim MM, 2010, ARCH INTERN MED, V170, P369, DOI 10.1001/archinternmed.2009.521
   Krapohl G, 2010, AM J CRIT CARE, V19, P490, DOI 10.4037/ajcc2010406
   Larson GE, 2018, AUST CRIT CARE, V31, P31, DOI 10.1016/j.aucc.2017.02.001
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Neuraz A, 2015, CRIT CARE MED, V43, P1587, DOI 10.1097/CCM.0000000000001015
   Orinovsky I, 2018, CRIT CARE NURSE, V38, P38, DOI 10.4037/ccn2018433
   Papathanassoglou EDE, 2012, AM J CRIT CARE, V21, pE41, DOI 10.4037/ajcc2012205
   Radosevich MA, 2017, J INTENSIVE CARE MED, V1, p885066617746089
   Rose L, 2007, AM J CRIT CARE, V16, P434
   Sakr Y, 2015, CRIT CARE MED, V43, P519, DOI 10.1097/CCM.0000000000000754
   Sevransky JE, 2015, CRIT CARE MED, V43, P2076, DOI 10.1097/CCM.0000000000001157
   Soares M, 2016, J CLIN ONCOL, V34, P3315, DOI 10.1200/JCO.2016.66.9549
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   von Elm E, 2007, B WORLD HEALTH ORGAN, V85, P867, DOI 10.2471/BLT.07.045120
   Wilcox ME, 2013, CRIT CARE MED, V41, P2253, DOI 10.1097/CCM.0b013e318292313a
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
   Zampieri Fernando Godinho, 2017, Rev. bras. ter. intensiva, V29, P418, DOI [10.5935/0103-507x.20170062, 10.5935/0103-507X.20170062]
NR 29
TC 6
Z9 6
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD NOV
PY 2019
VL 45
IS 11
BP 1599
EP 1607
DI 10.1007/s00134-019-05790-z
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA JG4IK
UT WOS:000492037600009
PM 31595349
DA 2020-12-01
ER

PT J
AU Dantas, LF
   Dalmas, B
   Andrade, RM
   Hamacher, S
   Bozza, FA
AF Dantas, L. F.
   Dalmas, B.
   Andrade, R. M.
   Hamacher, S.
   Bozza, F. A.
TI Predicting acquisition of carbapenem-resistant Gram-negative pathogens
   in intensive care units
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Article
DE Carbapenem resistance; Multi-drug resistance; Gram-negative;
   Healthcare-associated infection; Predictive models; Intensive care units
ID RISK-FACTORS; PSEUDOMONAS-AERUGINOSA; NOSOCOMIAL COLONIZATION;
   ACINETOBACTER-BAUMANNII; INFECTIONS; PATIENT; PREVALENCE; MORTALITY;
   BACTERIA; OUTCOMES
AB Background: Infections by multidrug-resistant Gram-negative (MDRGN) bacteria are among the greatest contemporary health concerns, especially in intensive care units (ICUs), and may be associated with increased hospitalization time, morbidity, costs, and mortality.
   Aim: The study aimed to predict carbapenem-resistant MDRGN acquisition in ICUs, to determine its risk factors, and to assess the impact of this acquisition on mortality rate.
   Methods: A matched case-control study was performed in patients admitted to the ICU at a large Brazilian hospital over a five-year period. Cases were defined as patients who acquired carbapenem-resistant MDRGN bacteria during hospitalization. Controls were defined as patients who had no detection of carbapenem-resistant MDRGN bacteria. Cases were matched to controls according to the admission period. Risk factors were identified by multiple logistic regression using a stepwise selection method.
   Findings: In total, 343 cases and 1029 controls were analysed. The 30-day mortality rate for subjects with ICU-associated carbapenem-resistant MDRGN was 37.6%. Five variables were identified as statistically significant and more relevant for the acquisition of multidrug-resistant strains: increased Simplified Acute Physiology Score 3, patients with severe chronic obstructive pulmonary disease and exposure to haemodialysis catheter, central venous catheter, or mechanical ventilation. Models developed displayed good results with an accuracy of similar to 90%. Patients who acquired MDRGN were 2.72 times more likely to die than non-MDRGN acquisition patients.
   Conclusion: Finding risk factors and developing predictive models may benefit patients through early detection and by controlling the spread of MDR. The presence of mechanical ventilation and central venous catheter were the main risk factors demonstrated, and their use requires special attention. (C) 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
C1 [Dantas, L. F.; Hamacher, S.] Pontifical Catholic Univ Rio de Janeiro, Ind Engn Dept, Rio De Janeiro, RJ, Brazil.
   [Dalmas, B.] Univ Clermont Auvergne, Ctr CIS, CNRS, Mines St Etienne,UMR LIMOS 6158, St Etienne, France.
   [Andrade, R. M.] Copa DOr Hosp, Rio De Janeiro, RJ, Brazil.
   [Andrade, R. M.] Fed Univ State Rio de Janeiro, Dept Gen Med, Rio De Janeiro, RJ, Brazil.
   [Bozza, F. A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, RJ, Brazil.
   [Bozza, F. A.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas INI, Rio De Janeiro, RJ, Brazil.
RP Bozza, FA (corresponding author), Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI hamacher, silvio/C-3325-2013; Dalmas, Benjamin/AAP-3899-2020; Dantas,
   Leila Figueiredo/U-5407-2019; Bozza, Fernando A/A-2618-2013
OI hamacher, silvio/0000-0002-3980-0342; Bozza, Fernando
   A/0000-0003-4878-0256; Dantas, Leila/0000-0001-8910-0961
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [169049/2017-5, 306802/2015-5, 403863/2016-3, 310523/2016-8];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [PDSE 88881.190042/2018-01, 001]; Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Pontificia
   Universidade Catolica do Rio de Janeiro
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) (grant numbers 169049/2017-5 to L.F.D.,
   306802/2015-5 and 403863/2016-3 to S.H., 310523/2016-8 to F.A.B.); the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) -
   PDSE 88881.190042/2018-01 and Finance Code 001; the Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ); and the Pontificia
   Universidade Catolica do Rio de Janeiro.
CR Aloush V, 2006, ANTIMICROB AGENTS CH, V50, P43, DOI 10.1128/AAC.50.1.43-48.2006
   Braga IA, 2018, J HOSP INFECT, V99, P318, DOI 10.1016/j.jhin.2018.03.003
   Cardoso T, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1304-2
   Centers for Disease Control and Prevention, 2019, NAT HEALTHC SAF NETW
   Chang YT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020029
   Chiang WC, 2007, AM J EMERG MED, V25, P597, DOI 10.1016/j.ajem.2006.11.024
   Clinical and Laboratory Standards Institute CLSI, 2017, M100S27 CLSI
   Defez C, 2004, J HOSP INFECT, V57, P209, DOI 10.1016/j.jhin.2004.03.022
   Ehrentraut C, 2018, HEALTH INFORM J, V24, P24, DOI 10.1177/1460458216656471
   Escolano S, 2000, STAT MED, V19, P3465, DOI 10.1002/1097-0258(20001230)19:24&lt;3465::AID-SIM658&gt;3.0.CO;2-6
   Falagas ME, 2006, J HOSP INFECT, V64, P7, DOI 10.1016/j.jhin.2006.04.015
   Falagas ME, 2008, INT J ANTIMICROB AG, V32, P450, DOI 10.1016/j.ijantimicag.2008.05.016
   Ferreira E, 2017, AM J INFECT CONTROL, V45, pE103, DOI 10.1016/j.ajic.2017.03.036
   Goodman KE, 2016, CLIN INFECT DIS, V63, P896, DOI 10.1093/cid/ciw425
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   James G., 2013, INTRO STAT LEARNING
   Jarrell AS, 2018, J CRIT CARE, V43, P321, DOI 10.1016/j.jcrc.2017.10.035
   Kollef MH, 2001, ANN INTERN MED, V134, P298, DOI 10.7326/0003-4819-134-4-200102200-00014
   Luna CM, 2014, CRIT CARE RES PRACT, DOI 10.1155/2014/480463
   Lye DC, 2012, CLIN MICROBIOL INFEC, V18, P502, DOI 10.1111/j.1469-0691.2011.03606.x
   MacVane SH, 2017, J INTENSIVE CARE MED, V32, P25, DOI 10.1177/0885066615619895
   Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x
   Papp-Wallace KM, 2011, ANTIMICROB AGENTS CH, V55, P4943, DOI 10.1128/AAC.00296-11
   Patel SJ, 2014, AM J INFECT CONTROL, V42, P626, DOI 10.1016/j.ajic.2014.01.027
   Rubio FG, 2013, BRAZ J INFECT DIS, V17, P480, DOI 10.1016/j.bjid.2012.12.004
   Safdar N, 2002, ANN INTERN MED, V136, P834, DOI 10.7326/0003-4819-136-11-200206040-00013
   van Duin D, 2016, INFECT DIS CLIN N AM, V30, P377, DOI 10.1016/j.idc.2016.02.004
   Vardakas KZ, 2013, J INFECTION, V66, P401, DOI 10.1016/j.jinf.2012.10.028
   Vasudevan A, 2013, PREV MED, V57, pS70, DOI 10.1016/j.ypmed.2012.12.003
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754
   Willmann M, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0650-9
   World Health Organization, 2017, GLOB PRIOR LIST ANT
NR 32
TC 3
Z9 4
U1 1
U2 8
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD OCT
PY 2019
VL 103
IS 2
BP 121
EP 127
DI 10.1016/j.jhin.2019.04.013
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA IZ3XZ
UT WOS:000487020200002
PM 31039381
DA 2020-12-01
ER

PT J
AU Goncalves, B
   Kurtz, P
   Turon, R
   Santos, T
   Prazeres, M
   Righy, C
   Bozza, FA
AF Goncalves, Bruno
   Kurtz, Pedro
   Turon, Ricardo
   Santos, Thayana
   Prazeres, Marco
   Righy, Cassia
   Bozza, Fernando Augusto
TI Incidence and impact of sepsis on long-term outcomes after subarachnoid
   hemorrhage: a prospective observational study
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Subarachnoid hemorrhage; Sepsis; Infection; Critical care outcomes
ID SERUM PROCALCITONIN; SEPTIC SHOCK; VASOSPASM; THERAPY; SCALE; AGE
AB Background Aneurysmal subarachnoid hemorrhage (SAH) is an acute cerebrovascular disease associated with high mortality and long-term functional impairment among survivors. Systemic inflammatory responses after acute injury and nosocomial infections are frequent complications, making the management of these patients challenging. Here, we hypothesized that sepsis might be associated with early and long-term mortality and functional outcomes. Our objective was to define the incidence of sepsis, diagnosed prospectively with the Sepsis-3 criteria, and to determine its impact on mortality and functional outcomes of patients with SAH. Methods We prospectively included all adult patients with aneurysmal SAH admitted to the intensive care unit (ICU) of a reference center between April 2016 and May 2018. Daily clinical and laboratory follow-up data were analyzed during the first 14 days, with data collected on sepsis according to the Sepsis-3 criteria. The main outcome was the functional outcome using the Modified Rankin Scale (mRS), which was assessed at hospital discharge and 3, 6 and 12 months post-discharge. Results In total, 149 patients were enrolled. The incidence of sepsis was 28%. Multivariable logistic regression analysis revealed that death or functional dependence (defined as an mRS score of 4 to 6) at hospital discharge was independently associated with sepsis (OR 3.4, 95% CI 1.16-9.96, p = 0.026) even after controlling for World Federation of Neurological Surgeons (WFNS) Scale (OR 4.66, 95% CI 1.69-12.88, p = 0.003), hydrocephalus (OR 4.55, 95% CI 1.61-12.85, p = 0.004) and DCI (OR 3.86, 95% CI 1.39-10.74, p = 0.01). Long-term follow-up mortality rates were significantly different in the septic and nonseptic groups (log-rank test p < 0.0001). The mortality rate of septic patients was 52.5%, and that of nonseptic patients was 16%. Conclusion Sepsis plays a significant role in the outcomes of patients with SAH, affecting both mortality and long-term functional outcomes. Combining high-level neurocritical care management of neurological complications and the optimal diagnosis and management of sepsis may effectively reduce secondary brain injury and improve patients' outcomes after SAH.
C1 [Goncalves, Bruno; Kurtz, Pedro; Turon, Ricardo; Santos, Thayana; Prazeres, Marco; Righy, Cassia] Inst Estadual Cerebro Paulo Niemeyer, Rua Rezende 156, BR-20230026 Rio De Janeiro, RJ, Brazil.
   [Goncalves, Bruno; Righy, Cassia; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Med Intens, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando Augusto] DOr Inst Res & Educ IDOR, R Diniz Cordeiro 30, Rio De Janeiro, Brazil.
RP Righy, C (corresponding author), Inst Estadual Cerebro Paulo Niemeyer, Rua Rezende 156, BR-20230026 Rio De Janeiro, RJ, Brazil.; Righy, C; Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Med Intens, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.; Bozza, FA (corresponding author), DOr Inst Res & Educ IDOR, R Diniz Cordeiro 30, Rio De Janeiro, Brazil.
EM brunogs@gmail.com; cassiarighy@gmail.com; bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013; Shinotsuka, Cassia Righy/H-9181-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (BP1C,
   CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (CNE,
   FAPERJ); Programa Print-Capes
FX FAB is a scholar from the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (BP1C, CNPq) and the Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (CNE, FAPERJ). We thank the
   Programa Print-Capes for financial support.
CR Abulhasan YB, 2018, WORLD NEUROSURG, V115, pE393, DOI 10.1016/j.wneu.2018.04.061
   Annane D, 2015, LANCET RESP MED, V3, P61, DOI 10.1016/S2213-2600(14)70246-2
   Baggio JAO, 2014, CEREBROVASC DIS, V38, P297, DOI 10.1159/000367646
   Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2
   Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4
   DRAKE CG, 1988, J NEUROSURG, V68, P985
   Festic E, 2014, NEUROCRIT CARE, V20, P375, DOI 10.1007/s12028-014-9960-4
   Flynn Liam, 2015, F1000Res, V4, DOI 10.12688/f1000research.6635.1
   Francoeur CL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1447-6
   Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA
   Goncalves B, 2018, WORLD NEUROSURG, V115, pE292, DOI 10.1016/j.wneu.2018.04.037
   Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490
   Machado FR, 2017, LANCET INFECT DIS, V17, P1180, DOI 10.1016/S1473-3099(17)30322-5
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402
   Okazaki T, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0297-5
   Rass V, 2018, CRIT CARE MED, V46, pE1152, DOI 10.1097/CCM.0000000000003429
   Righy C, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0291-4
   Rowan KM, 2017, NEW ENGL J MED, V376, P2223, DOI 10.1056/NEJMoa1701380
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Taufique Z, 2016, NEUROSURGERY, V78, P256, DOI 10.1227/NEU.0000000000001042
   TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862
   Tseng MY, 2010, J NEUROSURG, V112, P1235, DOI 10.3171/2009.10.JNS09954
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
NR 30
TC 1
Z9 1
U1 1
U2 4
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD AUG 20
PY 2019
VL 9
IS 1
AR 94
DI 10.1186/s13613-019-0562-3
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA IT3QJ
UT WOS:000482769000001
PM 31432283
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Zampieri, FG
   Aguiar, FJ
   Bozza, FA
   Salluh, JIF
   Soares, M
AF Zampieri, Fernando G.
   Aguiar, Fernanda J.
   Bozza, Fernando A.
   Salluh, Jorge I. F.
   Soares, Marcio
CA ORCHESTRA Study Investigators
TI Modulators of systemic inflammatory response syndrome presence in
   patients admitted to intensive care units with acute infection: a
   Bayesian network approach
SO INTENSIVE CARE MEDICINE
LA English
DT Letter
C1 [Zampieri, Fernando G.] HCor Hosp Coracao, Res Inst, Rua Abilio Soares 250,12th Floor, Sao Paulo, Brazil.
   [Zampieri, Fernando G.] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
   [Aguiar, Fernanda J.] Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.; Soares, Marcio] DOr, Inst Res & Educ, Rio De Janeiro, Brazil.
RP Zampieri, FG (corresponding author), HCor Hosp Coracao, Res Inst, Rua Abilio Soares 250,12th Floor, Sao Paulo, Brazil.
EM fgzampieri@gmail.com
RI Bozza, Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013; dantas,
   vicente c souza/L-2648-2013; Zampieri, Fernando/K-3305-2014
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Zampieri, Fernando/0000-0001-9315-6386
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); D'Or Institute for
   Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq), Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ) and by
   departmental funds from the D'Or Institute for Research and Education.
CR Scutari M, 2010, J STAT SOFTW, V35, P1, DOI 10.18637/jss.v035.i03
   Textor J, 2016, INT J EPIDEMIOL, V45, P1887, DOI 10.1093/ije/dyw341
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wester AL, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-346
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
NR 5
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD AUG
PY 2019
VL 45
IS 8
BP 1156
EP 1158
DI 10.1007/s00134-019-05595-0
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA IM4ME
UT WOS:000477968000022
PM 30868180
DA 2020-12-01
ER

PT J
AU Rosa, RG
   Falavigna, M
   da Silva, DB
   Sganzerla, D
   Santos, MMS
   Kochhann, R
   de Moura, RM
   Eugenio, CS
   Haack, TDR
   Barbosa, MG
   Robinson, CC
   Schneider, D
   de Oliveira, DM
   Jeffman, RW
   Cavalcanti, AB
   Machado, FR
   Azevedo, LCP
   Salluh, JIF
   Pellegrini, JAS
   Moraes, RB
   Foernges, RB
   Torelly, AP
   Ayres, LD
   Duarte, PAD
   Lovato, WJ
   Sampaio, PHS
   de Oliveira, LC
   Paranhos, JLD
   Dantas, AD
   de Brito, PIPGG
   Paulo, EAP
   Gallindo, MAC
   Pilau, J
   Valentim, HM
   Teles, JMM
   Nobre, V
   Birriel, DC
   Castro, LCE
   Specht, AM
   Medeiros, GS
   Tonietto, TF
   Mesquita, EC
   da Silva, NB
   Korte, JE
   Hammes, LS
   Giannini, A
   Bozza, FA
   Teixeira, C
   Siqueira, IDF
   de Albuquerque, GMA
   Monteiro, EL
   Volpati, NV
   Leao, TMZ
   Leite, LRA
   Estevam, JD
   Moreira, FAD
   Torres, MCD
   Costa, LS
   da Silva, CC
   Oliveira, KE
   Resutto, AD
   da Cruz, FMN
   Martins, AMD
   Melo, OW
   Ferreira, PHP
   de Oliveira, DC
   Freitas, KS
   Oliveira, ED
   de Melo, JVM
   Serra, MGD
   Casaes, DF
   Silva, ACA
   Santana, RMR
   Dantas, MAD
   Amaral, A
   Martins, AD
   Menezes, AP
   Padua, LSCC
   Castilho, MAM
   Silva, JR
   Braz, CKA
   de Carvalho, LM
   Oliveira, JD
   Pereira, CDMHM
   de Souza, R
   Paiva, ACD
   Ataide, TBLS
   Meireles, AD
   Santos, LJD
   Coelho, VCL
   de Oliveira, DC
   Wierman, IGD
   Ferreira, MJS
   Costa, ADC
   de Lima, RP
   da Silva, IM
   do Nascimento, IM
   Pereira, AMM
   Valentim, RLD
   Oliveira, KMDS
   Serrano, MDL
   Nobre, AMD
   Gomes, IV
   Gomes, CBD
   Leopoldino, MKT
   Maior, ADXS
   Bezerra, LM
   Mendes, CL
   Leite, AC
   de Barros, MAA
   Becker, D
   Schmidt, RC
   Lorencini, LAD
   Horochoski, AR
   Heidemann, TBD
   Waldow, LF
   Zaponi, RD
   Hoshino, GY
   Jorge, AC
   Porto, IRP
   Manzi, CRA
   Paiva, MD
   Chaves, MF
   Nogueira, DQ
   de Oliveira, KR
   Souza, MLBD
   Prates, RDG
   Xavier, SB
   Prestes, RM
   de Almeida, LSS
   Brito, FEV
   Lima, MM
   Alves, FML
   Santos, TD
   Silva, CMDDE
   Batista, MMD
   Sodre, AD
   Villela, CL
   Entrago, LAP
   da Silva, OMB
   Barcellos, TM
   Magalhas, PMMD
   Monteiro, JAD
   do Nascimento, ACL
   Miguel, LC
   Karnopp, C
   Bonatto, P
   Gomez, JAT
   Novakowski, CR
   dos Reis, HL
   Rutzen, W
   Bastos, RD
   Teixeira, CB
   Cargnelutti, V
   dos Santos, CD
   Fraporti, JD
   Foscarini, PT
   Tallamini, EZ
   Hochegger, T
   Schmitz, TDS
   Prieb, RGG
   da Silva, AL
   Forni, AA
   Carvalho, APM
   Ferreira, GG
   Pires, LGS
   dos Santos, MRP
   dos Santos, PJP
   Rodrigues, EM
   de Mello, AF
   Hohenreuther, R
   Susin, R
   Cremonese, RV
   Castro, PS
   Hoff, FC
   Silveira, LD
   Martins, EC
   Pizzato, HP
   Prestes, AO
   da Rosa, FS
   Beck, AD
   Lincho, CS
   Lazzari, RC
   Barilli, SLS
   Nedel, WL
   Netto, HS
   Dalpra, WVL
   Pettine, J
   dos Santos, MC
   Leivas, AFG
   Dobrinsky, L
   Carvalho, AS
   Rodrigues, RV
   de Souza, RR
   Brandenburg, K
   Hadrich, M
   de Souza, AS
   Fachini, C
   Tregnago, R
   Braga, CF
   Giacomazzi, J
   da Costa, S
   de Souza, DM
   da Silva, EG
   da Silva, LO
   Xis, CV
   Caldeira, M
   de Aguiar, RS
   Mohr, FE
   Souza, KD
   Arruda, MC
   Cerantola, RB
   de Carvalho, JB
   Sprioli, MA
   Perez, JD
   Gomes, TM
   Werneck, VA
   de Vasconcelos, R
   Dassi, DP
   Neves, RT
   Farran, JA
AF Rosa, Regis Goulart
   Falavigna, Maicon
   da Silva, Daiana Barbosa
   Sganzerla, Daniel
   Siqueira Santos, Mariana Martins
   Kochhann, Renata
   de Moura, Rafaela Moraes
   Eugenio, Claudia Severgnini
   Ribeiro Haack, Tarissa da Silva
   Barbosa, Mirceli Goulart
   Robinson, Caroline Cabral
   Schneider, Daniel
   de Oliveira, Debora Mariani
   Jeffman, Rodrigo Wiltgen
   Cavalcanti, Alexandre Biasi
   Machado, Flavia Ribeiro
   Pontes Azevedo, Luciano Cesar
   Figueira Salluh, Jorge Ibrain
   Santos Pellegrini, Jose Augusto
   Moraes, Rafael Barberena
   Foernges, Rafael Botelho
   Torelly, Andre Peretti
   Ayres, Lizandra de Oliveira
   Delfino Duarte, Pericles Almeida
   Lovato, Wilson Jose
   Santana Sampaio, Patrick Harrison
   de Oliveira Junior, Lucio Couto
   da Rocha Paranhos, Jorge Luiz
   Dantas, Alessandro da Silva
   Gouveia Gomes de Brito, Pollyanna Iracema Peixoto
   Peixoto Paulo, Eliane Aparecida
   Cavalcanti Gallindo, Marcos Antonio
   Pilau, Janaina
   Valentim, Helen Martins
   Meira Teles, Jose Mario
   Nobre, Vandack
   Birriel, Daniella Cunha
   Correa e Castro, Livia
   Specht, Andreia Martins
   Medeiros, Gregory Saraiva
   Tonietto, Tulio Frederico
   Mesquita, Emersom Cicilini
   da Silva, Nilton Brandao
   Korte, Jeffrey E.
   Hammes, Luciano Serpa
   Giannini, Alberto
   Bozza, Fernando Augusto
   Teixeira, Cassiano
   Ferraz Siqueira, Iris de Lima
   Angelim de Albuquerque, Gigliane Maria
   Monteiro, Edna Lopes
   Volpati, Natasha Varjao
   Zerbini Leao, Tatiana Mendes
   Arana Leite, Lucia Regina
   Estevam, Jullienne de Albuquerque
   da Silva Moreira, Fabiana Andrea
   de Abreu Torres, Maria Cleide
   Costa, Larisse Simoes
   da Silva, Cristiane Caetano
   Oliveira, Kalil Emmanuel
   Resutto, Alessandra de Sousa
   Nascimento da Cruz, Francisca Maria
   Do Carmo Martins, Arlecy Moraes
   Melo, Oriana Wilkens
   Panelli Ferreira, Paulo Henrique
   de Oliveira, Daniela Cunha
   Freitas, Katia Santana
   Oliveira, Eduardo da Silva
   Moraes de Melo, Joao Victor
   da Silva Serra, Mauricio Gomes
   Casaes, Deise Freitas
   Azevedo Silva, Ananda Catharina
   Rios Santana, Rosa Maria
   dos Santos Dantas, Maria Aparecida
   Amaral, Alexandre
   Martins, Aline Dias
   Menezes, Ana Paula
   Costa Correia Padua, Lilian Siqueira
   Mendes Castilho Junior, Marco Antonio
   Silva, Janaynna Rodrigues
   Aparecida Braz, Carla Keit
   de Carvalho, Luciana Mendonca
   Oliveira, Julia de Paula
   Helt Mantuano Pereira, Christiane de Freitas Mourao
   de Souza, Ronan
   de Oliveira Paiva, Ana Carolina
   Lana Silveira Ataide, Thiago Braganca
   Meireles, Adilson de Carvalho
   de Oliveira Santos, Leonardo Jose
   Lima Coelho, Valeria Cristina
   de Oliveira, Delmar Camelo
   da Silva Wierman, Iany Grinezia
   Sousa Ferreira, Marden Junio
   Cardoso Costa, Alline de Aguiar
   de Lima, Rodrigo Pedroso
   da Silva, Ilticiana Martins
   do Nascimento, Igor Mendonca
   Meireles Pereira, Alana Maria
   de Souza Valentim, Rosilene Linhares
   Duarte Silva Oliveira, Karla Maria
   Lima Serrano, Maria de Fatima
   Dantas Nobre, Amanda Manuella
   Gomes, Iago Vieira
   da Silva Gomes, Cristiana Barbosa
   Tenorio Leopoldino, Milena Kessia
   Xavier Souto Maior, Andrezza dos Santos
   Bezerra, Lucrecia Maria
   Mendes, Ciro Leite
   Leite, Adriana Coutinho
   Aires de Barros, Marcia Abath
   Becker, Delmiro
   Schmidt, Raysa Cristina
   Daniel Lorencini, Lucia Aparecida
   Horochoski, Audrey Regina
   da Silva Heidemann, Tatiane Borges
   Waldow, Loide Ferreira
   Zaponi, Renata de Souza
   Hoshino, Giseli Yumi
   Jorge, Amaury Cezar
   Pedreschi Porto, Itamar Regazzo
   Alcantara Manzi, Claudia Raquel
   Paiva Junior, Marcal Durval
   Chaves, Marcelo Fiuza
   Nogueira, Deyse Queiroz
   de Oliveira, Katia Regina
   Brasil de Lima Souza, Maria Luciana
   Gomes Prates, Renata de Carvalho
   Xavier, Saulo Bezerra
   Prestes, Rejane Martins
   Santos de Almeida, Lais Sousa
   Viana Brito, Francisco Eduardo
   Lima, Murilo Moura
   Lima Alves, Francisco Magno
   Santos, Tagora do Lago
   de Castro Dias e Silva, Carla Maria
   da Silva Batista, Martha Maria
   Sodre, Alexander de Oliveira
   Villela, Cid Leite
   Pereira Entrago, Leticia Alves
   Barros da Silva, Osvaldo Marques
   Barcellos, Thiago Matos
   Melo de Oliveira Magalhas, Patricia Manuella
   de Anchieta Monteiro, Jose Andre
   Lima do Nascimento, Amanda Cristina
   Miguel, Luciana Caccavo
   Karnopp, Carolina
   Bonatto, Patricia
   Trindade Gomez, Juana Aracy
   Novakowski, Cristiane Rolim
   dos Reis, Helton Lemos
   Rutzen, William
   Bastos, Ricardo da Silveira
   Teixeira, Clebio Barreto
   Cargnelutti, Vanessa
   dos Santos, Cassiele Daiane
   Fraporti, Juliane Disegna
   Foscarini, Priscila Tonial
   Tallamini, Elsa Zanette
   Hochegger, Tais
   Donato Schmitz, Thais Dos Santos
   Gomes Prieb, Rita Gigliola
   da Silva, Aloma Luz
   Forni, Amanda Andrade
   Melo Carvalho, Ana Paula
   Ferreira, Giovana Getelina
   Simoes Pires, Leticia Gorski
   Pereira dos Santos, Maria Renata
   Pereira dos Santos, Paula Jordana
   Rodrigues Filho, Edison Moraes
   de Mello, Alexandre Formighieri
   Hohenreuther, Raquel
   Susin, Ruth
   Cremonese, Rafael Viegas
   Castro, Priscylla Souza
   Hoff, Fabricia Cristina
   Silveira, Lilian da Fe
   Martins, Eduarda Cristina
   Pizzato, Higia Pires
   Prestes, Adriana Oliveira
   da Rosa, Fabio Silva
   Beck, Andrea Diez
   Lincho, Carla Silva
   Lazzari, Raquel Cristina
   Santin Barilli, Sofia Louise
   Nedel, Wagner Luis
   Netto, Henrique Saltz
   Lissa Dalpra, William Victor
   Pettine, Jose
   dos Santos, Moreno Calcagnotto
   Gallas Leivas, Ana Flivia
   Dobrinsky, Lourenco
   Carvalho, Andreia Schubert
   Rodrigues, Roberta Veleda
   de Souza, Roberto Ritter
   Brandenburg, Katiuscia
   Hadrich, Martha
   de Souza, Alldren Silva
   Fachini, Caroline
   Tregnago, Rogerio
   Braga, Carla Flores
   Giacomazzi, Juliana
   da Costa, Samanta
   de Souza, Danieli Madruga
   da Silva, Elisiane Gouveia
   da Silva, Luana Oliveira
   Xis, Clarisa Vargas
   Caldeira Filho, Milton
   de Aguiar, Raquel Souza
   Mohr, Fabiana Efting
   Souza, Kethe de Oliveira
   Arruda, Micheli Coral
   Cerantola, Rodrigo Barbosa
   de Carvalho, Julia Batista
   Sprioli, Maria Aline
   Perez, Janaina de Oliveira
   Gomes, Tania Mara
   Werneck, Vinicius Avellar
   de Vasconcelos, Rosianne
   Dassi, Daniele Penha
   Neves, Rafael Trevizoli
   Farran, Jorge Alcantara
CA ICU Visits Study Grp Investigators
   Brazilian Res Intensive Care
TI Effect of Flexible Family Visitation on Delirium Among Patients in the
   Intensive Care Unit The ICU Visits Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID POLICIES; GUIDELINES
AB Importance The effects of intensive care unit (ICU) visiting hours remain uncertain.
   Objective To determine whether a flexible family visitation policy in the ICU reduces the incidence of delirium.
   Design, Setting and Participants Cluster-crossover randomized clinical trial involving patients, family members, and clinicians from 36 adult ICUs with restricted visiting hours (<4.5 hours per day) in Brazil. Participants were recruited from April 2017 to June 2018, with follow-up until July 2018.
   Interventions Flexible visitation (up to 12 hours per day) supported by family education (n = 837 patients, 652 family members, and 435 clinicians) or usual restricted visitation (median, 1.5 hours per day; n = 848 patients, 643 family members, and 391 clinicians). Nineteen ICUs started with flexible visitation, and 17 started with restricted visitation.
   Main Outcomes and Measures Primary outcome was incidence of delirium during ICU stay, assessed using the CAM-ICU. Secondary outcomes included ICU-acquired infections for patients; symptoms of anxiety and depression assessed using the HADS (range, 0 [best] to 21 [worst]) for family members; and burnout for ICU staff (Maslach Burnout Inventory).
   Results Among 1685 patients, 1295 family members, and 826 clinicians enrolled, 1685 patients (100%) (mean age, 58.5 years; 47.2% women), 1060 family members (81.8%) (mean age, 45.2 years; 70.3% women), and 737 clinicians (89.2%) (mean age, 35.5 years; 72.9% women) completed the trial. The mean daily duration of visits was significantly higher with flexible visitation (4.8 vs 1.4 hours; adjusted difference, 3.4 hours [95% CI, 2.8 to 3.9]; P < .001). The incidence of delirium during ICU stay was not significantly different between flexible and restricted visitation (18.9% vs 20.1%; adjusted difference, -1.7% [95% CI, -6.1% to 2.7%]; P = .44). Among 9 prespecified secondary outcomes, 6 did not differ significantly between flexible and restricted visitation, including ICU-acquired infections (3.7% vs 4.5%; adjusted difference, -0.8% [95% CI, -2.1% to 1.0%]; P = .38) and staff burnout (22.0% vs 24.8%; adjusted difference, -3.8% [95% CI, -4.8% to 12.5%]; P = .36). For family members, median anxiety (6.0 vs 7.0; adjusted difference, -1.6 [95% CI, -2.3 to -0.9]; P < .001) and depression scores (4.0 vs 5.0; adjusted difference, -1.2 [95% CI, -2.0 to -0.4]; P = .003) were significantly better with flexible visitation.
   Conclusions and Relevance Among patients in the ICU, a flexible family visitation policy, vs standard restricted visiting hours, did not significantly reduce the incidence of delirium.
C1 [Rosa, Regis Goulart; da Silva, Daiana Barbosa; Eugenio, Claudia Severgnini; Ribeiro Haack, Tarissa da Silva; Medeiros, Gregory Saraiva; Tonietto, Tulio Frederico; Teixeira, Cassiano] Hosp Moinhos Vento, Intens Care Unit, Rua Ramiro Barcelos 910,3 Andar, BR-90035001 Porto Alegre, RS, Brazil.
   [Rosa, Regis Goulart; Falavigna, Maicon; da Silva, Daiana Barbosa; Sganzerla, Daniel; Kochhann, Renata; de Moura, Rafaela Moraes; Eugenio, Claudia Severgnini; Ribeiro Haack, Tarissa da Silva; Barbosa, Mirceli Goulart; Robinson, Caroline Cabral; Schneider, Daniel; Jeffman, Rodrigo Wiltgen; Medeiros, Gregory Saraiva; Hammes, Luciano Serpa; Santos, Tagora do Lago] HMV, Res Projects Off, Porto Alegre, RS, Brazil.
   [Rosa, Regis Goulart; Cavalcanti, Alexandre Biasi; Machado, Flavia Ribeiro; Pontes Azevedo, Luciano Cesar; Figueira Salluh, Jorge Ibrain; Nobre, Vandack; Bozza, Fernando Augusto; Teixeira, Clebio Barreto] Brazilian Res Intens Care Network BRICNet, Sao Paulo, Brazil.
   [Cavalcanti, Alexandre Biasi] HCor Res Inst, Sao Paulo, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo UNIFESP, Dept Anesthesiol Pain & Intens Care, Sao Paulo, SP, Brazil.
   [Pontes Azevedo, Luciano Cesar] Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, SP, Brazil.
   [Figueira Salluh, Jorge Ibrain; Mesquita, Emersom Cicilini; Bozza, Fernando Augusto] Inst DOr Pesquisa & Ensino, Dept Crit Care, Rio De Janeiro, RJ, Brazil.
   [Santos Pellegrini, Jose Augusto; Moraes, Rafael Barberena] HCPA, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Foernges, Rafael Botelho] Hosp Santa Cruz, Intens Care Unit, Santa Cruz Do Sul, RS, Brazil.
   [Torelly, Andre Peretti] Hosp Santa Rita, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Ayres, Lizandra de Oliveira; Delfino Duarte, Pericles Almeida] Hosp Univ Oeste Parana, Intens Care Unit, Cascavel, Parana, Brazil.
   [Delfino Duarte, Pericles Almeida] Hosp Canc Cascavel, Intens Care Unit, Cascavel, Parana, Brazil.
   [Lovato, Wilson Jose] Hosp Clin, Fac Med Ribeirao Preto, Intens Care Unit, Ribeirao Preto, SP, Brazil.
   [Santana Sampaio, Patrick Harrison] Santa Casa Misericordia Feira de Santana, Intens Care Unit, Feira De Santana, BA, Brazil.
   [de Oliveira Junior, Lucio Couto] Hosp Geral Cleriston Andrade, Intens Care Unit, Feira De Santana, BA, Brazil.
   [da Rocha Paranhos, Jorge Luiz] Santa Casa Misericordia Sao Joao Del Rei, Intens Care Unit, Sao Joao Del Rei, MG, Brazil.
   [Dantas, Alessandro da Silva; Aires de Barros, Marcia Abath] Hosp Reg Doutor Deoclecio Marques de Lucena, Intens Care Unit, Parnamirim, RN, Brazil.
   [Peixoto Paulo, Eliane Aparecida] Fundacao Hosp Adriano Jorge, Intens Care Unit, Manaus, Amazonas, Brazil.
   [Cavalcanti Gallindo, Marcos Antonio] Hosp Agamenon Magalhaes, Intens Care Unit, Recife, PE, Brazil.
   [Pilau, Janaina] Hosp Cidade, Intens Care Unit, Passo Fundo, RS, Brazil.
   [Valentim, Helen Martins] Hosp Mae Deus, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Meira Teles, Jose Mario] Hosp Urgencias Goiania, Intens Care Unit, Goiania, Go, Brazil.
   [Nobre, Vandack] Univ Fed Minas Gerais, Hosp Clin, Intens Care Unit, Belo Horizonte, MG, Brazil.
   [Birriel, Daniella Cunha] Pavilhao Pereira Filho, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Correa e Castro, Livia] Hosp Reg Baixo Amazonas, Intens Care Unit, Santarem, Para, Brazil.
   [Specht, Andreia Martins] Hosp Nossa Senhora Conceicao, Intens Care Unit, Porto Alegre, RS, Brazil.
   [da Silva, Nilton Brandao] UFCSPA, Sch Med, Porto Alegre, RS, Brazil.
   [Korte, Jeffrey E.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
   [Giannini, Alberto] Osped Bambini ASST Spedali Civili, Unit Pediat Anesthesia & Intens Care, Brescia, Italy.
   [Bozza, Fernando Augusto] Oswaldo Cruz Fdn FIOCRUZ, Rio De Janeiro, Brazil.
RP Rosa, RG (corresponding author), Hosp Moinhos Vento, Intens Care Unit, Rua Ramiro Barcelos 910,3 Andar, BR-90035001 Porto Alegre, RS, Brazil.
EM regis.rosa@hmv.org.br
RI Bozza, Fernando A/A-2618-2013; dantas, vicente c souza/L-2648-2013;
   Teixeira, Cassiano/V-8764-2019; Freitas, Katia Santana/AAW-5184-2020;
   Rosa, Regis Goulart/P-6422-2019; Azevedo, Luciano CP/H-2652-2012
OI Bozza, Fernando A/0000-0003-4878-0256; Freitas, Katia
   Santana/0000-0002-0491-6759; Azevedo, Luciano CP/0000-0001-6759-3910;
   Mesquita, Emersom/0000-0002-5132-3315
FU Brazilian Ministry of Health through the Brazilian Unified Health System
   Institutional Development Program (PROADI-SUS)
FX This study was funded by the Brazilian Ministry of Health through the
   Brazilian Unified Health System Institutional Development Program
   (PROADI-SUS).
CR CDC, 2019, BLOODSTR INF EV CENT
   Centers for Disease Control, 2019, PNEUM VENT ASS VAP N
   Centers for Disease Control and Prevention (CDC), 2019, UR TRACT INF CATH AS
   Colantuoni E, 2016, LANCET RESP MED, V4, P534, DOI 10.1016/S2213-2600(16)30138-2
   da Silva Ramos Fernando Jose, 2013, Ann Intensive Care, V3, P34, DOI 10.1186/2110-5820-3-34
   Davidson JE, 2017, CRIT CARE MED, V45, P103, DOI 10.1097/CCM.0000000000002169
   Devlin JW, 2018, CRIT CARE MED, V46, pE825, DOI 10.1097/CCM.0000000000003299
   Doulougeri K, 2016, COGENT MED, V3, P1237605, DOI DOI 10.1080/2331205X.2016.1237605
   Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983
   Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012
   Fumagalli S, 2006, CIRCULATION, V113, P946, DOI 10.1161/CIRCULATIONAHA.105.572537
   Garrouste-Orgeas M, 2008, CRIT CARE MED, V36, P30, DOI 10.1097/01.CCM.0000295310.29099.F8
   Garrouste-Orgeas M, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0185-x
   Giannini A, 2008, INTENS CARE MED, V34, P1256, DOI 10.1007/s00134-008-1037-4
   Giannini A, 2013, INTENS CARE MED, V39, P2180, DOI 10.1007/s00134-013-3087-5
   Hunter JD, 2010, ANAESTHESIA, V65, P1101, DOI 10.1111/j.1365-2044.2010.06506.x
   Kleinpell R, 2018, J CRIT CARE, V48, P251, DOI 10.1016/j.jcrc.2018.09.006
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Liu V, 2013, CRIT CARE, V17, DOI 10.1186/cc12677
   Livingston EH, 2009, ARCH SURG-CHICAGO, V144, P706, DOI 10.1001/archsurg.2009.150
   Malacarne P, 2011, AM J INFECT CONTROL, V39, P898, DOI 10.1016/j.ajic.2011.02.018
   Maslach C, 1996, MASLACH BURNOUT INVE
   Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258
   Morgon Fernanda Helena, 2004, Rev. Latino-Am. Enfermagem, V12, P198, DOI 10.1590/S0104-11692004000200008
   Nassar AP, 2018, CRIT CARE MED, V46, P1175, DOI 10.1097/CCM.0000000000003155
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46
   Ramos Fernando José da Silva, 2014, Rev. bras. ter. intensiva, V26, P339, DOI 10.5935/0103-507X.20140052
   Rosa RG, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021193
   Rosa RG, 2017, CRIT CARE MED, V45, P1660, DOI 10.1097/CCM.0000000000002588
   Schmidt M, 2012, CURR OPIN CRIT CARE, V18, P540, DOI 10.1097/MCC.0b013e328357f141
   Sganzerla D, 2018, TRIALS, V19, DOI 10.1186/s13063-018-3006-8
   Usher BM, 2016, CRIT CARE NURSE, V36, pE15, DOI 10.4037/ccn2016677
   van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420
   van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892
   Westphal GA, 2018, INTENS CARE MED, V44, P968, DOI 10.1007/s00134-018-5153-5
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 36
TC 13
Z9 15
U1 3
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 16
PY 2019
VL 322
IS 3
BP 216
EP 228
DI 10.1001/jama.2019.8766
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA IK7OO
UT WOS:000476780400013
PM 31310297
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Righy, C
   Rosa, RG
   da Silva, RTA
   Kochhann, R
   Migliavaca, CB
   Robinson, CC
   Teche, SP
   Teixeira, C
   Bozza, FA
   Falavigna, M
AF Righy, Cassia
   Rosa, Regis Goulart
   Amancio da Silva, Rodrigo Teixeira
   Kochhann, Renata
   Migliavaca, Celina Borges
   Robinson, Caroline Cabral
   Teche, Stefania Pigatto
   Teixeira, Cassiano
   Bozza, Fernando Augusto
   Falavigna, Maicon
TI Prevalence of post-traumatic stress disorder symptoms in adult critical
   care survivors: a systematic review and meta-analysis
SO CRITICAL CARE
LA English
DT Review
DE Critical care; Intensive care units; Meta-analysis; Post-traumatic
   stress disorder; Prevalence; Systematic review
ID ACUTE LUNG INJURY; QUALITY-OF-LIFE; INTENSIVE-CARE; PSYCHOLOGICAL
   DISTRESS; CRITICAL ILLNESS; SEPTIC SHOCK; UNIT; ICU; DEPRESSION; ANXIETY
AB BackgroundAs more patients are surviving intensive care, mental health concerns in survivors have become a research priority. Among these, post-traumatic stress disorder (PTSD) can have an important impact on the quality of life of critical care survivors. However, data on its burden are conflicting. Therefore, this systematic review and meta-analysis aimed to evaluate the prevalence of PTSD symptoms in adult critical care patients after intensive care unit (ICU) discharge.MethodsWe searched MEDLINE, EMBASE, LILACS, Web of Science, PsycNET, and Scopus databases from inception to September 2018. We included observational studies assessing the prevalence of PTSD symptoms in adult critical care survivors. Two reviewers independently screened studies and extracted data. Studies were meta-analyzed using a random-effects model to estimate PTSD symptom prevalence at different time points, also estimating confidence and prediction intervals. Subgroup and meta-regression analyses were performed to explore heterogeneity. Risk of bias was assessed using the Joanna Briggs Institute tool and the GRADE approach.ResultsOf 13,267 studies retrieved, 48 were included in this review. Overall prevalence of PTSD symptoms was 19.83% (95% confidence interval [CI], 16.72-23.13; I-2=90%, low quality of evidence). Prevalence varied widely across studies, with a wide range of expected prevalence (from 3.70 to 43.73% in 95% of settings). Point prevalence estimates were 15.93% (95% CI, 11.15-21.35; I-2=90%; 17 studies), 16.80% (95% CI, 13.74-20.09; I-2=66%; 13 studies), 18.96% (95% CI, 14.28-24.12; I-2=92%; 13 studies), and 20.21% (95% CI, 13.79-27.44; I-2=58%; 7 studies) at 3, 6, 12, and >12months after discharge, respectively.ConclusionPTSD symptoms may affect 1 in every 5 adult critical care survivors, with a high expected prevalence 12months after discharge. ICU survivors should be screened for PTSD symptoms and cared for accordingly, given the potential negative impact of PTSD on quality of life. In addition, action should be taken to further explore the causal relationship between ICU stay and PTSD, as well as to propose early measures to prevent PTSD in this population.Trial registrationPROSPERO, CRD42017075124, Registered 6 December 2017.
C1 [Righy, Cassia; Amancio da Silva, Rodrigo Teixeira; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Righy, Cassia] Inst Estadual Cerebro Paulo Niemeyer, Rua Rezende 156, BR-20230026 Rio De Janeiro, RJ, Brazil.
   [Rosa, Regis Goulart; Teixeira, Cassiano] HMV, Intens Care Unit, Rua Ramiro Barcelos 910,3 Andar, BR-90035001 Porto Alegre, RS, Brazil.
   [Rosa, Regis Goulart; Kochhann, Renata; Migliavaca, Celina Borges; Robinson, Caroline Cabral; Falavigna, Maicon] HMV, Res Projects Off, Porto Rua Ramiro Barcelos 910,3 Andar, BR-90035001 Porto Alegre, RS, Brazil.
   [Amancio da Silva, Rodrigo Teixeira] Hosp Fed Servidores Estado, Rua Sacadura Cabral 178, BR-20221903 Rio De Janeiro, RJ, Brazil.
   [Migliavaca, Celina Borges; Falavigna, Maicon] Univ Fed Rio Grande do Sul, Natl Inst Hlth Technol Assessment, Ave Paulo Gama 110, BR-90040060 Porto Alegre, RS, Brazil.
   [Teche, Stefania Pigatto] Univ Fed Rio Grande do Sul, Postgrad Program Psychiat & Behav Sci, Porto Alegre, RS, Brazil.
   [Teche, Stefania Pigatto] Hosp Clin Porto Alegre, PTSD Outpatient Program NET Trauma, Porto Alegre, RS, Brazil.
   [Bozza, Fernando Augusto] DOr Inst Res & Educ, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, RJ, Brazil.
RP Rosa, RG (corresponding author), HMV, Intens Care Unit, Rua Ramiro Barcelos 910,3 Andar, BR-90035001 Porto Alegre, RS, Brazil.; Rosa, RG (corresponding author), HMV, Res Projects Off, Porto Rua Ramiro Barcelos 910,3 Andar, BR-90035001 Porto Alegre, RS, Brazil.
EM cassiarighy@gmail.com; regis.rosa@hmv.org.br
RI Shinotsuka, Cassia Righy/H-9181-2013; Teixeira, Cassiano/V-8764-2019;
   Bozza, Fernando A/A-2618-2013; Rosa, Regis Goulart/P-6422-2019;
   Kochhann, Renata/C-5126-2018
OI Shinotsuka, Cassia Righy/0000-0002-9206-9552; Bozza, Fernando
   A/0000-0003-4878-0256; Kochhann, Renata/0000-0002-6328-8131
FU Brazilian Ministry of Health through the Program of Institutional
   Development of the Brazilian Unified Health System (PROADI-SUS)
FX The present systematic review and meta-analysis was supported by the
   Brazilian Ministry of Health through the Program of Institutional
   Development of the Brazilian Unified Health System (PROADI-SUS).
CR Abraham CM, 2014, ARCH PHYS MED REHAB, V95, P2382, DOI 10.1016/j.apmr.2014.08.005
   Aitken LM, 2017, J CRIT CARE, V38, P263, DOI 10.1016/j.jcrc.2016.12.003
   [Anonymous], 2013, DIAGN STAT MAN MENT
   Asimakopoulou E, 2015, J TRAUMA NURS, V22, P209, DOI 10.1097/JTN.0000000000000142
   Atwoli L, 2015, CURR OPIN PSYCHIATR, V28, P307, DOI 10.1097/YCO.0000000000000167
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bashar FR, 2018, J CRIT CARE, V43, P88, DOI 10.1016/j.jcrc.2017.08.034
   Bienvenu OJ, 2015, CRIT CARE MED, V43, P642, DOI 10.1097/CCM.0000000000000752
   Bienvenu OJ, 2013, CHEST, V144, P24, DOI 10.1378/chest.12-0908
   Bienvenu OJ, 2017, CRIT CARE CLIN, V33, P649, DOI 10.1016/j.ccc.2017.03.006
   Boer KR, 2008, INTENS CARE MED, V34, P664, DOI 10.1007/s00134-007-0941-3
   Bruck E, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-017-0272-6
   Bugedo Guillermo, 2013, Rev. bras. ter. intensiva, V25, P188, DOI 10.5935/0103-507X.20130034
   Castillo MI, 2016, AUST CRIT CARE, V29, P158, DOI 10.1016/j.aucc.2015.09.003
   Chahraoui K, 2015, J CRIT CARE, V30, P599, DOI 10.1016/j.jcrc.2015.02.016
   Costa Jaquilene Barreto da, 2012, J. bras. psiquiatr., V61, P13, DOI 10.1590/S0047-20852012000100004
   Cox CE, 2012, INTENS CARE MED, V38, P1289, DOI 10.1007/s00134-012-2567-3
   Cuthbertson BH, 2004, INTENS CARE MED, V30, P450, DOI 10.1007/s00134-003-2004-8
   Davydow DS, 2008, GEN HOSP PSYCHIAT, V30, P421, DOI 10.1016/j.genhosppsych.2008.05.006
   Davydow DS, 2013, GEN HOSP PSYCHIAT, V35, P226, DOI 10.1016/j.genhosppsych.2012.12.005
   Davydow DS, 2009, GEN HOSP PSYCHIAT, V31, P428, DOI 10.1016/j.genhosppsych.2009.05.007
   de Miranda S, 2011, CRIT CARE MED, V39, P112, DOI 10.1097/CCM.0b013e3181feb824
   Elliott R, 2016, REHABIL PSYCHOL, V61, P141, DOI 10.1037/rep0000074
   Engelhard IM, 2007, BRIT J CLIN PSYCHOL, V46, P449, DOI 10.1348/014466507X206883
   Garrouste-Orgeas M, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2283-y
   Garrouste-Orgeas M, 2012, CRIT CARE MED, V40, P2033, DOI 10.1097/CCM.0b013e31824e1b43
   Girard TD, 2007, CRIT CARE, V11, DOI 10.1186/cc5708
   Granja C, 2008, CRIT CARE MED, V36, P2801, DOI 10.1097/CCM.0b013e318186a3e7
   Griffiths J, 2006, INTENS CARE MED, V32, P445, DOI 10.1007/s00134-005-0048-7
   Griffiths J, 2007, INTENS CARE MED, V33, P1506, DOI 10.1007/s00134-007-0730-z
   Gunther A, 2017, ACTA ANAESTH SCAND, V61, P688, DOI 10.1111/aas.12890
   Hauer D, 2011, CRIT CARE MED, V39, P643, DOI 10.1097/CCM.0b013e318206bae6
   Hauer D, 2009, BRAIN RES, V1293, P114, DOI 10.1016/j.brainres.2009.04.014
   Hepp U, 2008, BRIT J PSYCHIAT, V192, P376, DOI 10.1192/bjp.bp.106.030569
   Huang MX, 2016, CRIT CARE MED, V44, P954, DOI 10.1097/CCM.0000000000001621
   IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247
   Iorio A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h870
   Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7
   Javidi H, 2012, INT J OCCUP ENV MED, V3, P2
   Joanna Briggs Institute, 2014, JOANN BRIGGS I REV M
   Jonasdottir RJ, 2018, INTENS CRIT CARE NUR, V44, P59, DOI 10.1016/j.iccn.2017.06.001
   Jones C, 2010, CRIT CARE, V14, DOI 10.1186/cc9260
   Jones JM, 2012, BRIT J HEALTH PSYCH, V17, P798, DOI 10.1111/j.2044-8287.2012.02074.x
   Jubran A, 2010, INTENS CARE MED, V36, P2030, DOI 10.1007/s00134-010-1972-8
   Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45
   Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lilly CM, 2017, CHEST, V152, P723, DOI 10.1016/j.chest.2017.06.050
   McGiffin JN, 2016, REHABIL PSYCHOL, V61, P120, DOI 10.1037/rep0000073
   Meyer N, 2018, CRIT CARE MED, V46, P354, DOI 10.1097/CCM.0000000000002872
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   Morina N, 2018, J AFFECT DISORDERS, V239, P328, DOI 10.1016/j.jad.2018.07.027
   Munn Z, 2015, INT J EVID-BASED HEA, V13, P147, DOI 10.1097/XEB.0000000000000054
   Myhren H, 2010, CRIT CARE, V14, DOI 10.1186/cc8870
   Myhren H, 2009, INTENS CARE MED, V35, P2078, DOI 10.1007/s00134-009-1614-1
   Nickel Marius, 2004, J Intensive Care Med, V19, P285, DOI 10.1177/0885066604267684
   Parker AM, 2015, CRIT CARE MED, V43, P1121, DOI 10.1097/CCM.0000000000000882
   Richter JC, 2006, PSYCHOSOMATICS, V47, P223, DOI 10.1176/appi.psy.47.3.223
   Roberts MB, 2018, CRIT CARE MED, V46, P1328, DOI 10.1097/CCM.0000000000003222
   Samuelson KAM, 2007, ACTA ANAESTH SCAND, V51, P671, DOI 10.1111/j.1399-6576.2007.01292.x
   Schelling G, 2001, BIOL PSYCHIAT, V50, P978, DOI 10.1016/S0006-3223(01)01270-7
   Schelling G, 1999, CRIT CARE MED, V27, P2678, DOI 10.1097/00003246-199912000-00012
   Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594
   Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.3389/FPSYG.2014.01521
   Scragg P, 2001, ANAESTHESIA, V56, P9, DOI 10.1046/j.1365-2044.2001.01714.x
   Shaw RJ, 2001, PSYCHOSOMATICS, V42, P35, DOI 10.1176/appi.psy.42.1.35
   Society of Critical Care Medicine, CRIT CAR STAT
   Steckler T, 2012, NEUROPHARMACOLOGY, V62, P617, DOI 10.1016/j.neuropharm.2011.06.012
   Stoll C, 1999, INTENS CARE MED, V25, P697, DOI 10.1007/s001340050932
   Strom T, 2011, CRIT CARE, V15, DOI 10.1186/cc10586
   Twigg E, 2008, ACTA ANAESTH SCAND, V52, P202, DOI 10.1111/j.1399-6576.2007.01531.x
   van der Schaaf M, 2009, J REHABIL MED, V41, P360, DOI 10.2340/16501977-0333
   van Ommeren M, 2005, BRIT MED J, V330, P1160, DOI 10.1136/bmj.330.7501.1160
   Wade DM, 2012, CRIT CARE, V16, DOI 10.1186/cc11677
   Wallen K, 2008, AM J CRIT CARE, V17, P534
   Weinert CR, 2008, INTENS CARE MED, V34, P82, DOI 10.1007/s00134-007-0829-2
   Wickham H., 2016, GGPLOT2 ELEGANT GRAP
   Wintermann GB, 2017, J NERV MENT DIS, V205, P780, DOI 10.1097/NMD.0000000000000714
NR 78
TC 16
Z9 17
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUN 11
PY 2019
VL 23
AR 213
DI 10.1186/s13054-019-2489-3
PG 13
WC Critical Care Medicine
SC General & Internal Medicine
GA IC7QV
UT WOS:000471172300002
PM 31186070
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Westphal, GA
   Robinson, CC
   Biasi, A
   Machado, FR
   Rosa, RG
   Teixeira, C
   de Andrade, J
   Franke, CA
   Azevedo, LCP
   Bozza, F
   Guterres, CM
   da Silva, DB
   Sganzerla, D
   do Prado, DZ
   Madalena, IC
   Rohden, AI
   da Silva, SS
   Giordani, NE
   Andrighetto, LV
   Benck, PS
   Roman, FR
   de Melo, MDRB
   Pereira, TB
   Grion, CMC
   Diniz, PC
   Oliveira, JFP
   Mecatti, GC
   Alves, FAC
   Moraes, RB
   Nobre, V
   Hammes, LS
   Meade, MO
   Nothen, RR
   Falavigna, M
AF Westphal, Glauco Adrieno
   Robinson, Caroline Cabral
   Biasi, Alexandre
   Machado, Flavia Ribeiro
   Rosa, Regis Goulart
   Teixeira, Cassiano
   de Andrade, Joel
   Franke, Cristiano Augusto
   Azevedo, Luciano Cesar Pontes
   Bozza, Fernando
   Guterres, Catia Moreira
   da Silva, Daiana Barbosa
   Sganzerla, Daniel
   do Prado, Debora Zechmeister
   Madalena, Itiana Cardoso
   Rohden, Adriane Isabel
   da Silva, Sabrina Souza
   Giordani, Natalia Elis
   Andrighetto, Luiza Vitelo
   Benck, Patricia Spessatto
   Roman, Fernando Roberto
   Rodrigues Buarque de Melo, Maria de Fatima
   Pereira, Thattyane Borba
   Carvalho Grion, Cintia Magalhaes
   Diniz, Pedro Carvalho
   Picollo Oliveira, Joao Fernando
   Mecatti, Giovana Colozza
   Cardona Alves, Flavio Andre
   Moraes, Rafael Barberena
   Nobre, Vandack
   Hammes, Luciano Serpa
   Meade, Maureen O.
   Nothen, Rosana Reis
   Falavigna, Maicon
CA DONORS Donation Network Optimise O
   BRICNet
TI DONORS (Donation Network to Optimise Organ Recovery Study): Study
   protocol to evaluate the implementation of an evidence-based checklist
   for brain-dead potential organ donor management in intensive care units,
   a cluster randomised trial
SO BMJ OPEN
LA English
DT Article
ID DECEASED-DONOR; QUALITY; GOALS; GUIDELINES; NUMBER; IMPACT;
   TRANSPLANTATION; INTERVENTION; MORTALITY; STRATEGY
AB Introduction There is an increasing demand for multi organ donors for organ transplantation programmes. This study protocol describes the Donation Network to Optimise Organ Recovery Study, a planned cluster randomised controlled trial that aims to evaluate the effectiveness of the implementation of an evidence-based, goal directed checklist for brain-dead potential organ donor management in intensive care units (ICUs) in reducing the loss of potential donors due to cardiac arrest.
   Methods and analysis The study will include ICUs of at least 60 Brazilian sites with an average of >= 10 annual notifications of valid potential organ donors. Hospitals will he randomly assigned (with a 1:1 allocation ratio) to the intervention group, which will involve the implementation of an evidence-based, goal-directed checklist for potential organ donor maintenance, or the control group, which will maintain the usual care practices of the ICU. Team members from all participating ICUs will receive training on how to conduct family interviews for organ donation. The primary outcome will be loss of potential donors due to cardiac arrest. Secondary outcomes will include the number of actual organ donors and the number of organs recovered per actual donor.
   Ethics and dissemination The institutional review board (IRB) of the coordinating centre and of each participating site individually approved the study. We requested a waiver of informed consent for the IRB of each site. Study results will be disseminated to the general medical community through publications in peer-reviewed medical journals.
C1 [Westphal, Glauco Adrieno; Robinson, Caroline Cabral; Guterres, Catia Moreira; Sganzerla, Daniel; do Prado, Debora Zechmeister; Madalena, Itiana Cardoso; Rohden, Adriane Isabel; da Silva, Sabrina Souza; Giordani, Natalia Elis; Andrighetto, Luiza Vitelo; Benck, Patricia Spessatto; Falavigna, Maicon] Hosp Moinhos de Vento HMV, Res Projects Off, Porto Alegre, RS, Brazil.
   [Westphal, Glauco Adrieno] Hosp Municipal Sao Jose, Joinville, SC, Brazil.
   [Westphal, Glauco Adrieno] Ctr Hospitalar Unimed, Joinville, SC, Brazil.
   [Biasi, Alexandre] Hosp Coracao HCor, Res Inst, Sao Paulo, SP, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo UNIFESP, Dept Anaesthesiol Pain & Intens Care, Sao Paulo, SP, Brazil.
   [Rosa, Regis Goulart; Teixeira, Cassiano; da Silva, Daiana Barbosa] Hosp Moinhos de Vento HMV, Adult Intens Care Unit, Porto Alegre, RS, Brazil.
   [Teixeira, Cassiano] Univ Fed Ciencias Saude Porto Alegre UFCSPA, Dept Internal Med, Porto Alegre, RS, Brazil.
   [Teixeira, Cassiano] Univ Fed Ciencias Saude Porto Alegre UFCSPA, Post Grad Program Rehabil Sci, Porto Alegre, RS, Brazil.
   [de Andrade, Joel] Organ Procurement Org Santa Catarina OPO SC, Florianopolis, SC, Brazil.
   [Franke, Cristiano Augusto; Moraes, Rafael Barberena] Hosp Clin Porto Alegre HCPA, Adult Intens Care Unit, Porto Alegre, RS, Brazil.
   [Franke, Cristiano Augusto] Hosp Pronto Socorro HPS, Trauma Intens Care Unit, Porto Alegre, RS, Brazil.
   [Azevedo, Luciano Cesar Pontes] Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, Brazil.
   [Bozza, Fernando] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando] DOr Inst Res & Educ, Grad Programme Translat Med, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando] Fundacao Oswaldo Cruz FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Giordani, Natalia Elis; Falavigna, Maicon] Univ Fed Rio Grande do Sul UFRGS, Post Grad Program Epidemiol, Porto Alegre, RS, Brazil.
   [Roman, Fernando Roberto] Hosp Bom Jesus Toledo, Adult Intens Care Unit, Toledo, Brazil.
   [Rodrigues Buarque de Melo, Maria de Fatima] Hosp Restauracao, Adult Intens Care Unit, Recife, PE, Brazil.
   [Pereira, Thattyane Borba] Hosp Pronto Socorro Joao Paulo II, Adult Intens Care Unit, Porto Velho, Brazil.
   [Carvalho Grion, Cintia Magalhaes] Hosp Evangel Londrina, Adult Intens Care Unit, Londrina, Parana, Brazil.
   [Carvalho Grion, Cintia Magalhaes] Hosp Univ Reg Norte Parana, Adult Intens Care Unit, Londrina, Parana, Brazil.
   [Diniz, Pedro Carvalho] Hosp Ensino Doutor Washington Antonio de Barros, Adult Intens Care Unit, Petrolina, Brazil.
   [Picollo Oliveira, Joao Fernando] Hosp Base Sao Jose do Rio Preto, Adult Intens Care Unit, Sao Jose Do Rio Preto, Brazil.
   [Mecatti, Giovana Colozza] Hosp Univ Sao Francisco Providencia Deus Braganca, Adult Intens Care Unit, Braganca Paulista, SP, Brazil.
   [Cardona Alves, Flavio Andre] Hosp Cristo Redentor, Adult Intens Care Unit, Porto Alegre, RS, Brazil.
   [Nobre, Vandack] Univ Fed Minas Gerais, Adult Intens Care Unit, Belo Horizonte, MG, Brazil.
   [Hammes, Luciano Serpa] Hosp Moinhos de Vento, Superintendence, Porto Alegre, RS, Brazil.
   [Meade, Maureen O.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Meade, Maureen O.] McMaster Univ, Dept Hlth Evidence & Impact, Hamilton, ON, Canada.
   [Nothen, Rosana Reis] Univ Fed Rio Grande do Sul UFRGS, Gen Hosp, Sch Med, Porto Alegre, RS, Brazil.
   [Nothen, Rosana Reis] Minist Saude, Gen Coordinat Off Natl Transplant Syst, Brasilia, DF, Brazil.
RP Westphal, GA (corresponding author), Hosp Moinhos de Vento HMV, Res Projects Off, Porto Alegre, RS, Brazil.; Westphal, GA (corresponding author), Hosp Municipal Sao Jose, Joinville, SC, Brazil.; Westphal, GA (corresponding author), Ctr Hospitalar Unimed, Joinville, SC, Brazil.
EM glauco.ww@gmail.com
RI Bozza, Fernando A/A-2618-2013; Teixeira, Cassiano/V-8764-2019; Rosa,
   Regis Goulart/P-6422-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Barbosa Cerantola,
   Rodrigo/0000-0003-4225-2196
FU Brazilian Ministry of Health through the Programme of Institutional
   Development of the Brazilian Unified Health System (PROADI-SUS)
FX This research was funded by the Brazilian Ministry of Health through the
   Programme of Institutional Development of the Brazilian Unified Health
   System (PROADI-SUS).
CR [Anonymous], 2011, Transplantation, V91 Suppl 11, pS29, DOI 10.1097/01.tp.0000399131.74618.a5
   Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458
   Cavalcanti AB, 2016, JAMA-J AM MED ASSOC, V315, P1480, DOI 10.1001/jama.2016.3463
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   CURTIS JR, 2001, CRIT CARE MED S, V29
   Dominguez-Gil B, 2011, TRANSPL INT, V24, P373, DOI 10.1111/j.1432-2277.2011.01243.x
   DuBose Joseph, 2008, J Intensive Care Med, V23, P367, DOI 10.1177/0885066608324208
   Franklin GA, 2010, AM SURGEON, V76, P587
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Helms AK, 2004, NEUROLOGY, V63, P1955, DOI 10.1212/01.WNL.0000144197.06562.24
   International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, 2018, INT C HARM TECHN REQ
   Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446
   Macdonald PS, 2012, CRIT CARE MED, V40, P1635, DOI 10.1097/CCM.0b013e3182416ee7
   Malinoski DJ, 2012, CRIT CARE MED, V40, P2773, DOI 10.1097/CCM.0b013e31825b252a
   Malinoski DJ, 2011, J TRAUMA, V71, P990, DOI 10.1097/TA.0b013e31822779e5
   Mascia L, 2010, JAMA-J AM MED ASSOC, V304, P2620, DOI 10.1001/jama.2010.1796
   National Academies of Sciences Engineering and Medicine, 2017, OPPORTUNITIES ORGAN
   Niemann CU, 2015, NEW ENGL J MED, V373, P405, DOI 10.1056/NEJMoa1501969
   Patel MS, 2014, JAMA SURG, V149, P969, DOI 10.1001/jamasurg.2014.967
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   Rech TH, 2013, TRANSPLANTATION, V95, P966, DOI 10.1097/TP.0b013e318283298e
   Rech Tatiana H., 2007, Rev. bras. ter. intensiva, V19, P85, DOI 10.1590/S0103-507X2007000100011
   Salim A, 2005, J TRAUMA, V58, P991, DOI 10.1097/01.TA.0000168708.78049.32
   Shemie SD, 2006, CAN MED ASSOC J, V174, pS13, DOI 10.1503/cmaj.045131
   Tullius SG, 2018, NEW ENGL J MED, V378, P1920, DOI 10.1056/NEJMra1507080
   Vincent A, 2012, BRIT J ANAESTH, V108, pI80, DOI 10.1093/bja/aer353
   Weiss CH, 2011, AM J RESP CRIT CARE, V184, P680, DOI 10.1164/rccm.201101-0037OC
   Westphal GA, 2012, TRANSPL P, V44, P2260, DOI 10.1016/j.transproceed.2012.07.019
   Westphal GA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1484-1
   Westphal Glauco Adrieno, 2012, Rev. bras. ter. intensiva, V24, P334, DOI 10.1590/S0103-507X2012000400007
   Wijdicks EFM, 2010, NEUROLOGY, V74, P1911, DOI 10.1212/WNL.0b013e3181e242a8
NR 33
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2019
VL 9
IS 6
AR e028570
DI 10.1136/bmjopen-2018-028570
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ND7XT
UT WOS:000562117100177
PM 31243035
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Campbell, RA
   Schwertz, H
   Hottz, ED
   Rowley, JW
   Manne, BK
   Washington, AV
   Hunter-Mellado, R
   Tolley, ND
   Christensen, M
   Eustes, AS
   Montenont, E
   Bhatlekar, S
   Ventrone, CH
   Kirkpatrick, BD
   Pierce, KK
   Whitehead, SS
   Diehl, SA
   Bray, PF
   Zimmerman, GA
   Kosaka, Y
   Bozza, PT
   Bozza, FA
   Weyrich, AS
   Rondina, MT
AF Campbell, Robert A.
   Schwertz, Hansjorg
   Hottz, Eugenio D.
   Rowley, Jesse W.
   Manne, Bhanu Kanth
   Washington, A. Valance
   Hunter-Mellado, Robert
   Tolley, Neal D.
   Christensen, Miles
   Eustes, Alicia S.
   Montenont, Emilie
   Bhatlekar, Seema
   Ventrone, Cassandra H.
   Kirkpatrick, Beth D.
   Pierce, Kristen K.
   Whitehead, Stephen S.
   Diehl, Sean A.
   Bray, Paul F.
   Zimmerman, Guy A.
   Kosaka, Yasuhiro
   Bozza, Patricia T.
   Bozza, Fernando A.
   Weyrich, Andrew S.
   Rondina, Matthew T.
TI Human megakaryocytes possess intrinsic antiviral immunity through
   regulated induction of IFITM3
SO BLOOD
LA English
DT Article
ID PLATELET ACTIVATION; INTERFERON-BETA; PRESENT ANTIGEN; DENGUE; VIRUS;
   INFECTION; RESPONSES; ALPHA; INHIBITION; EVENTS
AB Evolving evidence indicates that platelets and megakaryocytes (MKs) have unexpected activities in inflammation and infection; whether viral infections upregulate biologically active, antiviral immune genes in platelets and MKs is unknown, however. We examined antiviral immune genes in these cells in dengue and influenza infections, viruses that are global public health threats. Using complementary biochemical, pharmacological, and genetic approaches, we examined the regulation and function of interferon-induced transmembrane protein 3 (IFITM3), an antiviral immune effector gene not previously studied in human platelets and MKs. IFITM3 was markedly upregulated in platelets isolated from patients during clinical influenza and dengue virus (DENV) infections. Lower IFITM3 expression in platelets correlated with increased illness severity and mortality in patients. Administering a live, attenuated DENV vaccine to healthy subjects significantly increased platelet IFITM3 expression. Infecting human MKs with DENV selectively increased type I interferons and IFITM3. Overexpression of IFITM3 in MKs was sufficient to prevent DENV infection. In naturally occurring, genetic loss-of-function studies, MKs from healthy subjects harboring a homozygous mutation in IFITM3 (rs12252-C, a common single-nucleotide polymorphism in areas of the world where DENV is endemic) were significantly more susceptible to DENV infection. DENV-induced MK secretion of interferons prevented infection of bystander MKs and hematopoietic stem cells. Thus, viral infections upregulate IFITM3 in human platelets andMKs, and IFITM3 expression is associated with adverse clinical outcomes. These observations establish, for the first time, that human MKs possess antiviral functions, preventing DENV infection of MKs and hematopoietic stem cells after local immune signaling.
C1 [Campbell, Robert A.; Schwertz, Hansjorg; Hottz, Eugenio D.; Rowley, Jesse W.; Manne, Bhanu Kanth; Tolley, Neal D.; Eustes, Alicia S.; Montenont, Emilie; Bhatlekar, Seema; Bray, Paul F.; Zimmerman, Guy A.; Kosaka, Yasuhiro; Weyrich, Andrew S.; Rondina, Matthew T.] Univ Utah, Program Mol Med, Salt Lake City, UT USA.
   [Campbell, Robert A.; Schwertz, Hansjorg; Rowley, Jesse W.; Christensen, Miles; Bray, Paul F.; Zimmerman, Guy A.; Weyrich, Andrew S.; Rondina, Matthew T.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   [Schwertz, Hansjorg] Univ Utah, Rocky Mt Ctr Occupat & Environm Hlth, Salt Lake City, UT USA.
   [Hottz, Eugenio D.; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Washington, A. Valance; Hunter-Mellado, Robert] Univ Puerto Rico Rio Piedras, Dept Biol, San Juan, PR 00931 USA.
   [Washington, A. Valance; Hunter-Mellado, Robert] Univ Cent Caribe, Dept Internal Med, Bayamon, PR USA.
   [Ventrone, Cassandra H.; Kirkpatrick, Beth D.; Pierce, Kristen K.; Diehl, Sean A.] Univ Vermont, Dept Microbiol & Mol Genet, Larner Coll Med, Vaccine Testing Ctr, Burlington, VT 05405 USA.
   [Whitehead, Stephen S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, Rio De Janeiro, Brazil.
   [Rondina, Matthew T.] George E Wahlen Vet Affairs Med Ctr, Dept Internal Med, Salt Lake City, UT USA.
   [Rondina, Matthew T.] Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA.
RP Rondina, MT (corresponding author), Univ Utah, Hlth Sci Ctr, Eccles Inst Human Genet, 15 North 2030 East,Bldg 533,Suite 4220, Salt Lake City, UT 84112 USA.
EM matthew.rondina@hsc.utah.edu
RI Whitehead, Stephen/AAG-2787-2019; Diehl, Sean/AAE-2779-2020; Schwertz,
   Hansjorg/Q-3305-2019; Bozza, Fernando A/A-2618-2013; Hottz, Eugenio
   D/I-9850-2014
OI Diehl, Sean/0000-0001-9700-235X; Bozza, Fernando A/0000-0003-4878-0256;
   Bozza, Patricia/0000-0001-8349-9529; Weyrich, Andrew/0000-0001-9622-4647
FU National Institutes of Health, National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL112311, HL126547, R37HL044525]; National Institute
   on AgingUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [AG048022]; National Institute of Neurological Disorders and
   StrokeUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [U10NS086606]; National Institute on Minority
   Health and Health DisparitiesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Minority Health & Health Disparities (NIMHD) [2U54M D007587-03];
   Merit Review Award from the United States Department of Veterans Affairs
   Clinical Sciences RD Service [I01 CX001696]; National Institutes of
   Allergy and Infectious Diseases Intramural Research Program of the
   National Institutes of Health [HHSN272200900010C]; National Center for
   Research Resources of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR)
   [1S10RR026802-01]; National Cancer InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [P30CA042014]; Flow Cytometry Core at
   the University of Utah; special visiting professorship in the Science
   Without Borders Program of the Conselho de Desenvolvimento Cientifico e
   Tecnologico of the government of Brazil; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014, P30CA042014, P30CA042014, P30CA042014,
   P30CA042014, P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL130541, R01HL126547, R01HL130541,
   R01HL141424, U54HL112311, R01HL141424, R01HL130541, U54HL112311,
   R35HL145237, U54HL112311, R01HL141424, R35HL145237, U54HL112311,
   U54HL112311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [ZIAAI000987, ZIAAI000987,
   ZIAAI000987, ZIAAI000987] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [P20GM125498, P20GM125498,
   P20GM125498, P20GM125498, P20GM125498, P20GM125498, P20GM125498,
   P20GM125498, P20GM125498, P20GM125498, P20GM125498, P20GM125498,
   P20GM125498, P20GM125498, P20GM125498, P20GM125498, P20GM125498,
   P20GM125498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [U10NS086606]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [R01AG048022, R01AG048022,
   K01AG059892, K01AG059892] Funding Source: NIH RePORTER; National
   Institute on Minority Health and Health DisparitiesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Minority Health & Health Disparities
   (NIMHD) [U54MD007587, U54MD007587, U54MD007587, U54MD007587,
   U54MD007587, U54MD007587, U54MD007587, U54MD007587, U54MD007587,
   U54MD007587, U54MD007587, U54MD007587, U54MD007587, U54MD007587,
   U54MD007587, U54MD007587, U54MD007587, U54MD007587, U54MD007587,
   U54MD007587, U54MD007587, U54MD007587] Funding Source: NIH RePORTER;
   Veterans AffairsUS Department of Veterans Affairs [I01CX001696,
   I01CX001696] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health, National
   Heart, Lung, and Blood Institute (HL112311 and HL126547 [M.T.R.];
   R37HL044525 [G.A.Z.]), the National Institute on Aging (AG048022)
   (M.T.R.), the National Institute of Neurological Disorders and Stroke
   (U10NS086606) (R.A.C.), and the National Institute on Minority Health
   and Health Disparities (2U54M D007587-03) (R.H.-M.). This work was also
   supported in part by Merit Review Award Number I01 CX001696 from the
   United States Department of Veterans Affairs Clinical Sciences R&D
   Service. The dengue vaccine trial was supported the National Institutes
   of Allergy and Infectious Diseases Intramural Research Program of the
   National Institutes of Health (HHSN272200900010C). This material is the
   result of work supported with resources and the use of facilities at the
   George E. Wahlen VAMedical Center, Salt Lake City, Utah. G.A.Z. was
   supported by a special visiting professorship in the Science Without
   Borders Program of the Conselho de Desenvolvimento Cientifico e
   Tecnologico of the government of Brazil while some of this work was
   conducted. Research reported in this publication was supported by the
   National Center for Research Resources of the National Institutes of
   Health under award number 1S10RR026802-01. The project described was
   supported by award number P30CA042014 from the National Cancer
   Institute. The work was also supported by the Flow Cytometry Core at the
   University of Utah. Oligonucleotides were synthesized by the DNA/Peptide
   Facility, part of the Health Sciences Center Cores at the University of
   Utah.
CR Auerbach DJ, 2012, P NATL ACAD SCI USA, V109, P9569, DOI 10.1073/pnas.1207314109
   Boilard E, 2014, BLOOD, V123, P2854, DOI 10.1182/blood-2013-07-515536
   Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017
   Bunce PE, 2011, CLIN INFECT DIS, V52, pE14, DOI 10.1093/cid/ciq125
   Calore EE, 2011, PATHOL RES PRACT, V207, P86, DOI 10.1016/j.prp.2010.11.003
   Campbell RA, 2018, J IMMUNOL, V200, P295, DOI 10.4049/jimmunol.1700885
   Campbell RA, 2017, ARTERIOSCL THROM VAS, V37, P1819, DOI 10.1161/ATVBAHA.117.309794
   Chapman LM, 2012, J IMMUNOL, V189, P916, DOI 10.4049/jimmunol.1200580
   Clark KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052902
   Cunin P, 2017, J CLIN INVEST, V127, P1714, DOI 10.1172/JCI84598
   de la Cruz-Hernandez SI, 2013, AM J TROP MED HYG, V88, P446, DOI 10.4269/ajtmh.12-0023
   Trugilho MRD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006385
   Oliveira RAD, 2016, MEM I OSWALDO CRUZ, V111, P378, DOI 10.1590/0074-02760150453
   Everitt AR, 2012, NATURE, V484, P519, DOI 10.1038/nature10921
   Feeley EM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002337
   Franco C, 2010, BIOSECUR BIOTERROR, V8, P273, DOI 10.1089/bsp.2010.0032
   Gaertner F, 2017, CELL, V171, P1368, DOI 10.1016/j.cell.2017.11.001
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Gibellini Davide, 2013, World J Virol, V2, P91, DOI 10.5501/wjv.v2.i2.91
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Harms PW, 2010, AM J CLIN PATHOL, V134, P27, DOI 10.1309/AJCP35KOZSAVNQZW
   Honda S, 2009, AM J TROP MED HYG, V80, P841, DOI 10.4269/ajtmh.2009.80.841
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Kirkpatrick BD, 2015, J INFECT DIS, V212, P702, DOI 10.1093/infdis/jiv082
   Kraemer BF, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002355
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Lefrancais E, 2017, NATURE, V544, P105, DOI 10.1038/nature21706
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Ng CT, 2016, CELL, V164, P349, DOI 10.1016/j.cell.2015.12.027
   Ng CT, 2015, CELL HOST MICROBE, V17, P653, DOI 10.1016/j.chom.2015.04.005
   Ojha A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41697
   Povoa TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083386
   Rondina MT, 2016, J THROMB HAEMOST, V14, P1082, DOI 10.1111/jth.13281
   Rondina MT, 2013, CIRC RES, V112, P1506, DOI 10.1161/CIRCRESAHA.113.300512
   Rondina MT, 2012, CHEST, V141, P1490, DOI 10.1378/chest.11-2860
   Rowley JW, 2016, BLOOD, V127, P1743, DOI 10.1182/blood-2015-07-661371
   Schmidt AC, 2010, NEW ENGL J MED, V363, P484, DOI 10.1056/NEJMcibr1005904
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Schwertz H, 2018, ARTERIOSCL THROM VAS, V38, P801, DOI 10.1161/ATVBAHA.117.310552
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shim JM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080223
   Simon AY, 2015, BLOOD, V126, P378, DOI 10.1182/blood-2014-09-598029
   Sridharan A, 2013, J VIROL, V87, P11648, DOI 10.1128/JVI.01156-13
   Talarico LB, 2017, J CLIN VIROL, V97, P10, DOI 10.1016/j.jcv.2017.10.010
   Tsegaye TS, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-48
   Vieira-de-Abreu A, 2012, PLATELETS, P733
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003
   Yeaman MR, 2014, NAT REV MICROBIOL, V12, P426, DOI 10.1038/nrmicro3269
   Yu HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002985
   Zacour M, 2016, CLIN VACCINE IMMUNOL, V23, P236, DOI 10.1128/CVI.00613-15
   Zapata JC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002858
   Zhang YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2433
   Zufferey A, 2017, BLOOD ADV, V1, P1773, DOI 10.1182/bloodadvances.2017007021
   J VIROL, V74, P4957
   2014, J CLIN VIROL, V60, P196, DOI DOI 10.1016/J.JCV.2014.04.002
   2013, J THROMB HAEMOST, V11, P951, DOI DOI 10.1111/JTH.12178
   1991, BLOOD, V78, P2062
   1993, AM J TROP MED HYG, V48, P222
   2012, EXP HEMATOL, V40, P250, DOI DOI 10.1016/J.EXPHEM.2011.11.011
   1995, SCIENCE, V270, P1811
   2011, J THROMB HAEMOST, V9, P2477, DOI DOI 10.1111/J.1538-7836.2011.04530.X
NR 65
TC 25
Z9 25
U1 0
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 9
PY 2019
VL 133
IS 19
BP 2013
EP 2026
DI 10.1182/blood-2018-09-873984
PG 14
WC Hematology
SC Hematology
GA HX4QR
UT WOS:000467385500007
PM 30723081
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Quirino-Teixeira, AC
   Valls-de-Souza, R
   Zimmerman, GA
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Quirino-Teixeira, Anna Cecillia
   Valls-de-Souza, Rogerio
   Zimmerman, Guy A.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI Platelet function in HIV plus dengue coinfection associates with reduced
   inflammation and milder dengue illness
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMBINATION ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS;
   PERIPHERAL-BLOOD; VIRUS-INFECTION; SHOCK SYNDROME; CELL COUNT;
   ACTIVATION; MORTALITY; ADULTS; SEVERITY
AB HIV-infected subjects under virological control still exhibit a persistent proinflammatory state. Thus, chronic HIV infection changes the host homeostasis towards an adapted immune response that may affect the outcome of coinfections. However, little is known about the impact of HIV infection on inflammatory amplification and clinical presentation in dengue. Platelets have been shown to participate in immune response in dengue and HIV. We hypothesized that altered platelet responses in HIV-infected subjects may contribute to altered inflammatory milieu and disease progression in dengue. We prospectively followed a cohort of 84 DENV-infected patients of whom 29 were coinfected with HIV under virological control. We report that dengue and HIV coinfection progress with reduced inflammation and milder disease progression with lower risk of vascular instability. Even though the degree of thrombocytopenia and platelet activation were similar between dengue-infected and HIV plus dengue-coinfected patients, plasma levels of the platelet-derived chemokines RANTES/CCL5 and PF4/CXCL4 were lower in coinfection. Consistently, platelets from coinfected patients presented defective secretion of the stored-chemokines PF4 and RANTES, but not newly synthesized IL-1 beta, when cultured ex vivo. These data indicate that platelets from HIV-infected subjects release lower levels of chemokines during dengue illness, which may contribute to milder clinical presentation during coinfection.
C1 [Hottz, Eugenio D.; Bozza, Patricia T.] Fiocruz MS, Fundacao Oswaldo Cruz, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Quirino-Teixeira, Anna Cecillia] Univ Fed Juiz De Fora UFJF, ICB, Dept Bioquim, Lab Anal Glicoconjugados, Juiz De Fora, MG, Brazil.
   [Valls-de-Souza, Rogerio] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI, Lab Doencas Febris Agudas, Rio De Janeiro, Brazil.
   [Zimmerman, Guy A.] Univ Utah, Dept Internal Med, Mol Med Program, Salt Lake City, UT 84112 USA.
   [Bozza, Fernando A.] Fiocruz MS, INI, Lab Med Intens, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Inst Dor Pesquisa & Ensino IDOr, Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), Fiocruz MS, INI, Lab Med Intens, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), Inst Dor Pesquisa & Ensino IDOr, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com; pbozza@ioc.fiocruz.br
RI Hottz, Eugenio D/I-9850-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)CAPES; Programa Estrategico de Apoio a Pesquisa em
   Saude (PAPES)/Fiocruz; US National Institute of Healthy [NHLBI
   5R37HLO44525]; CNPq science without borders
FX The authors thank Edson Fernandes de Assis for technical assistance,
   Leonardo Bastos for statistical reviewing and the Programa de
   Desenvolvimento Tecnologico em Insumos para Saude (PDTIS) platform for
   multiplex analysis. This work was supported by grants from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Programa
   Estrategico de Apoio a Pesquisa em Saude (PAPES)/Fiocruz. Dr. Zimmerman
   was supported by the US National Institute of Healthy (NHLBI
   5R37HLO44525) and CNPq science without borders.
CR Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Baum PD, 2011, AIDS, V25, P2243, DOI 10.1097/QAD.0b013e32834d3cc3
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Binder D, 1997, J EXP MED, V185, P517, DOI 10.1084/jem.185.3.517
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Bridget W, 2009, AM J TROP MED HYG, V81, P638, DOI 10.4269/ajtmh.2009.08-0008
   Buggert M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004251
   Campbell RA, 2019, BLOOD, V133, P2013, DOI 10.1182/blood-2018-09-873984
   Chandele A, 2016, J VIROL, V90, P11259, DOI 10.1128/JVI.01424-16
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Cohen C, 2012, CLIN INFECT DIS, V55, P996, DOI 10.1093/cid/cis549
   Corrales-Medina VF, 2010, JAIDS-J ACQ IMM DEF, V54, P217, DOI 10.1097/QAI.0b013e3181c8f4c9
   Falcinelli E, 2013, THROMB HAEMOSTASIS, V110, P349, DOI 10.1160/TH12-07-0504
   Falconar AKI, 2006, CLIN VACCINE IMMUNOL, V13, P1044, DOI 10.1128/CVI.00105-06
   Feiterna-Sperling C, 2010, CLIN INFECT DIS, V51, pE90, DOI 10.1086/657121
   Gandini M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002257
   Goehringer F, 2017, AIDS RES HUM RETROV, V33, P187, DOI [10.1089/aid.2016.0222, 10.1089/AID.2016.0222]
   Cardozo FTGD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178820
   Green SA, 2015, AIDS, V29, P1297, DOI 10.1097/QAD.0000000000000701
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Holme P. A, 1998, FASEB J
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00121
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Isais F, 2010, J INFECTION, V61, P437, DOI 10.1016/j.jinf.2010.08.002
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Koletar SL, 2004, CLIN INFECT DIS, V39, P1500, DOI 10.1086/424882
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lazar R, 2017, CLIN INFECT DIS, V65, P469, DOI 10.1093/cid/cix343
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144
   Malavige GN, 2017, IMMUNOLOGY, V151, P261, DOI 10.1111/imm.12748
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Matsuura C, 2012, T ROY SOC TROP MED H, V106, P174, DOI 10.1016/j.trstmh.2011.10.009
   Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355
   McDonald B, 2013, AIDS RES HUM RETROV, V29, P993, DOI [10.1089/aid.2012.0309, 10.1089/AID.2012.0309]
   Mendes-Ribeiro AC, 2008, CLIN EXP PHARMACOL P, V35, P1143, DOI 10.1111/j.1440-1681.2008.04970.x
   Mesquita EC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33403-0
   Mesquita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101056
   Michels M, 2014, THROMB HAEMOSTASIS, V112, P352, DOI 10.1160/TH14-01-0056
   Middleton EA, 2016, PHYSIOL REV, V96, P1211, DOI 10.1152/physrev.00038.2015
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Mourao MPG, 2007, PLATELETS, V18, P605, DOI 10.1080/09537100701426604
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Nakanjako D, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-26
   Nascimento EJM, 2014, CRIT REV IMMUNOL, V34, P227, DOI 10.1615/CritRevImmunol.2014010212
   Huy NT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002412
   Nkambule BB, 2015, THROMB RES, V135, P1131, DOI 10.1016/j.thromres.2015.01.031
   Nkambule BB, 2015, PLATELETS, V26, P250, DOI 10.3109/09537104.2014.909021
   Nordell AD, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000844
   Nunez-Avellaneda D, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070357
   O'Brien M, 2013, JAIDS-J ACQ IMM DEF, V63, P280, DOI 10.1097/QAI.0b013e31828a292c
   O'Bryan Thomas A, 2015, BMC Res Notes, V8, P595, DOI 10.1186/s13104-015-1548-3
   O'Halloran JA, 2015, HIV MED, V16, P608, DOI 10.1111/hiv.12270
   Ojha A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41697
   Ormsby CE, 2011, AIDS, V25, P435, DOI 10.1097/QAD.0b013e3283434844
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Pang JX, 2015, AM J TROP MED HYG, V92, P1156, DOI 10.4269/ajtmh.15-0031
   Pang JX, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0649-2
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Riera M, 2010, AIDS, V24, P2460, DOI 10.1097/QAD.0b013e32833e508f
   Sa-Ngasang A, 2014, J INFECT DIS, V210, P138, DOI 10.1093/infdis/jiu042
   Satchell CS, 2011, J INFECT DIS, V204, P1202, DOI 10.1093/infdis/jir509
   Schechter ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam5441
   Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shu PY, 2003, CLIN DIAGN LAB IMMUN, V10, P622, DOI 10.1128/CDLI.10.4.622-630.2003
   Singh MV, 2014, J IMMUNOL, V192, P4674, DOI 10.4049/jimmunol.1302318
   Srikiatkhachorn A, 2017, SEMIN IMMUNOPATHOL, V39, P563, DOI 10.1007/s00281-017-0625-1
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Taylor KA, 2019, BRIT J PHARMACOL, V176, P879, DOI 10.1111/bph.14589
   Tien PC, 2010, JAIDS-J ACQ IMM DEF, V55, P316, DOI 10.1097/QAI.0b013e3181e66216
   Tomashek KM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005859
   Torrentes-Carvalho A, 2016, CLIN IMMUNOL, V164, P95, DOI 10.1016/j.clim.2016.01.005
   Trugilho M., 2017, PLOS PATHOG, V13, P1
   Tunjungputri RN, 2014, AIDS, V28, P2091, DOI 10.1097/QAD.0000000000000415
   van der Heijden WA, 2018, AIDS, V32, P2469, DOI 10.1097/QAD.0000000000001993
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Wang J, 2011, J THROMB HAEMOST, V9, P562, DOI 10.1111/j.1538-7836.2010.04168.x
   Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112
   (WHO) World Health Organization, 2009, WHOHTMNTDDEN20091 TD
   Wolf K, 2002, J INFECT DIS, V185, P456, DOI 10.1086/338572
NR 90
TC 3
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 8
PY 2019
VL 9
AR 7096
DI 10.1038/s41598-019-43275-7
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HX4LW
UT WOS:000467369200034
PM 31068600
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mesquita, EC
   Coelho, LE
   Amancio, RT
   Veloso, V
   Grinsztejn, B
   Luz, P
   Bozza, FA
AF Mesquita, Emersom Cicilini
   Coelho, Lara Esteves
   Amancio, Rodrigo Teixeira
   Veloso, Valdilea
   Grinsztejn, Beatriz
   Luz, Paula
   Bozza, Fernando Augusto
TI Severe infection increases cardiovascular risk among HIV-infected
   individuals
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Cardiovascular disease; Risk factor; HIV; AIDS; Severe infection; cART;
   CD4+
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYOCARDIAL-INFARCTION;
   ANTIRETROVIRAL THERAPY; DISEASE; INFLAMMATION; REPLICATION; PNEUMONIA;
   MORTALITY; STROKE; BRAZIL
AB Background: The identification and management of cardiovascular risk factors became a major clinical issue among HIV-infected individuals in the post-cART era. As in the past decades the link between acute infections and cardiovascular diseases became clear in the general population, we sorted to investigate the role of severe infections on incident cardiovascular diseases (CVDs) among HIV-infected individuals.
   Methods: HIV-infected individuals aged >= 18 years, with no history of CVD were followed from January 2000 to December 2013 until the occurrence of the first CVD event, death or end of study, whichever occurred first. To explore the effect of severe infections on the incidence of CVD we used extended Cox regression models and stratified post-hospitalization follow-up time into three periods: <3months, 3-12months and >12 months post discharge.
   Results: One hundred-eighty four persons from 3384 HIV-infected individuals developed incident CVD events during the follow-up (incidence rate = 11.10/1000 PY (95%CI: 9.60-12.82)). Risk of an incident CVD was 4-fold higher at < 3 months post-hospitalization for severe infections (adjusted hazard ratio [aHR], 4.52; 95% confidence interval [CI] 2.46-8.30), after adjusting for sociodemographic and clinical factors as well as comorbidities. This risk remained significant up to one year (3-12months post hospital discharge aHR 2.39, 95% CI 1.30-4.38). Additionally, non-white race/ethnicity (aHR 1.49, 95% CI 1.10-2.02), age >= 60 years (aHR 2.01, 95% CI 1.01-3.97) and hypertension (aHR 1.90, 95% CI 1.38-2.60) were associated with an increased risk of CVD events. High CD4 (>= 500 cells/mm(3): aHR 0.41, 95% CI 0.27-0.62) and cART use (aHR 0.21, 95% CI 0.14-0.31) reduced the risk of CVD events.
   Conclusions: We provide evidence for a time-dependent association between severe infection and incident cardiovascular disease in HIV-infected individuals. cART use, and high CD4 count were significantly associated with reduced hazards of CVD.
C1 [Mesquita, Emersom Cicilini; Amancio, Rodrigo Teixeira; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin Med Intens, Rio De Janeiro, Brazil.
   [Coelho, Lara Esteves; Veloso, Valdilea; Grinsztejn, Beatriz; Luz, Paula] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab HIV, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Inst DOr Pesquisa & Ensino IDOR, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Pesquisa Clin Med Intens, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), Inst DOr Pesquisa & Ensino IDOR, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Mesquita,
   Emersom/0000-0002-5132-3315; Luz, Paula/0000-0001-9746-719X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Programa Estrategico de Apoio a Pesquisa em
   Saude (PAPES)/FiocruzNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476] Funding Source: NIH RePORTER
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ), and Programa Estrategico
   de Apoio a Pesquisa em Saude (PAPES)/Fiocruz.
CR Amancio RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068730
   [Anonymous], WHO CARD DIS CVDS
   Armah KA, 2012, CLIN INFECT DIS, V55, P126, DOI 10.1093/cid/cis406
   Bakal DR, 2018, J ANTIMICROB CHEMOTH, V73, P2177, DOI 10.1093/jac/dky145
   Baker JV, 2012, JAIDS-J ACQ IMM DEF, V60, P128, DOI 10.1097/QAI.0b013e318252f99f
   Basevi V, 2011, DIABETES CARE, V34, P1887, DOI 10.2337/dc11-s011
   Baylin A, 2007, ANN EPIDEMIOL, V17, P112, DOI 10.1016/j.annepidem.2006.05.004
   Bernal E, 2012, J AIDS CLIN RES, V03, DOI [10.4172/2155-6113.1000164, DOI 10.4172/2155-6113.1000164]
   Butt AA, 2011, ARCH INTERN MED, V171, P737, DOI 10.1001/archinternmed.2011.151
   de Oliveira RDC, 2018, AIDS CARE, V30, P551, DOI 10.1080/09540121.2017.1391984
   Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229
   Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7
   Crane HM, 2017, JAMA CARDIOL, V2, P260, DOI 10.1001/jamacardio.2016.5139
   Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7
   Diaz CM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1735-4
   Falasca K, 2010, CURR HIV RES, V8, P405, DOI 10.2174/157016210791330365
   Freiberg MS, 2013, JAMA INTERN MED, V173, P614, DOI 10.1001/jamainternmed.2013.3728
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Greenberg JA, 2012, J CRIT CARE, V27, P51, DOI 10.1016/j.jcrc.2011.08.015
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grund B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155100
   Grundy SM, 2019, J AM COLL CARDIOL, V73, pE285, DOI 10.1016/j.jacc.2018.11.003
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kalayjian RC, 2010, J INFECT DIS, V201, P1796, DOI 10.1086/652750
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052
   Ludwig A, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0095-0
   Mesquita EC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33403-0
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Paisible AL, 2015, JAIDS-J ACQ IMM DEF, V68, P209, DOI 10.1097/QAI.0000000000000419
   Phillips AN, 2008, ANTIVIR THER, V13, P177
   Ramirez J, 2008, CLIN INFECT DIS, V47, P182, DOI 10.1086/589246
   Ribeiro SR, 2014, ANTIVIR THER, V19, P387, DOI 10.3851/IMP2716
   Saves M, 2003, CLIN INFECT DIS, V37, P292, DOI 10.1086/375844
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sico JJ, 2015, NEUROLOGY, V84, P1933, DOI 10.1212/WNL.0000000000001560
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   Stein JH, 2012, JAMA-J AM MED ASSOC, V308, P405, DOI 10.1001/jama.2012.8488
   Subramanian S, 2012, JAMA-J AM MED ASSOC, V308, P379, DOI 10.1001/jama.2012.6698
   Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397
   Torriani FJ, 2008, J AM COLL CARDIOL, V52, P569, DOI 10.1016/j.jacc.2008.04.049
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   Tseng ZH, 2012, J AM COLL CARDIOL, V59, P1891, DOI 10.1016/j.jacc.2012.02.024
   Ucciferri C, 2017, AIDS REV, V19, P198
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   World Health Organization, 2011, US GLYC HAEM HBA1C D
   Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC
   Yende S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022847
   Young J, 2015, JAIDS-J ACQ IMM DEF, V69, P413, DOI 10.1097/QAI.0000000000000662
NR 52
TC 1
Z9 1
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 11
PY 2019
VL 19
AR 319
DI 10.1186/s12879-019-3894-6
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA HT8UX
UT WOS:000464841300006
PM 30975092
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Goncalves, B
   Kurtz, P
   Bozza, FA
   Righy, C
AF Goncalves, Bruno
   Kurtz, Pedro
   Bozza, Fernando Augusto
   Righy, Cassia
TI In Reply to the Letter to the Editor Regarding "Effect of Early Brain
   Infarction After Subarachnoid Hemorrhage: A Systematic Review and
   Meta-Analysis"
SO WORLD NEUROSURGERY
LA English
DT Letter
C1 [Goncalves, Bruno; Kurtz, Pedro; Righy, Cassia] Paulo Niemeyer State Brain Inst, Intens Care Unit, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto; Righy, Cassia] Fundacao Oswaldo Cruz, Natl Inst Infectol, Rio De Janeiro, Brazil.
RP Goncalves, B (corresponding author), Paulo Niemeyer State Brain Inst, Intens Care Unit, Rio De Janeiro, Brazil.
EM brunogs@gmail.com
RI Shinotsuka, Cassia Righy/H-9181-2013; Bozza, Fernando A/A-2618-2013
OI Shinotsuka, Cassia Righy/0000-0002-9206-9552; Bozza, Fernando
   A/0000-0003-4878-0256
CR Goncalves B, 2018, WORLD NEUROSURG, V115, pE292, DOI 10.1016/j.wneu.2018.04.037
   Jabbarli R, 2015, EUR J NEUROL, V22, P941, DOI 10.1111/ene.12686
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD APR
PY 2019
VL 124
BP 473
EP 473
DI 10.1016/j.wneu.2019.01.043
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA HR4BE
UT WOS:000463087800195
PM 30684696
DA 2020-12-01
ER

PT J
AU Dantas, LF
   Marchesi, JF
   Peres, IT
   Hamacher, S
   Bozza, FA
   Neira, RAQ
AF Dantas, Leila F.
   Marchesi, Janaina F.
   Peres, Igor T.
   Hamacher, Silvio
   Bozza, Fernando A.
   Quintano Neira, Ricardo A.
TI Public hospitalizations for stroke in Brazil from 2009 to 2016
SO PLOS ONE
LA English
DT Article
ID CASE-FATALITY RATES; MORTALITY; TRENDS; EPIDEMIOLOGY; OUTCOMES; DISEASE
AB Background
   Stroke is the third major cause of death in the world and the second in Brazil. The purpose of this work was to assess the stroke-related hospitalization, in-hospital mortality, and case fatality rates under the Brazilian Unified Health System (SUS) from 2009 to 2016.
   Methods
   We evaluated the hospital admissions for stroke and their associated outcomes using data from the Hospital Information available at the Informatics Department of SUS. We selected hospitalization registries according to stroke diagnosis codes from the International Statistical Classification of Diseases and Related Health Problems (ICD-10). We identified the association of age and sex with patient death through multiple logistic regression and calculated the rates of hospitalization, mortality and case-fatality per 100,000 inhabitants using age-adjustment methodology.
   Results
   We analyzed 1,113,599 stroke hospitalizations. From 2009 to 2016, the number of admissions increased from 131,122 to 146,950 and the absolute number of in-hospital deaths increased from 28,731 to 31,937. Younger age and male sex were significantly associated with patient survival. Our results showed that the annual age-adjusted hospitalization and in-hospital mortality rates decreased by 11.8% and 12.6%, respectively, but the case fatality rate increased for patients older than 70 years.
   Conclusions
   Although the age-adjusted hospitalization and in-hospital mortality rates declined, the total number of hospitalization and deaths have increased. It is expected a continuous increase over the next years of stroke admissions with the rapid aging of the Brazilian population. Efforts should be renewed targeting risk factors, access to hospital and rehabilitation in particular for the elderly population.
C1 [Dantas, Leila F.; Marchesi, Janaina F.; Peres, Igor T.; Hamacher, Silvio; Quintano Neira, Ricardo A.] Pontifical Catolic Univ Rio De Janeiro, Dept Ind Engn, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ, IDOR, Rio De Janeiro, RJ, Brazil.
RP Bozza, FA (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, RJ, Brazil.; Bozza, FA (corresponding author), DOr Inst Res & Educ, IDOR, Rio De Janeiro, RJ, Brazil.
EM bozza.fernando@gmail.com
RI hamacher, silvio/C-3325-2013; Bozza, Fernando A/A-2618-2013; Dantas,
   Leila Figueiredo/U-5407-2019
OI hamacher, silvio/0000-0002-3980-0342; Bozza, Fernando
   A/0000-0003-4878-0256; Peres, Igor/0000-0001-9863-4690; Marchesi,
   Janaina/0000-0002-0262-5384; Dantas, Leila/0000-0001-8910-0961
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [306802/2015-5, 403863/2016-3, 140511/2018-0, 169049/2017-5];
   Carlos Chagas Filho Foundation (FAPERJ) [E-26/201.959/2017];
   Coordination for theImprovement of Higher Education Personnel
   (CAPES)CAPES; Pontifical Catholic University of Rio de Janeiro; Philips
   Research; Brazilian National Council for Scientific and Technological
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by the National Council for Scientific and
   Technological Development (CNPq) http://cnpq.br/[grant numbers
   306802/2015-5 and 403863/2016-3 to SH; 140511/2018-0 to RAQN;
   169049/2017-5 to LED]; Carlos Chagas Filho Foundation (FAPERJ)
   http://www.faperj.br/. [grant number E-26/201.959/2017 to JFM]; the
   Coordination for theImprovement of Higher Education Personnel (CAPES)
   http://www.capes.gov.br/; and the Pontifical Catholic University of Rio
   de Janeiro http://www.puc-rio.br/english/.The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; The authors would like to thank
   Coordination for the Improvement of Higher Education Personnel (CAPES),
   the Pontifical Catholic University of Rio de Janeiro, Philips Research
   and the Brazilian National Council for Scientific and Technological
   Development (CNPq) for their financial support.
CR Adami F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152739
   Ahmad B.O., 2001, AGE STANDARDIZATION, V31, P1
   Bejot Y, 2016, REV NEUROL-FRANCE, V172, P59, DOI 10.1016/j.neurol.2015.07.013
   Bejot Y, 2016, PRESSE MED, V45, pE391, DOI 10.1016/j.lpm.2016.10.003
   Cabral NL, 2009, J NEUROL NEUROSUR PS, V80, P749, DOI 10.1136/jnnp.2008.164475
   CSIS, BRAZ SIST UN SAUD SU
   de Santana Nathalia Matos, 2018, BMC Res Notes, V11, P735, DOI 10.1186/s13104-018-3842-3
   Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4
   de Carvalho JJF, 2011, STROKE, V42, P3341, DOI 10.1161/STROKEAHA.111.626523
   Garritano CR, 2012, ARQ BRAS CARDIOL, V98, P519, DOI 10.1590/S0066-782X2012005000041
   Global Burden of Disease 2016 Lifetime Risk of Stroke Collaborators, 2018, NEW ENGL J MED, V379, P2429, DOI [DOI 10.1056/NEJMOA1804492, 10.1056/NEJMoa1804492]
   Goulart AC, 2010, INT J STROKE, V5, P284, DOI 10.1111/j.1747-4949.2010.00441.x
   Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X
   Iser BPM, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0185-x
   Kamal N, 2015, CAN J NEUROL SCI, V42, P168, DOI 10.1017/cjn.2015.20
   Lackland DT, 2014, STROKE, V45, P315, DOI 10.1161/01.str.0000437068.30550.cf
   Lotufo PA, 2007, ARQ NEURO-PSIQUIAT, V65, P752, DOI 10.1590/S0004-282X2007000500004
   Lotufo PA, 2015, SAO PAULO MED J, V133, P457, DOI 10.1590/1516-3180.2015.13360510
   Malachias MVB, 2016, 7A DIRETRIZ BRASELLE
   Malta DC, 2015, SCIELO PUBLIC HLTH, V20, P631
   Mansur AD, 2016, ARQ BRAS CARDIOL, V107, P137, DOI 10.5935/abc.20160102
   Marinho F, 2018, LANCET, V392, P760, DOI 10.1016/S0140-6736(18)31221-2
   Massuda A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000829
   Minelli C, 2007, STROKE, V38, P2906, DOI 10.1161/STROKEAHA.107.484139
   Monteiro CA, 2017, VIGITEL BRASIL 2006
   O'Donnell MJ, 2016, LANCET, V388, P761, DOI 10.1016/S0140-6736(16)30506-2
   Passos VMA, 2016, ARQ NEURO-PSIQUIAT, V74, P376, DOI 10.1590/0004-282X20160055
   Picon RV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048255
   Rolim CLRC, 2011, CAD SAUDE PUBLICA, V27, P2105
   Sarfo FS, 2015, J NEUROL SCI, V357, P240, DOI 10.1016/j.jns.2015.07.043
   Team RStudio, 2015, INT DEV R
   Thrift AG, 2014, INT J STROKE, V9, P6, DOI 10.1111/ijs.12245
   World Health Organization (WHO), 2007, INT CLASS DIS
NR 33
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 19
PY 2019
VL 14
IS 3
AR e0213837
DI 10.1371/journal.pone.0213837
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HP3JN
UT WOS:000461573000034
PM 30889198
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Malfussi, H
   Santana, IV
   Gasparotto, J
   Righy, C
   Tomasi, CD
   Gelain, DP
   Bozza, FA
   Walz, R
   Dal-Pizzol, F
   Ritter, C
AF Malfussi, Hamilton
   Santana, Iara Vidigal
   Gasparotto, Juciano
   Righy, Cassia
   Tomasi, Cristiane Damiani
   Gelain, Daniel Pens
   Bozza, Fernando A.
   Walz, Roger
   Dal-Pizzol, Felipe
   Ritter, Cristiane
TI Anti-NMDA Receptor Autoantibody Is an Independent Predictor of Hospital
   Mortality but Not Brain Dysfunction in Septic Patients
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE delirium; brain dysfunction; sepsis; neuronal autoantibodies; ICU
ID MECHANICALLY VENTILATED PATIENTS; TRANSIENT ISCHEMIC ATTACK;
   GLUTAMATE-RECEPTOR; ENCEPHALITIS; ANTIBODIES; NEURORECEPTORS;
   RELIABILITY; MECHANISMS; EXPRESSION; PHYSIOLOGY
AB The presence of autoantibodies against neuronal cell surface or synaptic proteins and their relationship to autoimmune encephalitis have recently been characterized. These autoantibodies have been also reported in other pathologic conditions; however, their role during sepsis is not known. This study detected the presence of autoantibodies against neuronal cell surface or synaptic proteins in the serum of septic patients and determined their relationship to the occurrence of brain dysfunction and mortality. This prospective, observational cohort study was performed in four Brazilian intensive care units (ICUs). Sixty patients with community-acquired severe sepsis or septic shock admitted to the ICU were included. Blood samples were collected from patients within 24 h of ICU admission. Antibodies to six neuronal proteins were assessed, including glutamate receptors (types NMDA, AMPA1, and AMPA2); voltage-gated potassium channel complex (VGKC) proteins, leucine-rich glioma-inactivated protein 1 (LGI1), and contactin-associated protein-2 (Caspr2), as well as the GABAB1 receptor. There was no independent association between any of the measured autoantibodies and the occurrence of brain dysfunction (delirium or coma). However, there was an independent and significant relationship between anti-NMDAR fluorescence intensity and hospital mortality. In conclusion, anti-NMDAR was independently associated with hospital mortality but none of the measured antibodies were associated with brain dysfunction in septic patients.
C1 [Malfussi, Hamilton] Univ Fed Santa Catarina, Programa Posgrad Ciencias Med, Florianopolis, SC, Brazil.
   [Santana, Iara Vidigal; Tomasi, Cristiane Damiani; Dal-Pizzol, Felipe; Ritter, Cristiane] Univ Extreme Sul Catarinense, Lab Fisiopatol Expt, Criciuma, Brazil.
   [Gasparotto, Juciano; Gelain, Daniel Pens] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Ctr Estudos Estresse Oxidat, Dept Bioquim, Porto Alegre, RS, Brazil.
   [Righy, Cassia; Bozza, Fernando A.] Inst Estadual Cerebro Paulo Niemeyer, Rio De Janeiro, Brazil.
   [Righy, Cassia] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Tomasi, Cristiane Damiani] Univ Extremo Sul Catarinense, Programa Pasgrad Saeide Colet, Grp Pesquisa Gestao Cuidado Integralidade & Educ, Criciuma, Brazil.
   [Bozza, Fernando A.] Inst D Or Pesquisa & Ensino IDOR, Rua Dinz Cordeiro, Rio De Janeiro, Brazil.
   [Walz, Roger] Univ Fed Santa Catarina, Ctr Cirurgia Epilepsia Santa Catarina CEPESC, Ctr Neurociencias Aplicadas CeNAp, Serv Neurol,Dept Clin Med,HU, Florianopolis, SC, Brazil.
   [Dal-Pizzol, Felipe; Ritter, Cristiane] Hosp Sao Jose, Criciuma, Brazil.
RP Ritter, C (corresponding author), Univ Extreme Sul Catarinense, Lab Fisiopatol Expt, Criciuma, Brazil.; Ritter, C (corresponding author), Hosp Sao Jose, Criciuma, Brazil.
EM cristiane.ritter1@gmail.com
RI Bozza, Fernando A/A-2618-2013; Gelain, Daniel Pens/I-5144-2013;
   Shinotsuka, Cassia Righy/H-9181-2013; Walz, Roger/K-9096-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Gelain, Daniel
   Pens/0000-0001-5254-0509; Shinotsuka, Cassia Righy/0000-0002-9206-9552;
   Walz, Roger/0000-0002-9875-6687
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Foundation for Research and Innovation of the State of Santa
   Catarina (FAPESC); UNESC
FX The Laboratory of Experimental Pathophysiology is a member of the Centre
   of Excellence in Applied Neurosciences of Santa Catarina (NENASC). Its
   research is supported by grants from the National Council for Scientific
   and Technological Development (CNPq) (FD-P and CrR), the Foundation for
   Research and Innovation of the State of Santa Catarina (FAPESC) (FD-P),
   and UNESC (FD-P and CrR).
CR Annane D, 2015, LANCET RESP MED, V3, P61, DOI 10.1016/S2213-2600(14)70246-2
   Bai W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05574-9
   Bokesch PM, 2006, STROKE, V37, P1432, DOI 10.1161/01.STR.0000221295.14547.c8
   Burbelo PD, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-97
   Chi X, 2017, ACTA NEUROL SCAND, V136, P298, DOI 10.1111/ane.12723
   da Cunha AA, 2010, CHEST, V137, P297, DOI 10.1378/chest.09-1570
   Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050
   Dalmau J, 2016, NEUROLOGY, V87, P2471, DOI 10.1212/WNL.0000000000003414
   Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2
   Dambinova SA, 1997, J NEUROL SCI, V152, P93, DOI 10.1016/S0022-510X(97)00150-0
   Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752
   Dambinova SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042362
   Danielski LG, 2018, MOL NEUROBIOL, V55, P1045, DOI 10.1007/s12035-016-0356-7
   de Montmollin E, 2017, AM J RESP CRIT CARE, V195, P491, DOI 10.1164/rccm.201603-0507OC
   Dickerson F, 2012, BIPOLAR DISORD, V14, P547, DOI 10.1111/j.1399-5618.2012.01028.x
   Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Gappoeva MU, 2003, BIOCHEMISTRY-MOSCOW+, V68, P696, DOI 10.1023/A:1024678112357
   Gerosa M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00005
   Gofton TE, 2012, NAT REV NEUROL, V8, P557, DOI 10.1038/nrneurol.2012.183
   Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9
   Hammer C, 2014, MOL PSYCHIATR, V19, P1143, DOI 10.1038/mp.2013.110
   Hanly JG, 2011, ANN RHEUM DIS, V70, P2240, DOI 10.1136/ard.2010.148502corr1
   Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010
   Irani SR, 2010, BRAIN, V133, P1655, DOI 10.1093/brain/awq113
   Jin SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121637
   Kannan G, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.162
   Kannan G, 2016, NEUROBIOL DIS, V91, P307, DOI 10.1016/j.nbd.2016.03.005
   Kayser MS, 2013, JAMA NEUROL, V70, P1133, DOI 10.1001/jamaneurol.2013.3216
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Levite M, 2014, J NEURAL TRANSM, V121, P1029, DOI 10.1007/s00702-014-1193-3
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Lin CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132204
   Masdeu JC, 2016, TRENDS NEUROSCI, V39, P300, DOI 10.1016/j.tins.2016.02.006
   Mazeraud A, 2016, CLIN CHEST MED, V37, P333, DOI 10.1016/j.ccm.2016.01.013
   Moscato EH, 2014, ANN NEUROL, V76, P108, DOI 10.1002/ana.24195
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Planaguma J, 2016, ANN NEUROL, V80, P388, DOI 10.1002/ana.24721
   Planaguma J, 2015, BRAIN, V138, P94, DOI 10.1093/brain/awu310
   Pruss H, 2012, NEUROLOGY, V78, P1743, DOI 10.1212/WNL.0b013e318258300d
   Steiner J, 2013, JAMA PSYCHIAT, V70, P271, DOI 10.1001/2013.jamapsychiatry.86
   Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Weissman JD, 2011, J NEUROL SCI, V300, P97, DOI 10.1016/j.jns.2010.09.023
   Zhan LY, 2015, GENET MOL RES, V14, P13312, DOI 10.4238/2015.October.26.27
NR 45
TC 2
Z9 2
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD MAR 15
PY 2019
VL 10
AR 221
DI 10.3389/fneur.2019.00221
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA HP5EU
UT WOS:000461700800001
PM 30930837
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Souza, TML
   Vieira, YR
   Delatorre, E
   Barbosa-Lima, G
   Luiz, RLF
   Vizzoni, A
   Jain, K
   Miranda, MM
   Bhuva, N
   Gogarten, JF
   Ng, J
   Thakkar, R
   Calheiros, AS
   Monteiro, APT
   Bozza, PT
   Bozza, FA
   Tschoeke, DA
   Leomil, L
   de Mendonca, MCL
   Rodrigues, CDD
   Torres, MC
   de Filippis, AMB
   Nogueira, RMR
   Thompson, FL
   Lemos, C
   Durovni, B
   Cerbino-Neto, J
   Morel, CM
   Lipkin, WI
   Mishra, N
AF Souza, Thiago Moreno L.
   Vieira, Yasmine Rangel
   Delatorre, Edson
   Barbosa-Lima, Giselle
   Faria Luiz, Raul Leal
   Vizzoni, Alexandre
   Jain, Komal
   Miranda, Milene Mesquita
   Bhuva, Nishit
   Gogarten, Jan F.
   Ng, James
   Thakkar, Riddhi
   Calheiros, Andrea Surrage
   Teixeira Monteiro, Ana Paula
   Bozza, Patricia T.
   Bozza, Fernando A.
   Tschoeke, Diogo A.
   Leomil, Luciana
   Lima de Mendonca, Marcos Cesar
   dos Santos Rodrigues, Cintia Damasceno
   Torres, Maria C.
   Bispo de Filippis, Ana Maria
   Ribeiro Nogueira, Rita Maria
   Thompson, Fabiano L.
   Lemos, Cristina
   Durovni, Betina
   Cerbino-Neto, Jose
   Morel, Carlos M.
   Lipkin, W. Ian
   Mishra, Nischay
TI Emergence of the East-Central-South-African genotype of Chikungunya
   virus in Brazil and the city of Rio de Janeiro may have occurred years
   before surveillance detection
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ZIKA VIRUS; PHYLOGENETIC ANALYSES; POPULATION-DYNAMICS; MODEL;
   TRANSMISSION; INFERENCE; ACCURACY
AB Brazil, which is hyperendemic for dengue virus DENV), has had recent Zika ZIKV) and CHIKV) Chikungunya virus outbreaks. Since March 2016, CHIKV is the arbovirus infection most frequently diagnosed in Rio de Janeiro. In the analysis of 1835 syndromic patients, screened by real time RT-PCR, 56.4% of the cases were attributed to CHIKV, 29.6% to ZIKV, and 14.1% to DENV-4. Sequence analyses of CHIKV from sixteen samples revealed that the East-Central-South-African ECSA) genotype of CHIKV has been circulating in Brazil since 2013 [95% bayesian credible interval BCI): 03/2012-10/2013], almost a year before it was detected by arbovirus surveillance program. Brazilian cases are related to Central African Republic sequences from 1980's. To the best of our knowledge, given the available sequence published here and elsewhere, the ECSA genotype was likely introduced to Rio de Janeiro early on 2014 02/2014; BCI: 07/2013-08/2014) through a single event, after primary circulation in the Bahia state at the Northestern Brazil in the previous year. The observation that the ECSA genotype of CHIKV was circulating undetected underscores the need for improvements in molecular methods for viral surveillance.
C1 [Souza, Thiago Moreno L.; Vieira, Yasmine Rangel; Barbosa-Lima, Giselle; Faria Luiz, Raul Leal; Vizzoni, Alexandre; Bozza, Fernando A.; Cerbino-Neto, Jose] Fundacao Oswaldo Cruz Fiocruz, INI, Rio De Janeiro, RJ, Brazil.
   [Jain, Komal; Bhuva, Nishit; Gogarten, Jan F.; Ng, James; Thakkar, Riddhi; Lipkin, W. Ian; Mishra, Nischay] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
   [Delatorre, Edson] Fiocruz MS, IOC, Lab AIDS & Imunol Mol, Rio De Janeiro, RJ, Brazil.
   [Miranda, Milene Mesquita] Fiocruz MS, IOC, Lab Virus Resp & Sarampo, Rio De Janeiro, RJ, Brazil.
   [Souza, Thiago Moreno L.; Calheiros, Andrea Surrage; Teixeira Monteiro, Ana Paula; Bozza, Patricia T.] Fiocruz MS, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, RJ, Brazil.
   [Tschoeke, Diogo A.; Leomil, Luciana; Thompson, Fabiano L.] Univ Fed Rio De Janeiro UFRJ, Inst Biol, Rio De Janeiro, RJ, Brazil.
   [Lima de Mendonca, Marcos Cesar; dos Santos Rodrigues, Cintia Damasceno; Torres, Maria C.; Bispo de Filippis, Ana Maria; Ribeiro Nogueira, Rita Maria] Fiocruz MS, IOC, Lab Flavivirus, Rio De Janeiro, RJ, Brazil.
   [Thompson, Fabiano L.] Univ Fed Rio de Janeiro, SAGE COPPE, Rio de Janeiro, RJ, Brazil.
   [Lemos, Cristina; Durovni, Betina] Secretaria Municipal Saude, Rio De Janeiro, RJ, Brazil.
   [Souza, Thiago Moreno L.; Morel, Carlos M.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, INCT IDPN, Rio De Janeiro, RJ, Brazil.
   [Gogarten, Jan F.] Robert Koch Inst, Epidemiol Highly Pathogen Microorganisms, Berlin, Germany.
   [Gogarten, Jan F.] Free Univ Berlin, Inst Microbiol & Epizoot, Berlin, Germany.
RP Lipkin, WI (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect & Immun, New York, NY 10027 USA.
EM wil2001@cumc.columbia.edu
RI Neto, Jose Cerbino/P-3713-2018; Lipkin, W. Ian/ABE-6216-2020; Delatorre,
   Edson/J-8330-2015; Leomil, Luciana/O-4860-2019; Morel,
   Carlos/Q-9657-2019; Tschoeke, Diogo A/F-9913-2019; Vizzoni,
   Alexandre/W-8718-2019; Bozza, Fernando A/A-2618-2013; Monteiro, Ana
   Paula T/L-9540-2013
OI Neto, Jose Cerbino/0000-0001-9254-917X; Lipkin, W.
   Ian/0000-0002-8768-9386; Delatorre, Edson/0000-0002-5746-0820; Morel,
   Carlos/0000-0003-2752-0009; Tschoeke, Diogo A/0000-0001-8134-4259;
   Vizzoni, Alexandre/0000-0003-0004-5084; Bozza, Fernando
   A/0000-0003-4878-0256; Thompson, Fabiano/0000-0002-7562-1683; Souza,
   Thiago/0000-0003-2212-3899; Bozza, Patricia/0000-0001-8349-9529
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - Brasil (CAPES)CAPES; National Council for Scientific and
   Technological Development (CNPq), Ministry of Science, Technology,
   Information and Communications [465313/2014-0]; Ministry of
   Education/CAPESCAPES [465313/2014-0]; Research Foundation of the State
   of Rio de Janeiro/FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [465313/2014-0]; Oswaldo
   Cruz Foundation/FIOCRUZ; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [U19 AI109761]; DAADDeutscher Akademischer Austausch Dienst
   (DAAD); German Federal Ministry of Education and Research (BMBF)Federal
   Ministry of Education & Research (BMBF); People Programme (Marie Curie
   Actions) of the European Union's Seventh Framework Programme
   (FP7/2007-2013) under REAEuropean Union (EU) [605728]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI109761, U19AI109761, U19AI109761, U19AI109761, U19AI109761,
   U19AI109761, U19AI109761, U19AI109761, U19AI109761, U19AI109761,
   U19AI109761, U19AI109761, U19AI109761, U19AI109761, U19AI109761,
   U19AI109761, U19AI109761, U19AI109761, U19AI109761] Funding Source: NIH
   RePORTER
FX We appreciate the contribution from Rio de Janeiro's city surveillance
   SMS-RJ. This study was financed in part by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance
   Code 001. YRV and ED are funded by fellowships from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES). Funding
   was also provided by National Council for Scientific and Technological
   Development (CNPq), Ministry of Science, Technology, Information and
   Communications (No. 465313/2014-0); Ministry of Education/CAPES (No.
   465313/2014-0); Research Foundation of the State of Rio de
   Janeiro/FAPERJ (No. 465313/2014-0) and Oswaldo Cruz Foundation/FIOCRUZ.
   The study was also supported by the National Institutes of Health (U19
   AI109761) to N.M., W.I.L., K.J., R.T., J.N., N.B. at the Center for
   Infection and Immunity at Columbia University, New York; and J.F.G. is a
   fellow working at CII who was supported by the DAAD with funds from the
   German Federal Ministry of Education and Research (BMBF) and the People
   Programme (Marie Curie Actions) of the European Union's Seventh
   Framework Programme (FP7/2007-2013) under REA grant agreement no 605728
   (P.R.I.M.E. - Postdoctoral Researchers International Mobility
   Experience). Funders had no role in the experiment design or
   interpretation.
CR [Anonymous], 1969, B EP SECR VIG SAUD
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Benson DA, 2013, NUCLEIC ACIDS RES, V41, pD36, DOI [10.1093/nar/gkr1202, 10.1093/nar/gkt1030, 10.1093/nar/gks1195]
   Briese T, 2015, MBIO, V6, DOI 10.1128/mBio.01491-15
   Conteville LC, 2016, MEM I OSWALDO CRUZ, V111, P347, DOI 10.1590/0074-02760160004
   Costa-da-Silva AL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005630
   Cunha MS, 2017, EMERG INFECT DIS, V23, P1737, DOI 10.3201/eid2310.161855
   da Costa AC, 2017, EMERG INFECT DIS, V23, P1742, DOI 10.3201/eid2310.170307
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Gill MS, 2013, MOL BIOL EVOL, V30, P713, DOI 10.1093/molbev/mss265
   Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X
   Pinheiro TJ, 2016, ARQ NEURO-PSIQUIAT, V74, P937, DOI [10.1590/0004-282X20160138, 10.1590/0004-282x20160138]
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Rathore Mobeen H, 2017, Adv Pediatr, V64, P27, DOI 10.1016/j.yapd.2017.04.002
   Sacramento C. Q., 2016, BIORXIV, DOI [10.1101/061671, DOI 10.1101/061671]
   Souza Thiara Manuele Alves, 2017, PLoS Curr, V9, DOI 10.1371/currents.outbreaks.4200119978d62ccaa454599cd2735727
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Teixeira MG, 2015, EMERG INFECT DIS, V21, P906, DOI 10.3201/eid2105.141727
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201
   US Food and Drug Administration, 2017, CII ARBOVIROPLEX RRT
   Volk SM, 2010, J VIROL, V84, P6497, DOI 10.1128/JVI.01603-09
   Weaver SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002921
   World Health Organization, 2004, LAB BIOS MAN 3 ED
NR 33
TC 14
Z9 14
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 26
PY 2019
VL 9
AR 2760
DI 10.1038/s41598-019-39406-9
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HM7ZT
UT WOS:000459698900021
PM 30809003
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Kurtz, P
   d'Avila, JC
   Prado, D
   Madeira, C
   Vargas-Lopes, C
   Panizzutti, R
   Azevedo, LCP
   Bozza, FA
AF Kurtz, Pedro
   d'Avila, Joana C.
   Prado, Darwin
   Madeira, Caroline
   Vargas-Lopes, Charles
   Panizzutti, Rogerio
   Azevedo, Luciano C. P.
   Bozza, Fernando A.
TI CEREBRAL MULTIMODAL MONITORING IN SEPSIS: AN EXPERIMENTAL STUDY
SO SHOCK
LA English
DT Article
DE Acute brain dysfunction; cerebral multimodality monitoring;
   sepsis-associated encephalopathy
ID COGNITIVE IMPAIRMENT; INFLAMMATORY RESPONSE; GLUTAMATE; METABOLISM;
   DEFICITS; GLUCOSE; TERM
AB Acute brain dysfunction is a complication of sepsis, and its pathophysiology remains poorly understood. We studied the brain metabolism in a resuscitated animal model of sepsis. Twelve anesthetized, mechanically ventilated, and invasively monitored pigs were allocated to a sham procedure (N = 5) or sepsis (N = 7). Sepsis was induced through fecal inoculation in the peritoneum. Fluid resuscitation was maintained during the entire study period. Animalswere observed until spontaneous death or for a maximum of 24 h. In addition to global hemodynamic and laboratory assessment, intracranial pressure and cerebral microdialysis (MD) were evaluated at baseline, 6, 12, 18, and 24 h after sepsis induction. After euthanasia, the brain was rapidly removed and a fragment from the frontal cortex was analyzed for markers of neuroinflammation, metabolism, and neurotransmission. Septic animals developed a hyperdynamic state associated with increased arterial lactate. Cerebral microdialysis showed unchanged levels of lactate/pyruvate ratios and brain glucose between the groups. Brain/serum glucose ratios were increased in the septic animals during the study period despite a progressive decrease in serum glucose. Moreover, extracellular glutamine levels were elevated starting at 6 h after sepsis. Tissue analysis showed elevated glutamate, glutamine, and glutamine synthetase in the sepsis group. However, C-Fos, a marker of neuronal activity, was unchanged between groups. In this animal model of resuscitated sepsis, we found increased oxidative stress and alterations in neuroenergetics characterized by exacerbated activity of the glutamate/glutamine cycle and increased glucose utilization by the brain, however without any evidence of decompensated energy metabolism.
C1 [Bozza, Fernando A.] Oswado Cruz Fdn, Natl Inst Infectol, Rio De Janeiro, Brazil.
   DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Inst DOr Ensino & Pesquisa, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Oswado Cruz Fdn, Natl Inst Infectol, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), Inst DOr Ensino & Pesquisa, Rio De Janeiro, Brazil.; Kurtz, P (corresponding author), Paulo Niemeyer State Brain Inst, Rio De Janeiro, Brazil.
EM kurtzpedro@mac.com; bozza.fernando@gmail.com
RI Azevedo, Luciano CP/H-2652-2012; d'Avila, Joana/L-8970-2013; Bozza,
   Fernando A/A-2618-2013
OI Azevedo, Luciano CP/0000-0001-6759-3910; d'Avila,
   Joana/0000-0002-2045-0813; Bozza, Fernando A/0000-0003-4878-0256
FU Brazilian Council for Scientific and Technological DevelopmentNational
   Council for Scientific and Technological Development (CNPq); Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Research and Education Institute Hospital
   Sirio-Libanes
FX This work was supported by unrestricted grants from Brazilian Council
   for Scientific and Technological Development, Fundacao Carlos Chagas
   Filho de Amparo a Pesquisa do Estado do Rio de Janeiro and Research and
   Education Institute Hospital Sirio-Libanes.
CR Azabou E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139969
   Bak LK, 2006, J CEREBR BLOOD F MET, V26, P1285, DOI 10.1038/sj.jcbfm.9600281
   Barichello T, 2007, BRAZ J MED BIOL RES, V40, P831, DOI 10.1590/S0100-879X2007000600013
   Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Fairbairn L, 2011, J LEUKOCYTE BIOL, V89, P855, DOI 10.1189/jlb.1110607
   Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jeitner TM, 2015, NEUROCHEM RES, V40, P2544, DOI 10.1007/s11064-015-1667-1
   Jurcovicova J, 2014, Endocr Regul, V48, P35
   Magistretti PJ, 2015, NEURON, V86, P883, DOI 10.1016/j.neuron.2015.03.035
   McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444
   Moraes CA, 2015, MOL NEUROBIOL, V52, P653, DOI 10.1007/s12035-014-8868-5
   Novy J, 2016, J NEUROIMMUNOL, V297, P156, DOI 10.1016/j.jneuroim.2016.05.016
   Palmieri EM, 2017, ANTIOXID REDOX SIGN, V26, P351, DOI 10.1089/ars.2016.6715
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Pontes De Azevedo LC, 2007, CLINICS, V62, P491, DOI 10.1590/S1807-59322007000400017
   Porras OH, 2004, J NEUROSCI, V24, P9669, DOI 10.1523/JNEUROSCI.1882-04.2004
   Rosario AL, 2011, SHOCK, V36, P604, DOI 10.1097/SHK.0b013e3182336aa4
   Schousboe A, 2014, ADV NEUROBIOL, V11, P13, DOI 10.1007/978-3-319-08894-5_2
   Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
   Stobart JL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00038
   Taccone FS, 2014, CRIT CARE MED, V42, pE114, DOI 10.1097/CCM.0b013e3182a641b8
   Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205
   Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013
NR 26
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD FEB
PY 2019
VL 51
IS 2
BP 228
EP 234
DI 10.1097/SHK.0000000000001138
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA HQ8PZ
UT WOS:000462688400013
PM 29621117
OA Bronze
DA 2020-12-01
ER

PT J
AU Metsky, HC
   Siddle, KJ
   Gladden-Young, A
   Qu, J
   Yang, DK
   Brehio, P
   Goldfarb, A
   Piantadosi, A
   Wohl, S
   Carter, A
   Lin, AE
   Barnes, KG
   Tully, DC
   Corleis, B
   Hennigan, S
   Barbosa-Lima, G
   Vieira, YR
   Paul, LM
   Tan, AL
   Garcia, KF
   Parham, LA
   Odia, I
   Eromon, P
   Folarin, OA
   Goba, A
   Simon-Loriere, E
   Hensley, L
   Balmaseda, A
   Harris, E
   Kwon, DS
   Allen, TM
   Runstadler, JA
   Smole, S
   Bozza, FA
   Souza, TML
   Isern, S
   Michael, SF
   Lorenzana, I
   Gehrke, L
   Bosch, I
   Ebel, G
   Grant, DS
   Happi, CT
   Park, DJ
   Gnirke, A
   Sabeti, PC
   Matranga, CB
AF Metsky, Hayden C.
   Siddle, Katherine J.
   Gladden-Young, Adrianne
   Qu, James
   Yang, David K.
   Brehio, Patrick
   Goldfarb, Andrew
   Piantadosi, Anne
   Wohl, Shirlee
   Carter, Amber
   Lin, Aaron E.
   Barnes, Kayla G.
   Tully, Damien C.
   Corleis, Bjorn
   Hennigan, Scott
   Barbosa-Lima, Giselle
   Vieira, Yasmine R.
   Paul, Lauren M.
   Tan, Amanda L.
   Garcia, Kimberly F.
   Parham, Leda A.
   Odia, Ikponmwosa
   Eromon, Philomena
   Folarin, Onikepe A.
   Goba, Augustine
   Simon-Loriere, Etienne
   Hensley, Lisa
   Balmaseda, Angel
   Harris, Eva
   Kwon, Douglas S.
   Allen, Todd M.
   Runstadler, Jonathan A.
   Smole, Sandra
   Bozza, Fernando A.
   Souza, Thiago M. L.
   Isern, Sharon
   Michael, Scott F.
   Lorenzana, Ivette
   Gehrke, Lee
   Bosch, Irene
   Ebel, Gregory
   Grant, Donald S.
   Happi, Christian T.
   Park, Daniel J.
   Gnirke, Andreas
   Sabeti, Pardis C.
   Matranga, Christian B.
CA Viral Hemorrhagic Fever Consortium
TI Capturing sequence diversity in metagenomes with comprehensive and
   scalable probe design
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID VIRUS; GENOME; DNA; EVOLUTION; SELECTION; PATIENT; RNA; IDENTIFICATION;
   TRANSMISSION; ALGORITHMS
AB Metagenomic sequencing has the potential to transform microbial detection and characterization, but new tools are needed to improve its sensitivity. Here we present CATCH, a computational method to enhance nucleic acid capture for enrichment of diverse microbial taxa. CATCH designs optimal probe sets, with a specified number of oligonucleotides, that achieve full coverage of, and scale well with, known sequence diversity. We focus on applying CATCH to capture viral genomes in complex metagenomic samples. We design, synthesize, and validate multiple probe sets, including one that targets the whole genomes of the 356 viral species known to infect humans. Capture with these probe sets enriches unique viral content on average 18-fold, allowing us to assemble genomes that could not be recovered without enrichment, and accurately preserves within-sample diversity. We also use these probe sets to recover genomes from the 2018 Lassa fever outbreak in Nigeria and to improve detection of uncharacterized viral infections in human and mosquito samples. The results demonstrate that CATCH enables more sensitive and cost-effective metagenomic sequencing.
C1 [Metsky, Hayden C.; Siddle, Katherine J.; Gladden-Young, Adrianne; Qu, James; Yang, David K.; Brehio, Patrick; Piantadosi, Anne; Wohl, Shirlee; Carter, Amber; Lin, Aaron E.; Barnes, Kayla G.; Park, Daniel J.; Gnirke, Andreas; Sabeti, Pardis C.; Matranga, Christian B.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Metsky, Hayden C.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Siddle, Katherine J.; Yang, David K.; Wohl, Shirlee; Lin, Aaron E.; Barnes, Kayla G.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
   [Goldfarb, Andrew] Harvard Univ, Fac Arts & Sci, Cambridge, MA 02138 USA.
   [Piantadosi, Anne; Kwon, Douglas S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Barnes, Kayla G.; Happi, Christian T.; Sabeti, Pardis C.] Harvard Univ, Dept Immunol & Infect Dis, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
   [Tully, Damien C.; Corleis, Bjorn; Kwon, Douglas S.; Allen, Todd M.] Ragon Inst MGH MIT & Harvard, Cambridge, MA USA.
   [Hennigan, Scott; Smole, Sandra] Massachusetts Dept Publ Hlth, Boston, MA USA.
   [Barbosa-Lima, Giselle; Vieira, Yasmine R.; Bozza, Fernando A.; Souza, Thiago M. L.] Fundacao Oswaldo Cruz FIOCRUZ, Rio De Janeiro, RJ, Brazil.
   [Paul, Lauren M.; Tan, Amanda L.; Isern, Sharon; Michael, Scott F.] Florida Gulf Coast Univ, Dept Biol Sci, Coll Arts & Sci, Ft Myers, FL USA.
   [Garcia, Kimberly F.; Parham, Leda A.; Lorenzana, Ivette] Univ Nacl Autonoma Honduras, Inst Invest Microbiol, Tegucigalpa, Honduras.
   [Odia, Ikponmwosa; Happi, Christian T.] Irrua Specialist Teaching Hosp, Inst Lassa Fever Res & Control, Irrua, Nigeria.
   [Eromon, Philomena; Folarin, Onikepe A.; Happi, Christian T.] Redeemers Univ, ACEGID, Ede, Nigeria.
   [Folarin, Onikepe A.; Happi, Christian T.] Redeemers Univ, Coll Nat Sci, Dept Biol Sci, Ede, Nigeria.
   [Goba, Augustine; Grant, Donald S.] Kenema Govt Hosp, Lassa Fever Lab, Kenema, Sierra Leone.
   [Simon-Loriere, Etienne] Inst Pasteur, Dept Virol, Evolutionary Genom RNA Viruses, Paris, France.
   [Hensley, Lisa] NIAID, Integrated Res Facil, Div Clin Res, US Natl Inst Hlth, Frederick, MD USA.
   [Balmaseda, Angel] Minist Hlth, Ctr Nacl Diagnost & Referencia, Lab Nacl Virol, Managua, Nicaragua.
   [Harris, Eva] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.
   [Runstadler, Jonathan A.] Tufts Univ, Cummings Sch Vet Med, Dept Infect Dis & Global Hlth, North Grafton, MA USA.
   [Gehrke, Lee; Bosch, Irene] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Gehrke, Lee] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA USA.
   [Ebel, Gregory] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Grant, Donald S.] Univ Sierra Leone, Coll Med & Allied Hlth Sci, Freetown, Sierra Leone.
   [Sabeti, Pardis C.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Metsky, HC; Siddle, KJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Metsky, HC (corresponding author), MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.; Siddle, KJ (corresponding author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
EM hayden@mit.edu; kjsiddle@broadinstitute.org
RI Piantadosi, Anne/ABC-7451-2020; Bozza, Fernando A/A-2618-2013; Allen,
   Todd/F-5473-2011
OI Bozza, Fernando A/0000-0003-4878-0256; Allen, Todd/0000-0002-6609-1318;
   Bosch, Irene/0000-0003-1352-5888; Hensley, Lisa/0000-0003-1188-4342;
   Tully, Damien/0000-0002-7620-9340; Happi, Christian/0000-0002-3056-6705;
   Souza, Thiago/0000-0003-2212-3899; Metsky, Hayden/0000-0002-8871-2349;
   Paul, Lauren/0000-0001-5503-7570; Yang, David/0000-0002-9972-3035
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19AI110818]; NIH NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272200900049C, HHSN272201400008C, R01AI099210]; Henry M. Jackson
   Foundation award [W81XWH-11-2-0174]; Bill & Melinda Gates FoundationBill
   & Melinda Gates Foundation; Human Frontiers in Science ProgramHuman
   Frontier Science Program [LT000553/2016]; NIH NHGRIUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Human Genome Research Institute (NHGRI) [U01HG007480,
   U54HG007480]; World BankThe World Bank India [ACE019]; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [U54HG007480, U54HG007480,
   U54HG007480, U54HG007480, U54HG007480, U01HG007480, U54HG007480,
   U54HG007480, U54HG007480, U54HG007480, U54HG007480, U54HG007480,
   U54HG007480, U54HG007480, U54HG007480, U54HG007480, U54HG007480,
   U54HG007480, U54HG007480] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818] Funding Source: NIH RePORTER
FX We thank S. Ye, C. Myhrvold, S. Weingarten-Gabbay, C. Freije, S.
   Schaffner, and other members of the Sabeti laboratory for useful
   discussions and feedback on the manuscript; B. Chak for assistance with
   ethical approvals and compliance; and Boca Biolistics, the Florida
   Department of Health, Miami-Dade County Mosquito Control, Research Blood
   Components, the Ragon Institute Cellular Immunology Database, and
   Brigham and Women's Hospital's Crimson Core for support with samples.
   This project has been funded in whole or in part with federal funds from
   the National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services, under
   grant number U19AI110818 to the Broad Institute. This project was also
   funded in part by NIH NIAID contract HHSN272200900049C, a Broadnext10
   gift from the Broad Institute, Henry M. Jackson Foundation award
   W81XWH-11-2-0174, and the Bill & Melinda Gates Foundation. IAV samples
   were funded by NIH NIAID contract HHSN272201400008C to J.A.R. K.J.S. is
   supported by a fellowship from the Human Frontiers in Science Program
   (LT000553/2016). S.I. and S.F.M. are supported by NIH NIAID R01AI099210.
   C.T.H. is supported by NIH NHGRI U01HG007480 and U54HG007480 and by
   World Bank project ACE019.
CR Acland A, 2013, NUCLEIC ACIDS RES, V41, pD8, DOI [10.1093/nar/gks1189, 10.1093/nar/gkx1095, 10.1093/nar/gkv1290]
   Andersen KG, 2015, CELL, V162, P738, DOI 10.1016/j.cell.2015.07.020
   Andoni A, 2008, COMMUN ACM, V51, P117, DOI 10.1145/1327452.1327494
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Barnes KG, 2017, CLIN INFECT DIS, V65, P1400, DOI 10.1093/cid/cix518
   Bedford T, 2015, NATURE, V523, P217, DOI 10.1038/nature14460
   Beliveau BJ, 2018, P NATL ACAD SCI USA, V115, pE2183, DOI 10.1073/pnas.1714530115
   Bonsall David, 2015, F1000Res, V4, P1062, DOI 10.12688/f1000research.7111.1
   Borneman J, 2001, Bioinformatics, V17 Suppl 1, pS39
   Bowen MD, 2000, J VIROL, V74, P6992, DOI 10.1128/JVI.74.15.6992-7004.2000
   Briese T, 2015, MBIO, V6, DOI 10.1128/mBio.01491-15
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Broder AZ, 2000, J COMPUT SYST SCI, V60, P630, DOI 10.1006/jcss.1999.1690
   Brown JR, 2016, J CLIN MICROBIOL, V54, P2530, DOI 10.1128/JCM.01052-16
   Carpi G, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1634-x
   Chalkias S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0186945
   Chvatal V., 1979, Mathematics of Operations Research, V4, P233, DOI 10.1287/moor.4.3.233
   Clark K, 2016, NUCLEIC ACIDS RES, V44, pD67, DOI 10.1093/nar/gkv1276
   DasGupa B, 2005, BIOINFORMATICS, V21, P3424, DOI 10.1093/bioinformatics/bti547
   de Koning APJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002384
   Depledge DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027805
   Didelot X, 2014, MOL BIOL EVOL, V31, P1869, DOI 10.1093/molbev/msu121
   Dudas G, 2017, NATURE, V544, P309, DOI 10.1038/nature22040
   Duitama J, 2009, NUCLEIC ACIDS RES, V37, P2483, DOI 10.1093/nar/gkp073
   Feige U, 1998, J ACM, V45, P634, DOI 10.1145/285055.285059
   Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523
   Gu WJ, 2008, ANAL BIOCHEM, V380, P77, DOI 10.1016/j.ab.2008.05.015
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Houldcroft CJ, 2017, NAT REV MICROBIOL, V15, P183, DOI 10.1038/nrmicro.2016.182
   Hugall AF, 2016, MOL BIOL EVOL, V33, P281, DOI 10.1093/molbev/msv216
   Indyk P., 1998, Proceedings of the Thirtieth Annual ACM Symposium on Theory of Computing, P604, DOI 10.1145/276698.276876
   Jabado OJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1106
   Jabado OJ, 2006, NUCLEIC ACIDS RES, V34, P6605, DOI 10.1093/nar/gkl966
   JOHNSON DS, 1974, J COMPUT SYST SCI, V9, P256, DOI 10.1016/S0022-0000(74)80044-9
   Karamitros Timokratis, 2018, Methods Mol Biol, V1712, P43, DOI 10.1007/978-1-4939-7514-3_4
   Kivioja T, 2012, NAT METHODS, V9, P72, DOI [10.1038/NMETH.1778, 10.1038/nmeth.1778]
   Konstantinidis KT, 2006, PHILOS T R SOC B, V361, P1929, DOI 10.1098/rstb.2006.1920
   Lapa S, 2002, J CLIN MICROBIOL, V40, P753, DOI 10.1128/JCM.40.3.753-757.2002
   Lemey P, 2006, AIDS REV, V8, P125
   Lemieux JE, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.79, 10.1038/nmicrobiol.2016.79]
   LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013
   Li H., 2013, ARXIV
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085373
   Ma DY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06828-2
   Matranga CB, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0519-7
   Mayer C, 2016, MOL BIOL EVOL, V33, P1875, DOI 10.1093/molbev/msw056
   Melnikov A, 2011, GENOME BIOL, V12, DOI [10.1186/gb-2011-12-8-R73, 10.1186/gb-2011-12-8-r73]
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
   Newman CM, 2011, VECTOR-BORNE ZOONOT, V11, P1099, DOI 10.1089/vbz.2010.0144
   Noyes NR, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0361-8
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Ondov BD, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0997-x
   Palacios G, 2007, EMERG INFECT DIS, V13, P73, DOI 10.3201/eid1301.060837
   Park D., 2017, BROADINSTITUTE VIRAL
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Pearson WR, 1996, DISCRETE APPL MATH, V71, P231, DOI 10.1016/S0166-218X(96)00066-2
   Phillippy AM, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-293
   Piantadosi A, 2018, CLIN INFECT DIS, V66, P789, DOI 10.1093/cid/cix792
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Popic V, 2018, J COMPUT BIOL, V25, P677, DOI 10.1089/cmb.2017.0250
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rash S., 2002, P 6 ANN INT C COMP B, P254, DOI 10.1145/565196.565229
   Sathar MA, 2000, INT J EXP PATHOL, V81, P305, DOI 10.1111/j.1365-2613.2000.00166.x
   Shi M, 2016, NATURE, V540, P539, DOI 10.1038/nature20167
   Siddle KJ, 2018, NEW ENGL J MED, V379, P1745, DOI 10.1056/NEJMoa1804498
   Stremlau MH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003631
   Thomson E, 2016, J CLIN MICROBIOL, V54, P2470, DOI 10.1128/JCM.00330-16
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   Wilson MR, 2016, MSYSTEMS, V1, DOI 10.1128/mSystems.00058-16
   Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46
   Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
   Wylie TN, 2015, GENOME RES, V25, P1910, DOI 10.1101/gr.191049.115
   Yarza P, 2008, SYST APPL MICROBIOL, V31, P241, DOI 10.1016/j.syapm.2008.07.001
NR 75
TC 21
Z9 22
U1 2
U2 17
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD FEB
PY 2019
VL 37
IS 2
BP 160
EP +
DI 10.1038/s41587-018-0006-x
PG 13
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA HK0GH
UT WOS:000457576400020
PM 30718881
OA Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Ferreira, AC
   Reis, PA
   de Freitas, CS
   Sacramento, CQ
   Hoelz, LVB
   Bastos, MM
   Mattos, M
   Rocha, N
   Quintanilha, IGD
   Pedrosa, CDG
   Souza, LRQ
   Loiola, EC
   Trindade, P
   Vieira, YR
   Barbosa-Lima, G
   Faria, HCD
   Boechat, N
   Rehen, SK
   Bruning, K
   Bozza, FA
   Bozza, PT
   Souza, TML
AF Ferreira, Andre C.
   Reis, Patricia A.
   de Freitas, Caroline S.
   Sacramento, Carolina Q.
   Boas Hoelz, Lucas Villas
   Bastos, Monica M.
   Mattos, Mayara
   Rocha, Natasha
   de Azevedo Quintanilha, Isaclaudia Gomes
   Gouveia Pedrosa, Carolina da Silva
   Quintino Souza, Leticia Rocha
   Loiola, Erick Correia
   Trindade, Pablo
   Vieira, Yasmine Rangel
   Barbosa-Lima, Giselle
   de Castro Faria Neto, Hugo C.
   Boechat, Nubia
   Rehen, Stevens K.
   Bruning, Karin
   Bozza, Fernando A.
   Bozza, Patricia T.
   Souza, Thiago Moreno L.
TI Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits
   Chikungunya Virus Replication
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE chikungunya; chikungunya virus; arthralgia; antiviral; sofosbuvir; drug
ID INTERFERON-ALPHA; STEM-CELLS; ZIKA; INFECTION; ANTIVIRALS; IVERMECTIN;
   DISCOVERY; RIBAVIRIN; BINDING; GROWTH
AB Chikungunya virus (CHIKV) causes a febrile disease associated with chronic arthralgia, which may progress to neurological impairment. Chikungunya fever (CF) is an ongoing public health problem in tropical and subtropical regions of the world, where control of the CHIKV vector, Aedes mosquitos, has failed. As there is no vaccine or specific treatment for CHIKV, patients receive only palliative care to alleviate pain and arthralgia. Thus, drug repurposing is necessary to identify antivirals against CHIKV. CHIKV RNA polymerase is similar to the orthologue enzyme of other positive-sense RNA viruses, such as members of the Flaviviridae family. Among the Flaviviridae, not only is hepatitis C virus RNA polymerase susceptible to sofosbuvir, a clinically approved nucleotide analogue, but so is dengue, Zika, and yellow fever virus replication. Here, we found that sofosbuvir was three times more selective in inhibiting CHIKV production in human hepatoma cells than ribavirin, a panantiviral drug. Although CHIKV replication in human induced pluripotent stem cellderived astrocytes was less susceptible to sofosbuvir than were hepatoma cells, sofosbuvir nevertheless impaired virus production and cell death in a multiplicity of infection-dependent manner. Sofosbuvir also exhibited antiviral activity in vivo by preventing CHIKV-induced paw edema in adult mice at a dose of 20 mg/kg of body weight/day and prevented mortality in a neonate mouse model at 40-and 80-mg/kg/day doses. Our data demonstrate that a prototypic alphavirus, CHIKV, is also susceptible to sofosbuvir. As sofosbuvir is a clinically approved drug, our findings could pave the way to it becoming a therapeutic option against CF.
C1 [Ferreira, Andre C.; Reis, Patricia A.; de Freitas, Caroline S.; Sacramento, Carolina Q.; Mattos, Mayara; Rocha, Natasha; de Azevedo Quintanilha, Isaclaudia Gomes; de Castro Faria Neto, Hugo C.; Bozza, Fernando A.; Bozza, Patricia T.; Souza, Thiago Moreno L.] Fundacao Oswaldo Cruz Fiocruz, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Ferreira, Andre C.; Vieira, Yasmine Rangel; Barbosa-Lima, Giselle; Bozza, Fernando A.; Souza, Thiago Moreno L.] Fiocruz MS, INI, Rio De Janeiro, Brazil.
   [Boas Hoelz, Lucas Villas; Bastos, Monica M.; Boechat, Nubia] Fiocruz MS, Inst Tecnol Farmacos Farmanguinhos, Rio De Janeiro, Brazil.
   [Gouveia Pedrosa, Carolina da Silva; Quintino Souza, Leticia Rocha; Loiola, Erick Correia; Trindade, Pablo; Rehen, Stevens K.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Rehen, Stevens K.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Rio De Janeiro, Brazil.
   [Bruning, Karin] BMK Consortium, Rio De Janeiro, Brazil.
   [Ferreira, Andre C.; de Freitas, Caroline S.; Sacramento, Carolina Q.; Mattos, Mayara; Rocha, Natasha; Vieira, Yasmine Rangel; Souza, Thiago Moreno L.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, Rio De Janeiro, Brazil.
RP Souza, TML (corresponding author), Fundacao Oswaldo Cruz Fiocruz, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.; Souza, TML (corresponding author), Fiocruz MS, INI, Rio De Janeiro, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, Rio De Janeiro, Brazil.
EM tmoreno@cdts.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Souza, Thiago Moreno L./G-2900-2012;
   Trindade, Pablo/D-8913-2016; Boechat, Nubia/N-1406-2014; Rehen, Stevens
   K/J-5874-2012; Boechat, Nubia/K-2520-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Souza, Thiago Moreno
   L./0000-0003-2212-3899; Trindade, Pablo/0000-0001-5953-7054; Boechat,
   Nubia/0000-0003-0146-2218; Rehen, Stevens K/0000-0003-4216-9501;
   Boechat, Nubia/0000-0003-0146-2218; Bozza, Patricia/0000-0001-8349-9529
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Ministry of Science, Technology, Information and Communications
   [465313/2014-0]; Ministry of Education/CAPESCAPES [465313/2014-0];
   Research Foundation of the State of Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [465313/2014-0]; Oswaldo Cruz Foundation (Fiocruz)
FX Funding was provided by the National Council for Scientific and
   Technological Development (CNPq), Ministry of Science, Technology,
   Information and Communications (grants including, but not limited to,
   465313/2014-0), Ministry of Education/CAPES (465313/2014-0), Research
   Foundation of the State of Rio de Janeiro (FAPERJ) (grants including,
   but not limited to, 465313/2014-0), and the Oswaldo Cruz Foundation
   (Fiocruz). A competing financial interest exists for K.B., who is
   partner in a consortium able to produce generic sofosbuvir. The
   consortium and her participation were limited to providing sofosbuvir
   for this study. The BMK Consortium is comprised of Blanver Farmoquimica
   Ltd., Microbiologica Quimica e Farmaceutica Ltd., and Karin Bruning &
   Cia Ltd. A.C.F., P.A.R., C.S.D.F., C.Q.S., L.V.B.H., M.M.B., M.M., N.R.,
   I.G.A.Q., C.S.G.P., L.R.Q.S., E.C.L., P.T., Y.R.V., and G.B.-L.
   performed the experiments. H.C.C.F.N., N.B., S.K.R., K.B., F.A.B.,
   P.T.B., and T.M.L.S. conceptualized the experiments and raised funds.
   K.B. provided critical material. T.M.L.S. organized the study. All
   authors revised and approved the manuscript. Funders had no role in the
   experiment design or interpretation.
CR Abdelnabi R, 2015, ANTIVIR RES, V121, P59, DOI 10.1016/j.antiviral.2015.06.017
   Bhatia HK, 2014, J PHARMACOL PHARMACO, V5, P278, DOI 10.4103/0976-500X.142464
   Briolant S, 2004, ANTIVIR RES, V61, P111, DOI 10.1016/j.antiviral.2003.09.005
   Brizzi K, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0561-1
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Chen MW, 2017, ANTIVIR RES, V143, P38, DOI 10.1016/j.antiviral.2017.04.001
   CRUZ DJM, 2013, PLOS NEGLECT TROP D, V7
   da Costa AC, 2017, EMERG INFECT DIS, V23, P1742, DOI 10.3201/eid2310.170307
   da Silva-Junior EF, 2017, BIOORGAN MED CHEM, V25, P4219, DOI 10.1016/j.bmc.2017.06.049
   Das PK, 2014, J BIOL CHEM, V289, P5635, DOI 10.1074/jbc.M113.503433
   Delang L, 2014, J ANTIMICROB CHEMOTH, V69, P2770, DOI 10.1093/jac/dku209
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   European Medicines Agency, 2013, COMM MED PROD HUM US
   Ferreira AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09797-8
   Freitas C, 2018, YELLOW FEVER VIRUS I, DOI [10.1101/266361., DOI 10.1101/266361]
   Gallegos KM, 2016, J INFECT DIS, V214, P1192, DOI 10.1093/infdis/jiw358
   Ganesan VK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120368
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603-09
   Gasque P, 2016, J INFECT DIS, V214, pS446, DOI 10.1093/infdis/jiw362
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Gazos-Lopes F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003077
   Gilead Sciences, 2015, PROD MON PR SOV SOF
   Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200
   Hawman DW, 2013, J VIROL, V87, P13878, DOI 10.1128/JVI.02666-13
   Huang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34793
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Inglis FM, 2016, J NEUROVIROL, V22, P140, DOI 10.1007/s13365-015-0378-3
   Kaur P, 2013, ANTIMICROB AGENTS CH, V57, P155, DOI 10.1128/AAC.01467-12
   Khan M, 2011, ANTIVIR RES, V89, P1, DOI 10.1016/j.antiviral.2010.10.009
   Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010
   Krishnamoorthy K, 2009, J VECTOR DIS, V46, P26
   Lanciotti RS, 2007, EMERG INFECT DIS, V13, P764, DOI 10.3201/eid1305.070015
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li GY, 2006, ORG LETT, V8, P3613, DOI 10.1021/ol061525k
   MASON P. J., 1957, TRANS ROY SOC TROP MED AND HYG, V51, P238
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4
   van den Pol AN, 2017, J NEUROSCI, V37, P2161, DOI 10.1523/JNEUROSCI.3124-16.2017
   National Research Council, 2011, GUIDE CARE USE LAB A
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Pialoux G, 2007, LANCET INFECT DIS, V7, P319, DOI 10.1016/S1473-3099(07)70107-X
   Pinheiro TJ, 2016, ARQ NEURO-PSIQUIAT, V74, P937, DOI [10.1590/0004-282X20160138, 10.1590/0004-282x20160138]
   Rothan HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126360
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   Sangeetha K, 2017, BIOMED PHARMACOTHER, V87, P302, DOI 10.1016/j.biopha.2016.12.069
   SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Sofia MJ, 2010, J MED CHEM, V53, P7202, DOI 10.1021/jm100863x
   Souza TMA, 2017, PLOS CURR, V9
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   SVS-MS, 2018, MON CAS DENG FEBR CH
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   TONG XL, 2017, SCI REP UK, V7
   Varghese FS, 2016, J VIROL, V90, P9743, DOI 10.1128/JVI.01382-16
   Varghese FS, 2016, ANTIVIR RES, V126, P117, DOI 10.1016/j.antiviral.2015.12.012
   Vicenti I, 2018, VIRUS RES, V244, P64, DOI 10.1016/j.virusres.2017.11.003
   Weaver SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002921
   World Health Organization, 2008, GUID CLIN MAN CHIK F
   Yan YP, 2013, STEM CELL TRANSL MED, V2, P1022, DOI [10.5966/sctm.2013-0080erratum, 10.5966/sctm.2013-0080]
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhang HM, 2013, J MED CHEM, V56, P1074, DOI 10.1021/jm301519z
NR 63
TC 13
Z9 13
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2019
VL 63
IS 2
AR e01389-18
DI 10.1128/AAC.01389-18
PG 15
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA HJ3YN
UT WOS:000457110200025
PM 30455237
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Moreira-Soto, A
   Rockstroh, A
   Fischer, C
   Nascimento, AD
   Calheiros, AS
   Drosten, C
   Bozza, PT
   Souza, TML
   Ulbert, S
   Drexler, JF
AF Bozza, Fernando A.
   Moreira-Soto, Andres
   Rockstroh, Alexandra
   Fischer, Carlo
   Nascimento, Alessandra D.
   Calheiros, Andrea S.
   Drosten, Christian
   Bozza, Patricia T.
   Souza, Thiago Moreno L.
   Ulbert, Sebastian
   Drexler, Jan Felix
TI Differential Shedding and Antibody Kinetics of Zika and Chikungunya
   Viruses, Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID CROSS-REACTIVITY; SPREAD
AB In seroconversion panels obtained from patients from Brazil, diagnostic testing for Zika virus infection was improved by combining multiple antibody isotypes, techniques, and antigens, but sensitivity remained suboptimal. In contrast, chikungunya virus diagnostic testing was unambiguous. Recurrent recent arbovirus infections suggested by serologic data and unspecific symptoms highlight the need for exhaustive virologic testing.
C1 [Bozza, Fernando A.; Nascimento, Alessandra D.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Nascimento, Alessandra D.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Moreira-Soto, Andres; Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Charite Univ Med Berlin, Berlin, Germany.
   [Moreira-Soto, Andres; Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Moreira-Soto, Andres; Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Humboldt Univ, Berlin, Germany.
   [Moreira-Soto, Andres; Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Rockstroh, Alexandra; Ulbert, Sebastian] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany.
   [Calheiros, Andrea S.; Bozza, Patricia T.] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Drosten, Christian; Drexler, Jan Felix] German Ctr Infect Res, Berlin, Germany.
   [Souza, Thiago Moreno L.] Ctr Technol Dev Hlth, Rio De Janeiro, Brazil.
   [Drexler, Jan Felix] Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
RP Drexler, JF (corresponding author), Campus Charite Mitte, Inst Virol, Helmut Ruska Haus,Charitepl 1, D-10098 Berlin, Germany.
EM felix.drexler@charite.de
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529; Moreira-Soto, Andres/0000-0002-9224-5157;
   Drexler, Jan Felix/0000-0002-3509-0232; Souza,
   Thiago/0000-0003-2212-3899; Fischer, Carlo/0000-0001-9163-2406
FU European Union's Horizon 2020 Research and Innovation Programme through
   the ZIKAlliance project [734548]; German Centre for Infection Research
   through the ZIKApath project; Conselho Nacional de Desenvolvimento e
   Pesquisa (CNPq)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ)
FX This work was supported by the European Union's Horizon 2020 Research
   and Innovation Programme through the ZIKAlliance project (grant
   agreement no. 734548), the German Centre for Infection Research through
   the ZIKApath project, by the Conselho Nacional de Desenvolvimento e
   Pesquisa (CNPq) and Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ).
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Hassing RJ, 2010, EUROSURVEILLANCE, V15, P22
   Jain J, 2017, CLIN INFECT DIS, V65, P133, DOI 10.1093/cid/cix283
   L'Huillier AG, 2017, J CLIN MICROBIOL, V55, P2462, DOI 10.1128/JCM.00442-17
   Lindsey NP, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01115-17
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Steinhagen K, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   World Health Organization (WHO), UPD QUEST ANSW REL D
NR 15
TC 11
Z9 12
U1 0
U2 3
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD FEB
PY 2019
VL 25
IS 2
BP 311
EP 315
DI 10.3201/eid2502.180166
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HI0LV
UT WOS:000456134000015
PM 30666934
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Nassar, AP
   Zampieri, FG
   Salluh, JI
   Bozza, FA
   Machado, FR
   Guimaraes, HP
   Damiani, LP
   Cavalcanti, AB
AF Nassar, Antonio Paulo, Jr.
   Zampieri, Fernando G.
   Salluh, Jorge I.
   Bozza, Fernando A.
   Machado, Flavia Ribeiro
   Guimaraes, Helio Penna
   Damiani, Lucas P.
   Cavalcanti, Alexandre Biasi
TI Organizational factors associated with target sedation on the first 48h
   of mechanical ventilation: an analysis of checklist-ICU database
SO CRITICAL CARE
LA English
DT Article
DE Conscious sedation; Critical care; Deep sedation; Mechanical
   ventilation; Outcome and process assessment
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; LONG-TERM MORTALITY;
   PROTOCOLIZED SEDATION; CLINICAL-OUTCOMES; INTERRUPTION; IMPACT; DEPTH;
   PATTERNS; DELIRIUM
AB BackgroundAlthough light sedation levels are associated with several beneficial outcomes for critically ill patients on mechanical ventilation, the majority of patients are still deeply sedated. Organizational factors may play a role on adherence to light sedation levels. We aimed to identify organizational factors associated with a moderate to light sedation target on the first 48h of mechanical ventilation, as well as the association between early achievement of within-target sedation and mortality.MethodsThis study is a secondary analysis of a multicenter two-phase study (prospective cohort followed by a cluster-randomized controlled trial) performed in 118 Brazilian ICUs. We included all critically ill patients who were on mechanical ventilation 48h after ICU admission.A moderate to light level of sedation or being alert and calm (i.e., the Richmond Agitation-Sedation Scale of -3 to 0) was the target for all patients on mechanical ventilation during the study period. We collected data on the type of hospital (public, private, profit and private, nonprofit), hospital teaching status, nursing and physician staffing, and presence of sedation, analgesia, and weaning protocols. We used multivariate random-effects regression with ICU and study phase as random-effects and correction for patients' Simplified Acute Physiology Score 3 and Sequential Organ Failure Assessment. We also performed a mediation analysis to explore whether sedation level was just a mediator of the association between organizational factors and mortality.ResultsWe included 5719 patients. Only 1710 (29.9%) were on target sedation levels on day 2. Board-certified intensivists on the morning and afternoon shifts were associated with an adequate sedation level on day 2 (OR=2.43; CI 95%, 1.09-5.38). Target sedation levels were associated with reduced hospital mortality (OR=0.63; CI 95%, 0.55-0.72). Mediation analysis also suggested such an association, but did not suggest a relationship between the physician staffing model and hospital mortality.ConclusionsBoard-certified intensivists on morning and afternoon shifts were associated with an increased number of patients achieving lighter sedation goals. These findings reinforce the importance of organizational factors, such as intensivists' presence, as a modifiable quality improvement target.
C1 [Nassar, Antonio Paulo, Jr.] AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil.
   [Nassar, Antonio Paulo, Jr.] AC Camargo Canc Ctr, Postgrad Program, Sao Paulo, Brazil.
   [Zampieri, Fernando G.; Guimaraes, Helio Penna; Damiani, Lucas P.; Cavalcanti, Alexandre Biasi] HCor Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando G.] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
   [Salluh, Jorge I.] DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Salluh, Jorge I.] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.
   [Salluh, Jorge I.] Univ Fed Rio de Janeiro, Programa Posgrad Clin Med, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst DOr Pesquisa Ensino IDOR, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil.
   [Guimaraes, Helio Penna] Univ Fed Sao Paulo, Sao Paulo, Brazil.
RP Nassar, AP (corresponding author), AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil.; Nassar, AP (corresponding author), AC Camargo Canc Ctr, Postgrad Program, Sao Paulo, Brazil.
EM paulo.nassar@accamargo.org.br
RI Bozza, Fernando A/A-2618-2013; Nassar, Antonio P/I-5508-2015; Guimaraes,
   Helio Penna/AAD-8681-2019; dantas, vicente c souza/L-2648-2013;
   Zampieri, Fernando/K-3305-2014
OI Bozza, Fernando A/0000-0003-4878-0256; Nassar, Antonio
   P/0000-0002-0522-7445; Zampieri, Fernando/0000-0001-9315-6386
FU Brazilian Health Surveillance Agency (ANVISA); PROADI; Brazilian
   Development Bank (BNDES)
FX This study was conducted as part of the Program to Support Institutional
   Development of Universal Health System (PROADI) from the Brazilian
   Ministry of Health. It was funded mainly by the Brazilian Health
   Surveillance Agency (ANVISA), PROADI, and Brazilian Development Bank
   (BNDES). The funding bodies had no role in the design of the study,
   collection, analysis and interpretation of data, and in writing the
   manuscript.
CR Arabi YM, 2016, CRIT CARE MED, V44, pE940, DOI 10.1097/CCM.0000000000001854
   Azevedo LCP, 2013, CRIT CARE, V17, DOI 10.1186/cc12594
   Balzer F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0929-2
   Bucknall TK, 2008, CRIT CARE MED, V36, P1444, DOI 10.1097/CCM.0b013e318168f82d
   Cavalcanti AB, 2016, JAMA-J AM MED ASSOC, V315, P1520, DOI 10.1001/jama.2016.0154
   Cavalcanti AB, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-014-0190-0
   Chanques G, 2017, LANCET RESP MED, V5, P795, DOI 10.1016/S2213-2600(17)30304-1
   Costa DK, 2017, CHEST, V152, P304, DOI 10.1016/j.chest.2017.03.054
   Curley MAQ, 2015, JAMA-J AM MED ASSOC, V313, P379, DOI 10.1001/jama.2014.18399
   Estenssoro E, 2017, CRIT CARE MED, V45, P1325, DOI 10.1097/CCM.0000000000002413
   FOX J, 1992, J AM STAT ASSOC, V87, P178, DOI 10.2307/2290467
   Gershengorn HB, 2017, JAMA INTERN MED, V177, P388, DOI 10.1001/jamainternmed.2016.8457
   Gill KV, 2012, ANN PHARMACOTHER, V46, P1331, DOI 10.1345/aph.1R037
   Kim MM, 2010, ARCH INTERN MED, V170, P369, DOI 10.1001/archinternmed.2009.521
   Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541
   Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002
   Marshall J, 2008, CRIT CARE MED, V36, P427, DOI 10.1097/01.CCM.0000300275.63811.B3
   Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872
   Minhas MA, 2015, MAYO CLIN PROC, V90, P613, DOI 10.1016/j.mayocp.2015.02.016
   Sakr Y, 2015, CRIT CARE MED, V43, P519, DOI 10.1097/CCM.0000000000000754
   Shehabi Y, 2008, ANAESTH INTENS CARE, V36, P570, DOI 10.1177/0310057X0803600423
   Shehabi Y, 2018, CRIT CARE MED, V46, P490, DOI 10.1097/CCM.0000000000002902
   Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2
   Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Tanaka LMS, 2014, CRIT CARE, V18, DOI 10.1186/cc13995
   Stephens RJ, 2018, CRIT CARE MED, V46, P471, DOI 10.1097/CCM.0000000000002885
   Stephens RJ, 2017, CHEST, V152, P963, DOI 10.1016/j.chest.2017.05.041
   Sultan OW, 2018, AM J MED QUAL, V33, P576, DOI 10.1177/1062860618766614
   Vinci RJ, 2018, JAMA-J AM MED ASSOC, V320, P345, DOI 10.1001/jama.2018.9183
   Whitehouse T, 2017, CRIT CARE MED, V45, P949, DOI 10.1097/CCM.0000000000002373
   Wilcox ME, 2013, CRIT CARE MED, V41, P2253, DOI 10.1097/CCM.0b013e318292313a
   Young D, 2013, JAMA-J AM MED ASSOC, V309, P2121, DOI 10.1001/jama.2013.5154
NR 33
TC 6
Z9 6
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JAN 29
PY 2019
VL 23
AR 34
DI 10.1186/s13054-019-2323-y
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA HJ4JR
UT WOS:000457140800002
PM 30696474
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU de Freitas, CS
   Higa, LM
   Sacramento, CQ
   Ferreira, AC
   Reis, PA
   Delvecchio, R
   Monteiro, FL
   Barbosa-Lima, G
   Westgarth, HJ
   Vieira, YR
   Mattos, M
   Rocha, N
   Hoelz, LVB
   Leme, RPP
   Bastos, MM
   Rodrigues, GOL
   Lopes, CEM
   Queiroz, CM
   Lima, CX
   Costa, VV
   Teixeira, MM
   Bozza, FA
   Bozza, PT
   Boechat, N
   Tanuri, A
   Souza, TML
AF de Freitas, Caroline S.
   Higa, Luiza M.
   Sacramento, Carolina Q.
   Ferreira, Andre C.
   Reis, Patricia A.
   Delvecchio, Rodrigo
   Monteiro, Fabio L.
   Barbosa-Lima, Giselle
   Westgarth, Harrison James
   Vieira, Yasmine Rangel
   Mattos, Mayara
   Rocha, Natasha
   Boas Hoelz, Lucas Villas
   Paes Leme, Rennan Papaleo
   Bastos, Monica M.
   Rodrigues, Gisele Olinto L.
   Lopes, Carla Elizabeth M.
   Queiroz-Junior, Celso Martins
   Lima, Cristiano X.
   Costa, Vivian V.
   Teixeira, Mauro M.
   Bozza, Fernando A.
   Bozza, Patricia T.
   Boechat, Nubia
   Tanuri, Amilcar
   Souza, Thiago Moreno L.
TI Yellow fever virus is susceptible to sofosbuvir both in vitro and in
   vivo
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ZIKA VIRUS; RIBAVIRIN; REPLICATION; INTERFERON; POLYMERASE; MODELS;
   DENGUE
AB Yellow fever virus (YFV) is a member of the Flaviviridae family. In Brazil, yellow fever (YF) cases have increased dramatically in sylvatic areas neighboring urban zones in the last few years. Because of the high lethality rates associated with infection and absence of any antiviral treatments, it is essential to identify therapeutic options to respond to YFV outbreaks. Repurposing of clinically approved drugs represents the fastest alternative to discover antivirals for public health emergencies. Other Flaviviruses, such as Zika (ZIKV) and dengue (DENV) viruses, are susceptible to sofosbuvir, a clinically approved drug against hepatitis C virus (HCV). Our data showed that sofosbuvir docks onto YFV RNA polymerase using conserved amino acid residues for nucleotide binding. This drug inhibited the replication of both vaccine and wild-type strains of YFV on human hepatoma cells, with EC50 values around 5 M. Sofosbuvir protected YFV-infected neonatal Swiss mice and adult type I interferon receptor knockout mice (A129(-/-)) from mortality and weight loss. Because of its safety profile in humans and significant antiviral effects in vitro and in mice, Sofosbuvir may represent a novel therapeutic option for the treatment of YF. Key-words: Yellow fever virus; Yellow fever, antiviral; sofosbuvir
   Author summary Yellow fever virus is transmitted by mosquitoes and its infection may be asymptomatic or lead to a wide clinical spectrum ranging from a mild febrile illness to a potentially lethal viral hemorrhagic fever characterized by liver damage. Although a yellow fever vaccine is available, low coverage allows 80,000-200,000 cases and 30,000-60,000 deaths annually worldwide. There are no specific therapy and treatment relies on supportive care, reinforcing an urgent need for antiviral repourposing. Here, we showed that sofosbuvir, clinically approved against hepatitis C, inhibits yellow fever virus replication in liver cell lines and animal models. In vitro, sofosbuvir inhibits viral RNA replication, decreases the number of infected cells and the production of infectious virus particles. These data is particularly relevante since the liver is the main target of yellow fever infection. Sofosbuvir also protected infected animals from mortality, weight loss and liver injury, especially prophylatically. Our pre-clinical results supports a second use of sofosbuvir against yellow fever.
C1 [de Freitas, Caroline S.; Sacramento, Carolina Q.; Ferreira, Andre C.; Reis, Patricia A.; Mattos, Mayara; Rocha, Natasha; Bozza, Fernando A.; Bozza, Patricia T.; Souza, Thiago Moreno L.] Fdn Oswaldo Cruz Fiocruz, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [de Freitas, Caroline S.; Sacramento, Carolina Q.; Ferreira, Andre C.; Vieira, Yasmine Rangel; Mattos, Mayara; Rocha, Natasha; Souza, Thiago Moreno L.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Rio De Janeiro, RJ, Brazil.
   [Higa, Luiza M.; Delvecchio, Rodrigo; Monteiro, Fabio L.; Westgarth, Harrison James; Tanuri, Amilcar] Univ Fed Rio de Janeiro, Inst Biol, Lab Virol Mol, Rio de Janeiro, RJ, Brazil.
   [Barbosa-Lima, Giselle; Vieira, Yasmine Rangel; Bozza, Fernando A.; Souza, Thiago Moreno L.] Fiocruz MS, INI, Rio De Janeiro, RJ, Brazil.
   [Boas Hoelz, Lucas Villas; Paes Leme, Rennan Papaleo; Bastos, Monica M.; Boechat, Nubia] Fiocruz MS, Inst Tecnol Farm Farmanguinhos, Rio De Janeiro, RJ, Brazil.
   [Rodrigues, Gisele Olinto L.; Lopes, Carla Elizabeth M.; Costa, Vivian V.; Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Biol Sci ICB, Ctr Res & Dev Pharmaceut, Belo Horizonte, MG, Brazil.
   [Rodrigues, Gisele Olinto L.; Lopes, Carla Elizabeth M.; Costa, Vivian V.] Univ Fed Minas Gerais, Inst Biol Sci ICB, Dept Morphol, Res Grp Arboviral Dis, Belo Horizonte, MG, Brazil.
   [Queiroz-Junior, Celso Martins] Univ Fed Minas Gerais, Inst Biol Sci ICB, Dept Morphol, Cardiac Lab, Belo Horizonte, MG, Brazil.
   [Lima, Cristiano X.] Univ Fed Minas Gerais, Dept Cirurgia, Fac Med, Belo Horizonte, MG, Brazil.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Biol Sci ICB, Dept Biochem & Immunol, Immunopharmacol Lab, Belo Horizonte, MG, Brazil.
RP Souza, TML (corresponding author), Fdn Oswaldo Cruz Fiocruz, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, INI, Rio De Janeiro, RJ, Brazil.
EM tmoreno@cdts.fiocruz.br
RI Boechat, Nubia/N-1406-2014; Queiroz-Junior, Celso/L-5438-2013; Souza,
   Thiago Moreno L./G-2900-2012; Boechat, Nubia/K-2520-2019; Bozza,
   Fernando A/A-2618-2013; Higa, Luiza/W-2698-2019; Teixeira, Mauro
   M/A-4587-2008; Costa, Vivian VVC/I-2499-2018
OI Boechat, Nubia/0000-0003-0146-2218; Queiroz-Junior,
   Celso/0000-0002-7884-7709; Souza, Thiago Moreno L./0000-0003-2212-3899;
   Boechat, Nubia/0000-0003-0146-2218; Bozza, Fernando
   A/0000-0003-4878-0256; Teixeira, Mauro M/0000-0002-6944-3008; Costa,
   Vivian VVC/0000-0002-0175-642X; Lima Monteiro, Fabio
   Luis/0000-0002-9107-6865; Bozza, Patricia/0000-0001-8349-9529
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [E-26/201.573/2014]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [306389/2014-2,
   425636/2016-0]; National Institute of Science and Technology in Dengue
   (INCT dengue) - Brazilian National Science Council (CNPq, Brazil); Minas
   Gerais Foundation for Science (FAPEMIG, Brazil); National Council for
   Scientific and Technological Development (CNPq), Ministry of Science,
   Technology, Information and Communications [465313/2014-0]; Ministry of
   Education/CAPESCAPES [465313/2014-0]; Research Foundation of the State
   of Rio de Janeiro/FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [465313/2014-0]; Oswaldo
   Cruz Foundation/FIOCRUZ; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior Brasil (CAPES)CAPES [001]
FX The financial support was provided by Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ -http://www.faperj.br/ - Grant Number
   E-26/201.573/2014) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq - http://cnpq.br/-Grant Numbers 306389/2014-2 and
   425636/2016-0). TMLS received the funds. This work has received
   financial support from the National Institute of Science and Technology
   in Dengue (INCT dengue), a scheme funded by the Brazilian National
   Science Council (CNPq, Brazil) and Minas Gerais Foundation for Science
   (FAPEMIG, Brazil). Funding was also provided by National Council for
   Scientific and Technological Development (CNPq), Ministry of Science,
   Technology, Information and Communications (no. 465313/2014-0); Ministry
   of Education/CAPES (no. 465313/2014-0); Research Foundation of the State
   of Rio de Janeiro/FAPERJ (no. 465313/2014-0) and Oswaldo Cruz
   Foundation/FIOCRUZ to National Institute for Science and Technology on
   Innovation on Diseases of Neglected Populations (INCT/IDPN), Center for
   Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, RJ,
   Brazil. This study was financed in part by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) - Finance
   Code 001. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Amarela CF, 2017, 432017 INFORME
   [Anonymous], 2017, WILL YELL FEV STRIK
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Babusis D, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.02587-17
   Barnett ED, 2018, CLIN INFECT DIS, V44, P850
   Beasley DWC, 2015, ANTIVIR RES, V115, P48, DOI 10.1016/j.antiviral.2014.12.010
   Bhatia HK, 2014, J PHARMACOL PHARMACO, V5, P278, DOI 10.4103/0976-500X.142464
   Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002
   Buckwold VE, 2003, ANTIMICROB AGENTS CH, V47, P2293, DOI 10.1128/AAC.47.7.2293-2298.2003
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Butler D, 2016, NATURE, V532, P155, DOI 10.1038/532155a
   Costa VV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001663
   de Santana F, 2014, B FEBRE CHIKUNGUNYA
   Dutta S, 2009, MOL BIOTECHNOL, V42, P1, DOI 10.1007/s12033-008-9127-7
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Faria NR, 2018, SCIENCE, V361, P894, DOI 10.1126/science.aat7115
   FDA FaDA, COP RIB TABL 2015
   Ferreira AC, 2018, ANTIMICROB AGENTS CH
   Ferreira AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09797-8
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Gilead, PROD MON PR SOVALDI
   Gilead Sciences Canada I, 2015, PROD MON SOVALDI SOF
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Julander JG, 2007, ANTIVIR RES, V73, P140, DOI 10.1016/j.antiviral.2006.08.008
   Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010
   Kumar R, 2009, CLIN INFECT DIS, V48, P400, DOI 10.1086/596309
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Leyssen P, 2006, MOL PHARMACOL, V69, P1461, DOI 10.1124/mol.105.020057
   Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
   Lu J, 2011, J VIROL, V85, P2126, DOI 10.1128/JVI.01531-10
   Meier KC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000614
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Mir D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07873-7
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Paessler S, 2013, ANNU REV PATHOL-MECH, V8, P411, DOI 10.1146/annurev-pathol-020712-164041
   Paulo F-FdMdUdS, 1 LIVER TRANSPLANT D
   Quaresma JAS, 2007, T ROY SOC TROP MED H, V101, P161, DOI 10.1016/j.trstmh.2006.02.019
   Reed LJ, 1938, AM J HYG
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Smolders EJ, 2016, DRUG SAFETY, V39, P589, DOI 10.1007/s40264-016-0420-2
   Sofia MJ, 2010, J MED CHEM, V53, P7202, DOI 10.1021/jm100863x
   Song ATW, 2018, HEPATOLOGY
   Souza TML, 2008, ANTIVIR RES, V77, P20, DOI 10.1016/j.antiviral.2007.08.011
   Staples J. Erin, 2010, Morbidity and Mortality Weekly Report, V59, P1
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
   Villegoureix I., 2018, VILL I
   Xu HT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06612-2
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zhao YQ, 2015, P NATL ACAD SCI USA, V112, P14834, DOI 10.1073/pnas.1514978112
NR 51
TC 18
Z9 18
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2019
VL 13
IS 1
AR e0007072
DI 10.1371/journal.pntd.0007072
PG 22
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA HJ7SX
UT WOS:000457398700038
PM 30699122
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Sganzerla, D
   Teixeira, C
   Robinson, CC
   Kochhann, R
   Santos, MMS
   de Moura, RM
   Barbosa, MG
   da Silva, DB
   Ribeiro, T
   Eugenio, C
   Schneider, D
   Mariani, D
   Jeffman, RW
   Bozza, F
   Cavalcanti, AB
   Azevedo, LCP
   Machado, FR
   Salluh, JI
   Pellegrini, JAS
   Moraes, RB
   Damiani, LP
   da Silva, NB
   Falavigna, M
   Rosa, RG
AF Sganzerla, Daniel
   Teixeira, Cassiano
   Robinson, Caroline Cabral
   Kochhann, Renata
   Siqueira Santos, Mariana Martins
   de Moura, Rafaela Moraes
   Barbosa, Mirceli Goulart
   da Silva, Daiana Barbosa
   Ribeiro, Tarissa
   Eugenio, Claudia
   Schneider, Daniel
   Mariani, Debora
   Jeffman, Rodrigo Wiltgen
   Bozza, Fernando
   Cavalcanti, Alexandre Biasi
   Pontes Azevedo, Luciano Cesar
   Machado, Flavia Ribeiro
   Salluh, Jorge Ibrain
   Santos Pellegrini, Jose Augusto
   Moraes, Rafael Barberena
   Damiani, Lucas Petri
   da Silva, Nilton Brandao
   Falavigna, Maicon
   Rosa, Regis Goulart
TI Statistical analysis plan for a cluster-randomized crossover trial
   comparing the effectiveness and safety of a flexible family visitation
   model for delirium prevention in adult intensive care units (the ICU
   Visits Study)
SO TRIALS
LA English
DT Article
DE Critical care; Delirium; Cross infection; Family; Personal satisfaction;
   Anxiety; Depression; Health personnel; Burnout
ID CENTERED CARE; VALIDATION; POLICIES; SCALE
AB BackgroundMost adult intensive care units (ICUs) worldwide adopt restrictive family visitation models (RFVMs). However, evidence, mostly from non-randomized studies, suggests that flexible adult ICU visiting hours are safe policies that can result in benefits such as prevention of delirium and increase in satisfaction with care. Accordingly, the ICU Visits Study was designed to compare the effectiveness and safety of a flexible family visitation model (FFVM) vs. an RFVM on delirium prevention among ICU patients, and also to analyze its potential effects on family members and ICU professionals.Methods/designThe ICU Visits Study is a cluster-randomized crossover trial which compares an FFVM (12 consecutive ICU visiting hours per day) with an RFVM (<4.5 ICU visiting hours per day) in 40 Brazilian adult ICUs. Participant ICUs are randomly assigned to either an FFVM or RFVM in a 1:1 ratio. After enrollment and follow-up of 25 patients, each ICU is crossed over to the other visitation model, until 25 more patients per site are enrolled and followed. The primary outcome is the cumulative incidence of delirium measured by the Confusion Assessment Method for the ICU. Secondary and tertiary outcomes include relevant measures of effectiveness and safety of ICU visiting policies among patients, family members, and ICU professionals. Herein, we describe all primary statistical procedures that will be used to evaluate the results and perform exploratory and sensitivity analyses of this study. This pre-specified statistical analysis plan was written and submitted without knowledge of the study data.DiscussionThis a priori statistical analysis plan aims to enhance the transparency of our study, facilitating unbiased analyses of ICU visit study data, and provide guidance for statistical analysis for groups conducting studies in the same field.Trial registrationClinicalTrials.gov, NCT02932358. Registered on 11 October 2016.
C1 [Sganzerla, Daniel; Robinson, Caroline Cabral; Kochhann, Renata; Siqueira Santos, Mariana Martins; de Moura, Rafaela Moraes; Barbosa, Mirceli Goulart; Schneider, Daniel; Mariani, Debora; Jeffman, Rodrigo Wiltgen] HMV, Res Projects Off, 910 Moinhos Vento, BR-90035001 Porto Alegre, RS, Brazil.
   [Teixeira, Cassiano; da Silva, Daiana Barbosa; Ribeiro, Tarissa; Eugenio, Claudia; Rosa, Regis Goulart] HMV, Intens Care Unit, Rua Ramiro Barcelos 910, BR-90035001 Porto Alegre, RS, Brazil.
   [Bozza, Fernando] Inst DOr Pesquisa & Ensino IDOR, Dept Crit Care, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, RJ, Brazil.
   [Cavalcanti, Alexandre Biasi; Salluh, Jorge Ibrain; Damiani, Lucas Petri] HCor Res Inst, Rua Abilio Soares 250, BR-04005909 Sao Paulo, SP, Brazil.
   [Pontes Azevedo, Luciano Cesar] Hosp Sirio Libanes, Intens Care Unit, Rua Dona Adma Jafet 91, BR-01308050 Sao Paulo, SP, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo UNIFESP, Dept Anesthesiol Pain & Intens Care, Rua Napoleao de Barros 737, BR-04024900 Sao Paulo, SP, Brazil.
   [Santos Pellegrini, Jose Augusto] HCPA, Intens Care Unit, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.
   [da Silva, Nilton Brandao] UFCSPA, Sch Med, Dept Internal Med, Ctr Hist, Rua Sarmento Leite 245, BR-90050170 Porto Alegre, RS, Brazil.
   [Moraes, Rafael Barberena; Falavigna, Maicon] HMV, Inst Educ & Res, Rua Ramiro Barcelos 910, BR-90035001 Porto Alegre, RS, Brazil.
RP Rosa, RG (corresponding author), HMV, Intens Care Unit, Rua Ramiro Barcelos 910, BR-90035001 Porto Alegre, RS, Brazil.
EM daniel.sganzerla@hmv.org.br; regis.rosa@hmv.org.br
RI Azevedo, Luciano CP/H-2652-2012; Bozza, Fernando A/A-2618-2013; dantas,
   vicente c souza/L-2648-2013; Teixeira, Cassiano/V-8764-2019; Rosa, Regis
   Goulart/P-6422-2019; Kochhann, Renata/C-5126-2018
OI Azevedo, Luciano CP/0000-0001-6759-3910; Bozza, Fernando
   A/0000-0003-4878-0256; Kochhann, Renata/0000-0002-6328-8131
FU Brazilian Ministry of Health through the Program of Institutional
   Development of the Brazilian Unified Health System (PROADI-SUS)
FX The present study was funded by the Brazilian Ministry of Health through
   the Program of Institutional Development of the Brazilian Unified Health
   System (PROADI-SUS). The trial is coordinated by Hospital Moinhos de
   Vento and endorsed by the Brazilian Research in Intensive Care Network
   (BRICNet).
CR [Anonymous], 2017, PNEUM VENT ASS VAP N
   [Anonymous], 2016, R LANG ENV STAT COMP
   [Anonymous], 2017, UR TRACT INF CATH AS
   Botega NJ, 1995, REV SAUDE PUBL, V29, P355, DOI 10.1590/S0034-89101995000500004
   Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661
   Colantuoni E, 2016, LANCET RESP MED, V4, P534, DOI 10.1016/S2213-2600(16)30138-2
   Campos JADB, 2012, REV SAUDE PUBL, V46, P816, DOI [10.1590/S0034-89102012000500008, 10.1590/s0034-89102012000500008]
   Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012
   Fumis RRL, 2006, INTENS CARE MED, V32, P124, DOI 10.1007/s00134-005-2857-0
   Garrouste-Orgeas M, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0185-x
   Gerritsen RT, 2017, INTENS CARE MED, V43, P550, DOI 10.1007/s00134-017-4684-5
   Goldfarb MJ, 2017, CRIT CARE MED, V45, P1751, DOI 10.1097/CCM.0000000000002624
   Gusmao-Flores D, 2011, CRITICAL CARE, V15, P50, DOI DOI 10.1186/cc10198
   Lee MD, 2006, CRIT CARE MED, V35, P497, DOI 10.1097/01.CCM.0000254338.87182.AC
   Nassar AP, 2018, CRIT CARE MED, V46, P1175, DOI 10.1097/CCM.0000000000003155
   Noordermeer K., 2013, ISRN CRITICAL CARE, V2013, P1, DOI [10.5402/2013/137045, DOI 10.5402/2013/137045]
   Ramos Fernando José da Silva, 2014, Rev. bras. ter. intensiva, V26, P339, DOI 10.5935/0103-507X.20140052
   Rosa RG, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021193
   Rosa RG, 2017, CRIT CARE MED, V45, P1660, DOI 10.1097/CCM.0000000000002588
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420
   Westphal GA, 2018, INTENS CARE MED, V44, P968, DOI 10.1007/s00134-018-5153-5
NR 22
TC 1
Z9 1
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD NOV 19
PY 2018
VL 19
AR 636
DI 10.1186/s13063-018-3006-8
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA HB6SI
UT WOS:000451201700002
PM 30454019
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Patel, MB
   Bednarik, J
   Lee, P
   Shehabi, Y
   Salluh, JI
   Slooter, AJ
   Klein, KE
   Skrobik, Y
   Morandi, A
   Spronk, PE
   Naidech, AM
   Pun, BT
   Bozza, FA
   Marra, A
   John, S
   Pandharipande, PP
   Ely, EW
AF Patel, Mayur B.
   Bednarik, Josef
   Lee, Patricia
   Shehabi, Yahya
   Salluh, Jorge I.
   Slooter, Arjen J.
   Klein, Kate E.
   Skrobik, Yoanna
   Morandi, Alessandro
   Spronk, Peter E.
   Naidech, Andrew M.
   Pun, Brenda T.
   Bozza, Fernando A.
   Marra, Annachiara
   John, Sayona
   Pandharipande, Pratik P.
   Ely, E. Wesley
TI Delirium Monitoring in Neurocritically Ill Patients: A Systematic
   Review*
SO CRITICAL CARE MEDICINE
LA English
DT Review
DE delirium; intensive care unit; neurocritical care; neurotrauma; stroke;
   traumatic brain injury
ID INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; MECHANICALLY
   VENTILATED PATIENTS; TERM COGNITIVE IMPAIRMENT; QUALITY-OF-LIFE; TRAUMA
   PATIENTS; RISK-FACTORS; HOSPITAL LENGTH; ACUTE STROKE; OUTCOMES
AB Objectives: The Society of Critical Care Medicine recommends routine delirium monitoring, based on data in critically ill patients without primary neurologic injury. We sought to answer whether there are valid and reliable tools to monitor delirium in neurocritically ill patients and whether delirium is associated with relevant clinical outcomes (e.g., survival, length of stay, functional independence, cognition) in this population.
   Data Sources: We systematically reviewed Cumulative Index to Nursing and Allied Health Literature, Web of Science, and PubMed.
   Study Selection and Data Extraction: Inclusion criteria allowed any study design investigating delirium monitoring in neurocritically ill patients (e.g., neurotrauma, ischemic, and/or hemorrhagic stroke) of any age. We extracted data relevant to delirium tool sensitivity, specificity, negative predictive value, positive predictive value, interrater reliability, and associated clinical outcomes.
   Data Synthesis: Among seven prospective cohort studies and a total of 1,173 patients, delirium was assessed in neurocritically patients using validated delirium tools after considering primary neurologic diagnoses and associated complications, finding a pooled prevalence rate of 12-43%. When able to compare against a common reference standard, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the test characteristics showed a sensitivity of 62-76%, specificity of 74-98%, positive predictive value of 63-91%, negative predictive value of 70-94%, and reliability kappa of 0.64-0.94. Among four studies reporting multivariable analyses, delirium in neurocritically patients was associated with increased hospital length of stay (n = 3) and ICU length of stay (n = 1), as well as worse functional independence (n = 1) and cognition (n = 2), but not survival.
   Conclusions: These data from studies of neurocritically ill patients demonstrate that patients with primary neurologic diagnoses can meet diagnostic criteria for delirium and that delirious features may predict relevant untoward clinical outcomes. There is a need for ongoing investigations regarding delirium in these complicated neurocritically ill patients.
C1 [Patel, Mayur B.; Pun, Brenda T.; Marra, Annachiara; Pandharipande, Pratik P.; Ely, E. Wesley] Vanderbilt Univ, Crit Illness Brain Dysfunct & ICU Survivorship CI, Ctr Hlth Serv Res, Nashville, TN 37235 USA.
   [Patel, Mayur B.; Pandharipande, Pratik P.; Ely, E. Wesley] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, GRECC, Nashville, TN 37212 USA.
   [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Sect Surg Sci,Vanderbilt Brain Inst, Dept Surg,Div Trauma Surg Crit Care & Emergency G, Nashville, TN USA.
   [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Sect Surg Sci,Vanderbilt Brain Inst, Dept Neurosurg,Div Trauma Surg Crit Care & Emerge, Nashville, TN USA.
   [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Sect Surg Sci,Vanderbilt Brain Inst, Dept Hearing & Speech Sci,Div Trauma Surg Crit Ca, Nashville, TN USA.
   [Patel, Mayur B.] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Surg Serv, Nashville, TN USA.
   [Bednarik, Josef] Univ Hosp Brno, Dept Neurol, Brno, Czech Republic.
   [Bednarik, Josef] Masaryk Univ, Appl Neurosci Res Grp, Cent European Inst Technol, Brno, Czech Republic.
   [Lee, Patricia] Vanderbilt Univ, Ctr Med, Ctr Knowledge Management, Nashville, TN 37232 USA.
   [Shehabi, Yahya] Univ New South Wales, Prince Wales Hosp, Sch Clin Med, Randwick, NSW, Australia.
   [Salluh, Jorge I.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Slooter, Arjen J.] Univ Med Ctr Utrecht, Dept Intens Care Med, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.
   [Klein, Kate E.] Novant Hlth Presbyterian Med Ctr, Charlotte, NC USA.
   [Skrobik, Yoanna] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Morandi, Alessandro] Ancelle Hosp, Dept Rehabil & Aged Care, Fdn Camplani, Cremona, Italy.
   [Morandi, Alessandro] Geriatr Res Grp, Brescia, Italy.
   [Spronk, Peter E.] Gelre Ziekenhuizen Lukas, Dept Intens Care, Apeldoorn, Netherlands.
   [Naidech, Andrew M.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Stroke & Neurocrit Care, Chicago, IL 60611 USA.
   [Naidech, Andrew M.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Naidech, Andrew M.] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA.
   [Naidech, Andrew M.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA.
   [Naidech, Andrew M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med Hlth & Biomed Informat, Chicago, IL 60611 USA.
   [Pun, Brenda T.; Marra, Annachiara; Ely, E. Wesley] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Dept Med, Med Ctr, Nashville, TN 37235 USA.
   [Bozza, Fernando A.] Fdn Oswaldo Cruz FIOCRUZ, Chagas INI, Intens Care Lab, Inst Nacioinal Infectol Evandro, Rio De Janeiro, Brazil.
   [Marra, Annachiara] Univ Naples Federico II, Dept Neurosci, Naples, Italy.
   [Marra, Annachiara] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy.
   [John, Sayona] Rush Univ, Med Ctr, Dept Neurol Sci, Sect Neurocrit Care, Chicago, IL USA.
   [Pandharipande, Pratik P.] Vanderbilt Univ, Med Ctr, Div Crit Care Med, Dept Anesthesiol, Nashville, TN USA.
   [Pandharipande, Pratik P.] Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, Anesthesiol Serv, Nashville, TN USA.
RP Ely, EW (corresponding author), Vanderbilt Univ, Crit Illness Brain Dysfunct & ICU Survivorship CI, Ctr Hlth Serv Res, Nashville, TN 37235 USA.; Ely, EW (corresponding author), Tennessee Valley Healthcare Syst, Dept Vet Affairs Med Ctr, GRECC, Nashville, TN 37212 USA.; Ely, EW (corresponding author), Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Dept Med, Med Ctr, Nashville, TN 37235 USA.
EM wes.ely@vanderbilt.edu
RI Bednarik, Josef/Y-3032-2019; Marra, Annachiara/N-5026-2019; John,
   Sayona/AAR-6849-2020; Skrobik, Yoanna/K-8165-2014; Ely, E.
   Wesley/Z-2018-2019; dantas, vicente c souza/L-2648-2013; Bozza, Fernando
   A/A-2618-2013
OI Bednarik, Josef/0000-0001-7420-2383; John, Sayona/0000-0002-2133-7265;
   Skrobik, Yoanna/0000-0002-5315-6020; Ely, E. Wesley/0000-0003-3957-2172;
   Bozza, Fernando A/0000-0003-4878-0256; Pandharipande,
   Pratik/0000-0002-1389-8580; Marra, Annachiara/0000-0003-1705-6644; Lee,
   Patricia/0000-0001-7422-3539
FU Veterans Affairs Tennessee Valley Geriatric Research, Education and
   Clinical Center (Nashville, TN); National Institutes of Health
   (Bethesda, MD)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AG027472, AG035117,
   HL111111, GM120484]; National Institutes of Health (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [HL111111]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM120484];
   Pfizer/Hospira; Veterans Affairs (VA) Tennessee Valley Geriatric
   Research, Education and Clinical Center (Nashville, TN); NIH (Bethesda,
   MD)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AG027472, AG035117, HL111111,
   GM120484]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Hill Rom Co.; Agency
   for Healthcare Research and QualityUnited States Department of Health &
   Human ServicesAgency for Healthcare Research & Quality [K18 HS023437];
   Society of Critical Care Medicine; American Association of Critical Care
   Medicine; France Foundation; CSL Behring; Hospira; VAUS Department of
   Veterans Affairs; Orion Laboratories; Abbott LaboratoriesAbbott
   Laboratories; PfizerPfizer; Hospira Inc; AbbottAbbott Laboratories;
   Orion; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States
   Department of Health & Human ServicesAgency for Healthcare Research &
   Quality [K18HS023437, K18HS023437] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL111111, R01HL111111,
   R01HL111111, R01HL111111, R01HL111111, R01HL111111] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM120484, R01GM120484, R01GM120484, R01GM120484] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Aging (NIA) [R01AG035117, R01AG035117, R01AG035117,
   R01AG027472, R01AG035117, R01AG035117, R01AG027472, R01AG027472,
   R01AG035117, R01AG035117, R01AG027472, R01AG027472, R01AG027472] Funding
   Source: NIH RePORTER
FX Supported, in part, by Veterans Affairs Tennessee Valley Geriatric
   Research, Education and Clinical Center (Nashville, TN) and the National
   Institutes of Health AG027472, AG035117, HL111111, GM120484 (Bethesda,
   MD).; Dr. Patel's institution received funding from National Institutes
   of Health (NIH) HL111111 and NIH GM120484; he received funding from
   Pfizer/Hospira (education presentation); and he disclosed that funding
   was provided by federal sources including the Veterans Affairs (VA)
   Tennessee Valley Geriatric Research, Education and Clinical Center
   (Nashville, TN) and the NIH AG027472, AG035117, HL111111, GM120484
   (Bethesda, MD). Drs. Patel and Ely received support for article research
   from the NIH. Ms. Klein's institution received funding from Hill Rom Co.
   Dr. Naidech received support for article research from the Agency for
   Healthcare Research and Quality (K18 HS023437). Dr. Pun received funding
   from the Society of Critical Care Medicine, the American Association of
   Critical Care Medicine, and the France Foundation to provide continuing
   education. Dr. John disclosed other support from CSL Behring (speaker).
   Dr. Pandharipande's institution received funding from Hospira. Dr. Ely's
   institution received funding from NIH and VA funding, and he received
   funding from Orion Laboratories, Abbott Laboratories, and Pfizer. Dr.
   Pandharipande has received a research grant from Hospira Inc, in
   collaboration with the NIH. Dr. Ely has conducted Continuing Medical
   Education activities sponsored by Abbott, Hospira, and Orion. The
   remaining authors have disclosed that they do not have any potential
   conflicts of interest.
CR Agarwal S, 2015, J TRAUMA ACUTE CARE, V78, P211
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   Anderson BJ, 2016, J CRIT CARE, V36, P18, DOI 10.1016/j.jcrc.2016.06.012
   Angles EM, 2008, AM J SURG, V196, P864, DOI 10.1016/j.amjsurg.2008.07.037
   Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909
   Bigatello LM, 2013, J TRAUMA ACUTE CARE, V74, P876, DOI 10.1097/TA.0b013e31827e1b69
   Bleck TP, 2002, CRIT CARE MED, V30, P1176, DOI 10.1097/00003246-200205000-00047
   BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019
   Blondell RD, 2004, AM J SURG, V187, P332, DOI 10.1016/j.amjsurg.2003.12.027
   Branco BC, 2011, AM SURGEON, V77, P621
   Brummel NE, 2013, CRIT CARE MED, V41, P2196, DOI 10.1097/CCM.0b013e31829a6f1e
   Bryczkowski SB, 2014, J TRAUMA ACUTE CARE, V77, P944, DOI 10.1097/TA.0000000000000427
   Carin-Levy G, 2012, J NEUROL, V259, P1590, DOI 10.1007/s00415-011-6383-4
   Ceriana P, 2010, J CRIT CARE, V25, P136, DOI 10.1016/j.jcrc.2009.07.004
   Colombo R, 2012, MINERVA ANESTESIOL, V78, P1026
   Devlin JW, 2008, CRIT CARE, V12, DOI 10.1186/cc6793
   Duceppe MA, 2019, J INTENSIVE CARE MED, V34, P330, DOI 10.1177/0885066617698646
   Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012
   Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Frenette AJ, 2016, INTENS CARE MED, V42, P122, DOI 10.1007/s00134-015-3964-1
   Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1
   Guenther U, 2010, J CRIT CARE, V25, P144, DOI 10.1016/j.jcrc.2009.08.005
   Gunther ML, 2012, CRIT CARE MED, V40, P2022, DOI 10.1097/CCM.0b013e318250acc0
   Ingalls NK, 2016, MIL MED, V181, P209, DOI 10.7205/MILMED-D-15-00064
   Klein PMC, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6652
   Klimiec E, 2016, COGN BEHAV NEUROL, V29, P174, DOI 10.1097/WNN.0000000000000110
   Klimiec E, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0351-z
   Kostalova M, 2012, BRAIN INJURY, V26, P962, DOI 10.3109/02699052.2012.660510
   Kozak HH, 2017, NEUROL NEUROCHIR POL, V51, P38, DOI 10.1016/j.pjnns.2016.10.004
   Lat I, 2009, CRIT CARE MED, V37, P1898, DOI 10.1097/CCM.0b013e31819ffe38
   Lees R, 2013, STROKE, V44, P3078, DOI 10.1161/STROKEAHA.113.001724
   Mehta S, 2015, CRIT CARE MED, V43, P557, DOI 10.1097/CCM.0000000000000727
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Mitasova A, 2012, CRIT CARE MED, V40, P484, DOI 10.1097/CCM.0b013e318232da12
   Morandi A, 2017, J AM MED DIR ASSOC, V18, P12, DOI 10.1016/j.jamda.2016.07.014
   Morandi A, 2012, CRIT CARE MED, V40, P2182, DOI 10.1097/CCM.0b013e318250acdc
   Naidech AM, 2016, NEUROCRIT CARE, V24, P397, DOI 10.1007/s12028-015-0210-1
   Naidech AM, 2013, AM J RESP CRIT CARE, V188, P1331, DOI 10.1164/rccm.201307-1256OC
   Neto AS, 2012, CRIT CARE MED, V40, P2266, DOI 10.1097/CCM.0b013e31824fc115
   Neto AS, 2012, CRIT CARE MED, V40, P1946, DOI 10.1097/CCM.0b013e31824e16c9
   Oldenbeuving AW, 2011, NEUROLOGY, V76, P993, DOI 10.1212/WNL.0b013e318210411f
   Otter H, 2005, NEUROCRIT CARE, V2, P150, DOI 10.1385/NCC:2:2:150
   Ouimet S, 2007, INTENS CARE MED, V33, P1007, DOI 10.1007/s00134-007-0618-y
   Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC
   Rahme RJ, 2016, WORLD NEUROSURG, V94, P556, DOI 10.1016/j.wneu.2016.07.080
   Reddy DRS, 2016, J CRIT CARE, V34, P12, DOI 10.1016/j.jcrc.2016.03.008
   Robinson BRH, 2008, J TRAUMA, V65, P517, DOI 10.1097/TA.0b013e318181b8f6
   Rosenthal LJ, 2017, PSYCHOSOMATICS, V58, P19, DOI 10.1016/j.psym.2016.07.004
   Bajo BR, 2013, NEUROLOGIA, V28, P356, DOI 10.1016/j.nrl.2012.07.001
   Ryosuke T, 2014, J CRITICAL CARE, V29
   Salluh JIF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2538
   Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759
   Skrobik Y, 2012, CRIT CARE MED, V40, P676, DOI 10.1097/CCM.0b013e31823878c4
   Smith HAB, 2016, CRIT CARE MED, V44, P592, DOI 10.1097/CCM.0000000000001428
   Smith HAB, 2011, CRIT CARE MED, V39, P150, DOI 10.1097/CCM.0b013e3181feb489
   Soja SL, 2008, INTENS CARE MED, V34, P1263, DOI 10.1007/s00134-008-1031-x
   Traube C, 2014, CRIT CARE MED, V42, P656, DOI 10.1097/CCM.0b013e3182a66b76
   van den Boogaard M, 2012, CRIT CARE MED, V40, P112, DOI 10.1097/CCM.0b013e31822e9fc9
   van Eijk MM, 2011, AM J RESP CRIT CARE, V184, P340, DOI 10.1164/rccm.201101-0065OC
   van Rijsbergen MWA, 2011, J NEUROL SCI, V306, P138, DOI 10.1016/j.jns.2011.03.024
   Wolters AE, 2014, CRIT CARE, V18, DOI 10.1186/cc13929
   Young GB, 2008, DISORDERS CONSCIOUSN
   Yu A, 2013, CRIT CARE MED, V41, P2002, DOI 10.1097/CCM.0b013e31828e96c0
NR 70
TC 16
Z9 16
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD NOV
PY 2018
VL 46
IS 11
BP 1832
EP 1841
DI 10.1097/CCM.0000000000003349
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA GW5XM
UT WOS:000447016100029
PM 30142098
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Mesquita, EC
   Hottz, ED
   Amancio, RT
   Carneiro, AB
   Palhinha, L
   Coelho, LE
   Grinsztejn, B
   Zimmerman, GA
   Rondina, MT
   Weyrich, AS
   Bozza, PT
   Bozza, FA
AF Mesquita, Emersom C.
   Hottz, Eugenio D.
   Amancio, Rodrigo T.
   Carneiro, Alan B.
   Palhinha, Lohanna
   Coelho, Lara E.
   Grinsztejn, Beatriz
   Zimmerman, Guy A.
   Rondina, Matthew T.
   Weyrich, Andrew S.
   Bozza, Patricia T.
   Bozza, Fernando A.
TI Persistent platelet activation and apoptosis in virologically suppressed
   HIV-infected individuals
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMBINATION ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; P-SELECTIN;
   MICROBIAL TRANSLOCATION; HIV-1-INFECTED PATIENTS; MONONUCLEAR-CELLS;
   RISK-FACTOR; IN-VIVO; DC-SIGN; MORTALITY
AB Cardiovascular diseases and thrombotic events became major clinical problems in the combined antiretroviral therapy (cART) era. Although the precise mechanisms behind these clinical problems have not been fully elucidated, a persistent pro-inflammatory state plays a central role. As platelets play important roles on both, thrombus formation and inflammatory/immune response, we aimed at investigating platelet function in HIV-infected subjects virologically controlled through cART. We evaluate parameters of activation, mitochondrial function and activation of apoptosis pathways in platelets from 30 HIV-infected individuals under stable cART and 36 healthy volunteers. Despite viral control achieved through cART, HIV-infected individuals exhibited increased platelet activation as indicated by P-selectin expression and platelet spreading when adhered on fibrinogen-coated surfaces. Platelets from HIV-infected subjects also exhibited mitochondrial dysfunction and activation of apoptosis pathways. Finally, thrombin stimuli induced lower levels of P-selectin translocation and RANTES secretion, but not TXA(2) synthesis, in platelets from HIV-infected individuals compared to control; and labeling of platelet alpha granules showed reduced granule content in platelets from HIV-infected individuals when compared to healthy subjects. In summary, platelets derived from HIV-infected individuals under stable cART exhibit a phenotype of increased activation, activation of the intrinsic pathway of apoptosis and undermined granule secretion in response to thrombin.
C1 [Mesquita, Emersom C.; Amancio, Rodrigo T.; Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Med Intens, Rio De Janeiro, Brazil.
   [Coelho, Lara E.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab HIV, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Carneiro, Alan B.; Palhinha, Lohanna; Bozza, Patricia T.] Fundacao Oswaldo Cruz FIOCRUZ, IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.] Univ Fed Juiz de Fora UFJF, Inst Ciencias Biol, Dept Bioquim, Juiz De Fora, MG, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Zimmerman, Guy A.; Rondina, Matthew T.; Weyrich, Andrew S.] Univ Utah, Mol Med Program, Salt Lake City, UT USA.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab Med Intens, Rio De Janeiro, Brazil.; Bozza, FA (corresponding author), DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI Hottz, Eugenio D/I-9850-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Weyrich,
   Andrew/0000-0001-9622-4647; Bozza, Patricia/0000-0001-8349-9529;
   Palhinha, Lohanna/0000-0003-0163-3574; Zimmerman,
   Guy/0000-0003-1731-7074; Mesquita, Emersom/0000-0002-5132-3315; Rondina,
   Matthew/0000-0003-3455-3730
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [E-26/200.839/2017]; Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior-Brasil (CAPES)CAPES [001]; Programa Estrategico de
   Apoio a Pesquisa em Saude (PAPES)/Fiocruz; National Institute of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; National Institute of Allergy and
   Infectious Diseases (NHLBI) [5R37 HL044525, NHLBI R01 HL126547, NIA R01
   AG048022]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL126547,
   R01HL126547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGINGUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R01AG048022, R01AG048022] Funding Source: NIH RePORTER
FX We thank Joseph Aslan for critical discussion of the study and Edson
   Fernandes de Assis for technical assistance. This work was supported by
   grants from Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (PTB and FAB are scholars from CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ Grant: E-26/200.839/2017),
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES) - Finance Code 001, Programa Estrategico de Apoio a Pesquisa em
   Saude (PAPES)/Fiocruz; and National Institute of Health and National
   Institute of Allergy and Infectious Diseases (NHLBI Merit Award 5R37
   HL044525 to G. A. Z and NHLBI R01 HL126547 and NIA R01 AG048022 to A. S.
   W and M. T. R).
CR Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916
   Bociaga-Jasik M, 2013, CURR HIV RES, V11, P263, DOI 10.2174/1570162X113116660055
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Casper C, 2011, ANNU REV MED, V62, P157, DOI 10.1146/annurev-med-050409-103711
   Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06
   Choudhury A, 2008, CHEST, V134, P574, DOI 10.1378/chest.07-2745
   Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Falcinelli E, 2013, THROMB HAEMOSTASIS, V110, P349, DOI 10.1160/TH12-07-0504
   Fraietta JA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003658
   Goehringer F, 2017, AIDS RES HUM RETROV, V33, P187, DOI [10.1089/aid.2016.0222, 10.1089/AID.2016.0222]
   Grundler K, 2014, CRIT CARE, V18, DOI 10.1186/cc13724
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   HAMBURGER SA, 1990, BLOOD, V75, P550
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Holme PA, 1998, FASEB J, V12, P79
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00121
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Jirouskova M, 2007, BLOOD, V109, P5260, DOI 10.1182/blood-2006-10-054015
   Jobe SM, 2008, BLOOD, V111, P1257, DOI 10.1182/blood-2007-05-092684
   Kelesidis T, 2015, AIDS REV, V17, P191
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lazar R., 2013, CLIN INFECT DIS
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Leytin V, 2006, J THROMB HAEMOST, V4, P2656, DOI 10.1111/j.1538-7836.2006.02200.x
   Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144
   Marcantoni Emanuela, 2018, JACC Basic Transl Sci, V3, P9, DOI 10.1016/j.jacbts.2017.10.005
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037
   Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355
   McDonald B, 2013, AIDS RES HUM RETROV, V29, P993, DOI [10.1089/aid.2012.0309, 10.1089/AID.2012.0309]
   Monforte AD, 2004, AIDS, V18, P1811
   Nkambule BB, 2014, PLATELETS, P1
   Nkambule BB, 2015, THROMB RES, V135, P1131, DOI 10.1016/j.thromres.2015.01.031
   O'Brien M, 2013, JAIDS-J ACQ IMM DEF, V63, P280, DOI 10.1097/QAI.0b013e31828a292c
   O'Halloran JA, 2015, HIV MED, V16, P608, DOI 10.1111/hiv.12270
   Papakonstantinou VD, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-90
   Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce
   Pinto LMD, 2002, BLOOD, V99, P1666, DOI 10.1182/blood.V99.5.1666
   Pinto LMD, 2002, AIDS, V16, P329, DOI 10.1097/00002030-200202150-00003
   Rajasuriar R, 2010, J INFECT DIS, V202, P1254, DOI 10.1086/656369
   Satchell CS, 2011, J INFECT DIS, V204, P1202, DOI 10.1093/infdis/jir509
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Sternfeld T, 2009, HIV MED, V10, P512, DOI 10.1111/j.1468-1293.2009.00723.x
   Tien PC, 2010, JAIDS-J ACQ IMM DEF, V55, P316, DOI 10.1097/QAI.0b013e3181e66216
   Trevillyan JM, 2017, PLATELETS, V28, P301, DOI 10.1080/09537104.2016.1237627
   Tsoupras AB, 2012, ANGIOLOGY, V63, P343, DOI 10.1177/0003319711420608
   Tunjungputri RN, 2014, AIDS, V28, P2091, DOI 10.1097/QAD.0000000000000415
   van Lelyveld SFL, 2012, AIDS, V26, P465, DOI 10.1097/QAD.0b013e32834f32f8
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   von Hentig N, 2008, J ANTIMICROB CHEMOTH, V62, P1118, DOI 10.1093/jac/dkn333
   WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921
NR 56
TC 11
Z9 11
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 9
PY 2018
VL 8
AR 14999
DI 10.1038/s41598-018-33403-0
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GW3LB
UT WOS:000446802800005
PM 30301959
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Zampieri, FG
   Iwashyna, TJ
   Viglianti, EM
   Taniguchi, LU
   Viana, WN
   Costa, R
   Correa, TD
   Moreira, CEN
   Maia, MO
   Moralez, GM
   Lisboa, T
   Ferez, MA
   Freitas, CEF
   de Carvalho, CB
   Mazza, BF
   Lima, MFA
   Ramos, GV
   Silva, AR
   Bozza, FA
   Salluh, JIF
   Soares, M
AF Zampieri, Fernando G.
   Iwashyna, Theodore J.
   Viglianti, Elizabeth M.
   Taniguchi, Leandro U.
   Viana, William N.
   Costa, Roberto
   Correa, Thiago D.
   Moreira, Carlos Eduardo N.
   Maia, Marcelo O.
   Moralez, Giulliana M.
   Lisboa, Thiago
   Ferez, Marcus A.
   Freitas, Carlos Eduardo F.
   de Carvalho, Clayton B.
   Mazza, Bruno F.
   Lima, Mariza F. A.
   Ramos, Grazielle V.
   Silva, Aline R.
   Bozza, Fernando A.
   Salluh, Jorge. I. F.
   Soares, Marcio
CA ORCHESTRA Study Investigators
TI Association of frailty with short-term outcomes, organ support and
   resource use in critically ill patients
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Frailty; Modified frailty index; Organ support; Resource use; Outcomes;
   Critical care
ID INTENSIVE-CARE-UNIT; CRITICAL ILLNESS; ELDERLY-PATIENTS; MORTALITY;
   INDEX; ICU; MULTICENTER; DISABILITY; MORBIDITY; ADMISSION
AB Frail patients are known to experience poor outcomes. Nevertheless, we know less about how frailty manifests itself in patients' physiology during critical illness and how it affects resource use in intensive care units (ICU). We aimed to assess the association of frailty with short-term outcomes and organ support used by critically ill patients.
   Retrospective analysis of prospective collected data from 93 ICUs in Brazil from 2014 to 2015. We assessed frailty using the modified frailty index (MFI). The primary outcome was in-hospital mortality. Secondary outcomes were discharge home without need for nursing care, ICU and hospital length of stay (LOS), and utilization of ICU organ support and transfusion. We used mixed logistic regression and competing risk models accounting for relevant confounders in outcome analyses.
   The analysis consisted of 129,680 eligible patients. There were 40,779 (31.4%) non-frail (MFI = 0), 64,407 (49.7%) pre-frail (MFI = 1-2) and 24,494 (18.9%) frail (MFI >= 3) patients. After adjusted analysis, frailty was associated with higher in-hospital mortality (OR 2.42, 95% CI 1.89-3.08), particularly in patients admitted with lower SOFA scores. Frail patients were less likely to be discharged home (OR 0.36, 95% CI 0.54-0.79) and had higher hospital and ICU LOS than non-frail patients. Use of all forms of organ support (mechanical ventilation, non-invasive ventilation, vasopressors, dialysis and transfusions) were more common in frail patients and increased as MFI increased.
   Frailty, as assessed by MFI, was associated with several patient-centered endpoints including not only survival, but also ICU LOS and organ support.
C1 [Zampieri, Fernando G.] HCor Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   [Iwashyna, Theodore J.; Viglianti, Elizabeth M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Iwashyna, Theodore J.] Vet Affairs Ctr Clin Management Res, HSR&D Ctr Excellence, Ann Arbor, MI USA.
   [Taniguchi, Leandro U.] Hosp Sirio Libanes, ICU, Sao Paulo, Brazil.
   [Taniguchi, Leandro U.] Univ Sao Paulo, Hosp Clin HC FMUSP, Emergency Med Discipline, Sao Paulo, Brazil.
   [Viana, William N.] Hosp Copa DOr, ICU, Rio De Janeiro, Brazil.
   [Costa, Roberto] Hosp Quinta DOr, ICU, Rio De Janeiro, Brazil.
   [Correa, Thiago D.] Hosp Israelita Albert Einstein, Adult ICU, Sao Paulo, Brazil.
   [Moreira, Carlos Eduardo N.] Hosp Nove de Julho, ICU, Sao Paulo, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia Rede DOr Sao Luiz DF, ICU, Brasilia, DF, Brazil.
   [Moralez, Giulliana M.; Ramos, Grazielle V.; Silva, Aline R.; Bozza, Fernando A.; Salluh, Jorge. I. F.; Soares, Marcio] DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Moralez, Giulliana M.; Ramos, Grazielle V.; Silva, Aline R.; Bozza, Fernando A.; Salluh, Jorge. I. F.; Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.
   [Lisboa, Thiago] Santa Casa de Misericordia Porto Alegre, Hosp Santa Rita, ICU, Porto Alegre, RS, Brazil.
   [Ferez, Marcus A.] Hosp Sao Francisco, ICU, Ribeirao Preto, Brazil.
   [Freitas, Carlos Eduardo F.] Hosp Esperanca Olinda, ICU, Olinda, Brazil.
   [de Carvalho, Clayton B.] Hosp Brasilia, ICU, Brasilia, DF, Brazil.
   [Mazza, Bruno F.] Hosp Samaritano, ICU, Sao Paulo, Brazil.
   [Lima, Mariza F. A.] Hosp Esperanza, ICU, Recife, PE, Brazil.
   [Zampieri, Fernando G.] Hosp Alemao Oswaldo Cruz, ICU, Sao Paulo, Brazil.
   [Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.; Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Taniguchi, Leandro U/J-2099-2015; Lisboa, Thiago/W-2973-2019; Bozza,
   Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013; Taniguchi, Leandro
   Utino/L-6471-2015; dantas, vicente c souza/L-2648-2013
OI Taniguchi, Leandro U/0000-0003-4384-0408; Lisboa,
   Thiago/0000-0003-4306-2212; Bozza, Fernando A/0000-0003-4878-0256;
   Soares, Marcio/0000-0003-2503-6088; Taniguchi, Leandro
   Utino/0000-0003-4384-0408; Domingos Correa, Thiago/0000-0001-9546-3910
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); D'Or Institute for
   Research and Education; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
   [T32HL007749, T32HL007749, T32HL007749, T32HL007749, T32HL007749]
   Funding Source: NIH RePORTER
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq), Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ) and by
   departmental funds from the D'Or Institute for Research and Education.
   We dedicate this work to the memory of Dr. Ligia Sarmet Farah Cunha
   Rabello, ORCHESTRA Study investigator, who recently passed away.
CR Bagshaw SM, 2014, CAN MED ASSOC J, V186, pE95, DOI 10.1503/cmaj.130639
   Brummel NE, 2017, AM J RESP CRIT CARE, V196, P64, DOI 10.1164/rccm.201605-0939OC
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Farhat JS, 2012, J TRAUMA ACUTE CARE, V72, P1526, DOI 10.1097/TA.0b013e3182542fab
   Ferrante LE, 2018, CHEST, V153, P1378, DOI 10.1016/j.chest.2018.03.007
   Fisher C, 2015, ANAESTH INTENS CARE, V43, P361, DOI 10.1177/0310057X1504300313
   Flaatten H, 2017, INTENS CARE MED, V43, P1820, DOI 10.1007/s00134-017-4940-8
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Fried LP, 2004, J GERONTOL A-BIOL, V59, P255
   Hall DE, 2017, JAMA SURG, V152, P175, DOI 10.1001/jamasurg.2016.4202
   Heyland DK, 2015, INTENS CARE MED, V41, P1911, DOI 10.1007/s00134-015-4028-2
   Hope AA, 2015, J AM GERIATR SOC, V63, P1121, DOI 10.1111/jgs.13436
   Kizilarslanoglu MC, 2017, AGING CLIN EXP RES, V29, P247, DOI 10.1007/s40520-016-0557-y
   Langlais E, 2018, J CRIT CARE, V46, P67, DOI 10.1016/j.jcrc.2018.04.012
   Le Maguet P, 2014, INTENS CARE MED, V40, P674, DOI 10.1007/s00134-014-3253-4
   Mogal H, 2017, ANN SURG ONCOL, V24, P1714, DOI 10.1245/s10434-016-5715-0
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Mueller N, 2016, ANN SURG, V264, P1116, DOI 10.1097/SLA.0000000000001546
   Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0
   Pearl JA, 2017, CLIN GENITOURIN CANC, V15, pE615, DOI 10.1016/j.clgc.2016.12.013
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Venables W. N., 2002, MODERN APPL STAT S
   Vermillion SA, 2017, J SURG ONCOL, V115, P997, DOI 10.1002/jso.24617
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wachal B, 2017, JAMA OTOLARYNGOL, V143, P818, DOI 10.1001/jamaoto.2017.0412
   Wahl TS, 2017, JAMA SURG, V152, P749, DOI 10.1001/jamasurg.2017.1025
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
   Zampieri Fernando Godinho, 2017, Rev. bras. ter. intensiva, V29, P418, DOI [10.5935/0103-507x.20170062, 10.5935/0103-507X.20170062]
NR 28
TC 29
Z9 29
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2018
VL 44
IS 9
BP 1512
EP 1520
DI 10.1007/s00134-018-5342-2
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA GT1DC
UT WOS:000444197300013
PM 30105600
DA 2020-12-01
ER

PT J
AU Collet, MO
   Caballero, J
   Sonneville, R
   Bozza, FA
   Nydahl, P
   Schandl, A
   Woien, H
   Citerio, G
   van den Boogaard, M
   Hastbacka, J
   Haenggi, M
   Colpaert, K
   Rose, L
   Barbateskovic, M
   Lange, T
   Jensen, A
   Krog, MB
   Egerod, I
   Nibro, HL
   Wetterslev, J
   Perner, A
AF Collet, Marie O.
   Caballero, Jesus
   Sonneville, Romain
   Bozza, Fernando A.
   Nydahl, Peter
   Schandl, Anna
   Woien, Hilden
   Citerio, Giuseppe
   van den Boogaard, Mark
   Hastbacka, Johanna
   Haenggi, Matthias
   Colpaert, Kirsten
   Rose, Louise
   Barbateskovic, Marija
   Lange, Theis
   Jensen, Aksel
   Krog, Martin B.
   Egerod, Ingrid
   Nibro, Helle L.
   Wetterslev, Jorn
   Perner, Anders
CA AID-ICU Cohort Study Co-authors
TI Prevalence and risk factors related to haloperidol use for delirium in
   adult intensive care patients: the multinational AID-ICU inception
   cohort study
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Delirium; ICU; Haloperidol; Cohort; Critical care
ID CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; TERM
   COGNITIVE IMPAIRMENT; CRITICAL ILLNESS; SEDATION SCALE; CAM-ICU; UNIT;
   GUIDELINES; LEVEL; MULTICENTER
AB We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality.
   All acutely admitted, adult ICU patients were screened during a 2-week inception period. We followed the patient throughout their ICU stay and assessed 90-day mortality. We assessed patients and their variables in the first 24 and 72 h in ICU and studied their association together with that of ICU characteristics with haloperidol use.
   We included 1260 patients from 99 ICUs in 13 countries. Delirium occurred in 314/1260 patients [25% (95% confidence interval 23-27)] of whom 145 received haloperidol [46% (41-52)]. Other interventions for delirium were benzodiazepines in 36% (31-42), dexmedetomidine in 21% (17-26), quetiapine in 19% (14-23) and olanzapine in 9% (6-12) of the patients with delirium. In the first 24 h in the ICU, all subtypes of delirium [hyperactive, adjusted odds ratio (aOR) 29.7 (12.9-74.5); mixed 10.0 (5.0-20.2); hypoactive 3.0 (1.2-6.7)] and circulatory support 2.7 (1.7-4.3) were associated with haloperidol use. At 72 h after ICU admission, circulatory support remained associated with subsequent use of haloperidol, aOR 2.6 (1.1-6.9). Haloperidol use within 0-24 h and within 0-72 h of ICU admission was not associated with 90-day mortality [aOR 1.2 (0.5-2.5); p = 0.66] and [aOR 1.9 (1.0-3.9); p = 0.07], respectively.
   In our study, haloperidol was the main pharmacological agent used for delirium in adult patients regardless of delirium subtype. Benzodiazepines, other anti-psychotics and dexmedetomidine were other frequently used agents. Haloperidol use was not statistically significantly associated with increased 90-day mortality.
C1 [Collet, Marie O.; Egerod, Ingrid; Perner, Anders] Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, Copenhagen, Denmark.
   [Collet, Marie O.; Barbateskovic, Marija; Lange, Theis; Jensen, Aksel; Egerod, Ingrid; Nibro, Helle L.; Wetterslev, Jorn; Perner, Anders] Ctr Res Intens Care, Copenhagen, Denmark.
   [Caballero, Jesus] UAB, Hosp Univ Vall dHebron VHIR, Hosp Univ Arnau de Vilanova Lleida IRBLleida, Barcelona, Spain.
   [Sonneville, Romain] Bichat Claude Bernard Hosp, AP HP, Dept Intens Care Med & Infect Dis, Paris, France.
   [Sonneville, Romain] Paris Diderot Univ, Sorbonne Paris Cite, INSERM, LVTS,UMR1148, Paris, France.
   [Bozza, Fernando A.] Minist Hlth, Oswaldo Cruz Fdn, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Nydahl, Peter] Univ Hosp Schleswig Holstein, Dept Nursing Res, Kiel, Germany.
   [Nydahl, Peter] Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, Kiel, Germany.
   [Schandl, Anna] Karolinska Univ Hosp, Dept Perioperat Med & Intens Care, Stockholm, Sweden.
   [Woien, Hilden] Oslo Univ Hosp, Div Emergencies & Intens Care, Oslo, Norway.
   [Citerio, Giuseppe] Univ Milano Bicocca, H San Gerardo Monza, Sch Med & Surg, Neuroanaesthesia & Neurointens Care, Milan, Italy.
   [van den Boogaard, Mark] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, Nijmegen, Netherlands.
   [Hastbacka, Johanna] Univ Helsinki, Dept Anaesthesia Intens Care & Pain Med, Div Intens Care, Helsinki, Finland.
   [Hastbacka, Johanna] Helsinki Univ Hosp, Helsinki, Finland.
   [Haenggi, Matthias] Univ Bern, Univ Hosp Bern, Inselspital, Dept Intens Care Med, Bern, Switzerland.
   [Colpaert, Kirsten] Univ Hosp Gent, Intens Care Unit, Ghent, Belgium.
   [Rose, Louise] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada.
   [Rose, Louise] Kings Coll London, Florence Nightingale Fac Nursing Midwife & Pallia, London, England.
   [Barbateskovic, Marija; Wetterslev, Jorn] Rigshosp, Copenhagen Univ Hosp, Copenhagen Trial Unit, Copenhagen, Denmark.
   [Lange, Theis; Jensen, Aksel] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark.
   [Krog, Martin B.; Nibro, Helle L.] Univ Hosp Aarhus, Dept Intens Care, Aarhus, Denmark.
   [Lange, Theis] Peking Univ, Ctr Stat Sci, Beijing, Peoples R China.
RP Collet, MO (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, Copenhagen, Denmark.
EM marie.oxenboell-collet@regionh.dk
RI Rood, Paul/F-2595-2016; Wetterslev, Jorn/ABF-1251-2020; Haenggi,
   Matthias/A-8073-2008; Nydahl, Peter/V-4516-2019; Haenggi,
   Matthias/O-2642-2019; Citerio, Giuseppe/B-1839-2015; Bozza, Fernando
   A/A-2618-2013; Sonneville, Romain/AAE-7039-2020; van den Boogaard,
   M./N-5857-2014; Ferrer, Ricard/K-9022-2017; Collet, Marie/AAY-1594-2020
OI Rood, Paul/0000-0001-8013-1243; Wetterslev, Jorn/0000-0001-7778-1771;
   Haenggi, Matthias/0000-0001-5845-031X; Nydahl,
   Peter/0000-0002-5178-0364; Haenggi, Matthias/0000-0001-5845-031X;
   Citerio, Giuseppe/0000-0002-5374-3161; Bozza, Fernando
   A/0000-0003-4878-0256; Sonneville, Romain/0000-0003-0245-309X; van den
   Boogaard, M./0000-0003-4233-2903; Ferrer, Ricard/0000-0002-4859-4747;
   Collet, Marie/0000-0002-8387-3960; Sardo, Salvatore/0000-0001-7664-8928;
   Rose, Louise/0000-0003-1700-3972; Santafe, Manel/0000-0002-5462-5108;
   CABALLERO, JESUS/0000-0001-9005-9687; Estrup, Stine/0000-0002-1467-7085;
   Moreno Gonzalez, Gabriel Jesus/0000-0003-3281-1126; Martelli,
   Gabriele/0000-0001-6729-2982; LEGGIERI, Carlo/0000-0002-0910-889X;
   Lange, Theis/0000-0001-6807-8347; Marin-Corral,
   Judith/0000-0003-1320-4427; TERZI, Nicolas/0000-0003-4036-6245
FU Innovation Foundation Denmark
FX The AID-ICU study is funded by the Innovation Foundation Denmark.
CR Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Berman BD, 2011, NEUROHOSPITALIST, V1, P41, DOI 10.1177/1941875210386491
   Boustani M, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0141-2
   Burry LD, 2017, J CRIT CARE, V42, P268, DOI 10.1016/j.jcrc.2017.08.003
   Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008
   Duprey MS, 2016, INTENS CARE MED, V42, P1818, DOI 10.1007/s00134-016-4512-3
   Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Gaudreau JD, 2005, J PAIN SYMPTOM MANAG, V29, P368, DOI 10.1016/j.jpainsymman.2004.07.009
   Granholm A, 2018, ACTA ANAESTH SCAND, V62, P336, DOI 10.1111/aas.13048
   Gunther ML, 2008, CRIT CARE CLIN, V24, P45, DOI 10.1016/j.ccc.2007.10.002
   Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5
   Han JH, 2010, ANN EMERG MED, V56, P244, DOI 10.1016/j.annemergmed.2010.03.003
   Hipp DM, 2012, NEUROTHERAPEUTICS, V9, P158, DOI 10.1007/s13311-011-0102-9
   Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020
   Kalabalik Julie, 2014, J Pharm Pract, V27, P195, DOI 10.1177/0897190013513804
   Kanova M, 2017, BIOMED PAP, V161, P187, DOI 10.5507/bp.2017.004
   Krag M, 2015, INTENS CARE MED, V41, P833, DOI 10.1007/s00134-015-3725-1
   Lat I, 2009, CRIT CARE MED, V37, P1898, DOI 10.1097/CCM.0b013e31819ffe38
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Marquis F, 2007, CRIT CARE MED, V35, P2533, DOI 10.1097/01.CCM.0000284506.43390.F3
   Meyhoff TS, 2017, ACTA ANAESTH SCAND, V61, P513, DOI 10.1111/aas.12878
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Milbrandt EB, 2005, CRIT CARE MED, V33, P226, DOI 10.1097/01.CCM.0000150743.16005.9A
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Peterson JF, 2006, J AM GERIATR SOC, V54, P479, DOI 10.1111/j.1532-5415.2005.00621.x
   Pisani MA, 2015, CRIT CARE MED, V43, P996, DOI 10.1097/CCM.0000000000000863
   Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022
   Sakusic A, 2018, MAYO CLIN PROC, V93, P68, DOI 10.1016/j.mayocp.2017.11.005
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Schrijver EJM, 2016, EUR J INTERN MED, V27, P14, DOI 10.1016/j.ejim.2015.10.012
   Schuurmans Marieke J, 2003, Res Theory Nurs Pract, V17, P31, DOI 10.1891/rtnp.17.1.31.53169
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148
   Slooter AJC, 2017, HAND CLINIC, V141, P449, DOI 10.1016/B978-0-444-63599-0.00025-9
   STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521
   Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9
   Thiboutot Z, 2016, CAN J HOSP PHARM, V69, P107
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Zhang ZG, 2013, GEN HOSP PSYCHIAT, V35, P105, DOI 10.1016/j.genhosppsych.2012.11.003
NR 40
TC 21
Z9 21
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD JUL
PY 2018
VL 44
IS 7
BP 1081
EP 1089
DI 10.1007/s00134-018-5204-y
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA GO1GK
UT WOS:000439697600008
PM 29767323
OA Green Published
DA 2020-12-01
ER

PT J
AU Goncalves, B
   Turon, R
   Mendes, A
   Melo, N
   Lacerda, P
   Brasil, P
   Bozza, FA
   Kurtz, P
   Righy, C
AF Goncalves, Bruno
   Turon, Ricardo
   Mendes, Antenor
   Melo, Nivea
   Lacerda, Paula
   Brasil, Pedro
   Bozza, Fernando Augusto
   Kurtz, Pedro
   Righy, Cassia
TI Effect of Early Brain Infarction After Subarachnoid Hemorrhage: A
   Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain infarction; Brain injuries; Brain ischemia; Subarachnoid
   hemorrhage; Subarachnoid hemorrhage outcomes
ID EARLY CEREBRAL INFARCTION; RISK-FACTORS; INJURY; MANAGEMENT; ISCHEMIA;
   MECHANISMS; IMPACT
AB OBJECTIVE: Aneurysmal subarachnoid hemorrhage (aSAH) is an acute cerebrovascular event that leads to devastating consequences. Early brain infarction (EBI) develops very early, within the first 72 hours after bleeding, and may have a significant impact on long-term outcomes. The incidence and impact of EBI in the prognosis of aSAH remain uncertain. We performed a systematic review and meta-analysis to evaluate the incidence of EBI in patients with aSAH and determine its effect on mortality and functional outcomes.
   METHODS: We performed a systematic review and metaanalysis. Inclusion criteria were 1) studies that evaluated aSAH within 72 hours after bleeding; 2) performed a brain imaging study up to 72 hours of hemorrhage; 3) used computed tomography or magnetic resonance imaging; and 4) included a description of the findings of the brain imaging study (whether or not an infarct was present).
   RESULTS: Ten studies that met the criteria were included. The incidence of EBI was 17%. The risk ratio for 3-month mortality was 2.18 (95% confidence interval 1.48-3.30). The overall risk ratio for poor outcome was 2.26 (95% confidence interval 1.75-2.93).
   CONCLUSIONS: EBI plays an important role in the outcome of patients with aSAH. Its significant impact could represent a new therapeutic frontier for improving outcomes of these patients.
C1 [Goncalves, Bruno; Turon, Ricardo; Mendes, Antenor; Melo, Nivea; Lacerda, Paula; Kurtz, Pedro; Righy, Cassia] Paulo Niemeyer State Brain Inst, Intens Care Unit, Rio De Janeiro, Brazil.
   [Goncalves, Bruno; Brasil, Pedro; Bozza, Fernando Augusto; Righy, Cassia] Fundacao Oswaldo Cruz, Natl Inst Infectol, Rio De Janeiro, Brazil.
   [Goncalves, Bruno; Mendes, Antenor; Melo, Nivea; Kurtz, Pedro] Copa Star Hosp, Intens Care Unit, Rio De Janeiro, Brazil.
   [Turon, Ricardo] Neurocrit Care Unit, Niteroi Hosp Complex, Niteroi, RJ, Brazil.
   [Bozza, Fernando Augusto] DOr Inst Res & Eduact, Rio De Janeiro, Brazil.
RP Goncalves, B (corresponding author), Paulo Niemeyer State Brain Inst, Intens Care Unit, Rio De Janeiro, Brazil.; Goncalves, B (corresponding author), Fundacao Oswaldo Cruz, Natl Inst Infectol, Rio De Janeiro, Brazil.; Goncalves, B (corresponding author), Copa Star Hosp, Intens Care Unit, Rio De Janeiro, Brazil.
EM brunogs@gmail.com
RI Bozza, Fernando A/A-2618-2013; Shinotsuka, Cassia Righy/H-9181-2013;
   Brasil, Pedro Emmanuel/AAG-2280-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552; Brasil, Pedro Emmanuel/0000-0002-6700-2268;
   /0000-0002-4469-8645
CR Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Flynn L, 2015, F1000RES, V4, P1200
   Francoeur CL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1447-6
   Frontera JA, 2015, J NEUROL NEUROSUR PS, V86, P71, DOI 10.1136/jnnp-2013-307313
   Fu C, 2013, CURR NEUROVASC RES, V10, P316, DOI 10.2174/15672026113109990027
   Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2
   Helbok R, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0809-9
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Jabbarli R, 2015, EUR J NEUROL, V22, P941, DOI 10.1111/ene.12686
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Juvela S, 2012, EUR J NEUROL, V19, P332, DOI 10.1111/j.1468-1331.2011.03523.x
   Korbakis G, 2016, NEUROCRIT CARE, V24, P428, DOI 10.1007/s12028-015-0212-z
   Kumar A, 2013, NEUROSURGERY, V73, P617, DOI 10.1227/NEU.0000000000000057
   Kusaka G, 2004, J CEREBR BLOOD F MET, V24, P916, DOI 10.1097/01.WCB.0000125886.48838.7E
   Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490
   Marbacher S, 2014, INTENS CARE MED EXP, V2, DOI 10.1186/s40635-014-0030-1
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   Moussouttas M, 2013, J NEUROL, V260, P21, DOI 10.1007/s00415-012-6576-5
   Sato K, 2010, J CEREBR BLOOD F MET, V30, P1110, DOI 10.1038/jcbfm.2009.264
   Schmidt JM, 2007, NEUROCRIT CARE, V7, P10, DOI 10.1007/s12028-007-0003-2
   Sehba FA, 2012, PROG NEUROBIOL, V97, P14, DOI 10.1016/j.pneurobio.2012.02.003
   Shimoda M, 2010, ACTA NEUROCHIR, V152, P1197, DOI 10.1007/s00701-010-0640-7
   Siironen J, 2007, J NEUROSURG, V107, P1074, DOI 10.3171/JNS-07/12/1074
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   van der Kleij LA, 2017, STROKE, V48, P239, DOI 10.1161/STROKEAHA.116.011707
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
NR 27
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2018
VL 115
BP E292
EP E298
DI 10.1016/j.wneu.2018.04.037
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA GK8YL
UT WOS:000436519600039
PM 29660554
DA 2020-12-01
ER

PT J
AU Delatorre, E
   Miranda, M
   Tschoeke, DA
   de Sequeira, PC
   Sampaio, SA
   Barbosa-Lima, G
   Vieira, YR
   Leomil, L
   Bozza, FA
   Cerbino-Neto, J
   Bozza, PT
   Nogueira, RMR
   Brasil, P
   Thompson, FL
   de Filippis, AMB
   Souza, TML
AF Delatorre, Edson
   Miranda, Milene
   Tschoeke, Diogo A.
   de Sequeira, Patricia Carvalho
   Sampaio, Simone Alves
   Barbosa-Lima, Giselle
   Vieira, Yasmine Rangel
   Leomil, Luciana
   Bozza, Fernando A.
   Cerbino-Neto, Jose
   Bozza, Patricia T.
   Ribeiro Nogueira, Rita Maria
   Brasil, Patricia
   Thompson, Fabiano L.
   de Filippis, Ana M. B.
   Souza, Thiago Moreno L.
TI An observational clinical case of Zika virus-associated neurological
   disease is associated with primary IgG response and enhanced TNF levels
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
DE Zika virus; zika; neurological disease; neurotropism; Brazil; Rio de
   Janeiro
ID ANTIBODY-DEPENDENT ENHANCEMENT; GUILLAIN-BARRE-SYNDROME; PATHOGENESIS;
   INFECTION
AB Descriptive clinical data help to reveal factors that may provoke Zika virus (ZIKV) neuropathology. The case of a 24-year-old female with a ZIKV-associated severe acute neurological disorder was studied. The levels of ZIKV in the cerebrospinal fluid (CSF) were 50 times higher than the levels in other compartments. An acute anti-flavivirus IgG, together with enhanced TNFalpha levels, may have contributed to ZIKV invasion in the CSF, whereas the unbiased genome sequencing [obtained by next-generation sequencing (NGS)] of the CSF revealed that no virus mutations were associated with the anatomic compartments (CSF, serum, saliva and urine).
C1 [Delatorre, Edson] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Miranda, Milene] Fiocruz MS, IOC, Lab Virus Resp & Sarampo, Rio De Janeiro, RJ, Brazil.
   [Miranda, Milene; Tschoeke, Diogo A.; Leomil, Luciana; Thompson, Fabiano L.] Univ Fed Rio de Janeiro, Inst Biol, Rio De Janeiro, RJ, Brazil.
   [Miranda, Milene; Tschoeke, Diogo A.; Leomil, Luciana; Thompson, Fabiano L.] Univ Fed Rio de Janeiro, SAGE COPPE, Rio de Janeiro, RJ, Brazil.
   [Tschoeke, Diogo A.] Univ Fed Rio de Janeiro, Nucleo Ecol & Desenvolvimento Socioambiental Maca, Macae, RJ, Brazil.
   [de Sequeira, Patricia Carvalho; Sampaio, Simone Alves; Ribeiro Nogueira, Rita Maria; de Filippis, Ana M. B.] Fiocruz MS, IOC, Lab Flavivirus, Rio De Janeiro, RJ, Brazil.
   [Barbosa-Lima, Giselle; Vieira, Yasmine Rangel; Bozza, Fernando A.; Cerbino-Neto, Jose; Brasil, Patricia; Souza, Thiago Moreno L.] Fiocruz MS, Inst Nacl Infectol, Rio De Janeiro, RJ, Brazil.
   [Barbosa-Lima, Giselle; Vieira, Yasmine Rangel; Bozza, Fernando A.; Souza, Thiago Moreno L.] Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Barbosa-Lima, Giselle; Vieira, Yasmine Rangel; Souza, Thiago Moreno L.] Fiocruz MS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, RJ, Brazil.
RP Souza, TML (corresponding author), Fiocruz MS, Inst Nacl Infectol, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, RJ, Brazil.
EM tmoreno@cdts.fiocruz.br
RI Tschoeke, Diogo A/F-9913-2019; Bozza, Fernando A/A-2618-2013; Neto, Jose
   Cerbino/P-3713-2018; Delatorre, Edson/J-8330-2015; Leomil,
   Luciana/O-4860-2019
OI Tschoeke, Diogo A/0000-0001-8134-4259; Bozza, Fernando
   A/0000-0003-4878-0256; Neto, Jose Cerbino/0000-0001-9254-917X;
   Delatorre, Edson/0000-0002-5746-0820; Souza, Thiago/0000-0003-2212-3899;
   Thompson, Fabiano/0000-0002-7562-1683; Bozza,
   Patricia/0000-0001-8349-9529
FU Brazilian Ministry of Health; Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa no Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX Thanks are due to the Brazilian Ministry of Health, Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa no Estado do Rio de Janeiro (FAPERJ),
   and the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) for providing the funding to conduct this research.
CR Abbott NJ, 2005, CELL MOL NEUROBIOL, V25, P5, DOI 10.1007/s10571-004-1374-y
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Dahm T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8562805
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Kam YW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92428
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Oehler E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Ricciardi MJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006000
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   Smith DW, 2016, LANCET, V387, P1486, DOI 10.1016/S0140-6736(16)00564-X
   Solomon T, 2004, NEW ENGL J MED, V351, P370, DOI 10.1056/NEJMra030476
   Valadao ALC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01233
NR 21
TC 2
Z9 2
U1 0
U2 1
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD JUL
PY 2018
VL 99
IS 7
BP 913
EP 916
DI 10.1099/jgv.0.001080
PG 4
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA GL5TT
UT WOS:000437234800008
PM 29771234
OA Bronze
DA 2020-12-01
ER

PT J
AU Nogueira, ML
   Nery, NRR
   Estofolete, CF
   Terzian, ACB
   Guimaraes, GF
   Zini, N
   da Silva, RA
   Silva, GCD
   Franco, LCJ
   Rahal, P
   Bittar, C
   Carneiro, B
   Vasconcelos, PFC
   Henriques, DF
   Barbosa, DMU
   Rombola, PL
   de Grande, L
   Reis, AFN
   Palomares, SA
   Catelan, MW
   Cruz, LEAA
   Necchi, SH
   Mendonca, RCV
   dos Santos, INP
   Caron, SBA
   Costa, F
   Bozza, FA
   de Souza, AS
   de Mattos, CCB
   de Mattos, LC
   Vasilakis, N
   Oliani, AH
   Oliani, DCMV
   Ko, AI
AF Nogueira, M. L.
   Nery Junior, N. R. R.
   Estofolete, C. F.
   Bernardes Terzian, A. C.
   Guimaraes, G. F.
   Zini, N.
   Alves da Silva, R.
   Dutra Silva, G. C.
   Junqueira Franco, L. C.
   Rahal, P.
   Bittar, C.
   Carneiro, B.
   Vasconcelos, P. F. C.
   Freitas Henriques, D.
   Barbosa, D. M. U.
   Lopes Rombola, P.
   de Grande, L.
   Negri Reis, A. F.
   Palomares, S. A.
   Wakai Catelan, M.
   Cruz, L. E. A. A.
   Necchi, S. H.
   Mendonca, R. C. V.
   Penha dos Santos, I. N.
   Alavarse Caron, S. B.
   Costa, F.
   Bozza, F. A.
   Soares de Souza, A.
   Brandao de Mattos, C. C.
   de Mattos, L. C.
   Vasilakis, N.
   Oliani, A. H.
   Vaz Oliani, D. C. M.
   Ko, A. I.
TI Adverse birth outcomes associated with Zika virus exposure during
   pregnancy in Sao Jose do Rio Preto, Brazil
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE Adverse outcome; Arbovirus; Birth; Pregnancy; Zika virus
ID INFECTION; RUBELLA
AB Objectives: We aimed to report the first 54 cases of pregnant women infected by Zika virus (ZIKV) and their virologic and clinical outcomes, as well as their newborns' outcomes, in 2016, after the emergence of ZIKV in dengue-endemic areas of Sao Paulo, Brazil.
   Methods: This descriptive study was performed from February to October 2016 on 54 quantitative realtime PCR ZIKV-positive pregnant women identified by the public health authority of Sao Jose do Rio Preto, Sao Paulo, Brazil. The women were followed and had clinical and epidemiologic data collected before and after birth. Adverse outcomes in newborns were analysed and reported. Urine or blood samples from newborns were collected to identify ZIKV infection by reverse transcription PCR (RT-PCR).
   Results: A total of 216 acute Zika-suspected pregnant women were identified, and 54 had the diagnosis confirmed by RT-PCR. None of the 54 women miscarried. Among the 54 newborns, 15 exhibited adverse outcomes at birth. The highest number of ZIKV infections occurred during the second and third trimesters. No cases of microcephaly were reported, though a broad clinical spectrum of outcomes, including lenticulostriate vasculopathy, subependymal cysts, and auditory and ophthalmologic disorders, were identified. ZIKV RNA was detected in 18 of 51 newborns tested and in eight of 15 newborns with adverse outcomes.
   Conclusions: Although other studies have associated many newborn outcomes to ZIKV infection during pregnancy, these same adverse outcomes were rare or nonexistent in this study. The clinical presentation the newborns we studied was mild compared to other reports, suggesting that there is significant heterogeneity in congenital Zika infection. (C) 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Nogueira, M. L.; Estofolete, C. F.; Bernardes Terzian, A. C.; Guimaraes, G. F.; Zini, N.; Alves da Silva, R.; Dutra Silva, G. C.; Junqueira Franco, L. C.; Soares de Souza, A.; Brandao de Mattos, C. C.; de Mattos, L. C.; Oliani, A. H.; Vaz Oliani, D. C. M.] Sao Jose do Rio Preto Sch Med, Sao Jose Do Rio Preto, SP, Brazil.
   [Rahal, P.; Bittar, C.; Carneiro, B.] Sao Paulo State Univ, Sao Jose Do Rio Preto, SP, Brazil.
   [Barbosa, D. M. U.; Lopes Rombola, P.; de Grande, L.; Negri Reis, A. F.; Palomares, S. A.; Wakai Catelan, M.; Cruz, L. E. A. A.; Necchi, S. H.; Mendonca, R. C. V.; Penha dos Santos, I. N.; Alavarse Caron, S. B.] Hlth Secretariat, Sao Jose Do Rio Preto, SP, Brazil.
   [Nery Junior, N. R. R.; Costa, F.] Fundacao Oswaldo Cruz, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Vasconcelos, P. F. C.; Freitas Henriques, D.] Evandro Chagas Inst, Ananindeua, Para, Brazil.
   [Costa, F.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Bozza, F. A.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Vasilakis, N.] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Costa, F.; Ko, A. I.] Yale Sch Publ Hlth, New Haven, CT USA.
RP Nogueira, ML (corresponding author), Sao Jose do Rio Preto Sch Med FAMERP, 5416 Brigadeiro Faria Lima Ave, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
EM mnogueira@famerp.br
RI OLIANI, ANTONIO/O-1673-2019; Costa, Federico/G-1838-2015; de Mattos,
   Luiz Carlos/P-4005-2019; amsalu, ribka/G-8780-2019; Estofolete,
   Cassia/N-6673-2019; Bozza, Fernando A/A-2618-2013; de Mattos, Luiz
   Carlos/P-3574-2019; Carneiro, Bruno/P-2415-2019; DE MATTOS, LUIZ
   CARLOS/F-6739-2010; Vasconcelos, Pedro/AAH-3142-2019; Vasilakis,
   Nikos/ABE-7318-2020; Rahal, Paula/D-3871-2012; Ko, Albert
   Icksang/P-2343-2015; Nogueira, Mauricio L/B-7599-2012; Bittar,
   Cintia/A-5042-2015; de Mattos, Cinara Brandao/B-3650-2008
OI Costa, Federico/0000-0001-6951-2336; de Mattos, Luiz
   Carlos/0000-0002-8572-8177; Estofolete, Cassia/0000-0001-7324-1591;
   Bozza, Fernando A/0000-0003-4878-0256; DE MATTOS, LUIZ
   CARLOS/0000-0002-8572-8177; Rahal, Paula/0000-0001-5693-6148; Ko, Albert
   Icksang/0000-0001-9023-2339; Nogueira, Mauricio L/0000-0003-1102-2419;
   Bittar, Cintia/0000-0002-2048-4589; de Mattos, Cinara
   Brandao/0000-0002-4836-3113; Spegiorin, Ligia Cosentino Junqueira
   Franco/0000-0003-4405-8098; Oliani, Antonio Helio/0000-0003-1242-4364;
   Carneiro, Bruno/0000-0002-2355-7907; Rocha Nery Junior, Nivison
   Ruy/0000-0002-8164-0602
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2013/21719-3, 2016/15021-1, 2015/12295-0,
   2016/05115-9]; Zika Virus Fast Track program by the Coordination for the
   Improvement of Higher Level Education Personnel; Brazilian National
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [303999/2016-0, 440405/2016-5, 457664/2013-4]
FX Supported by the Sao Paulo Research Foundation (FAPESP) via grants
   2013/21719-3 and 2016/15021-1 to MLN, grant 2015/12295-0 to ACBT and
   grant 2016/05115-9 to LCM. The opinions, assumptions and conclusions or
   recommendations expressed in this material are the responsibility of the
   authors and do not necessarily reflect the views of FAPESP. PFCV was
   supported by the Zika Virus Fast Track program provided by the
   Coordination for the Improvement of Higher Level Education Personnel and
   the Brazilian National Council for Scientific and Technological
   Development (CNPq) by grants 303999/2016-0, 440405/2016-5 and
   457664/2013-4. MLM is a CNPq research fellow. All authors report no
   conflicts of interest relevant to this article.
CR [Anonymous], 2000, ASS PREN MAN TECN, P66
   [Anonymous], 2016, PROC SER AD VIG FEBR
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Terzian ACB, 2011, VECTOR-BORNE ZOONOT, V11, P291, DOI 10.1089/vbz.2009.0200
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Centers for Disease Control and Prevention, 2015, MMWR RECOMM REP, V64, P138
   de Oliveira WK, 2016, MMWR-MORBID MORTAL W, V65
   de Souza AS, 2016, CLIN INFECT DIS, V63, P1622, DOI 10.1093/cid/ciw613
   Enright Andrea M, 2002, Semin Neonatol, V7, P283, DOI 10.1016/S1084-2756(02)90115-6
   Estofolete CF, 2016, J CLIN VIROL, V81, P25, DOI 10.1016/j.jcv.2016.05.012
   Figueiredo L T, 1990, Rev Soc Bras Med Trop, V23, P13, DOI 10.1590/S0037-86821990000100003
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   MILLER E, 1982, LANCET, V2, P781
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mondini A, 2005, REV SAUDE PUBL, V39, P444, DOI [10.1590/S0034-89102005000300016, 10.1590/s0034-89102005000300016]
   Mondini A, 2007, J CLIN VIROL, V40, P84, DOI 10.1016/j.jcv.2007.06.007
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Nei M, 2000, MOL EVOLUTION PHYLOG, P333, DOI DOI 10.1371/JOURNAL.PONE.0118669
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   RORKE LB, 1973, ARCH OTOLARYNGOL, V98, P249
   Schaub B, 2017, LANCET INFECT DIS, V17, P520, DOI [10.1016/S1473-3099(17)30102-0, 10.1016/s1473-3099(17)30102-0]
   Shope RE, 1979, DIAGNOSTIC PROCEDURE, P767
   Silasi M, 2015, AM J REPROD IMMUNOL, V73, P199, DOI 10.1111/aji.12355
   Singh Sarman, 2016, Trop Parasitol, V6, P113
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   World Health Organization, 2016, ASS INF MICR CONT ZI, P2
NR 28
TC 26
Z9 26
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD JUN
PY 2018
VL 24
IS 6
BP 646
EP 652
DI 10.1016/j.cmi.2017.11.004
PG 7
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA GG1KS
UT WOS:000432446500017
PM 29133154
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Campbell, RA
   Schwertz, H
   Hottz, ED
   Rowley, J
   Tolley, ND
   Zimmerman, G
   Bozza, FA
   Weyrich, A
   Rondina, MT
AF Campbell, Robert A.
   Schwertz, Hansjorg
   Hottz, Eugenio D.
   Rowley, Jesse
   Tolley, Neal D.
   Zimmerman, Guy
   Bozza, Fernando A.
   Weyrich, Andy
   Rondina, Matthew T.
TI TYPE I INTERFERONS UPREGULATE IFITM3 IN HUMAN PLATELETS AND
   MEGAKARYOCYTES TO CONTROL VIRAL INFECTIVITY
SO SHOCK
LA English
DT Meeting Abstract
CT 41st Annual Conference on Shock
CY JUN 09-12, 2018
CL Scottsdale, AZ
SP Shock Soc
C1 [Campbell, Robert A.; Schwertz, Hansjorg; Rowley, Jesse; Tolley, Neal D.; Zimmerman, Guy; Weyrich, Andy; Rondina, Matthew T.] Univ Utah, Salt Lake City, UT USA.
   [Hottz, Eugenio D.] Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   George E Wahlen VAMC GRECC, Salt Lake City, UT USA.
RI Bozza, Fernando A/A-2618-2013; Schwertz, Hansjorg/Q-3305-2019
OI Bozza, Fernando A/0000-0003-4878-0256; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2018
VL 49
IS 6
SU 1
MA P202
BP 126
EP 126
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA GQ0XL
UT WOS:000441343800272
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Bozza, Fernando A.
   Bozza, Patrcia T.
TI Platelets in Immune Response to Virus and Immunopathology of Viral
   Infections
SO FRONTIERS IN MEDICINE
LA English
DT Review
DE platelet; HIV infection; dengue; influenza; immunology and virology;
   viruses
ID DENGUE HEMORRHAGIC-FEVER; HEPATITIS-C-VIRUS; COMBINATION ANTIRETROVIRAL
   THERAPY; NEUTROPHIL EXTRACELLULAR TRAPS; IDIOPATHIC THROMBOCYTOPENIC
   PURPURA; 2009 INFLUENZA A(H1N1); TOLL-LIKE RECEPTORS; CD8(+) T-CELLS;
   MHC CLASS-I; BONE-MARROW
AB Platelets are essential effector cells in hemostasis. Aside from their role in coagulation, platelets are now recognized as major inflammatory cells with key roles in the innate and adaptive arms of the immune system. Activated platelets have key thromboinflammatory functions linking coagulation to immune responses in various infections, including in response to virus. Recent studies have revealed that platelets exhibit several pattern recognition receptors (PRR) including those from the toll-like receptor, NOD-like receptor, and C-type lectin receptor family and are first-line sentinels in detecting and responding to pathogens in the vasculature. Here, we review the main mechanisms of platelets interaction with viruses, including their ability to sustain viral infection and replication, their expression of specialized PRR, and activation of thromboinflammatory responses against viruses. Finally, we discuss the role of platelet-derived mediators and platelet interaction with vascular and immune cells in protective and pathophysiologic responses to dengue, influenza, and human immunodeficiency virus 1 infections.
C1 [Hottz, Eugenio D.; Bozza, Patrcia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.] Univ Fed Juiz de Fora, Dept Bioquim, Juiz De Fora, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Lab Med Intens, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, Rio De Janeiro, Brazil.
RP Hottz, ED; Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.; Hottz, ED (corresponding author), Univ Fed Juiz de Fora, Dept Bioquim, Juiz De Fora, Brazil.
EM eugeniohottz@gmail.com; pbozza@ioc.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Hottz, Eugenio D/I-9850-2014
OI Bozza, Fernando A/0000-0003-4878-0256; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); PAPES/FIOCRUZ
FX The work of the authors is supported by CNPq, CAPES, FAPERJ, and
   PAPES/FIOCRUZ.
CR Alexander JS, 1998, AM J PHYSIOL-HEART C, V274, pH115
   Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Anabel AS, 2014, HUM IMMUNOL, V75, P1244, DOI 10.1016/j.humimm.2014.09.013
   Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916
   Arthur CM, 2016, BLOOD, V127, P1823, DOI 10.1182/blood-2015-10-673426
   Ashar HK, 2018, AM J PATHOL, V188, P135, DOI 10.1016/j.ajpath.2017.09.014
   Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562
   Aslam R, 2006, BLOOD, V107, P637, DOI 10.1182/blood-2005-06-2202
   Assinger A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00649
   Auerbach DJ, 2012, P NATL ACAD SCI USA, V109, P9569, DOI 10.1073/pnas.1207314109
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P46, DOI 10.1111/j.1574-695X.2008.00399.x
   Baum PD, 2011, AIDS, V25, P2243, DOI 10.1097/QAD.0b013e32834d3cc3
   Beaulieu LM, 2014, ARTERIOSCL THROM VAS, V34, P552, DOI 10.1161/ATVBAHA.113.302700
   Beaulieu LM, 2011, BLOOD, V117, P5963, DOI 10.1182/blood-2010-09-304949
   BHAMARAP.N, 1967, ANN TROP MED PARASIT, V61, P500, DOI 10.1080/00034983.1967.11686519
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Blasius AL, 2010, IMMUNITY, V32, P305, DOI 10.1016/j.immuni.2010.03.012
   Blijleven JS, 2016, SEMIN CELL DEV BIOL, V60, P78, DOI 10.1016/j.semcdb.2016.07.007
   Boilard E, 2014, BLOOD, V123, P2854, DOI 10.1182/blood-2013-07-515536
   Bonmarin Isabelle, 2015, Euro Surveill, V20, DOI 10.2807/1560-7917.ES.2015.20.46.30066
   BOONPUCKNAVIG S, 1979, ARCH PATHOL LAB MED, V103, P463
   Boukour S, 2006, J THROMB HAEMOST, V4, P426, DOI 10.1111/j.1538-7836.2006.01749.x
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brass AL, 2009, CELL, V139, P1243, DOI 10.1016/j.cell.2009.12.017
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Bridget W, 2009, AM J TROP MED HYG, V81, P638, DOI 10.4269/ajtmh.2009.08-0008
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575
   Cecchetti L, 2011, BLOOD, V118, P1903, DOI 10.1182/blood-2010-12-324517
   Chabert A, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0092-1
   Chagan-Yasutan H, 2014, THROMB RES, V134, P449, DOI 10.1016/j.thromres.2014.05.003
   Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06
   Chapman LM, 2012, J IMMUNOL, V189, P916, DOI 10.4049/jimmunol.1200580
   Chelucci C, 1998, BLOOD, V91, P1225, DOI 10.1182/blood.V91.4.1225
   Chow L, 2010, BLOOD, V115, P1247, DOI 10.1182/blood-2009-09-244772
   Clark KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052902
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Cognasse F, 2005, IMMUNOL CELL BIOL, V83, P196, DOI 10.1111/j.1440-1711.2005.01314.x
   Cognasse F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00083
   Corrales-Medina VF, 2010, JAIDS-J ACQ IMM DEF, V54, P217, DOI 10.1097/QAI.0b013e3181c8f4c9
   Cruz-Oliveira C, 2015, FEMS MICROBIOL REV, V39, P155, DOI 10.1093/femsre/fuu004
   D'Atri LP, 2015, J THROMB HAEMOST, V13, P839, DOI 10.1111/jth.12842
   Loria GD, 2013, BLOOD, V121, P940, DOI 10.1182/blood-2011-08-376822
   Davidson DC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051793
   Davidson DC, 2011, J IMMUNOL, V186, P584, DOI 10.4049/jimmunol.1001911
   de Almeida AJ, 2009, HEPATO-GASTROENTEROL, V56, P429
   de Almeida AJ, 2004, ANN HEMATOL, V83, P434, DOI 10.1007/s00277-004-0844-0
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Trugilho MRD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006385
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Diallo YL, 2016, J ANTIMICROB CHEMOTH, V71, P3506, DOI 10.1093/jac/dkw303
   Dixon DA, 2006, J CLIN INVEST, V116, P2727, DOI 10.1172/JC127209
   Dominguez-Cherit G, 2016, CRIT CARE MED, V44, P1861, DOI 10.1097/CCM.0000000000001830
   Dutartre H, 2016, J VIROL, V90, P7607, DOI 10.1128/JVI.00407-16
   Falcinelli E, 2013, THROMB HAEMOSTASIS, V110, P349, DOI 10.1160/TH12-07-0504
   Flaujac C, 2010, CELL MOL LIFE SCI, V67, P545, DOI 10.1007/s00018-009-0209-x
   Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676
   de Araujo JMG, 2009, J VIROL METHODS, V155, P34, DOI 10.1016/j.jviromet.2008.09.023
   Garraud Olivier, 2010, Inflammation & Allergy Drug Targets, V9, P322
   Ghosh K, 2008, J ELECTRON MICROSC, V57, P113, DOI 10.1093/jmicro/dfn007
   Goehringer F, 2017, AIDS RES HUM RETROV, V33, P187, DOI [10.1089/aid.2016.0222, 10.1089/AID.2016.0222]
   Cardozo FTGD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178820
   Gomes L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113394
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Green SA, 2015, AIDS, V29, P1297, DOI 10.1097/QAD.0000000000000701
   Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2
   Guo L, 2017, MUCOSAL IMMUNOL, V10, P1529, DOI 10.1038/mi.2017.1
   Hamaia S, 2001, BLOOD, V98, P2293, DOI 10.1182/blood.V98.8.2293
   Harms PW, 2010, AM J CLIN PATHOL, V134, P27, DOI 10.1309/AJCP35KOZSAVNQZW
   HASELTON FR, 1992, AM J PHYSIOL, V263, pL670
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Her Z, 2017, J INFECT DIS, V215, P42, DOI 10.1093/infdis/jiw494
   Ho-Tin-Noe B, 2011, J THROMB HAEMOST, V9, P56, DOI 10.1111/j.1538-7836.2011.04317.x
   Holme PA, 1998, FASEB J, V12, P79
   Hotter D, 2018, J LEUKOCYTE BIOL, V103, P465, DOI 10.1002/JLB.3MR0717-307R
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/435783
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Duyen HTL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14640-1
   Iannacone M, 2005, NAT MED, V11, P1167, DOI 10.1038/nm1317
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Jeewandara C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003459
   Jenne CN, 2013, CELL HOST MICROBE, V13, P169, DOI 10.1016/j.chom.2013.01.005
   Jones LD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151702
   Kamaladasa A, 2016, ANTIVIR RES, V133, P183, DOI 10.1016/j.antiviral.2016.07.016
   Kar M, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx051
   Kim SJ, 2016, SEMIN IMMUNOL, V28, P546, DOI 10.1016/j.smim.2016.10.013
   Koupenova M, 2015, ARTERIOSCL THROM VAS, V35, P1030, DOI 10.1161/ATVBAHA.114.304954
   Koupenova M, 2014, BLOOD, V124, P791, DOI 10.1182/blood-2013-11-536003
   Kraemer BF, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002355
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kubelka CF, 2010, J INFECTION, V61, P501, DOI 10.1016/j.jinf.2010.09.020
   Kuiken T, 2012, CURR OPIN VIROL, V2, P276, DOI 10.1016/j.coviro.2012.02.013
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489
   Lanza GA, 2011, J INTERN MED, V269, P118, DOI 10.1111/j.1365-2796.2010.02285.x
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Laurence J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187185
   Layne K, 2016, CARDIOVASC RES, V111, P26, DOI 10.1093/cvr/cvw089
   Lazar R, 2017, CLIN INFECT DIS, V65, P469, DOI 10.1093/cid/cix343
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Li JJ, 2001, THROMB HAEMOSTASIS, V85, P204
   Li X, 1999, J VIRAL HEPATITIS, V6, P107, DOI 10.1046/j.1365-2893.1999.00140.x
   Liang H, 2015, CELL MOL IMMUNOL, V12, P435, DOI 10.1038/cmi.2014.66
   Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144
   Lin CK, 2017, SCI REP-UK, V7, DOI 10.1038/srep44701
   Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581
   LO SK, 1988, AM J PHYSIOL, V254, pH763
   Lutteke N, 2010, VIROLOGY, V405, P70, DOI 10.1016/j.virol.2010.05.028
   Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398
   Malavige GN, 2017, IMMUNOLOGY, V151, P261, DOI 10.1111/imm.12748
   Mammoto T, 2015, AM J RESP CELL MOL, V52, P56, DOI 10.1165/rcmb.2014-0076OC
   Marakalala MJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006333
   Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   Matsuura C, 2012, T ROY SOC TROP MED H, V106, P174, DOI 10.1016/j.trstmh.2011.10.009
   Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355
   McDonald B, 2013, AIDS RES HUM RETROV, V29, P993, DOI [10.1089/aid.2012.0309, 10.1089/AID.2012.0309]
   McDonald B, 2012, CELL HOST MICROBE, V12, P324, DOI 10.1016/j.chom.2012.06.011
   Mendes-Ribeiro AC, 2008, CLIN EXP PHARMACOL P, V35, P1143, DOI 10.1111/j.1440-1681.2008.04970.x
   Michels A, 2016, J THROMB HAEMOST, V14, P2274, DOI 10.1111/jth.13493
   Michels M, 2015, J INFECTION, V71, P480, DOI 10.1016/j.jinf.2015.06.014
   Michels M, 2014, THROMB HAEMOSTASIS, V112, P352, DOI 10.1160/TH14-01-0056
   Michels M, 2012, AM J TROP MED HYG, V87, P943, DOI 10.4269/ajtmh.2012.12-0020
   Middleton EA, 2016, PHYSIOL REV, V96, P1211, DOI 10.1152/physrev.00038.2015
   MITRAKUL C, 1977, AM J TROP MED HYG, V26, P975, DOI 10.4269/ajtmh.1977.26.975
   Monforte AD, 2004, AIDS, V18, P1811
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Monteiro JT, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9030059
   Mourao MPG, 2007, PLATELETS, V18, P605, DOI 10.1080/09537100701426604
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Murgue B, 1997, J INFECT DIS, V175, P1497, DOI 10.1086/516486
   Nachman RL, 2008, NEW ENGL J MED, V359, P1261, DOI 10.1056/NEJMra0800887
   Nakahara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075961
   NAKAO S, 1989, BLOOD, V74, P1235
   NANAKORN S, 1966, B WORLD HEALTH ORGAN, V35, P54
   Negrotto S, 2011, J THROMB HAEMOST, V9, P2477, DOI 10.1111/j.1538-7836.2011.04530.x
   Huy NT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002412
   Nkambule BB, 2015, THROMB RES, V135, P1131, DOI 10.1016/j.thromres.2015.01.031
   Nkambule BB, 2015, PLATELETS, V26, P250, DOI 10.3109/09537104.2014.909021
   Noisakran S, 2012, EXP HEMATOL, V40, P250, DOI 10.1016/j.exphem.2011.11.011
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   O'Brien M, 2013, JAIDS-J ACQ IMM DEF, V63, P280, DOI 10.1097/QAI.0b013e31828a292c
   O'Halloran JA, 2015, HIV MED, V16, P608, DOI 10.1111/hiv.12270
   Ojha A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41697
   Olsson B, 2003, NAT MED, V9, P1123, DOI 10.1038/nm921
   Onlamoon N, 2010, BLOOD, V115, P1823, DOI 10.1182/blood-2009-09-242990
   Oshiumi H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00200
   Padovani JL, 2013, REV SOC BRAS MED TRO, V46, P154, DOI 10.1590/0037-8682-1627-2013
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Pang JX, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0649-2
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Panigrahi S, 2013, CIRC RES, V112, P103, DOI 10.1161/CIRCRESAHA.112.274241
   Panitsas FP, 2004, BLOOD, V103, P2645, DOI 10.1182/blood-2003-07-2268
   D'Atri LP, 2017, FRONT BIOSCI-LANDMRK, V22, P1867, DOI 10.2741/4576
   Passacquale G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025595
   Patil S, 1997, AM J PHYSIOL-HEART C, V273, pH2304
   Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042
   Povoa TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083386
   Pozner RG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000847
   Preeyasombat C, 1999, J Med Assoc Thai, V82 Suppl 1, pS16
   Puerta-Guardo H, 2013, J VIROL, V87, P7486, DOI 10.1128/JVI.00085-13
   Rivadeneyra L, 2015, THROMB HAEMOSTASIS, V114, P982, DOI 10.1160/TH14-11-0951
   Rondina MT, 2011, J THROMB HAEMOST, V9, P748, DOI 10.1111/j.1538-7836.2011.04208.x
   Rondina MT, 2012, CHEST, V141, P1490, DOI 10.1378/chest.11-2860
   Rowley JW, 2011, BLOOD, V118, pE101, DOI 10.1182/blood-2011-03-339705
   Sa-Ngasang A, 2014, J INFECT DIS, V210, P138, DOI 10.1093/infdis/jiu042
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Satchell CS, 2011, J INFECT DIS, V204, P1202, DOI 10.1093/infdis/jir509
   Schechter ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam5441
   Schmid MA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00647
   Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Shiokawa M, 2017, CURR OPIN MICROBIOL, V40, P123, DOI 10.1016/j.mib.2017.11.004
   Short KR, 2014, LANCET INFECT DIS, V14, P57, DOI 10.1016/S1473-3099(13)70286-X
   Simon AY, 2015, BLOOD, V126, P378, DOI 10.1182/blood-2014-09-598029
   Singh MV, 2014, J IMMUNOL, V192, P4674, DOI 10.4049/jimmunol.1302318
   Sosothikul D, 2007, THROMB HAEMOSTASIS, V97, P627, DOI 10.1160/TH06-02-0094
   Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106
   Srichaikul Tanomsri, 2008, Journal of the Medical Association of Thailand, V91, P104
   Sridharan A, 2013, J VIROL, V87, P11648, DOI 10.1128/JVI.01156-13
   Srikiatkhachorn A, 2017, SEMIN IMMUNOPATHOL, V39, P563, DOI 10.1007/s00281-017-0625-1
   Stahl AL, 2006, BLOOD, V108, P167, DOI 10.1182/blood-2005-08-3219
   Sugiyama MG, 2016, J VIROL, V90, P1812, DOI 10.1128/JVI.02599-15
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Sui Z, 2007, J IMMUNOL, V178, P3226, DOI 10.4049/jimmunol.178.5.3226
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Thein TL, 2015, J INFECT DIS, V212, P711, DOI 10.1093/infdis/jiv122
   Thon JN, 2012, J CELL BIOL, V198, P561, DOI 10.1083/jcb.201111136
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Tien PC, 2010, JAIDS-J ACQ IMM DEF, V55, P316, DOI 10.1097/QAI.0b013e3181e66216
   Tomashek KM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005859
   Tsai JJ, 2011, J INNATE IMMUN, V3, P530, DOI 10.1159/000322904
   Tsegaye TS, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-48
   Tunjungputri RN, 2014, AIDS, V28, P2091, DOI 10.1097/QAD.0000000000000415
   Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van Lelyveld SFL, 2012, AIDS, V26, P465, DOI 10.1097/QAD.0b013e32834f32f8
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   von Hentig N, 2008, J ANTIMICROB CHEMOTH, V62, P1118, DOI 10.1093/jac/dkn333
   Voulgaropoulou F, 2000, VIROLOGY, V269, P78, DOI 10.1006/viro.2000.0193
   Le VB, 2015, AM J RESP CRIT CARE, V191, P804, DOI 10.1164/rccm.201406-1031OC
   Wang J, 2011, J THROMB HAEMOST, V9, P562, DOI 10.1111/j.1538-7836.2010.04168.x
   WANG SG, 1995, VIROLOGY, V213, P254, DOI 10.1006/viro.1995.1567
   Weyrich AS, 2007, BLOOD, V109, P1975, DOI 10.1182/blood-2006-08-042192
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Weyrich AS, 2005, CIRCULATION, V111, P633, DOI 10.1161/01.CIR.0000154607.90506.45
   Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389
   Wolf K, 2002, J INFECT DIS, V185, P456, DOI 10.1086/338572
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wu WL, 2009, EUR J IMMUNOL, V39, P3413, DOI 10.1002/eji.200939306
   Wygrecka M, 2017, AM J RESP CRIT CARE, V196, P186, DOI 10.1164/rccm.201604-0712OC
   Yacoub S, 2017, CLIN INFECT DIS, V65, P1453, DOI 10.1093/cid/cix567
   Yamane A, 2008, BLOOD, V112, P542, DOI 10.1182/blood-2007-12-125906
   YANG KD, 1995, J INFECT DIS, V172, P604, DOI 10.1093/infdis/172.2.604
   Yong YK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1226-4
   YOUNG NS, 1990, JAMA-J AM MED ASSOC, V263, P3065, DOI 10.1001/jama.263.22.3065
   Youssefian T, 2002, BLOOD, V99, P4021, DOI 10.1182/blood-2001-12-0191
   Zahn A, 2006, J GEN VIROL, V87, P2243, DOI 10.1099/vir.0.81826-0
   Zhang S, 2015, CIRCULATION, V131, P1160, DOI 10.1161/CIRCULATIONAHA.114.013743
   Zhou H. L., 2014, BUILD CONSTR, V10, P1182
   ZUCKERFRANKLIN D, 1990, BLOOD, V75, P1920
   Zufferey A, 2017, BLOOD ADV, V1, P1773, DOI 10.1182/bloodadvances.2017007021
NR 235
TC 31
Z9 32
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD APR 30
PY 2018
VL 5
AR 121
DI 10.3389/fmed.2018.00121
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA GE4NL
UT WOS:000431192600001
PM 29761104
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rosa, RG
   Falavigna, M
   Robinson, CC
   da Silva, DB
   Kochhann, R
   de Moura, RM
   Santos, MMS
   Sganzerla, D
   Giordani, NE
   Eugenio, C
   Ribeiro, T
   Cavalcanti, AB
   Bozza, F
   Azevedo, LCP
   Machado, FR
   Salluh, JIF
   Pellegrini, JAS
   Moraes, RB
   Hochegger, T
   Amaral, A
   Teles, JMM
   da Luz, LG
   Barbosa, MG
   Birriel, DC
   Ferraz, ID
   Nobre, V
   Valentim, HM
   Castro, LCE
   Duarte, PAD
   Tregnago, R
   Barilli, SLS
   Brandao, N
   Giannini, A
   Teixeira, C
AF Rosa, Regis Goulart
   Falavigna, Maicon
   Robinson, Caroline Cabral
   da Silva, Daiana Barbosa
   Kochhann, Renata
   de Moura, Rafaela Moraes
   Siqueira Santos, Mariana Martins
   Sganzerla, Daniel
   Giordani, Natalia Elis
   Eugenio, Claudia
   Ribeiro, Tarissa
   Cavalcanti, Alexandre Biasi
   Bozza, Fernando
   Pontes Azevedo, Luciano Cesar
   Machado, Flavia Ribeiro
   Figueira Salluh, Jorge Ibrain
   Santos Pellegrini, Jose Augusto
   Moraes, Rafael Barberena
   Hochegger, Tais
   Amaral, Alexandre
   Meira Teles, Jose Mario
   da Luz, Lucas Gobetti
   Barbosa, Mirceli Goulart
   Birriel, Daniella Cunha
   Ferraz, Iris de Lima
   Nobre, Vandack
   Valentim, Helen Martins
   Correa e Castro, Livia
   Delfino Duarte, Pericles Almeida
   Tregnago, Rogerio
   Santin Barilli, Sofia Louise
   Brandao, Nilton
   Giannini, Alberto
   Teixeira, Cassiano
CA ICU Visits Study Grp Investigators
TI Study protocol to assess the effectiveness and safety of a flexible
   family visitation model for delirium prevention in adult intensive care
   units: a cluster-randomised, crossover trial (The ICU Visits Study)
SO BMJ OPEN
LA English
DT Article
ID CONFUSION ASSESSMENT METHOD; CRITICALLY-ILL PATIENTS; POLICIES;
   SATISFACTION; VALIDATION; DEPRESSION; SEDATION; ANXIETY; MEMBERS; HEALTH
AB Introduction Flexible intensive care unit (ICU) visiting hours have been proposed as a means to improve patient-centred and family-centred care. However, randomised trials evaluating the effects of flexible family visitation models (FFVMs) are scarce. This study aims to compare the effectiveness and safety of an FFVM versus a restrictive family visitation model (RFVM) on delirium prevention among ICU patients, as well as to analyse its potential effects on family members and ICU professionals.
   Methods and analysis A cluster-randomised crossover trial involving adult ICU patients, family members and ICU professionals will be conducted. Forty medical-surgical Brazilian ICUs with RFVMs (<4.5 hours/day) will be randomly assigned to either an RFVM (visits according to local policies) or an FFVM (visitation during 12 consecutive hours per day) group at a 1:1 ratio. After enrolment and follow-up of 25 patients, each ICU will be switched over to the other visitation model, until 25 more patients per site are enrolled and followed. The primary outcome will be the cumulative incidence of delirium among ICU patients, measured twice a day using the Confusion Assessment Method for the ICU. Secondary outcome measures will include daily hazard of delirium, ventilator-free days, any ICU-acquired infections, ICU length of stay and hospital mortality among the patients; symptoms of anxiety and depression and satisfaction among the family members; and prevalence of burnout symptoms among the ICU professionals. Tertiary outcomes will include infection among the patients; self-perception of involvement in patient care among the family members; and satisfaction among the ICU professionals.
   Ethics and dissemination The study protocol has been approved by the research ethics committee of all participant institutions. We aim to disseminate the findings through conferences and peer-reviewed journals.
C1 [Rosa, Regis Goulart; da Silva, Daiana Barbosa; Eugenio, Claudia; Ribeiro, Tarissa; da Luz, Lucas Gobetti; Teixeira, Cassiano] HMV, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Falavigna, Maicon] HMV, Inst Educ & Res, Porto Alegre, RS, Brazil.
   [Robinson, Caroline Cabral; Kochhann, Renata; de Moura, Rafaela Moraes; Siqueira Santos, Mariana Martins; Sganzerla, Daniel; Giordani, Natalia Elis; Barbosa, Mirceli Goulart] HMV, Res Projects Off, Porto Alegre, RS, Brazil.
   [Cavalcanti, Alexandre Biasi] HCor, Res Inst, Sao Paulo, Brazil.
   [Bozza, Fernando; Figueira Salluh, Jorge Ibrain] Inst DOr Pesquisa & Ensino IDOR, Dept Crit Care, Rio De Janeiro, Brazil.
   [Pontes Azevedo, Luciano Cesar] Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, Brazil.
   [Machado, Flavia Ribeiro] Univ Fed Sao Paulo UNIFESP, Dept Anesthesiol Pain & Intens Care, Sao Paulo, Brazil.
   [Santos Pellegrini, Jose Augusto; Moraes, Rafael Barberena; Hochegger, Tais] HCPA, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Amaral, Alexandre; Meira Teles, Jose Mario] Hosp Urgencias Goiania, Intens Care Unit, Goiania, Go, Brazil.
   [Birriel, Daniella Cunha] Ctr Historico, Intens Care Unit, Pavilhao Pereira Filho, Porto Alegre, RS, Brazil.
   [Ferraz, Iris de Lima] Hosp Urgencia Emergencia Rio Branco, Intens Care Unit, Rio Branco, Brazil.
   [Nobre, Vandack] Univ Fed Minas Gerais, Hosp Clin, Intens Care Unit, Belo Horizonte, MG, Brazil.
   [Valentim, Helen Martins] Hosp Mae Deus, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Correa e Castro, Livia] Hosp Reg Baixo Amazonas, Intens Care Unit, Santarem, Brazil.
   [Delfino Duarte, Pericles Almeida] Hosp Canc Cascavel, Intens Care Unit, Cascavel, Brazil.
   [Delfino Duarte, Pericles Almeida] Hosp Univ Oeste Parana, Intens Care, Cascavel, Brazil.
   [Tregnago, Rogerio] Hosp Tacchini, Intens Care Unit, Bento Goncalves, Brazil.
   [Santin Barilli, Sofia Louise] Hosp Conceicao, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Brandao, Nilton] UFCSPA, Sch Med, Dept Internal Med, Porto Alegre, RS, Brazil.
   [Giannini, Alberto] Spedali Civil Brescia, Osped Bambini ASST, Unit Pediat Anesthesia & Intens Care, Brescia, Italy.
RP Rosa, RG (corresponding author), HMV, Intens Care Unit, Porto Alegre, RS, Brazil.
EM regis.rosa@hmv.org.br
RI Rosa, Regis Goulart/P-6422-2019; Azevedo, Luciano CP/H-2652-2012; Bozza,
   Fernando A/A-2618-2013; Teixeira, Cassiano/V-8764-2019; dantas, vicente
   c souza/L-2648-2013; Kochhann, Renata/C-5126-2018; Rosa,
   Regis/M-2291-2015
OI Azevedo, Luciano CP/0000-0001-6759-3910; Bozza, Fernando
   A/0000-0003-4878-0256; Barbosa Cerantola, Rodrigo/0000-0003-4225-2196;
   Kochhann, Renata/0000-0002-6328-8131; Rosa, Regis/0000-0001-7881-9866;
   Vasconcelos, Rosianne/0000-0001-8573-9143
FU Brazilian Ministry of Health through the Program of Institutional
   Development of the Brazilian Unified Health System (PROADI-SUS)
FX The present study was funded by the Brazilian Ministry of Health through
   the Program of Institutional Development of the Brazilian Unified Health
   System (PROADI-SUS).
CR Balas MC, 2014, CRIT CARE MED, V42, P1024, DOI 10.1097/CCM.0000000000000129
   Berwick DM, 2004, JAMA-J AM MED ASSOC, V292, P736, DOI 10.1001/jama.292.6.736
   Botega NJ, 1995, REV SAUDE PUBL, V29, P355, DOI 10.1590/S0034-89101995000500004
   Brummel NE, 2013, CRIT CARE CLIN, V29, P51, DOI 10.1016/j.ccc.2012.10.007
   Centers for Disease Control and Prevention, 2017, UR TRACT INF CATH AS
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chapman DK, 2016, AM J CRIT CARE, V25, P46, DOI 10.4037/ajcc2016789
   Colantuoni E, 2016, LANCET RESP MED, V4, P534, DOI 10.1016/S2213-2600(16)30138-2
   Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655
   Ramos FJD, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-34
   Davidson JE, 2017, CRIT CARE MED, V45, P103, DOI 10.1097/CCM.0000000000002169
   Campos JADB, 2012, REV SAUDE PUBL, V46, P816, DOI [10.1590/S0034-89102012000500008, 10.1590/s0034-89102012000500008]
   Eghbali-Babadi Maryam, 2017, Iran J Nurs Midwifery Res, V22, P327, DOI 10.4103/1735-9066.212985
   Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012
   Fumagalli S, 2006, CIRCULATION, V113, P946, DOI 10.1161/CIRCULATIONAHA.105.572537
   Fumis RRL, 2006, INTENS CARE MED, V32, P124, DOI 10.1007/s00134-005-2857-0
   Garrouste-Orgeas M, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0185-x
   Giannini A, 2014, INTENS CARE MED, V40, P730, DOI 10.1007/s00134-014-3267-y
   Giannini A, 2013, INTENS CARE MED, V39, P2180, DOI 10.1007/s00134-013-3087-5
   Gonzalez CE, 2004, AM J CRIT CARE, V13, P194, DOI 10.4037/ajcc2004.13.3.194
   Gusmao-Flores D, 2011, CRITICAL CARE, V15, P50, DOI DOI 10.1186/cc10198
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446
   Levy MM, 2013, INTENS CARE MED, V39, P2223, DOI 10.1007/s00134-013-3119-1
   Liu V, 2013, CRIT CARE, V17, DOI 10.1186/cc12677
   Malacarne P, 2011, AM J INFECT CONTROL, V39, P898, DOI 10.1016/j.ajic.2011.02.018
   Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258
   Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007
   Ramos Fernando José da Silva, 2014, Rev. bras. ter. intensiva, V26, P339, DOI 10.5935/0103-507X.20140052
   Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705
   Rosa RG, 2017, CRIT CARE MED, V45, P1660, DOI 10.1097/CCM.0000000000002588
   Rosendahl J, 2013, CRIT CARE MED, V41, P69, DOI 10.1097/CCM.0b013e31826766b0
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Salluh JIF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2538
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Siddiqi N, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005563.pub3
   Spreen Afien E, 2011, Intensive Crit Care Nurs, V27, P27, DOI 10.1016/j.iccn.2010.10.002
   Martinez FT, 2012, AGE AGEING, V41, P629, DOI [10.1093/ageing/afs060, 10.1093/ageing/afs125]
   Trogrlic Z, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0886-9
   van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420
   van Eijk MM, 2011, AM J RESP CRIT CARE, V184, P340, DOI 10.1164/rccm.201101-0065OC
   van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892
NR 42
TC 5
Z9 5
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD APR
PY 2018
VL 8
IS 4
AR e021193
DI 10.1136/bmjopen-2017-021193
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA GJ3FT
UT WOS:000435176700228
PM 29654049
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mazeraud, A
   Bozza, FA
   Sharshar, T
AF Mazeraud, Aurelien
   Bozza, Fernando A.
   Sharshar, Tarek
TI Sepsis-associated Encephalopathy Is Septic
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
C1 [Mazeraud, Aurelien; Sharshar, Tarek] Inst Pasteur, Dept Infect & Epidemiol, Paris, France.
   [Mazeraud, Aurelien; Sharshar, Tarek] Med & Surg Neurointens Care Ctr Hospitalier St An, Paris, France.
   [Mazeraud, Aurelien; Sharshar, Tarek] Univ Paris 05, Paris, France.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Mazeraud, A (corresponding author), Inst Pasteur, Dept Infect & Epidemiol, Paris, France.; Mazeraud, A (corresponding author), Med & Surg Neurointens Care Ctr Hospitalier St An, Paris, France.; Mazeraud, A (corresponding author), Univ Paris 05, Paris, France.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Bernard SC, 2014, NAT MED, V20, P725, DOI 10.1038/nm.3563
   Branton WG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054673
   Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350
   Disson O, 2012, VIRULENCE, V3, P213, DOI 10.4161/viru.19586
   Dramsi S, 1998, INFECT IMMUN, V66, P4461
   Kim KS, 2008, NAT REV MICROBIOL, V6, P625, DOI 10.1038/nrmicro1952
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z
   Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x
   Singer BH, 2018, AM J RESP CRIT CARE, V197, P747, DOI 10.1164/rccm.201708-1559OC
NR 10
TC 5
Z9 11
U1 1
U2 12
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAR 15
PY 2018
VL 197
IS 6
BP 698
EP 699
DI 10.1164/rccm.201712-2593ED
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA FZ4ZL
UT WOS:000427600800003
PM 29360405
OA Green Published
DA 2020-12-01
ER

PT J
AU da Silva, DS
   Teixeira, LAC
   Beghini, DG
   Ferreira, ATD
   Pinho, MDM
   Rosa, PS
   Ribeiro, MR
   Freire, MD
   Hacker, MA
   Nery, JAD
   Pessolani, MCV
   Tovar, AMF
   Sarno, EN
   Perales, J
   Bozza, FA
   Esquenazi, D
   Monteiro, RQ
   Lara, FA
AF da Silva, Debora Santos
   Castro Teixeira, Lisandra Antonia
   Beghini, Daniela Gois
   da Silva Ferreira, Andre Teixeira
   Moreira Pinho, Marcia de Berredo
   Rosa, Patricia Sammarco
   Ribeiro, Marli Rambaldi
   Freire, Monica Di Calafiori
   Hacker, Mariana Andrea
   da Costa Nery, Jose Augusto
   Vidal Pessolani, Maria Cristina
   Freire Tovar, Ana Maria
   Sarno, Euzenir Nunes
   Perales, Jonas
   Bozza, Fernando Augusto
   Esquenazi, Danuza
   Monteiro, Robson Queiroz
   Lara, Flavio Alves
TI Blood coagulation abnormalities in multibacillary leprosy patients
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ERYTHEMA-NODOSUM LEPROSUM; MYCOBACTERIUM-LEPRAE; STATISTICAL-MODEL;
   LIPID DROPLETS; SCHWANN-CELLS; MACROPHAGES; ACTIVATION; THROMBOSIS;
   INFLAMMATION; THALIDOMIDE
AB Background
   Leprosy is a chronic dermato-neurological disease caused by Mycobacterium leprae infection. In 2016, more than 200,000 new cases of leprosy were detected around the world, representing the most frequent cause of infectious irreversible deformities and disabilities.
   Principal findings
   In the present work, we demonstrate a consistent procoagulant profile on 40 reactional and non-reactional multibacillary leprosy patients. A retrospective analysis in search of signs of coagulation abnormalities among 638 leprosy patients identified 35 leprosy patients (5.48%) which displayed a characteristic lipid-like clot formed between blood clot and serum during serum harvesting, herein named 'leprosum clot'. Most of these patients (n = 16, 45.7%) belonged to the lepromatous leprosy pole of the disease. In addition, formation of the leprosum clot was directly correlated with increased plasma levels of soluble tissue factor and von Willebrand factor. High performance thin layer chromatography demonstrated a high content of neutral lipids in the leprosum clot, and proteomic analysis demonstrated that the leprosum clot presented in these patients is highly enriched in fibrin. Remarkably, differential 2D-proteomics analysis between leprosum clots and control clots identified two proteins present only in leprosy patients clots: complement component 3 and 4 and inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP). In agreement with those observations we demonstrated that M. leprae induces hepatocytes release of IHRP in vitro.
   Conclusions
   We demonstrated that leprosy MB patients develop a procoagulant status due to high levels of plasmatic fibrinogen, anti-cardiolipin antibodies, von Willebrand factor and soluble tissue factor. We propose that some of these components, fibrinogen for example, presents potential as predictive biomarkers of leprosy reactions, generating tools for earlier diagnosis and treatment of these events.
C1 [da Silva, Debora Santos; Moreira Pinho, Marcia de Berredo; Vidal Pessolani, Maria Cristina; Lara, Flavio Alves] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Cellular Microbiol, Rio De Janeiro, Brazil.
   [Castro Teixeira, Lisandra Antonia; Freire Tovar, Ana Maria] Univ Fed Rio de Janeiro, Lab Conjunct Tissue, Inst Med Biochem, Rio De Janeiro, Brazil.
   [Beghini, Daniela Gois; da Silva Ferreira, Andre Teixeira; Perales, Jonas] Fundacao Oswaldo Cruz, Lab Toxinol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Rosa, Patricia Sammarco] Lauro de Souza Lima Inst, Dept Biol, Bauru, Brazil.
   [Ribeiro, Marli Rambaldi; Freire, Monica Di Calafiori] DASA, Dept Hematol, Lab Dr Sergio Franco, Rio De Janeiro, Brazil.
   [Hacker, Mariana Andrea; da Costa Nery, Jose Augusto; Sarno, Euzenir Nunes; Esquenazi, Danuza] Fundacao Oswaldo Cruz, Lab Leprosy, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Dept Crit Care, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Monteiro, Robson Queiroz] Univ Fed Rio de Janeiro, Lab Hemostasis & Poisons, Inst Med Biochem, Rio De Janeiro, Brazil.
RP Lara, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Cellular Microbiol, Rio De Janeiro, Brazil.
EM flavioalveslara2000@gmail.com
RI Lara, Flavio Alves/L-1861-2013; Bozza, Fernando A/A-2618-2013; de
   Queiroz Monteiro, Robson/M-7097-2019; DE QUEIROZ MONTEIRO,
   ROBSON/B-8007-2014
OI Bozza, Fernando A/0000-0003-4878-0256; de Queiroz Monteiro,
   Robson/0000-0002-5260-2332; 
FU Fundacao de Amparo a Pesquisa do Estado do Rio de JaneiroCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [E-26/110.3461/2011]; Programa Institucional de Bolsas de
   Iniciacao Cientifica PIBIC, from Oswaldo Cruz Foundation
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (www.faperj.br) E-26/110.3461/2011 and the Programa
   Institucional de Bolsas de Iniciacao Cientifica PIBIC, from Oswaldo Cruz
   Foundation (www.pibic.fiocruz.br). The sources of funds had no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bahia El Idrissi N, 2016, CLIN EXPT IMMUNOLOGY
   Bellamy MC, 2004, LIVER TRANSPLANT, V10, P273, DOI 10.1002/lt.20061
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Silva SRB, 2010, MEM I OSWALDO CRUZ, V105, P627, DOI 10.1590/S0074-02762010000500005
   Choi-Miura NH, 2000, INFLAMM RES, V49, P305, DOI 10.1007/PL00000211
   COLTEN HR, 1972, J CLIN INVEST, V51, P725, DOI 10.1172/JCI106866
   de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842
   de Larranaga GF, 2005, LUPUS, V14, P967, DOI 10.1191/0961203305lu2232cr
   de Mattos KA, 2012, MEM I OSWALDO CRUZ, V107, P156, DOI 10.1590/S0074-02762012000900023
   DESAI SD, 1989, INFECT IMMUN, V57, P1311, DOI 10.1128/IAI.57.4.1311-1317.1989
   El Idrissi NB, 2015, ACTA NEUROPATHOL, V129, P653, DOI 10.1007/s00401-015-1404-5
   Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345
   Esquenazi D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127416
   Francischetti IMB, 2008, MICROCIRCULATION, V15, P81, DOI 10.1080/10739680701451516
   GUPTA M, 1975, INT J LEPROSY, V43, P327
   Havey TC, 2012, AM J TROP MED HYG, V86, P264, DOI 10.4269/ajtmh.2012.11-0598
   Kahawita IP, 2008, T ROY SOC TROP MED H, V102, P329, DOI 10.1016/j.trstmh.2008.01.004
   KARAT ABA, 1971, BRIT MED J, V1, P307, DOI 10.1136/bmj.1.5744.307
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kothari H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045700
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Levi M, 2006, SEMIN THROMB HEMOST, V32, P33, DOI 10.1055/s-2006-933338
   Lobato LS, 2014, ANTIMICROB AGENTS CH, V58, P5766, DOI 10.1128/AAC.01826-13
   Martinuzzo ME, 2002, CLIN EXP RHEUMATOL, V20, P477
   Mattos KA, 2014, CELL MICROBIOL, V16, P797, DOI 10.1111/cmi.12279
   Mattos KA, 2011, CELL MICROBIOL, V13, P259, DOI 10.1111/j.1462-5822.2010.01533.x
   Nery J A, 2000, Indian J Lepr, V72, P457
   NERY JA, 1993, LEPROSY REV, V64, P77
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nunzie E, 2014, LEPROSY REV, V85, P194
   OHISHI S, 1984, THROMB RES, V33, P371, DOI 10.1016/0049-3848(84)90076-8
   OKADA S, 1954, Int J Lepr, V22, P41
   Organization WH, 2017, GLOB LEPR UPD 2016 A, V1, P501
   Petiti-Martin GH, 2013, ACTAS DERMO-SIFILOGR, V104, P67, DOI 10.1016/j.ad.2011.12.002
   Petito RB, 2013, J NEUROPATH EXP NEUR, V72, P351, DOI 10.1097/NEN.0b013e31828bfc60
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   ROGERS JH, 1960, ANN INTERN MED, V53, P746, DOI 10.7326/0003-4819-53-4-746
   Ruiz JI, 1997, J LIPID RES, V38, P1482
   Sales AM, 2007, BRAZ J MED BIOL RES, V40, P243, DOI 10.1590/S0100-879X2006005000070
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   Stefani MM, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-75
   TOBE T, 1995, CYTOGENET CELL GENET, V71, P296, DOI 10.1159/000134130
   Valentini A, 1999, Rev Soc Bras Med Trop, V32, P131, DOI 10.1590/S0037-86821999000200003
   van der Poll T, 2011, CURR OPIN INFECT DIS, V24, P273, DOI 10.1097/QCO.0b013e328344c078
   Wakahara K, 2005, J INFECT DIS, V191, P930, DOI 10.1086/428134
   Walsh SN, 2010, J AM ACAD DERMATOL, V62, P1005, DOI 10.1016/j.jaad.2009.08.006
   Westermeier Reiner, 2011, Methods Biochem Anal, V54, P411
   Wirawan R, 1979, Southeast Asian J Trop Med Public Health, V10, P393
   World Health Organization, 2017, GLOB LEPR UPD 2016 A, V35, P501
   Woth G, 2011, J THROMB THROMBOLYS, V31, P6, DOI 10.1007/s11239-010-0486-0
   Zhuo LS, 2002, GLYCOCONJUGATE J, V19, P241, DOI 10.1023/A:1025331929373
NR 51
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAR
PY 2018
VL 12
IS 3
AR e0006214
DI 10.1371/journal.pntd.0006214
PG 20
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA GE5NI
UT WOS:000431268900012
PM 29565968
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU d'Avila, JC
   Siqueira, LD
   Mazeraud, A
   Azevedo, EP
   Foguel, D
   Castro-Faria-Neto, HC
   Sharshar, T
   Chretien, F
   Bozza, FA
AF d'Avila, Joana Costa
   Siqueira, Luciana Domett
   Mazeraud, Aurelien
   Azevedo, Estefania Pereira
   Foguel, Debora
   Castro-Faria-Neto, Hugo Caire
   Sharshar, Tarek
   Chretien, Fabrice
   Bozza, Fernando Augusto
TI Age-related cognitive impairment is associated with long-term
   neuroinflammation and oxidative stress in a mouse model of episodic
   systemic inflammation
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Aging; Microglia; Nox2; Sepsis; Brain; Cytokines
ID CHRONIC NEURODEGENERATION; PERIPHERAL INFECTION; MEMORY CONSOLIDATION;
   MICROGLIA; BRAIN; MICE; DYSFUNCTION; SEPSIS; HIPPOCAMPUS; IL-1-BETA
AB Background: Microglia function is essential to maintain the brain homeostasis. Evidence shows that aged microglia are primed and show exaggerated response to acute inflammatory challenge. Systemic inflammation signals to the brain inducing changes that impact cognitive function. However, the mechanisms involved in age-related cognitive decline associated to episodic systemic inflammation are not completely understood. The aim of this study was to identify neuropathological features associated to age-related cognitive decline in a mouse model of episodic systemic inflammation.
   Methods: Young and aged Swiss mice were injected with low doses of LPS once a week for 6 weeks to induce episodic systemic inflammation. Sickness behavior, inflammatory markers, and neuroinflammation were assessed in different phases of systemic inflammation in young and aged mice. Behavior was evaluated long term after episodic systemic inflammation by open field, forced swimming, object recognition, and water maze tests.
   Results: Episodic systemic inflammation induced systemic inflammation and sickness behavior mainly in aged mice. Systemic inflammation induced depressive-like behavior in both young and aged mice. Memory and learning were significantly affected in aged mice that presented lower exploratory activity and deficits in episodic and spatial memories, compared to aged controls and to young after episodic systemic inflammation. Systemic inflammation induced acute microglia activation in young mice that returned to base levels long term after episodic systemic inflammation. Aged mice presented dystrophic microglia in the hippocampus and entorhinal cortex at basal level and did not change morphology in the acute response to SI. Regardless of their dystrophic microglia, aged mice produced higher levels of pro-inflammatory (IL-1 beta and IL-6) as well as pro-resolution (IL-10 and IL-4) cytokines in the brain. Also, higher levels of Nox2 expression, oxidized proteins and lower antioxidant defenses were found in the aged brains compared to the young after episodic systemic inflammation.
   Conclusions: Our data show that aged mice have increased susceptibility to episodic systemic inflammation. Aged mice that showed cognitive impairments also presented higher oxidative stress and abnormal production of cytokines in their brains. These results indicate that a neuroinflammation and oxidative stress are pathophysiological mechanisms of age-related cognitive impairments.
C1 [d'Avila, Joana Costa; Castro-Faria-Neto, Hugo Caire] Oswaldo Cruz Fdn FIOCRUZ, Lab Immunopharmacol, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Minist Hlth, Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Mazeraud, Aurelien; Sharshar, Tarek; Chretien, Fabrice] Pasteur Inst, Human Histopathol & Anim Models, Paris, France.
   [Siqueira, Luciana Domett; Azevedo, Estefania Pereira; Foguel, Debora] Univ Fed Rio de Janeiro, Inst Med Biochem Leopoldo DeMeis, Rio De Janeiro, Brazil.
RP d'Avila, JC (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Lab Immunopharmacol, Rio De Janeiro, Brazil.
EM joanacpdavila@gmail.com
RI d'Avila, Joana/L-8970-2013; Chretien, fabrice/D-4035-2018; Bozza,
   Fernando A/A-2618-2013
OI d'Avila, Joana/0000-0002-2045-0813; Chretien,
   fabrice/0000-0002-2794-1383; Bozza, Fernando A/0000-0003-4878-0256;
   Foguel, Debora/0000-0001-7312-7115
FU FAPERJ (Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); FIOCRUZ-Pasteur grant
FX This work was supported by the FAPERJ (Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro). JCD and FAB were the recipients of
   fellowships from FAPERJ. Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq) and FIOCRUZ-Pasteur grant.
CR Barrientos RM, 2015, NEUROSCIENCE, V309, P84, DOI 10.1016/j.neuroscience.2015.03.007
   Barrientos RM, 2006, NEUROBIOL AGING, V27, P723, DOI 10.1016/j.neurobiolaging.2005.03.010
   Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016
   Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002
   Beard JR, 2016, LANCET, V387, P2145, DOI 10.1016/S0140-6736(15)00516-4
   Bhayadia R, 2016, J GERONTOL A-BIOL, V71, P161, DOI 10.1093/gerona/glv008
   Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003
   Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98
   Conde JR, 2006, NEUROBIOL AGING, V27, P1451, DOI 10.1016/j.neurobiolaging.2005.07.012
   Cunningham C, 2011, BIOCHEM SOC T, V39, P945, DOI 10.1042/BST0390945
   Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297
   Droge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474-9726.2007.00294.x
   Eichenbaum H, 2012, NEUROSCI BIOBEHAV R, V36, P1597, DOI 10.1016/j.neubiorev.2011.07.006
   Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014
   Fischer CW, 2015, J NEUROIMMUNOL, V288, P40, DOI 10.1016/j.jneuroim.2015.08.011
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Frank MG, 2016, NEUROBIOL STRESS, V4, P62, DOI 10.1016/j.ynstr.2015.12.004
   Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje
   Gomez-Nicola D, 2015, NEUROSCIENTIST, V21, P169, DOI 10.1177/1073858414530512
   Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002
   Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36
   Howcroft TK, 2013, AGING-US, V5, P84, DOI 10.18632/aging.100531
   Huang Y, 2008, NEUROBIOL AGING, V29, P1744, DOI 10.1016/j.neurobiolaging.2007.04.012
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   Le Y, 2014, PLOS ONE, V9, P2
   Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Collazo E, 2013, CRIT CARE, V17, DOI 10.1186/cc13110
   Mazeraud A, 2016, CLIN CHEST MED, V37, P333, DOI 10.1016/j.ccm.2016.01.013
   Moraes CA, 2015, MOL NEUROBIOL, V52, P653, DOI 10.1007/s12035-014-8868-5
   Navarro A, 2002, AM J PHYSIOL-REG I, V282, pR985, DOI 10.1152/ajpregu.00537.2001
   Nikodemova M, 2016, PHYSL GENOMICS
   Niraula A, 2016, NEUROPSYCHOPHARMACOL, V42, P1
   Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x
   OENZIL F, 1994, MECH AGEING DEV, V76, P157, DOI 10.1016/0047-6374(94)91590-3
   Ortega-Gomez A, 2013, EMBO MOL MED, V5, P661, DOI 10.1002/emmm.201202382
   Pereira BI, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00445
   Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015
   Perry VH, 2013, SEMIN IMMUNOPATHOL, V35, P601, DOI 10.1007/s00281-013-0382-8
   Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032
   Qiu LL, 2016, BRAIN BEHAV IMMUN, V51, P109, DOI 10.1016/j.bbi.2015.08.002
   Revel F, 2015, J ALZHEIMERS DIS, V45, P553, DOI 10.3233/JAD-141797
   Riazi K, 2015, J NEUROSCI, V35, P4942, DOI 10.1523/JNEUROSCI.4485-14.2015
   Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325
   Sankowski R, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00028
   Schlesiger MI, 2015, NAT NEUROSCI, V18, P1123, DOI 10.1038/nn.4056
   Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319
   Streit WJ, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0142-6
   Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6
   von Bernhardi R, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00124
   Wohleb E.S., 2016, PROG NEUROPSYCHOPHAR
   Wohleb ES, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00544
   Wu YW, 2015, TRENDS IMMUNOL, V36, P605, DOI 10.1016/j.it.2015.08.008
   Youm YH, 2013, CELL METAB, V18, P519, DOI 10.1016/j.cmet.2013.09.010
NR 57
TC 28
Z9 28
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JAN 30
PY 2018
VL 15
AR 28
DI 10.1186/s12974-018-1059-y
PG 13
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA FU2XB
UT WOS:000423712200003
PM 29382344
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Ramos, GV
   Japiassu, AM
   Bozza, FA
   Guaraldo, L
AF Ramos, Grazielle Viana
   Japiassu, Andre Miguel
   Bozza, Fernando Augusto
   Guaraldo, Lusiele
TI Preventable adverse drug events in critically ill HIV patients: Is the
   detection of potential drug-drug interactions a useful tool?
SO CLINICS
LA English
DT Article
DE Drug-Related Side Effects and Adverse Reactions; Drug Interactions;
   Intensive Care Units
ID INTENSIVE-CARE-UNIT
AB OBJECTIVES: The aim of this study was to develop a strategy to identify adverse drug events associated with drug-drug interactions by analyzing the prescriptions of critically ill patients.
   METHODS: This retrospective study included HIV/AIDS patients who were admitted to an intensive care unit between November 2006 and September 2008. Data were collected in two stages. In the first stage, three prescriptions administered throughout the entire duration of these patients' hospitalization were reviewed, with the Micromedex database used to search for potential drug-drug interactions. In the second stage, a search for adverse drug events in all available medical, nursing and laboratory records was performed. The probability that a drug-drug interaction caused each adverse drug events was assessed using the Naranjo algorithm.
   RESULTS: A total of 186 drug prescriptions of 62 HIV/AIDS patients were analyzed. There were 331 potential drug-drug interactions, and 9% of these potential interactions resulted in adverse drug events in 16 patients; these adverse drug events included treatment failure (16.7%) and adverse reactions (83.3%). Most of the adverse drug reactions were classified as possible based on the Naranjo algorithm.
   CONCLUSIONS: The approach used in this study allowed for the detection of adverse drug events related to 9% of the potential drug-drug interactions that were identified; these adverse drug events affected 26% of the study population. With the monitoring of adverse drug events based on prescriptions, a combination of the evaluation of potential drug-drug interactions by clinical pharmacy services and the monitoring of critically ill patients is an effective strategy that can be used as a complementary tool for safety assessments and the prevention of adverse drug events.
C1 [Ramos, Grazielle Viana; Japiassu, Andre Miguel; Bozza, Fernando Augusto; Guaraldo, Lusiele] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Ramos, Grazielle Viana; Bozza, Fernando Augusto] Inst DOr Pesquisa & Ensino, Rio De Janeiro, RJ, Brazil.
RP Guaraldo, L (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
EM lusiele.guaraldo@ini.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Pesquisa e Desenvolvimento
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Post-Graduation Program of INI-Fiocruz
FX This work was supported by grants from the Fundacao de Amparo a Pesquisa
   do Estado do Rio de Janeiro (FAPERJ), the Conselho Nacional de Pesquisa
   e Desenvolvimento (CNPq) and the Post-Graduation Program of INI-Fiocruz.
CR [Anonymous], MICR 2 0 DRUG INT
   Bucsa C, 2013, EUR J INTERN MED, V24, P27, DOI 10.1016/j.ejim.2012.09.011
   Committee of Experts on Management of Safety and Quality in Health Care (SP- SQS), 2005, EXP GROUP SAF MED PR
   DiPoto JP, 2015, DRUG SAFETY, V38, P311, DOI 10.1007/s40264-015-0272-1
   Iniesta-Navalon C, 2015, HIV MED, V16, P273, DOI 10.1111/hiv.12205
   Ismail M, 2016, INT J CLIN PHARM-NET, V38, P1052, DOI 10.1007/s11096-016-0340-3
   Kane-Gill SL, 2010, CRIT CARE MED, V38, pS83, DOI 10.1097/CCM.0b013e3181dd8364
   Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Reis AMM, 2011, CLINICS, V66, P9, DOI 10.1590/S1807-59322011000100003
   Morimoto T, 2004, QUAL SAF HEALTH CARE, V13, P306, DOI 10.1136/qshc.2004.010611
   Moura C, 2011, CLIN DRUG INVEST, V31, P309, DOI 10.2165/11586200-000000000-00000
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Ramos GV, 2015, J CLIN PHARM THER, V40, P63, DOI 10.1111/jcpt.12222
   Strandell J, 2008, BRIT J CLIN PHARMACO, V65, P144, DOI 10.1111/j.1365-2125.2007.02981.x
   Vargas E, 1998, CLIN DRUG INVEST, V15, P353, DOI 10.2165/00044011-199815040-00011
   WHO Collaborating Centre for Drug Statistics Methodology, 2016, ATC CLASS IND DDDS
NR 17
TC 0
Z9 0
U1 0
U2 0
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2018
VL 73
AR e148
DI 10.6061/clinics/2018/e148
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA FW9AP
UT WOS:000425628400001
PM 29466493
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Zampieri, FG
   Lisboa, TC
   Correa, TD
   Bozza, FA
   Ferez, M
   Fernandes, HS
   Japiassu, AM
   Verdeal, JCR
   Carvalho, ACP
   Knibel, MF
   Mazza, BF
   Colombari, F
   Vieira, JM
   Viana, WN
   Costa, R
   Godoy, MM
   Maia, MO
   Caser, EB
   Salluh, JIF
   Soares, M
AF Zampieri, Fernando G.
   Lisboa, Thiago C.
   Correa, Thiago D.
   Bozza, Fernando A.
   Ferez, Marcus
   Fernandes, Haggeas S.
   Japiassu, Andre M.
   Verdeal, Juan Carlos R.
   Carvalho, Ana Claudia P.
   Knibel, Marcos F.
   Mazza, Bruno F.
   Colombari, Fernando
   Vieira, Jose Mauro
   Viana, William N.
   Costa, Roberto
   Godoy, Michele M.
   Maia, Marcelo O.
   Caser, Eliana B.
   Salluh, Jorge I. F.
   Soares, Marcio
TI Role of organisational factors on the 'weekend effect' in critically ill
   patients in Brazil: a retrospective cohort analysis
SO BMJ OPEN
LA English
DT Article
ID INTENSIVE-CARE UNITS; RANDOMIZED CLINICAL-TRIAL; IN-HOSPITAL MORTALITY;
   ORGAN DYSFUNCTION/FAILURE; ICU ADMISSION; OUTCOMES; WEEKDAYS; SURGERY;
   ASSOCIATION; MULTICENTER
AB Introduction Higher mortality for patients admitted to intensive care units (ICUs) during the weekends has been occasionally reported with conflicting results that could be related to organisational factors. We investigated the effects of ICU organisational and staffing patterns on the potential association between weekend admission and outcomes in critically ill patients.
   Methods We included 59 614 patients admitted to 78 ICUs participating during 2013. We defined 'weekend admission' as any ICU admission from Friday 19:00 until Monday 07:00. We assessed the association between weekend admission with hospital mortality using a mixed logistic regression model controlling for both patient level (illness severity, age, comorbidities, performance status and admission type) and ICU-level (decrease in nurse/bed ratio on weekend, full-time intensivist coverage, use of checklists on weekends and number of institutional protocols) confounders. We performed secondary analyses in the subgroup of scheduled surgical admissions.
   Results A total of 41 894 patients (70.3%) were admitted on weekdays and 17 720 patients (29.7%) on weekends. In univariable analysis, weekend admitted patients had higher ICU (10.9% vs 9.0%, P<0.001) and hospital (16.5% vs 13.5%, P<0.001) mortality. After adjusting for confounders, weekend admission was not associated with higher hospital mortality (OR 1.05, 950/0CI 0.99 to 1.12, P=0.095). However, a 'weekend effect' was still observed in scheduled surgical admissions, as well as in ICUs riot using checklists during the weekends. For unscheduled admissions, no 'weekend effect' was observed regardless of ICU's characteristics. For scheduled surgical admissions, a 'weekend effect' was present only in ICUs with a low number of implemented protocols and those with a reduction in the nurse/bed ratio and not applying checklists during weekends.
   Conclusions ICU organisational factors, such as decreased nurse-to-patient ratio, absence of checklists and fewer standardised protocols, may explain, in part, increases in mortality in patients admitted to the ICU mortality on weekends.
C1 [Zampieri, Fernando G.] Hosp Coracao IEP HCor, Res Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando G.; Colombari, Fernando] Hosp Alemao Oswaldo Cruz, ICU, Sao Paulo, Brazil.
   [Lisboa, Thiago C.] Santa Casa de Misericerdia Porto Alegre, Complexo Hosp, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Correa, Thiago D.] Hosp Israelite Albert Einstein, ICU, Sao Paulo, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Japiassu, Andre M.] Inst Oswald Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Ferez, Marcus] Hosp Sao Francisco, ICU, Ribeirao Preto, Brazil.
   [Fernandes, Haggeas S.] Hosp Sao Luiz Brasil, ICU, Santo Andre, Brazil.
   [Japiassu, Andre M.] Rede Amil Hosp, Intens Care Unit, Rio De Janeiro, Brazil.
   [Verdeal, Juan Carlos R.] Hosp Barra DOr, ICU, Rio De Janeiro, Brazil.
   [Carvalho, Ana Claudia P.] UDI Hosp, ICU, Sao Luis, Brazil.
   [Knibel, Marcos F.] Hosp Sao Lucas Copacabana, ICU, Rio De Janeiro, Brazil.
   [Mazza, Bruno F.] Hosp Sao Luiz Morumbi, ICU, Sao Paulo, Brazil.
   [Mazza, Bruno F.] Hosp Samaritano, ICU, Sao Paulo, Brazil.
   [Vieira, Jose Mauro] Hosp Sirio Libanes, ICU, Sao Paulo, Brazil.
   [Viana, William N.] Hosp Copa DOr, ICU, Rio De Janeiro, Brazil.
   [Costa, Roberto] Hosp Quinta DOr, ICU, Rio De Janeiro, Brazil.
   [Godoy, Michele M.] Hosp Esperanca Olinda, ICU, Olinda, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia, ICU, Brasilia, DF, Brazil.
   [Caser, Eliana B.] Hosp Unimed Vitoria, ICU, Vitoria, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rio De Janeiro, Brazil.; Soares, M (corresponding author), DOr Inst Res & Educ, Grad Program Translat Med, Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI dantas, vicente c souza/L-2648-2013; Lisboa, Thiago/W-2973-2019; Soares,
   Marcio/B-3083-2013; Bozza, Fernando A/A-2618-2013
OI Lisboa, Thiago/0000-0003-4306-2212; Soares, Marcio/0000-0003-2503-6088;
   Bozza, Fernando A/0000-0003-4878-0256; Domingos Correa,
   Thiago/0000-0001-9546-3910; vieira Junior, Jose
   Mauro/0000-0002-1944-6980
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [304240/2014-1]; Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   D'Or Institute for Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq) (Grant No 304240/2014-1), Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) and by departmental funds from the D'Or Institute for Research
   and Education.
CR Arulkumaran N, 2017, BRIT J ANAESTH, V118, P112, DOI 10.1093/bja/aew398
   Barnett MJ, 2002, MED CARE, V40, P530, DOI 10.1097/00005650-200206000-00010
   Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376
   Bingold TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134329
   Black N, 2016, JAMA-J AM MED ASSOC, V316, P2593, DOI 10.1001/jama.2016.16410
   Brunot V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168548
   Cavalcanti AB, 2016, JAMA-J AM MED ASSOC, V315, P1480, DOI 10.1001/jama.2016.3463
   Cavallazzi R, 2010, CHEST, V138, P68, DOI 10.1378/chest.09-3018
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Core Team R, 2015, R LANG ENV STAT COMP
   DuBose J, 2010, J TRAUMA, V69, P855, DOI 10.1097/TA.0b013e3181c4526f
   Glance LG, 2016, MED CARE, V54, P608, DOI 10.1097/MLR.0000000000000532
   Li LX, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2648
   Mohammed MA, 2016, QJM, DOI [10.1093/qjmed/hcw104, DOI 10.1093/QJMED/HCW104]
   Mohammed MA, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-87
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Neuraz A, 2015, CRIT CARE MED, V43, P1587, DOI 10.1097/CCM.0000000000001015
   Penoyer DA, 2010, CRIT CARE MED, V38, P1521, DOI 10.1097/CCM.0b013e3181e47888
   Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310
   Pucher PH, 2014, BRIT J SURG, V101, P1666, DOI 10.1002/bjs.9654
   Ruiz M, 2015, BMJ QUAL SAF, V24, P492, DOI 10.1136/bmjqs-2014-003467
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Uematsu H, 2016, RESPIROLOGY, V21, P905, DOI 10.1111/resp.12788
   Uusaro A, 2003, INTENS CARE MED, V29, P2144, DOI 10.1007/s00134-003-2035-1
   Verma AM, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3996
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   von Elm E, 2007, BMJ-BRIT MED J, V335, P806
   Worni M, 2012, ARCH SURG-CHICAGO, V147, P649, DOI 10.1001/archsurg.2012.825
   Zampieri FG, 2017, INTENS CARE MED, V43, P39, DOI 10.1007/s00134-016-4563-5
NR 30
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JAN
PY 2018
VL 8
IS 1
AR e018541
DI 10.1136/bmjopen-2017-018541
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA GF2BO
UT WOS:000431743500066
PM 29371274
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Wang, LM
   Wu, Q
   Kirk, RA
   Horn, KP
   Salem, AHE
   Hoffman, JM
   Yap, JT
   Sonnen, JA
   Towner, RA
   Bozza, FA
   Rodrigues, RS
   Morton, KA
AF Wang, Li-Ming
   Wu, Qi
   Kirk, Ryan A.
   Horn, Kevin P.
   Salem, Ahmed H. Ebada
   Hoffman, John M.
   Yap, Jeffrey T.
   Sonnen, Joshua A.
   Towner, Rheal A.
   Bozza, Fernando A.
   Rodrigues, Rosana S.
   Morton, Kathryn A.
TI Lipopolysaccharide endotoxemia induces amyloid-beta and p-tau formation
   in the rat brain
SO AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE Lipopolysaccharide; LPS; sepsis; neuroinflammation; amyloid beta;
   phosphorylated tau; brain
ID POSITRON-EMISSION-TOMOGRAPHY; TERM COGNITIVE IMPAIRMENT; FLORBETAPIR F
   18; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES;
   OXIDATIVE STRESS; SURVIVORS; ENCEPHALOPATHY; DYSFUNCTION
AB Amyloid beta (A beta) plaques are not specific to Alzheimer's disease and occur with aging and neurodegenerative disorders. Soluble brain A beta may be neuroprotective and increases in response to neuroinflammation. Sepsis is associated with neurocognitive compromise. The objective was to determine, in a rat endotoxemia model of sepsis, whether neuroinflammation and soluble A beta production are associated with A beta plaque and hyperphosphorylated tau deposition in the brain. Male Sprague Dawley rats received a single intraperitoneal injection of 10 mg/kg of lipopolysaccharide endotoxin (LPS). Brain and blood levels of IL-1 beta, IL-6, and TNF alpha and cortical microglial density were measured in LPS-injected and control animals. Soluble brain A beta and p-tau were compared and A beta plaques were quantified and characterized. Brain uptake of [F-18]flutemetamol was measured by phosphor imaging. LPS endotoxemia resulted in elevations of cytokines in blood and brain. Microglial density was increased in LPS-treated rats relative to controls. LPS resulted in increased soluble A beta and in p-tau levels in whole brain. Progressive increases in morphologically-diffuse A beta plaques occurred throughout the interval of observation (to 7-9 days post LPS). LPS endotoxemia resulted in increased [F-18] flutemetamol in the cortex and increased cortex: white matter ratios of activity. In conclusion, LPS endotoxemia causes neuroinflammation, increased soluble A beta and A beta diffuse plaques in the brain. A beta PET tracers may inform this neuropathology. Increased p-tau in the brain of LPS treated animals suggests that downstream consequences of A beta plaque formation may occur. Further mechanistic and neurocognitive studies to understand the causes and consequences of LPS-induced neuropathology are warranted.
C1 [Wang, Li-Ming; Wu, Qi; Kirk, Ryan A.; Salem, Ahmed H. Ebada; Hoffman, John M.; Yap, Jeffrey T.; Morton, Kathryn A.] Univ Utah, Dept Radiol & Imaging Sci, Salt Lake City, UT 84132 USA.
   [Horn, Kevin P.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
   [Sonnen, Joshua A.] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA.
   [Towner, Rheal A.] Oklahoma Med Res Fdn, Adv Magnet Resonance Ctr, 825 NE 13th St, Oklahoma City, OK 73104 USA.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Crit Care Lab & Immunopharmacol Lab, Rio De Janeiro, Brazil.
   [Rodrigues, Rosana S.] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
RP Morton, KA (corresponding author), Univ Utah, Sch Med, Dept Radiol & Imaging Sci, 20 N 1900 E,Room 1A071, Salt Lake City, UT 84132 USA.
EM kathryn.morton@hsc.utah.edu
RI Yap, Jeffrey/L-7024-2019; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Yap, Jeffrey/0000-0001-5306-2860
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [RO1NS-092458];
   Center for Quantitative Cancer Imaging, Huntsman Cancer Institute,
   University of Utah; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) fellowshipCAPES; Conselho Nacional de Pesquisa (CNPq)
   fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01NS092458, R01NS092458, R01NS092458,
   R01NS092458] Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Institutes of
   Health (NIH RO1NS-092458). Additional support was provided by the Center
   for Quantitative Cancer Imaging, Huntsman Cancer Institute, University
   of Utah. R.S.R. was supported by a Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) fellowship and F.A.B. by a Conselho
   Nacional de Pesquisa (CNPq) fellowship. The authors declare no competing
   financial interests.
CR Adam N, 2013, EXPERT REV ANTI-INFE, V11, P211, DOI [10.1586/ERI.12.159, 10.1586/eri.12.159]
   Aizenstein HJ, 2008, ARCH NEUROL-CHICAGO, V65, P1509, DOI 10.1001/archneur.65.11.1509
   Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1
   BRAAK H, 1990, J NEURAL TRANSM-PARK, V2, P45, DOI 10.1007/BF02251245
   Chen JX, 2010, J ALZHEIMERS DIS, V20, pS569, DOI 10.3233/JAD-2010-100357
   Chetelat G, 2013, NEUROIMAGE-CLIN, V2, P356, DOI 10.1016/j.nicl.2013.02.006
   Doraiswamy PM, 2014, MOL PSYCHIATR, V19, P1044, DOI 10.1038/mp.2014.9
   Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2
   Eikelenboom P, 2011, CURR ALZHEIMER RES, V8, P142, DOI 10.2174/156720511795256080
   EIKELENBOOM P, 1989, VIRCHOWS ARCH B, V56, P259
   Ellison D, 2004, NEUROPATHOLOGY REFER, P551
   Erickson MA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-150
   Ferrer I, 2012, PROG NEUROBIOL, V97, P38, DOI 10.1016/j.pneurobio.2012.03.005
   Ferretti MT, 2011, CURR ALZHEIMER RES, V8, P164
   Fink MP, 2014, VIRULENCE, V5, P143, DOI 10.4161/viru.26083
   Fleisher AS, 2011, ARCH NEUROL-CHICAGO, V68, P1404, DOI 10.1001/archneurol.2011.150
   Giuffrida ML, 2010, REV NEUROSCIENCE, V21, P83
   Giuffrida ML, 2009, J NEUROSCI, V29, P10582, DOI 10.1523/JNEUROSCI.1736-09.2009
   HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V
   Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jackson James C, 2011, Anesthesiol Clin, V29, P751, DOI 10.1016/j.anclin.2011.09.012
   Johnson KA, 2013, J NUCL MED, V54, P476, DOI 10.2967/jnumed.113.120618
   Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x
   Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505
   Lamar CD, 2011, J NEUROPSYCH CLIN N, V23, P236, DOI 10.1176/appi.neuropsych.23.3.237
   Landau SM, 2012, ANN NEUROL, V72, P578, DOI 10.1002/ana.23650
   Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37
   Ly PTT, 2011, JOVE-J VIS EXP, DOI 10.3791/2831
   Lyman M, 2014, NEUROSCI RES, V79, P1, DOI 10.1016/j.neures.2013.10.004
   Mason NS, 2013, J LABELLED COMPD RAD, V56, P89, DOI 10.1002/jlcr.2989
   Meade T, 2018, ARTHRIT CARE RES, V70, P39, DOI 10.1002/acr.23243
   Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC
   NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F
   Navarro A, 2002, AM J PHYSIOL-REG I, V282, pR985, DOI 10.1152/ajpregu.00537.2001
   Obrenovich ME, 2002, NEUROBIOL AGING, V23, P1097, DOI 10.1016/S0197-4580(02)00038-6
   Ossenkoppele R, 2013, ALZHEIMERS DEMENT, V9, P414, DOI 10.1016/j.jalz.2012.07.003
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Petrella JR, 2013, RADIOLOGY, V269, P671, DOI 10.1148/radiol.13122503
   Rabinovici GD, 2009, BEHAV NEUROL, V21, P117, DOI [10.1155/2009/609839, 10.3233/BEN-2009-0232]
   Rosano C, 2012, AGING DIS, V3, P16
   Schwalm MT, 2014, MOL NEUROBIOL, V49, P380, DOI 10.1007/s12035-013-8526-3
   Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
   Shin SY, 2013, J RHEUMATOL, V40, P236, DOI 10.3899/jrheum.120871
   Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001
   Spuch Carlos, 2012, J Aging Res, V2012, P324968, DOI 10.1155/2012/324968
   Stonnington Cynthia M, 2014, Alzheimers Dement, V10, pe1, DOI 10.1016/j.jalz.2013.01.009
   Veerhuis R, 1996, ACTA NEUROPATHOL, V91, P53
   Vlassenko AG, 2011, ANN NEUROL, V70, P857, DOI 10.1002/ana.22608
   Zlokovic BV, 2010, J NEUROCHEM, V115, P1077, DOI 10.1111/j.1471-4159.2010.07002.x
NR 50
TC 16
Z9 16
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2160-8407
J9 AM J NUCL MED MOLEC
JI Am. J. Nucl. Med. Molec. Imaging
PY 2018
VL 8
IS 2
BP 86
EP 99
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA GF0CJ
UT WOS:000431597200002
PM 29755842
DA 2020-12-01
ER

PT J
AU Costa, RC
   Bozza, FA
AF Costa-Filho, Rubens C.
   Bozza, Fernando A.
TI Platelets: an outlook from biology through evidence-based achievements
   in critical care
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Platelet; thrombosis; antithrombotic drugs; Limulus; Limulus Amoebocyte
   Lysate (LAL) test; cancer; protease-activated receptor 1 (PAR-1);
   glycoprotein (GP) Ib/IX/V complex; purinoceptor; NETosis
ID SECONDARY PREVENTION; CURRENT STATE; HEMOSTASIS; INFLAMMATION;
   CLOPIDOGREL; AGGREGATION; COAGULATION; ACTIVATION; THROMBOSIS;
   INHIBITION
AB Since the original observations by Bizzozero and Osler, we have seen tremendous advances in the understanding of platelets far beyond haemostasis and the restoration of injured endothelium. In this mini-review on platelets, we will briefly outline their historical description and the importance of their evolution, focusing on a 450 million years old living fossil of Limulus polyphemus, a marine chelicerate arthropod, which helped researchers explain the basis for the immunity role of platelets and make correlations with platelet ultrastructure and function. In addition, the impact of the Limulus Amoebocyte Lysate (LAL) test for modern medicine is highlighted. The role of platelets in cardiovascular diseases, their relevance in arterial and venous thrombosis, and the utilization of antithrombotic drugs as therapeutic agents are also reported. Furthermore, platelet receptors are crucial in aggravating or mitigating other diseases, such as cancer and infections, which can recruit cells and have numerous interactions in a process recently coined "NETosis formation", which is also briefly depicted.
C1 [Costa-Filho, Rubens C.] Hosp Pro Cardiaco, Dept Crit Care, Rua Gal Polidoro, Rio De Janeiro, RJ, Brazil.
   [Costa-Filho, Rubens C.] Trombocore Haemostasis & Thrombosis Studies roTEM, Rua Dona Mariana, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Inst Or Pesquisa & Ensino IDOR, Rua Diniz Cordeiro, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Estr Manguinhos, Rio De Janeiro, RJ, Brazil.
RP Costa, RC (corresponding author), Praca Atahualpa 60 Part 310, BR-22441130 Rio De Janeiro, Brazil.
EM rubenscosta@me.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Andrews RK, 2014, THROMB HAEMOSTASIS, V112, P659, DOI 10.1160/TH14-05-0455
   Aschoff L., 1893, ARCH PATHOL ANAT PHY, V134
   Assinger A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00649
   Bakchoul T, 2016, THROMB HAEMOSTASIS, V116, P781, DOI 10.1160/TH16-09-0742
   BAYER AS, 1995, INFECT IMMUN, V63, P3634, DOI 10.1128/IAI.63.9.3634-3641.1995
   Beaulieu LM, 2013, PLATELETS, P313, DOI DOI 10.1016/B978-0-12-387837-3.00017-1
   Bliden KP, 2008, J AM COLL CARDIOL, V52, P531, DOI 10.1016/j.jacc.2008.04.045
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Brinkmann V, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00413
   CANIZARES C, 1988, MICROSC ELECTRON BIO, V12, P1
   Cartwright-Taylor L, 2009, AQUAT BIOL, V8, P61, DOI 10.3354/ab00206
   Caudrillier A, 2012, CURR PHARM DESIGN, V18, P3260, DOI 10.2174/1381612811209023260
   Cavender MA, 2015, CIRCULATION, V131, P1047, DOI 10.1161/CIRCULATIONAHA.114.013774
   Clemetson KJ, 2013, PLATELETS, P169
   Coller BS, 2013, PLATELETS, P19
   de Latour RP, 2004, AM J CLIN ONCOL-CANC, V27, P333, DOI 10.1097/01.COC.0000071461.61445.9A
   Trugilho MRD, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006385
   Della Coletta AM, PLOS NEGL TROP DIS
   Engelmann B, 2013, NAT REV IMMUNOL, V13, P34, DOI 10.1038/nri3345
   Fennrich S, 2016, ATLA-ALTERN LAB ANIM, V44, P239, DOI 10.1177/026119291604400305
   Frampton JE, 2015, DRUGS, V75, P797, DOI 10.1007/s40265-015-0387-9
   Franchi F, 2015, NAT REV CARDIOL, V12, P30, DOI 10.1038/nrcardio.2014.156
   Franchini M, 2007, BLOOD COAGUL FIBRIN, V18, P589, DOI 10.1097/MBC.0b013e32822d2a3c
   Gachet C, 2015, J THROMB HAEMOST, V13, pS313, DOI 10.1111/jth.12947
   Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004
   Gopel T, 2015, ZOOLOGY, V118, P221, DOI 10.1016/j.zool.2014.12.004
   Grewal PK, 2008, NAT MED, V14, P648, DOI 10.1038/nm1760
   Grozovsky R, 2015, BLOOD, V126, P1877, DOI 10.1182/blood-2015-01-569129
   Harrington M, 2015, LAB ANIMAL, V44, P85, DOI 10.1038/laban.715
   Healy LD, 2017, J BIOL CHEM, V292, P8616, DOI 10.1074/jbc.M116.768309
   Hess PR, 2014, J CLIN INVEST, V124, P273, DOI 10.1172/JCI70422
   Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958
   Hoffman M, 2007, HEMATOL ONCOL CLIN N, V21, P1, DOI 10.1016/j.hoc.2006.11.004
   Italiano JE, 2013, PLATELETS, P27
   Khunger Niti, 2017, J Cutan Aesthet Surg, V10, P1, DOI 10.4103/JCAS.JCAS_32_17
   Kile BT, 2014, BRIT J HAEMATOL, V165, P217, DOI 10.1111/bjh.12757
   Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325
   Krauel K, 2012, BLOOD, V120, P3345, DOI 10.1182/blood-2012-06-434985
   Krauel K, 2011, BLOOD, V117, P1370, DOI 10.1182/blood-2010-08-301424
   Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111
   Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826
   Levin J, 2013, PLATELETS, P3
   Li C, 2012, ADV HEMATOL, V2012, P1, DOI DOI 10.1155/2012/384685
   Lindemann S, 2007, J THROMB HAEMOST, V5, P203, DOI 10.1111/j.1538-7836.2007.02517.x
   Mackman N, 2008, NATURE, V451, P914, DOI 10.1038/nature06797
   Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037
   Maule J, 2008, NASA TECHNICAL REPOR
   Mazzarello P, NAT REV MOL CELL BIO
   Metharom P, 2015, ARTERIOSCL THROM VAS, V35, P1327, DOI 10.1161/ATVBAHA.114.303413
   Michelson AD, 2013, PLATELETS
   Mitsios A, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00678
   Moon JY, 2017, J CARDIOVASC PHARM T
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350
   Nishimura S, 2015, J CELL BIOL, V209, P453, DOI 10.1083/jcb.201410052
   Nurden AT, 2008, FRONT BIOSCI-LANDMRK, V13, DOI 10.2741/2947
   Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170
   Ribatti D, 2007, LEUKEMIA RES, V31, P1339, DOI 10.1016/j.leukres.2007.02.008
   ROBBSMITH AH, 1967, BRIT J HAEMATOL, V13, P618, DOI 10.1111/j.1365-2141.1967.tb00769.x
   Roop RP, 2013, CLIN BREAST CANCER, V13, P409, DOI 10.1016/j.clbc.2013.08.006
   Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8
   Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227
   Sackett DL, 1997, LANCET, V349, P570, DOI 10.1016/S0140-6736(97)80122-5
   Schrottmaier WC, 2015, THROMB HAEMOSTASIS, V114, P478, DOI 10.1160/TH14-11-0943
   Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227
   Sitia G, 2013, J HEPATOL, V59, P1135, DOI 10.1016/j.jhep.2013.05.040
   Sudoyo AW, 2015, ACTA MED INDONES, V47, P11
   Trenk D, 2008, J AM COLL CARDIOL, V51, P1925, DOI 10.1016/j.jacc.2007.12.056
   Trier DA, 2008, INFECT IMMUN, V76, P5706, DOI 10.1128/IAI.00935-08
   Wahid FSA, 2001, INT J HEMATOL, V73, P399, DOI 10.1007/BF02981970
   Wang Y, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059449, 10.1155/2013/189105]
   Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072
   Wang YM, 2016, CELL MOL LIFE SCI, V73, P3265, DOI 10.1007/s00018-016-2225-y
   Wang YM, 2016, CURR OPIN HEMATOL, V23, P280, DOI 10.1097/MOH.0000000000000237
   Wang YM, 2014, J CLIN INVEST, V124, P4281, DOI 10.1172/JCI74630
   Wang YH, 2015, BLOOD, V125, P3627, DOI 10.1182/blood-2014-08-593053
   White JG, 2013, PLATELETS, P117
   Xu XHR, 2016, THROMB J, V14, DOI 10.1186/s12959-016-0100-6
NR 78
TC 2
Z9 2
U1 0
U2 3
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD NOV
PY 2017
VL 5
IS 22
AR 449
DI 10.21037/atm.2017.11.04
PG 15
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA FP9QD
UT WOS:000417982700008
PM 29264366
OA Green Published
DA 2020-12-01
ER

PT J
AU Machado, FR
   Cavalcanti, AB
   Bozza, FA
   Ferreira, EM
   Carrara, FSA
   Sousa, JL
   Caixeta, N
   Salomao, R
   Angus, DC
   Azevedo, LCP
AF Machado, Flavia R.
   Cavalcanti, Alexandre Biasi
   Bozza, Fernando Augusto
   Ferreira, Elaine M.
   Angotti Carrara, Fernanda Sousa
   Sousa, Juliana Lubarino
   Caixeta, Noemi
   Salomao, Reinaldo
   Angus, Derek C.
   Pontes Azevedo, Luciano Cesar
CA SPREAD Investigators
   Latin American Sepsis Institute Ne
TI The epidemiology of sepsis in Brazilian intensive care units (the Sepsis
   PREvalence Assessment Database, SPREAD): an observational study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID CRITICALLY-ILL; SEPTIC SHOCK; MORTALITY; MULTICENTER; GUIDELINES;
   AMERICA; COUNTRY
AB Background The sepsis burden on acute care services in middle-income countries is a cause for concern. We estimated incidence, prevalence, and mortality of sepsis in adult Brazilian intensive care units (ICUs) and association of ICU organisational factors with outcome.
   Methods We did a 1-day point prevalence study with follow-up of patients in ICU with sepsis in a nationally representative pseudo-random sample. We produced a sampling frame initially stratified by geographical region. Each stratum was then stratified by hospitals' main source of income (serving general public vs privately insured individuals) and ICU size (ten or fewer beds vs more than ten beds), finally generating 40 strata. In each stratum we selected a random sample of ICUs so as to enrol the total required beds in 1690 Brazilian adult ICUs. We followed up patients until hospital discharge censored at 60 days, estimated incidence from prevalence and length of stay, and generated national estimates. We assessed mortality prognostic factors using random-effects logistic regression models.
   Findings On Feb 27, 2014, 227 (72%) of 317 ICUs that were randomly selected provided data on 2632 patients, of whom 794 had sepsis (30.2 septic patients per 100 ICU beds, 95% CI 28.4-31.9). The ICU sepsis incidence was 36.3 per 1000 patient-days (95% CI 29.8-44.0) and mortality was observed in 439 (55.7%) of 788 patients (95% CI 52.2-59.2). Low availability of resources (odds ratio [OR] 1.67, 95% CI 1.02-2.75, p=0.045) and adequacy of treatment (OR 0.56, 0.37-0.84, p=0.006) were independently associated with mortality. The projected incidence rate is 290 per 100 000 population (95% CI 237.9-351.2) of adult cases of ICU-treated sepsis per year, which yields about 420 000 cases annually, of whom 230 000 die in hospital.
   Interpretation The incidence, prevalence, and mortality of ICU-treated sepsis is high in Brazil. Outcome varies considerably, and is associated with access to adequate resources and treatment. Our results show the burden of sepsis in resource-limited settings, highlighting the need to establish programmes aiming for sepsis prevention, early diagnosis, and adequate treatment.
C1 [Machado, Flavia R.] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil.
   [Salomao, Reinaldo] Univ Fed Sao Paulo, Infect Dis Dept, Sao Paulo, Brazil.
   [Machado, Flavia R.; Cavalcanti, Alexandre Biasi; Bozza, Fernando Augusto; Ferreira, Elaine M.; Angotti Carrara, Fernanda Sousa; Sousa, Juliana Lubarino; Caixeta, Noemi; Salomao, Reinaldo; Pontes Azevedo, Luciano Cesar] Latin Amer Sepsis Inst, Sao Paulo, Brazil.
   [Machado, Flavia R.; Cavalcanti, Alexandre Biasi; Bozza, Fernando Augusto; Pontes Azevedo, Luciano Cesar] Brazilian Res Intens Care Network BRICNet, Sao Paulo, Brazil.
   [Cavalcanti, Alexandre Biasi] Hosp Coracao HCor, Res Inst, Sao Paulo, Brazil.
   [Bozza, Fernando Augusto] Oswaldo Cruz Fdn FIOCRUZ, Rio De Janeiro, Brazil.
   [Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.
   [Pontes Azevedo, Luciano Cesar] Hosp Sirio Libanes, Sao Paulo, Brazil.
RP Machado, FR (corresponding author), Univ Fed Sao Paulo, Latin Amer Sepsis Inst, BR-04039002 Sao Paulo, Brazil.
EM frmachado@unifesp.br
RI Angus, Derek C/E-9671-2012; Bozza, Fernando A/A-2618-2013; Silva,
   Gisele/H-3082-2013; Azevedo, Luciano CP/H-2652-2012; Vieira,
   Manuela/V-7860-2017; Lage, Silvia HG/D-4068-2012; Rea-Neto,
   Alvaro/AAR-7909-2020; Salomao, Reinaldo/C-6419-2013; Pinheiro, Bruno
   V/J-1699-2014
OI Bozza, Fernando A/0000-0003-4878-0256; Silva,
   Gisele/0000-0002-3247-3123; Azevedo, Luciano CP/0000-0001-6759-3910;
   Vieira, Manuela/0000-0002-1150-9895; Lage, Silvia
   HG/0000-0003-2870-6999; Rea-Neto, Alvaro/0000-0001-5524-0907; Salomao,
   Reinaldo/0000-0003-1149-4598; Pinheiro, Bruno V/0000-0002-5288-3533;
   Falcao, Antonio/0000-0002-1630-7889; Gut, Ana Lucia/0000-0001-5763-0829
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP).
CR Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1
   Almeida M, 2013, CRIT CARE, V17, DOI 10.1186/cc12689
   AMIB, REL UN TER INT 2010
   Andrews B, 2014, CRIT CARE MED, V42, P2315, DOI 10.1097/CCM.0000000000000541
   Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762
   Baelani I, 2011, CRIT CARE, V15, DOI 10.1186/cc9410
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Cardoso LTQ, 2011, CRIT CARE, V15, DOI 10.1186/cc9975
   Carrillo-Esper R, 2009, CIR CIR, V77, P301
   Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI 10.1007/s00134-012-2769-8
   Engel C, 2007, INTENS CARE MED, V33, P606, DOI 10.1007/s00134-006-0517-7
   Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330
   Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC
   Guzman-Blanco M, 2014, BRAZ J INFECT DIS, V18, P421, DOI 10.1016/j.bjid.2013.10.005
   Kubler A, 2015, ANAESTH INTENSIVE TH, V47, P315, DOI 10.5603/AIT.2015.0047
   Machado FR, 2017, CRIT CARE MED, V45, P1650, DOI 10.1097/CCM.0000000000002585
   Mark NM, 2015, INTENS CARE MED, V41, P1572, DOI 10.1007/s00134-015-3810-5
   Murthy Srinivas, 2013, Ann Am Thorac Soc, V10, P509, DOI 10.1513/AnnalsATS.201307-246OT
   Conde KAP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064790
   Prin M, 2014, AM J RESP CRIT CARE, V190, P1210, DOI 10.1164/rccm.201406-1117PP
   Rosenthal VD, 2014, AM J INFECT CONTROL, V42, P942, DOI 10.1016/j.ajic.2014.05.029
   ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P43
   Sales Jr HR, 2006, REV BRASILEIRA TERAP, V18, P9
   Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Soares M, 2011, CRIT CARE, V15, DOI 10.1186/cc9962
   Sogayar AMC, 2008, PHARMACOECONOMICS, V26, P425, DOI 10.2165/00019053-200826050-00006
   Stevenson EK, 2014, CRIT CARE MED, V42, P625, DOI 10.1097/CCM.0000000000000026
   Tanriover MD, 2006, EPIDEMIOL INFECT, V134, P315, DOI 10.1017/S0950268805004978
   van Gestel A, 2004, CRIT CARE, V8, pR153, DOI 10.1186/cc2858
   Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8
   Zhou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092828
NR 32
TC 73
Z9 84
U1 0
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2017
VL 17
IS 11
BP 1180
EP 1189
DI 10.1016/S1473-3099(17)30322-5
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA FL2PP
UT WOS:000414059800041
PM 28826588
DA 2020-12-01
ER

PT J
AU Andrade, HB
   Shinotsuka, CR
   da Silva, IRF
   Donini, CS
   Li, HY
   de Carvalho, FB
   do Brasil, PEAA
   Bozza, FA
   Japiassu, AM
AF Andrade, Hugo Boechat
   Shinotsuka, Cassia Righy
   Ferreira da Silva, Ivan Rocha
   Donini, Camila Sunaitis
   Li, Ho Yeh
   de Carvalho, Frederico Bruzzi
   Alvarenga Americano do Brasil, Pedro Emmanuel
   Bozza, Fernando Augusto
   Japiassu, Andre Miguel
TI Highly active antiretroviral therapy for critically ill HIV patients: A
   systematic review and meta-analysis
SO PLOS ONE
LA English
DT Review
ID AIDS-DEFINING ILLNESSES; VIRUS-INFECTED PATIENTS; INTENSIVE-CARE; SEVERE
   SEPSIS; SURVIVAL; ERA; EPIDEMIOLOGY; MORTALITY; SPECTRUM; OUTCOMES
AB Introduction
   It is unclear whether the treatment of an HIV infection with highly active antiretroviral therapy (HAART) affects intensive care unit (ICU) outcomes. In this paper, we report the results of a systematic review and meta-analysis performed to summarize the effects of HAART on the prognosis of critically ill HIV positive patients.
   Materials and methods
   A bibliographic search was performed in 3 databases (PubMed, Web of Science and Scopus) to identify articles that investigated the use of HAART during ICU admissions for shortand long-term mortality or survival. Eligible articles were selected in a staged process and were independently assessed by two investigators. The methodological quality of the selected articles was evaluated using the Methodological Index for Non-Randomized Studies (MINORS) tool.
   Results
   Twelve articles met the systematic review inclusion criteria and examined short-term mortality. Six of them also examined long-term mortality (>= 90 days) after ICU discharge. The short-term mortality meta-analysis showed a significant beneficial effect of initiating or maintaining HAART during the ICU stay (random effects odds ratio 0.53, p = 0.02). The data analysis of long-term outcomes also suggested a reduced mortality when HAART was used, but the effect of HAART on long-term mortality of HIV positive critically ill patients remains uncertain.
   Conclusions
   This meta-analysis suggests improved survival rates for HIV positive patients who were treated with HAART during their ICU admission.
C1 [Andrade, Hugo Boechat; Shinotsuka, Cassia Righy; Ferreira da Silva, Ivan Rocha; Alvarenga Americano do Brasil, Pedro Emmanuel; Bozza, Fernando Augusto; Japiassu, Andre Miguel] Fundacao Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Intens Care Unit, Rio De Janeiro, RJ, Brazil.
   [Donini, Camila Sunaitis; Li, Ho Yeh] Univ Sao Paulo, Faculdade Medicina, Hosp Clin, Infect Dis Intens Care Unit, Sao Paulo, SP, Brazil.
   [de Carvalho, Frederico Bruzzi] Fundacao Hosp Estado Minas Gerais, Hosp Eduardo, Intens Care Unit, Belo Horizonte, MG, Brazil.
RP Japiassu, AM (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Intens Care Unit, Rio De Janeiro, RJ, Brazil.
EM andrejapi@gmail.com
RI Shinotsuka, Cassia Righy/H-9181-2013; Ho, Yeh Li/A-7197-2013; Bozza,
   Fernando A/A-2618-2013; de Carvalho, Frederico Bruzzi/ABB-3911-2020;
   Carvalho, Frederico B/J-4879-2012; Brasil, Pedro Emmanuel/AAG-2280-2019;
   Boechat Andrade, Hugo/M-6631-2013
OI Shinotsuka, Cassia Righy/0000-0002-9206-9552; Ho, Yeh
   Li/0000-0001-8719-2508; Bozza, Fernando A/0000-0003-4878-0256; de
   Carvalho, Frederico Bruzzi/0000-0002-9752-5625; Carvalho, Frederico
   B/0000-0002-9752-5625; Brasil, Pedro Emmanuel/0000-0002-6700-2268; rocha
   ferreira da silva, ivan/0000-0001-8572-9631; Boechat Andrade,
   Hugo/0000-0001-6781-6125
CR Adlakha A, 2011, INT J STD AIDS, V22, P498, DOI 10.1258/ijsa.2011.010496
   Altman DG, 1984, SCI REV RES
   Amancio FF, 2012, INT J STD AIDS, V23, P692, DOI 10.1258/ijsa.2012.011389
   Barbier F, 2009, INTENS CARE MED, V35, P1678, DOI 10.1007/s00134-009-1559-4
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7
   Chiang H-H, 2006, CRIT CARE, P15
   Cribbs SK, 2015, CRIT CARE MED, V43, P1638, DOI 10.1097/CCM.0000000000001003
   Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7
   Easterbrook P, 2001, J ROY SOC MED, V94, P442
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Forrest DM, 1998, CLIN INFECT DIS, V27, P1379, DOI 10.1086/515030
   Greenberg JA, 2012, J CRIT CARE, V27, P51, DOI 10.1016/j.jcrc.2011.08.015
   Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/s001340050261
   Ives NJ, 2001, J INFECTION, V42, P134, DOI 10.1053/jinf.2001.0810
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843
   Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72
   Maggiolo F, 2009, J ANTIMICROB CHEMOTH, V64, P910, DOI 10.1093/jac/dkp334
   Meybeck A, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-27
   Michaels SH, 1999, CLIN INFECT DIS, V29, P468, DOI 10.1086/520251
   Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017
   Morquin D, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-25
   Morris A, 2003, AIDS, V17, P73, DOI 10.1097/00002030-200301030-00010
   Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Ramos GV, 2014, J CLIN PHARM THER
   Schwarcz SK, 2014, AIDS PATIENT CARE ST, V28, P517, DOI 10.1089/apc.2014.0079
   Sedgwick P, 2013, BMJ-BRIT MED J, P346
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   van Lelyveld SFL, 2011, EUR J CLIN MICROBIOL, V30, P1085, DOI 10.1007/s10096-011-1196-z
   Vargas-Infante YA, 2007, ARCH MED RES, V38, P827, DOI 10.1016/j.arcmed.2007.05.007
   Wit FWNM, 2002, J INFECT DIS, V186, P23, DOI 10.1086/341084
   Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575
NR 36
TC 15
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2017
VL 12
IS 10
AR e0186968
DI 10.1371/journal.pone.0186968
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FK5VD
UT WOS:000413568900057
PM 29065165
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bosch, I
   de Puig, H
   Hiley, M
   Carre-Camps, M
   Perdomo-Celis, F
   Narvaez, CF
   Salgado, DM
   Senthoor, D
   O'Grady, M
   Phillips, E
   Durbin, A
   Fandos, D
   Miyazaki, H
   Yen, CW
   Gelvez-Ramirez, M
   Warke, RV
   Ribeiro, LS
   Teixeira, MM
   Almeida, RP
   Munoz-Medina, JE
   Ludert, JE
   Nogueira, ML
   Colombo, TE
   Terzian, ACB
   Bozza, PT
   Calheiros, AS
   Vieira, YR
   Barbosa-Lima, G
   Vizzoni, A
   Cerbino-Neto, J
   Bozza, FA
   Souza, TML
   Trugilho, MRO
   de Filippis, AMB
   de Sequeira, PC
   Marques, ETA
   Magalhaes, T
   Diaz, FJ
   Restrepo, BN
   Marin, K
   Mattar, S
   Olson, D
   Asturias, EJ
   Lucera, M
   Singla, M
   Medigeshi, GR
   de Bosch, N
   Tam, J
   Gomez-Marquez, J
   Clavet, C
   Villar, L
   Hamad-Schifferli, K
   Gehrke, L
AF Bosch, Irene
   de Puig, Helena
   Hiley, Megan
   Carre-Camps, Marc
   Perdomo-Celis, Federico
   Narvaez, Carlos F.
   Salgado, Doris M.
   Senthoor, Dewahar
   O'Grady, Madeline
   Phillips, Elizabeth
   Durbin, Ann
   Fandos, Diana
   Miyazaki, Hikaru
   Yen, Chun-Wan
   Gelvez-Ramirez, Margarita
   Warke, Rajas V.
   Ribeiro, Lucas S.
   Teixeira, Mauro M.
   Almeida, Roque P.
   Munoz-Medina, Jose E.
   Ludert, Juan E.
   Nogueira, Mauricio L.
   Colombo, Tatiana E.
   Terzian, Ana C. B.
   Bozza, Patricia T.
   Calheiros, Andrea S.
   Vieira, Yasmine R.
   Barbosa-Lima, Giselle
   Vizzoni, Alexandre
   Cerbino-Neto, Jose
   Bozza, Fernando A.
   Souza, Thiago M. L.
   Trugilho, Monique R. O.
   de Filippis, Ana M. B.
   de Sequeira, Patricia C.
   Marques, Ernesto T. A.
   Magalhaes, Tereza
   Diaz, Francisco J.
   Restrepo, Berta N.
   Marin, Katerine
   Mattar, Salim
   Olson, Daniel
   Asturias, Edwin J.
   Lucera, Mark
   Singla, Mohit
   Medigeshi, Guruprasad R.
   de Bosch, Norma
   Tam, Justina
   Gomez-Marquez, Jose
   Clavet, Charles
   Villar, Luis
   Hamad-Schifferli, Kimberly
   Gehrke, Lee
TI Rapid antigen tests for dengue virus serotypes and Zika virus in patient
   serum
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID OF-CARE TESTS; NS1 ANTIGEN; DIAGNOSIS; URINE; INFECTIONS; SAMPLES;
   SALIVA; IGM
AB The recent Zika virus (ZIKV) outbreak demonstrates that cost-effective clinical diagnostics are urgently needed to detect and distinguish viral infections to improve patient care. Unlike dengue virus (DENV), ZIKV infections during pregnancy correlate with severe birth defects, including microcephaly and neurological disorders. Because ZIKV and DENV are related flaviviruses, their homologous proteins and nucleic acids can cause cross-reactions and false-positive results in molecular, antigenic, and serologic diagnostics. We report the characterization of monoclonal antibody pairs that have been translated into rapid immunochromatography tests to specifically detect the viral nonstructural 1 (NS1) protein antigen and distinguish the four DENV serotypes (DENV1-4) and ZIKV without cross-reaction. To complement visual test analysis and remove user subjectivity in reading test results, we used image processing and data analysis for data capture and test result quantification. Using a 30-ml serum sample, the sensitivity and specificity values of the DENV1-4 tests and the pan-DENV test, which detects all four dengue serotypes, ranged from 0.76 to 1.00. Sensitivity/specificity for the ZIKV rapid test was 0.81/0.86, respectively, using a 150-mu l serum input. Serum ZIKV NS1 protein concentrations were about 10-fold lower than corresponding DENV NS1 concentrations in infected patients; moreover, ZIKV NS1 protein was not detected in polymerase chain reactionpositive patient urine samples. Our rapid immunochromatography approach and reagents have immediate application in differential clinical diagnosis of acute ZIKV and DENV cases, and the platform can be applied toward developing rapid antigen diagnostics for emerging viruses.
C1 [Bosch, Irene; de Puig, Helena; Hiley, Megan; Carre-Camps, Marc; Senthoor, Dewahar; O'Grady, Madeline; Phillips, Elizabeth; Durbin, Ann; Fandos, Diana; Miyazaki, Hikaru; Yen, Chun-Wan; Tam, Justina; Gomez-Marquez, Jose; Gehrke, Lee] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
   [Bosch, Irene] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   [de Puig, Helena; Hamad-Schifferli, Kimberly] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
   [Carre-Camps, Marc; Fandos, Diana] Univ Ramon Llull, Inst Quim Sarria, Barcelona, Spain.
   [Perdomo-Celis, Federico; Narvaez, Carlos F.; Salgado, Doris M.] Univ Surcolombiana, Fac Salud, Programa Med, Neiva, Colombia.
   [Durbin, Ann] Harvard Med Sch, Div Med Sci, Program Virol, Boston, MA 02115 USA.
   [Gelvez-Ramirez, Margarita; Villar, Luis] Univ Ind Santander, Santander, Colombia.
   [Gelvez-Ramirez, Margarita; Villar, Luis] AEDES Program, Santander, Colombia.
   [Warke, Rajas V.] HiMedia Labs Pvt Ltd, Bombay, Maharashtra, India.
   [Ribeiro, Lucas S.; Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Immunopharmacol Grp, Ave Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
   [Almeida, Roque P.] Univ Fed Sergipe, Hosp Univ, Empresa Brasileira Serv Hosp EBSERH, Dept Med Interna & Patol, Aracaju, Brazil.
   [Munoz-Medina, Jose E.] Inst Mexicano Seguro Social, Lab Cent Epidemiol, Ave Jacarandas S-N, Mexico City 02990, DF, Mexico.
   [Ludert, Juan E.] Inst Politecn Nacl CINVESTAV IPN, Ctr Invest & Estudios Avanzados, Dept Infect & Patogenesis Mol, Mexico City, DF, Mexico.
   [Nogueira, Mauricio L.; Colombo, Tatiana E.; Terzian, Ana C. B.] Fac Med Sao Jose Rio Preto FAMERP, Sao Jose Do Rio Preto, Brazil.
   [Bozza, Patricia T.; Calheiros, Andrea S.; Souza, Thiago M. L.] Fiocruz MS, Oswaldo Cruz Fdn, Immunopharmacol Lab, Rio De Janeiro, Brazil.
   [Vieira, Yasmine R.; Barbosa-Lima, Giselle; Vizzoni, Alexandre; Cerbino-Neto, Jose; Bozza, Fernando A.] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Souza, Thiago M. L.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Rio De Janeiro, Brazil.
   [Trugilho, Monique R. O.] Fiocruz MS, Toxinol Lab, Rio De Janeiro, Brazil.
   [Trugilho, Monique R. O.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, Brazil.
   [de Filippis, Ana M. B.; de Sequeira, Patricia C.] Fiocruz MS, Flavivirus Lab, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A.; Magalhaes, Tereza] Fiocruz MS, Aggeu Magalhaes Res Ctr, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA.
   [Magalhaes, Tereza] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Diaz, Francisco J.] Univ Antioquia, Sch Med, Immunovirol Grp, Medellin, Colombia.
   [Restrepo, Berta N.; Marin, Katerine] Univ CES, ICMT, Sabaneta, Antioquia, Colombia.
   [Mattar, Salim] Univ Cordoba, Monteria, Cordoba, Colombia.
   [Olson, Daniel; Asturias, Edwin J.] Univ Colorado, Sch Med, Dept Pediat, Div Infect Dis, Aurora, CO 80045 USA.
   [Lucera, Mark] Univ Colorado, Sch Med, Dept Med, Div Infect Dis, Aurora, CO 80045 USA.
   [Singla, Mohit] All India Inst Med Sci, Dept Paediat, New Delhi, India.
   [Medigeshi, Guruprasad R.] Translat Hlth Sci & Technol Inst, Faridabad, India.
   [de Bosch, Norma] Univ Cent Venezuela, Caracas, Venezuela.
   [Tam, Justina; Clavet, Charles] WEAC, Winchester, MA 01890 USA.
   [Hamad-Schifferli, Kimberly] Univ Massachusetts, Dept Engn, Boston, MA 02125 USA.
   [Gehrke, Lee] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
RP Gehrke, L (corresponding author), MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.; Hamad-Schifferli, K (corresponding author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.; Hamad-Schifferli, K (corresponding author), Univ Massachusetts, Dept Engn, Boston, MA 02125 USA.; Gehrke, L (corresponding author), Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
EM kim.hamad@umb.edu; lgehrke@mit.edu
RI Marques, Ernesto T. A/L-4967-2013; Vizzoni, Alexandre/W-8718-2019;
   Ludert, Juan E./H-5658-2019; Nogueira, Mauricio L/B-7599-2012; Neto,
   Jose Cerbino/P-3713-2018; Medigeshi, Guruprasad/V-1566-2019; Esteban,
   Munoz Medina Jose/B-6186-2015; Bozza, Fernando A/A-2618-2013; Teixeira,
   Mauro M/A-4587-2008; Magalhaes, Tereza/V-6632-2019; Asturias,
   Edwin/D-9842-2016
OI Marques, Ernesto T. A/0000-0003-3826-9358; Vizzoni,
   Alexandre/0000-0003-0004-5084; Nogueira, Mauricio L/0000-0003-1102-2419;
   Neto, Jose Cerbino/0000-0001-9254-917X; Esteban, Munoz Medina
   Jose/0000-0002-1289-4457; Bozza, Fernando A/0000-0003-4878-0256;
   Teixeira, Mauro M/0000-0002-6944-3008; Souza,
   Thiago/0000-0003-2212-3899; /0000-0002-5368-6996; Perdomo Celis,
   Federico/0000-0003-0119-8306; Secchim Ribeiro,
   Lucas/0000-0001-8876-3827; MARIN VELASQUEZ,
   KATERINE/0000-0003-0028-0500; Narvaez, Carlos/0000-0003-0129-5210;
   Medigeshi, Guruprasad/0000-0001-5333-9743; Bozza,
   Patricia/0000-0001-8349-9529; Asturias, Edwin/0000-0002-1275-0787
FU National Council for Scientific and Technological Development of
   BrazilNational Council for Scientific and Technological Development
   (CNPq); Foundation for Research Support of the State of Rio de Janeiro,
   Brazil (FAPERJ); European Union's Horizon program [734857, 734584];
   Programa Pesquisa para o SUS-Fundacao de Amparo a Ciencia e Tecnologia
   (PPSUS-FACEPE) project of the Cura Zika Alliance, University of
   Pittsburgh [APQ-0302-4.01/13]; Department of Biotechnology, Government
   of IndiaDepartment of Biotechnology (DBT) India
   [BT/PR5132/MED/15/84/2012]; Wellcome Trust/DBT India AllianceWellcome
   Trust [IA/S/14/1/501291]; U.S. Public Health ServiceUnited States Public
   Health Service [AI100190]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [13/21719-3, 16/15021-1]; Science, Technology and Innovation
   Fund; Colombia-Fondo de Ciencia, Tecnologia e Innovacion of Sistema
   General de Regalias [BPIN 2013000100011]; AEDES Network; La Caixa
   FellowshipLa Caixa Foundation; Rafael del Pino Foundation; Broshy
   Fellowship; MIT-Tata Center for Technology and Design fellowship;
   MIT-Singapore University of Technology and Design International Design
   Center grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R33AI100190, R21AI100190, R33AI100190,
   R33AI100190, R21AI100190, R33AI100190] Funding Source: NIH RePORTER
FX F.A.B., M.M.T., A.C.B.T., and P.C.d.-S. received funding from the
   National Council for Scientific and Technological Development of Brazil
   and from the Foundation for Research Support of the State of Rio de
   Janeiro, Brazil (FAPERJ). A.M.B.d.F. was supported by the European
   Union's Horizon 2020 program under grant agreement numbers 734857 and
   734584. E.T.A.M. was supported by Programa Pesquisa para o SUS-Fundacao
   de Amparo a Ciencia e Tecnologia (PPSUS-FACEPE) project APQ-0302-4.01/13
   of the Cura Zika Alliance, University of Pittsburgh. G.R.M. received
   research support from the Department of Biotechnology, Government of
   India (sanction no. BT/PR5132/MED/15/84/2012) and Wellcome Trust/DBT
   India Alliance (IA/S/14/1/501291). L.G. received support from the U.S.
   Public Health Service (grant AI100190). M.L.N. received support from
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (grants
   13/21719-3 and 16/15021-1). L.V. received support from the Science,
   Technology and Innovation Fund, Colombia-Fondo de Ciencia, Tecnologia e
   Innovacion of Sistema General de Regalias (BPIN 2013000100011) and the
   AEDES Network. H.d.P. received support from a La Caixa Fellowship, a
   Rafael del Pino Foundation, a Broshy Fellowship, an MIT-Tata Center for
   Technology and Design fellowship, and an MIT-Singapore University of
   Technology and Design International Design Center grant. M. Benioff and
   L. Benioffprovided support toward obtaining commercially available Zika
   samples.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Andries AC, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1551-x
   Andries AC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004100
   Andries AC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001993
   Becerra A, 2009, J MED VIROL, V81, P1403, DOI 10.1002/jmv.21538
   Becerra A, 2009, J GEN VIROL, V90, P810, DOI 10.1099/vir.0.004416-0
   Bhamla MS, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-016-0009
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bingham AM, 2016, MMWR MORB MORTAL WKL, V65
   Blacksell SD, 2011, CLIN VACCINE IMMUNOL, V18, P2095, DOI 10.1128/CVI.05285-11
   Brown WC, 2016, NAT STRUCT MOL BIOL, V23, P865, DOI 10.1038/nsmb.3268
   Chuansumrit A, 2011, DIAGN MICR INFEC DIS, V71, P467, DOI 10.1016/j.diagmicrobio.2011.08.020
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Estofolete CF, 2016, J CLIN VIROL, V81, P25, DOI 10.1016/j.jcv.2016.05.012
   FALCONAR AKI, 1991, J GEN VIROL, V72, P961, DOI 10.1099/0022-1317-72-4-961
   Forshey BM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004398
   Fry SR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001199
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Kao Chuan-Liang, 2005, Journal of Microbiology Immunology and Infection, V38, P5
   Korhonen EM, 2014, J CLIN VIROL, V61, P353, DOI 10.1016/j.jcv.2014.08.021
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lee J, 2015, DIAGN MICR INFEC DIS, V82, P128, DOI 10.1016/j.diagmicrobio.2015.03.009
   Lukman N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5253842
   Miller R. K., 1989, MACHINE VISION
   Muller DA, 2017, J INFECT DIS, V215, pS89, DOI 10.1093/infdis/jiw649
   Muller DA, 2013, ANTIVIR RES, V98, P192, DOI 10.1016/j.antiviral.2013.03.008
   Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191
   O'Farrell B., 2013, IMMUNOASSAY HDB, P89
   Ong A, 2007, INT J INFECT DIS, V11, P263, DOI 10.1016/j.ijid.2006.02.012
   Osorio L, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-361
   Pardee K, 2016, CELL, V165, P1255, DOI 10.1016/j.cell.2016.04.059
   Peeling RW, 2010, CLIN MICROBIOL INFEC, V16, P1062, DOI 10.1111/j.1469-0691.2010.03279.x
   Peeling RW, 2010, NAT REV MICROBIOL, pS30, DOI 10.1038/nrmicro2459
   Saito Y, 2015, JPN J INFECT DIS, V68, P455, DOI 10.7883/yoken.JJID.2014.441
   Tricou V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001309
   Tricou V, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-142
   Tyrrell C. H., 2013, LATERAL FLOW SMART P
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Vivek R, 2017, DIAGN MICR INFEC DIS, V87, P229, DOI 10.1016/j.diagmicrobio.2016.09.020
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Wang SM, 2010, AM J TROP MED HYG, V83, P690, DOI 10.4269/ajtmh.2010.10-0117
   Zhang B, 2017, NAT MED, V23, P548, DOI 10.1038/nm.4302
   ZIKV Detect IgM Capture ELISA by InBios International Inc, 2016, MEDWATCH FDA SAF INF
NR 47
TC 65
Z9 67
U1 3
U2 32
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 27
PY 2017
VL 9
IS 409
AR eaan1589
DI 10.1126/scitranslmed.aan1589
PG 13
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA FI3PX
UT WOS:000411879400005
PM 28954927
OA Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Ferreira, AC
   Zaverucha-do-Valle, C
   Reis, PA
   Barbosa-Lima, G
   Vieira, YR
   Mattos, M
   Silva, PD
   Sacramento, C
   Neto, HCDF
   Campanati, L
   Tanuri, A
   Bruning, K
   Bozza, FA
   Bozza, PT
   Souza, TML
AF Ferreira, Andre C.
   Zaverucha-do-Valle, Camila
   Reis, Patricia A.
   Barbosa-Lima, Giselle
   Vieira, Yasmine Rangel
   Mattos, Mayara
   Silva, Priscila de Paiva
   Sacramento, Carolina
   de Castro Faria Neto, Hugo C.
   Campanati, Loraine
   Tanuri, Amilcar
   Bruning, Karin
   Bozza, Fernando A.
   Bozza, Patricia T.
   Souza, Thiago Moreno L.
TI Sofosbuvir protects Zika virus-infected mice from mortality, preventing
   short- and long-term sequelae
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INHIBITORS; BRAIN; DISEASE; SCREEN; DRUGS; CELLS
AB Zika virus (ZIKV) causes significant public health concerns because of its association with congenital malformations, neurological disorders in adults, and, more recently, death. Considering the necessity to mitigate ZIKV-associated diseases, antiviral interventions are an urgent necessity. Sofosbuvir, a drug in clinical use against hepatitis C virus (HCV), is among the FDA-approved substances endowed with anti-ZIKV activity. In this work, we further investigated the in vivo activity of sofosbuvir against ZIKV. Neonatal Swiss mice were infected with ZIKV (2 x 10(7) PFU) and treated with sofosbuvir at 20 mg/kg/day, a concentration compatible with pre-clinical development of this drug. We found that sofosbuvir reduced acute levels of ZIKV from 60 to 90% in different anatomical compartments, such as the blood plasma, spleen, kidney, and brain. Early treatment with sofosbuvir doubled the percentage and time of survival of ZIKV-infected animals. Sofosbuvir also prevented the acute neuromotor impairment triggered by ZIKV. In the long-term behavioural analysis of ZIKV-associated sequelae, sofosbuvir prevented loss of hippocampal-and amygdala-dependent memory. Our results indicate that sofosbuvir inhibits ZIKV replication in vivo, which is consistent with the prospective necessity of antiviral drugs to treat ZIKV-infected individuals.
C1 [Ferreira, Andre C.; Zaverucha-do-Valle, Camila; Reis, Patricia A.; Mattos, Mayara; Silva, Priscila de Paiva; Sacramento, Carolina; de Castro Faria Neto, Hugo C.; Bozza, Fernando A.; Bozza, Patricia T.; Souza, Thiago Moreno L.] Fundacao Oswaldo Cruz, FIOCRUZ, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Zaverucha-do-Valle, Camila; Barbosa-Lima, Giselle; Vieira, Yasmine Rangel; Bozza, Fernando A.; Souza, Thiago Moreno L.] Fiocruz MS, Inst Nacl Infectol, Rio De Janeiro, RJ, Brazil.
   [Campanati, Loraine] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, RJ, Brazil.
   [Tanuri, Amilcar] Univ Fed Rio de Janeiro, Inst Biol, Rio De Janeiro, RJ, Brazil.
   [Bruning, Karin] BMK Consortium Blanver Farmoquim Ltda Microbiol Q, Taboao Da Serra, SP, Brazil.
   [Souza, Thiago Moreno L.] Fiocruz MS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, RJ, Brazil.
RP Souza, TML (corresponding author), Fundacao Oswaldo Cruz, FIOCRUZ, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Inst Nacl Infectol, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, RJ, Brazil.
EM tmoreno@cdts.fiocruz.br
RI Campanati, Loraine/V-2632-2018; Bozza, Fernando A/A-2618-2013; Souza,
   Thiago Moreno L./G-2900-2012
OI Campanati, Loraine/0000-0001-9172-1951; Bozza, Fernando
   A/0000-0003-4878-0256; Souza, Thiago Moreno L./0000-0003-2212-3899;
   Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento e Pesquisa (CNPq)National Council
   for Scientific and Technological Development (CNPq); Fundacao de Amparo
   a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
FX Thanks are due to Drs. Carlos M. Morel, Marcio L. Rodrigues, Renata
   Curi, and Fabricia Pimenta for their strong advisement and support
   regarding the technological development underlying this project. This
   work was supported by Conselho Nacional de Desenvolvimento e Pesquisa
   (CNPq), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ). The BMK consortium did not provide funding for this project.
CR [Anonymous], 2017, STUD HEP C TREATM PR
   Coelho SVA, 2017, J VIROL METHODS, V246, P65, DOI 10.1016/j.jviromet.2017.04.011
   Au-TGA Australian Therapeutic Goods and Administration, 2015, AUSTR THER GOODS ADM
   Azevedo RSS, 2016, J CLIN VIROL, V85, P56, DOI 10.1016/j.jcv.2016.10.024
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   CDC, 2016, REV DIAGN TEST ZIK C
   Cerbino-Neto J, 2016, EMERG INFECT DIS, V22, P1318, DOI 10.3201/eid2207.160375
   Chia R, 2005, NAT GENET, V37, P1181, DOI 10.1038/ng1665
   Dean A, 2014, OPENEPI OPEN SOURCE
   Delvecchio R., 2016, CHLOROQUINE INHIBITS, DOI [10.1101/051268, DOI 10.1101/051268(2016)]
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Eyer L, 2016, J INFECT DIS, V214, P707, DOI 10.1093/infdis/jiw226
   Fernandes NCCA, 2017, EXP TOXICOL PATHOL, V69, P63, DOI 10.1016/j.etp.2016.11.004
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Hirsch AJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006219
   Huang WC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34793
   Kilkenny C, 2012, OSTEOARTHR CARTILAGE, V20, P256, DOI 10.1016/j.joca.2012.02.010
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17
   Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4
   van den Pol AN, 2017, J NEUROSCI, V37, P2161, DOI 10.1523/JNEUROSCI.3124-16.2017
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
   Simonin Y, 2016, EBIOMEDICINE, V12, P161, DOI 10.1016/j.ebiom.2016.09.020
   Solomon T, 2016, LANCET INFECT DIS, V16, P402, DOI 10.1016/S1473-3099(16)00125-0
   Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001
   Stauft C. B., 2016, BIORXIV, DOI [10.1101/075747,075747, DOI 10.1101/075747,075747(2016)]
   Swaminathan S, 2016, NEW ENGL J MED, V375, P1907, DOI 10.1056/NEJMc1610613
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 36
TC 38
Z9 41
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 25
PY 2017
VL 7
AR 9409
DI 10.1038/s41598-017-09797-8
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FE8IF
UT WOS:000408448100002
PM 28842610
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Serafim, RB
   Soares, M
   Bozza, FA
   Silva, JRLE
   Dal-Pizzol, F
   Paulino, MC
   Povoa, P
   Salluh, JIF
AF Serafim, Rodrigo B.
   Soares, Marcio
   Bozza, Fernando A.
   Lapa e Silva, Jose R.
   Dal-Pizzol, Felipe
   Paulino, Maria Carolina
   Povoa, Pedro
   Salluh, Jorge I. F.
TI Outcomes of subsyndromal delirium in ICU: a systematic review and
   meta-analysis
SO CRITICAL CARE
LA English
DT Review
DE Subsyndromal delirium; Delirium; ICU; Critically ill
ID CONFUSION ASSESSMENT METHOD; MECHANICALLY VENTILATED PATIENTS;
   PROGNOSTIC-SIGNIFICANCE; RISK-FACTORS; SEVERITY; SURGERY
AB Background: Subsyndromal delirium (SSD) is a frequent condition and has been commonly described as an intermediate stage between delirium and normal cognition. However, the true frequency of SSD and its impact on clinically relevant outcomes in the intensive care unit (ICU) remains unclear.
   Methods: We performed a systematic search in PubMed, Embase, CINAHL, Cochrane Library, and PsychINFO, with no language restrictions, up to 1 October 2016 to identify publications that evaluated SSD in ICU patients.
   Results: The six eligible studies were evaluated. SSD was present in 950 (36%) patients. Four studies evaluated only surgical patients. Four studies used the Intensive Care Delirium Screening Checklist (ICDSC) and two used the Confusion Assessment Method (CAM) score to diagnose SSD. The meta-analysis showed an increased hospital length of stay (LOS) in SSD patients (0.31, 0.12-0.51, p = 0.002; I-2 = 34%). Hospital mortality was described in two studies but it was not significant (hazard ratio 0.97, 0.61-1.55, p = 0.90 and 5% vs 9%, p = 0.05). The use of antipsychotics in SSD patients to prevent delirium was evaluated in two studies but it did not modify ICU LOS (6.5 (4-8) vs 7 (4-9) days, p = 0.66 and 2 (2-3) vs 3 (2-3) days, p = 0.517) or mortality (9 (26.5%) vs 7 (20.6%), p = 0.55).
   Conclusions: SSD occurs in one-third of the ICU patients and has limited impact on the outcomes. The current literature concerning SSD is composed of small-sample studies with methodological differences, impairing a clear conclusion about the association between SSD and progression to delirium or worse ICU clinical outcomes.
C1 [Serafim, Rodrigo B.; Soares, Marcio; Bozza, Fernando A.; Salluh, Jorge I. F.] Inst DOr Pesquisa & Ensino, Rua Diniz Cordeiro,30 Botafogo, BR-22281100 Rio De Janeiro, RJ, Brazil.
   [Serafim, Rodrigo B.] Hosp Copa DOr, Rio De Janeiro, Brazil.
   [Serafim, Rodrigo B.; Lapa e Silva, Jose R.] Univ Fed Rio de Janeiro, Fac Med, Hosp Univ Clementino Fraga Filho, Inst Doencas Torax, Av Prof Rodolpho Paulo Rocco 255, BR-21941913 Rio De Janeiro, RJ, Brazil.
   [Soares, Marcio; Salluh, Jorge I. F.] Univ Fed Rio de Janeiro, Programa Pos Grad Clin Med, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Paulino, Maria Carolina; Povoa, Pedro] Hosp Sao Francisco Xavier, Ctr Hosp Lisboa Ocidental, Unidade Cuidados Intens Polivalente, Estr Forte Alto Duque, P-1449005 Lisbon, Portugal.
   [Povoa, Pedro] Univ Nova Lisboa, NOVA Med Sch, CEDOC, Lisbon, Portugal.
   [Dal-Pizzol, Felipe] Univ Extremos Sul Catarinense, Programa Grad Ciencias Med, Lab Patofisiol Expt, Ave Univ 1105,C Postal 3167, BR-88806000 Criciuma, SC, Brazil.
RP Serafim, RB (corresponding author), Inst DOr Pesquisa & Ensino, Rua Diniz Cordeiro,30 Botafogo, BR-22281100 Rio De Janeiro, RJ, Brazil.; Serafim, RB (corresponding author), Hosp Copa DOr, Rio De Janeiro, Brazil.
EM rodrigobserafim@gmail.com
RI Bozza, Fernando A/A-2618-2013; Lapa e Silva, Jose R./AAS-4793-2020;
   dantas, vicente c souza/L-2648-2013; Soares, Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Lapa e Silva, Jose
   R./0000-0003-3116-0253; Soares, Marcio/0000-0003-2503-6088
CR Al-Qadheeb NS, 2016, CRIT CARE MED, V44, P583, DOI 10.1097/CCM.0000000000001411
   American Psychiatric Association, 2013, TASK FORC DSM 5 DIAG, P947
   American Psychiatric Association and American Psychiatric Association, 2000, TASK FORC DSM 4 DIAG, p[943, xxxvii]
   [Anonymous], 2014, REV MAN COMP PROGR V
   Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909
   Breu A, 2015, SCAND CARDIOVASC J, V49, P207, DOI 10.3109/14017431.2015.1041423
   Cole M, 2003, J AM GERIATR SOC, V51, P754, DOI 10.1046/j.1365-2389.2003.51255.x
   Cole MG, 2013, INT J GERIATR PSYCH, V28, P771, DOI 10.1002/gps.3891
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Hakim SM, 2012, ANESTHESIOLOGY, V116, P987, DOI 10.1097/ALN.0b013e31825153cc
   Inouye SK, 2014, ANN INTERN MED, V160, P526, DOI 10.7326/M13-1927
   INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941
   Jeon K, 2016, RESPIROLOGY, V21, P313, DOI 10.1111/resp.12673
   Khan BA, 2017, CRIT CARE MED, V45, P851, DOI 10.1097/CCM.0000000000002368
   Levkoff SE, 1996, AM J GERIAT PSYCHIAT, V4, P320, DOI 10.1097/00019442-199622440-00006
   Li HC, 2015, J CARDIOVASC NURS, V30, P340, DOI 10.1097/JCN.0000000000000170
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Lowery DP, 2010, INT J GERIATR PSYCH, V25, P945, DOI 10.1002/gps.2430
   Ouimet S, 2007, INTENS CARE MED, V33, P1007, DOI 10.1007/s00134-007-0618-y
   Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC
   Pitrowsky Melissa Tassano, 2010, Rev. bras. ter. intensiva, V22, P274, DOI 10.1590/S0103-507X2010000300010
   Sachdev PS, 2014, NAT REV NEUROL, V10, P634, DOI 10.1038/nrneurol.2014.181
   Salluh JIF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2538
   Serafim RB, 2015, J CRIT CARE, V30, P799, DOI 10.1016/j.jcrc.2015.04.005
   Shim J, 2015, PSYCHOSOMATICS, V56, P644, DOI 10.1016/j.psym.2015.05.002
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan MC, 2008, AM J GERIAT PSYCHIAT, V16, P575, DOI 10.1097/JGP.0b013e318172b418
   Wells G, 2006, NEWCASTLE OTTAWA SCA
   Zaal IJ, 2015, CRIT CARE MED, V43, P40, DOI 10.1097/CCM.0000000000000625
NR 30
TC 13
Z9 15
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD JUL 12
PY 2017
VL 21
AR 179
DI 10.1186/s13054-017-1765-3
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA FA7AL
UT WOS:000405596500001
PM 28697802
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Righy, C
   do Brasil, PEA
   Valles, J
   Bozza, FA
   Martin-Loeches, I
AF Righy, Cassia
   Americano do Brasil, Pedro Emmanuel
   Valles, Jordi
   Bozza, Fernando A.
   Martin-Loeches, Ignacio
TI Systemic antibiotics for preventing ventilator-associated pneumonia in
   comatose patients: a systematic review and meta-analysis
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Systematic review; Meta-analysis; Ventilator-associated pneumonia; Coma
ID TRAUMATIC BRAIN-INJURY; EARLY-ONSET PNEUMONIA; INTENSIVE-CARE-UNIT;
   HOSPITAL-ACQUIRED PNEUMONIA; RISK-FACTORS; PROPHYLAXIS; INFECTIONS;
   MORTALITY; PATHOGENS; IMPACT
AB Background: Early-onset ventilator-associated pneumonia (EO-VAP) is the leading cause of morbidity and mortality in comatose patients. However, VAP prevention bundles focus mainly on late-onset VAP and may be less effective in preventing EO-VAP in comatose patients. Systemic antibiotic administration at the time of intubation may have a role in preventing EO-VAP. Therefore, we evaluated the effectiveness of systemic antibiotic administration in VAP prevention in comatose patients through a systematic review and meta-analysis.
   Methods: We searched for studies published through December 2015 that evaluated systemic antibiotic prophylaxis in comatose patients. Two authors independently selected and evaluated full-length reports of randomized clinical trials or prospective cohorts in patients aged > 16 years that evaluated the impact of systemic antibiotics at the time of intubation on EO-VAP compared to placebo or no prophylaxis. The outcome variables were the incidence of EOVAP, the duration of mechanical ventilation, ICU length of stay, and ICU mortality.
   Results: We identified 10,988 citations, yielding 26 articles for further analysis; three studies with 267 patients were finally analyzed. Most patients (n = 135) were comatose due to head trauma. Systemic antibiotic administration was associated with decreased incidence of EO-VAP (RR 0.32; 95% CI 0.19-0.54) and shorter ICU LOS (standardized mean difference -0.32; 95% CI -0.56 to -0.08), but had no effect on mortality (RR 1.03; 95% CI 0.7-1.53) or duration of mechanical ventilation (standardized mean difference -0.16; 95% CI -0.41 to 0.08).
   Conclusions: Antibiotic prophylaxis in comatose patients reduced the incidence of EO-VAP and decreased the ICU stay slightly. Future trials are needed to confirm these results.
C1 [Righy, Cassia; Americano do Brasil, Pedro Emmanuel; Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Righy, Cassia] Paulo Niemeyer Brain Inst, ICU, Rio De Janeiro, Brazil.
   [Valles, Jordi; Martin-Loeches, Ignacio] CIBERES, Barcelona, Spain.
   [Valles, Jordi] Hosp Sabadell, Crit Care Ctr, CIBER Enfermedades Resp, Sabadell, Spain.
   [Bozza, Fernando A.] DOr Inst Res & Educ, IDOR, Rio De Janeiro, Brazil.
   [Martin-Loeches, Ignacio] St Jamess Univ Hosp Dublin, Dept Clin Med, Trinity Ctr Hlth Sci, MICRO,Wellcome Trust,HRB Clin Res, Dublin, Ireland.
   [Martin-Loeches, Ignacio] ICVB, Dublin, Ireland.
RP Righy, C (corresponding author), Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
EM cassiarighy@gmail.com
RI Bozza, Fernando A/A-2618-2013; Brasil, Pedro Emmanuel/AAG-2280-2019;
   Shinotsuka, Cassia Righy/H-9181-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Brasil, Pedro
   Emmanuel/0000-0002-6700-2268; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552
FU Clinical Research Collaboration (CRC) by European Respiratory Society
FX Clinical Research Collaboration (CRC) by European Respiratory Society.
CR Acquarolo A, 2005, INTENS CARE MED, V31, P510, DOI 10.1007/s00134-005-2585-5
   [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST
   Asehnoune K, 2014, LANCET RESP MED, V2, P706, DOI 10.1016/S2213-2600(14)70144-4
   Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6
   Boehme AK, 2013, J STROKE CEREBROVASC, V22, pE582, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.020
   Bornstain C, 2004, CLIN INFECT DIS, V38, P1401, DOI 10.1086/386321
   Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009
   Chastre J, 2003, JAMA-J AM MED ASSOC, V290, P2588, DOI 10.1001/jama.290.19.2588
   Croce MA, 2013, J TRAUMA ACUTE CARE, V74, P354, DOI 10.1097/TA.0b013e31827a0c65
   Depuydt PO, 2008, CRIT CARE, V12, DOI 10.1186/cc7119
   Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1
   Giard M, 2008, J CRIT CARE, V23, P27, DOI 10.1016/j.jcrc.2007.08.005
   Gould CV, 2006, INFECT CONT HOSP EP, V27, P920, DOI 10.1086/507280
   Harbarth S, 2000, CIRCULATION, V101, P2916, DOI 10.1161/01.CIR.101.25.2916
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Imran H, 2008, EUR J CLIN MICROBIOL, V27, P53, DOI 10.1007/s10096-007-0397-y
   Jovanovic B, 2016, MED PRIN PRACT, V25, P435, DOI 10.1159/000447566
   Kalil AC, 2016, CLIN INFECT DIS, V63, P575, DOI 10.1093/cid/ciw504
   Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526
   Lepelletier D, 2010, J NEUROSURG ANESTH, V22, P32, DOI 10.1097/ANA.0b013e3181bdf52f
   Liu Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009413.pub2
   Maier IL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116836
   Martin-Loeches I, 2015, LANCET RESP MED, V3, P859, DOI 10.1016/S2213-2600(15)00326-4
   Mascia L, 2009, NEUROCRIT CARE, V11, P417, DOI 10.1007/s12028-009-9242-8
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097]
   Nseir S, 2014, CRIT CARE, V18, DOI 10.1186/cc13940
   Pileggi C, 2011, CRIT CARE, V15, DOI 10.1186/cc10285
   de Antonio LAR, 2011, NEUROLOGIA, V26, P150, DOI 10.1016/j.nrl.2010.07.030
   Ruhnke AM, ONLINE SUPPLEMENTARY
   Scheitz JF, 2015, INT J STROKE, V10, P61, DOI 10.1111/j.1747-4949.2012.00864.x
   Schuts EC, 2016, LANCET INFECT DIS, V16, P847, DOI 10.1016/S1473-3099(16)00065-7
   Seguin P, 2014, CRIT CARE MED, V42, P1, DOI 10.1097/CCM.0b013e3182a2770f
   Shah SV, 2015, J STROKE CEREBROVASC, V24, P1969, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.037
   Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884
   Sykora M, 2015, STROKE, V46, P1269, DOI 10.1161/STROKEAHA.114.008260
   Valles J, 2007, INTENS CARE MED, V33, P1363, DOI 10.1007/s00134-007-0721-0
   Valles J, 2013, CHEST, V143, P1219, DOI 10.1378/chest.12-1361
   Westendorp WF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008530.pub2
   Winklewski PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0213-4
   Zilahi G, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0199-4
NR 40
TC 9
Z9 11
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD JUN 15
PY 2017
VL 7
AR 67
DI 10.1186/s13613-017-0291-4
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA EZ5QV
UT WOS:000404773400001
PM 28620893
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Metsky, HC
   Matranga, CB
   Wohl, S
   Schaffner, SF
   Freije, CA
   Winnicki, SM
   West, K
   Qu, J
   Baniecki, ML
   Gladden-Young, A
   Lin, AE
   Tomkins-Tinch, CH
   Ye, SH
   Park, DJ
   Luo, CY
   Barnes, KG
   Shah, RR
   Chak, B
   Barbosa-Lima, G
   Delatorre, E
   Vieira, YR
   Paul, LM
   Tan, AL
   Barcellona, CM
   Porcelli, MC
   Vasquez, C
   Cannons, AC
   Cone, MR
   Hogan, KN
   Kopp, EW
   Anzinger, JJ
   Garcia, KF
   Parham, LA
   Ramirez, RMG
   Montoya, MCM
   Rojas, DP
   Brown, CM
   Hennigan, S
   Sabina, B
   Scotland, S
   Gangavarapu, K
   Grubaugh, ND
   Oliveira, G
   Robles-Sikisaka, R
   Rambaut, A
   Gehrke, L
   Smole, S
   Halloran, ME
   Villar, L
   Mattar, S
   Lorenzana, I
   Cerbino-Neto, J
   Valim, C
   Degrave, W
   Bozza, PT
   Gnirke, A
   Andersen, KG
   Isern, S
   Michael, SF
   Bozza, FA
   Souza, TML
   Bosch, I
   Yozwiak, NL
   MacInnis, BL
   Sabeti, PC
AF Metsky, Hayden C.
   Matranga, Christian B.
   Wohl, Shirlee
   Schaffner, Stephen F.
   Freije, Catherine A.
   Winnicki, Sarah M.
   West, Kendra
   Qu, James
   Baniecki, Mary Lynn
   Gladden-Young, Adrianne
   Lin, Aaron E.
   Tomkins-Tinch, Christopher H.
   Ye, Simon H.
   Park, Daniel J.
   Luo, Cynthia Y.
   Barnes, Kayla G.
   Shah, Rickey R.
   Chak, Bridget
   Barbosa-Lima, Giselle
   Delatorre, Edson
   Vieira, Yasmine R.
   Paul, Lauren M.
   Tan, Amanda L.
   Barcellona, Carolyn M.
   Porcelli, Mario C.
   Vasquez, Chalmers
   Cannons, Andrew C.
   Cone, Marshall R.
   Hogan, Kelly N.
   Kopp, Edgar W.
   Anzinger, Joshua J.
   Garcia, Kimberly F.
   Parham, Leda A.
   Gelvez Ramirez, Rosa M.
   Miranda Montoya, Maria C.
   Rojas, Diana P.
   Brown, Catherine M.
   Hennigan, Scott
   Sabina, Brandon
   Scotland, Sarah
   Gangavarapu, Karthik
   Grubaugh, Nathan D.
   Oliveira, Glenn
   Robles-Sikisaka, Refugio
   Rambaut, Andrew
   Gehrke, Lee
   Smole, Sandra
   Halloran, M. Elizabeth
   Villar, Luis
   Mattar, Salim
   Lorenzana, Ivette
   Cerbino-Neto, Jose
   Valim, Clarissa
   Degrave, Wim
   Bozza, Patricia T.
   Gnirke, Andreas
   Andersen, Kristian G.
   Isern, Sharon
   Michael, Scott F.
   Bozza, Fernando A.
   Souza, Thiago M. L.
   Bosch, Irene
   Yozwiak, Nathan L.
   MacInnis, Bronwyn L.
   Sabeti, Pardis C.
TI Zika virus evolution and spread in the Americas
SO NATURE
LA English
DT Article
ID EBOLA; TRANSMISSION; PERFORMANCE; ACCURACY; DATABASE; MODELS
AB Although the recent Zika virus (ZIKV) epidemic in the Americas and its link to birth defects have attracted a great deal of attention(1,2), much remains unknown about ZIKV disease epidemiology and ZIKV evolution, in part owing to a lack of genomic data. Here we address this gap in knowledge by using multiple sequencing approaches to generate 110 ZIKV genomes from clinical and mosquito samples from 10 countries and territories, greatly expanding the observed viral genetic diversity from this outbreak. We analysed the timing and patterns of introductions into distinct geographic regions; our phylogenetic evidence suggests rapid expansion of the outbreak in Brazil and multiple introductions of outbreak strains into Puerto Rico, Honduras, Colombia, other Caribbean islands, and the continental United States. We find that ZIKV circulated undetected in multiple regions for many months before the first locally transmitted cases were confirmed, highlighting the importance of surveillance of viral infections. We identify mutations with possible functional implications for ZIKV biology and pathogenesis, as well as those that might be relevant to the effectiveness of diagnostic tests.
C1 [Metsky, Hayden C.; Matranga, Christian B.; Wohl, Shirlee; Schaffner, Stephen F.; Freije, Catherine A.; Winnicki, Sarah M.; West, Kendra; Qu, James; Baniecki, Mary Lynn; Gladden-Young, Adrianne; Lin, Aaron E.; Tomkins-Tinch, Christopher H.; Ye, Simon H.; Park, Daniel J.; Luo, Cynthia Y.; Barnes, Kayla G.; Shah, Rickey R.; Chak, Bridget; Gnirke, Andreas; Yozwiak, Nathan L.; MacInnis, Bronwyn L.; Sabeti, Pardis C.] Broad Inst MIT & Harvard, Cambridge, MA USA.
   [Metsky, Hayden C.] MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Wohl, Shirlee; Schaffner, Stephen F.; Freije, Catherine A.; Lin, Aaron E.; Luo, Cynthia Y.; Barnes, Kayla G.; Chak, Bridget; Yozwiak, Nathan L.; Sabeti, Pardis C.] Harvard Univ, Dept Organism & Evolutionary Biol, Ctr Syst Biol, Cambridge, MA 02138 USA.
   [Schaffner, Stephen F.; Barnes, Kayla G.; Valim, Clarissa; MacInnis, Bronwyn L.; Sabeti, Pardis C.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Ye, Simon H.] MIT, Harvard Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Shah, Rickey R.] Harvard Univ, Extens Sch, Cambridge, MA 02138 USA.
   [Barbosa-Lima, Giselle; Vieira, Yasmine R.; Cerbino-Neto, Jose; Bozza, Fernando A.] Fdn Oswaldo Cruz FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Delatorre, Edson] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Imunol Mol, Rio De Janeiro, Brazil.
   [Paul, Lauren M.; Tan, Amanda L.; Barcellona, Carolyn M.; Isern, Sharon; Michael, Scott F.] Florida Gulf Coast Univ, Coll Arts & Sci, Dept Biol Sci, Ft Myers, FL USA.
   [Porcelli, Mario C.; Vasquez, Chalmers] Miami Dade Cty Mosquito Control, Miami, FL USA.
   [Cannons, Andrew C.; Cone, Marshall R.; Hogan, Kelly N.; Kopp, Edgar W.] Bur Publ Hlth Labs, Div Dis Control & Hlth Protect, Florida Dept Hlth, Tampa, FL USA.
   [Anzinger, Joshua J.] Univ West Indies, Dept Microbiol, Kingston, Jamaica.
   [Garcia, Kimberly F.; Parham, Leda A.; Lorenzana, Ivette] Univ Nacl Autonoma Honduras, Inst Invest Microbiol, Tegucigalpa, Honduras.
   [Gelvez Ramirez, Rosa M.; Miranda Montoya, Maria C.; Villar, Luis] Univ Ind Santander, Grp Epidemiol Clin, Bucaramanga, Colombia.
   [Rojas, Diana P.] Univ Florida, Dept Epidemiol, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA.
   [Brown, Catherine M.; Hennigan, Scott; Sabina, Brandon; Scotland, Sarah; Smole, Sandra] Massachusetts Dept Publ Hlth, Jamaica, NY USA.
   [Gangavarapu, Karthik; Grubaugh, Nathan D.; Robles-Sikisaka, Refugio; Andersen, Kristian G.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Oliveira, Glenn; Andersen, Kristian G.] Scripps Translat Sci Inst, La Jolla, CA USA.
   [Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3FL, Midlothian, Scotland.
   [Rambaut, Andrew] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
   [Gehrke, Lee; Bosch, Irene] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Gehrke, Lee] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA USA.
   [Halloran, M. Elizabeth] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Halloran, M. Elizabeth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Mattar, Salim] Univ Cordoba, Inst Trop Biol Res, Monteria, Cordoba, Colombia.
   [Valim, Clarissa] Michigan State Univ, Dept Osteopath Med Specialties, E Lansing, MI 48824 USA.
   [Degrave, Wim] Fiocruz MS, Inst Oswaldo Cruz, Lab Genem Func & Bioinformat, Rio De Janeiro, Brazil.
   [Bozza, Patricia T.] Inst Oswaldo Cruz, Fdn Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Andersen, Kristian G.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Bozza, Fernando A.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Souza, Thiago M. L.] Fiocruz MS, Natl Inst Sci & Technol Innovat Neglected Dis, Rio De Janeiro, Brazil.
   [Souza, Thiago M. L.] Fiocruz MS, Ctr Technol Dev Hlth, Rio De Janeiro, Brazil.
   [Sabeti, Pardis C.] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP MacInnis, BL (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA USA.; MacInnis, BL (corresponding author), Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Souza, TML (corresponding author), Fiocruz MS, Natl Inst Sci & Technol Innovat Neglected Dis, Rio De Janeiro, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Ctr Technol Dev Hlth, Rio De Janeiro, Brazil.
EM tmoreno@cdts.fiocruz.br; bronwyn@broadinstitute.org
RI Rojas, Diana Patricia/AAC-2469-2019; Souza, Thiago Moreno
   L./G-2900-2012; Rambaut, Andrew/B-2481-2009; Neto, Jose
   Cerbino/P-3713-2018; Schaffner, Stephen F/D-1189-2011; Bozza, Fernando
   A/A-2618-2013; Delatorre, Edson/J-8330-2015
OI Rojas, Diana Patricia/0000-0003-0241-6416; Souza, Thiago Moreno
   L./0000-0003-2212-3899; Rambaut, Andrew/0000-0003-4337-3707; Neto, Jose
   Cerbino/0000-0001-9254-917X; Bozza, Fernando A/0000-0003-4878-0256;
   Delatorre, Edson/0000-0002-5746-0820; Rambaut FRSE, Professor
   Andrew/0000-0002-1278-598X; Grubaugh, Nathan/0000-0003-2031-1933; Bozza,
   Patricia/0000-0001-8349-9529; Miranda Montoya, Maria
   Consuelo/0000-0001-5730-0723; Shah, Rickey/0000-0002-3231-0367; Paul,
   Lauren/0000-0001-5503-7570; Metsky, Hayden/0000-0002-8871-2349; Lin,
   Aaron/0000-0001-7400-4125; Tomkins-Tinch,
   Christopher/0000-0002-9114-6421
FU Marc and Lynne Benioff; NIH NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [U19AI110818,
   1R01AI099210, AI100190, HHSN272201400048C]; Howard Hughes Medical
   InstituteHoward Hughes Medical Institute; Harvard University Burke
   Global Health Fellowship; Broad Institute BroadNext10 program; AWS Cloud
   Credits for Research; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq) [440909/2016-3]; Fundacao de Amparo a Pesquisa do Estado do Rio
   de JaneiroCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E 26/201.320/2016, E 26/201.332/2016,
   E 26/010.000194/2015]; MIDAS National Institute of General Medical
   Sciences [U54GM111274]; AEDES Network; Colombian Science, Technology and
   Innovation Fund of Sistema General de Regalias-BPIN [2013000100011];
   ASTMH Shope Fellowship; NSF DGENational Science Foundation (NSF)NSF-
   Directorate for Education & Human Resources (EHR) [1144152]; PNPD/CAPES
   Postdoctoral Fellowship; Fulbright Colciencias Doctoral Scholarship;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5T32AI007244 33]; EUEuropean Union
   (EU) [278433 PREDEMICS, 643476 COMPARE]; NIH NCATS CTSAUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001114]; Ray Thomas Foundation; Pew Biomedical Scholarship;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001114, UL1TR001114, UL1TR001114, UL1TR001114, UL1TR001114,
   UL1TR001114, UL1TR001114] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   T32AI007244, R33AI100190, T32AI007244, T32AI007244, U19AI110818,
   T32AI007244, U19AI110818, R33AI100190, U19AI110818, T32AI007244,
   T32AI007244, U19AI110818, U19AI110818, U19AI110818, R33AI100190,
   T32AI007244, U19AI110818, T32AI007244, T32AI007244, T32AI007244,
   R33AI100190, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   T32AI007244, U19AI110818, R21AI100190, T32AI007244, U19AI110818,
   U19AI110818, T32AI007244, U19AI110818, U19AI110818, T32AI007244,
   U19AI110818, U19AI110818, T32AI007244, T32AI007244, U19AI110818,
   T32AI007244, U19AI110818, T32AI007244, T32AI007244, T32AI007244,
   U19AI110818, U19AI110818, R01AI099210, R01AI099210, T32AI007244,
   U19AI110818, U19AI110818, U19AI110818, U19AI110818, R01AI099210,
   T32AI007244, T32AI007244, U19AI110818, T32AI007244, U19AI110818,
   U19AI110818, T32AI007244, U19AI110818, U19AI110818, T32AI007244,
   U19AI110818, U19AI110818, U19AI110818, T32AI007244, U19AI110818,
   T32AI007244, U19AI110818, U19AI110818, U19AI110818, R21AI100190,
   T32AI007244, U19AI110818, U19AI110818, U19AI110818, U19AI110818,
   T32AI007244, T32AI007244, U19AI110818, U19AI110818, U19AI110818,
   U19AI110818, T32AI007244, T32AI007244, T32AI007244, T32AI007244,
   U19AI110818, T32AI007244, U19AI110818, R01AI099210, U19AI110818,
   T32AI007244, U19AI110818] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274, U54GM111274, U54GM111274,
   U54GM111274, U54GM111274, U54GM111274] Funding Source: NIH RePORTER
FX We thank M. and L. Benioff for their vision and support; L. Brown, E.
   Lee, M. Giovanni, J. LevinAllerhand and E. S. Lander for support and
   guidance; M. Schleicher, E. Lipscomb, A. Felix, A. Saltzman, and S.
   Donnelly for assistance with IRB and ethics processes; E. Mair, L.
   Nogelo and E. Carmean for legal counsel; T. Mason and the Broad
   Institute Genomics Platform for sequencing support; A. Matthews, S.
   Chapman, D. Neafsey, and B. Birren for management and guidance; O. Pybus
   and ZiBRA Project colleagues for sharing data before publication; D.
   Olson, E. Asturias, M. Salit, and E. Simon-Loriere for sharing samples
   and reagents; and E. Holmes, G. Bello, R. Tewhey, A. Piantadosi, C.
   Edwards and the Sabeti Laboratory for discussions and reading of the
   manuscript. We are indebted to Zika patients and clinical teams for
   making this work possible. Funding was provided by: Marc and Lynne
   Benioff (P. C. S.); NIH NIAID U19AI110818 (Broad Institute); Howard
   Hughes Medical Institute (P. C. S.); Harvard University Burke Global
   Health Fellowship (P. C. S.); Broad Institute BroadNext10 program (A. G.
   and P. C. S.); AWS Cloud Credits for Research (P. C. S.); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (440909/2016-3) and
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (E
   26/201.320/2016, E 26/201.332/2016, E 26/010.000194/2015) (P. T. B. and
   F. A. B.); NIH NIAID 1R01AI099210 (S. I. and S. F. M.); MIDAS National
   Institute of General Medical Sciences U54GM111274 (M. E. H. and D. P.
   R.); NIH NIAID AI100190 (I. B. and L. G.); AEDES Network (I. B.) and
   Colombian Science, Technology and Innovation Fund of Sistema General de
   Regalias-BPIN 2013000100011 (L. V., R. M. G. R., M. C. M. M., and I.
   B.); ASTMH Shope Fellowship (K. G. B.); NSF DGE 1144152 (A. E. L.);
   PNPD/CAPES Postdoctoral Fellowship (E. D.); Fulbright Colciencias
   Doctoral Scholarship (D. P. R.); NIH training grant 5T32AI007244 33 (N.
   D. G.); EU under grant agreements 278433 PREDEMICS and 643476 COMPARE
   (A. R.); and NIH NCATS CTSA UL1TR001114, NIH NIAID contract
   HHSN272201400048C, The Ray Thomas Foundation, and Pew Biomedical
   Scholarship (K. G. A.).
CR Acland A, 2013, NUCLEIC ACIDS RES, V41, pD8, DOI [10.1093/nar/gks1189, 10.1093/nar/gkx1095, 10.1093/nar/gkv1290]
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Baele G, 2013, MOL BIOL EVOL, V30, P239, DOI 10.1093/molbev/mss243
   Baele G, 2012, MOL BIOL EVOL, V29, P2157, DOI 10.1093/molbev/mss084
   Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Brinton MA, 2015, VIRUS RES, V206, P108, DOI 10.1016/j.virusres.2015.02.006
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Centers for Disease Control and Prevention, 2015, 1 CAS ZIK VIR REP PU
   Clark K, 2016, NUCLEIC ACIDS RES, V44, pD67, DOI 10.1093/nar/gkv1276
   Corman V. M., 2016, B WHO
   Cribari-Neto F, 2010, J STAT SOFTW, V34, P1
   de Vigilancia, 2016, PROTOCOLO VIGILANCIA
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Duchene S, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862-015-0312-6
   Faria N. R., 2017, NATURE
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Faye O, 2008, J CLIN VIROL, V43, P96, DOI 10.1016/j.jcv.2008.05.005
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565
   Gire SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/science.1259657
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Grubaugh N. D., 2017, NATURE
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915
   Hyatt D, 2012, BIOINFORMATICS, V28, P2223, DOI 10.1093/bioinformatics/bts429
   Josse J, 2016, J STAT SOFTW, V70
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Matranga CB, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0519-7
   Morlan JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042882
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Pan American Health Organization, 2017, ZIK EP REP DOM REP
   Pan American Health Organization, 2015, EP UPD ZIK VIR INF
   Pan American Health Organization, 2017, ZIK EP REP HOND
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Paz-Bailey G., 2017, N ENGL J MED
   Piantadosi A, 2009, AIDS, V23, P579, DOI 10.1097/QAD.0b013e328328f76e
   Pyke A. T., 2014, PLOS CURR
   Quick J., 2017, NAT PROTOCOLS
   R Core Team, 2016, R LANG ENV STAT COMP
   Rambaut A., 2014, FIGTREE VERSION 1 4
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Sall AA, 2010, J VIROL, V84, P765, DOI 10.1128/JVI.01738-09
   Sardi SI, 2016, J CLIN MICROBIOL, V54, P2348, DOI 10.1128/JCM.00877-16
   Schieffelin JS, 2014, NEW ENGL J MED, V371, P2092, DOI 10.1056/NEJMoa1411680
   Shapiro B, 2006, MOL BIOL EVOL, V23, P7, DOI 10.1093/molbev/msj021
   Shapiro B, 2011, MOL BIOL EVOL, V28, P879, DOI 10.1093/molbev/msq262
   Tappe D, 2014, EUROSURVEILLANCE, V19, P12, DOI 10.2807/1560-7917.ES2014.19.4.20685
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   Tomkins-Tinch C., 2016, BROAD I VIRAL NGS V1
   Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201
   U. S. Food and Drug Administration, 2017, ZIK VIR RESP UPD FDA
   Villabona-Arenas CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063496
   Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46
   World Health Organization, 2017, ZIK SIT REP ZIK VIR
   Worobey M, 2016, NATURE, V539, P98, DOI 10.1038/nature19827
   Yang ZH, 1996, J MOL EVOL, V42, P587, DOI 10.1007/BF02352289
   Yarza P, 2008, SYST APPL MICROBIOL, V31, P241, DOI 10.1016/j.syapm.2008.07.001
NR 68
TC 154
Z9 161
U1 3
U2 69
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 15
PY 2017
VL 546
IS 7658
BP 411
EP +
DI 10.1038/nature22402
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX5BK
UT WOS:000403250900036
PM 28538734
OA Green Published, Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Moralez, GM
   Rabello, LSCF
   Lisboa, TC
   Lima, MDA
   Hatum, RM
   De Marco, FVC
   Alves, A
   Pinto, JEDS
   de Araujo, HBN
   Ramos, GV
   Silva, AR
   Fernandes, GC
   Faria, GBA
   Mendes, CL
   Ramos, RA
   de Souza, VP
   do Brasil, PEAA
   Bozza, FA
   Salluh, JIF
   Soares, M
AF Moralez, Giulliana Martines
   Cunha Farah Rabello, Ligia Sarmet
   Lisboa, Thiago Costa
   Andrade Lima, Mariza da Fonte
   Hatum, Rodrigo Marques
   Cesar De Marco, Fernando Vinicius
   Alves, Alessandra
   da Silva Soares Pinto, Jorge Eduardo
   Nunes de Araujo, Helia Beatriz
   Ramos, Grazielle Viana
   Silva, Aline Reis
   Fernandes, Guilherme Cortes
   Alves Faria, Guilherme Brenande
   Mendes, Ciro Leite
   Ramos Filho, Roberto Alvaro
   de Souza, Valdenia Pereira
   Alvarenga Americano do Brasil, Pedro Emmanuel
   Bozza, Fernando Augusto
   Figueira Salluh, Jorge Ibrain
   Soares, Marcio
CA ORCHESTRA Study Investig
TI External validation of SAPS 3 and MPM0-III scores in 48,816 patients
   from 72 Brazilian ICUs
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Severity-of-illness scores; Validation; Intensive care units; Outcomes;
   Standardized mortality rate
ID INTENSIVE-CARE-UNIT; HOSPITAL MORTALITY; APACHE IV; PROGNOSTIC MODEL;
   ACUTE PHYSIOLOGY; PERFORMANCE; SEVERITY; COHORT
AB Background: The performance of severity-of-illness scores varies in different scenarios and must be validated prior of being used in a specific settings and geographic regions. Moreover, models' calibration may deteriorate overtime and performance of such instruments should be reassessed regularly. Therefore, we aimed at to validate the SAPS 3 in a large contemporary cohort of patients admitted to Brazilian ICUs. In addition, we also compared the performance of the SAPS 3 with the MPM0-III.
   Methods: This is a retrospective cohort study in which 48,816 (medical admissions = 67.9%) adult patients are admitted to 72 Brazilian ICUs during 2013. We evaluated models' discrimination using the area under the receiver operating characteristic curve (AUROC). We applied the calibration belt to evaluate the agreement between observed and expected mortality rates (calibration).
   Results: Mean SAPS 3 score was 44.3 +/- 15.4 points. ICU and hospital mortality rates were 11.0 and 16.5%. We estimated predicted mortality using both standard (SE) and Central and South American (CSA) customized equations. Predicted mortality rates were 16.4 +/- 19.3% (SAPS 3-SE), 21.7 +/- 23.2% (SAPS 3-CSA) and 14.3 +/- 14.0% (MPM0-III). Standardized mortality ratios (SMR) obtained for each model were: 1.00 (95% CI, 0.98-0.102) for the SAPS 3-SE, 0.75 (0.74-0.77) for the SAPS 3-CSA and 1.15 (1.13-1.18) for the MPM0-III. Discrimination was better for SAPS 3 models (AUROC = 0.85) than for MPM0-III (AUROC = 0.80) (p < 0.001). We applied the calibration belt to evaluate the agreement between observed and expected mortality rates (calibration): the SAPS 3-CSA overestimated mortality throughout all risk classes while the MPM0-III underestimated it uniformly. The SAPS 3-SE did not show relevant deviations from ideal calibration.
   Conclusions: In a large contemporary database, the SAPS 3-SE was accurate in predicting outcomes, supporting its use for performance evaluation and benchmarking in Brazilian ICUs.
C1 [Moralez, Giulliana Martines] DOr Inst Res & Educ IDOR, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Cunha Farah Rabello, Ligia Sarmet; Figueira Salluh, Jorge Ibrain; Soares, Marcio] Univ Fed Rio de Janeiro, PPG Internal Med, Rio De Janeiro, Brazil.
   [Cunha Farah Rabello, Ligia Sarmet] Hosp Copa DOr, ICU, Rio De Janeiro, Brazil.
   [Lisboa, Thiago Costa] Santa Casa de Misericordia Porto Alegre, Complexo Hosp, Porto Alegre, RS, Brazil.
   [Andrade Lima, Mariza da Fonte] Hosp Esperanca Recife, ICU, Recife, PE, Brazil.
   [Hatum, Rodrigo Marques] Hosp Total Cor, ICU, Rio De Janeiro, Brazil.
   [Cesar De Marco, Fernando Vinicius] Hosp viValle, ICU, Sao Jose Dos Campos, Brazil.
   [Alves, Alessandra] Hosp Rios DOr, ICU, Rio De Janeiro, Brazil.
   [da Silva Soares Pinto, Jorge Eduardo] Hosp Norte DOr, ICU, Rio De Janeiro, Brazil.
   [Nunes de Araujo, Helia Beatriz] Hosp Coracao Brasil, Brasilia, DF, Brazil.
   [Ramos, Grazielle Viana; Silva, Aline Reis; Alvarenga Americano do Brasil, Pedro Emmanuel; Bozza, Fernando Augusto] DOr Inst Res & Educ IDOR, Dept Crit Care, Rio De Janeiro, Brazil.
   [Fernandes, Guilherme Cortes] Santa Casa Misericordia Juiz de Fora, ICU, Juiz De Fora, Brazil.
   [Alves Faria, Guilherme Brenande] Hosp Oeste DOr, ICU, Rio De Janeiro, Brazil.
   [Mendes, Ciro Leite] Hosp Univ Lauro Wanderley, ICU, Joao Pessoa, Paraiba, Brazil.
   [Ramos Filho, Roberto Alvaro] Hosp Sao Luiz, ICU, Unidade Jabaquara, Sao Paulo, Brazil.
   [de Souza, Valdenia Pereira] Complexo Hosp Niteroi, Niteroi, RJ, Brazil.
   [Alvarenga Americano do Brasil, Pedro Emmanuel; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Figueira Salluh, Jorge Ibrain; Soares, Marcio] DOr Inst Res & Educ IDOR, Dept Crit Care, Rio De Janeiro, Brazil.
   [Figueira Salluh, Jorge Ibrain; Soares, Marcio] DOr Inst Res & Educ IDOR, Grad Program Translat Med, Rio De Janeiro, Brazil.
   [Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Brasil, Pedro Emmanuel/AAG-2280-2019; Lisboa, Thiago/W-2973-2019;
   Soares, Marcio/B-3083-2013; Bozza, Fernando A/A-2618-2013; Faria,
   Guilherme/AAB-3002-2019; dantas, vicente c souza/L-2648-2013
OI Brasil, Pedro Emmanuel/0000-0002-6700-2268; Lisboa,
   Thiago/0000-0003-4306-2212; Soares, Marcio/0000-0003-2503-6088; Bozza,
   Fernando A/0000-0003-4878-0256; 
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [304240/2014-1]; Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   D'Or Institute for Research and Education
FX This study was supported in part by the National Council for Scientific
   and Technological Development (CNPq) (Grant No. 304240/2014-1), Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) and departmental funds from the D'Or Institute for
   Research and Education.
CR Alves Carlos José, 2009, Rev. bras. ter. intensiva, V21, P1, DOI 10.1590/S0103-507X2009000100001
   Associacao Brasileira de Terapia Intensiva (AMIB), 2009, REG TECN FUNC UN TER
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Silva VTCE, 2011, NEPHROL DIAL TRANSPL, V26, P3894, DOI 10.1093/ndt/gfr201
   de Oliveira VM, 2013, CLINICS, V68, P153, DOI [10.6061/CLINICS/2013(02)OA06, 10.6061/clinics/2013(02)OA06]
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Finazzi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016110
   Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F
   Keegan MT, 2011, CRIT CARE MED, V39, P163, DOI 10.1097/CCM.0b013e3181f96f81
   Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0
   Maccariello Elizabeth R., 2008, Rev. bras. ter. intensiva, V20, P115, DOI 10.1590/S0103-507X2008000200001
   Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Nassar AP, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.08.016
   Nassar AP, 2013, SAO PAULO MED J, V131, P173, DOI 10.1590/1516-3180.2013.1313474
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Peek N, 2007, J CLIN EPIDEMIOL, V60, P491, DOI 10.1016/j.jclinepi.2006.08.011
   Poole D, 2012, INTENS CARE MED, V38, P1280, DOI 10.1007/s00134-012-2578-0
   Reineck LA, 2014, CRIT CARE MED, V42, P1055, DOI 10.1097/CCM.0000000000000132
   Salluh JIF, 2014, CURR OPIN CRIT CARE, V20, P557, DOI 10.1097/MCC.0000000000000135
   Neto AS, 2015, SAO PAULO MED J, V133, P199, DOI 10.1590/1516-3180.2013.8120014
   Silva JM, 2010, REV BRAS ANESTESIOL, V60, P20, DOI 10.1590/S0034-70942010000100003
   Soares M, 2006, INTENS CARE MED, V32, P1839, DOI 10.1007/s00134-006-0374-4
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Soares M, 2010, INTENS CARE MED, V36, P1188, DOI 10.1007/s00134-010-1807-7
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0
NR 27
TC 7
Z9 8
U1 0
U2 8
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD MAY 18
PY 2017
VL 7
AR 53
DI 10.1186/s13613-017-0276-3
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA FF4GZ
UT WOS:000408897200001
PM 28523584
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Hammond, NE
   Taylor, C
   Finfer, S
   Machado, FR
   An, YZ
   Billot, L
   Bloos, F
   Bozza, F
   Cavalcanti, AB
   Correa, M
   Du, B
   Hjortrup, PB
   Li, Y
   McIntryre, L
   Saxena, M
   Schortgen, F
   Watts, NR
   Myburgh, J
AF Hammond, Naomi E.
   Taylor, Colman
   Finfer, Simon
   Machado, Flavia R.
   An, YouZhong
   Billot, Laurent
   Bloos, Frank
   Bozza, Fernando
   Cavalcanti, Alexandre Biasi
   Correa, Maryam
   Du, Bin
   Hjortrup, Peter B.
   Li, Yang
   McIntryre, Lauralyn
   Saxena, Manoj
   Schortgen, Frederique
   Watts, Nicola R.
   Myburgh, John
CA Fluid-TRIPS Fluidos Investigators
   George Inst Global Hlth
   ANZICS Clinical Trials Grp
   BRICNet
   REVA Res Network
TI Patterns of intravenous fluid resuscitation use in adult intensive care
   patients between 2007 and 2014: An international cross-sectional study
SO PLOS ONE
LA English
DT Article
ID IN-HOSPITAL MORTALITY; HYDROXYETHYL STARCH 130/0.4; CRITICALLY-ILL
   ADULTS; KIDNEY INJURY; ASSOCIATION; SEPSIS; SALINE; CHOICE; SCORE; SHOCK
AB Background
   In 2007, the Saline versus Albumin Fluid Evaluation D Translation of Research Into Practice Study (SAFE-TRIPS) reported that 0.9% sodium chloride (saline) and hydroxyethyl starch (HES) were the most commonly used resuscitation fluids in intensive care unit (ICU) patients. Evidence has emerged since 2007 that these fluids are associated with adverse patient-centred outcomes. Based on the published evidence since 2007, we sought to determine the current type of fluid resuscitation used in clinical practice and the predictors of fluid choice and determine whether these have changed between 2007 and 2014.
   Methods
   In 2014, an international, cross-sectional study was conducted (Fluid-TRIPS) to document current patterns of intravenous resuscitation fluid use and determine factors associated with fluid choice. We examined univariate and multivariate associations between patients and prescriber characteristics, geographical region and fluid type. Additionally, we report secular trends of resuscitation fluid use in a cohort of ICUs that participated in both the 2007 and 2014 studies. Regression analysis were conducted to determine changes in the administration of crystalloid or colloid between 2007 and 2014.
   Findings
   In 2014, a total of 426 ICUs in 27 countries participated. Over the 24 hour study day, 1456/ 6707 (21.7%) patients received resuscitation fluid during 2716 resuscitation episodes. Crystalloids were administered to 1227/1456 (84.3%) patients during 2208/2716 (81.3%) episodes and colloids to 394/1456 (27.1%) patients during 581/2716 (21.4%) episodes. In multivariate analyses, practice significantly varied between geographical regions. Additionally, patients with a traumatic brain injury were less likely to receive colloid when compared to patients with no trauma (adjusted OR 0.24; 95% CI 0.1 to 0.62; p = 0.003). Patients in the ICU for one or more days where more likely to receive colloid compared to patients in the ICU on their admission date (adjusted OR 1.75; 95% CI 1.27 to 2.41; p = < 0.001).
   For secular trends in fluid resuscitation, 84 ICUs in 17 countries contributed data. In 2007, 527/1663 (31.7%) patients received fluid resuscitation during 1167 episodes compared to 491/1763 (27.9%) patients during 960 episodes in 2014. The use of crystalloids increased from 498/1167 (42.7%) in 2007 to 694/960 (72.3%) in 2014 (odds ratio (OR) 3.75, 95% confidence interval (CI) 2.95 to 4.77; p = < 0.001), primarily due to a significant increase in the use of buffered salt solutions. The use of colloids decreased from 724/1167 (62.0%) in 2007 to 297/960 (30.9%) in 2014 (OR 0.29, 95% CI 0.19 to 0.43; p = < 0.001), primarily due to a decrease in the use of HES, but an overall increase in the use of albumin.
   Conclusions
   Clinical practices of intravenous fluid resuscitation have changed between 2007 and 2014. Geographical location remains a strong predictor of the type of fluid administered for fluid resuscitation. Overall, there is a preferential use of crystalloids, specifically buffered salt solutions, over colloids. There is now an imperative to conduct a trial determining the safety and efficacy of these fluids on patient-centred outcomes.
C1 [Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Correa, Maryam; Li, Yang; Saxena, Manoj; Watts, Nicola R.; Myburgh, John] George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.
   [Hammond, Naomi E.; Finfer, Simon] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, Sydney, NSW, Australia.
   [Hammond, Naomi E.; Taylor, Colman; Finfer, Simon; Billot, Laurent] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
   [Hammond, Naomi E.; Saxena, Manoj; Myburgh, John] Univ New South Wales, Fac Med, St George Clin Sch, Sydney, NSW, Australia.
   [Machado, Flavia R.] Univ Fed Sao Paulo, Pain & Intens Care Dept, Anesthesiol, Sao Paulo, Brazil.
   Peking Univ, Peoples Hosp, Dept Crit Care Med, Beijing, Peoples R China.
   George Inst Global Hlth, Stat Div, Sydney, NSW, Australia.
   Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany.
   DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   Peking Union Med Coll Hosp, Med Intens Care Unit, Beijing, Peoples R China.
   Copenhagen Univ Hosp, Rigshosp, Dept Intens Care, Copenhagen, Denmark.
   Ottawa Hosp, Res Inst, Dept Med Crit Care, Ottawa, ON, Canada.
   St George Hosp, Dept Intens Care Med, Sydney, NSW, Australia.
   Reanimat Med Grp Hosp Henri Mondor, Assistance Publ Hop Paris, Creteil, France.
RP Hammond, NE (corresponding author), George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Royal North Shore Hosp, Malcolm Fisher Dept Intens Care Med, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.; Hammond, NE (corresponding author), Univ New South Wales, Fac Med, St George Clin Sch, Sydney, NSW, Australia.
EM nhammond@georgeinstitute.org.au
RI Christian, Mike/AAO-6338-2020; Billot, Laurent/Y-1241-2019; Bloos,
   Frank/AAY-8265-2020; Christian, Michael/AAZ-4452-2020; Bozza, Fernando
   A/A-2618-2013; Biondi, Rodrigo S/H-5212-2016; Colombo,
   Riccardo/AAK-9081-2020; Cavalcanti, Alexandre/K-5529-2013; Du,
   Bin/K-4283-2013
OI Christian, Mike/0000-0001-9644-9950; Billot,
   Laurent/0000-0002-4975-9793; Bloos, Frank/0000-0002-0767-7941;
   Christian, Michael/0000-0001-9644-9950; Bozza, Fernando
   A/0000-0003-4878-0256; Biondi, Rodrigo S/0000-0002-9242-6062; Colombo,
   Riccardo/0000-0002-9616-803X; Cavalcanti, Alexandre/0000-0003-2798-6263;
   Hammond, Naomi/0000-0002-6559-7747; Saxena, Manoj/0000-0002-0385-6731;
   Du, Bin/0000-0001-6237-2895; Schortgen, Frederique/0000-0003-1756-7508;
   Deeb, Ahmad/0000-0002-3680-7338; Banner-Goodspeed,
   Valerie/0000-0002-7644-2521; Finfer, Simon/0000-0002-2785-5864
FU Baxter Healthcare; CSL Behring; National Health and Medical Research
   Council of AustraliaNational Health and Medical Research Council of
   Australia [APP1039312]
FX This study was partially supported by unrestricted fluid grants from
   Baxter Healthcare and CSL Behring paid to The George Institute for
   Global Health. NH received a National Health and Medical Research
   Council of Australia Postgraduate Scholarship (2012-2014) that has
   supported part of this work [APP1039312]. The funders had no role in the
   design and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation of the manuscript; or decision
   to submit the manuscript for publication.
CR Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502
   Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716
   Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727
   Cecconi M, 2015, INTENS CARE MED, V41, P1529, DOI 10.1007/s00134-015-3850-x
   EMA, 2013, PRAC REC SUSP MARK A
   FDA, 2013, HYDR STARCH SOL FDA
   Finfer S, 2004, NEW ENGL J MED, V350, P2247
   Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6
   Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293
   Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6
   Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358
   Hammond NE, 2015, INTENS CARE MED, V41, P1611, DOI 10.1007/s00134-015-3878-y
   Hammond Naomi, 2015, Rev. bras. ter. intensiva, V27, P309, DOI 10.5935/0103-507X.20150053
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Krajewski ML, 2015, BRIT J SURG, V102, P24, DOI 10.1002/bjs.9651
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   MHRA, 2013, HYDR STARCH HES PROD
   Myburgh J, 2007, NEW ENGL J MED, V357, P874
   Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759
   Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242
   R Core Team, 2015, R LANG ENV STAT COMP
   Raghunathan K, 2015, ANESTHESIOLOGY, V123, P1385, DOI 10.1097/ALN.0000000000000861
   Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305
   Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3
   Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   TGA, 2014, HYDR STRACH VOL VOL
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334
   Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356
NR 30
TC 42
Z9 43
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2017
VL 12
IS 5
AR e0176292
DI 10.1371/journal.pone.0176292
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EU8UR
UT WOS:000401314500003
PM 28498856
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Trugilho, MRD
   Hottz, ED
   Brunoro, GVF
   Teixeira-Ferreira, A
   Carvalho, PC
   Salazar, GA
   Zimmerman, GA
   Bozza, FA
   Bozza, PT
   Perales, J
AF de Oliveira Trugilho, Monique Ramos
   Hottz, Eugenio Damaceno
   Flor Brunoro, Giselle Villa
   Teixeira-Ferreira, Andre
   Carvalho, Paulo Costa
   Salazar, Gustavo Adolfo
   Zimmerman, Guy A.
   Bozza, Fernando A.
   Bozza, Patricia T.
   Perales, Jonas
TI Platelet proteome reveals novel pathways of platelet activation and
   platelet-mediated immunoregulation in dengue
SO PLOS PATHOGENS
LA English
DT Article
ID MHC-CLASS-I; EXTRACELLULAR HISTONES; VIRUS-INFECTION; GENE-EXPRESSION;
   CELLS; MECHANISMS; ANTIGEN; FEVER; THROMBOCYTOPENIA; FRACTIONATION
AB Dengue is the most prevalent human arbovirus disease worldwide. Dengue virus (DENV) infection causes syndromes varying from self-limiting febrile illness to severe dengue. Although dengue pathophysiology is not completely understood, it is widely accepted that increased inflammation plays important roles in dengue pathogenesis. Platelets are blood cells classically known as effectors of hemostasis which have been increasingly recognized to have major immune and inflammatory activities. Nevertheless, the phenotype and effector functions of platelets in dengue pathogenesis are not completely understood. Here we used quantitative proteomics to investigate the protein content of platelets in clinical samples from patients with dengue compared to platelets from healthy donors. Our assays revealed a set of 252 differentially abundant proteins. In silico analyses associated these proteins with key molecular events including platelet activation and inflammatory responses, and with events not previously attributed to platelets during dengue infection including antigen processing and presentation, proteasome activity, and expression of histones. From these results, we conducted functional assays using samples from a larger cohort of patients and demonstrated evidence for platelet activation indicated by P-selectin (CD62P) translocation and secretion of granule-stored chemokines by platelets. In addition, we found evidence that DENV infection triggers HLA class I synthesis and surface expression by a mechanism depending on functional proteasome activity. Furthermore, we demonstrate that cell-free histone H2A released during dengue infection binds to platelets, increasing platelet activation. These findings are consistent with functional importance of HLA class I, proteasome subunits, and histones that we found exclusively in proteome analysis of platelets in samples from dengue patients. Our study provides the first in-depth characterization of the platelet proteome in dengue, and sheds light on new mechanisms of platelet activation and platelet-mediated immune and inflammatory responses.
C1 [de Oliveira Trugilho, Monique Ramos; Flor Brunoro, Giselle Villa; Teixeira-Ferreira, Andre; Perales, Jonas] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Toxinol, Rio De Janeiro, Brazil.
   [de Oliveira Trugilho, Monique Ramos] Fundacao Oswaldo Cruz, CDTS, Rio De Janeiro, Brazil.
   [Hottz, Eugenio Damaceno; Zimmerman, Guy A.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Hottz, Eugenio Damaceno] Univ Fed Juiz de Fora, Inst Ciencias Biol, Dept Bioquim, Lab Anal Glicoconjugados, Juiz de Fora, MG, Brazil.
   [Carvalho, Paulo Costa] Fiocruz MS, ICC, Lab Prote & Engn Prot, Curitiba, Parana, Brazil.
   [Salazar, Gustavo Adolfo] Univ Cape Town, Fac Hlth Sci, Computat Biol Grp, Cape Town, South Africa.
   [Zimmerman, Guy A.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas INI, Rio De Janeiro, Brazil.
RP Perales, J (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Toxinol, Rio De Janeiro, Brazil.; Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br; jonasperales@gmail.com
RI Bozza, Fernando A/A-2618-2013; Hottz, Eugenio D/I-9850-2014; Brunoro,
   Giselle Villa Flor/Z-5294-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Brunoro, Giselle Villa
   Flor/0000-0002-6414-6987; Salazar, Gustavo A/0000-0001-9208-4966; Bozza,
   Patricia/0000-0001-8349-9529
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Programa de Desenvolvimento Tecnologico em Insumos
   para Saude da Fundacao Oswaldo Cruz (PDTIS-Fiocruz); PAPES/Fiocruz;
   PRONEX Dengue; U.S. National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R37HLO44525]; Science Without Borders - CNPq
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq); Programa de Desenvolvimento Tecnologico
   em Insumos para Saude da Fundacao Oswaldo Cruz (PDTIS-Fiocruz);
   PAPES/Fiocruz, and PRONEX Dengue, GAZs contributions were supported in
   part by MERIT award R37HLO44525 from the U.S. National Institutes of
   Health and a Special Visiting Professorship from Science Without Borders
   funded by CNPq. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Arthur CM, 2016, BLOOD, V127, P1823, DOI 10.1182/blood-2015-10-673426
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Bridget W, 2009, AM J TROP MED HYG, V81, P638, DOI 10.4269/ajtmh.2009.08-0008
   Carvalho PC, 2016, NAT PROTOC, V11, P102, DOI 10.1038/nprot.2015.133
   Carvalho PC, 2012, BIOINFORMATICS, V28, P1652, DOI 10.1093/bioinformatics/bts247
   Carvalho PC, 2012, PROTEOMICS, V12, P944, DOI 10.1002/pmic.201100529
   Chapman LM, 2012, J IMMUNOL, V189, P916, DOI 10.4049/jimmunol.1200580
   Chow L, 2010, BLOOD, V115, P1247, DOI 10.1182/blood-2009-09-244772
   Clark KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052902
   Conceicao TM, 2010, J INFECTION, V60, P65, DOI 10.1016/j.jinf.2009.10.003
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Ekaney ML, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0543-8
   Eng JK, 2013, PROTEOMICS, V13, P22, DOI 10.1002/pmic.201200439
   Falconar AKI, 2006, CLIN VACCINE IMMUNOL, V13, P1044, DOI 10.1128/CVI.00105-06
   Brunoro GVF, 2015, J PROTEOMICS, V117, P86, DOI 10.1016/j.jprot.2015.01.011
   Fragnoud R, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1271-7
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Fuchs TA, 2011, BLOOD, V118, P3708, DOI 10.1182/blood-2011-01-332676
   Garraud O, 2011, THROMB RES, V127, P283, DOI 10.1016/j.thromres.2010.10.015
   Ghosh K, 2008, J ELECTRON MICROSC, V57, P113, DOI 10.1093/jmicro/dfn007
   Guo L, 2014, BLOOD, V123, P422, DOI 10.1182/blood-2013-08-523308
   HA TTN, 2011, PLOS ONE, V0006
   Hansen TH, 2009, NAT REV IMMUNOL, V9, P503, DOI 10.1038/nri2575
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/435783
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Jamison J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093968
   Johnson BW, 2005, VECTOR-BORNE ZOONOT, V5, P137, DOI 10.1089/vbz.2005.5.137
   Klockenbusch C, 2014, MOL CELL PROTEOMICS, V13, P3308, DOI 10.1074/mcp.M113.031757
   Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kumar SVR, 2015, J AM SOC NEPHROL, V26, P2399, DOI 10.1681/ASN.2014070673
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   Lane L, 2012, NUCLEIC ACIDS RES, V40, pD76, DOI 10.1093/nar/gkr1179
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   Michels A, 2016, J THROMB HAEMOST, V14, P2274, DOI 10.1111/jth.13493
   Michels M, 2014, THROMB HAEMOSTASIS, V112, P352, DOI 10.1160/TH14-01-0056
   Mourao MPG, 2007, PLATELETS, V18, P605, DOI 10.1080/09537100701426604
   Nakahara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075961
   Napirei M, 2004, ARTHRITIS RHEUM-US, V50, P1873, DOI 10.1002/art.20267
   Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084
   Noisakran S, 2012, EXP HEMATOL, V40, P250, DOI 10.1016/j.exphem.2011.11.011
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   Olsson B, 2003, NAT MED, V9, P1123, DOI 10.1038/nm921
   Ostrowska H, 2003, PLATELETS, V14, P151, DOI 10.1080/0953710031000092802
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Placke T, 2012, CANCER RES, V72, P440, DOI 10.1158/0008-5472.CAN-11-1872
   Rowley JW, 2011, BLOOD, V118, pE101, DOI 10.1182/blood-2011-03-339705
   Salazar GA, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-129
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Schmidt AC, 2010, NEW ENGL J MED, V363, P484, DOI 10.1056/NEJMcibr1005904
   Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Shu PY, 2003, CLIN DIAGN LAB IMMUN, V10, P622, DOI 10.1128/CDLI.10.4.622-630.2003
   Simon AY, 2015, BLOOD, V126, P378, DOI 10.1182/blood-2014-09-598029
   Stephan F, 2014, ARTHRITIS RHEUMATOL, V66, P686, DOI 10.1002/art.38265
   Tsai JJ, 2011, J INNATE IMMUN, V3, P530, DOI 10.1159/000322904
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Weyrich AS, 2005, CIRCULATION, V111, P633, DOI 10.1161/01.CIR.0000154607.90506.45
   Xu J, 2009, NAT MED, V15, P1318, DOI 10.1038/nm.2053
   Yang XY, 2016, THROMB RES, V137, P211, DOI 10.1016/j.thromres.2015.10.012
   Yost CC, 2016, J CLIN INVEST, V126, P3783, DOI 10.1172/JCI83873
   Zhang Y, 2010, ANAL CHEM, V82, P2272, DOI 10.1021/ac9023999
   Zhang YA, 2010, ELECTROPHORESIS, V31, P3797, DOI 10.1002/elps.201000401
NR 71
TC 33
Z9 33
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2017
VL 13
IS 5
AR e1006385
DI 10.1371/journal.ppat.1006385
PG 27
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA EW9ZK
UT WOS:000402877700036
PM 28542641
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rodrigues, RS
   Bozza, FA
   Hanrahan, CJ
   Wang, LM
   Wu, Q
   Hoffman, JM
   Zimmerman, GA
   Morton, KA
AF Rodrigues, Rosana S.
   Bozza, Fernando A.
   Hanrahan, Christopher J.
   Wang, Li-Ming
   Wu, Qi
   Hoffman, John M.
   Zimmerman, Guy A.
   Morton, Kathryn A.
TI F-18-fluoro-2-deoxyglucose PET informs neutrophil accumulation and
   activation in lipopolysaccharide-induced acute lung injury
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE F-18-fluordeoxyglucose; FDG; Neutrophils; ARDS; Lipopolysaccharide;
   Acute lung injury
ID POSITRON-EMISSION-TOMOGRAPHY; RESPIRATORY-DISTRESS-SYNDROME; MESENCHYMAL
   STEM-CELLS; FDG-PET; PULMONARY INFLAMMATION; INTRAVENOUS CONTRAST;
   INFECTION; BIOMARKER; KINETICS; SEPSIS
AB Introduction: Molecular imaging of the earliest events related to the development of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) could facilitate therapeutic development and patient management. We previously reported that F-18-fluoro-2-deoxyglucose (F-18-FDG) PET identifies ALI/ARDS prior to radiographic abnormalities. The purpose of this study was to establish the time courses of F-18-FDG uptake, edema and neutrophil recruitment in an endotoxin-induced acute lung injury model and to examine molecular events required for C-14-2DG uptake in activated neutrophils.
   Methods: Lung uptake of F-18-FDG was measured by PET in control male Sprague Dawley rats and at 2, 6 and 24 h following the intraperitoneal injection of 10 mg/kg LPS. Lung edema (attenuation) was measured by microCT. Neutrophil influx into the lungs was measured by myeloperoxidase assay. Control and activated human donor neutrophils were compared for uptake of 1(4)C-2DG, transcription and content of hexokinase and GLUT isoforms and for hexokinase (HK) activity.
   Results: Significant uptake of F-18-FDG occurred by 2 h following LPS, and progressively increased to 24 h. Lung uptake of F-18-FDG preceded increased CT attenuation (lung edema). Myeloperoxidase activity in the lungs, supporting neutrophil influx, paralleled F-18-FDG uptake. Activation of isolated human neutrophils resulted in increased uptake of C-14-2DG, expression of GLUT 3 and GLUT 4 and expression and increased HK1 activity.
   Conclusion: Systemic endotoxin-induced ALI results in very early and progressive uptake of F-18-FDG, parallels neutrophil accumulation and occurs earlier than lung injury edema. Activated neutrophils show increased uptake of C-14-2DG, expression of specific GLUTS, GLUT4 and HK1 protein and HK activity. Advances in knowledge and implications for patient care: F-18-FDG pulmonary uptake is an early biomarker of neutrophil recruitment in ALI and is associated with specific molecular events that mediate C-14-2DG uptake in activated neutrophils. F-18-FDG PET may provide a potential mechanism for early diagnosis and therapeutic assessment of ALI/ARDS. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Rodrigues, Rosana S.] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Hanrahan, Christopher J.; Wang, Li-Ming; Wu, Qi; Hoffman, John M.; Morton, Kathryn A.] Univ Utah, Sch Med, Dept Radiol & Imaging Sci, Room 1A71,50 N Med Dr, Salt Lake City, UT 84132 USA.
   [Zimmerman, Guy A.] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA.
RP Morton, KA (corresponding author), Univ Utah, Sch Med, Dept Radiol & Imaging Sci, Room 1A71,50 N Med Dr, Salt Lake City, UT 84132 USA.
EM kathryn.morton@hsc.utah.edu
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU National Center for Research Resources, National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [5UL1TR001067-02]; National Center for Advancing
   Translational Sciences, National Institutes of Health (NIH)
   [5UL1TR001067-02]; Center for Quantitative Cancer Imaging, Huntsman
   Cancer Institute, University of Utah; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) fellowshipCAPES; Conselho Nacional de
   Pesquisa (CNPq) fellowshipNational Council for Scientific and
   Technological Development (CNPq); NIHUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R37 HL044525,
   U54 HL112311]; CNPqNational Council for Scientific and Technological
   Development (CNPq); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR001067, UL1TR001067, UL1TR001067,
   UL1TR001067, UL1TR001067, UL1TR001067, UL1TR001067, UL1TR001067,
   UL1TR001067] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R37HL044525, R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525, R37HL044525, R37HL044525,
   R37HL044525, R37HL044525] Funding Source: NIH RePORTER
FX This work was partially supported by the National Center for Research
   Resources and the National Center for Advancing Translational Sciences,
   National Institutes of Health (NIH), through Grant 5UL1TR001067-02.
   Additional support was provided by the Center for Quantitative Cancer
   Imaging, Huntsman Cancer Institute, University of Utah. R.S.R. was
   supported by a Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) fellowship and F.A.B. by a Conselho Nacional de
   Pesquisa (CNPq) fellowship. G.A.Z. was supported by NIH R37 HL044525 and
   U54 HL112311 and a Science Without Borders Professorship from CNPq. The
   authors declare no competing financial interests.
CR An YS, 2007, ANN NUCL MED, V21, P585, DOI 10.1007/s12149-007-0066-3
   ANDERSON BO, 1991, J SURG RES, V50, P510, DOI 10.1016/0022-4804(91)90033-I
   Bakheet SM, 2000, CLIN NUCL MED, V25, P273, DOI 10.1097/00003072-200004000-00007
   Bellani G, 2011, MINERVA ANESTESIOL, V77, P439
   Bellani G, 2017, CURR OPIN CRIT CARE, V23, P30, DOI 10.1097/MCC.0000000000000380
   Bellani G, 2009, CRIT CARE MED, V37, P2216, DOI 10.1097/CCM.0b013e3181aab31f
   BOZZA PT, 1994, EUR J PHARM-ENVIRON, V270, P143, DOI 10.1016/0926-6917(94)90056-6
   Chen DL, 2006, MOL PHARMACEUT, V3, P488, DOI 10.1021/mp060050w
   Chen DL, 2009, AM J RESP CRIT CARE, V180, P533, DOI 10.1164/rccm.200904-0501OC
   Chen DL, 2006, J APPL PHYSIOL, V100, P1602, DOI 10.1152/japplphysiol.01429.2005
   Chen DL, 2004, AM J PHYSIOL-LUNG C, V286, pL834, DOI 10.1152/ajplung.00339.2003
   Coleman MT, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009500
   Coleman MT, 2014, INFECT IMMUN, V82, P2400, DOI 10.1128/IAI.01599-13
   de Prost N, 2014, J NUCL MED, V55, P1871, DOI 10.2967/jnumed.114.140962
   de Prost N, 2010, AM J ROENTGENOL, V195, P292, DOI 10.2214/AJR.10.4499
   Dittrich AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047588
   Donahoe Michael, 2011, Pulm Circ, V1, P192, DOI 10.4103/2045-8932.83454
   GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978
   Gotts JE, 2011, CRIT CARE CLIN, V27, P719, DOI 10.1016/j.ccc.2011.04.004
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Harris RS, 2011, J NUCL MED, V52, P1713, DOI 10.2967/jnumed.110.086355
   Horkheimer I, 2002, ADV SEPSIS, V2, P2
   Houshmand S, 2016, PET CLIN, V11, P65, DOI 10.1016/j.cpet.2015.07.003
   Jacene HA, 2004, CLIN NUCL MED, V29, P786, DOI 10.1097/00003072-200412000-00002
   Kangelaris KN, 2015, AM J PHYSIOL-LUNG C, V308, pL1102, DOI 10.1152/ajplung.00380.2014
   Kono M, 2015, CLIN NUCL MED, V40, P679, DOI 10.1097/RLU.0000000000000831
   Lin X, 2011, CRIT CARE CLIN, V27, P705, DOI 10.1016/j.ccc.2011.04.002
   Madsen PH, 2013, HELL J NUCL MED, V16, P121
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Miotla JM, 1998, AM J RESP CELL MOL, V18, P197, DOI 10.1165/ajrcmb.18.2.2846
   Musch G, 2007, ANESTHESIOLOGY, V106, P723, DOI 10.1097/01.anes.0000264748.86145.ac
   Paik JY, 2004, J NUCL MED, V45, P124
   Rodrigues RS, 2008, INTENS CARE MED, V34, P2273, DOI 10.1007/s00134-008-1220-7
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Sagy M, 2013, CURR PROB PEDIATR AD, V43, P260, DOI 10.1016/j.cppeds.2013.10.001
   Saha D, 2013, MOL IMAGING BIOL, V15, P19, DOI 10.1007/s11307-012-0575-x
   SCHEER WD, 1978, ANAL BIOCHEM, V91, P451, DOI 10.1016/0003-2697(78)90531-6
   Schuster DP, 2007, AM J PHYSIOL-LUNG C, V292, pL845, DOI 10.1152/ajplung.00350.2006
   Schuster DP, 2003, EXP LUNG RES, V29, P45, DOI 10.1080/01902140303760
   Shozushima M, 2003, ANN NUCL MED, V17, P555, DOI 10.1007/BF03006668
   Toner P, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1091-6
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175
   Yau YY, 2005, J NUCL MED, V46, P283
   Yost CC, 2010, BIOCHIMIE, V92, P692, DOI 10.1016/j.biochi.2010.02.011
   Zambelli V, 2012, INTENS CARE MED, V38, P694, DOI 10.1007/s00134-011-2456-1
   Zhou ZH, 2005, AM J PHYSIOL-LUNG C, V289, pL760, DOI 10.1152/ajplung.00146.2005
   Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020
NR 48
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0969-8051
EI 1872-9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD MAY
PY 2017
VL 48
BP 52
EP 62
DI 10.1016/j.nucmedbio.2017.01.005
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA ES1CJ
UT WOS:000399265200008
PM 28237630
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Sacramento, CQ
   de Melo, GR
   de Freitas, CS
   Rocha, N
   Hoelz, LVB
   Miranda, M
   Fintelman-Rodrigues, N
   Marttorelli, A
   Ferreira, AC
   Barbosa-Lima, G
   Abrantes, JL
   Vieira, YR
   Bastos, MM
   Volotao, EDM
   Nunes, EP
   Tschoeke, DA
   Leomil, L
   Loiola, EC
   Trindade, P
   Rehen, SK
   Bozza, FA
   Bozza, PT
   Boechat, N
   Thompson, FL
   de Filippis, AMB
   Bruning, K
   Souza, TML
AF Sacramento, Carolina Q.
   de Melo, Gabrielle R.
   de Freitas, Caroline S.
   Rocha, Natasha
   Hoelz, Lucas Villas Boas
   Miranda, Milene
   Fintelman-Rodrigues, Natalia
   Marttorelli, Andressa
   Ferreira, Andre C.
   Barbosa-Lima, Giselle
   Abrantes, Juliana L.
   Vieira, Yasmine Rangel
   Bastos, Monica M.
   Volotao, Eduardo de Mello
   Nunes, Estevao Portela
   Tschoeke, Diogo A.
   Leomil, Luciana
   Loiola, Erick Correia
   Trindade, Pablo
   Rehen, Stevens K.
   Bozza, Fernando A.
   Bozza, Patricia T.
   Boechat, Nubia
   Thompson, Fabiano L.
   de Filippis, Ana M. B.
   Bruning, Karin
   Souza, Thiago Moreno L.
TI The clinically approved antiviral drug sofosbuvir inhibits Zika virus
   replication (vol 7, 40920, 2017)
SO SCIENTIFIC REPORTS
LA English
DT Correction
RI Boechat, Nubia/K-2520-2019; Bozza, Fernando A/A-2618-2013; Boechat,
   Nubia/N-1406-2014; Rehen, Stevens K/J-5874-2012
OI Boechat, Nubia/0000-0003-0146-2218; Bozza, Fernando
   A/0000-0003-4878-0256; Boechat, Nubia/0000-0003-0146-2218; Rehen,
   Stevens K/0000-0003-4216-9501; Bozza, Patricia/0000-0001-8349-9529;
   Souza, Thiago/0000-0003-2212-3899
CR Sacramento CQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40920
NR 1
TC 1
Z9 1
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 24
PY 2017
VL 7
AR 46772
DI 10.1038/srep46772
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET1XW
UT WOS:000400063400001
PM 28436989
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Soares, M
   Silva, UVA
   Homena, WS
   Fernandes, GC
   De Moraes, APP
   Brauer, L
   Lima, MF
   De Marco, FV
   Bozza, FA
   Salluh, JIF
AF Soares, Marcio
   Silva, Ulysses V. A.
   Homena, Walter S., Jr.
   Fernandes, Guilherme C.
   De Moraes, Ana Paula P.
   Brauer, Leonardo
   Lima, Mariza F.
   De Marco, Fernando V.
   Bozza, Fernando A.
   Salluh, Jorge I. F.
CA ORCHESTRA ORg CHaractEeriSTics
TI Family care, visiting policies, ICU performance, and efficiency in
   resource use: insights from the ORCHESTRA study
SO INTENSIVE CARE MEDICINE
LA English
DT Letter
C1 [Soares, Marcio; De Marco, Fernando V.; Bozza, Fernando A.] DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro,30 Botafogo, BR-22281100 Rio De Janeiro, Brazil.
   [Silva, Ulysses V. A.] Hosp Canc Barretos, Fundacao Pio 12, ICU, Barretos, Brazil.
   [Homena, Walter S., Jr.] Hosp Barra DOr, Surg ICU, Rio De Janeiro, Brazil.
   [Fernandes, Guilherme C.] ICU Santa Casa Misericordia Juiz Fora, Juiz De Fora, Brazil.
   [De Moraes, Ana Paula P.] Hosp Canc Maranhao Dr Tarquinio Lopes Filho, ICU, Sao Luis, Brazil.
   [Brauer, Leonardo] Hosp Sao Luiz, Unidade Itaim, ICU, Sao Paulo, Brazil.
   [Lima, Mariza F.] Hosp Esperanca Recife, ICU, Recife, PE, Brazil.
   [De Marco, Fernando V.] Hosp viValle, ICU, Sao Jose Dos Campos, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro,30 Botafogo, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Soares, Marcio/B-3083-2013; V.A.Silva, Ulysses/AAZ-3336-2020; dantas,
   vicente c souza/L-2648-2013; Bozza, Fernando A/A-2618-2013
OI Soares, Marcio/0000-0003-2503-6088; V.A.Silva,
   Ulysses/0000-0002-1284-2016; Bozza, Fernando A/0000-0003-4878-0256
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [304240/2014-1]; Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   D'Or Institute for Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq) (Grant No. 304240/2014-1), Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ), and by departmental funds from the D'Or Institute for
   Research and Education.
CR Fumis RRL, 2014, REV BRAS TER INTENSI, V26, P339, DOI [10.5935/0103-507X.20140052, DOI 10.5935/0103-507X.20140052]
   Garrouste-Orgeas M, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0185-x
   Giannini A, 2014, INTENS CARE MED, V40, P730, DOI 10.1007/s00134-014-3267-y
   Liu V, 2013, CRIT CARE, V17, DOI 10.1186/cc12677
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
NR 5
TC 11
Z9 13
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD APR
PY 2017
VL 43
IS 4
BP 590
EP 591
DI 10.1007/s00134-016-4654-3
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA EP3XK
UT WOS:000397314800024
PM 28028553
DA 2020-12-01
ER

PT J
AU Heming, N
   Mazeraud, A
   Verdonk, F
   Bozza, FA
   Chretien, F
   Sharshar, T
AF Heming, Nicholas
   Mazeraud, Aurelien
   Verdonk, Franck
   Bozza, Fernando A.
   Chretien, Fabrice
   Sharshar, Tarek
TI Neuroanatomy of sepsis-associated encephalopathy
SO CRITICAL CARE
LA English
DT Review
ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; TERM COGNITIVE
   IMPAIRMENT; NITRIC-OXIDE SYNTHASE; SPECTRAL-ANALYSIS APPROACH; SEPTIC
   SHOCK; BRAIN-INJURY; ACTIVATED MICROGLIA; CRITICAL ILLNESS;
   CONTROLLED-TRIAL
AB This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2017. Other selected articles can be found online at http://ccforum.com/series/annualupdate2017. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901.
   Originally published in the Annual Update in Intensive Care and Emergency Medicine 2017. The number of authors differs in the two versions due to constraints regarding the number of authors in the Annual Update in Intensive Care and Emergency Medicine. In the Annual Update version of the review, the three senior authors appear in the acknowledgement section. In the Critical Care version, these three senior authors appear as full authors of the manuscript. All authors helped draft and revise the manuscript for critical intellectual content.
C1 [Heming, Nicholas] AP HP, Hop Raymond Poincare, Reanim Med, 104 Blvd Raymond Poincare, F-92380 Garches, France.
   [Mazeraud, Aurelien; Verdonk, Franck] Inst Pasteur, Human Histopathol & Anim Models, F-75015 Paris, France.
   [Bozza, Fernando A.] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Chretien, Fabrice] St Anne Hosp, Unit Neuropathol, Paris, France.
   [Sharshar, Tarek] Hop Raymond Poincare, Gen ICU, Garches, France.
RP Heming, N (corresponding author), AP HP, Hop Raymond Poincare, Reanim Med, 104 Blvd Raymond Poincare, F-92380 Garches, France.
EM nicholas.heming@aphp.fr
RI Bozza, Fernando A/A-2618-2013; Chretien, fabrice/D-4035-2018
OI Bozza, Fernando A/0000-0003-4878-0256; Chretien,
   fabrice/0000-0002-2794-1383
FU Groupe d'Investigation Clinique en Reanimation (GICR)
FX Publication of this article was funded by the Groupe d'Investigation
   Clinique en Reanimation (GICR).
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Aboab J, 2008, CRIT CARE MED, V36, P1481, DOI 10.1097/CCM.0b013e31816f48f2
   Adembri C, 2014, CRIT CARE MED, V42, pE570, DOI 10.1097/CCM.0000000000000414
   Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Anforth HR, 1998, EUR CYTOKINE NETW, V9, P279
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Annane D, 1999, AM J RESP CRIT CARE, V160, P458, DOI 10.1164/ajrccm.160.2.9810073
   Annane D, 2015, LANCET RESP MED, V3, P61, DOI 10.1016/S2213-2600(14)70246-2
   Azabou E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139969
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P1036, DOI 10.3174/ajnr.A0928
   Basler T, 2002, INTENS CARE MED, V28, P293, DOI 10.1007/s00134-002-1217-6
   Carlson DE, 2007, EXP NEUROL, V205, P485, DOI 10.1016/j.expneurol.2007.03.015
   Comim CM, 2008, MITOCHONDRION, V8, P313, DOI 10.1016/j.mito.2008.07.002
   Dantzer R, 2004, EUR J PHARMACOL, V500, P399, DOI 10.1016/j.ejphar.2004.07.040
   Di Paola M, 2008, HIPPOCAMPUS, V18, P719, DOI 10.1002/hipo.20432
   Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Escartin C, 2013, FRONT NEUROENERGETIC, V5, P1
   Grandi C, 2011, J CRIT CARE, V26, P133, DOI 10.1016/j.jcrc.2010.10.006
   Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008
   Henckens MJAG, 2010, J NEUROSCI, V30, P12725, DOI 10.1523/JNEUROSCI.3112-10.2010
   Hunter RG, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00018
   Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94
   Jacob A, 2011, NEUROCHEM INT, V58, P472, DOI 10.1016/j.neuint.2011.01.004
   Kadoi Y, 1996, CRIT CARE MED, V24, P298, DOI 10.1097/00003246-199602000-00020
   Kadoi Y, 1996, J SURG RES, V61, P496, DOI 10.1006/jsre.1996.0153
   Khakpour S, 2015, INNATE IMMUN-LONDON, V21, P827, DOI 10.1177/1753425915606525
   Korcok J, 2002, J NEUROCHEM, V81, P185, DOI 10.1046/j.1471-4159.2002.00814.x
   Liu LL, 2014, BRAIN RES, V1589, P78, DOI 10.1016/j.brainres.2014.09.030
   Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23
   Lund-Sorensen H, 2016, JAMA PSYCHIAT, V73, P912, DOI 10.1001/jamapsychiatry.2016.1594
   Muscatell KA, 2015, BRAIN BEHAV IMMUN, V43, P46, DOI 10.1016/j.bbi.2014.06.201
   Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Retamal MA, 2007, J NEUROSCI, V27, P13781, DOI 10.1523/JNEUROSCI.2042-07.2007
   Reyes EP, 2012, ADV EXP MED BIOL, V758, P185, DOI 10.1007/978-94-007-4584-1_26
   Rosengarten B, 2012, CRIT CARE, V16, DOI 10.1186/cc11310
   Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2
   Schelling G, 1999, CRIT CARE MED, V27, P2678, DOI 10.1097/00003246-199912000-00012
   Schroeder S, 2001, CRIT CARE MED, V29, P310, DOI 10.1097/00003246-200102000-00017
   Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870
   Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003
   Sharshar T, 2005, CRIT CARE, V9, P37, DOI 10.1186/cc2951
   Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x
   Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4
   Sharshar T, 2002, CRIT CARE MED, V30, P2371, DOI 10.1097/00003246-200210000-00031
   Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y
   Sharshar T, 2011, CRIT CARE MED, V39, P1960, DOI 10.1097/CCM.0b013e31821b843b
   Siami S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080190
   Siami S, 2010, CRIT CARE MED, V38, P1962, DOI 10.1097/CCM.0b013e3181eb9acf
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   SKOOG KM, 1990, AM J PHYSIOL, V258, pR1472
   Sonneville R, 2015, SHOCK, V44, P245, DOI 10.1097/SHK.0000000000000403
   Sonneville R, 2010, BRAIN PATHOL, V20, P613, DOI 10.1111/j.1750-3639.2009.00355.x
   Stare J, 2015, J NEUROSCI, V35, P12188, DOI 10.1523/JNEUROSCI.5420-13.2015
   Steckert AV, 2015, NEUROSCI LETT, V595, P134, DOI 10.1016/j.neulet.2015.04.019
   Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200
   van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7
   van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2
   Viviani B, 2014, NEUROTOXICOLOGY, V43, P10, DOI 10.1016/j.neuro.2014.03.004
   Voigt K, 2002, FREE RADICAL RES, V36, P735, DOI 10.1080/10715760290032557
   Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611
   Wintermann GB, 2015, CRIT CARE MED, V43, P1213, DOI 10.1097/CCM.0000000000000936
   YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016
NR 70
TC 35
Z9 38
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD MAR 21
PY 2017
VL 21
AR 65
DI 10.1186/s13054-017-1643-z
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA EO6DH
UT WOS:000396781500007
PM 28320461
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Reis, PA
   Alexandre, PCB
   D'Avila, JC
   Siqueira, LD
   Antunes, B
   Estato, V
   Tibirica, EV
   Verdonk, F
   Sharshar, T
   Chretien, F
   Castro-Faria-Neto, HC
   Bozza, FA
AF Reis, Patricia A.
   Alexandre, Pedro C. B.
   D'Avila, Joana C.
   Siqueira, Luciana D.
   Antunes, Barbara
   Estato, Vanessa
   Tibirica, Eduardo V.
   Verdonk, Franck
   Sharshar, Tarek
   Chretien, Fabrice
   Castro-Faria-Neto, Hugo C.
   Bozza, Fernando A.
TI Statins prevent cognitive impairment after sepsis by reverting
   neuroinflammation, and microcirculatory/endothelial dysfunction
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Statin; Cognition; Sepsis; Neuroinflammation; Endothelium
ID TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; ROSUVASTATIN;
   MORTALITY; THERAPY; DISEASE; MODEL; RATS
AB Acute brain dysfunction is a frequent condition in sepsis patients and is associated with increased mortality and long-term neurocognitive consequences. Impaired memory and executive function are common findings in sepsis survivors. Although neuroinflammation and blood-brain barrier dysfunction have been associated with acute brain dysfunction and its consequences, no specific treatments are available that prevent cognitive impairment after sepsis. Experimental sepsis was induced in Swiss Webster mice by intraperitoneal injection of cecal material (5 mg/kg, 500 mu L). Control groups (n = 5/group each experiment) received 500 mu L of saline. Support therapy recover (saline 0.9%, 1 mL and imipenem 30 mg/kg) were applied (6, 24 and 48 h post injection, n = 5-10/group, each experiment), together or not with additive orally treatment with statins (atorvastatin/simvastatin 20 mg/kg b.w.). Survival rate was monitored at 6, 24 and 48 h. In a setting of experiments, animals were euthanized at 6 and 24 h after induction for biochemical, immunohistochemistry and intravital analysis. Statins did not prevented mortality in septic mice, however survivors presented lower clinical score. At another setting of experiments, after 15 days, mice survivors from fecal supernatant peritoneal sepsis presented cognitive dysfunction for contextual hippocampal and aversive amygdala-dependent memories, which was prevented by atorvastatin/simvastatin treatment. Systemic and brain tissue levels of proinflammatory cytokines/chemokines and activation of microglial were lower in septic mice treated with statins. Brain lipid peroxidation and myeloperoxidase levels were also reduced by statins treatment. Intravital examination of the brain vessels of septic animals revealed decreased functional capillary density and increased rolling and adhesion of leukocytes, and blood flow impairment, which were reversed by treatment with statins. In addition, treatment with statins restored the cholinergic vasodilator response due to sepsis. Taken together, these data demonstrated that statins reverse microvascular dysfunction and reduce neuroinflammation during sepsis, preventing the development of long-term cognitive decline. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Reis, Patricia A.; Alexandre, Pedro C. B.; D'Avila, Joana C.; Siqueira, Luciana D.; Castro-Faria-Neto, Hugo C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, Rio De Janeiro, Brazil.
   [Antunes, Barbara; Estato, Vanessa; Tibirica, Eduardo V.] Fiocruz MS, Inst Oswaldo Cruz, Lab Cardiovasc Invest, Rio De Janeiro, Brazil.
   [Verdonk, Franck; Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Dept Histopathol & Anim Models, Paris, France.
   [Bozza, Fernando A.] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, Hugo C.] Univ Estacio Sa, Fac Med, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FiOCRUZ, Evandro Chagas Natl Inst Infect Dis, Lab Crit Care, Av Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ipec.fiocruz.br
RI d'Avila, Joana/L-8970-2013; Estato, Vanessa/AAJ-9060-2020; Chretien,
   fabrice/D-4035-2018; Bozza, Fernando A/A-2618-2013
OI d'Avila, Joana/0000-0002-2045-0813; Chretien,
   fabrice/0000-0002-2794-1383; Bozza, Fernando A/0000-0003-4878-0256
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   BrasilCAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), BrasilNational Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), BrasilCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); Institute
   Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem
   (INBEB), Brasil; Fundacao Oswaldo Cruz, Brasil and Institute Pasteur,
   France
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brasil, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brasil, Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brasil,
   Institute Nacional de Ciencia e Tecnologia de Biologia Estrutural e
   Bioimagem (INBEB), Brasil, Fundacao Oswaldo Cruz, Brasil and Institute
   Pasteur, France. HCCFN is a fellow on the program Pesquisa Produtividade
   from Universidade Estacio de Sa.
CR Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1
   Bozza FA, 2010, J CEREBR BLOOD F MET, V30, P440, DOI 10.1038/jcbfm.2009.215
   Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003
   Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141
   Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005
   Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839
   Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36
   Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jukema JW, 2012, J AM COLL CARDIOL, V60, P875, DOI 10.1016/j.jacc.2012.07.007
   Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kwok JMF, 2013, VASC PHARMACOL, V58, P21, DOI 10.1016/j.vph.2012.10.003
   Lim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081218
   Londono D, 2011, J IMMUNOL, V186, P7176, DOI 10.4049/jimmunol.1100060
   Merx MW, 2005, CIRCULATION, V112, P117, DOI 10.1161/CIRCULATIONAHA.104.502195
   Moraes CA, 2014, MOL NEUROBIOL
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Needham DM, 2016, LANCET RESP MED, V4, P203, DOI 10.1016/S2213-2600(16)00005-9
   Pesic S, 2002, PHARMACOLOGY, V64, P182, DOI 10.1159/000056169
   Quevedo J, 1999, LEARN MEMORY, V6, P600, DOI 10.1101/lm.6.6.600
   Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099
   Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963
   Tralhao AFR, 2014, POSTGRAD MED, V126, DOI 10.3810/pgm.2014.11.2832
   Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551
   Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051
   Sabino B, 2008, J CARDIOVASC PHARM, V51, P402, DOI 10.1097/FJC.0b013e3181673bc5
   Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883
   Sharshar T, 2016, LANCET RESP MED, V4, P169, DOI 10.1016/S2213-2600(16)00028-X
   Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z
   Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4
   Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205
   Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520
   Wang B, 2012, J NEUROL SCI, V319, P117, DOI 10.1016/j.jns.2012.04.015
   Winters BD, 2010, CRIT CARE MED, V38, P1276, DOI 10.1097/CCM.0b013e3181d8cc1d
   Yasuda H, 2006, KIDNEY INT, V69, P1535, DOI 10.1038/sj.ki.5000300
   Yende S, 2016, CRIT CARE MED, V44, P1461, DOI 10.1097/CCM.0000000000001658
NR 37
TC 30
Z9 31
U1 1
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD FEB
PY 2017
VL 60
BP 293
EP 303
DI 10.1016/j.bbi.2016.11.006
PG 11
WC Immunology; Neurosciences; Psychiatry
SC Immunology; Neurosciences & Neurology; Psychiatry
GA EH6UA
UT WOS:000391908200030
PM 27833044
DA 2020-12-01
ER

PT J
AU Sacramento, CQ
   de Melo, GR
   de Freitas, CS
   Rocha, N
   Hoelz, LVB
   Miranda, M
   Fintelman-Rodrigues, N
   Marttorelli, A
   Ferreira, AC
   Barbosa-Lima, G
   Abrantes, JL
   Vieira, YR
   Bastos, MM
   Volotao, ED
   Nunes, EP
   Tschoeke, DA
   Leomil, L
   Loiola, EC
   Trindade, P
   Rehen, SK
   Bozza, FA
   Bozza, PT
   Boechat, N
   Thompson, FL
   de Filippis, AMB
   Bruning, K
   Souza, TML
AF Sacramento, Carolina Q.
   de Melo, Gabrielle R.
   de Freitas, Caroline S.
   Rocha, Natasha
   Boas Hoelz, Lucas Villas
   Miranda, Milene
   Fintelman-Rodrigues, Natalia
   Marttorelli, Andressa
   Ferreira, Andre C.
   Barbosa-Lima, Giselle
   Abrantes, Juliana L.
   Vieira, Yasmine Rangel
   Bastos, Monica M.
   Volotao, Eduardo de Mello
   Nunes, Estevao Portela
   Tschoeke, Diogo A.
   Leomil, Luciana
   Loiola, Erick Correia
   Trindade, Pablo
   Rehen, Stevens K.
   Bozza, Fernando A.
   Bozza, Patricia T.
   Boechat, Nubia
   Thompson, Fabiano L.
   de Filippis, Ana M. B.
   Bruning, Karin
   Souza, Thiago Moreno L.
TI The clinically approved antiviral drug sofosbuvir inhibits Zika virus
   replication
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DEPENDENT-RNA-POLYMERASE; INFECTION; DENGUE; CELLS
AB Zika virus (ZIKV) is a member of the Flaviviridae family, along with other agents of clinical significance such as dengue (DENV) and hepatitis C (HCV) viruses. Since ZIKV causes neurological disorders during fetal development and in adulthood, antiviral drugs are necessary. Sofosbuvir is clinically approved for use against HCV and targets the protein that is most conserved among the members of the Flaviviridae family, the viral RNA polymerase. Indeed, we found that sofosbuvir inhibits ZIKV RNA polymerase, targeting conserved amino acid residues. Sofosbuvir inhibited ZIKV replication in different cellular systems, such as hepatoma (Huh-7) cells, neuroblastoma (SH-Sy5y) cells, neural stem cells (NSC) and brain organoids. In addition to the direct inhibition of the viral RNA polymerase, we observed that sofosbuvir also induced an increase in A-to-G mutations in the viral genome. Together, our data highlight a potential secondary use of sofosbuvir, an anti-HCV drug, against ZIKV.
C1 [Sacramento, Carolina Q.; de Melo, Gabrielle R.; de Freitas, Caroline S.; Rocha, Natasha; Fintelman-Rodrigues, Natalia; Marttorelli, Andressa; Ferreira, Andre C.; Barbosa-Lima, Giselle; Abrantes, Juliana L.; Vieira, Yasmine Rangel; Bozza, Fernando A.; Bozza, Patricia T.; Souza, Thiago Moreno L.] Fundacao Oswaldo Cruz Fiocruz, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Sacramento, Carolina Q.; de Melo, Gabrielle R.; de Freitas, Caroline S.; Rocha, Natasha; Fintelman-Rodrigues, Natalia; Marttorelli, Andressa; Ferreira, Andre C.; Barbosa-Lima, Giselle; Abrantes, Juliana L.; Vieira, Yasmine Rangel; Nunes, Estevao Portela; Bozza, Fernando A.; Souza, Thiago Moreno L.] Fiocruz MS, INI, Rio De Janeiro, RJ, Brazil.
   [Sacramento, Carolina Q.; de Melo, Gabrielle R.; de Freitas, Caroline S.; Rocha, Natasha; Fintelman-Rodrigues, Natalia; Marttorelli, Andressa; Ferreira, Andre C.; Barbosa-Lima, Giselle; Vieira, Yasmine Rangel; Souza, Thiago Moreno L.] Fiocruz MS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, RJ, Brazil.
   [Boas Hoelz, Lucas Villas; Bastos, Monica M.; Boechat, Nubia] Fiocruz MS, Inst Tecnol Farmacos Farmanguinhos, Rio De Janeiro, RJ, Brazil.
   [Miranda, Milene] Fiocruz MS, IOC, Lab Virus Resp & Sarampo, Rio De Janeiro, RJ, Brazil.
   [Miranda, Milene; Tschoeke, Diogo A.; Leomil, Luciana; Thompson, Fabiano L.] Univ Fed Rio de Janeiro UFRJ, Inst Biol, Rio De Janeiro, RJ, Brazil.
   [Abrantes, Juliana L.; Rehen, Stevens K.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, RJ, Brazil.
   [Volotao, Eduardo de Mello] Fiocruz MS, IOC, Lab Virol Comparada & Ambiental, Rio De Janeiro, RJ, Brazil.
   [Tschoeke, Diogo A.; Leomil, Luciana; Thompson, Fabiano L.] Univ Fed Rio de Janeiro, SAGE COPPE, Rio de Janeiro, RJ, Brazil.
   [Tschoeke, Diogo A.] Univ Fed Rio de Janeiro, Nucleo Ecol & Desenvolvimento Socioambiental Maca, Rio De Janeiro, Brazil.
   [Loiola, Erick Correia; Trindade, Pablo; Rehen, Stevens K.] DOr Inst Res & Educ IDOR, Rio De Janeiro, RJ, Brazil.
   [de Filippis, Ana M. B.] Fiocruz MS, IOC, Lab Flavivirus, Rio De Janeiro, RJ, Brazil.
   [Bruning, Karin] BMK Consortium, Rio De Janeiro, RJ, Brazil.
   [Bruning, Karin] Blanver Farmoquim Ltd, Taboao Da Serra, Brazil.
   [Bruning, Karin] Microbiol Quim & Farmaceut Ltd, Taboao Da Serra, Brazil.
   [Bruning, Karin] Karin Bruning & Cia Ltd, Taboao Da Serra, Brazil.
RP Souza, TML (corresponding author), Fundacao Oswaldo Cruz Fiocruz, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, INI, Rio De Janeiro, RJ, Brazil.; Souza, TML (corresponding author), Fiocruz MS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Ctr Technol Dev Hlth CDTS, Rio De Janeiro, RJ, Brazil.
EM tmoreno@cdts.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Boechat, Nubia/K-2520-2019; Leomil,
   Luciana/O-4860-2019; Boechat, Nubia/N-1406-2014; Souza, Thiago Moreno
   L./G-2900-2012; Tschoeke, Diogo A/F-9913-2019; Rehen, Stevens
   K/J-5874-2012; Hoelz, Lucas/C-6584-2017; Trindade, Pablo/D-8913-2016;
   Loiola, Erick/I-4106-2016
OI Bozza, Fernando A/0000-0003-4878-0256; Boechat,
   Nubia/0000-0003-0146-2218; Boechat, Nubia/0000-0003-0146-2218; Souza,
   Thiago Moreno L./0000-0003-2212-3899; Tschoeke, Diogo
   A/0000-0001-8134-4259; Rehen, Stevens K/0000-0003-4216-9501; Hoelz,
   Lucas/0000-0002-9163-1574; Trindade, Pablo/0000-0001-5953-7054; Bozza,
   Patricia/0000-0001-8349-9529; Thompson, Fabiano/0000-0002-7562-1683;
   Loiola, Erick/0000-0002-7926-795X
FU Conselho Nacional de Desenvolvimento e Pesquisa (CNPq)National Council
   for Scientific and Technological Development (CNPq); Fundacao de Amparo
   a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
FX Thanks are due to Drs Carlos M. Morel, Marcio L. Rodrigues, Renata Curi
   and Fabricia Pimenta for their strong advisement and support regarding
   the technological development underlying this project. This work was
   supported by Conselho Nacional de Desenvolvimento e Pesquisa (CNPq),
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ).
CR Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Bhatia HK, 2014, J PHARMACOL PHARMACO, V5, P278, DOI 10.4103/0976-500X.142464
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cerbino-Neto J, 2016, EMERG INFECT DIS, V22, P1318, DOI 10.3201/eid2207.160375
   Chutaputti A, 2000, J GASTROEN HEPATOL, V15, pE156, DOI 10.1046/j.1440-1746.2000.02114.x
   Day CW, 2005, ANTIVIR RES, V67, P38, DOI 10.1016/j.antiviral.2005.04.002
   De Clercq E, 2013, MED RES REV, V33, P1249, DOI 10.1002/med.21281
   Delvecchio R, 2016, BIORXIV, DOI [10.1101/051268, DOI 10.1101/051268]
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Dutta S, 2009, MOL BIOTECHNOL, V42, P1, DOI 10.1007/s12033-008-9127-7
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Eyer L, 2016, J INFECT DIS, V214, P707, DOI 10.1093/infdis/jiw226
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Ferron F, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-255
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Gilead, 2015, PROD MON PR SOVALDI
   Guo DH, 2014, DNA CELL BIOL, V33, P20, DOI 10.1089/dna.2013.2193
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   Huang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114910
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Leyssen P, 2006, MOL PHARMACOL, V69, P1461, DOI 10.1124/mol.105.020057
   Lu GL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003549
   Lu J, 2011, J VIROL, V85, P2126, DOI 10.1128/JVI.01531-10
   Malet H, 2007, J BIOL CHEM, V282, P10678, DOI 10.1074/jbc.M607273200
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nurk S, 2013, J COMPUT BIOL, V20, P714, DOI 10.1089/cmb.2013.0084
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Piperno A, 2014, CURR MED CHEM, V21, P1843, DOI 10.2174/0929867321666131228205935
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Sacramento C. Q., 2016, BIORXIV, DOI [10.1101/061671, DOI 10.1101/061671]
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Schmieder R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017288
   Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026
   Smith DW, 2016, LANCET, V387, P1486, DOI 10.1016/S0140-6736(16)00564-X
   Solomon T, 2016, LANCET INFECT DIS, V16, P402, DOI 10.1016/S1473-3099(16)00125-0
   Souza TML, 2008, ANTIVIR RES, V77, P20, DOI 10.1016/j.antiviral.2007.08.011
   Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
   Zhao YQ, 2015, P NATL ACAD SCI USA, V112, P14834, DOI 10.1073/pnas.1514978112
   Zhong LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22635
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
NR 50
TC 95
Z9 98
U1 0
U2 61
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 18
PY 2017
VL 7
AR 40920
DI 10.1038/srep40920
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI0GT
UT WOS:000392151800001
PM 28098253
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Zampieri, FG
   Bozza, FA
   Moralez, GM
   Mazza, DDS
   Scotti, AV
   Santino, MS
   Ribeiro, RAB
   Rodrigues, EM
   Cabral, MM
   Maia, MO
   D'Alessandro, PS
   Oliveira, SV
   Menezes, MAM
   Caser, EB
   Lannes, RS
   Neto, MSA
   Machado, MM
   Sousa, MF
   Salluh, JIF
   Soares, M
AF Zampieri, Fernando G.
   Bozza, Fernando A.
   Moralez, Giulliana M.
   Mazza, Debora D. S.
   Scotti, Alexandre V.
   Santino, Marcelo S.
   Ribeiro, Rubens A. B.
   Rodrigues Filho, Edison M.
   Cabral, Mauricio M.
   Maia, Marcelo O.
   D'Alessandro, Patricia S.
   Oliveira, Sandro V.
   Menezes, Marcia A. M.
   Caser, Eliana B.
   Lannes, Roberto S.
   Alencar Neto, Meton S.
   Machado, Maristela M.
   Sousa, Marcelo F.
   Salluh, Jorge I. F.
   Soares, Marcio
TI The effects of performance status one week before hospital admission on
   the outcomes of critically ill patients
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Performance status; Critical care; Outcomes; Markers of baseline health
   status
ID INTENSIVE-CARE UNITS; COOPERATIVE-ONCOLOGY-GROUP; PROSPECTIVE
   MULTICENTER; NET RECLASSIFICATION; RISK PREDICTION; LUNG-CANCER;
   MORTALITY; ICU; MALIGNANCIES; ASSOCIATION
AB To assess the impact of performance status (PS) impairment 1 week before hospital admission on the outcomes in patients admitted to intensive care units (ICU).
   Retrospective cohort study in 59,693 patients (medical admissions, 67 %) admitted to 78 ICUs during 2013. We classified PS impairment according to the Eastern Cooperative Oncology Group (ECOG) scale in absent/minor (PS = 0-1), moderate (PS = 2) or severe (PS = 3-4). We used univariate and multivariate logistic regression analyses to investigate the association between PS impairment and hospital mortality.
   PS impairment was moderate in 17.3 % and severe in 6.9 % of patients. The hospital mortality was 14.4 %. Overall, the worse the PS, the higher the ICU and hospital mortality and length of stay. In addition, patients with worse PS were less frequently discharged home. PS impairment was associated with worse outcomes in all SAPS 3, Charlson Comorbidity Index and age quartiles as well as according to the admission type. Adjusting for other relevant clinical characteristics, PS impairment was associated with higher hospital mortality (odds-ratio (OR) = 1.96 (95 % CI 1.63-2.35), for moderate and OR = 4.22 (3.32-5.35), for severe impairment). The effects of PS on the outcome were particularly relevant in the medium range of severity-of-illness. These results were consistent in the subgroup analyses. However, adding PS impairment to the SAPS 3 score improved only slightly its discriminative capability.
   PS impairment was associated with worse outcomes independently of other markers of chronic health status, particularly for patients in the medium range of severity of illness.
C1 [Zampieri, Fernando G.] Hosp Coracao HCor, Res Inst, Sao Paulo, Brazil.
   [Zampieri, Fernando G.] Hosp Alemao Oswaldo Cruz, Intens Care Unit, Sao Paulo, Brazil.
   [Bozza, Fernando A.; Moralez, Giulliana M.; Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Inst Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Moralez, Giulliana M.] Hosp Estadual Getulio Vargas, Intens Care Unit, Rio De Janeiro, Brazil.
   [Mazza, Debora D. S.] Hosp Sao Luiz Unidade Jabaquara, Intens Care Unit, Sao Paulo, Brazil.
   [Scotti, Alexandre V.] Hosp Israelita Albert Sabin, Intens Care Unit, Rio De Janeiro, Brazil.
   [Santino, Marcelo S.] Hosp Barra DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Ribeiro, Rubens A. B.] Hosp Anchieta, Intens Care Unit, Taguatinga, Brazil.
   [Rodrigues Filho, Edison M.] Complexo Hosp Santa Casa Misericordia Porto Alegr, Porto Alegre, RS, Brazil.
   [Cabral, Mauricio M.] Hosp Sao Marcos, Intens Care Unit, Recife, PE, Brazil.
   [Maia, Marcelo O.] Hosp Santa Luzia, Intens Care Unit, Brasilia, DF, Brazil.
   [D'Alessandro, Patricia S.] Clin Sao Vicente, Intens Care Unit, Rio De Janeiro, Brazil.
   [Oliveira, Sandro V.] Hosp Bangu, Intens Care Unit, Rio De Janeiro, Brazil.
   [Menezes, Marcia A. M.] Hosp Oeste DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Caser, Eliana B.] Hosp Unimed Vitoria, Intens Care Unit, Vitoria, Brazil.
   [Lannes, Roberto S.] Hosp Municipal Souza Aguiar, Intens Care Unit, Rio De Janeiro, Brazil.
   [Alencar Neto, Meton S.] Hosp Reg Cariri, Intens Care Unit, Juazeiro Do Norte, Brazil.
   [Machado, Maristela M.] Hosp Agenor Paiva, Intens Care Unit, Salvador, BA, Brazil.
   [Sousa, Marcelo F.] Santa Casa Caridade Diamantina, Intens Care Unit, Diamantina, Brazil.
   [Salluh, Jorge I. F.; Soares, Marcio] Univ Fed Rio de Janeiro, Postgrad Program Internal Med, Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI dantas, vicente c souza/L-2648-2013; Bozza, Fernando A/A-2618-2013;
   Soares, Marcio/B-3083-2013; Zampieri, Fernando/K-3305-2014
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Zampieri, Fernando/0000-0001-9315-6386
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [304240/2014-1]; Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   D'Or Institute for Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq) (Grant No 304240/2014-1), Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) and by departmental funds from the D'Or Institute for Research
   and Education.
CR Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365
   Bagshaw SM, 2014, CAN MED ASSOC J, V186, pE95, DOI 10.1503/cmaj.130639
   Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402
   Dolgin NH, 2016, CLIN TRANSPLANT, V30, P1403, DOI 10.1111/ctr.12808
   Forte DN, 2012, INTENS CARE MED, V38, P404, DOI 10.1007/s00134-011-2400-4
   Harrell FE, 2001, REGRESSION MODELING, DOI [10.1007/978-1-4757-3462-1, DOI 10.1007/978-1-4757-3462-1]
   Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F
   Kerr KF, 2014, EPIDEMIOLOGY, V25, P114, DOI 10.1097/EDE.0000000000000018
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Parikh CR, 2014, J AM SOC NEPHROL, V25, P1621, DOI 10.1681/ASN.2013121300
   Park CM, 2014, J CRIT CARE, V29, P409, DOI 10.1016/j.jcrc.2014.01.016
   Pencina MJ, 2012, STAT MED, V31, P101, DOI 10.1002/sim.4348
   Prigerson HG, 2015, JAMA ONCOL, V1, P778, DOI 10.1001/jamaoncol.2015.2378
   R Core Team, 2015, R LANG ENV STAT COMP
   Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014
   Salluh JIF, 2014, CURR OPIN CRIT CARE, V20, P557, DOI 10.1097/MCC.0000000000000135
   Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04
   Soares M, 2014, ANN ONCOL, V25, P1829, DOI 10.1093/annonc/mdu234
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Torres VBL, 2015, ANN AM THORAC SOC, V12, P1185, DOI 10.1513/AnnalsATS.201501-046OC
   Vesin A, 2013, INTENS CARE MED, V39, P1396, DOI 10.1007/s00134-013-2949-1
   Vickers AJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-13
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Zampieri FG, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-59
   Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0
NR 32
TC 26
Z9 27
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD JAN
PY 2017
VL 43
IS 1
BP 39
EP 47
DI 10.1007/s00134-016-4563-5
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA EG9EG
UT WOS:000391360400004
PM 27686352
DA 2020-12-01
ER

PT J
AU Mesquita, EC
   Cerbino-Neto, J
   Ramos, GV
   Varela, M
   Parreira, V
   Souza, T
   Vizzoni, A
   Bozza, P
   Bozza, F
AF Mesquita, E. C.
   Cerbino-Neto, J.
   Viana Ramos, G.
   Varela, M.
   Parreira, V.
   Souza, T.
   Vizzoni, A.
   Bozza, P.
   Bozza, F.
TI Active syndromic surveillance program of arboviruses in Rio de Janeiro,
   Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Mesquita, E. C.; Cerbino-Neto, J.; Varela, M.; Parreira, V.; Vizzoni, A.; Bozza, F.] Fiocruz MS, Inst Nacl Infectol Evandro Chagas INI FIOCRUZ, Rio De Janeiro, Brazil.
   [Viana Ramos, G.] Inst DOr Pesquisa Ensino IDOR, Rio De Janeiro, Brazil.
   [Souza, T.] Fiocruz MS, Inst Nacl Ciencia & Tecnol Inovacao Doencas Negli, Rio De Janeiro, Brazil.
   [Bozza, P.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, Fundacao Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
RI Neto, Jose Cerbino/P-3713-2018; Bozza, Fernando A/A-2618-2013; Vizzoni,
   Alexandre/W-8718-2019
OI Neto, Jose Cerbino/0000-0001-9254-917X; Bozza, Fernando
   A/0000-0003-4878-0256; Vizzoni, Alexandre/0000-0003-0004-5084; Souza,
   Thiago/0000-0003-2212-3899
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2016
VL 53
SU S
MA 20.143
BP 140
EP 140
DI 10.1016/j.ijid.2016.11.345
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA VE8AG
UT WOS:000440378400330
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Torres, VBL
   Vassalo, J
   Silva, UVA
   Caruso, P
   Torelly, AP
   Silva, E
   Teles, JMM
   Knibel, M
   Rezende, E
   Netto, JJS
   Piras, C
   Azevedo, LCP
   Bozza, FA
   Spector, N
   Salluh, JIF
   Soares, M
AF Torres, Viviane B. L.
   Vassalo, Juliana
   Silva, Ulysses V. A.
   Caruso, Pedro
   Torelly, Andre P.
   Silva, Eliezer
   Teles, Jose M. M.
   Knibel, Marcos
   Rezende, Ederlon
   Netto, Jose J. S.
   Piras, Claudio
   Azevedo, Luciano C. P.
   Bozza, Fernando A.
   Spector, Nelson
   Salluh, Jorge I. F.
   Soares, Marcio
TI Outcomes in Critically Ill Patients with Cancer-Related Complications
SO PLOS ONE
LA English
DT Article
ID INTENSIVE-CARE-UNIT; ACUTE RESPIRATORY-FAILURE; LONG-TERM SURVIVAL;
   VENTILATORY SUPPORT; EMERGENCY-SURGERY; LUNG-CANCER; PROGNOSIS;
   ADMISSION; SEPSIS; PERFORATION
AB Introduction
   Cancer patients are at risk for severe complications related to the underlying malignancy or its treatment and, therefore, usually require admission to intensive care units (ICU). Here, we evaluated the clinical characteristics and outcomes in this subgroup of patients.
   Materials and Methods
   Secondary analysis of two prospective cohorts of cancer patients admitted to ICUs. We used multivariable logistic regression to identify variables associated with hospital mortality.
   Results
   Out of 2,028 patients, 456 (23%) had cancer-related complications. Compared to those without cancer-related complications, they more frequently had worse performance status (PS) (57% vs 36% with PS >= 2), active malignancy (95% vs 58%), need for vasopressors (45% vs 34%), mechanical ventilation (70% vs 51%) and dialysis (12% vs 8%) (P<0.001 for all analyses). ICU (47% vs. 27%) and hospital (63% vs. 38%) mortality rates were also higher in patients with cancer-related complications (P<0.001). Chemo/radiation therapyinduced toxicity (6%), venous thromboembolism (5%), respiratory failure (4%), gastrointestinal involvement (3%) and vena cava syndrome (VCS) (2%) were the most frequent cancer-related complications. In multivariable analysis, the presence of cancer-related complications per se was not associated with mortality [odds ratio (OR) = 1.25 (95% confidence interval, 0.94-1.66), P = 0.131]. However, among the individual cancer-related complications, VCS [OR = 3.79 (1.11-12.92), P = 0.033], gastrointestinal involvement [OR = 3.05 (1.57-5.91), P = <0.001] and respiratory failure [OR = 1.96(1.04-3.71), P = 0.038] were independently associated with in-hospital mortality.
   Conclusions
   The prognostic impact of cancer-related complications was variable. Although some complications were associated with worse outcomes, the presence of an acute cancer-related complication per se should not guide decisions to admit a patient to ICU.
C1 [Torres, Viviane B. L.; Vassalo, Juliana; Spector, Nelson; Salluh, Jorge I. F.; Soares, Marcio] Univ Fed Rio de Janeiro, Sch Med, Postgrad Program Internal Med, Rio De Janeiro, RJ, Brazil.
   [Silva, Ulysses V. A.] Hosp Canc Barretos, Fundacao Pio 12, ICU, Barretos, Brazil.
   [Caruso, Pedro] AC Camargo Canc Ctr, ICU, Sao Paulo, Brazil.
   [Torelly, Andre P.] Irmandade Santa Casa Misericordia Porto Alegre, RIPIMI, Porto Alegre, RS, Brazil.
   [Silva, Eliezer] Hosp Israelita Albert Einstein, ICU, Sao Paulo, Brazil.
   [Teles, Jose M. M.] Hosp Portugues, ICU, Salvador, BA, Brazil.
   [Knibel, Marcos] Hosp Sao Lucas, Travessa Frederico Pamplona 32, Rio De Janeiro, Brazil.
   [Rezende, Ederlon] Hosp Servidor Publ Estadual, ICU, Sao Paulo, Brazil.
   [Netto, Jose J. S.] Hosp Canc II, Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   [Piras, Claudio] Vitoria Apart Hosp, ICU, Vitoria, Brazil.
   [Azevedo, Luciano C. P.] Hosp Sirio Libanes, Res & Educ Inst, Sao Paulo, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ, IDOR, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Soares, Marcio] Inst Nacl Canc, Postgrad Program, Rio De Janeiro, Brazil.
RP Soares, M (corresponding author), Univ Fed Rio de Janeiro, Sch Med, Postgrad Program Internal Med, Rio De Janeiro, RJ, Brazil.; Soares, M (corresponding author), DOr Inst Res & Educ, IDOR, Rio De Janeiro, Brazil.; Soares, M (corresponding author), Inst Nacl Canc, Postgrad Program, Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Azevedo, Luciano CP/H-2652-2012; Soares, Marcio/B-3083-2013; dantas,
   vicente c souza/L-2648-2013; Bozza, Fernando A/A-2618-2013; V.A.Silva,
   Ulysses/AAZ-3336-2020
OI Azevedo, Luciano CP/0000-0001-6759-3910; Soares,
   Marcio/0000-0003-2503-6088; Bozza, Fernando A/0000-0003-4878-0256;
   V.A.Silva, Ulysses/0000-0002-1284-2016
FU Institute National de Cancer; Brazilian Research in Intensive Care
   Network (BRICNet); National Council for Scientific and Technological
   Development of Brazil (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao Carlos Chagas Filho de Amparo
   a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
FX This study was supported in part by Institute National de Cancer and
   sponsored by the Brazilian Research in Intensive Care Network (BRICNet).
   MS, FAB and JIFS are supported in part by individual research grants
   from National Council for Scientific and Technological Development of
   Brazil (CNPq) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ). The funding institutions had no
   active role in the design, analysis and interpretation of the results or
   publication process.
CR Abdelrazeq AS, 2008, COLORECTAL DIS, V10, P775, DOI 10.1111/j.1463-1318.2007.01412.x
   Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   Azevedo LCP, 2014, CHEST, V146, P257, DOI 10.1378/chest.13-1870
   Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb
   Azoulay E, 2003, AM J RESP CRIT CARE, V167, P1329, DOI 10.1164/rccm.200206-554OC
   Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365
   Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5
   Azoulay E, 2010, AM J RESP CRIT CARE, V182, P1038, DOI 10.1164/rccm.201001-0018OC
   Baldwin KJ, 2012, NEUROL CLIN, V30, P101, DOI 10.1016/j.ncl.2011.09.004
   Banaszkiewicz Z, 2014, WSPOLCZESNA ONKOL, V18, P414, DOI 10.5114/wo.2014.46362
   Benoit DD, 2003, CRIT CARE MED, V31, P104, DOI 10.1097/00003246-200301000-00017
   Benoit DD, 2014, INTENS CARE MED, V40, P1576, DOI 10.1007/s00134-014-3480-8
   Brenner H, 2002, LANCET, V360, P1131, DOI 10.1016/S0140-6736(02)11199-8
   Cairo MS, 2004, BRIT J HAEMATOL, V127, P3, DOI 10.1111/j.1365-2141.2004.05094.x
   Caruso P, 2010, EUR J CANCER CARE, V19, P260, DOI 10.1111/j.1365-2354.2008.01031.x
   Clines GA, 2005, ENDOCR-RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Kallogjeri D, 2012, J GERIATR ONCOL, V3, P238, DOI 10.1016/j.jgo.2012.01.006
   Kasakura Y, 2002, J SURG ONCOL, V80, P181, DOI 10.1002/jso.10127
   Katabathina VS, 2013, RADIOGRAPHICS, V33, P1533, DOI 10.1148/rg.336135508
   Khan UA, 2014, EMERG MED CLIN N AM, V32, P495, DOI 10.1016/j.emc.2014.04.001
   Khorana AA, 2009, J CLIN ONCOL, V27, P4839, DOI 10.1200/JCO.2009.22.3271
   KIM HJ, 1993, AM J ROENTGENOL, V161, P539, DOI 10.2214/ajr.161.3.8352099
   Lecuyer L, 2007, CRIT CARE MED, V35, P808, DOI 10.1097/01.CCM.0000256846.27192.7A
   Lee HJ, 2006, DIGEST SURG, V23, P217, DOI 10.1159/000094753
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   McCurdy MT, 2012, CRIT CARE MED, V40, P2212, DOI 10.1097/CCM.0b013e31824e1865
   Mokart D, 2015, INTENS CARE MED, V41, P296, DOI 10.1007/s00134-014-3615-y
   Mokart D, 2013, LEUKEMIA LYMPHOMA, V54, P1724, DOI 10.3109/10428194.2012.753446
   Nam HS, 2014, TUBERC RESPIR DIS, V76, P211, DOI 10.4046/trd.2014.76.5.211
   Puxty K, 2014, INTENS CARE MED, V40, P1409, DOI 10.1007/s00134-014-3471-9
   Reignier J, 2008, CRIT CARE MED, V36, P2076, DOI 10.1097/CCM.0b013e31817c0ea7
   Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014
   Shen HN, 2009, AM J CLIN ONCOL-CANC, V32, P467, DOI 10.1097/COC.0b013e3181931236
   Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04
   Soares M, 2014, ANN ONCOL, V25, P1829, DOI 10.1093/annonc/mdu234
   Soares M, 2007, CHEST, V131, P840, DOI 10.1378/chest.06-2244
   Soares M, 2006, J CLIN ONCOL, V24, P4003, DOI 10.1200/JCO.2006.05.7869
   Soares M, 2013, LANCET ONCOL, V14, pE337, DOI 10.1016/S1470-2045(13)70269-9
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Song JU, 2012, INTENS CARE MED, V38, P1505, DOI 10.1007/s00134-012-2594-0
   Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Valade S, 2015, THROMB RES, V135, P610, DOI 10.1016/j.thromres.2015.01.010
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 49
TC 11
Z9 11
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2016
VL 11
IS 10
AR e016453
DI 10.1371/journal.pone.0164537
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ9NZ
UT WOS:000386204500040
PM 27764143
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Soares, M
   Bozza, FA
   Azevedo, LCP
   Silva, UVA
   Correa, TD
   Colombari, F
   Torelly, AP
   Varaschin, P
   Viana, WN
   Knibel, MF
   Damasceno, M
   Espinoza, R
   Ferez, M
   Silveira, JG
   Lobo, SA
   Moraes, APP
   Lima, RA
   de Carvalho, AGR
   do Brasil, PEAA
   Kahn, JM
   Angus, DC
   Salluh, JIF
AF Soares, Marcio
   Bozza, Fernando A.
   Azevedo, Luciano C. P.
   Silva, Ulysses V. A.
   Correa, Thiago D.
   Colombari, Fernando
   Torelly, Andre P.
   Varaschin, Pedro
   Viana, William N.
   Knibel, Marcos F.
   Damasceno, Moyzes
   Espinoza, Rodolfo
   Ferez, Marcus
   Silveira, Juliana G.
   Lobo, Suzana A.
   Moraes, Ana Paula P.
   Lima, Ricardo A.
   de Carvalho, Alexandre G. R.
   do Brasil, Pedro E. A. A.
   Kahn, Jeremy M.
   Angus, Derek C.
   Salluh, Jorge I. F.
TI Effects of Organizational Characteristics on Outcomes and Resource Use
   in Patients With Cancer Admitted to Intensive Care Units
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; PROSPECTIVE MULTICENTER; CRITICAL ILLNESS; CASE
   VOLUME; ICU; IMPACT; MORTALITY; MALIGNANCIES; ADMISSION; SURVIVAL
AB Purpose
   To investigate the impact of organizational characteristics and processes of care on hospital mortality and resource use in patients with cancer admitted to intensive care units (ICUs).
   Patients and Methods
   We performed a retrospective cohort study of 9,946 patients with cancer (solid, n = 8,956; hematologic, n = 990) admitted to 70 ICUs (51 located in general hospitals and 19 in cancer centers) during 2013. We retrieved patients' clinical and outcome data from an electronic ICU quality registry. We surveyed ICUs regarding structure, organization, staffing patterns, and processes of care. We used mixed multivariable logistic regression analysis to identify characteristics associated with hospital mortality and efficient resource use in the ICU.
   Results
   Median number of patients with cancer per center was 110 (interquartile range, 58 to 154), corresponding to 17.9% of all ICU admissions. ICU and hospital mortality rates were 15.9% and 25.4%, respectively. After adjusting for relevant patient characteristics, presence of clinical pharmacists in the ICU (odds ratio [OR], 0.67; 95% CI, 0.49 to 0.90), number of protocols (OR, 0.92; 95% CI, 0.87 to 0.98), and daily meetings between oncologists and intensivists for care planning (OR, 0.69; 95% CI, 0.52 to 0.91) were associated with lower mortality. Implementation of protocols (OR, 1.52; 95% CI, 1.11 to 2.07) and meetings between oncologists and intensivists (OR, 4.70; 95% CI, 1.15 to 19.22) were also independently associated with more efficient resource use. Neither admission to ICUs in cancer centers compared with general hospitals nor annual case volume had an impact on mortality or resource use.
   Conclusion
   Organizational aspects, namely the implementation of protocols and presence of clinical pharmacists in the ICU, and close collaboration between oncologists and ICU teams are targets to improve mortality and resource use in critically ill patients with cancer. (C) 2016 by American Society of Clinical Oncology
C1 [Soares, Marcio; Bozza, Fernando A.; do Brasil, Pedro E. A. A.; Salluh, Jorge I. F.] DOr Inst Res & Educ, Botafogo, RJ, Brazil.
   [Bozza, Fernando A.; do Brasil, Pedro E. A. A.] Inst Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Manguinho, RJ, Brazil.
   [Varaschin, Pedro] Pasteur Hosp, Rio De Janeiro, Brazil.
   [Viana, William N.] Hosp Copa DOr, Rio De Janeiro, Brazil.
   [Knibel, Marcos F.] Hosp Sao Lucas Copacabana, Rio De Janeiro, Brazil.
   [Espinoza, Rodolfo] Hosp Canc II, Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Silveira, Juliana G.] Hosp Quinta DOr, Rio De Janeiro, Brazil.
   [Lima, Ricardo A.] Hosp Samaritano, Rio De Janeiro, Brazil.
   [Azevedo, Luciano C. P.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Correa, Thiago D.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Colombari, Fernando] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
   [Silva, Ulysses V. A.] Fundacao Pio XII Hosp Canc Barretos, Barretos, Brazil.
   [Torelly, Andre P.] Santa Casa Miseriordia Porto Alegre, Complexo Hosp, Porto Alegre, RS, Brazil.
   [Damasceno, Moyzes] Complexo Hosp Niteroi, Niteroi, RJ, Brazil.
   [Ferez, Marcus] Hosp Sao Francisco, Ribeirao Preto, Brazil.
   [Lobo, Suzana A.] Hosp Base Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil.
   [Moraes, Ana Paula P.] Hosp Canc Maranhao Dr Tarquinio Lopes Filho, Sao Luis, Brazil.
   [de Carvalho, Alexandre G. R.] UDI Hosp, Sao Luis, Brazil.
   [Kahn, Jeremy M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
   [Kahn, Jeremy M.; Angus, Derek C.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro 30, Botafogo, RJ, Brazil.
EM marciosoaresms@gmail.com
RI V.A.Silva, Ulysses/AAZ-3336-2020; Brasil, Pedro Emmanuel/AAG-2280-2019;
   Azevedo, Luciano CP/H-2652-2012; Soares, Marcio/B-3083-2013; dantas,
   vicente c souza/L-2648-2013; Bozza, Fernando A/A-2618-2013; Angus, Derek
   C/E-9671-2012
OI V.A.Silva, Ulysses/0000-0002-1284-2016; Brasil, Pedro
   Emmanuel/0000-0002-6700-2268; Azevedo, Luciano CP/0000-0001-6759-3910;
   Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256; Domingos Correa, Thiago/0000-0001-9546-3910;
   Kahn, Jeremy/0000-0001-9688-5576
FU National Council for Scientific and Technological DevelopmentNational
   Council for Scientific and Technological Development (CNPq)
   [304240/2014-1]; D'Or Institute for Research and Education; Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro
FX Supported by the National Council for Scientific and Technological
   Development (Grant No. 304240/2014-1), by the Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro, and by
   departmental funds from the D'Or Institute for Research and Education.
CR Azoulay E, 2015, BLOOD REV, V29, P359, DOI 10.1016/j.blre.2015.04.002
   Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365
   Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5
   Benoit DD, 2014, INTENS CARE MED, V40, P1576, DOI 10.1007/s00134-014-3480-8
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7
   Hawari FI, 2009, CRIT CARE MED, V37, P1967, DOI 10.1097/CCM.0b013e3181a0077c
   Kavanagh BP, 2016, AM J RESP CRIT CARE, V193, P17, DOI 10.1164/rccm.201502-0314CP
   Lecuyer L, 2008, EUR RESPIR J, V32, P748, DOI 10.1183/09031936.00142907
   MacLaren R, 2008, CRIT CARE MED, V36, P3184, DOI 10.1097/CCM.0b013e31818f2269
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Nazer Lama H, 2014, J Pharm Pract, V27, P208, DOI 10.1177/0897190013513302
   Nguyen YL, 2010, CURR OPIN CRIT CARE, V16, P487, DOI 10.1097/MCC.0b013e32833d9180
   Noritomi DT, 2014, INTENS CARE MED, V40, P182, DOI 10.1007/s00134-013-3131-5
   Ranzani OT, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0580-3
   Rhodes Andrew, 2012, Rev. bras. ter. intensiva, V24, P322, DOI 10.1590/S0103-507X2012000400005
   Rothen HU, 2007, INTENS CARE MED, V33, P1329, DOI 10.1007/s00134-007-0690-3
   Sakr Y, 2015, CRIT CARE MED, V43, P519, DOI 10.1097/CCM.0000000000000754
   Shih YCT, 2013, J CLIN ONCOL, V31, P4151, DOI 10.1200/JCO.2013.51.0651
   Soares M, 2014, ANN ONCOL, V25, P1829, DOI 10.1093/annonc/mdu234
   Soares M, 2015, INTENS CARE MED, V41, P2149, DOI 10.1007/s00134-015-4076-7
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Song JU, 2012, INTENS CARE MED, V38, P1505, DOI 10.1007/s00134-012-2594-0
   Vesin A, 2013, INTENS CARE MED, V39, P1396, DOI 10.1007/s00134-013-2949-1
   Vincent JL, 2014, LANCET RESP MED, V2, P380, DOI 10.1016/S2213-2600(14)70061-X
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zuber B, 2012, CRIT CARE MED, V40, P55, DOI 10.1097/CCM.0b013e31822d74ba
NR 27
TC 38
Z9 40
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 20
PY 2016
VL 34
IS 27
BP 3315
EP +
DI 10.1200/JCO.2016.66.9549
PG 12
WC Oncology
SC Oncology
GA DW9CN
UT WOS:000383952600014
PM 27432921
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Grinsztejn, B
AF Bozza, Fernando A.
   Grinsztejn, Beatriz
TI Key points on Zika infection for the intensivist
SO INTENSIVE CARE MEDICINE
LA English
DT Editorial Material
ID VIRUS-INFECTION; BRAZIL; OUTBREAK; STATES
C1 [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, HIV Lab, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cerbino-Neto J, 2016, EMERG INFECT DIS, V22, P1318, DOI 10.3201/eid2207.160375
   Cunha MS, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00032-16
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Roth A, 2014, EURO SURVEILL, V19
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
NR 15
TC 2
Z9 2
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2016
VL 42
IS 9
BP 1490
EP 1492
DI 10.1007/s00134-016-4378-4
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA DU2IJ
UT WOS:000382034200027
PM 27172823
OA Bronze
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Grinsztejn, B
AF Bozza, Fernando A.
   Grinsztejn, Beatriz
TI Key points on Zika infection for the intensivist (vol 42, pg 1490, 2016)
SO INTENSIVE CARE MEDICINE
LA English
DT Correction
C1 [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, HIV Lab, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Intens Care Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ini.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Bozza FA, 2016, INTENS CARE MED, V42, P1490, DOI 10.1007/s00134-016-4378-4
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2016
VL 42
IS 9
BP 1522
EP 1522
DI 10.1007/s00134-016-4408-2
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA DU2IJ
UT WOS:000382034200042
PM 27299353
OA Bronze
DA 2020-12-01
ER

PT J
AU Yende, S
   Austin, S
   Rhodes, A
   Finfer, S
   Opal, S
   Thompson, T
   Bozza, FA
   LaRosa, SP
   Ranieri, VM
   Angus, DC
AF Yende, Sachin
   Austin, Shamly
   Rhodes, Andrew
   Finfer, Simon
   Opal, Steven
   Thompson, Taylor
   Bozza, Fernando A.
   LaRosa, Steven P.
   Ranieri, V. Marco
   Angus, Derek C.
TI Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of
   Two International Trials
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE quality of life; sepsis
ID SEPTIC SHOCK; CRITICAL ILLNESS; ADULTS; BURDEN; CARE
AB Objectives: To describe the quality of life among sepsis survivors.
   Design: Secondary analyses of two international, randomized clinical trials (A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis [derivation cohort] and PROWESS-SHOCK [validation cohort]).
   Setting: ICUs in North and South America, Europe, Africa, Asia, and Australia.
   Patients: Adults with severe sepsis. We analyzed only patients who were functional and living at home without help before sepsis hospitalization (n = 1,143 and 987 from A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, respectively).
   Interventions: None.
   Measurements and Main Results: In A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, the average age of patients living at home independently was 63 and 61 years; 400 (34.9%) and 298 (30.2%) died by 6 months. In A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis, 580 patients had a quality of life measured using EQ-5D at 6 months. Of these, 41.6% could not live independently (22.7% were home but required help, 5.1% were in nursing home or rehabilitation facilities, and 5.3% were in acute care hospitals). Poor quality of life at 6 months, as evidenced by problems in mobility, usual activities, and self-care domains were reported in 37.4%, 43.7%, and 20.5%, respectively, and the high incidence of poor quality of life was also seen in patients in PROWESS-SHOCK. Over 45% of patients with mobility and self-care problems at 6 months in A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis died or reported persistent problems at 1 year.
   Conclusions: Among individuals enrolled in a clinical trial who lived independently prior to severe sepsis, one third had died and of those who survived, a further one third had not returned to independent living by 6 months. Both mortality and quality of life should be considered when designing new interventions and considering endpoints for sepsis trials.
C1 [Yende, Sachin; Austin, Shamly; Bozza, Fernando A.; Angus, Derek C.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illnes CRIS, Dept Crit Care Med, Pittsburgh, PA 15260 USA.
   [Yende, Sachin] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
   [Austin, Shamly] Gateway Hlth, Res & Dev, Qual Improvement Dept, Pittsburgh, PA USA.
   [Rhodes, Andrew] NHS Fdn Trust, St Georges Univ Hosp, Adult Crit Care, London, England.
   [Finfer, Simon] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia.
   [Opal, Steven] Brown Univ, Alpert Med Sch, Div Infect Dis, Pawtucket, RI USA.
   [Thompson, Taylor] Massachusetts Gen Hosp, Pulm & Crit Care Div, Boston, MA 02114 USA.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [LaRosa, Steven P.] Lahey Hlth Syst, Beverly Hosp, Beverly, MA USA.
   [Ranieri, V. Marco] Univ Sapienza Rome, Policlin Umberto I Hosp, Dept Anesthesia & Intens Care Med, Rome, Italy.
RP Yende, S (corresponding author), Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illnes CRIS, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Yende, S (corresponding author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
EM yendes@upmc.edu
RI Angus, Derek C/E-9671-2012; Bozza, Fernando A/A-2618-2013; Rhodes,
   Andrew/G-4265-2011; Austin, Shamly/AAG-1414-2020
OI Bozza, Fernando A/0000-0003-4878-0256; Rhodes,
   Andrew/0000-0002-8737-574X; Austin, Shamly/0000-0003-1307-9849
FU NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM097471,
   R01GM097471, R01GM097471, R01GM097471, R01GM097471, R01GM097471] Funding
   Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01 GM097471] Funding
   Source: Medline; Wellcome TrustWellcome Trust Funding Source: Medline
CR Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI 10.1056/NEJMra1208623
   Granja C, 2004, CRIT CARE, V8, pR91, DOI 10.1186/cc2818
   Hofhuis JGM, 2008, ANESTH ANALG, V107, P1957, DOI 10.1213/ane.0b013e318187bbd8
   Holland R, 2004, HEALTH ECON, V13, P793, DOI 10.1002/hec.858
   Iwashyna TJ, 2012, J AM GERIATR SOC, V60, P1070, DOI 10.1111/j.1532-5415.2012.03989.x
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Karlsson S, 2009, CRIT CARE MED, V37, P1268, DOI 10.1097/CCM.0b013e31819c13ac
   Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194
   Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290
   Shah FA, 2013, AM J RESP CRIT CARE, V188, P586, DOI 10.1164/rccm.201212-2154OC
   Winters BD, 2010, CRIT CARE MED, V38, P1276, DOI 10.1097/CCM.0b013e3181d8cc1d
NR 13
TC 87
Z9 92
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2016
VL 44
IS 8
BP 1461
EP 1467
DI 10.1097/CCM.0000000000001658
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA DS2RK
UT WOS:000380631000002
PM 26992066
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Rotman, V
   Carvalho, AR
   Rodrigues, RS
   Medeiros, DM
   Pinto, EC
   Bozza, FA
   Carvalho, CRR
AF Rotman, Vivian
   Carvalho, Alysson Roncally
   Rodrigues, Rosana Souza
   Medeiros, Denise Machado
   Pinto, Eduardo Costa
   Bozza, Fernando Augusto
   Ribeiro Carvalho, Carlos Roberto
TI Effects of the open lung concept following ARDSnet ventilation in
   patients with early ARDS
SO BMC ANESTHESIOLOGY
LA English
DT Article
DE Lung -adult respiratory distress syndrome; Measurement techniques -
   tomography; Ventilation - effects
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; MECHANICAL
   VENTILATION; RECRUITMENT MANEUVERS; INJURY; STRATEGY; HYPERINFLATION;
   STRETCH; TRIAL; CELLS
AB Background: Ventilation with low tidal volume (V-T) is well recognized as a protective approach to patients with acute respiratory distress syndrome (ARDS), but the optimal level of positive end-expiratory pressure (PEEP) remains uncertain. This study aims to evaluate two protective ventilatory strategies sequentially applied in patients with early ARDS.
   Methods: In this prospective cohort study, fifteen patients were ventilated during 24 h with positive end-expiratory pressure (PEEP) adjusted according to the ARDSnet low-PEEP table (ARDSnet-24 h). During the next 24 h, nine patients with PaO2/FIO2 ratio below 350 mmHg were ventilated with PEEP titrated according to the Open Lung Concept protocol (ARDSnet + OLC). In the other six patients, regardless of their PaO2/FIO2 ratio, the ARDSnet remained for a further 24 h (ARDSnet-48 h). Ventilatory variables, arterial blood-gas and cytokine were obtained at baseline, 24 and 48 h. Additionally, whole-lung-computed tomography was acquired at 24 and 48 h.
   Results: A sustained improvement in PaO2/FIO2 ratio (P = 0.008) with a decrease in collapsed regions (P = 0.008) was observed in the ARDSnet + OLC group compared with the ARDSnet-24 h group. A reduction in IL-6 in plasma (P < 0.02) was observed throughout the protocol in the ARDSnet + OLC group. Compared with the ARDSnet-48 h group, the ARDSnet + OLC presented smaller amounts of collapsed areas (P = 0.018) without significant differences in hyperinflated regions and in driving and plateau pressures.
   Conclusions: In this set of patients with early ARDS, mechanical ventilation with an individually tailored PEEP sustained improved pulmonary function with better aeration, without significant increase in hyperinflated areas".
C1 [Rotman, Vivian] Univ Fed Rio de Janeiro, Dept Internal Med, Rua Reseda 23-401, BR-22471230 Rio De Janeiro, Brazil.
   [Carvalho, Alysson Roncally] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Respirat Physiol, Rio De Janeiro, Brazil.
   [Rodrigues, Rosana Souza] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
   [Rodrigues, Rosana Souza; Bozza, Fernando Augusto] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Medeiros, Denise Machado; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Pinto, Eduardo Costa] Copa DOr Hosp, ICU, Rio De Janeiro, Brazil.
   [Ribeiro Carvalho, Carlos Roberto] Univ Sao Paulo, InCor Hosp Clin, Resp ICU, Sao Paulo, Brazil.
RP Rotman, V (corresponding author), Univ Fed Rio de Janeiro, Dept Internal Med, Rua Reseda 23-401, BR-22471230 Rio De Janeiro, Brazil.
EM vrotman@gmail.com
RI Bozza, Fernando A/A-2618-2013; rotman, vivian/AAF-9140-2020; Carvalho,
   Alysson/AAF-1022-2019; de Carvalho, Carlos Roberto Ribeiro/N-9827-2018
OI Bozza, Fernando A/0000-0003-4878-0256; de Carvalho, Carlos Roberto
   Ribeiro/0000-0002-1618-8509; Carvalho, Alysson/0000-0003-2708-7735
CR Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602
   Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-976OC
   Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Carvalho ARS, 2007, CRIT CARE, V11, DOI 10.1186/cc6093
   Constantin JM, 2010, CRIT CARE MED, V38, P1108, DOI 10.1097/CCM.0b013e3181d451ec
   de Matos GFJ, 2012, CRIT CARE, V16, DOI 10.1186/cc10602
   Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121
   Gattinoni L, 2008, JAMA-J AM MED ASSOC, V299, P691, DOI 10.1001/jama.299.6.691
   Gattinoni L, 2010, CURR OPIN CRIT CARE, V16, P39, DOI 10.1097/MCC.0b013e3283354723
   Grasso S, 2007, AM J RESP CRIT CARE, V176, P761, DOI 10.1164/rccm.200702-193OC
   IBA T, 1991, CIRC SHOCK, V35, P193
   Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104
   Kacmarek RM, 2007, RESP CARE, V52, P622
   LASSEN HCA, 1953, LANCET, V264, P37
   Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637
   Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646
   Priolet B, 2003, AM J RESP CRIT CARE, V167, P1717, DOI 10.1164/ajrccm.167.12.910
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54
   Rubenfeld GD, 2010, JAMA-J AM MED ASSOC, V303, P883, DOI 10.1001/jama.2010.226
   Slutsky A S, 2000, Respir Res, V1, P73, DOI 10.1186/rr15
   Suarez-Sipmann F, 2009, CRIT CARE, V13, DOI 10.1186/cc7763
   Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC
   Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01
   Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC
   Vlahakis NE, 1999, AM J PHYSIOL-LUNG C, V277, pL167
NR 28
TC 2
Z9 2
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2253
J9 BMC ANESTHESIOL
JI BMC Anesthesiol.
PD JUL 20
PY 2016
VL 16
DI 10.1186/s12871-016-0206-1
PG 10
WC Anesthesiology
SC Anesthesiology
GA DR6FU
UT WOS:000379998500001
PM 27439509
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cerbino-Neto, J
   Mesquita, EC
   Souza, TML
   Parreira, V
   Wittlin, BB
   Durovni, B
   Lemos, MCF
   Vizzoni, A
   de Filippis, AMB
   Sampaio, SA
   Goncalves, BD
   Bozza, FA
AF Cerbino-Neto, Jose
   Mesquita, Emersom Cicilini
   Souza, Thiago Moreno L.
   Parreira, Viviane
   Wittlin, Bernardo Bastos
   Durovni, Betina
   Ferreira Lemos, Maria Cristina
   Vizzoni, Alexandre
   Bispo de Filippis, Ana Maria
   Sampaio, Simone Alves
   Goncalves, Bianca de Santis
   Bozza, Fernando A.
TI Clinical Manifestations of Zika Virus Infection, Rio de Janeiro, Brazil,
   2015
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
ID TRANSMISSION; MICRONESIA; OUTBREAK
C1 [Cerbino-Neto, Jose; Mesquita, Emersom Cicilini; Souza, Thiago Moreno L.; Parreira, Viviane; Vizzoni, Alexandre; Bispo de Filippis, Ana Maria; Sampaio, Simone Alves; Goncalves, Bianca de Santis; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Wittlin, Bernardo Bastos; Durovni, Betina; Ferreira Lemos, Maria Cristina] Secretaria Municipal Saude Estado Rio de Janeiro, Rio De Janeiro, Brazil.
RP Cerbino-Neto, J (corresponding author), Inst Nacl Infectol Evandro Chagas INI Fiocruz, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM cerbino@fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Neto, Jose Cerbino/P-3713-2018; Souza,
   Thiago Moreno L./G-2900-2012; Vizzoni, Alexandre/W-8718-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Neto, Jose
   Cerbino/0000-0001-9254-917X; Souza, Thiago Moreno
   L./0000-0003-2212-3899; Vizzoni, Alexandre/0000-0003-0004-5084;
   Mesquita, Emersom/0000-0002-5132-3315
CR Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Martinez de Salazar P, 2016, ENFERM INFE IN PRESS
   Thomas DL, 2016, MMWR-MORBID MORTAL W, V65, P154, DOI 10.15585/mmwr.mm6506e2
   WHO, 2016, ZIK SIT REP
   World Health Organization, 2015, ZIK VIR DIS
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 10
TC 47
Z9 50
U1 0
U2 15
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD JUL
PY 2016
VL 22
IS 7
BP 1318
EP 1320
DI 10.3201/eid2207.160375
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DP5UR
UT WOS:000378563900041
PM 27070847
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Verdonk, F
   Roux, P
   Flamant, P
   Fiette, L
   Bozza, FA
   Simard, S
   Lemaire, M
   Plaud, B
   Shorte, SL
   Sharshar, T
   Chretien, F
   Danckaert, A
AF Verdonk, Franck
   Roux, Pascal
   Flamant, Patricia
   Fiette, Laurence
   Bozza, Fernando A.
   Simard, Sebastien
   Lemaire, Marc
   Plaud, Benoit
   Shorte, Spencer L.
   Sharshar, Tarek
   Chretien, Fabrice
   Danckaert, Anne
TI Phenotypic clustering: a novel method for microglial morphology analysis
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Microglial cell morphology; Neuroinflammation; Automated high-content
   analysis; Clustering; Sub-population behaviour; Complexity index
ID PREFRONTAL CORTEX; INFLAMMATORY RESPONSE; REGIONAL DIFFERENCE; BRAIN;
   CELLS; ACTIVATION; LIPOPOLYSACCHARIDE; EXPRESSION; RECEPTORS;
   NEUROINFLAMMATION
AB Background: Microglial cells are tissue-resident macrophages of the central nervous system. They are extremely dynamic, sensitive to their microenvironment and present a characteristic complex and heterogeneous morphology and distribution within the brain tissue. Many experimental clues highlight a strong link between their morphology and their function in response to aggression. However, due to their complex "dendritic-like" aspect that constitutes the major pool of murine microglial cells and their dense network, precise and powerful morphological studies are not easy to realize and complicate correlation with molecular or clinical parameters.
   Methods: Using the knock-in mouse model CX3CR1(GFP/+), we developed a 3D automated confocal tissue imaging system coupled with morphological modelling of many thousands of microglial cells revealing precise and quantitative assessment of major cell features: cell density, cell body area, cytoplasm area and number of primary, secondary and tertiary processes. We determined two morphological criteria that are the complexity index (CI) and the covered environment area (CEA) allowing an innovative approach lying in (i) an accurate and objective study of morphological changes in healthy or pathological condition, (ii) an in situ mapping of the microglial distribution in different neuroanatomical regions and (iii) a study of the clustering of numerous cells, allowing us to discriminate different sub-populations.
   Results: Our results on more than 20,000 cells by condition confirm at baseline a regional heterogeneity of the microglial distribution and phenotype that persists after induction of neuroinflammation by systemic injection of lipopolysaccharide (LPS). Using clustering analysis, we highlight that, at resting state, microglial cells are distributed in four microglial sub-populations defined by their CI and CEA with a regional pattern and a specific behaviour after challenge.
   Conclusions: Our results counteract the classical view of a homogenous regional resting state of the microglial cells within the brain. Microglial cells are distributed in different defined sub-populations that present specific behaviour after pathological challenge, allowing postulating for a cellular and functional specialization. Moreover, this new experimental approach will provide a support not only to neuropathological diagnosis but also to study microglial function in various disease models while reducing the number of animals needed to approach the international ethical statements.
C1 [Verdonk, Franck; Flamant, Patricia; Fiette, Laurence; Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Infect & Epidemiol Dept, Human Histopathol & Anim Models Unit, Paris, France.
   [Roux, Pascal; Simard, Sebastien; Shorte, Spencer L.; Danckaert, Anne] Imagopole CITech, Inst Pasteur, Paris, France.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, Rio De Janeiro, Brazil.
   [Verdonk, Franck; Lemaire, Marc] Paris Saclay Res Ctr, Med R&D, World Business Line Healthcare, Air Liquide Sante Int, 1 Chemin Porte Loges, Jouy En Josas, France.
   [Plaud, Benoit] St Louis Univ Hosp, Dept Anaesthesiol & Surg Intens Care, Paris, France.
   [Sharshar, Tarek] Raymond Poincare Univ Hosp, Dept Intens Care, Garches, France.
   [Chretien, Fabrice] Ctr Hosp St Anne, Lab Hosp Univ Neuropathol, Paris, France.
   [Sharshar, Tarek] Versailles St Quentin Univ, Versailles, France.
   [Plaud, Benoit] Paris Diderot Univ, Paris, France.
   [Chretien, Fabrice] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France.
   [Chretien, Fabrice] TRIGGERSEP, F CRIN Network, Toulouse, France.
RP Chretien, F (corresponding author), Inst Pasteur, Infect & Epidemiol Dept, Human Histopathol & Anim Models Unit, Paris, France.; Danckaert, A (corresponding author), Imagopole CITech, Inst Pasteur, Paris, France.; Chretien, F (corresponding author), Ctr Hosp St Anne, Lab Hosp Univ Neuropathol, Paris, France.; Chretien, F (corresponding author), Paris Descartes Univ, Sorbonne Paris Cite, Paris, France.; Chretien, F (corresponding author), TRIGGERSEP, F CRIN Network, Toulouse, France.
EM fabrice.chretien@pasteur.fr; anne.danckaert@pasteur.fr
RI Bozza, Fernando A/A-2618-2013; Chretien, fabrice/D-4035-2018
OI Bozza, Fernando A/0000-0003-4878-0256; Chretien,
   fabrice/0000-0002-2794-1383; Shorte, Spencer/0000-0002-2125-8663
FU Fondation des Gueules Cassees; Comite d'Interface SFAR (Societe
   Francaise d'Anesthesie-Reanimation); SRLF (Societe de Reanimation de
   Langue Francaise); INSERMInstitut National de la Sante et de la
   Recherche Medicale (Inserm); Fondation Pierre Deniker; ANRT (Association
   Nationale de la Recherche et de la Technologie) through an Air
   Liquide-CIFREFrench National Research Agency (ANR) [2012/1315]; French
   National Research AgencyFrench National Research Agency (ANR)
   [ANR-10-INSB-04-01]; Conseil de la Region Ile-de-FranceRegion
   Ile-de-France; Wellcome TrustWellcome Trust [095931/Z/11/Z]
FX This work was supported by the Fondation des Gueules Cassees, the Comite
   d'Interface SFAR (Societe Francaise d'Anesthesie-Reanimation), SRLF
   (Societe de Reanimation de Langue Francaise), INSERM and the Fondation
   Pierre Deniker. Franck Verdonk received financial support from ANRT
   (Association Nationale de la Recherche et de la Technologie) through an
   Air Liquide-CIFRE contract 2012/1315. The Imagopole is part of the
   France BioImaging infrastructure supported by the French National
   Research Agency (ANR-10-INSB-04-01, "Investments for the future") and is
   grateful for support from the Conseil de la Region Ile-de-France
   (programme Sesame 2007, project Imagopole, S.L. Shorte). SS's work was
   supported by the Wellcome Trust (095931/Z/11/Z; awardee Jason Swedlow,
   Dundee University and SLS local partner).
CR Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901
   Allan C, 2012, NAT METHODS, V9, P245, DOI [10.1038/nmeth.1896, 10.1038/NMETH.1896]
   Altschuler SJ, 2010, CELL, V141, P559, DOI 10.1016/j.cell.2010.04.033
   Arganda-Carreras I, 2010, MICROSC RES TECHNIQ, V73, P1019, DOI 10.1002/jemt.20829
   Avignone E, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0421-6
   Baron R, 2014, AGING CELL, V13, P584, DOI 10.1111/acel.12210
   Berry M, 2002, GREENFIELDS NEUROPAT, P75
   Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029
   Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
   Bonow RH, 2009, PHARMACOGENOMICS J, V9, P116, DOI 10.1038/tpj.2008.15
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   De Lucia C, 2016, BRAIN BEHAV IMMUN, V55, P179, DOI 10.1016/j.bbi.2015.11.001
   del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, V2, P482
   Dissing-Olesen L, 2014, J NEUROSCI, V34, P10511, DOI 10.1523/JNEUROSCI.0405-14.2014
   Doens D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-48
   Fan K, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0268-x
   Fourgeaud L, 2016, NATURE, V532, P240, DOI 10.1038/nature17630
   Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Hinwood M, 2013, CEREB CORTEX, V23, P1784, DOI 10.1093/cercor/bhs151
   Hirasawa T, 2005, J NEUROSCI RES, V81, P357, DOI 10.1002/jnr.20480
   Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101
   Ingalhalikar M, 2012, LECT NOTES COMPUT SC, V7511, P254, DOI 10.1007/978-3-642-33418-4_32
   Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Kim I, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.403
   Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000
   Kongsui R, 2015, NEUROSCIENCE, V310, P629, DOI 10.1016/j.neuroscience.2015.09.061
   Kongsui R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0182-7
   Kozlowski C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031814
   Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027
   LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W
   Lovatt D, 2014, NAT METHODS, V11, P190, DOI [10.1038/nmeth.2804, 10.1038/NMETH.2804]
   Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8
   More SV, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/952375
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Ohyu J, 1999, BRAIN DEV-JPN, V21, P248, DOI 10.1016/S0387-7604(99)00018-2
   Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529
   Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174
   Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015
   Pintado C, 2011, J NEUROIMMUNOL, V238, P44, DOI 10.1016/j.jneuroim.2011.06.017
   Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184
   Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467
   Scheffel J, 2012, GLIA, V60, P1930, DOI 10.1002/glia.22409
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9
   Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J
   Sun J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0394-5
   Thrane VR, 2012, NEUROSCIENCE, V220, P247, DOI 10.1016/j.neuroscience.2012.06.022
   Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12
   Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527
   Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358
   Umekawa T, 2015, GLIA, V63, P2220, DOI 10.1002/glia.22887
   Vallotton P, 2007, CYTOM PART A, V71A, P889, DOI 10.1002/cyto.a.20462
   Valous NA, 2013, J NEUROSCI METH, V213, P250, DOI 10.1016/j.jneumeth.2012.12.017
   VELA JM, 1995, J COMP NEUROL, V361, P602, DOI 10.1002/cne.903610405
   Walker FR, 2013, CURR DRUG TARGETS, V14, P1262
NR 60
TC 30
Z9 30
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUN 17
PY 2016
VL 13
AR 153
DI 10.1186/s12974-016-0614-7
PG 15
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA DQ0BF
UT WOS:000378861600003
PM 27317566
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Pecego, AC
   Amancio, RT
   Ribeiro, C
   Mesquita, EC
   Medeiros, DM
   Cerbino, J
   Grinsztejn, B
   Bozza, FA
   Japiassu, AM
AF Pecego, Ana Carla
   Amancio, Rodrigo T.
   Ribeiro, Camila
   Mesquita, Emersom C.
   Medeiros, Denise M.
   Cerbino, Jose
   Grinsztejn, Beatriz
   Bozza, Fernando A.
   Japiassu, Andre M.
TI Six-month survival of critically ill patients with HIV-related disease
   and tuberculosis: a retrospective study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; AIDS; Tuberculosis; Critical care; Patient outcome
ID INTENSIVE-CARE-UNIT; ACTIVE ANTIRETROVIRAL THERAPY; RIO-DE-JANEIRO;
   IMMUNODEFICIENCY-VIRUS-INFECTION; ACUTE RESPIRATORY-FAILURE; LONG-TERM
   SURVIVAL; PULMONARY TUBERCULOSIS; ORGAN DYSFUNCTION/FAILURE;
   PROGNOSTIC-FACTORS; ICU
AB Background: Tuberculosis is one of the leading causes of death from infectious diseases worldwide, mainly after the human immunodeficiency virus (HIV) epidemics. Patient with HIV-related illness are more likely to present with severe TB due to immunosuppression. Very few studies have explored HIV/TB co-infection in critically ill patients. The goal of this study was to analyze factors associated with long-term mortality in critically ill patient with HIV-related disease coinfected with TB.
   Methods: We conducted a retrospective study in an infectious disease reference center in Brazil that included all patient with HIV-related illness admitted to the ICU with laboratory-confirmed tuberculosis from March 2007 until June 2012. Clinical and laboratory variables were analyzed based on six-month survival.
   Results: Forty-four patients with HIV-related illness with a confirmed diagnosis of tuberculosis were analyzed. The six-month mortality was 52 % (23 patients). The main causes of admission were respiratory failure (41 %), severe sepsis/septic shock (32 %) and coma/torpor (14 %). The median time between HIV diagnosis and ICU admission was 5 (1-60) months, and 41 % of patients received their HIV infection diagnosis = 30 days before admission. The median CD4 count was 72 (IQR: 23-136) cells/mm(3). The clinical presentation was pulmonary tuberculosis in 22 patients (50 %) and disseminated TB in 20 patients (45.5 %). No aspect of TB diagnosis or treatment was different between survivors and nonsurvivors. Neurological dysfunction was more prevalent among nonsurvivors (43 % vs. 14 %, p = 0.04). The nadir CD4 cell count lower than 50 cells/mm3 was independently associated with Six-month mortality (hazard ratio 4.58 [1.64-12.74], p < 0.01), while HIV diagnosis less than three months after positive serology was protective (hazard ratio 0.27, CI 95 % [0.10-0.72], p = 0.01).
   Conclusion: The Six-month mortality of HIV critically ill patients with TB coinfection is high and strongly associated with the nadir CD4 cell count less than 50 cels/mm(3).
C1 [Pecego, Ana Carla; Amancio, Rodrigo T.; Ribeiro, Camila; Mesquita, Emersom C.; Medeiros, Denise M.; Cerbino, Jose; Bozza, Fernando A.; Japiassu, Andre M.] Natl Inst Infect Dis, Intens Care Clin Res Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Natl Inst Infect Dis, STD AIDS Clin Res Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, RJ, Brazil.
RP Japiassu, AM (corresponding author), Natl Inst Infect Dis, Intens Care Clin Res Lab, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM andrejapi@gmail.com
RI Neto, Jose Cerbino/P-3713-2018; Bozza, Fernando A/A-2618-2013; MIZEKA,
   PANU/A-3952-2017
OI Neto, Jose Cerbino/0000-0001-9254-917X; Bozza, Fernando
   A/0000-0003-4878-0256; Mesquita, Emersom/0000-0002-5132-3315; Pecego da
   Silva, Ana Carla/0000-0002-4131-1425
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Research Funding Agency of the State of Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476] Funding Source: NIH RePORTER
FX National Council of Technological and Scientific Development (CNPq).;
   Research Funding Agency of the State of Rio de Janeiro (FAPERJ).
CR Afessa B, 2000, CHEST, V118, P138, DOI 10.1378/chest.118.1.138
   Alshimemeri A A, 2011, CRIT CARE SHOCK, V14, P1
   Amancio FF, 2012, INT J STD AIDS, V23, P692, DOI 10.1258/ijsa.2012.011389
   Amancio RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068730
   Balkema CA, 2014, INT J TUBERC LUNG D, V18, P824, DOI 10.5588/ijtld.13.0044
   Barbier F, 2009, INTENS CARE MED, V35, P1678, DOI 10.1007/s00134-009-1559-4
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2011, MAN REC CONTR TUB A
   Bray S, 2012, HIV AIDS-RES PALLIAT, V4, P135, DOI 10.2147/HIV.S35374
   Burman W, 2007, INT J TUBERC LUNG D, V11, P1282
   Cardoso SW, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0699-5
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Casalino E, 1998, CHEST, V113, P421, DOI 10.1378/chest.113.2.421
   Chiang HH, 2011, CRIT CARE, V15, DOI 10.1186/cc10419
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   Corona A, 2009, CURR HIV RES, V7, P569, DOI 10.2174/157016209789973592
   Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7
   Crump JA, 2012, CLIN INFECT DIS, V55, P242, DOI 10.1093/cid/cis409
   Dickson SJ, 2007, THORAX, V62, P964, DOI 10.1136/thx.2006.072256
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Erbes R, 2006, EUR RESPIR J, V27, P1223, DOI 10.1183/09031936.06.00088105
   Gary J, 2013, SEMIN RESP CRIT CARE, V34
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Hagan G, 2013, CRIT CARE, V17, DOI 10.1186/cc12760
   Holland DP, 2009, PHARMACOTHERAPY, V29, P503, DOI 10.1592/phco.29.5.503
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kim YJ, 2008, EUR RESPIR J, V32, P1625, DOI 10.1183/09031936.00070907
   Kogmar S, 2013, PLOS ONE, V8
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lockman S, 2003, INT J TUBERC LUNG D, V7, P714
   Meybeck A, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-27
   Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005
   Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931
   Morris A, 2006, CRIT CARE MED, V34, P42, DOI 10.1097/01.CCM.0000194539.50905.81
   Morris AM, 2000, AM J RESP CRIT CARE, V162, P612, DOI 10.1164/ajrccm.162.2.9912058
   Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
   Nickas G, 2000, ARCH INTERN MED, V160, P541, DOI 10.1001/archinte.160.4.541
   Nicolls DJ, 2005, LANCET INFECT DIS, V5, P795, DOI 10.1016/S1473-3099(05)70299-1
   Orsini J, 2013, INTERDISCIP PERSPECT, V2013
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003132
   Pawlowski A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002464
   Powell K, 2009, CHEST, V135, P11, DOI 10.1378/chest.08-0980
   Sarkar P, 2013, CRIT CARE, V17, DOI 10.1186/cc12552
   Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR
   Silva DR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-54
   Silva DR, 2012, J BRAS PNEUMOL, V38, P386, DOI 10.1590/S1806-37132012000300015
   Sonneville R, 2011, J INFECTION, V62, P301, DOI 10.1016/j.jinf.2011.02.003
   Thwaites GE, 2013, LANCET NEUROL, V12, P999, DOI 10.1016/S1474-4422(13)70168-6
   Torok ME, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001772
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Waddell RD, 2001, AIDS, V15, P55, DOI 10.1097/00002030-200101050-00009
   WHO, GLOB TUB REP 2014
   Wilkinson KA, 2012, SAMJ S AFR MED J, V102, P512, DOI 10.7196/SAMJ.5358
   World Health Organization. Communicable Diseases Cluster Stop TB Department, 2011, UN ACC DIAGN TREATM
   Wunderink RG, 2012, AM J RESP CRIT CARE, V185, P1261, DOI 10.1164/rccm.201203-0540UP
   Zahar JR, 2001, INTENS CARE MED, V27, P513, DOI 10.1007/s001340000849
   Zumla A, 2013, NEW ENGL J MED, V368, P745, DOI 10.1056/NEJMra1200894
NR 58
TC 5
Z9 5
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 10
PY 2016
VL 16
AR 270
DI 10.1186/s12879-016-1644-6
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA DO7FY
UT WOS:000377949000001
PM 27286652
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cavalcanti, AB
   Bozza, FA
   Machado, FR
   Salluh, JIF
   Campagnucci, VP
   Vendramim, P
   Guimaraes, HP
   Normilio-Silva, K
   Damiani, LP
   Romano, E
   Carrara, F
   de Souza, JLD
   Silva, AR
   Ramos, GV
   Teixeira, C
   da Silva, NB
   Chang, CCH
   Angus, DC
   Berwanger, O
AF Cavalcanti, Alexandre B.
   Bozza, Fernando Augusto
   Machado, Flavia R.
   Salluh, Jorge I. F.
   Campagnucci, Valquiria Pelisser
   Vendramim, Patricia
   Guimaraes, Helio Penna
   Normilio-Silva, Karina
   Damiani, Lucas Petri
   Romano, Edson
   Carrara, Fernanda
   Diniz de Souza, Juliana Lubarino
   Silva, Aline Reis
   Ramos, Grazielle Viana
   Teixeira, Cassiano
   da Silva, Nilton Brandao
   Chang, Chung-Chou H.
   Angus, Derek C.
   Berwanger, Otavio
CA Writing Grp CHECKLIST-ICU
   Brazilian Res Intensive Care
TI Effect of a Quality Improvement Intervention With Daily Round
   Checklists, Goal Setting, and Clinician Prompting on Mortality of
   Critically Ill Patients A Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID BLOOD-STREAM INFECTIONS; INTENSIVE-CARE UNITS; SAFETY CHECKLISTS; SEVERE
   SEPSIS; GUIDELINES; CRITERIA; OUTCOMES
AB IMPORTANCE The effectiveness of checklists, daily goal assessments, and clinician prompts as quality improvement interventions in intensive care units (ICUs) is uncertain.
   OBJECTIVE To determine whether a multifaceted quality improvement intervention reduces the mortality of critically ill adults.
   DESIGN, SETTING, AND PARTICIPANTS This study had 2 phases. Phase 1 was an observational study to assess baseline data on work climate, care processes, and clinical outcomes, conducted between August 2013 and March 2014 in 118 Brazilian ICUs. Phase 2 was a cluster randomized trial conducted between April and November 2014 with the same ICUs. The first 60 admissions of longer than 48 hours per ICU were enrolled in each phase.
   INTERVENTIONS Intensive care units were randomized to a quality improvement intervention, including a daily checklist and goal setting during multidisciplinary rounds with follow-up clinician prompting for 11 care processes, or to routine care.
   MAIN OUTCOMES AND MEASURES In-hospital mortality truncated at 60 days (primary outcome) was analyzed using a random-effects logistic regression model, adjusted for patients' severity and the ICU's baseline standardized mortality ratio. Exploratory secondary outcomes included adherence to care processes, safety climate, and clinical events.
   RESULTS A total of 6877 patients (mean age, 59.7 years; 3218 [46.8%] women) were enrolled in the baseline (observational) phase and 6761 (mean age, 59.6 years; 3098 [45.8%] women) in the randomized phase, with 3327 patients enrolled in ICUs (n = 59) assigned to the intervention group and 3434 patients in ICUs (n = 59) assigned to routine care. There was no significant difference in in-hospital mortality between the intervention group and the usual care group, with 1096 deaths (32.9%) and 1196 deaths (34.8%), respectively (odds ratio, 1.02; 95% CI, 0.82-1.26; P = .88). Among 20 prespecified secondary outcomes not adjusted for multiple comparisons, 6 were significantly improved in the intervention group (use of low tidal volumes, avoidance of heavy sedation, use of central venous catheters, use of urinary catheters, perception of team work, and perception of patient safety climate), whereas there were no significant differences between the intervention group and the control group for 14 outcomes (ICU mortality, central line-associated bloodstream infection, ventilator-associated pneumonia, urinary tract infection, mean ventilator-free days, mean ICU length of stay, mean hospital length of stay, bed elevation to >= 30 degrees, venous thromboembolism prophylaxis, diet administration, job satisfaction, stress reduction, perception of management, and perception of working conditions).
   CONCLUSIONS AND RELEVANCE Among critically ill patients treated in ICUs in Brazil, implementation of a multifaceted quality improvement intervention with daily checklists, goal setting, and clinician prompting did not reduce in-hospital mortality.
C1 [Cavalcanti, Alexandre B.; Guimaraes, Helio Penna; Normilio-Silva, Karina; Damiani, Lucas Petri; Romano, Edson; Berwanger, Otavio] HCor Hosp Coracao, Res Inst, Rua Abilio Soares 250,12th Floor, BR-04005000 Sao Paulo, SP, Brazil.
   [Bozza, Fernando Augusto; Salluh, Jorge I. F.; Silva, Aline Reis; Ramos, Grazielle Viana] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Machado, Flavia R.; Carrara, Fernanda; Diniz de Souza, Juliana Lubarino] Latin Amer Sepsis Inst, Sao Paulo, Brazil.
   [Campagnucci, Valquiria Pelisser; Vendramim, Patricia] Hosp Samaritano, Sao Paulo, Brazil.
   [Teixeira, Cassiano; da Silva, Nilton Brandao] Hosp Moinhos Vento, Porto Alegre, RS, Brazil.
   [Chang, Chung-Chou H.; Angus, Derek C.] Univ Pittsburgh, Pittsburgh, PA USA.
RP Cavalcanti, AB (corresponding author), HCor Hosp Coracao, Res Inst, Rua Abilio Soares 250,12th Floor, BR-04005000 Sao Paulo, SP, Brazil.
EM abiasi@hcor.com.br
RI dantas, vicente c souza/L-2648-2013; Borges, Marcos
   Carvalho/A-3585-2014; Angus, Derek C/E-9671-2012; Teixeira,
   Cassiano/V-8764-2019; Bozza, Fernando A/A-2618-2013; Guimaraes, Helio
   Penna/AAD-8681-2019; Cavalcanti, Alexandre/K-5529-2013; Damiani,
   Lucas/F-8576-2015
OI Borges, Marcos Carvalho/0000-0001-6280-0714; Bozza, Fernando
   A/0000-0003-4878-0256; Cavalcanti, Alexandre/0000-0003-2798-6263;
   Damiani, Lucas/0000-0002-5836-3379; Pereira da Silva,
   Eliane/0000-0002-3364-5046
FU Brazilian Health Surveillance Agency (ANVISA); PROADI; Brazilian
   Development Bank (BNDES); D'Or Institute for Research and Education
FX This study was conducted as part of the Program to Support Institutional
   Development of Universal Health System (PROADI) from the Brazilian
   Ministry of Health. It was funded mainly by the Brazilian Health
   Surveillance Agency (ANVISA), PROADI, and Brazilian Development Bank
   (BNDES). D'Or Institute for Research and Education also contributed with
   additional funding.
CR Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1
   [Anonymous], SURV VENT ASS EV
   Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Bion J, 2013, BMJ QUAL SAF, V22, P110, DOI 10.1136/bmjqs-2012-001325
   BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502
   Carvalho REFL, 2011, ADAPTACAO TRANSCULTU
   Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475
   Damiani LP, 2015, CRIT CARE RESUSC, V17, P113
   Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af
   Dondorpa AM, 2014, T ROY SOC TROP MED H, V108, P453, DOI 10.1093/trstmh/tru099
   DuBose J, 2010, J TRAUMA, V69, P855, DOI 10.1097/TA.0b013e3181c4526f
   Finkelstein A, 2015, SCIENCE, V347, P720, DOI 10.1126/science.aaa2362
   Giraudeau B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040436
   Rigobello MCG, 2012, ACTA PAUL ENFERM, V25, P728, DOI 10.1590/S0103-21002012000500013
   Harhay MO, 2014, AM J RESP CRIT CARE, V189, P1469, DOI 10.1164/rccm.201401-0056CP
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Healthcare Infection Control Practices Advisory Committee, GUID PREV CATH ASS U
   Hofstede G, 2010, CULTURES ORG SOFTWAR, V3
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Klompas M, 2014, INFECT CONT HOSP EP, V35, P915, DOI [10.1017/S0899823X00193894, 10.1086/677144]
   Ko HCH, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-211
   Leon AC, 2005, J BIOPHARM STAT, V15, P839, DOI 10.1081/BIP-200067922
   Machado F, 2015, IMPLEMENT SCI, V10, P8
   Marsteller JA, 2012, CRIT CARE MED, V40, P2933, DOI 10.1097/CCM.0b013e31825fd4d8
   Niel-Weise BS, 2011, CRIT CARE, V15, DOI 10.1186/cc10135
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   Russ S, 2013, ANN SURG, V258, P856, DOI 10.1097/SLA.0000000000000206
   Scales DC, 2011, JAMA-J AM MED ASSOC, V305, P363, DOI 10.1001/jama.2010.2000
   Sexton JB, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-44
   Urbach DR, 2014, NEW ENGL J MED, V370, P1029, DOI 10.1056/NEJMsa1308261
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Vincent JL, 2005, CRIT CARE MED, V33, P1225, DOI 10.1097/01.CCM.0000165962.16682.46
   Walsh TS, 2004, BRIT J ANAESTH, V92, P793, DOI 10.1093/bja/aeh139
   Weiss CH, 2011, AM J RESP CRIT CARE, V184, P680, DOI 10.1164/rccm.201101-0037OC
NR 37
TC 66
Z9 68
U1 1
U2 27
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 12
PY 2016
VL 315
IS 14
BP 1480
EP 1490
DI 10.1001/jama.2016.3463
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ0EE
UT WOS:000373873800014
PM 27115264
OA Bronze
DA 2020-12-01
ER

PT J
AU Cavalcanti, AB
   Damiani, LP
   Bozza, FA
AF Cavalcanti, Alexandre B.
   Damiani, Lucas P.
   Bozza, Fernando A.
TI Acute Kidney Injury With Buffered Crystalloids vs Saline Among ICU
   Patients
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Cavalcanti, Alexandre B.; Damiani, Lucas P.] Hosp Coracao, Res Inst, Rua Abilio Soares 250,12th Floor, BR-04005000 Sao Paulo, SP, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Cavalcanti, AB (corresponding author), Hosp Coracao, Res Inst, Rua Abilio Soares 250,12th Floor, BR-04005000 Sao Paulo, SP, Brazil.
EM abiasi@hcor.com.br
RI Bozza, Fernando A/A-2618-2013; Damiani, Lucas/F-8576-2015; Cavalcanti,
   Alexandre/K-5529-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Damiani,
   Lucas/0000-0002-5836-3379; Cavalcanti, Alexandre/0000-0003-2798-6263
CR Donner A., 2000, DESIGN ANAL CLUSTER
   Forbes AB, 2015, CLIN TRIALS, V12, P34, DOI 10.1177/1740774514559610
   Wellington Intensive Care Unit, STAT AN PLAN 0 9 SAL
   Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334
NR 4
TC 4
Z9 4
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 12
PY 2016
VL 315
IS 14
BP 1520
EP 1520
DI 10.1001/jama.2016.0154
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DJ0EE
UT WOS:000373873800024
PM 27115274
DA 2020-12-01
ER

PT J
AU Torrentes-Carvalho, A
   Hottz, ED
   Marinho, CF
   da Silva, JBC
   Pinto, LMD
   Fialho, LG
   Bozza, FA
   Cunha, RV
   Damasco, PV
   Kubelka, CF
   de Azeredo, EL
AF Torrentes-Carvalho, Amanda
   Hottz, Eugenio Damaceno
   Marinho, Cintia Ferreira
   da Silva, Jessica Badolato-Correa
   de Oliveira Pinto, Luzia Maria
   Fialho, Luciana Gomes
   Bozza, Fernando Augusto
   Cunha, Rivaldo Venancio
   Damasco, Paulo Vieira
   Kubelka, Claire Fernandes
   de Azeredo, Elzinandes Leal
TI Characterization of clinical and immunological features in patients
   coinfected with dengue virus and HIV
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Coinfection; Lymphocytes; Cytokines; Dengue; HIV
ID RIO-DE-JANEIRO; INFECTED PATIENTS; HEMORRHAGIC-FEVER; CYTOKINE PATTERNS;
   CXCR4 EXPRESSION; SERUM-LEVELS; IFN-GAMMA; T-CELLS; IL-10; MARKERS
AB The pathogenesis of dengue in subjects coinfected with HIV remains largely unknown. We investigate clinical and immunological parameters in coinfected DENV/HIV patients. According to the new dengue classification, most coinfected DENV/HIV patients presented mild clinical manifestations of dengue infection. Herein, we show that DENV/HIV coinfected patients had higher CD8 T cells percentages reflected as a lower CD4/CD8 ratio. Furthermore, CCR5 expression on CD4 T cells and CD107a expression on both T subsets were significantly higher in coinfected patients when compared with monoinfected DENV and HIV individuals respectively. Increased inflammatory response was observed in treated HAART coinfected patients despite undetectable HIV load. These data indicate that DENV infection may influence the clinical profile and immune response in individuals concomitantly infected with HIV. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Torrentes-Carvalho, Amanda; Marinho, Cintia Ferreira; da Silva, Jessica Badolato-Correa; de Oliveira Pinto, Luzia Maria; Fialho, Luciana Gomes; Kubelka, Claire Fernandes; de Azeredo, Elzinandes Leal] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunol Viral, BR-21045900 Rio De Janeiro, Brazil.
   [Hottz, Eugenio Damaceno; Bozza, Fernando Augusto] Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, Brazil.
   [Cunha, Rivaldo Venancio] Univ Fed Mato Grosso do Sul, FM, Dept Clin Med, Campo Grande, MS, Brazil.
   [Damasco, Paulo Vieira] Univ Fed Estado Rio de Janeiro UNI RIO, Hosp Univ Gaffree Guinle, Rio De Janeiro, Brazil.
RP Torrentes-Carvalho, A; de Azeredo, EL (corresponding author), Lab Imunol Viral, Ave Brasil,4365 Manguinhos, BR-2104360 Rio De Janeiro, Brazil.
EM biotorrentes@gmail.com; elzinandes@ioc.fiocruz.br
RI /AAD-2097-2020; Kubelka, Claire F/C-5558-2009; Hottz, Eugenio
   D/I-9850-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU IOC; PAPES/FIOCRUZ; CNPq/DECITNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX We gratefully thank Dr Ana Rita Motta Castro and her team, for their
   help and assistance with patient recruitment and sample collection; to
   Daniela Beghini for the help in the FACS CyAn facility; and MSc Marcio
   Cipitelli for assembly and resolution of figures. We are indebted to the
   Flavivirus Laboratory team at FIOCRUZ-RJ, especially Jaqueline Bastos
   Simoes and MSc Fernanda Bruycker. We also would like to thank the
   Institute of Clinical Research Evandro Chagas for laboratory diagnosis
   of dengue and coinfected cases. We gratefully acknowledge the
   voluntarily participation from patients and healthy individuals in this
   study. This work was financially supported by IOC and PAPES/FIOCRUZ,
   CNPq/DECIT and FAPERJ.
CR Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brites-Alves C, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/174215
   Brockman MA, 2009, BLOOD, V114, P346, DOI 10.1182/blood-2008-12-191296
   Carpenter AC, 2010, NAT IMMUNOL, V11, P666, DOI 10.1038/ni.1887
   Catalfamo M, 2012, CYTOKINE GROWTH F R, V23, P207, DOI 10.1016/j.cytogfr.2012.05.007
   Chaturvedi UC, 2000, FEMS IMMUNOL MED MIC, V28, P183, DOI 10.1111/j.1574-695X.2000.tb01474.x
   Chen RF, 2005, FEMS IMMUNOL MED MIC, V44, P43, DOI 10.1016/j.femsim.2004.11.012
   CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3
   Faria NRD, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002095
   Daumas RP, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-77
   de Azeredo EL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/313842
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Ebert LM, 2002, J IMMUNOL, V168, P65, DOI 10.4049/jimmunol.168.1.65
   Frahm MA, 2012, J IMMUNOL, V188, P4289, DOI 10.4049/jimmunol.1103701
   Freed EO, 2004, TRENDS MICROBIOL, V12, P170, DOI 10.1016/j.tim.2004.02.001
   Freeman M.L., 2015, CLIN INFECT DIS
   Gonzalez D, 2009, J INFECT DEV COUNTR, V3, P318
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9
   Hattori J, 2007, MICROBIOL IMMUNOL, V51, P193, DOI 10.1111/j.1348-0421.2007.tb03901.x
   Kadhiravan T, 2010, IMMUNE NETW, V10, P164
   Kamat A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030881
   Kedzierska Katherine, 2001, Antiviral Chemistry and Chemotherapy, V12, P133
   Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093
   Limonta D, 2014, J MED VIROL, V86, P1437, DOI 10.1002/jmv.23832
   Macedo GA, 2013, T ROY SOC TROP MED H, V107, P141, DOI 10.1093/trstmh/trs091
   McLinden JH, 2008, J INFECT DIS, V198, P860, DOI 10.1086/591254
   Mendes WDS, 2006, AM J TROP MED HYG, V74, P905
   Ministerio da Saude, 2015, B EPIDEMIOL, V46
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Nicholson JKA, 2001, J ACQ IMMUN DEF SYND, V27, P105, DOI 10.1097/00126334-200106010-00002
   O'Bryan Thomas A, 2015, BMC Res Notes, V8, P595, DOI 10.1186/s13104-015-1548-3
   Pandey N, 2015, ARCH VIROL, V160, P1463, DOI 10.1007/s00705-015-2410-6
   Pang JX, 2015, AM J TROP MED HYG, V92, P1156, DOI 10.4269/ajtmh.15-0031
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   Picker LJ, 2012, ANNU REV MED, V63, P95, DOI 10.1146/annurev-med-042010-085643
   Pierdominici M, 2002, J ACQ IMMUN DEF SYND, V29, P122, DOI 10.1097/00042560-200202010-00003
   Lima MDQ, 2014, J VIROL METHODS, V204, P105, DOI 10.1016/j.jviromet.2014.02.031
   Rachman Andhika, 2006, Acta Med Indones, V38, P105
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Roe B, 2007, J INFECT DIS, V196, P1053, DOI 10.1086/520935
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Serrano-Villar S, 2014, HIV MED, V15, P40, DOI 10.1111/hiv.12081
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Servais J, 2001, J ACQ IMMUN DEF SYND, V28, P221, DOI 10.1097/00042560-200111010-00003
   Shive CL, 2014, J INFECT DIS, V210, P619, DOI 10.1093/infdis/jiu125
   Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x
   Siong Wong Chia, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P260
   Srikiatkhachorn A, 2010, CURR TOP MICROBIOL, V338, P67, DOI 10.1007/978-3-642-02215-9_6
   Stapleton JT, 2004, J CLIN MICROBIOL, V42, P3915, DOI 10.1128/JCM.42.9.3915-3919.2004
   Stylianou E, 2000, CLIN EXP IMMUNOL, V119, P479, DOI 10.1046/j.1365-2249.2000.01144.x
   Stylianou E, 1999, CLIN EXP IMMUNOL, V116, P115
   Suharti C, 2003, EUR CYTOKINE NETW, V14, P172
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
   Torrentes-Carvalho A., 2014, REV IMMUNOLOGY UNPUB
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   Verhagen LM, 2014, J INFECTION, V69, pS77, DOI 10.1016/j.jinf.2014.07.020
   Watt G, 2003, CLIN INFECT DIS, V36, P1067, DOI 10.1086/374600
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wilson EB, 2011, CURR TOP MICROBIOL, V350, P39, DOI 10.1007/82_2010_96
   Ferreira RAX, 2015, ACTA TROP, V149, P138, DOI 10.1016/j.actatropica.2015.04.023
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
   Zhang W, 2003, NAT STRUCT BIOL, V10, P907, DOI 10.1038/nsb990
NR 71
TC 9
Z9 9
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD MAR
PY 2016
VL 164
BP 95
EP 105
DI 10.1016/j.clim.2016.01.005
PG 11
WC Immunology
SC Immunology
GA DH3CT
UT WOS:000372665800013
PM 26826597
DA 2020-12-01
ER

PT J
AU Sharshar, T
   Polito, A
   Bozza, F
   Chretien, F
AF Sharshar, Tarek
   Polito, Andrea
   Bozza, Fernando
   Chretien, Fabrice
TI Statins and brain dysfunction in intensive care
SO LANCET RESPIRATORY MEDICINE
LA English
DT Editorial Material
ID DELIRIUM; DEATH
C1 [Sharshar, Tarek; Polito, Andrea] Univ Versailles St Quentin En Yvelines, Raymond Poincare Hosp, AP HP, Gen Intens Care Med, F-92380 Paris, France.
   [Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Dept Histopathol & Anim Models, Paris, France.
   [Bozza, Fernando] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bozza, Fernando] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RP Sharshar, T (corresponding author), Univ Versailles St Quentin En Yvelines, Raymond Poincare Hosp, AP HP, Gen Intens Care Med, F-92380 Paris, France.; Sharshar, T (corresponding author), Inst Pasteur, Dept Histopathol & Anim Models, Paris, France.
EM tarek.sharshar@rpc.aphp.fr
RI Bozza, Fernando A/A-2618-2013; Chretien, fabrice/D-4035-2018
OI Bozza, Fernando A/0000-0003-4878-0256; Chretien,
   fabrice/0000-0002-2794-1383
CR Annane D, 2015, LANCET RESP MED, V3, P61, DOI 10.1016/S2213-2600(14)70246-2
   Azabou E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139969
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Morandi A, 2014, CRIT CARE MED, V42, P1899, DOI 10.1097/CCM.0000000000000398
   Needham DM, 2016, LANCET RESP MED
   Page VJ, 2014, AM J RESP CRIT CARE, V189, P666, DOI 10.1164/rccm.201306-1150OC
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099
   Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4
   Sharshar T, 2011, CRIT CARE MED, V39, P1960, DOI 10.1097/CCM.0b013e31821b843b
   Thomas G, 2015, MINERVA ANESTESIOL, V81, P921
   Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1
NR 13
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD MAR
PY 2016
VL 4
IS 3
BP 169
EP 170
DI 10.1016/S2213-2600(16)00028-X
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DG0JK
UT WOS:000371750900004
PM 26832962
DA 2020-12-01
ER

PT J
AU Zamith-Miranda, D
   Palma, ML
   Matos, GS
   Schiebel, JG
   Maya-Monteiro, CM
   Aronovich, M
   Bozza, PT
   Bozza, FA
   Nimrichter, L
   Montero-Lomeli, M
   Marques, ETA
   Martins, FS
   Douradinha, B
AF Zamith-Miranda, Daniel
   Palma, Mariana L.
   Matos, Gabriel S.
   Schiebel, Johnathon G.
   Maya-Monteiro, Clarissa M.
   Aronovich, Marcos
   Bozza, Patricia T.
   Bozza, Fernando A.
   Nimrichter, Leonardo
   Montero-Lomeli, Monica
   Marques, Ernesto T. A., Jr.
   Martins, Flaviano S.
   Douradinha, Bruno
TI Lipid droplet levels vary heterogeneously in response to simulated
   gastrointestinal stresses in different probiotic Saccharomyces
   cerevisiae strains
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Saccharomyces cerevisiae var boulardii; Saccharomyces cerevisiae;
   Probiotics; Lipid droplets; Gastrointestinal tract stresses; Stress
   resistance
ID YEAST STRAINS; CELL-DEATH; BOULARDII; VIABILITY; LIPOLYSIS; PRODUCTS;
   IMMUNITY; SYSTEM; TRACT; S288C
AB To exert their therapeutic action, probiotic Saccharomyces cerevisiae strains must survive harsh digestive environments. Lipid droplets accumulate in cells which undergo stress-inducing situations, supposedly having a protective role. We assessed lipid droplet levels, either naturally accumulated or induced in response to digestive challenges, of probiotic strains S. boulardii, S. cerevisiae A-905, S. cerevisiae Sc47 and S. cerevisiae L11, and of non-probiotic strains S. cerevisiae BY4741 and S. cerevisiae BY4743. Strains 905 and Sc47 had lower and higher lipid droplet levels, respectively, when compared to the remaining strains, showing that higher accumulation of these neutral lipids is not a feature shared by all probiotic Saccharomyces strains. When submitted to simulated gastric or bile salts environments, lipid droplet levels increase in all tested probiotic strains, at least for one to the induced stresses, suggesting that lipid droplets participate in the protective mechanisms against gastrointestinal stresses in probiotic Saccharomyces yeasts. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Zamith-Miranda, Daniel; Nimrichter, Leonardo] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Lab Glicobiol Eucariotos, BR-21941590 Rio De Janeiro, RJ, Brazil.
   [Palma, Mariana L.] Univ Sao Paulo, Fac Med, Lab Dermatol & Imunodeficiencias, BR-05508070 Sao Paulo, SP, Brazil.
   [Palma, Mariana L.; Schiebel, Johnathon G.; Marques, Ernesto T. A., Jr.; Douradinha, Bruno] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15261 USA.
   [Matos, Gabriel S.; Montero-Lomeli, Monica] Univ Fed Rio de Janeiro, Inst Bioquirn Med Leopoldo de Meis, BR-21941590 Rio De Janeiro, RJ, Brazil.
   [Maya-Monteiro, Clarissa M.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040360 Manguinho, RJ, Brazil.
   [Aronovich, Marcos] Pesagro Rio, BR-24120191 Niteroi, RJ, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Manguinho, RJ, Brazil.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz Pernambuco, Ctr Pesquisa Aggeu Magalhaes, Lab Virol & Terapia Expt, BR-50740465 Recife, PE, Brazil.
   [Martins, Flaviano S.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Douradinha, Bruno] Fdn RiMED, I-90133 Palermo, Italy.
RP Douradinha, B (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Room 9052, Pittsburgh, PA 15213 USA.
EM douradinha@pitt.edu
RI Nimrichter, Leonardo/L-3545-2014; Zamith-Miranda, Daniel/E-8877-2013;
   Bozza, Fernando A/A-2618-2013; Marques, Ernesto T. A/L-4967-2013;
   Douradinha, Bruno/R-5832-2017
OI Nimrichter, Leonardo/0000-0001-9281-6856; Zamith-Miranda,
   Daniel/0000-0001-7532-2432; Bozza, Fernando A/0000-0003-4878-0256;
   Marques, Ernesto T. A/0000-0003-3826-9358; Douradinha,
   Bruno/0000-0002-9980-4505; Soares Matos, Gabriel/0000-0001-8806-6212;
   Martins, Flaviano/0000-0003-0741-3062; Bozza,
   Patricia/0000-0001-8349-9529
FU Conselho Nacional de Ciencia e Tecnologia (CNPq; Brasilia, DF, Brazil);
   Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Rio de Janeiro,
   RJ, Brazil); Fundacao de Amparo a Pesquisa de Minas Gerais (FAPEMIG,
   Belo Horizonte, MG, Brazil); Fondazione RiMED (Palermo, PA, Italy);
   FAPERJ Cientistas do Nosso Estado grant; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX We thank Professor Claudio A. Masuda from Universidade Federal do Rio de
   Janeiro, Brazil, for critically reviewing this manuscript and helpful
   scientific discussions, Stefan Lamers for manuscript editing and Jens
   Rietdorf (CAPES/CTDS) for technical assistance. This work was supported
   by grants from Conselho Nacional de Ciencia e Tecnologia (CNPq;
   Brasilia, DF, Brazil), Fundacao de Amparo a Pesquisa do Rio de Janeiro
   (FAPERJ, Rio de Janeiro, RJ, Brazil), Fundacao de Amparo a Pesquisa de
   Minas Gerais (FAPEMIG, Belo Horizonte, MG, Brazil) and Fondazione RiMED
   (Palermo, PA, Italy). MM-L is the recipient of a FAPERJ Cientistas do
   Nosso Estado grant. GSM is the recipient of a CNPq Iniciacao Cientifica
   fellowship. FSM is the recipient of a CNPq research fellowship. BD is a
   Fondazione RIMED Associate Scholar. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BLEHAUT H, 1989, BIOPHARM DRUG DISPOS, V10, P353, DOI 10.1002/bdd.2510100403
   Bourque Simon D, 2009, J Vis Exp, DOI 10.3791/1513
   Bozaquel-Morais BL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013692
   Brachmann CB, 1998, YEAST, V14, P115
   Cascio V, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-35
   Czabany T, 2008, J BIOL CHEM, V283, P17065, DOI 10.1074/jbc.M800401200
   Czerucka D, 2007, ALIMENT PHARM THER, V26, P767, DOI 10.1111/j.1365-2036.2007.03442.x
   Diosma G, 2014, WORLD J MICROB BIOT, V30, P43, DOI 10.1007/s11274-013-1419-9
   Douradinha B, 2014, BIOENGINEERED, V5, P21, DOI 10.4161/bioe.26271
   Edwards-Ingram L, 2007, APPL ENVIRON MICROB, V73, P2458, DOI 10.1128/AEM.02201-06
   EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012, EFSA J, V10, P2531, DOI [10.2903/j.efsa.2012.2531, DOI 10.2903/J.EFSA.2012.2531]
   Fei WH, 2009, BIOCHEM J, V424, P61, DOI 10.1042/BJ20090785
   FERNANDES PB, 1992, NEW APPROACHES ANTIF
   Ferraretto LF, 2012, J DAIRY SCI, V95, P4017, DOI 10.3168/jds.2011-5190
   Fietto JLR, 2004, CAN J MICROBIOL, V50, P615, DOI 10.1139/W04-050
   Garaiova M, 2014, FEMS YEAST RES, V14, P310, DOI 10.1111/1567-1364.12107
   Gaspar ML, 2008, J BIOL CHEM, V283, P25735, DOI 10.1074/jbc.M802685200
   Graff S, 2008, J GEN APPL MICROBIOL, V54, P221, DOI 10.2323/jgam.54.221
   Hapala I, 2011, BIOL CELL, V103, P271, DOI 10.1042/BC20100144
   Khor VK, 2013, CURR OPIN CLIN NUTR, V16, P632, DOI 10.1097/MCO.0b013e3283651106
   Kourelis A, 2010, J APPL MICROBIOL, V109, P260, DOI 10.1111/j.1365-2672.2009.04651.x
   Kuhle AVDA, 2005, INT J FOOD MICROBIOL, V101, P29, DOI 10.1016/j.ijfoodmicro.2004.10.039
   Kurat CF, 2006, J BIOL CHEM, V281, P491, DOI 10.1074/jbc.M508414200
   Madeira JB, 2015, MOL CELL BIOL, V35, P737, DOI 10.1128/MCB.01314-14
   Martinez M, 2002, ADV DRUG DELIVER REV, V54, P825, DOI 10.1016/S0169-409X(02)00071-6
   Montanes FM, 2011, MOL MICROBIOL, V79, P1008, DOI 10.1111/j.1365-2958.2010.07502.x
   Martins FS, 2009, LETT APPL MICROBIOL, V49, P738, DOI 10.1111/j.1472-765X.2009.02732.x
   Martins FS, 2005, J GEN APPL MICROBIOL, V51, P83, DOI 10.2323/jgam.51.83
   Palma ML, 2015, APPL MICROBIOL BIOT, V99, P6563, DOI 10.1007/s00253-015-6776-x
   Perez-Sotelo Luis Salvador, 2005, Rev Latinoam Microbiol, V47, P70
   Perricone M, 2014, FOOD MICROBIOL, V38, P26, DOI 10.1016/j.fm.2013.08.006
   Saka HA, 2012, ANNU REV CELL DEV BI, V28, P411, DOI 10.1146/annurev-cellbio-092910-153958
   Sant'Ana GD, 2009, FEMS YEAST RES, V9, P701, DOI 10.1111/j.1567-1364.2009.00523.x
   Schmidt C, 2013, METHOD CELL BIOL, V116, P15, DOI 10.1016/B978-0-12-408051-5.00002-4
   Stovicek Vratislav, 2015, Metabolic Engineering Communications, V2, P13, DOI 10.1016/j.meteno.2015.03.001
   Vieira AT, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00445
   WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107
   Zanello G, 2013, VET IMMUNOL IMMUNOP, V152, P20, DOI 10.1016/j.vetimm.2012.09.023
   Zanghellini J, 2008, FEBS J, V275, P5552, DOI 10.1111/j.1742-4658.2008.06681.x
NR 39
TC 4
Z9 4
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD MAR
PY 2016
VL 21
BP 193
EP 200
DI 10.1016/j.jff.2015.12.013
PG 8
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA DF3XO
UT WOS:000371281900019
OA Bronze
DA 2020-12-01
ER

PT J
AU Ribeiro, GCM
   Carvalho, N
   Bergamini, BC
   Medeiros, DM
   Bozza, FA
   Beda, A
   Reske, AW
   Pino, AV
   Giannella-Neto, A
   Zin, WA
   Amato, MBP
   Wrigge, H
   Carvalho, AR
AF Motta Ribeiro, G. C.
   Carvalho, N.
   Bergamini, B. C.
   Medeiros, D. M.
   Bozza, F. A.
   Beda, A.
   Reske, A. W.
   Pino, A. V.
   Giannella-Neto, A.
   Zin, W. A.
   Amato, M. B. P.
   Wrigge, H.
   Carvalho, A. R.
TI Peak Driving Pressure As A Surrogate To Respiratory System Elastance
   During Positive End Expiratory Pressure Titration
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT International Conference of the American-Thoracic-Society (ATS)
CY MAY 13-18, 2016
CL San Francisco, CA
SP Amer Thorac Soc
C1 [Motta Ribeiro, G. C.; Carvalho, N.; Bergamini, B. C.; Pino, A. V.; Giannella-Neto, A.; Zin, W. A.; Carvalho, A. R.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Medeiros, D. M.; Bozza, F. A.] Fundacao Oswaldo Cruz, Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Beda, A.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Reske, A. W.; Wrigge, H.] Univ Leipzig, Leipzig, Germany.
   [Amato, M. B. P.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Reske, Andreas W/E-8141-2010; Beda, Alessandro/AAC-5519-2019; Carvalho,
   Alysson/AAF-1022-2019; Bozza, Fernando A/A-2618-2013; amato, Marcelo
   Britto Passo/L-5001-2016
OI Reske, Andreas W/0000-0002-2759-0245; Beda,
   Alessandro/0000-0002-1867-9846; Bozza, Fernando A/0000-0003-4878-0256;
   amato, Marcelo Britto Passo/0000-0003-3525-8282
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2016
VL 193
MA A5232
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA EG0VE
UT WOS:000390749604746
DA 2020-12-01
ER

PT J
AU Righy, C
   Bozza, MT
   Oliveira, MF
   Bozza, FA
AF Righy, Cassia
   Bozza, Marcelo T.
   Oliveira, Marcus F.
   Bozza, Fernando A.
TI Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage:
   Are the Enemies Within?
SO CURRENT NEUROPHARMACOLOGY
LA English
DT Article
DE Heme; hemorrhagic stroke; inflammatory response; intracranial bleeding;
   iron; reactive oxygen species; subarachnoid hemorrhage
ID ACTIVATED-RECEPTOR-GAMMA; BLOOD-BRAIN-BARRIER; EXPERIMENTAL SUBARACHNOID
   HEMORRHAGE; HEME OXYGENASE-1 INDUCTION; PRIOR STATIN USE; RAT MODEL;
   AGONIST ROSIGLITAZONE; HEMATOMA RESOLUTION; INDUCED ATTENUATION;
   PERIHEMATOMA EDEMA
AB Hemorrhagic stroke is a disease with high incidence and mortality rates. In addition to the mass lesions that result from hemorrhagic stroke, substances such as the blood-derived products (BDP) (hemoglobin (Hb), heme and iron) induce a potent inflammatory response and exert direct toxic effects on neurons, astrocytes, and microglia. In the present review, we discuss the mechanisms of brain injury secondary to hemorrhagic stroke, focusing on the involvement of BDP as major players of cellular redox imbalance, inflammation, and glutamate excitotoxicity. Potential natural mechanisms of protection against free Hb and heme such as haptoglobin and hemopexin, respectively, are highlighted. We finally discuss the experimental and clinical trials targeting free iron and heme scavenging as well as inflammation, as potential new therapies to minimize the devastating effects of hemorrhagic stroke on brain structure and function.
C1 [Righy, Cassia; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Med Intens, Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Lab Bioquim Resposta Ao Estresse, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Nacl Ciencia & Tecnol Biol Estrutural & Bioi, Lab Inflamacao & Metab, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RP Righy, C (corresponding author), Ave Brasil 4-365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM cassiarighy@gmail.com
RI Bozza, Fernando A/A-2618-2013; Shinotsuka, Cassia Righy/H-9181-2013;
   Oliveira, Marcus/G-3158-2011
OI Bozza, Fernando A/0000-0003-4878-0256; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552; Oliveira, Marcus/0000-0002-9890-8425
CR AFT RL, 1983, J BIOL CHEM, V258, P2069
   Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   ANTONINI E, 1966, J BIOL CHEM, V241, P3236
   Auriat AM, 2012, EXP NEUROL, V234, P136, DOI 10.1016/j.expneurol.2011.12.030
   Ayer RE, 2013, ACTA NEUROCHIR SUPPL, V115, P259, DOI 10.1007/978-3-7091-1192-5_46
   Biffi A, 2011, NEUROLOGY, V76, P1581, DOI 10.1212/WNL.0b013e3182194be9
   Caliaperumal J, 2012, EXP NEUROL, V237, P363, DOI 10.1016/j.expneurol.2012.07.001
   Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002
   Chen CW, 2012, AUTOPHAGY, V8, P1510, DOI 10.4161/auto.21289
   Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577
   Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187
   Chen LF, 2011, J NEUROSURG, V114, P1159, DOI 10.3171/2010.10.JNS10861
   Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036
   Cui JJ, 2012, CELL BIOCHEM BIOPHYS, V62, P87, DOI 10.1007/s12013-011-9264-7
   DAVIES MJ, 1988, BIOCHIM BIOPHYS ACTA, V964, P28, DOI 10.1016/0304-4165(88)90063-3
   Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x
   Dowlatshahi D, 2012, STROKE, V43, P1518, DOI 10.1161/STROKEAHA.111.645978
   DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3
   Duan Shu-rong, 2007, Zhonghua Yi Xue Za Zhi, V87, P1904
   Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g
   Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   FitzMaurice E, 2008, STROKE, V39, P2151, DOI 10.1161/STROKEAHA.107.508861
   Flaherty ML, 2010, SEMIN NEUROL, V30, P565, DOI 10.1055/s-0030-1268866
   Frantzias J, 2011, ANN NEUROL, V69, P389, DOI 10.1002/ana.22243
   Galea J, 2012, J NEUROCHEM, V121, P785, DOI 10.1111/j.1471-4159.2012.07716.x
   Germano A, 2007, J NEUROTRAUM, V24, P732, DOI 10.1089/neu.2006.0181
   Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633
   Gonzales NR, 2013, INT J STROKE, V8, P388, DOI 10.1111/j.1747-4949.2011.00761.x
   Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Hahl P, 2013, J NEUROCHEM, V125, P89, DOI 10.1111/jnc.12165
   HESS JR, 1993, J APPL PHYSIOL, V74, P1769
   HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28
   Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185
   Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025
   Im DS, 2012, BRAIN RES, V1455, P114, DOI 10.1016/j.brainres.2012.03.025
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681
   Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85
   Kirkpatrick PJ, 2014, LANCET NEUROL, V13, P666, DOI 10.1016/S1474-4422(14)70084-5
   Koeppen AH, 1995, J NEUROL SCI, V134, P102, DOI 10.1016/0022-510X(95)00215-N
   Koeppen AH, 1995, J NEUROL SCI, V134, P1, DOI 10.1016/0022-510X(95)00202-D
   Lara FA, 2009, J CEREBR BLOOD F MET, V29, P1109, DOI 10.1038/jcbfm.2009.34
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Li H, 2009, J NEUROCHEM, V110, P1774, DOI 10.1111/j.1471-4159.2009.06271.x
   Liu X, 2010, NEUROL SCI, V31, P699, DOI 10.1007/s10072-010-0241-5
   Lou M, 2009, CEREBROVASC DIS, V27, P266, DOI 10.1159/000199464
   Mairuae N, 2011, NEUROSCI LETT, V500, P36, DOI 10.1016/j.neulet.2011.06.001
   Mantle D, 2001, CLIN CHIM ACTA, V312, P185, DOI 10.1016/S0009-8981(01)00623-4
   MARLET JM, 1982, J FORENSIC SCI, V27, P880
   Mehdiratta M, 2008, STROKE, V39, P1165, DOI 10.1161/STROKEAHA.107.501213
   Merlo L, 2011, J NEUROTRAUM, V28, P2493, DOI 10.1089/neu.2010.1624
   Nagy E, 2010, ARTERIOSCL THROM VAS, V30, P1347, DOI 10.1161/ATVBAHA.110.206433
   Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672
   Naval NS, 2008, NEUROCRIT CARE, V8, P6, DOI 10.1007/s12028-007-0080-2
   Naval NS, 2008, NEUROCRIT CARE, V8, P13, DOI 10.1007/s12028-007-0081-1
   Pan H, 2011, NEUROCHEM RES, V36, P2434, DOI 10.1007/s11064-011-0571-6
   Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553
   Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902
   Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236
   Rincon F, 2012, TRANSL STROKE RES, V3, pS10, DOI 10.1007/s12975-012-0175-8
   Rouault TA, 2013, NAT REV NEUROSCI, V14, P551, DOI 10.1038/nrn3453
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Sabri M, 2011, J CEREBR BLOOD F MET, V31, P190, DOI 10.1038/jcbfm.2010.76
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   SADRZADEH SMH, 1988, J CLIN INVEST, V82, P1510, DOI 10.1172/JCI113759
   SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865
   SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354
   Schalinske KL, 1998, J BIOL CHEM, V273, P3740, DOI 10.1074/jbc.273.6.3740
   Schipper HM, 2009, CURR ALZHEIMER RES, V6, P424, DOI 10.2174/156720509789207985
   Selim M, 2011, STROKE, V42, P3067, DOI 10.1161/STROKEAHA.111.617589
   Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104
   Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066
   Song LY, 2007, J NEUROSCI RES, V85, P2186, DOI 10.1002/jnr.21367
   Song S, 2008, ACTA NEUROCHIR SUPPL, V105, P13
   Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Vellimana AK, 2011, STROKE, V42, P776, DOI 10.1161/STROKEAHA.110.607200
   Vesely MJJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1087
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
   Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802
   Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703
   Wang GQ, 2011, ACTA NEUROCHIR, V153, P319, DOI 10.1007/s00701-010-0750-2
   Wang J, 2008, NEUROSCIENCE, V155, P1133, DOI 10.1016/j.neuroscience.2008.07.004
   Wang J, 2005, CIRC RES, V97, P821, DOI 10.1161/01.RES.0000185833.42544.06
   Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020
   Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009
   Wang L, 2012, TRANSL STROKE RES, V3, P107, DOI 10.1007/s12975-011-0099-8
   Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x
   Warkentin LM, 2010, BRAIN RES, V1309, P95, DOI 10.1016/j.brainres.2009.10.058
   Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025
   Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209
   Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680
   Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45
   Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7
   Wu Y, 2011, J NEUROL SCI, V305, P85, DOI 10.1016/j.jns.2011.03.006
   Wu Y, 2010, BRAIN RES, V1322, P102, DOI 10.1016/j.brainres.2010.01.073
   Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991
   Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820
   Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361
   Yabluchanskiy A, 2012, CRIT CARE MED, V40, P544, DOI 10.1097/CCM.0b013e31822f0d64
   Yu J, 2009, BRAIN RES, V1257, P102, DOI 10.1016/j.brainres.2008.12.030
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
   Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011
   Zhang X, 2006, GLIA, V54, P795, DOI 10.1002/glia.20416
   Zhao F, 2011, STROKE, V42, P3587, DOI 10.1161/STROKEAHA.111.623926
   Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506
   Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097
   Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233
   Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009
   Zhou Q, 2010, CIRC J, V74, P818, DOI 10.1253/circj.CJ-10-0110
NR 114
TC 22
Z9 22
U1 1
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-159X
EI 1875-6190
J9 CURR NEUROPHARMACOL
JI Curr. Neuropharmacol.
PY 2016
VL 14
IS 4
BP 392
EP 402
DI 10.2174/1570159X14666151230110058
PG 11
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DK4HN
UT WOS:000374878300011
PM 26714583
OA Green Published
DA 2020-12-01
ER

PT J
AU Soares, M
   Bozza, FA
   Angus, DC
   Japiassu, AM
   Viana, WN
   Costa, R
   Brauer, L
   Mazza, BF
   Correa, TD
   Nunes, ALB
   Lisboa, T
   Colombari, F
   Maciel, AT
   Azevedo, LCP
   Damasceno, M
   Fernandes, HS
   Cavalcanti, AB
   do Brasil, PEAA
   Kahn, JM
   Salluh, JIF
AF Soares, Marcio
   Bozza, Fernando A.
   Angus, Derek C.
   Japiassu, Andre M.
   Viana, William N.
   Costa, Roberto
   Brauer, Leonardo
   Mazza, Bruno F.
   Correa, Thiago D.
   Nunes, Andre L. B.
   Lisboa, Thiago
   Colombari, Fernando
   Maciel, Alexandre T.
   Azevedo, Luciano C. P.
   Damasceno, Moyzes
   Fernandes, Haggeas S.
   Cavalcanti, Alexandre B.
   do Brasil, Pedro E. A. A.
   Kahn, Jeremy M.
   Salluh, Jorge I. F.
TI Organizational characteristics, outcomes, and resource use in 78
   Brazilian intensive care units: the ORCHESTRA study
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Organizational factors; Outcomes; Standardized resource use; Intensive
   care unit; Protocols
ID CRITICALLY-ILL PATIENTS; MIDDLE-INCOME COUNTRIES; CRITICAL ILLNESS;
   MECHANICAL VENTILATION; CLINICAL-OUTCOMES; MORTALITY; VOLUME; IMPACT;
   VARIABILITY; SEPSIS
AB Detailed information on organization and process of care in intensive care units (ICU) in emerging countries is scarce. Here, we investigated the impact of organizational factors on the outcomes and resource use in a large sample of Brazilian ICUs.
   Retrospective cohort study of 59,693 patients (medical admissions, 67 %) admitted to 78 ICUs during 2013. We retrieved patients' data from an ICU quality registry and surveyed ICUs regarding structure, organization, staffing patterns, and process of care. We used multilevel logistic regression analysis to identify factors associated with hospital mortality. Efficient resource use was assessed by estimating standardized resource use and mortality rates adjusted for the SAPS 3 score.
   ICUs were mostly medical-surgical (79 %) and located at private hospitals (86 %). Median nurse to bed ratio was 0.20 (IQR, 0.15-0.28) and board-certified intensivists were present 24/7 in 16 (21 %) of ICUs. Multidisciplinary rounds occurred in 67 (86 %) and daily checklists were used in 36 (46 %) ICUs. Most frequent protocols focused on sepsis management and prevention of healthcare-associated infections. Hospital mortality was 14.4 %. In multivariable analysis, the number of protocols was the only organizational characteristic associated with mortality [odds ratio = 0.944 (95 % CI 0.904-0.987)]. The effects of protocols were consistent across subgroups including surgical and medical patients as well as the SAPS 3 tertiles. We also observed a significant trend toward efficient resource use as the number of protocols increased.
   In emerging countries such as Brazil, organizational factors, including the implementation of protocols, are potential targets to improve patient outcomes and resource use in ICUs.
C1 [Soares, Marcio; Bozza, Fernando A.; do Brasil, Pedro E. A. A.; Salluh, Jorge I. F.] DOr Inst Res & Educ, Dept Crit Care, BR-22281100 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Japiassu, Andre M.] Inst Oswaldo Cruz Fiocruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Angus, Derek C.; Kahn, Jeremy M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
   [Japiassu, Andre M.] Rede Amil Hosp, Dept Crit Care, Rio De Janeiro, Brazil.
   [Viana, William N.] Hosp Copa DOr, ICU, Rio De Janeiro, Brazil.
   [Costa, Roberto] Hosp Quinta DOr, ICU, Rio De Janeiro, Brazil.
   [Brauer, Leonardo] Hosp Sao Luiz, ICU, Unidade Itaim, Sao Paulo, Brazil.
   [Brauer, Leonardo; Nunes, Andre L. B.; Maciel, Alexandre T.] Imed Grp, Dept Crit Care, Sao Paulo, Brazil.
   [Mazza, Bruno F.] Hosp Sao Luiz, ICU, Unidade Morumbi, Sao Paulo, Brazil.
   [Correa, Thiago D.] Hosp Israelita Albert Einstein, ICU, Sao Paulo, Brazil.
   [Nunes, Andre L. B.] Hosp Sao Luiz, ICU, Unidade Analia Franco, Sao Paulo, Brazil.
   [Lisboa, Thiago] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Colombari, Fernando] Hosp Alemao Oswaldo Cruz, ICU, Sao Paulo, Brazil.
   [Maciel, Alexandre T.] Hosp Sao Camilo Pompeia, ICU, Sao Paulo, Brazil.
   [Azevedo, Luciano C. P.] Hosp Sirio Libanes, ICU, Sao Paulo, Brazil.
   [Damasceno, Moyzes] Complexo Hosp Nitero, ICU, Niteroi, RJ, Brazil.
   [Fernandes, Haggeas S.] Hosp Sao Luiz, ICU, Unidade Brasil, Santo Andre, Brazil.
   [Cavalcanti, Alexandre B.] Hosp Coracao IEP HCor, Res Inst, Sao Paulo, Brazil.
   [Kahn, Jeremy M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Dept Crit Care, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Brasil, Pedro Emmanuel/AAG-2280-2019; Bozza, Fernando A/A-2618-2013;
   Azevedo, Luciano CP/H-2652-2012; Angus, Derek C/E-9671-2012; Soares,
   Marcio/B-3083-2013; dantas, vicente c souza/L-2648-2013; Lisboa,
   Thiago/W-2973-2019; Cavalcanti, Alexandre/K-5529-2013
OI Brasil, Pedro Emmanuel/0000-0002-6700-2268; Bozza, Fernando
   A/0000-0003-4878-0256; Azevedo, Luciano CP/0000-0001-6759-3910; Soares,
   Marcio/0000-0003-2503-6088; Lisboa, Thiago/0000-0003-4306-2212; Kahn,
   Jeremy/0000-0001-9688-5576; Cavalcanti, Alexandre/0000-0003-2798-6263;
   Domingos Correa, Thiago/0000-0001-9546-3910
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [304240/2014-1]; Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   D'Or Institute for Research and Education
FX This study was supported by the National Council for Scientific and
   Technological Development (CNPq) (Grant No. 304240/2014-1), Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ), and by departmental funds from the D'Or Institute for
   Research and Education. We dedicate this work to the memory of our
   colleague, Dr. Marcelo Lugarinho, who recently passed away. A complete
   list of collaborators can be found in the electronic supplementary
   material (file 2).
CR Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1
   Austin S, 2014, INTENS CARE MED, V40, P342, DOI 10.1007/s00134-013-3174-7
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Bozza FA, 2010, LANCET INFECT DIS, V10, P290, DOI 10.1016/S1473-3099(10)70074-8
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7
   Chittawatanarat Kaweesak, 2014, Journal of the Medical Association of Thailand, V97, pS22
   Cooke CR, 2012, CRIT CARE MED, V40, P2569, DOI 10.1097/CCM.0b013e3182591eee
   Costa DK, 2015, CRIT CARE MED, V43, P2275, DOI 10.1097/CCM.0000000000001259
   Du B, 2013, CRIT CARE MED, V41, P84, DOI 10.1097/CCM.0b013e31826a4082
   Kahn JM, 2013, INTENS CARE MED, V39, P1635, DOI 10.1007/s00134-013-2992-y
   Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993
   Kim MM, 2010, ARCH INTERN MED, V170, P369, DOI 10.1001/archinternmed.2009.521
   Mills A, 2014, NEW ENGL J MED, V370, P552, DOI 10.1056/NEJMra1110897
   Neuraz A, 2015, CRIT CARE MED, V43, P1587, DOI 10.1097/CCM.0000000000001015
   Nguyen YL, 2010, CURR OPIN CRIT CARE, V16, P487, DOI 10.1097/MCC.0b013e32833d9180
   Noritomi DT, 2014, INTENS CARE MED, V40, P182, DOI 10.1007/s00134-013-3131-5
   Phua J, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3245
   Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151
   Ranzani OT, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0580-3
   Reineck LA, 2014, CRIT CARE MED, V42, P1055, DOI 10.1097/CCM.0000000000000132
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Rhodes Andrew, 2012, Rev. bras. ter. intensiva, V24, P322, DOI 10.1590/S0103-507X2012000400005
   Rothen HU, 2007, INTENS CARE MED, V33, P1329, DOI 10.1007/s00134-007-0690-3
   Sakr Y, 2015, CRIT CARE MED, V43, P519, DOI 10.1097/CCM.0000000000000754
   Sevransky JE, 2015, CRIT CARE MED, V43, P2076, DOI 10.1097/CCM.0000000000001157
   Vesin A, 2013, INTENS CARE MED, V39, P1396, DOI 10.1007/s00134-013-2949-1
   Vincent JL, 2014, LANCET RESP MED, V2, P380, DOI 10.1016/S2213-2600(14)70061-X
   Vukoja M, 2014, GLOB HEART, V9, P337, DOI 10.1016/j.gheart.2014.08.002
   Wallace DJ, 2012, NEW ENGL J MED, V366, P2093, DOI 10.1056/NEJMsa1201918
   Weled BJ, 2015, CRIT CARE MED, V43, P1520, DOI 10.1097/CCM.0000000000000978
   Wunsch H, 2015, AM J RESP CRIT CARE, V191, P186, DOI 10.1164/rccm.201408-1525OC
   Nguyen YL, 2011, CRIT CARE MED, V39, P2470, DOI 10.1097/CCM.0b013e3182257631
NR 33
TC 53
Z9 60
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD DEC
PY 2015
VL 41
IS 12
BP 2149
EP 2160
DI 10.1007/s00134-015-4076-7
PG 12
WC Critical Care Medicine
SC General & Internal Medicine
GA CV0WO
UT WOS:000363974600010
PM 26499477
DA 2020-12-01
ER

PT J
AU Evangelista, L
   Cervino, A
   Michieletto, S
   Saibene, T
   Bezzon, E
   Pomerri, F
   Bozza, F
   Ghiotto, C
   Saladini, G
AF Evangelista, L.
   Cervino, A.
   Michieletto, S.
   Saibene, T.
   Bezzon, E.
   Pomerri, F.
   Bozza, F.
   Ghiotto, C.
   Saladini, G.
TI The addictional value of 18F-FDG PET/CT in pre and post-operative
   setting in patients with locally advanced breast cancer
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT 28th Annual Congress of the European-Association-of-Nuclear-Medicine
   (EANM)
CY OCT 10-14, 2015
CL Hamburg, GERMANY
SP European Assoc Nucl Med
C1 [Evangelista, L.; Cervino, A.; Michieletto, S.; Saibene, T.; Bezzon, E.; Pomerri, F.; Bozza, F.; Ghiotto, C.; Saladini, G.] Ist Oncol Veneto IRCCS, Padua, Italy.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2015
VL 42
SU 1
MA P584
BP S618
EP S618
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CT7RW
UT WOS:000363013203087
DA 2020-12-01
ER

PT J
AU Moraes, CA
   Santos, G
   Spohr, TCLDE
   D'Avila, JC
   Lima, FRS
   Benjamim, CF
   Bozza, FA
   Gomes, FCA
AF Moraes, Carolina A.
   Santos, Gabriel
   Leite de Sampaio e Spohr, Tania Cristina
   D'Avila, Joana C.
   Souza Lima, Flavia Regina
   Benjamim, Claudia Farias
   Bozza, Fernando A.
   Alcantara Gomes, Flavia Carvalho
TI Activated Microglia-Induced Deficits in Excitatory Synapses Through IL-1
   beta: Implications for Cognitive Impairment in Sepsis
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Sepsis; Microglia; Astrocyte; Synapse; Cognitive deficit
ID ASTROCYTE-SECRETED PROTEINS; CNS SYNAPTOGENESIS; SEPTIC ENCEPHALOPATHY;
   SYNAPTIC PLASTICITY; MOUSE MODEL; DYSFUNCTION; LIPOPOLYSACCHARIDE;
   ENHANCEMENT; EXPRESSION; CYTOKINES
AB Recent clinical studies have shown that sepsis survivors may develop long-term cognitive impairments. The cellular and molecular mechanisms involved in these events are not well understood. This study investigated synaptic deficits in sepsis and the involvement of glial cells in this process. Septic animals showed memory impairment and reduced numbers of hippocampal and cortical excitatory synapses, identified by synaptophysin/PSD-95 co-localization, 9 days after disease onset. The behavioral deficits and synaptophysin/PSD-95 co-localization were rescued to normal levels within 30 days post-sepsis. Septic mice presented activation of microglia and reactive astrogliosis, which are hallmarks of brain injury and could be involved in the associated synaptic deficits. We treated neuronal cultures with conditioned medium derived from cultured astrocytes (ACM) and microglia (MCM) that were either non-stimulated or stimulated with lipopolysaccharide (LPS) to investigate the molecular mechanisms underlying synaptic deficits in sepsis. ACM and MCM increased the number of synapses between cortical neurons in vitro, and these effects were antagonized by LPS stimulation. LPS-MCM reduced the number of synapses by 50 %, but LPS-ACM increased the number of synapses by 500 %. Analysis of the composition of these conditioned media revealed increased levels of IL-1 beta in LPS-MCM. Furthermore, inhibition of IL-1 beta signaling through the addition of a soluble IL-1 beta receptor antagonist (IL-1 Ra) fully prevented the synaptic deficit induced by LPS-MCM. These results suggest that sepsis induces a transient synaptic deficit associated with memory impairments mediated by IL-1 beta secreted by activated microglia.
C1 [Moraes, Carolina A.; Santos, Gabriel; Leite de Sampaio e Spohr, Tania Cristina; Souza Lima, Flavia Regina; Benjamim, Claudia Farias; Alcantara Gomes, Flavia Carvalho] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Moraes, Carolina A.; D'Avila, Joana C.; Bozza, Fernando A.] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Inst DOr Ensino & Pesquisa, Rio De Janeiro, Brazil.
RP Gomes, FCA (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM fgomes@icb.ufrj.br
RI Bozza, Fernando A/A-2618-2013; Spohr, Tania/I-4299-2015; Benjamim,
   Claudia/T-5090-2019; d'Avila, Joana/L-8970-2013; Gomes,
   Flavia/C-5383-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Spohr, Tania/0000-0001-8691-5962;
   Benjamim, Claudia/0000-0001-6247-9596; d'Avila,
   Joana/0000-0002-2045-0813; Gomes, Flavia/0000-0003-2966-0638; Souza
   Lima, Flavia Regina/0000-0003-0799-9235
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Institute of Glia (iGLIA/CNPq); Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES)CAPES; Fundacao Carlos Chagas Filho
   de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ)
FX We thank Marcelo Meloni for technical assistance. This work was
   supported by grants from the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Institute of Glia (iGLIA/CNPq),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ). The authors declare no conflicts of interest.
CR Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013
   Allen NJ, 2012, NATURE, V486, P410, DOI 10.1038/nature11059
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Azevedo EP, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.325
   Bertaina-Anglade V., 2006, Journal of Pharmacological and Toxicological Methods, V54, P99, DOI 10.1016/j.vascn.2006.04.001
   Bialas AR, 2013, NAT NEUROSCI, V16, P1773, DOI 10.1038/nn.3560
   Bibb JA, 2010, J NEUROSCI, V30, P14987, DOI 10.1523/JNEUROSCI.4419-10.2010
   Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1
   Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020
   Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484
   De Felice FG, 2007, CURR ALZHEIMER RES, V4, P263
   Di Filippo M, 2013, NEUROBIOL DIS, V52, P229, DOI 10.1016/j.nbd.2012.12.009
   Diniz LP, 2012, J BIOL CHEM, V287, P41432, DOI 10.1074/jbc.M112.380824
   Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1
   Gofton TE, 2012, NAT REV NEUROL, V8, P557, DOI 10.1038/nrneurol.2012.183
   Hama H, 2004, NEURON, V41, P405, DOI 10.1016/S0896-6273(04)00007-8
   Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003
   Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161
   Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36
   Holtzman DM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006312
   Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC
   Imamura Y, 2011, NEUROSCIENCE, V187, P63, DOI 10.1016/j.neuroscience.2011.04.063
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   Kucukdereli H, 2011, P NATL ACAD SCI USA, V108, pE440, DOI 10.1073/pnas.1104977108
   Lim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081218
   Lima FRS, 2001, J NEUROSCI, V21, P2028, DOI 10.1523/JNEUROSCI.21-06-02028.2001
   MALLAT M, 1994, J LEUKOCYTE BIOL, V56, P416
   Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354
   Mina F, 2014, MOL NEUROBIOL, V49, P1069, DOI 10.1007/s12035-013-8581-9
   Mishra A, 2012, J NEUROIMMUNE PHARM, V7, P571, DOI 10.1007/s11481-012-9342-7
   Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009
   Morris GP, 2013, NEUROBIOL LEARN MEM, V105, P40, DOI 10.1016/j.nlm.2013.07.002
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Serantes R, 2006, J BIOL CHEM, V281, P14632, DOI 10.1074/jbc.M512489200
   Siskova Z, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/425845
   Stipursky J, 2012, NEUROCHEM RES, V37, P2402, DOI 10.1007/s11064-012-0798-x
   Terrando N, 2010, CRIT CARE, V14, DOI 10.1186/cc9019
   Tremblay ME, 2011, NEURON GLIA BIOL, V7, P67, DOI 10.1017/S1740925X12000038
   Tuon L, 2008, INTENS CARE MED, V34, P1724, DOI 10.1007/s00134-008-1129-1
   Welser-Alves JV, 2013, NEUROCHEM INT, V63, P47, DOI 10.1016/j.neuint.2013.04.007
   Wilcox ME, 2013, CRIT CARE MED, V41, pS81, DOI 10.1097/CCM.0b013e3182a16946
   Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015
NR 44
TC 68
Z9 71
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD AUG
PY 2015
VL 52
IS 1
BP 653
EP 663
DI 10.1007/s12035-014-8868-5
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CN3QO
UT WOS:000358341600057
PM 25257696
DA 2020-12-01
ER

PT J
AU Torres, VBL
   Azevedo, LCP
   Silva, UVA
   Caruso, P
   Torelly, AP
   Silva, E
   Carvalho, FB
   Vianna, A
   Souza, PCP
   Godoy, MMG
   Azevedo, JRA
   Spector, N
   Bozza, FA
   Salluh, JIF
   Soares, M
AF Torres, Viviane B. L.
   Azevedo, Luciano C. P.
   Silva, Ulysses V. A.
   Caruso, Pedro
   Torelly, Andre P.
   Silva, Eliezer
   Carvalho, Frederico B.
   Vianna, Arthur
   Souza, Paulo C. P.
   Godoy, Michele M. G.
   Azevedo, Jose R. A.
   Spector, Nelson
   Bozza, Fernando A.
   Salluh, Jorge I. F.
   Soares, Marcio
TI Sepsis-Associated Outcomes in Critically Ill Patients with Malignancies
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
DE cancer; infection; intensive care; malignancy; sepsis
AB Rationale: Sepsis is a major cause of mortality among critically ill patients with cancer. Information about clinical outcomes and factors associated with increased risk of death in these patients is necessary to help physicians recognize those patients who are most likely to benefit from ICU therapy and identify possible targets for intervention.
   Objectives: In this study, we evaluated cancer patients with sepsis chosen from a multicenter prospective study to characterize their clinical characteristics and to identify independent risk factors associated with hospital mortality.
   Methods: Subgroup analysis of a multicenter prospective cohort study conducted in 28 Brazilian intensive care units (ICUs) to evaluate adult cancer patients with severe sepsis and septic shock. We used logistic regression to identify variables associated with hospital mortality.
   Measurements and Main Results: Of the 717 patients admitted to the participating ICUs, 268 (37%) had severe sepsis (n = 142, 53%) or septic shock (n = 126, 47%). These patients comprised the population of the present study. The mean score on the third version of the Simplified Acute Physiology Score was 62.9 +/- 17.7 points, and the median Sequential Organ Failure Assessment score was 9 (7-12) points. The most frequent sites of infection were the lungs (48%), intraabdominal region (25%), bloodstream as primary infection (19%), and urinary tract (17%). Half of the patients had microbiologically proven infections, and Gram-negative bacteria were the most common pathogens causing sepsis (31%). ICU and hospital mortality rates were 42% and 56%, respectively. In multivariable analysis, the number of acute organ dysfunctions (odds ratio [OR], 1.48; 95% confidence interval [CI], 1.16-1.87), hematological malignancies (OR, 2.57; 95% CI, 1.05-6.27), performance status 2-4 (OR, 2.53; 95% CI, 1.44-4.43), and polymicrobial infections (OR, 3.74; 95% CI, 1.52-9.21) were associated with hospital mortality.
   Conclusions: Sepsis is a common cause of critical illness in patients with cancer and remains associated with high mortality. Variables related to underlying malignancy, sepsis severity, and characteristics of infection are associated with a grim prognosis.
C1 [Torres, Viviane B. L.; Spector, Nelson; Salluh, Jorge I. F.; Soares, Marcio] Univ Fed Rio de Janeiro, Sch Med, Postgrad Program Internal Med, Rio De Janeiro, Brazil.
   [Azevedo, Luciano C. P.; Salluh, Jorge I. F.; Soares, Marcio] Natl Canc Inst, Postgrad Program, Rio De Janeiro, Brazil.
   [Vianna, Arthur] ICU, Clin Sao Vicente, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Oswaldo Cruz Fdn FIOCRUZ, Natl Inst Infect Dis Evandro Chagas, Rio De Janeiro, Brazil.
   [Azevedo, Luciano C. P.] Hosp Sirio Libanes, Res & Educ Inst, Sao Paulo, Brazil.
   [Caruso, Pedro] AC Camargo Canc Ctr, ICU, Sao Paulo, Brazil.
   [Silva, Eliezer] Hosp Israelita Albert Einstein, ICU, Sao Paulo, Brazil.
   [Silva, Ulysses V. A.] Hosp Canc Barretos, ICU, Pio Fdn 12, Barretos, Brazil.
   [Torelly, Andre P.] Irmandade Santa Casa Misericordia Porto Alegre, RIPIMI, Porto Alegre, RS, Brazil.
   [Carvalho, Frederico B.] Hosp Mater Dei, ICU, Belo Horizonte, MG, Brazil.
   [Souza, Paulo C. P.] Hosp Clin Niteroi, ICU, Niteroi, RJ, Brazil.
   [Godoy, Michele M. G.] Univ Fed Pernambuco, Hosp Clin, ICU, Recife, PE, Brazil.
   [Azevedo, Jose R. A.] ICU Hosp Sao Domingos Sao Luis, Sao Luis, MA, Brazil.
RP Soares, M (corresponding author), Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Soares, Marcio/B-3083-2013; V.A.Silva, Ulysses/AAZ-3336-2020; Azevedo,
   Luciano CP/H-2652-2012; Caruso, Pedro/B-6054-2016; dantas, vicente c
   souza/L-2648-2013; Bozza, Fernando A/A-2618-2013; Carvalho, Frederico
   B/J-4879-2012
OI Soares, Marcio/0000-0003-2503-6088; V.A.Silva,
   Ulysses/0000-0002-1284-2016; Azevedo, Luciano CP/0000-0001-6759-3910;
   Caruso, Pedro/0000-0002-1051-8458; Bozza, Fernando
   A/0000-0003-4878-0256; Carvalho, Frederico B/0000-0002-9752-5625;
   Salluh, Jorge/0000-0002-8164-1453
FU Brazilian National Cancer Institute; Brazilian Research in Intensive
   Care Network (BRICNet)
FX Supported in part by the Brazilian National Cancer Institute and
   sponsored by the Brazilian Research in Intensive Care Network (BRICNet).
CR Aygencel G, 2014, J CRIT CARE, V29, P618, DOI 10.1016/j.jcrc.2014.01.014
   Azevedo LCP, 2014, CHEST, V146, P257, DOI 10.1378/chest.13-1870
   Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365
   Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5
   Bozza FA, 2010, LANCET INFECT DIS, V10, P290, DOI 10.1016/S1473-3099(10)70074-8
   Danai PA, 2006, CHEST, V129, P1432, DOI 10.1378/chest.129.6.1432
   de Montmollin E, 2013, SHOCK, V39, P250, DOI 10.1097/SHK.0b013e3182866d32
   ELTING LS, 1986, MEDICINE, V65, P218, DOI 10.1097/00005792-198607000-00002
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Kallogjeri D, 2012, J GERIATR ONCOL, V3, P238, DOI 10.1016/j.jgo.2012.01.006
   Khassawneh BY, 2002, CHEST, V121, P185, DOI 10.1378/chest.121.1.185
   Larche J, 2003, INTENS CARE MED, V29, P1688, DOI 10.1007/s00134-003-1957-y
   Legrand M, 2012, CRIT CARE MED, V40, P43, DOI 10.1097/CCM.0b013e31822b50c2
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Marin M, 2014, J INFECTION, V69, P417, DOI 10.1016/j.jinf.2014.05.018
   McKenzie FE, 2006, J CLIN EPIDEMIOL, V59, P760, DOI 10.1016/j.jclinepi.2005.12.009
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Rolston KVI, 2005, CLIN INFECT DIS, V40, pS246, DOI 10.1086/427331
   Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014
   Soares M, 2013, LANCET ONCOL, V14, pE337, DOI 10.1016/S1470-2045(13)70269-9
   Soares M, 2012, CRIT CARE MED, V40, P308, DOI 10.1097/CCM.0b013e31823294af
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Song JU, 2012, INTENS CARE MED, V38, P1505, DOI 10.1007/s00134-012-2594-0
   Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713
   Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016
   Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Williams MD, 2004, CRIT CARE, V8, pR291, DOI 10.1186/cc2893
   Wisplinghoff H, 2003, CLIN INFECT DIS, V36, P1103, DOI 10.1086/374339
   Yadegarynia D, 2003, CLIN INFECT DIS, V37, P1144, DOI 10.1086/378305
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 31
TC 31
Z9 34
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD AUG
PY 2015
VL 12
IS 8
BP 1185
EP 1192
DI 10.1513/AnnalsATS.201501-046OC
PG 8
WC Respiratory System
SC Respiratory System
GA VD6BY
UT WOS:000437242300013
PM 26086679
DA 2020-12-01
ER

PT J
AU Palma, ML
   Zamith-Miranda, D
   Martins, FS
   Bozza, FA
   Nimrichter, L
   Montero-Lomeli, M
   Marques, ETA
   Douradinha, B
AF Palma, Mariana L.
   Zamith-Miranda, Daniel
   Martins, Flaviano S.
   Bozza, Fernando A.
   Nimrichter, Leonardo
   Montero-Lomeli, Monica
   Marques, Ernesto T. A., Jr.
   Douradinha, Bruno
TI Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is
   there room for improvement?
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review
DE Probiotics; Saccharomyces cerevisiae; Saccharomyces cerevisiae var
   boulardii; Mechanisms of action; Expression of heterologous proteins
ID ESCHERICHIA-COLI; BACTERIAL TRANSLOCATION; ANTIBIOTIC-RESISTANCE;
   IMMUNE-SYSTEM; YEAST STRAINS; BOULARDII; GENE; GUT; TYPHIMURIUM;
   EXPRESSION
AB The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application.
C1 [Palma, Mariana L.] Univ Sao Paulo, Fac Med, Lab Dermatol & Imunodeficiencias, Sao Paulo, Brazil.
   [Palma, Mariana L.; Marques, Ernesto T. A., Jr.; Douradinha, Bruno] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15213 USA.
   [Zamith-Miranda, Daniel; Nimrichter, Leonardo] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil.
   [Martins, Flaviano S.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Montero-Lomeli, Monica] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz Pernambuco, Ctr Pesquisa Aggeu Magalhaes, Lab Virol & Terapia Expt, Recife, PE, Brazil.
   [Douradinha, Bruno] Fdn RiMED, Palermo, Italy.
RP Douradinha, B (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, Room 9052, Pittsburgh, PA 15213 USA.
EM brd49@pitt.edu
RI Nimrichter, Leonardo/L-3545-2014; Douradinha, Bruno/R-5832-2017;
   Marques, Ernesto T. A/L-4967-2013; Bozza, Fernando A/A-2618-2013;
   Zamith-Miranda, Daniel/E-8877-2013
OI Nimrichter, Leonardo/0000-0001-9281-6856; Marques, Ernesto T.
   A/0000-0003-3826-9358; Bozza, Fernando A/0000-0003-4878-0256;
   Zamith-Miranda, Daniel/0000-0001-7532-2432; Douradinha,
   Bruno/0000-0002-9980-4505; Martins, Flaviano/0000-0003-0741-3062
FU Fondazione RiMED (Palermo, Italy); Fundacao para o Amparo da Pesquisa do
   Estado do Rio de Janeiro (FAPERJ, Rio de Janeiro, Brazil)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ)
FX We thank the reviewers for their helpful comments and suggestions. We
   are grateful to Professor Claudio A. Masuda, from Universidade Federal
   do Rio de Janeiro, Brazil, for critically reviewing this manuscript and
   helpful scientific discussions, and to Stefan Lamers, for English
   language editing of the manuscript. We thank the funding organisms
   Fondazione RiMED (Palermo, Italy) and Fundacao para o Amparo da Pesquisa
   do Estado do Rio de Janeiro (FAPERJ, Rio de Janeiro, Brazil).
CR Ardiani A, 2010, FEMS YEAST RES, V10, P1060, DOI 10.1111/j.1567-1364.2010.00665.x
   Batista TM, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.01345-14
   Reis VCB, 2012, J IND MICROBIOL BIOT, V39, P1673, DOI 10.1007/s10295-012-1170-5
   Brandao RL, 1998, APPL ENVIRON MICROB, V64, P564
   Buts JP, 2006, DIGEST DIS SCI, V51, P1485, DOI 10.1007/s10620-005-9016-x
   Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599
   Cummins Joe, 2005, Microbial Ecology in Health and Disease, V17, P66, DOI 10.1080/08910600510044480
   Czerucka D, 2007, ALIMENT PHARM THER, V26, P767, DOI 10.1111/j.1365-2036.2007.03442.x
   Da Silva NA, 2012, FEMS YEAST RES, V12, P197, DOI 10.1111/j.1567-1364.2011.00769.x
   Dalmasso G, 2006, RES MICROBIOL, V157, P456, DOI 10.1016/j.resmic.2005.11.007
   Diosma G, 2014, WORLD J MICROB BIOT, V30, P43, DOI 10.1007/s11274-013-1419-9
   Douradinha B, 2014, BIOENGINEERED, V5, P21, DOI 10.4161/bioe.26271
   Edwards-Ingram L, 2007, APPL ENVIRON MICROB, V73, P2458, DOI 10.1128/AEM.02201-06
   Edwards-Ingram LC, 2004, GENOME RES, V14, P1043, DOI 10.1101/gr.2114704
   Feizizadeh S, 2014, PEDIATRICS, V134, pE176, DOI 10.1542/peds.2013-3950
   Ferraretto LF, 2012, J DAIRY SCI, V95, P4017, DOI 10.3168/jds.2011-5190
   Fietto JLR, 2004, CAN J MICROBIOL, V50, P615, DOI 10.1139/W04-050
   Foligne B, 2010, WORLD J GASTROENTERO, V16, P2134, DOI 10.3748/wjg.v16.i17.2134
   Gedek BR, 1999, MYCOSES, V42, P261, DOI 10.1046/j.1439-0507.1999.00449.x
   Generoso SV, 2010, ARCH MICROBIOL, V192, P477, DOI 10.1007/s00203-010-0574-8
   Girardin M, 2011, DIGEST DIS, V29, P574, DOI 10.1159/000332980
   Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B
   Gottardi R, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-30
   GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8
   Hamedi Hassan, 2013, Avicenna Journal of Medical Biotechnology, V5, P29
   Hudson LE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112660
   Kawai Shigeyuki, 2010, Bioeng Bugs, V1, P395, DOI 10.4161/bbug.1.6.13257
   Khatri I, 2013, GUT PATHOG, V5, DOI 10.1186/1757-4749-5-30
   Kourelis A, 2010, J APPL MICROBIOL, V109, P260, DOI 10.1111/j.1365-2672.2009.04651.x
   Kuhle AVDA, 2005, INT J FOOD MICROBIOL, V101, P29, DOI 10.1016/j.ijfoodmicro.2004.10.039
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   Latorre-Garcia L, 2008, WORLD J MICROB BIOT, V24, P2957, DOI 10.1007/s11274-008-9837-9
   Martins FS, 2007, J MED MICROBIOL, V56, P352, DOI 10.1099/jmm.0.46525-0
   Martins FS, 2013, MICROBES INFECT, V15, P270, DOI 10.1016/j.micinf.2012.12.007
   Martins FS, 2011, INT J MED MICROBIOL, V301, P359, DOI 10.1016/j.ijmm.2010.11.002
   Martins FS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008925
   Martins FS, 2005, J GEN APPL MICROBIOL, V51, P83, DOI 10.2323/jgam.51.83
   Mathur S, 2005, INT J FOOD MICROBIOL, V105, P281, DOI 10.1016/j.ijfoodmicro.2005.03.008
   McFarland LV, 2010, WORLD J GASTROENTERO, V16, P2202, DOI 10.3748/wjg.v16.i18.2202
   Michael S, 2013, INFLAMM BOWEL DIS, V19, P185, DOI 10.1002/ibd.23006
   Mumy KL, 2008, AM J PHYSIOL-GASTR L, V294, pG599, DOI 10.1152/ajpgi.00391.2007
   O'Horo JC, 2014, INFECTION, V42, P43, DOI 10.1007/s15010-013-0496-x
   Oliveira AF, 2012, MICROBIOL IMMUNOL, V56, P513, DOI 10.1111/j.1348-0421.2012.00477.x
   Owen JL, 2013, CURR OPIN CHEM BIOL, V17, P918, DOI 10.1016/j.cbpa.2013.06.013
   Perez-Sotelo Luis Salvador, 2005, Rev Latinoam Microbiol, V47, P70
   Perricone M, 2014, FOOD MICROBIOL, V38, P26, DOI 10.1016/j.fm.2013.08.006
   Plaza-Diaz J, 2014, WORLD J GASTROENTERO, V20, P15632, DOI 10.3748/wjg.v20.i42.15632
   Pohlmann C, 2013, BIOENGINEERED, V4, P172, DOI 10.4161/bioe.22646
   Pothoulakis C, 2009, ALIMENT PHARM THER, V30, P826, DOI 10.1111/j.1365-2036.2009.04102.x
   Rodrigues ACP, 2000, J APPL MICROBIOL, V89, P404, DOI 10.1046/j.1365-2672.2000.01128.x
   Romanin D, 2010, INT J FOOD MICROBIOL, V140, P102, DOI 10.1016/j.ijfoodmicro.2010.04.014
   Salyers AA, 2004, TRENDS MICROBIOL, V12, P412, DOI 10.1016/j.tim.2004.07.004
   Sazawal S, 2006, LANCET INFECT DIS, V6, P374, DOI 10.1016/S1473-3099(06)70495-9
   Schneiter R, 2004, GENETICS MOL CELL BI
   Sivignon A, 2015, INFLAMM BOWEL DIS, V21, P276, DOI 10.1097/MIB.0000000000000280
   Smith IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096595
   Soares RLS, 2014, WORLD J GASTROENTERO, V20, P12144, DOI 10.3748/wjg.v20.i34.12144
   Sougioultzis S, 2006, BIOCHEM BIOPH RES CO, V343, P69, DOI 10.1016/j.bbrc.2006.02.080
   Temmerman R, 2003, INT J FOOD MICROBIOL, V81, P1, DOI 10.1016/S0168-1605(02)00162-9
   Tiago FCP, 2012, J MED MICROBIOL, V61, P1194, DOI 10.1099/jmm.0.042283-0
   Vieira AT, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00445
   Wang TT, 2014, FUNGAL GENET BIOL, V64, P1, DOI 10.1016/j.fgb.2013.11.006
   Whelan K, 2007, P NUTR SOC, V66, P299, DOI 10.1017/S0029665107005551
   Wu X, 2008, AM J PHYSIOL-GASTR L, V294, pG295, DOI 10.1152/ajpgi.00173.2007
   Zanello G, 2013, VET IMMUNOL IMMUNOP, V152, P20, DOI 10.1016/j.vetimm.2012.09.023
   Zanello G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018573
NR 66
TC 39
Z9 41
U1 2
U2 43
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD AUG
PY 2015
VL 99
IS 16
BP 6563
EP 6570
DI 10.1007/s00253-015-6776-x
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA CN4DO
UT WOS:000358380300001
PM 26142388
DA 2020-12-01
ER

PT J
AU Serafim, RB
   Bozza, FA
   Soares, M
   do Brasil, PEAA
   Tura, BR
   Ely, EW
   Salluh, JIF
AF Serafim, Rodrigo B.
   Bozza, Fernando A.
   Soares, Marcio
   do Brasil, Pedro Emanuel A. A.
   Tura, Bernardo R.
   Ely, E. Wesley
   Salluh, Jorge I. F.
TI Pharmacologic prevention and treatment of delirium in intensive care
   patients: A systematic review.
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Delirium; Prevention; ICU; Surgical
ID CRITICALLY-ILL PATIENTS; POSTOPERATIVE DELIRIUM; CARDIAC-SURGERY;
   HALOPERIDOL PROPHYLAXIS; ELDERLY-PATIENTS; DOUBLE-BLIND;
   DEXMEDETOMIDINE; SEDATION; UNIT; RISK
AB Purpose: The purpose of the study is to determine if pharmacologic approaches are effective in prevention and treatment of delirium in critically ill patients.
   Materials and methods: We performed a systematic search to identify publications (from January 1980 to September 2014) that evaluated the pharmacologic interventions to treat or prevent delirium in intensive care unit (ICU) patients.
   Results: From 2646 citations, 15 studies on prevention (6729 patients) and 7 studies on treatment (1784 patients) were selected and analyzed. Among studies that evaluated surgical patients, the pharmacologic interventions were associated with a reduction in delirium prevalence, ICU length of stay, and duration of mechanical ventilation, but with high heterogeneity (respectively, I-2 = 81%, P = .0013; I-2 = 97%, P < .001; and I-2 = 97%). Considering treatment studies, only 1 demonstrated a significant decrease in ICU length of stay using dexmedetomidine compared to haloperidol (Relative Risk, 0.62 [1.29-0.06]; I-2 = 97%), and only 1 found a shorter time to resolution of delirium using quetiapine (1.0 [confidence interval, 0.5-3.0] vs 4.5 [confidence interval, 2.0-7.0] days; P = .001).
   Conclusion: The use of antipsychotics for surgical ICU patients and dexmedetomidine for mechanically ventilated patients as a preventive strategy may reduce the prevalence of delirium in the ICU. None of the studied agents that were used for delirium treatment improved major clinical outcome, including mortality. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Serafim, Rodrigo B.; Bozza, Fernando A.; Soares, Marcio; do Brasil, Pedro Emanuel A. A.; Tura, Bernardo R.; Salluh, Jorge I. F.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Serafim, Rodrigo B.] Hosp Copa DOr, Rio De Janeiro, Brazil.
   [Serafim, Rodrigo B.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Soares, Marcio; Salluh, Jorge I. F.] Inst Nacl Canc, Postgrad Program, Rio De Janeiro, Brazil.
   [Ely, E. Wesley] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Ely, E. Wesley] Vet Affairs Tennessee Valley Geriatr Res Educ Cli, Nashville, TN USA.
RP Salluh, JIF (corresponding author), Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, RJ, Brazil.
EM rodrigobserafim@gmail.com; bozza.fernando@gmail.com;
   marciosoaresms@gmail.com; pedro.brasil@idor.org; tura@centroin.com.br;
   wes.ely@vanderbilt.edu; jorgesalluh@gmail.com
RI Ely, E. Wesley/Z-2018-2019; dantas, vicente c souza/L-2648-2013; Brasil,
   Pedro Emmanuel/AAG-2280-2019; Soares, Marcio/B-3083-2013; Bozza,
   Fernando A/A-2618-2013
OI Ely, E. Wesley/0000-0003-3957-2172; Brasil, Pedro
   Emmanuel/0000-0002-6700-2268; Soares, Marcio/0000-0003-2503-6088; Bozza,
   Fernando A/0000-0003-4878-0256; Salluh, Jorge/0000-0002-8164-1453
FU Hospira, Inc
FX The study was performed with institutional funds. JIFS has received
   honoraria and unrestricted research grants from Hospira, Inc; however,
   it did not interfere with the adherence to the requirements of the
   journal. The others authors state that they have no competing interest
   with the subject.
CR Anton E, 2006, NEW ENGL J MED, V354, P2509
   Atalan N, 2013, J CARDIOTHOR VASC AN, V27, P933, DOI 10.1053/j.jvca.2013.01.017
   Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Clegg A, 2011, AGE AGEING, V40, P23, DOI 10.1093/ageing/afq140
   Dasta JF, 2010, CRIT CARE MED, V38, P497, DOI 10.1097/CCM.0b013e3181bc81c9
   Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302
   Ely EW, 2004, CRIT CARE MED, V32, P106, DOI 10.1097/01.CCM.0000098033.94737.84
   Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2
   Flaherty JH, 2011, J AM GERIATR SOC, V59, pS269, DOI 10.1111/j.1532-5415.2011.03675.x
   Gamberini M, 2009, CRIT CARE MED, V37, P1762, DOI 10.1097/CCM.0b013e31819da780
   Girard TD, 2010, CRIT CARE MED, V38, P428, DOI 10.1097/CCM.0b013e3181c58715
   Hakim SM, 2012, ANESTHESIOLOGY, V116, P987, DOI 10.1097/ALN.0b013e31825153cc
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hipp DM, 2012, NEUROTHERAPEUTICS, V9, P158, DOI 10.1007/s13311-011-0102-9
   Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901
   Katznelson R, 2009, ANESTHESIOLOGY, V110, P67, DOI 10.1097/ALN.0b013e318190b4d9
   Klein PMC, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6652
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   Maldonado JR, 2009, PSYCHOSOMATICS, V50, P206, DOI 10.1176/appi.psy.50.3.206
   Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x
   Mardani D, 2013, J RES MED SCI, V18, P137
   Mariscalco G, 2012, ANN THORAC SURG, V93, P1439, DOI 10.1016/j.athoracsur.2012.02.012
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001
   Page VJ, 2014, AM J RESP CRIT CARE, V189, P666, DOI 10.1164/rccm.201306-1150OC
   Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8
   Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608
   Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC
   Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC
   Prakanrattana U, 2007, ANAESTH INTENS CARE, V35, P714, DOI 10.1177/0310057X0703500509
   Reade MC, 2009, CRIT CARE, V13, DOI 10.1186/cc7890
   Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56
   Rubino AS, 2010, INTERACT CARDIOV TH, V10, P58, DOI 10.1510/icvts.2009.217562
   Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004
   Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783
   Skrobik YK, 2004, INTENS CARE MED, V30, P444, DOI 10.1007/s00134-003-2117-0
   van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420
   van den Boogaard M, 2013, CRIT CARE, V17, DOI 10.1186/cc11933
   van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7
   Vasilevskis EE, 2010, CHEST, V138, P1224, DOI 10.1378/chest.10-0466
   Wang W, 2012, CRIT CARE MED, V40, P731, DOI 10.1097/CCM.0b013e3182376e4f
NR 47
TC 51
Z9 56
U1 0
U2 34
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD AUG
PY 2015
VL 30
IS 4
BP 799
EP 807
DI 10.1016/j.jcrc.2015.04.005
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA CK2TO
UT WOS:000356066100026
PM 25957498
DA 2020-12-01
ER

PT J
AU Barroso, SPC
   Nico, D
   Nascimento, D
   Santos, ACV
   Couceiro, JNSS
   Bozza, FA
   Ferreira, AMA
   Ferreira, DF
   Palatnik-de-Sousa, CB
   Souza, TML
   Gomes, AMO
   Silva, JL
   Oliveira, AC
AF Barroso, Shana P. C.
   Nico, Dirlei
   Nascimento, Danielle
   Santos, Ana Clara V.
   Couceiro, Jose Nelson S. S.
   Bozza, Fernando A.
   Ferreira, Ana M. A.
   Ferreira, Davis F.
   Palatnik-de-Sousa, Clarisa B.
   Souza, Thiago Moreno L.
   Gomes, Andre M. O.
   Silva, Jerson L.
   Oliveira, Andrea C.
TI Intranasal Immunization with Pressure Inactivated Avian Influenza
   Elicits Cellular and Humoral Responses in Mice
SO PLOS ONE
LA English
DT Article
ID FC-ALPHA-RI; HYDROSTATIC-PRESSURE; A-VIRUS; HIGH IMMUNOGENICITY;
   IMMUNE-RESPONSES; VACCINE; PROTECTION; CHALLENGE; INFECTION; H5N1
AB Influenza viruses pose a serious global health threat, particularly in light of newly emerging strains, such as the avian influenza H5N1 and H7N9 viruses. Vaccination remains the primary method for preventing acquiring influenza or for avoiding developing serious complications related to the disease. Vaccinations based on inactivated split virus vaccines or on chemically inactivated whole virus have some important drawbacks, including changes in the immunogenic properties of the virus. To induce a greater mucosal immune response, intranasally administered vaccines are highly desired as they not only prevent disease but can also block the infection at its primary site. To avoid these drawbacks, hydrostatic pressure has been used as a potential method for viral inactivation and vaccine production. In this study, we show that hydrostatic pressure inactivates the avian influenza A H3N8 virus, while still maintaining hemagglutinin and neuraminidase functionalities. Challenged vaccinated animals showed no disease signs (ruffled fur, lethargy, weight loss, and huddling). Similarly, these animals showed less Evans Blue dye leakage and lower cell counts in their bronchoalveolar lavage fluid compared with the challenged non-vaccinated group. We found that the whole inactivated particles were capable of generating a neutralizing antibody response in serum, and IgA was also found in nasal mucosa and feces. After the vaccination and challenge we observed Th1/Th2 cytokine secretion with a prevalence of IFN-gamma Our data indicate that the animals present a satisfactory immune response after vaccination and are protected against infection. Our results may pave the way for the development of a novel pressure-based vaccine against influenza virus.
C1 [Barroso, Shana P. C.; Santos, Ana Clara V.; Gomes, Andre M. O.; Silva, Jerson L.; Oliveira, Andrea C.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Barroso, Shana P. C.; Santos, Ana Clara V.; Bozza, Fernando A.; Gomes, Andre M. O.; Silva, Jerson L.; Oliveira, Andrea C.] Inst Nacl Ciencia & Tecnol Biol Estrutural & Bioi, Rio De Janeiro, Brazil.
   [Nico, Dirlei; Couceiro, Jose Nelson S. S.; Ferreira, Ana M. A.; Ferreira, Davis F.; Palatnik-de-Sousa, Clarisa B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, BR-21941590 Rio De Janeiro, RJ, Brazil.
   [Nascimento, Danielle; Bozza, Fernando A.] Fundacao Oswaldo Cruz FIOCRUZ, Fundacao Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Barroso, Shana P. C.; Souza, Thiago Moreno L.] Fiocruz MS, Inst Oswaldo Cruz, WHO NIC, Lab Virus Resp, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Oliveira, AC (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM cheble@bioqmed.ufrj.br
RI Souza, Thiago Moreno L./G-2900-2012; Bozza, Fernando A/A-2618-2013;
   NASCIMENTO, DANIELLE/ABE-1057-2020; Ferreira, Davis/D-9356-2014;
   Couceiro, Jose Nelson SS/J-3933-2016; Silva, Jerson/J-8984-2014; Gomes,
   Andre/C-4009-2014
OI Souza, Thiago Moreno L./0000-0003-2212-3899; Bozza, Fernando
   A/0000-0003-4878-0256; NASCIMENTO, DANIELLE/0000-0001-8946-6998;
   Couceiro, Jose Nelson SS/0000-0001-8712-4847; Silva,
   Jerson/0000-0001-9523-9441; Gomes, Andre/0000-0003-1052-8004; de Amorim
   Ferreira, Ana Maria/0000-0003-2507-0171; Palatnik-de-Sousa, Clarisa
   B./0000-0002-6231-0608
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Instituto
   Milenio de Biologia Estrutural em Biomedicina e Biotecnologia (IMBEBB);
   Instituto Nacional de Ciencia e Tecnologia de Biologia Estrutural e
   Bioimagem (INBEB); Programa de Apoio a Nucleos de Excelencia (PRONEX)
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   Instituto Milenio de Biologia Estrutural em Biomedicina e Biotecnologia
   (IMBEBB), Instituto Nacional de Ciencia e Tecnologia de Biologia
   Estrutural e Bioimagem (INBEB), and Programa de Apoio a Nucleos de
   Excelencia (PRONEX) to J.L.S., A.M.O.G., and A.C.O. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Adams S, 2010, MED PRIN PRACT, V19, P421, DOI 10.1159/000320299
   Amorij JP, 2008, PHARM RES-DORDR, V25, P1256, DOI 10.1007/s11095-008-9559-6
   [Anonymous], 2003, INFL OV
   Asanuma H, 2007, VACCINE, V25, P6975, DOI 10.1016/j.vaccine.2007.06.060
   Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9
   Belser JA, 2010, J VIROL, V84, P4194, DOI 10.1128/JVI.02742-09
   Boonyaratanakornkit BB, 2002, BBA-PROTEIN STRUCT M, V1595, P235, DOI 10.1016/S0167-4838(01)00347-8
   Calci KR, 2005, APPL ENVIRON MICROB, V71, P339, DOI 10.1128/AEM.71.1.339-343.2005
   Capua I, 2004, AVIAN PATHOL, V33, P393, DOI 10.1080/03079450410001724085
   Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027
   Castleman WL, 2010, VET PATHOL, V47, P507, DOI 10.1177/0300985810363718
   Ceylan C, 2012, VET MICROBIOL, V154, P266, DOI 10.1016/j.vetmic.2011.07.026
   Chawla R, 2011, J FOOD SCI TECH MYS, V48, P260, DOI 10.1007/s13197-010-0180-4
   Committee for Proprietary Medicinal Products (CPMP), 1997, NOT GUID HARM REQ IN
   Cox RJ, 2009, INFLUENZA OTHER RESP, V3, P107, DOI 10.1111/j.1750-2659.2009.00082.x
   Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x
   Crawford PC, 2005, SCIENCE, V310, P482, DOI 10.1126/science.1117950
   Dumard CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080785
   Epstein SL, 2002, EMERG INFECT DIS, V8, P796
   Freitas TRP, 2003, J VIROL METHODS, V108, P205, DOI 10.1016/S0166-0934(02)00289-6
   Fukushi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021207
   Gaspar LP, 2008, J VIROL METHODS, V150, P57, DOI 10.1016/j.jviromet.2008.03.002
   Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138
   Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x
   Gehlen Marcelo Luiz, 2004, Arq. Bras. Oftalmol., V67, P219, DOI 10.1590/S0004-27492004000200007
   Gomes AMO, 2003, BIOCHEMISTRY-US, V42, P5540, DOI 10.1021/bi027207k
   Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025
   Hehme N, 2002, MED MICROBIOL IMMUN, V191, P203, DOI 10.1007/s00430-002-0147-9
   Heremans K, 1998, BBA-PROTEIN STRUCT M, V1386, P353, DOI 10.1016/S0167-4838(98)00102-2
   Hierholzer JC, 1995, VIROLOGY METHODS MAN, P25
   Hoffman AM, 1997, VET CLIN N AM-EQUINE, V13, P463, DOI 10.1016/S0749-0739(17)30224-9
   INGRAM DK, 1982, MECH AGEING DEV, V20, P253, DOI 10.1016/0047-6374(82)90092-6
   JAKAB GJ, 1983, AM REV RESPIR DIS, V128, P730
   JURKIEWICZ E, 1995, P NATL ACAD SCI USA, V92, P6935, DOI 10.1073/pnas.92.15.6935
   KIDA H, 1987, VIROLOGY, V159, P109, DOI 10.1016/0042-6822(87)90353-9
   Kingsley DH, 2007, APPL ENVIRON MICROB, V73, P581, DOI 10.1128/AEM.02117-06
   Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711
   Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07
   LaMere MW, 2011, J VIROL, V85, P5027, DOI 10.1128/JVI.00150-11
   Lamm ME, 2002, J EXP MED, V195, pF5, DOI 10.1084/jem.20011910
   Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368
   Li JE, 2013, SCI CHINA LIFE SCI, V56, P619, DOI 10.1007/s11427-013-4504-2
   Liu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069649
   Longhi MP, 2008, PLOS PATHOG, V4, DOI [10.1371/ journal. ppat. 1000006, DOI 10.1371/J0URNAL.PPAT.1000006]
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LU BL, 1982, INFECT IMMUN, V38, P530, DOI 10.1128/IAI.38.2.530-535.1982
   Marchal S, 2005, BRAZ J MED BIOL RES, V38, P1175, DOI 10.1590/S0100-879X2005000800004
   Masson Patrick, 2001, Journal of Biomedicine and Biotechnology, V1, P85, DOI 10.1155/S1110724301000158
   Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07
   Mei L, 2013, BIOSCI TRENDS, V7, P64, DOI 10.5582/bst.2013.v7.2.64
   Mesquita M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101056
   Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952
   Otten MA, 2004, IMMUNOL LETT, V92, P23, DOI 10.1016/j.imlet.2003.11.018
   PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034
   Proietti E, 2002, J IMMUNOL, V169, P375, DOI 10.4049/jimmunol.169.1.375
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Riberdy JM, 1999, J VIROL, V73, P1453, DOI 10.1128/JVI.73.2.1453-1459.1999
   Rovozzo GC, 1973, MANUAL VIROLOGICAL B
   Schwarcz WD, 2004, CELL MOL BIOL, V50, P419
   Silva JL, 2014, CHEM REV, V114, P7239, DOI 10.1021/cr400204z
   SILVA JL, 1992, J VIROL, V66, P2111, DOI 10.1128/JVI.66.4.2111-2117.1992
   Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6
   Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1
   Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010
   Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10
   Sundararajan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034377
   Szretter Kristy J, 2006, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/0471729256.mc15g01s3
   Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237
   Tian SM, 2000, EUR J BIOCHEM, V267, P4486, DOI 10.1046/j.1432-1327.2000.01496.x
   Tian SM, 1999, ACTA BIOCH BIOPH SIN, V31, P334
   van Egmond M, 2000, NAT MED, V6, P680
   Van Reeth K, 2000, VET MICROBIOL, V74, P109, DOI 10.1016/S0378-1135(00)00171-1
   van Schaik SM, 2000, J MED VIROL, V62, P257, DOI 10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M
   Vandegrift KJ, 2010, ANN NY ACAD SCI, V1195, P113, DOI 10.1111/j.1749-6632.2010.05451.x
   Wilschut JC, 2006, INFLUENZA, P150
   WOOD JM, 1998, TXB INFLUENZA, P333
   World Health Organization, MAN AN INFL DIAGN SU
   Yondon M, 2014, EMERG INFECT DIS, V20, P2144, DOI 10.3201/eid2012.140435
   Zosky GR, 2009, J APPL PHYSIOL, V107, P1472, DOI 10.1152/japplphysiol.00393.2009
NR 79
TC 5
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2015
VL 10
IS 6
AR e0128785
DI 10.1371/journal.pone.0128785
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK6PC
UT WOS:000356349000030
PM 26056825
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Damiani, LP
   Cavalcanti, AB
   Moreira, FR
   Machado, F
   Bozza, FA
   Salluh, JIF
   Campagnucci, VP
   Normilio-Silva, K
   Chiattone, VC
   Angus, DC
   Berwanger, O
   Chang, CCH
AF Damiani, Lucas P.
   Cavalcanti, Alexandre B.
   Moreira, Frederico R.
   Machado, Flavia
   Bozza, Fernando A.
   Salluh, Jorge I. F.
   Campagnucci, Valquiria P.
   Normilio-Silva, Karina
   Chiattone, Viviane C.
   Angus, Derek C.
   Berwanger, Otavio
   Chang, Chung-Chou H.
TI A cluster-randomised trial of a multifaceted quality improvement
   intervention in Brazilian intensive care units (Checklist-ICU trial):
   statistical analysis plan
SO CRITICAL CARE AND RESUSCITATION
LA English
DT Article
ID BLOOD-STREAM INFECTIONS; SAFETY CHECKLISTS; MULTICENTER; ERROR; TOOL
AB Background: The Checklist During Multidisciplinary Visits for Reduction of Mortality in Intensive Care Units (Checklist-ICU) trial is a pragmatic, two-arm, cluster-randomised trial involving 118 intensive care units in Brazil, with the primary objective of determining if a multifaceted quality-improvement intervention with a daily checklist, definition of daily care goals during multidisciplinary daily rounds and clinician prompts can reduce in hospital mortality.
   Objective: To describe our trial statistical analysis plan (SAP).
   Methods: This is an ongoing trial conducted in two phases. In the preparatory observational phase, we collect three sets of baseline data: ICU characteristics; patient characteristics, processes of care and outcomes; and completed safety attitudes questionnaires (SAQs). In the randomised phase, ICUs are assigned to the experimental or control arms and we collect patient data and repeat the SAQ.
   Results: Our SAP includes the prespecified model for the primary and secondary outcome analyses, which account for the cluster-randomised design and availability of baseline data. We also detail the multiple mediation models that we will use to assess our secondary hypothesis (that the effect of the intervention on inhospital mortality is mediated not only through care processes targeted by the checklist, but also through changes in safety culture). We describe our approach to sensitivity and subgroup analyses and missing data.
   Conclusion: We report our SAP before closing our study database and starting analysis. We anticipate that this should prevent analysis bias and enhance the utility of results.
C1 [Damiani, Lucas P.; Moreira, Frederico R.; Normilio-Silva, Karina; Chiattone, Viviane C.] Hosp Coracao, Res Inst, Sao Paulo, Brazil.
   [Cavalcanti, Alexandre B.] Hosp Coracao, Res Inst, Clin Trial Unit, Sao Paulo, Brazil.
   [Berwanger, Otavio] Hosp Coracao, Res Inst, HCor Res Inst, Sao Paulo, Brazil.
   [Machado, Flavia] Univ Fed Sao Paulo, Univ Hosp, Intens Care Unit, Sao Paulo, Brazil.
   [Machado, Flavia] Latin Amer Sepsis Inst, Sao Paulo, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswald Cruz, Intens Care Res Lab, Rio De Janeiro, Brazil.
   [Campagnucci, Valquiria P.] Hosp Samaritano, Intens Care Unit, Sao Paulo, Brazil.
   [Angus, Derek C.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA.
   [Angus, Derek C.] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Pittsburgh, PA USA.
   [Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Med, Pittsburgh, PA USA.
   [Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Med, Pittsburgh, PA 15261 USA.
RP Damiani, LP (corresponding author), Hosp Coracao, Res Inst, Sao Paulo, Brazil.
EM ldamiani@hcor.com.br
RI Bozza, Fernando A/A-2618-2013; Angus, Derek C/E-9671-2012; dantas,
   vicente c souza/L-2648-2013; Cavalcanti, Alexandre/K-5529-2013; Damiani,
   Lucas/F-8576-2015
OI Bozza, Fernando A/0000-0003-4878-0256; Cavalcanti,
   Alexandre/0000-0003-2798-6263; Damiani, Lucas/0000-0002-5836-3379
FU ANVISA; Brazilian Ministry of Health; Brazilian Development and Social
   Bank; Hospital do Coracao; Hospital Samaritano; D'Or Institute for
   Research and Education
FX The study is funded by ANVISA, the Brazilian Ministry of Health and the
   Brazilian Development and Social Bank, through the Program to Support
   Institutional Development of Universal Health System, in partnership
   with Hospital do Coracao and Hospital Samaritano. The D'Or Institute for
   Research and Education also contributed funding for the trial, and the
   Latin American Sepsis Institute provided support for the study. The
   funding sources have no role in the design, execution, analysis, or
   decision to publish the results.
CR Aberegg Scott K, 2010, Crit Care, V14, pR77, DOI 10.1186/cc8990
   BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502
   Cavalcanti AB, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-014-0190-0
   Cribari-Neto F, 2010, J STAT SOFTW, V34, P1
   DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359
   Finfer S, 2009, CRIT CARE RESUSC, V11, P5
   de Carvalho REFL, 2012, REV LAT-AM ENFERM, V20, P575, DOI 10.1590/S0104-11692012000300020
   Gawande Atul, 2010, CHECKLIST MANIFESTO
   Hales BM, 2006, J CRIT CARE, V21, P231, DOI 10.1016/j.jcrc.2006.06.002
   Hayes RJ, 2009, INTERD STAT, P3
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Huang DT, 2010, INT J QUAL HEALTH C, V22, P151, DOI 10.1093/intqhc/mzq017
   Ko HCH, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-211
   Marsteller JA, 2012, CRIT CARE MED, V40, P2933, DOI 10.1097/CCM.0b013e31825fd4d8
   Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745
   Sexton JB, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-44
   Stroup WW, 2013, GEN LINEAR MIXED MOD
   Tingley D, 2014, J STAT SOFTW, V59
   Urbach DR, 2014, NEW ENGL J MED, V370, P1029, DOI 10.1056/NEJMsa1308261
   Zhang Z, 2009, ORGAN RES METHODS, V12, P695, DOI 10.1177/1094428108327450
NR 24
TC 5
Z9 5
U1 0
U2 7
PU AUSTRALASIAN MED PUBL CO LTD
PI PYRMONT
PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA
SN 1441-2772
J9 CRIT CARE RESUSC
JI Crit Care Resusc.
PD JUN
PY 2015
VL 17
IS 2
BP 113
EP 121
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA CJ0ID
UT WOS:000355158100011
PM 26017129
DA 2020-12-01
ER

PT J
AU Evangelista, L
   Cervino, A
   Ghiotto, C
   Saibene, T
   Michieletto, S
   Bozza, F
   Saladini, G
AF Evangelista, Laura
   Cervino, Anna
   Ghiotto, Cristina
   Saibene, Tania
   Michieletto, Silvia
   Bozza, Fernando
   Saladini, Giorgio
TI Could whole-body maximum standardized uptake value and metabolic tumor
   volume by FDG PET/CT further stratify the prognosis of locally advanced
   breast cancer patients?
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging
CY JUN 06-10, 2015
CL Baltimore, MD
SP Soc Nucl Med & Mol Imaging
C1 [Evangelista, Laura; Cervino, Anna; Ghiotto, Cristina; Saibene, Tania; Michieletto, Silvia; Bozza, Fernando; Saladini, Giorgio] Veneto Inst Oncol, Padua, Italy.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY 1
PY 2015
VL 56
IS 3
SU 3
MA 290
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN9AU
UT WOS:000358738800290
DA 2020-12-01
ER

PT J
AU Ramos, GV
   Guaraldo, L
   Japiassu, AM
   Bozza, FA
AF Ramos, G. V.
   Guaraldo, L.
   Japiassu, A. M.
   Bozza, F. A.
TI Comparison of two databases to detect potential drug-drug interactions
   between prescriptions of HIV/AIDS patients in critical care
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Article
DE AIDS; critically ill; drug prescriptions; drug-drug interactions;
   intensive care unit; pharmacovigilance
ID HIV-INFECTED PATIENTS; UNIT; IMPACT; MANAGEMENT; EVENTS; ICU
AB What is known and objectiveAdverse drug events (ADE), common and underestimated in ICU patients, have direct consequences on length of stay, mortality and hospital costs. Critically ill patients with HIV/AIDS are at a high risk of ADE because of their need for multiple drug therapies. ADE can be prevented, especially by the identification of potentially harmful drug-drug interactions (DDIs). Electronic databases are useful tools for the investigation of DDIs to avoid potential ADEs, thereby increasing patient safety. The purpose of this study was to compare the classification and severity rating of potential adverse drug interactions seen in the prescriptions for patients with HIV/AIDS in two databases, one with free access () and another requiring payment for access (Micromedex((R))).
   MethodsA cross-sectional retrospective study of the prescriptions issued for 40 ICU HIV/AIDS patients on mechanical ventilation, admitted for more than 48h, in a referral hospital for infectious diseases in Rio de Janeiro, Brazil, was undertaken. One prescription was reviewed each week for each patient from the second day after admission. A list of all drug-drug interactions was generated for each patient using the two drug-drug interactions databases. The weighted kappa index was estimated to assess the agreement between the classifications of DDIs identified by both databases and qualitative assessment made of any discordant classification of recorded drug-drug interactions.
   Results and discussionOf the 106 prescriptions analysed, Micromedex((R)) and identified 347 and 615 potential DDIs, respectively. A predominance of moderate interactions and pharmacokinetic interactions was observed. The agreement between the databases regarding the severity rating was only 683%. The weighted kappa of 044 is considered moderate. Better agreement (824%) was observed in the classification of mechanism of interaction, with a weighted kappa of 061.
   What is new and ConclusionDDIs are common between the prescriptions of patients with HIV/AIDS admitted to the ICU. Although both databases were able to identify the clinically relevant DDIs, we observed a significant discrepancy in the classification of the severity of DDIs in the two bases. The free access database could serve as an alternative to the identification of DDIs in resource-limited settings; however, there is a need for better evidence-based assessments for your use on clinical management of more serious DDIs.
C1 [Ramos, G. V.; Guaraldo, L.; Japiassu, A. M.; Bozza, F. A.] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Av Brasil,4365 Manguinhos, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Conselho Nacional de Pesquisa e Desenvolvimento
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Pesquisa e
   Desenvolvimento (CNPq) and Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES).
CR [Anonymous], MICR 2 0 HEALTHC SER
   Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7
   Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003
   Kane-Gill SL, 2010, CRIT CARE MED, V38, pS83, DOI 10.1097/CCM.0b013e3181dd8364
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lin D, 2006, ANN PHARMACOTHER, V40, P1594, DOI 10.1345/aph.1G525
   Mangus D, 2002, J CLIN PHARM THER, V27, P377
   Masur Henry, 2006, Proc Am Thorac Soc, V3, P96, DOI 10.1513/pats.200511-122JH
   Reis AMM, 2011, CLINICS, V66, P9, DOI 10.1590/S1807-59322011000100003
   Moura C, 2011, CLIN DRUG INVEST, V31, P309, DOI 10.2165/11586200-000000000-00000
   Papadopoulos J, 2010, CRIT CARE MED, V38, pS126, DOI 10.1097/CCM.0b013e3181de0acf
   Smithburger PL, 2010, DRUG SAFETY, V33, P879, DOI 10.2165/11532340-000000000-00000
   Vargas E, 1998, CLIN DRUG INVEST, V15, P353, DOI 10.2165/00044011-199815040-00011
   Vincent B, 2004, INTENS CARE MED, V30, P859, DOI 10.1007/s00134-004-2158-z
   WHO Collaborating Centre for Drug Statistics Methodology, 2011, AN THER CHEM ATC CLA
   [World Health Organization; WHO UNAIDS UNICEF], 2011, EP UPD HLTH SECT PRO
NR 17
TC 19
Z9 19
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD FEB
PY 2015
VL 40
IS 1
BP 63
EP 67
DI 10.1111/jcpt.12222
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AX9RR
UT WOS:000347240200010
PM 25329640
DA 2020-12-01
ER

PT J
AU Souza, TMLE
   Fintelman-Rodrigues, N
   Resende, PC
   Mesquita, M
   Gregianini, TS
   Bozza, FA
   Pecego, AC
   Fernandes, SB
   Cury, ALF
   Riediger, IN
   Siqueira, MM
AF Lopes e Souza, Thiago Moreno
   Fintelman-Rodrigues, Natalia
   Resende, Paola Cristina
   Mesquita, Milene
   Gregianini, Tatiana Schaffer
   Bozza, Fernando A.
   Pecego, Ana Carla
   Fernandes, Sandra Bianchini
   Furtado Cury, Ana Luisa
   Riediger, Irina Nastassja
   Siqueira, Marilda M.
TI Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil
   are endowed with permissive mutations, which compensate the loss of
   fitness imposed by antiviral resistance
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE influenza A(H1N1)pdm09; oseltamivir; antiviral; resistance; H275Y;
   permissive mutation
ID COMMUNITY CLUSTER; VIRUSES
AB The 2009 pandemic influenza A virus outbreak led to the systematic use of the neuraminidase (NA) inhibitor oseltamivir (OST). Consequently, OST-resistant strains, carrying the mutation H275Y, emerged in the years after the pandemics, with a prevalence of 1-2%. Currently, OST-resistant strains have been found in community settings, in untreated individuals. To spread in community settings, H275Y mutants must contain additional mutations, collectively called permissive mutations. We display the permissive mutations in NA of OST-resistant A(H1N1)pdm09 virus found in Brazilian community settings. The NAs from 2013 are phylogenetically distinct from those of 2012, indicating a tendency of positive selection of NAs with better fitness. Some previously predicted permissive mutations, such as V241I and N369K, found in different countries, were also detected in Brazil. Importantly, the change D344N, also predicted to compensate loss of fitness imposed by H275Y mutation, was found in Brazil, but not in other countries in 2013. Our results reinforce the notion that OST-resistant A(H1N1)pdm09 strains with compensatory mutations may arise in an independent fashion, with samples being identified in different states of Brazil and in different countries. Systematic circulation of these viral strains may jeopardise the use of the first line of anti-influenza drugs in the future.
C1 [Lopes e Souza, Thiago Moreno; Fintelman-Rodrigues, Natalia; Resende, Paola Cristina; Mesquita, Milene; Siqueira, Marilda M.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Virus Respirat Sarampo, Rio De Janeiro, RJ, Brazil.
   [Lopes e Souza, Thiago Moreno] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.; Pecego, Ana Carla] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Lab Med Intens, Rio De Janeiro, RJ, Brazil.
   [Lopes e Souza, Thiago Moreno] Fundacao Oswaldo Cruz, Ctr Desenvolvimento Tecnol Saude, Rio De Janeiro, RJ, Brazil.
   [Gregianini, Tatiana Schaffer] Fundacao Estadual Prod Pesquisa Saude Publ, Secao Virol, Lab Cent Saude Publ Estado Rio Grande Sul, Porto Alegre, RS, Brazil.
   [Fernandes, Sandra Bianchini] Lab Cent Saude Publ Estado Santa Catarina, Florianopolis, SC, Brazil.
   [Furtado Cury, Ana Luisa] Fundacao Ezequiel Dias, Inst Octavio Magalhaes, Lab Cent Saude Publ Estado Minas Gerais, Belo Horizonte, MG, Brazil.
   [Riediger, Irina Nastassja] Lab Cent Saude Publ Estado Parana, Curitiba, PR, Brazil.
RP Souza, TMLE (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Virus Respirat Sarampo, Rio De Janeiro, RJ, Brazil.
EM tmoreno@ioc.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Souza, Thiago Moreno L./G-2900-2012;
   Resende, Paola Cristina/P-5002-2015
OI Bozza, Fernando A/0000-0003-4878-0256; Souza, Thiago Moreno
   L./0000-0003-2212-3899; Resende, Paola Cristina/0000-0002-2884-3662;
   Pecego da Silva, Ana Carla/0000-0002-4131-1425
FU FIOCRUZ; MS/DECIT-SVS; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX FIOCRUZ, MS/DECIT-SVS; MMS was supported in part by individual research
   from CNPq, MMS and TMLS used in part individual research from FAPERJ and
   CNPq.
CR Baillie GJ, 2012, J VIROL, V86, P11, DOI 10.1128/JVI.05347-11
   Bloom JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022201
   Butler J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004065
   CDC - Centers for Disease Control and Prevention, 2013, WEEKL US INFL SURV R
   Correia V, 2015, J MED VIROL, V87, P45, DOI 10.1002/jmv.23986
   Deyde VM, 2010, ANTIMICROB AGENTS CH, V54, P1102, DOI 10.1128/AAC.01417-09
   Dixit Rashmi, 2013, Infectious Disorders - Drug Targets, V13, P34
   Hurt AC, 2012, J INFECT DIS, V206, P148, DOI 10.1093/infdis/jis337
   Hurt AC, 2011, NEW ENGL J MED, V365, P2541, DOI 10.1056/NEJMc1111078
   Hurt AC, 2009, ANTIVIR RES, V83, P90, DOI 10.1016/j.antiviral.2009.03.003
   IBGE, 2010, CENS 2010
   Kelso A, 2012, NAT MED, V18, P1470, DOI 10.1038/nm.2954
   Lackenby A, 2011, EUROSURVEILLANCE, V16, P10
   Meijer A, 2007, Euro Surveill, V12, pE3
   MS - Ministerio da Saude Brasil, 2009, PROT MAN CLIN VIG EP
   Santesso N, 2013, INFLUENZA OTHER RESP, V7, P76, DOI 10.1111/irv.12085
   Souza TML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080081
   Storms AD, 2012, EMERG INFECT DIS, V18, P308, DOI 10.3201/eid1802.111466
   Szretter KJ, 2006, CURR PROTOC MICROB S, V3
   Takashita E, 2014, EUROSURVEILLANCE, V19, P4, DOI 10.2807/1560-7917.ES2014.19.1.20666
   WHO - World Health Organization, 2011, WHO GLOB INFL NETW 2
   World Health Organization, 2009, CDC PROT REALT RTPCR
   Zaraket H, 2014, INTERVIROLOGY, V57, P344, DOI 10.1159/000365758
NR 23
TC 6
Z9 6
U1 0
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2015
VL 110
IS 1
BP 101
EP 105
DI 10.1590/0074-02760140330
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CC9OB
UT WOS:000350699000009
PM 25742269
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Monteiro, APT
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Monteiro, Ana Paula T.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI Inflammasome in Platelets: Allying Coagulation and Inflammation in
   Infectious and Sterile Diseases?
SO MEDIATORS OF INFLAMMATION
LA English
DT Review
ID DENGUE VIRUS-INFECTION; DC-SIGN; CEREBRAL MALARIA; MESSENGER-RNA;
   CYTOKINE PRODUCTION; CELL-DEATH; ACTIVATION; EXPRESSION;
   LIPOPOLYSACCHARIDE; SECRETION
AB Platelets are crucial effector cells in hemostasis. In addition, platelets are increasingly recognized as major inflammatory cells with key roles in innate and adaptive immune responses. Activated platelets have key thromboinflammatory activities linking coagulation to inflammatory response in a variety of coagulation disorders and vasculopathies. Recently identified inflammatory activities of platelets include the synthesis of IL-1 beta. from spliced pre-RNA, as well as the presence and assembly of inflammasome which intermediate IL-1 beta. secretion. Here we review the mechanisms by which platelets activate translation machinery and inflammasome assembly to synthesize and release IL-1 beta. The contributions of these processes to protective and pathogenic responses during infectious and inflammatory diseases are discussed.
C1 [Hottz, Eugenio D.; Monteiro, Ana Paula T.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Hottz, Eugenio D.; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Lab Med Intens, Inst Nacl Infectol Evandro Chagas, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, BR-22281100 Rio De Janeiro, RJ, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Lab Med Intens, Inst Nacl Infectol Evandro Chagas, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM bozza.fernando@gmail.com; pbozza@ioc.fiocruz.br
RI Monteiro, Ana Paula T/L-9540-2013; Bozza, Fernando A/A-2618-2013; Hottz,
   Eugenio D/I-9850-2014
OI Bozza, Fernando A/0000-0003-4878-0256; Reis,
   AlessanRSS/0000-0001-8486-7469; Bozza, Patricia/0000-0001-8349-9529
CR Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143
   Aggrey AA, 2013, J IMMUNOL, V190, P4685, DOI 10.4049/jimmunol.1202672
   Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916
   Beaulieu LM, 2014, ARTERIOSCL THROM VAS, V34, P552, DOI 10.1161/ATVBAHA.113.302700
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928
   Boukour S, 2006, J THROMB HAEMOST, V4, P426, DOI 10.1111/j.1538-7836.2006.01749.x
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brown GT, 2013, J IMMUNOL, V191, P5196, DOI 10.4049/jimmunol.1300354
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Campos FMF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-327
   Coelho HCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063410
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Faille D, 2009, THROMB HAEMOSTASIS, V102, P1093, DOI 10.1160/TH09-05-0337
   Flaujac C, 2010, CELL MOL LIFE SCI, V67, P545, DOI 10.1007/s00018-009-0209-x
   Freedman JE, 2005, CIRCULATION, V112, P2725, DOI 10.1161/CIRCULATIONAHA.104.494468
   Gawaz M, 1998, CIRCULATION, V98, P1164, DOI 10.1161/01.CIR.98.12.1164
   HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785
   HAWRYLOWICZ CM, 1989, J IMMUNOL, V143, P4015
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2014, J IMMUNOL, V193, P1864, DOI 10.4049/jimmunol.1400091
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   KAPLANSKI G, 1993, BLOOD, V81, P2492
   Lamkanfi M, 2011, J IMMUNOL, V187, P597, DOI 10.4049/jimmunol.1100229
   Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500
   Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058
   Loppnow H, 1998, BLOOD, V91, P134, DOI 10.1182/blood.V91.1.134.134_134_141
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mayne E, 2012, JAIDS-J ACQ IMM DEF, V59, P340, DOI 10.1097/QAI.0b013e3182439355
   Mourao MPG, 2007, PLATELETS, V18, P605, DOI 10.1080/09537100701426604
   Moxon CA, 2013, BLOOD, V122, P842, DOI 10.1182/blood-2013-03-490219
   Nishimura S, 2012, BLOOD, V119, pE45, DOI 10.1182/blood-2011-09-381400
   Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042
   Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170
   Rivadeneyra L, 2014, THROMB RES, V133, P235, DOI 10.1016/j.thromres.2013.11.028
   Rondina MT, 2011, J THROMB HAEMOST, V9, P748, DOI 10.1111/j.1538-7836.2011.04208.x
   Rowley JW, 2011, BLOOD, V118, pE101, DOI 10.1182/blood-2011-03-339705
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871
   Srivastava Kalyan, 2008, Cell host & microbe, V4, P179, DOI 10.1016/j.chom.2008.07.003
   Stahl AL, 2006, BLOOD, V108, P167, DOI 10.1182/blood-2005-08-3219
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643
   Varga-Szabo D, 2008, ARTERIOSCL THROM VAS, V28, P403, DOI 10.1161/ATVBAHA.107.150474
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   WHO, 2009, SENG GUID DIAGN TREA
   Yang H, 2013, J INFECT DIS, V207, P50, DOI 10.1093/infdis/jis651
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou Z, 2013, CIRCULATION, V127, P476, DOI 10.1161/CIRCULATIONAHA.112.132126
NR 58
TC 23
Z9 24
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
VL 2015
AR 435783
DI 10.1155/2015/435783
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CD4SU
UT WOS:000351074800001
PM 25814789
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cruz, MR
   Camilo, LM
   Paula, LFSC
   Japiassu, AM
   Beda, A
   Carvalho, AR
   Bozza, FA
   Medeiros, DM
AF Cruz, Monica R.
   Camilo, Luciana M.
   Paula, Luis Felipe S. C.
   Japiassu, Andre M.
   Beda, Alessandro
   Carvalho, Alysson R.
   Bozza, Fernando A.
   Medeiros, Denise M.
TI Effects of Different Levels of Pressure Support on Intra-Individual
   Breath-to-Breath Variability
SO RESPIRATORY CARE
LA English
DT Article
DE pressure support ventilation; breath-to-breath variability;
   patient-ventilator interaction; coefficient of variation
ID MECHANICAL VENTILATION; VARIATIONAL ACTIVITY; PREDICTOR
AB BACKGROUND: Evidence exists that during pressure support ventilation (PSV), the addition of an extrinsic (ie, ventilator-generated) breath-to-breath variability (BBV) of breathing pattern improves respiratory function. If BBV is beneficial per se, choosing the PS level that maximizes it could be considered a valid strategy for conventional PSV. In this study, we evaluated the effect of different PS levels on intrinsic BBV in acutely ill, mechanically ventilated subjects to determine whether a significant relationship exists between PS level and BBV magnitude. METHODS: Fourteen invasively mechanically ventilated subjects were prospectively studied. PS was adjusted at 20 cm H2O and sequentially reduced to 15, 10, and 5 cm H2O. Arterial blood gas analysis and pressure at 0.1 s after the onset of inspiration (P-0.1) were measured at each PS level. Airway and esophageal pressure and air flow were continuously recorded. Peak inspiratory flow, tidal volume (V-T), breathing frequency, and pressure-time product (PTP) were calculated on a breath-by-breath basis. The breathing pattern variability was assessed by the coefficient of variation of the time series of V-T, peak inspiratory flow, and breathing frequency from similar to 60 consecutive breath cycles at each PS level. A general linear model for repeated measures was applied, with PS as an independent factor. A significance level of .05 was considered. RESULTS: Despite a large inter-individual difference in all measured variables (P < .001), the coefficient of variation was as low as 30%, and no significant differences in the coefficient of variation of peak inspiratory flow, breathing frequency, and V-T between PS levels were observed (P > .15). Additionally, a significant increase in P-0.1, PTP, and breathing frequency (P < .01) and a reduction in VT (P < .001) were observed with PS reduction. CONCLUSIONS: Despite a significant increase in spontaneous activity with PS reduction, BBV was not influenced by the PS level and was as low as 30% for all evaluated parameters. (C) 2014 Daedalus Enterprises
C1 [Cruz, Monica R.; Japiassu, Andre M.; Bozza, Fernando A.; Medeiros, Denise M.] Fundacao Oswaldo Cruz, Natl Inst Infect Dis, Lab Clin Res Intens Care Med, BR-21040360 Rio De Janeiro, Brazil.
   [Camilo, Luciana M.; Paula, Luis Felipe S. C.; Carvalho, Alysson R.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Respirat Physiol, BR-21941 Rio De Janeiro, Brazil.
   [Beda, Alessandro] Univ Fed Minas Gerais, Dept Elect, Belo Horizonte, MG, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RP Medeiros, DM (corresponding author), Fundacao Oswaldo Cruz, Natl Inst Infect Dis, Lab Clin Res Intens Care Med, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM bozza.femando@gmail.com; denise.medeiros@ipec.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; CAMILO, LUCIANA MOISES/W-7144-2019;
   Carvalho, Alysson/AAF-1022-2019; Beda, Alessandro/AAC-5519-2019; Beda,
   Alessandro/K-6015-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Beda,
   Alessandro/0000-0002-1867-9846; Beda, Alessandro/0000-0002-1867-9846;
   Carvalho, Alysson/0000-0003-2708-7735
FU Centers of Excellence Program (Programa de Apoio a Nucleos de
   Excelencia-Ministerio da Ciencia e Tecnologia and Ministerio da Ciencia
   e Tecnologia-Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro);
   Brazilian Council for Scientific and Technological Development
   (Ministerio da Ciencia e Tecnologia/Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico); Rio de Janeiro State Research Foundation
   (Fundacao de Amparo Pesquisa do Estado do Rio de Janeiro)
FX This study was supported by the Centers of Excellence Program (Programa
   de Apoio a Nucleos de Excelencia-Ministerio da Ciencia e Tecnologia and
   Ministerio da Ciencia e Tecnologia-Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro), the Brazilian Council for Scientific and
   Technological Development (Ministerio da Ciencia e Tecnologia/Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico), and the Rio de
   Janeiro State Research Foundation (Fundacao de Amparo Pesquisa do Estado
   do Rio de Janeiro). The authors have disclosed no conflicts of interest.
CR BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788
   Bien MY, 2011, CRIT CARE MED, V39, P2253, DOI 10.1097/CCM.0b013e31822279ed
   Bien MY, 2004, INTENS CARE MED, V30, P241, DOI 10.1007/s00134-003-2073-8
   Boker A, 2004, ANESTHESIOLOGY, V100, P608, DOI 10.1097/00000542-200403000-00022
   Boker A, 2002, AM J RESP CRIT CARE, V165, P456, DOI 10.1164/ajrccm.165.4.2108006
   Brack T, 1998, AM J RESP CRIT CARE, V157, P1756, DOI 10.1164/ajrccm.157.6.9704114
   Brack T, 1997, AM J RESP CRIT CARE, V155, P1341, DOI 10.1164/ajrccm.155.4.9105077
   de Abreu MG, 2008, CRIT CARE MED, V36, P818, DOI 10.1097/01.CCM.0000299736.55039.3A
   Giraldo BF, 2013, IEEE ENG MED BIO, P3849, DOI 10.1109/EMBC.2013.6610384
   Jubran A, 2005, AM J RESP CRIT CARE, V171, P1252, DOI 10.1164/rccm.200503-356OC
   JUBRAN A, 1995, AM J RESP CRIT CARE, V152, P129, DOI 10.1164/ajrccm.152.1.7599811
   KURATOMI Y, 1985, JPN J MED, V24, P141
   Mitsis GD, 2009, J APPL PHYSIOL, V106, P1038, DOI 10.1152/japplphysiol.90769.2008
   Mutch WAC, 2000, BRIT J ANAESTH, V84, P197
   Saponjic J, 2003, RESP PHYSIOL NEUROBI, V138, P223, DOI 10.1016/j.resp.2003.08.002
   SASSOON CSH, 1991, AM REV RESPIR DIS, V143, P469, DOI 10.1164/ajrccm/143.3.469
   Spieth PM, 2013, CRIT CARE, V17, DOI 10.1186/cc13091
   Spieth PM, 2011, CRIT CARE MED, V39, P746, DOI 10.1097/CCM.0b013e318206bda6
   Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8
   TOBIN MJ, 1983, CHEST, V84, P286, DOI 10.1378/chest.84.3.286
   TOBIN MJ, 1988, J APPL PHYSIOL, V65, P309
   Wysocki M, 2006, CRIT CARE MED, V34, P2076, DOI 10.1097/01.CCM.0000227175.83575.E9
NR 22
TC 0
Z9 0
U1 0
U2 2
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD DEC
PY 2014
VL 59
IS 12
BP 1888
EP 1894
DI 10.4187/respcare.02853
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CA8WH
UT WOS:000349201100013
PM 25118312
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Barbieri, RR
   Sales, AM
   Illarramendi, X
   Moraes, MO
   Nery, JAD
   Moreira, SJM
   Sarno, EN
   Machado, AD
   Bozza, FA
AF Barbieri, Raquel Rodrigues
   Sales, Anna Maria
   Illarramendi, Ximena
   Moraes, Milton Ozorio
   da Costa Nery, Jose Augusto
   Maria Moreira, Suelen Justo
   Sarno, Euzenir Nunes
   Machado, Alice de Miranda
   Bozza, Fernando Augusto
TI Diagnostic challenges of single plaque-like lesion paucibacillary
   leprosy
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE paucibacillary leprosy; diagnosis; quantitative polymerase chain
   reaction
ID REAL-TIME PCR; MYCOBACTERIUM-LEPRAE DNA; CLASSIFICATION; SPECIMENS
AB The diagnosis of single-lesion paucibacillary leprosy remains a challenge. Reviews by expert dermatopathologists and quantitative polymerase chain reaction (qPCR) results obtained from 66 single-plaque biopsy samples were compared. Histological findings were graded as high (HP), medium (MP) or low (LP) probability of leprosy or other dermatopathy (OD). Mycobacterium leprae-specific genes were detected using qPCR. The biopsies of 47 out of 57 clinically diagnosed patients who received multidrug therapy were classified as HP/MP, eight of which were qPCR negative. In the LP/OD (n = 19), two out of eight untreated patients showed positive qPCR results. In the absence of typical histopathological features, qPCR may be utilised to aid in final patient diagnosis, thus reducing overtreatment and delay in diagnosis.
C1 [Barbieri, Raquel Rodrigues; Bozza, Fernando Augusto] Inst Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, BR-20001 Rio De Janeiro, RJ, Brazil.
   [Sales, Anna Maria; Illarramendi, Ximena; Moraes, Milton Ozorio; da Costa Nery, Jose Augusto; Maria Moreira, Suelen Justo; Sarno, Euzenir Nunes; Machado, Alice de Miranda] Inst Oswaldo Cruz, FIOCRUZ, Lab Hanseniase, BR-20001 Rio De Janeiro, RJ, Brazil.
RP Sarno, EN (corresponding author), Inst Oswaldo Cruz, FIOCRUZ, Inst Nacl Infectol Evandro Chagas, BR-20001 Rio De Janeiro, RJ, Brazil.
EM euzenir@fiocruz.br
RI Illarramendi, Ximena/G-2592-2019; Bozza, Fernando A/A-2618-2013; Moraes,
   Milton Ozorio/G-9753-2011
OI Illarramendi, Ximena/0000-0003-1504-1553; Bozza, Fernando
   A/0000-0003-4878-0256; Moraes, Milton Ozorio/0000-0003-2653-0037; Nunes
   Sarno, Euzenir/0000-0003-0129-2159
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX CNPq, FAPERJ
CR Altman D.G., 1991, PRACTICAL STAT MED R
   BHATIA AS, 1993, INT J LEPROSY, V61, P433
   Buhrer-Sekula S, 2009, ACTA TROP, V111, P172, DOI 10.1016/j.actatropica.2009.04.009
   FINE PEM, 1993, INT J LEPROSY, V61, P270
   Gupte M D, 1990, Indian J Lepr, V62, P281
   Kumar B, 2009, INDIAN J DERMATOL VE, V75, P111, DOI 10.4103/0378-6323.48653
   Lini N, 2009, J MED MICROBIOL, V58, P753, DOI 10.1099/jmm.0.007252-0
   Martinez AN, 2006, J CLIN MICROBIOL, V44, P3154, DOI 10.1128/JCM.02250-05
   Martinez AN, 2009, J CLIN MICROBIOL, V47, P2124, DOI 10.1128/JCM.00512-09
   Martinez AN, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001354
   MS/CNS - Ministerio da Saude Brasil/Conselho Nacional de Saude, 1996, 19696 MS CNS
   RIDLEY DS, 1973, J PATHOL, V111, P191, DOI 10.1002/path.1711110307
   Rudeeaneksin J, 2008, FEMS IMMUNOL MED MIC, V54, P263, DOI 10.1111/j.1574-695X.2008.00472.x
   Scollard DM, 2006, CLIN MICROBIOL REV, V19, P338, DOI 10.1128/CMR.19.2.338-381.2006
   SEHGAL VN, 1977, INT J LEPROSY, V45, P278
NR 15
TC 8
Z9 8
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD NOV
PY 2014
VL 109
IS 7
BP 944
EP 947
DI 10.1590/0074-0276140212
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AU2FD
UT WOS:000345430900015
PM 25411000
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Lisboa, T
   Bozza, FA
   Soares, M
   Povoa, P
AF Salluh, Jorge I. F.
   Lisboa, Thiago
   Bozza, Fernando A.
   Soares, Marcio
   Povoa, Pedro
TI Management of severe community-acquired pneumonia: A survey on the
   attitudes of 468 physicians in Iberia and South America
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Severe community-acquired pneumonia; Sepsis; Mechanical ventilation;
   Antimicrobials; Multiple organ failure
ID INFECTIOUS-DISEASES-SOCIETY; NATIONAL GUIDELINES; ANTIBIOTIC-THERAPY;
   CLINICAL-COURSE; OUTCOMES; CARE; CORTICOSTEROIDS; VALIDATION;
   CHALLENGES; ADMISSION
AB Purpose: The purpose of this study is to characterize the practices of pulmonary, internal medicine, and critical care physicians toward the management of patients with severe community-acquired pneumonia (CAP).
   Materials and methods: A cross-sectional international anonymous survey was conducted among a convenience sample of critical care, pulmonary, emergency, and internal medicine physicians from Portugal, Spain, and South America between October and December 2008. The electronic survey evaluated physicians' attitudes toward diagnosis, risk assessment, and therapeutic interventions for patients with severe CAP.
   Results: Four hundred sixty-eight physicians responded being 84.6% from 4 countries (Brazil, Portugal, Spain, and Argentina) whom 66.9% had more than 10 years experience. Risk assessment of severe CAP was very heterogeneous being clinical evaluation the most frequent. Although blood cultures were recognized as presenting a poor diagnostic performance, they were performed by 77.1%. In opposition, the presence of urinary pneumococcal and Legionella antigen was asked by less than one-third of physicians. The great majority (95%) prescribes antibiotics according to a guideline being the combination of beta-lactam plus macrolide the most frequent choice.
   Conclusions: Despite the recent advances of knowledge reflected in the present study in the management of severe CAP, several of them are still incompletely translated into clinical practice. Significant variation in practice is observed among physicians and represents a potential target for future research and educational interventions. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Salluh, Jorge I. F.; Bozza, Fernando A.; Soares, Marcio] Dor Inst Res & Educ, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Soares, Marcio] Inst Nacl Canc, Postgraduat Program, Rio De Janeiro, Brazil.
   [Lisboa, Thiago] Univ Fed Rio Grande do Sul, Intens Care Unit, Porto Alegre, RS, Brazil.
   [Lisboa, Thiago] Univ Fed Rio Grande do Sul, Hosp Clin, Postgrad Program Pneumol, Infect Control Comm, Porto Alegre, RS, Brazil.
   [Lisboa, Thiago] Complexo Hosp Santa Casa, RIPIMI, Porto Alegre, RS, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Povoa, Pedro] Univ Nova Lisboa, Hosp Sao Francisco Xavier, Fac Med Sci, Ctr Hosp Lisboa Ocidental,CEDOC,Polyvalent Intens, Lisbon, Portugal.
RP Salluh, JIF (corresponding author), Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI Lisboa, Thiago/W-2973-2019; Bozza, Fernando A/A-2618-2013; Soares,
   Marcio/B-3083-2013; dantas, vicente c souza/L-2648-2013
OI Lisboa, Thiago/0000-0003-4306-2212; Bozza, Fernando
   A/0000-0003-4878-0256; Soares, Marcio/0000-0003-2503-6088; Salluh,
   Jorge/0000-0002-8164-1453
FU BRICNet
FX The study was supported by the infrastructure of BRICNet.
CR Angus DC, 2002, AM J RESP CRIT CARE, V166, P717, DOI 10.1164/rccm.2102084
   Arnold FW, 2009, ARCH INTERN MED, V169, P1515, DOI 10.1001/archinternmed.2009.265
   Barlow G, 2007, THORAX, V62, P253, DOI 10.1136/thx.2006.067371
   Charles PGP, 2008, CLIN INFECT DIS, V47, P375, DOI 10.1086/589754
   Christ-Crain M, CRIT CARE, V14, P203
   Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC
   Coelho L, 2007, CRIT CARE, V11, DOI 10.1186/cc6105
   Collini P, 2007, POSTGRAD MED J, V83, P552, DOI 10.1136/pgmj.2006.056556
   Dean NC, 2006, CHEST, V130, P794, DOI 10.1378/chest.130.3.794
   Jones AE, 2007, ACAD EMERG MED, V14, P1072, DOI 10.1197/j.aem.2007.04.014
   Kalassian KG, 2002, CRIT CARE, V6, P11
   Laterre PF, 2005, CRIT CARE MED, V33, P952, DOI 10.1097/01.CCM.0000162381.24074.D7
   Laterre PF, 2008, CLIN INFECT DIS, V46, P1510, DOI 10.1086/587666
   Liapikou A, 2009, CLIN INFECT DIS, V48, P377, DOI 10.1086/596307
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Lisboa T, 2010, CRIT CARE MED, V38, pS656, DOI 10.1097/CCM.0b013e3181f2453a
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Martin-Loeches I, 2010, INTENS CARE MED, V36, P612, DOI 10.1007/s00134-009-1730-y
   Niederman MS, 2007, CHEST, V131, P1205, DOI 10.1378/chest.06-1994
   Povoa P, 2008, CURR OPIN INFECT DIS, V21, P157, DOI 10.1097/QCO.0b013e3282f47c32
   Rello J, 2007, INTENS CARE MED, V33, P2043, DOI 10.1007/s00134-007-0896-4
   Rello Jordi, 2009, Curr Infect Dis Rep, V11, P343, DOI 10.1007/s11908-009-0049-8
   Restrepo MI, 2008, CHEST, V133, P828, DOI 10.1378/chest.07-2887
   Rodriguez A, 2007, CRIT CARE MED, V35, P1493, DOI 10.1097/01.CCM.0000266755.75844.05
   Salluh JIF, 2008, CRIT CARE, V12, DOI 10.1186/cc6922
   Salluh JIF, 2008, CHEST, V134, P947, DOI 10.1378/chest.08-1382
   Salluh JIF, 2011, J CRIT CARE, V26, P193, DOI 10.1016/j.jcrc.2010.07.014
   Schuetz P, 2009, JAMA-J AM MED ASSOC, V302, P1059, DOI 10.1001/jama.2009.1297
   Waterer GW, 2011, AM J RESP CRIT CARE, V183, P157, DOI 10.1164/rccm.201002-0272CI
   Yende SK, 2006, P AM THORAC SOC, V3, pA836
NR 30
TC 3
Z9 4
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD OCT
PY 2014
VL 29
IS 5
BP 743
EP 747
DI 10.1016/j.jcrc.2014.05.019
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA AN9LL
UT WOS:000340928000010
PM 24973102
DA 2020-12-01
ER

PT J
AU d'Avila, JC
   Siqueira, LD
   Bozza, FA
   Foguel, D
   Azevedo, E
AF d'Avila, J. C.
   Siqueira, L. D.
   Bozza, F. A.
   Foguel, D.
   Azevedo, E.
TI Age-related memory impairment induced by recurrent low-grade systemic
   inflammation is associated to a deregulation of inflammatory response
SO BRAIN PATHOLOGY
LA English
DT Meeting Abstract
CT 18th International Congress of Neuropathology
CY SEP 14-18, 2014
CL Rio de Janeiro, BRAZIL
C1 [d'Avila, J. C.; Siqueira, L. D.; Bozza, F. A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Foguel, D.; Azevedo, E.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1015-6305
EI 1750-3639
J9 BRAIN PATHOL
JI Brain Pathol.
PD SEP
PY 2014
VL 24
SU 1
SI SI
MA P11-02
BP 55
EP 55
PG 1
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA AP6CT
UT WOS:000342165800203
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Medeiros-de-Moraes, IM
   Vieira-de-Abreu, A
   de Assis, EF
   Vals-de-Souza, R
   Castro-Faria-Neto, HC
   Weyrich, AS
   Zimmerman, GA
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Medeiros-de-Moraes, Isabel M.
   Vieira-de-Abreu, Adriana
   de Assis, Edson F.
   Vals-de-Souza, Rogerio
   Castro-Faria-Neto, Hugo C.
   Weyrich, Andrew S.
   Zimmerman, Guy A.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI Platelet Activation and Apoptosis Modulate Monocyte Inflammatory
   Responses in Dengue
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID VIRUS-INFECTIONS; P-SELECTIN; CELL-DEATH; PERMEABILITY; FEVER;
   MACROPHAGES; EXPRESSION; SEVERITY; IMMUNOPATHOGENESIS;
   PHOSPHATIDYLSERINE
AB Dengue is the most prevalent human arbovirus disease in the world. Dengue infection has a large spectrum of clinical manifestations, from self-limited febrile illness to severe syndromes accompanied by bleeding and shock. Thrombocytopenia and vascular leak with altered cytokine profiles in plasma are features of severe dengue. Although monocytes have been recognized as important sources of cytokines in dengue, the contributions of platelet-monocyte interactions to inflammatory responses in dengue have not been addressed. Patients with dengue were investigated for platelet-monocyte aggregate formation. Platelet-induced cytokine responses by monocytes and underlying mechanisms were also investigated in vitro. We observed increased levels of platelet-monocyte aggregates in blood samples from patients with dengue, especially patients with thrombocytopenia and increased vascular permeability. Moreover, the exposure of monocytes from healthy volunteers to platelets from patients with dengue induced the secretion of the cytokines IL-1 beta, IL-8, IL-10 and MCP-1, whereas exposure to platelets from healthy volunteers only induced the secretion of MCP-1. In addition to the well-established modulation of monocyte cytokine responses by activated platelets through P-selectin binding, we found that interaction of monocytes with apoptotic platelets mediate IL-10 secretion through phosphatidylserine recognition in platelet-monocyte aggregates. Moreover, IL-10 secretion required plateletmonocyte contact but not phagocytosis. Together, our results demonstrate that activated and apoptotic platelets aggregate with monocytes during dengue infection and signal specific cytokine responses that may contribute to the pathogenesis of dengue.
C1 [Hottz, Eugenio D.; Medeiros-de-Moraes, Isabel M.; Vieira-de-Abreu, Adriana; de Assis, Edson F.; Castro-Faria-Neto, Hugo C.; Zimmerman, Guy A.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Vals-de-Souza, Rogerio; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Weyrich, Andrew S.; Zimmerman, Guy A.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [Weyrich, Andrew S.] Univ Utah, Mol Med Program, Salt Lake City, UT 84112 USA.
   [Bozza, Fernando A.] Inst DOr Pesquisa & Ensino, BR-22281110 Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
EM Fernando.bozza@ipec.fiocruz.br; pbozza@ioc.fiocruz.br
RI Hottz, Eugenio D/I-9850-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Weyrich,
   Andrew/0000-0001-9622-4647; Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de JaneiroCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Programa Estrategico de Apoio a Pesquisa em Saude/Fundacao Oswaldo Cruz;
   Programa de Apoio a Nucleos de Excelencia Dengue; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HL066277, HL091754, R37HL044525];
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL066277, R37HL044525,
   R01HL066277, R37HL044525, R01HL066277, R37HL044525, R01HL066277,
   R37HL044525, R01HL091754, R37HL044525, R01HL066277, R01HL091754,
   R37HL044525, R01HL066277, R01HL066277, R01HL066277, R01HL066277,
   R01HL066277, R01HL091754, R37HL044525, R37HL044525, R01HL066277,
   R37HL044525, R01HL091754, R01HL066277, R37HL044525] Funding Source: NIH
   RePORTER
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Fundacao de Amparo a Pesquisa
   do Estado do Rio de Janeiro, Programa Estrategico de Apoio a Pesquisa em
   Saude/Fundacao Oswaldo Cruz, Programa de Apoio a Nucleos de Excelencia
   Dengue, and the National Institutes of Health (Grants HL066277,
   HL091754, and R37HL044525 to A.S.W. and G.A.Z). G.A.Z. is the recipient
   of a Ciencia Sem Fronteiras special visiting professorship from Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico.
CR Aggrey AA, 2013, J IMMUNOL, V190, P4685, DOI 10.4049/jimmunol.1202672
   Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Aslam R, 2007, TRANSFUSION, V47, P2161, DOI 10.1111/j.1537-2995.2007.01441.x
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Chung EY, 2007, IMMUNITY, V27, P952, DOI 10.1016/j.immuni.2007.11.014
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Dixon DA, 2006, J CLIN INVEST, V116, P2727, DOI 10.1172/JC127209
   Falconar AKI, 2006, CLIN VACCINE IMMUNOL, V13, P1044, DOI 10.1128/CVI.00105-06
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Gerber DE, 2011, CLIN CANCER RES, V17, P6888, DOI 10.1158/1078-0432.CCR-11-1074
   Gudbrandsdottir S, 2013, J IMMUNOL, V191, P4059, DOI 10.4049/jimmunol.1201103
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Houghton-Trivino N, 2010, BIOMEDICA, V30, P587
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Jobe SM, 2008, BLOOD, V111, P1257, DOI 10.1182/blood-2007-05-092684
   Kling D, 2013, THROMB RES, V131, P401, DOI 10.1016/j.thromres.2013.02.020
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Malavige GN, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002409
   Malavige GN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050387
   Maugeri N, 2009, BLOOD, V113, P5254, DOI 10.1182/blood-2008-09-180794
   Mourao MPG, 2007, PLATELETS, V18, P605, DOI 10.1080/09537100701426604
   Onlamoon N, 2010, BLOOD, V115, P1823, DOI 10.1182/blood-2009-09-242990
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Priyadarshini D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008709
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Schmidt AC, 2010, NEW ENGL J MED, V363, P484, DOI 10.1056/NEJMcibr1005904
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shu PY, 2003, CLIN DIAGN LAB IMMUN, V10, P622, DOI 10.1128/CDLI.10.4.622-630.2003
   Stephen J, 2013, J IMMUNOL, V191, P5677, DOI 10.4049/jimmunol.1301250
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   Tardif JC, 2013, J AM COLL CARDIOL, V61, P2048, DOI 10.1016/j.jacc.2013.03.003
   Tsai JJ, 2011, J INNATE IMMUN, V3, P530, DOI 10.1159/000322904
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Weyrich AS, 2005, CIRCULATION, V111, P633, DOI 10.1161/01.CIR.0000154607.90506.45
   Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x
   World Health Organization, 2009, DENG GUID DIAGN TREA
NR 47
TC 67
Z9 71
U1 1
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2014
VL 193
IS 4
BP 1864
EP 1872
DI 10.4049/jimmunol.1400091
PG 9
WC Immunology
SC Immunology
GA AO2HK
UT WOS:000341139300037
PM 25015827
OA Bronze, Green Accepted
DA 2020-12-01
ER

PT J
AU Azevedo, LCP
   Caruso, P
   Silva, UVA
   Torelly, AP
   Silva, E
   Rezende, E
   Netto, JJ
   Piras, C
   Lobo, SMA
   Knibel, MF
   Teles, JM
   Lima, RA
   Ferreira, BS
   Friedman, G
   Rea-Neto, A
   Dal-Pizzol, F
   Bozza, FA
   Salluh, JIF
   Soares, M
AF Azevedo, Luciano C. P.
   Caruso, Pedro
   Silva, Ulysses V. A.
   Torelly, Andre P.
   Silva, Eliezer
   Rezende, Ederlon
   Netto, Jose J.
   Piras, Claudio
   Lobo, Suzana M. A.
   Knibel, Marcos F.
   Teles, Jose M.
   Lima, Ricardo. A.
   Ferreira, Bruno S.
   Friedman, Gilberto
   Rea-Neto, Alvaro
   Dal-Pizzol, Felipe
   Bozza, Fernando A.
   Salluh, Jorge I. F.
   Soares, Marcio
CA Brazilian Res Intensive Care Netwo
TI Outcomes for Patients With Cancer Admitted to the ICU Requiring
   Ventilatory Support Results From a Prospective Multicenter Study
SO CHEST
LA English
DT Article
ID ACUTE RESPIRATORY-FAILURE; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE
   UNITS; NONINVASIVE VENTILATION; MECHANICAL VENTILATION; HEMATOLOGIC
   MALIGNANCY; PROGNOSTIC-FACTORS; MORTALITY; ADMISSION; SURVIVAL
AB BACKGROUND: This study was undertaken to evaluate the clinical characteristics and outcomes of patients with cancer requiring nonpalliative ventilatory support.
   METHODS: This was a secondary analysis of a prospective cohort study conducted in 28 Brazilian ICUs evaluating adult patients with cancer requiring invasive mechanical ventilation (MV) or noninvasive ventilation (NIV) during the first 48 h of their ICU stay. We used logistic regression to identify the variables associated with hospital mortality.
   RESULTS: Of 717 patients, 263 (37%) (solid tumors 5 227; hematologic malignancies 5 36) received ventilatory support. NIV was initially used in 85 patients (32%), and 178 (68%) received MV. Additionally, NIV followed by MV occurred in 45 patients (53%). Hospital mortality rates were 67% in all patients, 40% in patients receiving NIV only, 69% when NIV was followed by MV, and 73% in patients receiving MV only (P<.001). Adjusting for the type of admission, newly diagnosed malignancy (OR, 3.59; 95% CI, 1.28-10.10), recurrent or progressive malignancy (OR, 3.67; 95% CI, 1.25-10.81), tumoral airway involvement (OR, 4.04; 95% CI, 1.30-12.56), performance status (PS) 2 to 4 (OR, 2.39; 95% CI, 1.24-4.59), NIV followed by MV (OR, 3.00; 95% CI, 1.09-8.18), MV as initial ventilatory strategy (OR, 3.53; 95% CI, 1.45-8.60), and Sequential Organ Failure Assessment score (each point except the respiratory domain) (OR, 1.15; 95% CI, 1.03-1.29) were associated with hospital mortality. Hospital survival in patients with good PS and nonprogressive malignancy and without tumoral airway involvement was 53%. Conversely, patients with poor functional capacity and cancer progression had unfavorable outcomes.
   CONCLUSIONS: Patients with cancer with good PS and nonprogressive disease requiring ventilatory support should receive full intensive care, because one-half of these patients survive. On the other hand, provision of palliative care should be considered the main goal for patients with poor PS and progressive underlying malignancy.
C1 [Azevedo, Luciano C. P.] Hosp Sirio Libanes, ICU, Sao Paulo, Brazil.
   [Caruso, Pedro] Hosp AC Camargo Fund Antonio Prudente, ICU, Sao Paulo, Brazil.
   [Silva, Ulysses V. A.] Hosp Israelita Albert Einstein, ICU, Sao Paulo, Brazil.
   [Rezende, Ederlon] Hosp Servidor Publ Estadual, ICU, Sao Paulo, Brazil.
   [Azevedo, Luciano C. P.; Salluh, Jorge I. F.; Soares, Marcio] Hosp Canc II, Inst Nacl Canc, Programa Posgrad Oncol, Rio De Janeiro, Brazil.
   [Netto, Jose J.] Hosp Canc II, Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   [Lima, Ricardo. A.] Hosp Samaritano, ICU, Rio De Janeiro, Brazil.
   [Knibel, Marcos F.] Hosp Sao Lucas, ICU, Rio De Janeiro, Brazil.
   [Ferreira, Bruno S.] Pasteur Hosp, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ, BR-22281100 Rio De Janeiro, Brazil.
   [Silva, Eliezer] Hosp Canc Barretos, Fdn Pio 12, ICU, Barretos, Brazil.
   [Torelly, Andre P.] Santa Casa Misericordia Porto Alegre, ICU, Porto Alegre, RS, Brazil.
   [Friedman, Gilberto] Univ Fed Rio Grande do Sul, ICU, Porto Alegre, RS, Brazil.
   [Piras, Claudio] Vitoria Apart Hosp, ICU, Vitoria, Brazil.
   [Lobo, Suzana M. A.] Med Sch & Hosp Base, Dept Internal Med, Div Crit Care Med, Sao Jose Do Rio Preto, Brazil.
   [Teles, Jose M.] Hosp Portugues, ICU, Salvador, BA, Brazil.
   [Rea-Neto, Alvaro] Univ Fed Parana, Hosp Clin, ICU, BR-80060000 Curitiba, Parana, Brazil.
   [Dal-Pizzol, Felipe] Univ Extremo Sul Catarinense, Programa Posgrad Ciencias Saude, Lab Fisiopatol Expt, Unidade Acad Ciencias Saude, Criciuma, Brazil.
RP Soares, M (corresponding author), DOr Inst Res & Educ, Rua Diniz Cordeiro 30, BR-22281100 Rio De Janeiro, Brazil.
EM marciosoaresms@gmail.com
RI Rea-Neto, Alvaro/AAR-7909-2020; V.A.Silva, Ulysses/AAZ-3336-2020;
   Azevedo, Luciano CP/H-2652-2012; dantas, vicente c souza/L-2648-2013;
   Bozza, Fernando A/A-2618-2013; Caruso, Pedro/B-6054-2016; Dal-Pizzol,
   Felipe/F-2756-2015; Friedman, Gilberto/F-7208-2015; Friedman,
   Gilberto/F-7212-2015; Soares, Marcio/B-3083-2013
OI Rea-Neto, Alvaro/0000-0001-5524-0907; V.A.Silva,
   Ulysses/0000-0002-1284-2016; Azevedo, Luciano CP/0000-0001-6759-3910;
   Bozza, Fernando A/0000-0003-4878-0256; Caruso,
   Pedro/0000-0002-1051-8458; Dal-Pizzol, Felipe/0000-0003-3003-8977;
   Friedman, Gilberto/0000-0001-9369-2488; Soares,
   Marcio/0000-0003-2503-6088; Salluh, Jorge/0000-0002-8164-1453
FU Instituto Nacional de Cancer; National Council for Scientific and
   Technological Development of Brazil (CNPq)National Council for
   Scientific and Technological Development (CNPq); Fundacao Carlos Chagas
   Filho de Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ)
FX This article was supported by the Instituto Nacional de Cancer, the
   National Council for Scientific and Technological Development of Brazil
   (CNPq), and Fundacao Carlos Chagas Filho de Amparo Pesquisa do Estado do
   Rio de Janeiro (FAPERJ).
CR Adda M, 2008, CRIT CARE MED, V36, P2766, DOI 10.1097/CCM.0b013e31818699f6
   Azevedo LCP, 2013, CRIT CARE, V17, DOI 10.1186/cc12594
   Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb
   Azoulay E, 2001, CRIT CARE MED, V29, P519, DOI 10.1097/00003246-200103000-00009
   Azoulay E, 2006, INTENS CARE MED, V32, P808, DOI 10.1007/s00134-006-0129-2
   Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365
   Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5
   Benoit DD, 2003, CRIT CARE MED, V31, P104, DOI 10.1097/00003246-200301000-00017
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6
   Demoule A, 2006, INTENS CARE MED, V32, P1747, DOI 10.1007/s00134-006-0229-z
   Depuydt PO, 2010, J CRIT CARE, V25, P30, DOI 10.1016/j.jcrc.2009.02.016
   Depuydt PO, 2004, CHEST, V126, P1299, DOI 10.1378/chest.126.4.1299
   Gayat E, 2010, INTENS CARE MED, V36, P1993, DOI 10.1007/s00134-010-1991-5
   Gristina GR, 2011, CRIT CARE MED, V39, P2232, DOI 10.1097/CCM.0b013e3182227a27
   Groeger JS, 1999, J CLIN ONCOL, V17, P991, DOI 10.1200/JCO.1999.17.3.991
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Kallogjeri D, 2012, J GERIATR ONCOL, V3, P238, DOI 10.1016/j.jgo.2012.01.006
   Lecuyer L, 2008, EUR RESPIR J, V32, P748, DOI 10.1183/09031936.00142907
   Levy MM, 2001, CRIT CARE MED, V2003, P530, DOI DOI 10.1097/01.CCM.0000050454.01978.3B
   Molina R, 2012, CRIT CARE, V16, DOI 10.1186/cc11438
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Rosolem MM, 2012, J CRIT CARE, V27, P301, DOI 10.1016/j.jcrc.2011.06.014
   Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983
   Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04
   Soares M, 2006, CRIT CARE MED, V34, P715, DOI 10.1097/01.CCM.0000201883.05900.3F
   Soares M, 2005, INTENS CARE MED, V31, P408, DOI 10.1007/s00134-005-2554-z
   Soares M, 2007, CHEST, V131, P840, DOI 10.1378/chest.06-2244
   Soares M, 2010, CRIT CARE CLIN, V26, P41, DOI 10.1016/j.ccc.2009.09.005
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Song JU, 2012, INTENS CARE MED, V38, P1505, DOI 10.1007/s00134-012-2594-0
   Staudinger T, 2000, CRIT CARE MED, V28, P1322, DOI 10.1097/00003246-200005000-00011
   Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713
   Tanvetyanon T, 2003, CRIT CARE MED, V31, P60, DOI 10.1097/00003246-200301000-00009
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 36
TC 81
Z9 84
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD AUG
PY 2014
VL 146
IS 2
BP 257
EP 266
DI 10.1378/chest.13-1870
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AN3JB
UT WOS:000340482400032
PM 24480886
DA 2020-12-01
ER

PT J
AU Sharshar, T
   Bozza, F
   Chretien, F
AF Sharshar, Tarek
   Bozza, Fernando
   Chretien, Fabrice
TI Neuropathological processes in sepsis Comment
SO LANCET NEUROLOGY
LA English
DT Editorial Material
ID SEPTIC SHOCK; DYSFUNCTION; DEATH
C1 [Sharshar, Tarek] Univ Versailles, Raymond Poincare Hosp, AP HP, F-92380 Paris, France.
   [Sharshar, Tarek; Chretien, Fabrice] Inst Pasteur, Dept Histopathol & Anim Models, Paris, France.
   [Bozza, Fernando] Fundacao Oswaldo Cruz, Evandro Chagas Inst, Rio De Janeiro, Brazil.
   [Bozza, Fernando] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RP Sharshar, T (corresponding author), Univ Versailles, Raymond Poincare Hosp, AP HP, F-92380 Paris, France.
EM tarek.sharshar@rpc.aphp.fr
RI Bozza, Fernando A/A-2618-2013; Chretien, fabrice/D-4035-2018
OI Bozza, Fernando A/0000-0003-4878-0256; Chretien,
   fabrice/0000-0002-2794-1383
CR Adam N, 2013, EXPERT REV ANTI-INFE, V11, P211, DOI [10.1586/ERI.12.159, 10.1586/eri.12.159]
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Shah FA, 2013, AM J RESP CRIT CARE, V188, P586, DOI 10.1164/rccm.201212-2154OC
   Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x
   Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4
   Sharshar T, 2011, CRIT CARE MED, V39, P1960, DOI 10.1097/CCM.0b013e31821b843b
   van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7
   Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1
NR 11
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
EI 1474-4465
J9 LANCET NEUROL
JI Lancet Neurol.
PD JUN
PY 2014
VL 13
IS 6
BP 534
EP 536
DI 10.1016/S1474-4422(14)70064-X
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA AI8YK
UT WOS:000337212700007
PM 24849853
DA 2020-12-01
ER

PT J
AU Rodrigues, RS
   Brum, ALG
   Paes, MV
   Povoa, TF
   Basilio-de-Oliveira, CA
   Marchiori, E
   Borghi, DP
   Ramos, GV
   Bozza, FA
AF Rodrigues, Rosana Souza
   Garcia Brum, Ana Livia
   Paes, Marciano Viana
   Povoa, Tiago Fajardo
   Basilio-de-Oliveira, Carlos Alberto
   Marchiori, Edson
   Borghi, Danielle Provencano
   Ramos, Grazielle Viana
   Bozza, Fernando Augusto
TI Lung in Dengue: Computed Tomography Findings
SO PLOS ONE
LA English
DT Article
ID DIFFUSE ALVEOLAR HEMORRHAGE; IMMUNOCOMPETENT PATIENTS; VIRUS-INFECTION;
   PLASMA LEAKAGE; FEVER; MANIFESTATIONS; LEPTOSPIROSIS; AMERICA
AB Background: Dengue is the most important mosquito-borne viral disease in the world. Dengue virus infection may be asymptomatic or lead to undifferentiated fever, dengue fever with or without warning signs, or severe dengue. Lower respiratory symptoms are unusual and lung-imaging data in patients with dengue are scarce.
   Methodology/Principal Findings: To evaluate lung changes associated with dengue infection, we retrospectively analyzed 2,020 confirmed cases of dengue. Twenty-nine of these patients (11 females and 18 males aged 16-90 years) underwent chest computed tomography (CT), which yielded abnormal findings in 17 patients: 16 patients had pleural effusion (the sole finding in six patients) and 11 patients had pulmonary abnormalities. Lung parenchyma involvement ranged from subtle to moderate unilateral and bilateral abnormalities. The most common finding was ground-glass opacity in eight patients, followed by consolidation in six patients. Less common findings were airspace nodules (two patients), interlobular septal thickening (two patients), and peribronchovascular interstitial thickening (one patient). Lung histopathological findings in four fatal cases showed thickening of the alveolar septa, hemorrhage, and interstitial edema.
   Conclusions/Significance: In this largest series involving the use of chest CT to evaluate lung involvement in patients with dengue, CT findings of lower respiratory tract involvement were uncommon. When abnormalities were present, pleural effusion was the most frequent finding and lung involvement was often mild or moderate and bilateral. Extensive lung abnormalities are infrequent even in severe disease and when present should lead physicians to consider other diagnostic possibilities.
C1 [Rodrigues, Rosana Souza; Garcia Brum, Ana Livia; Ramos, Grazielle Viana; Bozza, Fernando Augusto] DOr Inst Res & Educ, Rio De Janeiro, RJ, Brazil.
   [Rodrigues, Rosana Souza; Marchiori, Edson] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
   [Paes, Marciano Viana; Povoa, Tiago Fajardo] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Basilio-de-Oliveira, Carlos Alberto] Fed Univ State Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
   [Borghi, Danielle Provencano] Corpo Bombeiros Mil Estado Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
   [Ramos, Grazielle Viana; Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Rio De Janeiro, RJ, Brazil.
RP Rodrigues, RS (corresponding author), DOr Inst Res & Educ, Rio De Janeiro, RJ, Brazil.
EM rosana.souzarodrigues@gmail.com; bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Paes,
   Marciano/0000-0002-2266-2801; Marchiori, Edson/0000-0001-8797-7380
FU D'Or Institute for Research and Education
FX D'Or Institute for Research and Education has supported the work. The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Balasubramanian S, 2006, INDIAN PEDIATR, V43, P334
   Basílio-de-Oliveira C.A., 2005, Braz J Infect Dis, V9, P341, DOI 10.1590/S1413-86702005000400012
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Ejaz K, 2011, SAUDI MED J, V32, P46
   Elicker BM, 2010, EMERG RADIOL, V17, P299, DOI 10.1007/s10140-010-0859-x
   Ellis T, 2008, VECTOR-BORNE ZOONOT, V8, P541, DOI 10.1089/vbz.2007.0241
   Fried JR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000617
   Gluecker T, 1999, RADIOGRAPHICS, V19, P1507, DOI 10.1148/radiographics.19.6.g99no211507
   Gulati S, 2007, TROP MED INT HEALTH, V12, P1087, DOI 10.1111/j.1365-3156.2007.01891.x
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Halsey ES, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001638
   HALSTEAD SB, 1989, REV INFECT DIS, V11, pS830
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Marchiori E, 2002, J THORAC IMAG, V17, P151, DOI 10.1097/00005382-200204000-00007
   Marchiori E, 2012, RESP MED, V106, P1807, DOI 10.1016/j.rmed.2012.07.014
   Marchiori E, 2011, EUR J RADIOL, V77, P80, DOI 10.1016/j.ejrad.2009.06.017
   Marchiori E, 2011, LUNG, V189, P1, DOI 10.1007/s00408-010-9273-0
   Marchiori E, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-8
   Mergo PJ, 1999, J THORAC IMAG, V14, P122, DOI 10.1097/00005382-199904000-00011
   Mustafa B, 2010, Med J Malaysia, V65, P291
   PRAMULJO HS, 1991, PEDIATR RADIOL, V21, P100, DOI 10.1007/BF02015615
   Sharma S K, 2007, J Assoc Physicians India, V55, P729
   Srikiatkhachorn A, 2007, PEDIATR INFECT DIS J, V26, P283, DOI 10.1097/01.inf.0000258612.26743.10
   Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846
   von Ranke FM, 2013, LUNG, V191, P9, DOI 10.1007/s00408-012-9431-7
   Wang CC, 2007, AM J TROP MED HYG, V77, P291, DOI 10.4269/ajtmh.2007.77.291
   World Health Organization, 2009, DENG GUID DIAGN TREA
   World Health Organization & Special Programme for Research and Training in Tropical Diseases, 2012, HDB CLIN MAN DENG
NR 31
TC 15
Z9 15
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2014
VL 9
IS 5
AR e96313
DI 10.1371/journal.pone.0096313
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1NZ
UT WOS:000339614800014
PM 24836605
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Austin, S
   Murthy, S
   Wunsch, H
   Adhikari, NKJ
   Karir, V
   Rowan, K
   Jacob, ST
   Salluh, J
   Bozza, F
   Du, B
   An, YZ
   Lee, B
   Wu, F
   Nguyen, YL
   Oppong, C
   Venkataraman, R
   Velayutham, V
   Duenas, C
   Angus, DC
AF Austin, Shamly
   Murthy, Srinivas
   Wunsch, Hannah
   Adhikari, Neill K. J.
   Karir, Veena
   Rowan, Kathryn
   Jacob, Shevin T.
   Salluh, Jorge
   Bozza, Fernando A.
   Du, Bin
   An, Youzhong
   Lee, Bruce
   Wu, Felicia
   Yen-Lan Nguyen
   Oppong, Chris
   Venkataraman, Ramesh
   Velayutham, Vimalraj
   Duenas, Carmelo
   Angus, Derek C.
CA Int Forum Acute Care Trialists
TI Access to urban acute care services in high- vs. middle-income
   countries: an analysis of seven cities
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Urban population; Acute care services; Global burden of disease;
   Hospital beds; Intensive care beds; Ambulances
ID INTENSIVE-CARE
AB Cities are expanding rapidly in middle-income countries, but their supply of acute care services is unknown. We measured acute care services supply in seven cities of diverse economic background.
   In a cross-sectional study, we compared cities from two high-income (Boston, USA and Paris, France), three upper-middle-income (Bogota, Colombia; Recife, Brazil; and Liaocheng, China), and two lower-middle-income (Chennai, India and Kumasi, Ghana) countries. We collected standardized data on hospital beds, intensive care unit beds, and ambulances. Where possible, information was collected from local authorities. We expressed results per population (from United Nations) and per acute illness deaths (from Global Burden of Disease project).
   Supply of hospital beds where intravenous fluids could be delivered varied fourfold from 72.4/100,000 population in Kumasi to 241.5/100,000 in Boston. Intensive care unit (ICU) bed supply varied more than 45-fold from 0.4/100,000 population in Kumasi to 18.8/100,000 in Boston. Ambulance supply varied more than 70-fold. The variation widened when supply was estimated relative to disease burden (e.g., ICU beds varied more than 65-fold from 0.06/100 deaths due to acute illnesses in Kumasi to 4.11/100 in Bogota; ambulance services varied more than 100-fold). Hospital bed per disease burden was associated with gross domestic product (GDP) (R (2) = 0.88, p = 0.01), but ICU supply was not (R (2) = 0.33, p = 0.18). No city provided all requested data, and only two had ICU data.
   Urban acute care services vary substantially across economic regions, only partially due to differences in GDP. Cities were poor sources of information, which may hinder their future planning.
C1 [Austin, Shamly; Angus, Derek C.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA 15261 USA.
   [Murthy, Srinivas] Univ British Columbia, BC Childrens Hosp, Div Crit Care, Vancouver, BC V5Z 1M9, Canada.
   [Wunsch, Hannah] Columbia Univ, Dept Anesthesiol, New York, NY USA.
   [Wunsch, Hannah] Columbia Univ, Dept Epidemiol, New York, NY USA.
   [Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada.
   [Adhikari, Neill K. J.] Univ Toronto, Toronto, ON, Canada.
   [Karir, Veena] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA.
   [Rowan, Kathryn] Intens Care Natl Audit & Res Ctr, London, England.
   [Jacob, Shevin T.] Univ Washington, Dept Med, Int Resp & Severe Illness Ctr INTERSECT, Div Allergy & Infect Dis, Seattle, WA 98195 USA.
   [Salluh, Jorge] DOR Inst Res & Educ, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Du, Bin] Beijing Union Med Coll Hosp, Beijing, Peoples R China.
   [An, Youzhong] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China.
   [Lee, Bruce] Johns Hopkins Bloomberg Sch Publ Hlth, Publ Hlth Computat & Operat Res PHICOR Grp, Baltimore, MD USA.
   [Wu, Felicia] Michigan State Univ, Dept Food Sci & Human Nutr, E Lansing, MI 48824 USA.
   [Yen-Lan Nguyen] Paris Descartes Univ, Cochin Acad Hosp, AP HP, Surg ICU, Paris, France.
   [Yen-Lan Nguyen] Univ Paris 06, Unites INSERM U738, U707, Paris, France.
   [Oppong, Chris] Komfo Anokye Teaching Hosp, Dept Emergency Med, Kumasi, Ghana.
   [Venkataraman, Ramesh] Apollo Hosp, Chennai, Tamil Nadu, India.
   [Velayutham, Vimalraj] Stanley Med Coll Hosp, Chennai, Tamil Nadu, India.
   [Duenas, Carmelo] Univ Cartagena, Cartagena, Colombia.
   [Duenas, Carmelo] Hosp Santa Cruz Bocagrande, Cartagena, Colombia.
   [Duenas, Carmelo] Inst Simulac Med, Bogota, Colombia.
RP Angus, DC (corresponding author), Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, 3550 Terrace St,614 Scaife Hall, Pittsburgh, PA 15261 USA.
EM angusdc@upmc.edu
RI Angus, Derek C/E-9671-2012; dantas, vicente c souza/L-2648-2013;
   velayutham, vimalraj/E-4892-2011; Bozza, Fernando A/A-2618-2013; Austin,
   Shamly/AAG-1414-2020; Murthy, Srinivas/AAS-7243-2020
OI Bozza, Fernando A/0000-0003-4878-0256; Austin,
   Shamly/0000-0003-1307-9849; Salluh, Jorge/0000-0002-8164-1453; Murthy,
   Srinivas/0000-0002-9476-839X; Jacob, Shevin/0000-0003-2425-9394
CR Annez PC, 2010, AGENDA FOR RESEARCH
   [Anonymous], 2008, THE GLOBAL BURDEN OF
   Brazilian Institute of Geography and Statistics (IBGE), 2012, POPULATION ESTIMATES
   Firth P, 2012, NEW ENGL J MED, V367, P1974, DOI 10.1056/NEJMp1204957
   Ghana Statistical Services. Social and Demographic Statistics, 2010, SOCIAL AND DEMOGRAPH
   Goldfrad C, 2000, LANCET, V355, P1138, DOI 10.1016/S0140-6736(00)02062-6
   Hsiao M, 2013, LANCET, V381, P993, DOI 10.1016/S0140-6736(13)60707-2
   Murthy S, 2013, CRIT CARE SUPPL 2, V17, pP489
   National Institute of Statistics and Economic Studies (INSEE), 2012, THE POPULATION CENSU
   The China Science Center of International Eurasian Academy of Sciences China Association of Mayors UN Habitat, 2010, THE STATE OF CHINAS
   The International Bank for Reconstruction and Development/The World Bank, 2002, CITIES ON THE MOVE A
   U. S. Census Bureau, 2012, STATE AND COUNTY QUI
   [UNICEF WHO], 2013, PROGRESS ON SANITATI
   United Nations Department of Economic and Social Affairs, 2011, POPULATION DISTRIBUT
   United Nations Department of Economic and Social Affairs Population Division, 2010, WORLD URBANIZATION P
   United Nations Department of Economic and Social Affairs Population Division, 2011, 2009 2010 UN DEMOGRA
   United Nations Human Settlements Programme (UN- Habitat), 2011, PLANNING SUSTAINABLE
   United Nations Population Fund, 2008, STATE OF WORLD POPUL
   United Nations Population Fund, 2007, URBANIZATION A MAJOR
   United NationsDepartment of Economic and Social Affairs/Population Division, 2012, WORLD URBANIZATION P
   World Bank, 2013, GDP PER CAPITA PPP C
   World Health Organization, 2009, INVESTING IN OUR COM
   World Health Organization, 2013, GLOBAL BURDEN OF DIS
   Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8
NR 24
TC 36
Z9 38
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD MAR
PY 2014
VL 40
IS 3
BP 342
EP 352
DI 10.1007/s00134-013-3174-7
PG 11
WC Critical Care Medicine
SC General & Internal Medicine
GA AC3YL
UT WOS:000332457400004
PM 24337401
OA Other Gold, Green Published
DA 2020-12-01
ER

PT J
AU Hernandes, MS
   D'Avila, JC
   Trevelin, SC
   Reis, PA
   Kinjo, ER
   Lopes, LR
   Castro-Faria-Neto, HC
   Cunha, FQ
   Britto, LRG
   Bozza, FA
AF Hernandes, Marina S.
   D'Avila, Joana C.
   Trevelin, Silvia C.
   Reis, Patricia A.
   Kinjo, Erika R.
   Lopes, Lucia R.
   Castro-Faria-Neto, Hugo C.
   Cunha, Fernando Q.
   Britto, Luiz R. G.
   Bozza, Fernando A.
TI The role of Nox2-derived ROS in the development of cognitive impairment
   after sepsis
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Systemic inflammation; Brain; NADPH oxidase; Oxidative stress;
   Encephalopathy
ID INDUCED LUNG INFLAMMATION; NADPH OXIDASE; GENE-EXPRESSION; MICROGLIAL
   ACTIVATION; OXIDATIVE DAMAGE; CECAL LIGATION; BRAIN; INHIBITION;
   APOCYNIN; INJURY
AB Background: Sepsis-associated encephalopathy (SAE) is an early and common feature of severe infections. Oxidative stress is one of the mechanisms associated with the pathophysiology of SAE. The goal of this study was to investigate the involvement of NADPH oxidase in neuroinflammation and in the long-term cognitive impairment of sepsis survivors.
   Methods: Sepsis was induced in WT and gp91(phox) knockout mice (gp91(phox-/-)) by cecal ligation and puncture (CLP) to induce fecal peritonitis. We measured oxidative stress, Nox2 and Nox4 gene expression and neuroinflammation in the hippocampus at six hours, twenty-four hours and five days post-sepsis. Mice were also treated with apocynin, a NADPH oxidase inhibitor. Behavioral outcomes were evaluated 15 days after sepsis with the inhibitory avoidance test and the Morris water maze in control and apocynin-treated WT mice.
   Results: Acute oxidative damage to the hippocampus was identified by increased 4-HNE expression in parallel with an increase in Nox2 gene expression after sepsis. Pharmacological inhibition of Nox2 with apocynin completely inhibited hippocampal oxidative stress in septic animals. Pharmacologic inhibition or the absence of Nox2 in gp91(phox-/-) mice prevented glial cell activation, one of the central mechanisms associated with SAE. Finally, treatment with apocynin and inhibition of hippocampal oxidative stress in the acute phase of sepsis prevented the development of long-term cognitive impairment.
   Conclusions: Our results demonstrate that Nox2 is the main source of reactive oxygen species (ROS) involved in the oxidative damage to the hippocampus in SAE and that Nox2-derived ROS are determining factors for cognitive impairments after sepsis. These findings highlight the importance of Nox2-derived ROS as a central mechanism in the development of neuroinflammation associated with SAE.
C1 [Hernandes, Marina S.; Kinjo, Erika R.; Britto, Luiz R. G.] Univ Sao Paulo, Dept Physiol & Biophys, Sao Paulo, Brazil.
   [Lopes, Lucia R.] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, Brazil.
   [D'Avila, Joana C.; Reis, Patricia A.; Castro-Faria-Neto, Hugo C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Trevelin, Silvia C.; Cunha, Fernando Q.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, Sao Paulo, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Inst DOr Pesquisa Ensino IDOR, Rio De Janeiro, Brazil.
   [Hernandes, Marina S.] Univ Sao Paulo, Inst Biomed Sci, Lab Cellular Neurobiol, BR-05508900 Sao Paulo, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Hernandes, MS (corresponding author), Univ Sao Paulo, Dept Physiol & Biophys, Sao Paulo, Brazil.
EM marinash@icb.usp.br; fernando.bozza@ipec.fiocruz.br
RI Cunha, Fernando Q/M-3090-2014; Bozza, Fernando A/A-2618-2013; Kinjo,
   Erika R/C-9381-2014; d'Avila, Joana/L-8970-2013; Trevelin, Silvia
   Cellone/I-5678-2018; Lopes, Lucia R/B-9063-2012
OI Bozza, Fernando A/0000-0003-4878-0256; d'Avila,
   Joana/0000-0002-2045-0813; Trevelin, Silvia Cellone/0000-0003-2722-2458;
   Lopes, Lucia R/0000-0003-0530-7805; Kinjo, Erika/0000-0003-2788-0880;
   Cunha, Fernando Queiroz/0000-0003-4755-1670
FU FAPERJ (Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   University of Sao Paulo-NAPNA; CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico)National Council for Scientific
   and Technological Development (CNPq); FAPERJCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX Work supported by FAPERJ (Fundacao de Amparo a Pesquisa do Estado do Rio
   de Janeiro), FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo), University of Sao Paulo-NAPNA and CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico). JCD and FAB were the
   recipients of fellowships from FAPERJ. MSH and SCT were the recipients
   of fellowships from FAPESP. ERK and FAB were recipients of fellowships
   from CNPq.
CR Adam N, 2013, EXPERT REV ANTI-INFE, V11, P211, DOI [10.1586/ERI.12.159, 10.1586/eri.12.159]
   Alves JC, 2009, P NATL ACAD SCI USA, V106, P4018, DOI 10.1073/pnas.0900196106
   Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476
   Babior BM, 2002, ANTIOXID REDOX SIGN, V4, P35, DOI 10.1089/152308602753625834
   Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12
   Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96
   Barja G, 2000, FASEB J, V14, P312
   Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48
   Boillee S, 2008, J CLIN INVEST, V118, P474, DOI [10.1172/JC134613, 10.1172/JCI34613]
   Borrelli E, 1996, CRIT CARE MED, V24, P392, DOI 10.1097/00003246-199603000-00006
   Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334
   Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023
   Brown KL, 2008, CLIN IMMUNOL, V129, P90, DOI 10.1016/j.clim.2008.06.005
   Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47
   Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x
   Chuang CC, 2006, CRIT CARE, V10, DOI 10.1186/cc4826
   Comim CM, 2011, NEUROCHEM RES, V36, P304, DOI 10.1007/s11064-010-0320-2
   Cowley HC, 1996, CRIT CARE MED, V24, P1179, DOI 10.1097/00003246-199607000-00019
   Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114
   Ebels E J, 1981, Acta Neuropathol Suppl, V7, P352
   Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470
   FORBES G B, 1954, Postgrad Med, V15, P157
   Ghosh A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-241
   Gomes RN, 2013, SHOCK, V39, P63, DOI 10.1097/SHK.0b013e31827802b5
   GOODE HF, 1995, CRIT CARE MED, V23, P646, DOI 10.1097/00003246-199504000-00011
   Guerreiro MO, 2010, J TRAUMA, V69, pE102, DOI 10.1097/TA.0b013e3181dbb289
   Han W, 2013, J IMMUNOL, V190, P4786, DOI 10.4049/jimmunol.1201809
   Hernandes MS, 2010, NEUROSCIENCE, V170, P1249, DOI 10.1016/j.neuroscience.2010.07.065
   Hernandes MS, 2012, CURR NEUROPHARMACOL, V10, P321, DOI 10.2174/157015912804143540
   Hsieh HL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-110
   Huet O, 2007, CRIT CARE MED, V35, P821, DOI 10.1097/01.CCM.0000257464.79067.AF
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jensen MD, 2009, NEUROCHEM INT, V55, P362, DOI 10.1016/j.neuint.2009.04.002
   Lafeber FPJG, 1999, RHEUMATOLOGY, V38, P1088, DOI 10.1093/rheumatology/38.11.1088
   Lekstrom-Himes JA, 2005, J IMMUNOL, V174, P411, DOI 10.4049/jimmunol.174.1.411
   MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0
   Nohl H, 2003, BIOCHEM SOC T, V31, P1308
   Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200
   Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644
   Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963
   Ritter C, 2003, INTENS CARE MED, V29, P1782, DOI 10.1007/s00134-003-1789-9
   Rodriguez-Pallares J, 2007, J NEUROCHEM, V103, P145, DOI 10.1111/j.1471-4159.2007.04699.x
   Schappi MG, 2008, J PATHOL, V214, P434, DOI 10.1002/path.2298
   Sebollela A, 2012, J BIOL CHEM, V287, P7436, DOI 10.1074/jbc.M111.298471
   Segal BH, 2007, AM J PHYSIOL-LUNG C, V292, pL760, DOI 10.1152/ajplung.00281.2006
   Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020
   Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x
   SIMONS JM, 1990, FREE RADICAL BIO MED, V8, P251, DOI 10.1016/0891-5849(90)90070-Y
   Sipos I, 2003, J NEUROCHEM, V84, P112, DOI 10.1046/j.1471-4159.2003.01513.x
   Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]
   STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341
   Sugawara T, 2003, ANTIOXID REDOX SIGN, V5, P597, DOI 10.1089/152308603770310266
   Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511
   Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4
   Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6
   Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060
   Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471-4159.2003.02242.x
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
   Yoshioka H, 2011, J CEREBR BLOOD F MET, V31, P868, DOI 10.1038/jcbfm.2010.166
   YOUNG RSK, 1983, PEDIATR RES, V17, P349, DOI 10.1203/00006450-198305000-00008
   Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504
NR 65
TC 72
Z9 77
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD FEB 27
PY 2014
VL 11
AR 36
DI 10.1186/1742-2094-11-36
PG 12
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA AD4SG
UT WOS:000333240200001
PM 24571599
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Almeida, ICT
   Soares, M
   Bozza, FA
   Shinotsuka, CR
   Bujokas, R
   Souza-Dantas, VC
   Ely, EW
   Salluh, JIF
AF Almeida, Isabel C. T.
   Soares, Marcio
   Bozza, Fernando A.
   Shinotsuka, Cassia Righy
   Bujokas, Renata
   Souza-Dantas, Vicente Ces
   Ely, E. Wesley
   Salluh, Jorge I. F.
TI The Impact of Acute Brain Dysfunction in the Outcomes of Mechanically
   Ventilated Cancer Patients
SO PLOS ONE
LA English
DT Article
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; CONFUSION ASSESSMENT
   METHOD; DELIRIUM; ICU; RELIABILITY; ADMISSION; SEDATION; VALIDITY; TRIAL
AB Introduction: Delirium and coma are a frequent source of morbidity for ICU patients. Several factors are associated with the prognosis of mechanically ventilated (MV) cancer patients, but no studies evaluated delirium and coma (acute brain dysfunction). The present study evaluated the frequency and impact of acute brain dysfunction on mortality.
   Methods: The study was performed at National Cancer Institute, Rio de Janeiro, Brazil. We prospectively enrolled patients ventilated >48 h with a diagnosis of cancer. Acute brain dysfunction was assessed during the first 14 days of ICU using RASS/CAM-ICU. Patients were followed until hospital discharge. Univariate and multivariable analysis were performed to evaluate factors associated with hospital mortality.
   Results: 170 patients were included. 73% had solid tumors, age 65 [53-72 (median, IQR 25%-75%)] years. SAPS II score was 54[46-63] points and SOFA score was (7 [6-9]) points. Median duration of MV was 13 (6-21) days and ICU stay was 14 (7.5-22) days. ICU mortality was 54% and hospital mortality was 66%. Acute brain dysfunction was diagnosed in 161 patients (95%). Survivors had more delirium/coma-free days [4(1,5-6) vs 1(0-2), p<0.001]. In multivariable analysis the number of days of delirium/coma-free days were associated with better outcomes as they were independent predictors of lower hospital mortality [0.771 (0.681 to 0.873), p<0.001].
   Conclusions: Acute brain dysfunction in MV cancer patients is frequent and independently associated with increased hospital mortality. Future studies should investigate means of preventing or mitigating acute brain dysfunction as they may have a significant impact on clinical outcomes.
C1 [Almeida, Isabel C. T.; Soares, Marcio; Shinotsuka, Cassia Righy; Bujokas, Renata; Souza-Dantas, Vicente Ces; Salluh, Jorge I. F.] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
   [Almeida, Isabel C. T.; Soares, Marcio; Shinotsuka, Cassia Righy; Bujokas, Renata; Souza-Dantas, Vicente Ces; Salluh, Jorge I. F.] Inst Nacl Canc, Postgrad Program, Rio De Janeiro, Brazil.
   [Soares, Marcio; Bozza, Fernando A.; Shinotsuka, Cassia Righy; Salluh, Jorge I. F.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Intens Care Lab, IPEC, Rio De Janeiro, Brazil.
   [Ely, E. Wesley] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Ely, E. Wesley] Vet Affairs Tennessee Valley Geriatr Res Educ Cli, Nashville, TN USA.
RP Salluh, JIF (corresponding author), Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
EM jorgesalluh@gmail.com
RI dantas, vicente c souza/L-2648-2013; Almeida, Igor C./AAF-9409-2019;
   Ely, E. Wesley/Z-2018-2019; Shinotsuka, Cassia Righy/H-9181-2013; Bozza,
   Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013
OI Almeida, Igor C./0000-0002-2443-8213; Ely, E.
   Wesley/0000-0003-3957-2172; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552; Bozza, Fernando A/0000-0003-4878-0256;
   Soares, Marcio/0000-0003-2503-6088
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX MS and JIFS received individual research grants from CNPq and FAPERJ,
   Brazilian governmental agencies for research funding. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb
   Azoulay E, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-5
   Caraceni A, 2000, CANCER-AM CANCER SOC, V89, P1145, DOI 10.1002/1097-0142(20000901)89:5<1145::AID-CNCR24>3.0.CO;2-X
   Clegg A, 2011, AGE AGEING, V40, P23, DOI 10.1093/ageing/afq140
   Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1
   Gusmao-Flores D, 2012, CRIT CARE, V16, DOI 10.1186/cc11407
   Gusmao-Flores D, 2011, CLINICS, V66, P1917, DOI 10.1590/S1807-59322011001100011
   JJS MD, 2012, BEST PRACT RES CLIN, V26, P327, DOI [10.1016/j.bpa.2012.08.003., DOI 10.1016/J.BPA.2012.08.003]
   Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002
   Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786
   Lecuyer L, 2007, CRIT CARE MED, V35, P808, DOI 10.1097/01.CCM.0000256846.27192.7A
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   MD GM, 2012, BEST PRACT RES CLIN, V26, P311, DOI [10.1016/j.bpa.2012.07.001., DOI 10.1016/J.BPA.2012.07.001]
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Neufeld KJ, 2011, PSYCHOSOMATICS, V52, P133, DOI 10.1016/j.psym.2010.12.018
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56
   Rosolem M, 2009, CRIT CARE, V13, pP56, DOI [10.1186/cc7858., DOI 10.1186/CC7858]
   Saczynski JS, 2012, NEW ENGL J MED, V367, P30, DOI 10.1056/NEJMoa1112923
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9
   Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04
   Soares M, 2010, INTENS CARE MED, V36, P1188, DOI 10.1007/s00134-010-1807-7
   Soares M, 2010, CRIT CARE CLIN, V26, P41, DOI 10.1016/j.ccc.2009.09.005
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713
   Takeuchi M, 2012, ANN SURG ONCOL, V19, P3963, DOI 10.1245/s10434-012-2432-1
   Thiery G, 2005, J CLIN ONCOL, V23, P4406, DOI 10.1200/JCO.2005.01.487
NR 32
TC 12
Z9 16
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2014
VL 9
IS 1
AR e85332
DI 10.1371/journal.pone.0085332
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297VL
UT WOS:000330283100037
PM 24465538
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Ribeiro, SR
   Luz, PM
   Campos, DP
   Moreira, RI
   Coelho, L
   Japiassu, A
   Bozza, F
   Veloso, VG
   Chene, G
   Grinsztejn, B
AF Ribeiro, Sayonara R.
   Luz, Paula M.
   Campos, Dayse P.
   Moreira, Ronaldo I.
   Coelho, Lara
   Japiassu, Andre
   Bozza, Fernando
   Veloso, Valdilea G.
   Chene, Genevieve
   Grinsztejn, Beatriz
TI Incidence and determinants of severe morbidity among HIV-infected
   patients from Rio de Janeiro, Brazil, 2000-2010
SO ANTIVIRAL THERAPY
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; LONGITUDINAL DATA-ANALYSIS;
   UNITED-STATES; CLINICAL CARE; HAART ERA; COHORT; MORTALITY; EFFICACY;
   TRENDS; AIDS
AB Background: Reliable information on severe morbidity is essential for identifying priorities for case management and to guide resource allocation within the health sector.
   Methods: This study describes overall, AIDS-and non-AIDS-related severe morbidity as well as mortality and its determinants in an urban cohort of HIV-infected individuals from a public healthcare institution, the Evandro Chagas Research Institute (IPEC) of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Severe morbid events were defined as all clinical diagnoses listed in hospitalization discharge records; all diagnoses were checked and validated. Generalized estimating equation models were used to estimate incidence rates while adjusting for within-subject correlation.
   Results: Between 2000 and 2010, 3,537 patients were followed for a total of 16,960 person-years (PY) of follow-up. Over the years, annual incidence rate of severe morbid events, AIDS-related events, non-AIDS-related events, and deaths significantly decreased from, respectively, 36.6, 12.9, 23.7 and 3.2 per 100 PY in 2000 to 25.3, 7.9, 17.4 and 1.9 per 100 PY in 2010. Patients' immunological profiles significantly improved with time; 84% of the patients used combination antiretroviral therapy (cART) per year. Immunodeficiency was associated with a higher incidence rate of AIDS-and non-AIDS-related events as well as with the incidence rate of specific non-AIDS events (bacterial infections, toxicities, cardiovascular, renal and respiratory diseases).
   Conclusions: Our results show that in a middle income country with access to cART, non-AIDS-related events represent an important cause of severe morbidity alongside a still high incidence rate of AIDS-related events.
C1 [Ribeiro, Sayonara R.; Luz, Paula M.; Campos, Dayse P.; Moreira, Ronaldo I.; Coelho, Lara; Japiassu, Andre; Bozza, Fernando; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Chene, Genevieve] INSERM, U593, Bordeaux, France.
RP Luz, PM (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM luzpaulamendes@gmail.com
RI chene, genevieve/H-8665-2014; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Luz, Paula/0000-0001-9746-719X
CR Anglaret X, 2012, CLIN INFECT DIS, V54, P714, DOI 10.1093/cid/cir898
   Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672
   Belloso WH, 2010, HIV MED, V11, P554, DOI 10.1111/j.1468-1293.2010.00824.x
   Berry SA, 2012, JAIDS-J ACQ IMM DEF, V59, P368, DOI 10.1097/QAI.0b013e318246b862
   Bonnet F, 2009, CLIN INFECT DIS, V48, P633, DOI 10.1086/596766
   Bonnet F, 2007, HIV MED, V8, P547, DOI 10.1111/j.1468-1293.2007.00508.x
   Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b
   Cardoso SW, 2010, AIDS RES HUM RETROV, V26, P865, DOI 10.1089/aid.2009.0274
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d
   Crum-Cianflone NF, 2010, JAIDS-J ACQ IMM DEF, V54, P248, DOI 10.1097/QAI.0b013e3181c8ef22
   DeJesus E, 2012, HIV CLIN TRIALS, V13, P228, DOI 10.1310/hct1304-228
   Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626
   Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Katlama C, 2007, AIDS, V21, P395, DOI 10.1097/QAD.0b013e328013d9d7
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267
   Ministerio da Saude Brazil, REC TER ANT AD INF P
   Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x
   Mocroft A, 2010, JAIDS-J ACQ IMM DEF, V55, P262, DOI 10.1097/QAI.0b013e3181e9be6b
   Molina JM, 2010, JAIDS-J ACQ IMM DEF, V53, P323, DOI 10.1097/QAI.0b013e3181c990bf
   Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Sogaard OS, 2008, CLIN INFECT DIS, V47, P1345, DOI 10.1086/592692
   Yehia BR, 2011, HIV MED, V12, P535, DOI 10.1111/j.1468-1293.2011.00919.x
   Zwahlen M, 2009, INT J EPIDEMIOL, V38, P1624, DOI 10.1093/ije/dyp306
NR 30
TC 12
Z9 12
U1 0
U2 5
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2014
VL 19
IS 4
BP 387
EP 397
DI 10.3851/IMP2716
PG 11
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA CA0IQ
UT WOS:000348601800008
PM 24445387
DA 2020-12-01
ER

PT J
AU Nascimento, EJM
   Hottz, ED
   Garcia-Bates, TM
   Bozza, F
   Marques, ETA
   Barratt-Boyes, SM
AF Nascimento, Eduardo J. M.
   Hottz, Eugenio D.
   Garcia-Bates, Tatiana M.
   Bozza, Fernando
   Marques, Ernesto T. A., Jr.
   Barratt-Boyes, Simon M.
TI Emerging Concepts in Dengue Pathogenesis: Interplay between
   Plasmablasts, Platelets, and Complement in Triggering Vasculopathy
SO CRITICAL REVIEWS IN IMMUNOLOGY
LA English
DT Article
DE Cell activation; immune dysregulation; immune complexes; inflammation
ID VIRUS NONSTRUCTURAL PROTEIN-1; HUMAN MONOCLONAL-ANTIBODIES; ORIGINAL
   ANTIGENIC SIN; HUMAN-BONE-MARROW; MESSENGER-RNA; ACTIVATED PLATELETS;
   IMMUNE-RESPONSES; FEVER PATIENTS; CELL-DEATH; DC-SIGN
AB Dengue is a mosquito-borne disease caused by infection with dengue virus (DENV) that represents a serious and expanding global health threat. Most DENY infections are inapparent or produce mild and self-limiting illness; however a significant proportion results in severe disease characterized by vasculopathy and plasma leakage that may culminate in shock and death. The cause of dengue-associated vasculopathy is likely to be multifactorial but remains essentially unknown. Severe disease is manifest during a critical phase from 4 to 7 days after onset of symptoms, once the virus has disappeared from the circulation but before the peak of T-cell activation, suggesting that other factors mediate vasculopathy. Here, we present evidence for a combined role of plasmablasts, complement, and platelets in driving severe disease in DENY infection. Massive expansion of virus-specific plasmablasts peaks during the critical phase of infection, coincident with activation of complement and activation and depletion of platelets. We propose a step-wise model in which virus-specific antibodies produced by plasmablasts form immune complexes, leading to activation of complement and release of vasoactive anaphylatoxins. Platelets become activated through binding of complement- and antibody-coated virus, as well as direct binding of virus to DC-SIGN, leading to the release of inflammatory microparticles and cytokines and sequestration of platelets in the microvasculature. We suggest that the combined effects of anaphylatoxins, inflammatory microparticles, and platelet sequestration serve as triggers of vasculopathy in severe dengue.
C1 [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Nascimento, Eduardo J. M.; Marques, Ernesto T. A., Jr.; Barratt-Boyes, Simon M.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Garcia-Bates, Tatiana M.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
   [Barratt-Boyes, Simon M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA.
   [Hottz, Eugenio D.; Bozza, Fernando] Inst Oswaldo Cruz, Lab Immunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Marques, Ernesto T. A., Jr.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Dept Virol & Terapia Expt, Recife, PE, Brazil.
RP Barratt-Boyes, SM (corresponding author), Univ Pittsburgh, Ctr Vaccine Res, 3501 Fifth Ave, Pittsburgh, PA 15260 USA.
EM smbb@pitt.edu
RI Nascimento, Eduardo/J-4590-2014; Marques, Ernesto T. A/L-4967-2013;
   Bozza, Fernando A/A-2618-2013; Hottz, Eugenio D/I-9850-2014
OI Nascimento, Eduardo/0000-0002-9851-2332; Marques, Ernesto T.
   A/0000-0003-3826-9358; Bozza, Fernando A/0000-0003-4878-0256; Barratt
   Boyes, Simon/0000-0002-8869-4945; Garcia-Bates,
   Tatiana/0000-0001-7579-5272
FU U.S. National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI049820];
   "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" - CNPq
   project [550140/2010-7]; "Fundacao de Amparo a Ciencia e Tecnologia de
   Pernambuco" - FACEPE project [APQ-1516-4.01/10]; Fundacao de Amparo a
   Ciencia e Tecnologia do Rio de Janeiro - FAPERJ; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820, T32AI049820,
   T32AI049820, T32AI049820, T32AI049820, T32AI049820] Funding Source: NIH
   RePORTER
FX This work was supported by U.S. National Institutes of Health research
   grant AI049820 (to E.T.A.M. and S.M.B.-B.) and training grant AI049820
   (to T.M.G.-B.); "Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico" - CNPq project 550140/2010-7 (to E.T.A.M.); "Fundacao de
   Amparo a Ciencia e Tecnologia de Pernambuco" - FACEPE project
   APQ-1516-4.01/10 (to E.T.A.M.); and Fundacao de Amparo a Ciencia e
   Tecnologia do Rio de Janeiro - FAPERJ (to F.B.)
CR Acioli-Santos B, 2008, HUM IMMUNOL, V69, P122, DOI 10.1016/j.humimm.2008.01.005
   Aggrey AA, 2013, J IMMUNOL, V190, P4685, DOI 10.4049/jimmunol.1202672
   Aird WC, 2003, MAYO CLIN PROC, V78, P869, DOI 10.4065/78.7.869
   Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Antczak AJ, 2010, CELL IMMUNOL, V263, P129, DOI 10.1016/j.cellimm.2010.03.009
   Avirutnan P, 2006, J INFECT DIS, V193, P1078, DOI 10.1086/500949
   Balakrishnan T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029430
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P46, DOI 10.1111/j.1574-695X.2008.00399.x
   Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Berlacher MD, 2013, AM J PATHOL, V182, P244, DOI 10.1016/j.ajpath.2012.09.005
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bhoopat L, 1996, ASIAN PAC J ALLERGY, V14, P107
   Bokisch V A, 1973, Trans Assoc Am Physicians, V86, P102
   BOONPUCKNAVIG S, 1979, ARCH PATHOL LAB MED, V103, P463
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Buckner CM, 2013, J VIROL, V87, P5800, DOI 10.1128/JVI.00094-13
   BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172
   Clark KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052902
   COWAN DH, 1976, JAMA-J AM MED ASSOC, V235, P1230, DOI 10.1001/jama.235.12.1230
   Crill WD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004991
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Dixon DA, 2006, J CLIN INVEST, V116, P2727, DOI 10.1172/JC127209
   Duran A, 2013, J CLIN VIROL, V56, P199, DOI 10.1016/j.jcv.2012.11.007
   Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005
   EVANS G, 1969, BRIT J SURG, V56, P624
   Falconar AKI, 2007, CLIN VACCINE IMMUNOL, V14, P493, DOI 10.1128/CVI.00371-06
   Fitzgerald JR, 2006, MOL MICROBIOL, V59, P212, DOI 10.1111/j.1365-2958.2005.04922.x
   Fuchs A, 2010, CELL HOST MICROBE, V8, P186, DOI 10.1016/j.chom.2010.07.007
   FUNAHARA Y, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P351
   de Araujo JMG, 2009, J VIROL METHODS, V155, P34, DOI 10.1016/j.jviromet.2008.09.023
   Garcia G, 2011, INT J INFECT DIS, V15, pE38, DOI 10.1016/j.ijid.2010.09.008
   Trinidad AG, 2006, J LEUKOCYTE BIOL, V79, P1073, DOI 10.1189/jlb.1205701
   Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350
   GAWAZ M, 1995, EUR J CLIN INVEST, V25, P843, DOI 10.1111/j.1365-2362.1995.tb01694.x
   Ghosh K, 2008, J ELECTRON MICROSC, V57, P113, DOI 10.1093/jmicro/dfn007
   Guabiraba R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015680
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Hamad OA, 2010, J IMMUNOL, V184, P2686, DOI 10.4049/jimmunol.0902810
   Honda S, 2009, AM J TROP MED HYG, V80, P841, DOI 10.4269/ajtmh.2009.80.841
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Hottz ED, 2013, BLOOD
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Jacobs MG, 2000, FASEB J, V14, P1603, DOI 10.1096/fj.14.11.1603
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   Koraka P, 2003, J CLIN MICROBIOL, V41, P4154, DOI 10.1128/JCM.41.9.4154-4159.2003
   Koraka P, 2001, J CLIN MICROBIOL, V39, P4332, DOI 10.1128/JCM.39.12.4332-4338.2001
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kumar Y, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001887
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Lin CF, 2008, LAB INVEST, V88, P1079, DOI 10.1038/labinvest.2008.70
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Loughman A, 2005, MOL MICROBIOL, V57, P804, DOI 10.1111/j.1365-2958.2005.04731.x
   Lutz HU, 2007, MOL IMMUNOL, V44, P3862, DOI 10.1016/j.molimm.2007.06.146
   Mei HE, 2009, BLOOD, V113, P2461, DOI 10.1182/blood-2008-04-153544
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   MOUTHON L, 1995, P NATL ACAD SCI USA, V92, P3839, DOI 10.1073/pnas.92.9.3839
   Murgue B, 1997, J INFECT DIS, V175, P1497, DOI 10.1086/516486
   NAKAO S, 1989, BLOOD, V74, P1235
   Nascimento EJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006782
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   Nishioka K, 1974, Allerg Immunol (Leipz), V20-21, P385
   Noisakran S, 2012, INT J HEMATOL, V96, P600, DOI 10.1007/s12185-012-1175-x
   Noisakran S, 2012, EXP HEMATOL, V40, P250, DOI 10.1016/j.exphem.2011.11.011
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   OhAinle M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003084
   Onlamoon N, 2010, BLOOD, V115, P1823, DOI 10.1182/blood-2009-09-242990
   Pastor AF, 2013, HUM IMMUNOL, V74, P1225, DOI 10.1016/j.humimm.2013.05.005
   Peerschke EIB, 1997, J IMMUNOL, V159, P5594
   PHAN DT, 1991, HAEMATOLOGIA, V24, P13
   Priyadarshini D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008709
   Qian Y, 2010, CYTOM PART B-CLIN CY, V78B, pS69, DOI 10.1002/cyto.b.20554
   Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Rondina MT, 2011, J THROMB HAEMOST, V9, P748, DOI 10.1111/j.1538-7836.2011.04208.x
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Rothwell SW, 1996, AM J TROP MED HYG, V54, P503, DOI 10.4269/ajtmh.1996.54.503
   Schieffelin JS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-28
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Smith SA, 2013, J INFECT DIS, V207, P1898, DOI 10.1093/infdis/jit119
   Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106
   Srichaikul T, 2000, BEST PRACT RES CL HA, V13, P261, DOI 10.1053/beha.2000.0073
   Sridharan A, 2013, J VIROL, V87, P11648, DOI 10.1128/JVI.01156-13
   Steinberg BE, 2012, ANTIVIR RES, V93, P2, DOI 10.1016/j.antiviral.2011.10.019
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Sun DS, 2007, J THROMB HAEMOST, V5, P2291, DOI 10.1111/j.1538-7836.2007.02754.x
   Tam DTH, 2012, CLIN INFECT DIS, V55, P1216, DOI 10.1093/cid/cis655
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   THEIN S, 1993, J MED VIROL, V40, P102, DOI 10.1002/jmv.1890400205
   Nguyen THT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002592
   Tsai JJ, 2011, J INNATE IMMUN, V3, P530, DOI 10.1159/000322904
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Wahala WMPB, 2009, VIROLOGY, V392, P103, DOI 10.1016/j.virol.2009.06.037
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   WANG SG, 1995, VIROLOGY, V213, P254, DOI 10.1006/viro.1995.1567
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   Warkentin Theodore E, 2003, Hematology Am Soc Hematol Educ Program, P497
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Weyrich AS, 2005, CIRCULATION, V111, P633, DOI 10.1161/01.CIR.0000154607.90506.45
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Wrammert J, 2009, J CLIN IMMUNOL, V29, P151, DOI 10.1007/s10875-008-9267-3
   Xu MH, 2012, J IMMUNOL, V189, P5877, DOI 10.4049/jimmunol.1201688
   Yang Kuender D., 1995, Acta Microbiologica et Immunologica Hungarica, V42, P403
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
   Zompi S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001568
NR 129
TC 18
Z9 21
U1 0
U2 5
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1040-8401
EI 2162-6472
J9 CRIT REV IMMUNOL
JI Crit. Rev. Immunol.
PY 2014
VL 34
IS 3
BP 227
EP 240
DI 10.1615/CritRevImmunol.2014010212
PG 14
WC Immunology
SC Immunology
GA AI0QI
UT WOS:000336553300004
PM 24941075
DA 2020-12-01
ER

PT J
AU Retamal, J
   Bergamini, BC
   Carvalho, AR
   Bozza, FA
   Borzone, G
   Borges, JB
   Larsson, A
   Hedenstierna, G
   Bugedo, G
   Bruhn, A
AF Retamal, Jaime
   Bergamini, Bruno Curty
   Carvalho, Alysson R.
   Bozza, Fernando A.
   Borzone, Gisella
   Borges, Joao Batista
   Larsson, Anders
   Hedenstierna, Goeran
   Bugedo, Guillermo
   Bruhn, Alejandro
TI Non-lobar atelectasis generates inflammation and structural alveolar
   injury in the surrounding healthy tissue during mechanical ventilation
SO CRITICAL CARE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; INDUCED LUNG INJURY; SURFACTANT
   DEPLETION; MODEL; INHOMOGENEITY; HETEROGENEITY; HYPOTHERMIA; EXPRESSION;
   STRATEGIES; REST
AB Introduction: When alveoli collapse the traction forces exerted on their walls by adjacent expanded units may increase and concentrate. These forces may promote its re-expansion at the expense of potentially injurious stresses at the interface between the collapsed and the expanded units. We developed an experimental model to test the hypothesis that a local non-lobar atelectasis can act as a stress concentrator, contributing to inflammation and structural alveolar injury in the surrounding healthy lung tissue during mechanical ventilation.
   Methods: A total of 35 rats were anesthetized, paralyzed and mechanically ventilated. Atelectasis was induced by bronchial blocking: after five minutes of stabilization and pre-oxygenation with FIO2 = 1.0, a silicon cylinder blocker was wedged in the terminal bronchial tree. Afterwards, the animals were randomized between two groups: 1) Tidal volume (V-T) = 10 ml/kg and positive end-expiratory pressure (PEEP) = 3 cmH(2)O (V(T)10/PEEP3); and 2) V-T=20 ml/kg and PEEP = 0 cmH2O (V(T)20/zero end-expiratory pressure (ZEEP)). The animals were then ventilated during 180 minutes. Three series of experiments were performed: histological (n = 12); tissue cytokines (n = 12); and micro-computed tomography (microCT; n = 2). An additional six, non-ventilated, healthy animals were used as controls.
   Results: Atelectasis was successfully induced in the basal region of the lung of 26 out of 29 animals. The microCT of two animals revealed that the volume of the atelectasis was 0.12 and 0.21 cm(3). There were more alveolar disruption and neutrophilic infiltration in the peri-atelectasis region than the corresponding contralateral lung (control) in both groups. Edema was higher in the peri-atelectasis region than the corresponding contralateral lung (control) in the V(T)20/ZEEP than VT10/PEEP3 group. The volume-to-surface ratio was higher in the peri-atelectasis region than the corresponding contralateral lung (control) in both groups. We did not find statistical difference in tissue interleukin-1 beta and cytokine-induced neutrophil chemoattractant-1 between regions.
   Conclusions: The present findings suggest that a local non-lobar atelectasis acts as a stress concentrator, generating structural alveolar injury and inflammation in the surrounding lung tissue.
C1 [Retamal, Jaime; Bugedo, Guillermo; Bruhn, Alejandro] Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Santiago, Chile.
   [Retamal, Jaime; Borges, Joao Batista; Larsson, Anders] Uppsala Univ, Hedenstierna Lab, Sect Anaesthesiol & Crit Care, Dept Surg Sci,Hosp, S-75185 Uppsala, Sweden.
   [Bergamini, Bruno Curty; Carvalho, Alysson R.] Univ Fed Rio de Janeiro, Physiol Resp Lab, Inst Biophys CCS, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, IPEC, Lab Invest Med Intens, Rio De Janeiro, RJ, Brazil.
   [Borzone, Gisella] Pontificia Univ Catolica Chile, Fac Med, Dept Enfermedades Resp, Santiago, Chile.
   [Borges, Joao Batista] Univ Sao Paulo, Fac Med, Lab Pneumol LIM 09, Disciplina Pneumol,Heart Inst Incor,Hosp Clin, Sao Paulo, Brazil.
   [Hedenstierna, Goeran] Uppsala Univ, Dept Med Sci, Clin Physiol, Hedenstierna Lab, S-75185 Uppsala, Sweden.
RP Retamal, J (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Alameda 340, Santiago, Chile.
EM jaime.retamal@surgsci.uu.se
RI Bozza, Fernando A/A-2618-2013; Borges, Joao/AAM-3887-2020; Bruhn,
   Alejandro/AAH-2684-2019; retamal, jaime/AAM-5712-2020; Carvalho,
   Alysson/AAF-1022-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Borges, Joao/0000-0001-8132-8304;
   Bruhn, Alejandro/0000-0001-8034-1937; Hedenstierna,
   Goran/0000-0002-2923-6012; Carvalho, Alysson/0000-0003-2708-7735
CR Albert RK, 2012, AM J RESP CRIT CARE, V185, P702, DOI 10.1164/rccm.201109-1667PP
   Baumgardner JE, 2011, J APPL PHYSIOL, V111, P1233, DOI 10.1152/japplphysiol.01054.2011
   Bellani G, 2011, AM J RESP CRIT CARE, V183, P1193, DOI 10.1164/rccm.201008-1318OC
   Borges JB, 2014, CRIT CARE MED, V42, pE279, DOI 10.1097/CCM.0000000000000161
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cereda M, 2013, CRIT CARE MED, V41, P527, DOI 10.1097/CCM.0b013e31826ab1f2
   Cressoni M, 2014, AM J RESP CRIT CARE, V189, P149, DOI 10.1164/rccm.201308-1567OC
   de Prost N, 2011, J APPL PHYSIOL, V111, P1249, DOI 10.1152/japplphysiol.00311.2011
   Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014
   Fanelli V, 2009, CRIT CARE MED, V37, P1046, DOI 10.1097/CCM.0b013e3181968e7e
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gattinoni L, 2012, CURR OPIN ANESTHESIO, V25, P141, DOI 10.1097/ACO.0b013e3283503125
   GLAZIER JB, 1967, J APPL PHYSIOL, V23, P694
   Grasso S, 2009, AM J RESP CRIT CARE, V180, P415, DOI 10.1164/rccm.200901-0156OC
   Hong SB, 2005, CRIT CARE MED, V33, P2049, DOI 10.1097/01.CCM.0000178186.37167.53
   Kira S, 2005, ACTA ANAESTH SCAND, V49, P351, DOI 10.1111/j.1399-6576.2005.00593.x
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   MEAD J, 1970, J APPL PHYSIOL, V28, P596
   MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774
   Otto CM, 2008, J APPL PHYSIOL, V104, P1485, DOI 10.1152/japplphysiol.01089.2007
   Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X
   Rausch SMK, 2011, ANN BIOMED ENG, V39, P2835, DOI 10.1007/s10439-011-0328-z
   Rotta AT, 2001, CRIT CARE MED, V29, P2176, DOI 10.1097/00003246-200111000-00021
   ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC
   Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259
   Tsuchida S, 2006, AM J RESP CRIT CARE, V174, P279, DOI 10.1164/rccm.200506-1006OC
   WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23
   Wellman TJ, 2012, J APPL PHYSIOL, V113, P947, DOI 10.1152/japplphysiol.01631.2011
   Yoshida T, 2013, AM J RESP CRIT CARE, V188, P1420, DOI 10.1164/rccm.201303-0539OC
NR 31
TC 45
Z9 47
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2014
VL 18
IS 5
AR 505
DI 10.1186/s13054-014-0505-1
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA CE5DM
UT WOS:000351850600024
PM 25200702
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Towner, RA
   Garteiser, P
   Bozza, F
   Smith, N
   Saunders, D
   d'Avila, JCP
   Magno, F
   Oliveira, MF
   Ehrenshaft, M
   Lupu, F
   Silasi-Mansat, R
   Ramirez, DC
   Gomez-Mejiba, SE
   Mason, RP
   Faria-Neto, HCC
AF Towner, Rheal A.
   Garteiser, Philippe
   Bozza, Fernando
   Smith, Nataliya
   Saunders, Debra
   d'Avila, Joana C. P.
   Magno, Flora
   Oliveira, Marcus F.
   Ehrenshaft, Marilyn
   Lupu, Florea
   Silasi-Mansat, Robert
   Ramirez, Dario C.
   Gomez-Mejiba, Sandra E.
   Mason, Ronald P.
   Castro Faria-Neto, Hugo C.
TI In vivo detection of free radicals in mouse septic encephalopathy using
   molecular MRI and immuno-spin trapping
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Immuno-spin trapping; Free radicals; Molecular MRI; Sepsis; Cecal
   ligation and puncture; Mice; in vivo; DMPO; Fluorescence microscopy;
   4-Hydroxynonenal; 3-Nitrotyrosine
ID NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; BRAIN; SEPSIS; INFLAMMATION;
   INVOLVEMENT; DYSFUNCTION; ACTIVATION; EXPRESSION; INJURY
AB Free radicals are known to play a major role in sepsis. Combined immuno-spin trapping and molecular magnetic resonance imaging (MRI) was used to detect in vivo and in situ levels of free radicals in murine septic encephalopathy after cecal ligation and puncture (CLP). DMPO (5,5-dimethyl pyrroline N-oxide) was injected over 6 h after CLP, before administration of an anti-DMPO probe (anti-DMPO antibody bound to albumin-gadolinium-diethylene triamine pentaacetic acid-biotin MRI targeting contrast agent). In vitro assessment of the anti-DMPO probe in oxidatively stressed mouse astrocytes significantly decreased T-1 relaxation (P < 0.0001) compared to controls. MRI detected the presence of anti-DMPO adducts via a substantial decrease in % T1 change within the hippocampus, striatum, occipital, and medial cortex brain regions (p < 0.01 for all) in septic animals compared to shams, which was sustained for over 60 mm (p < 0.05 for all). Fluorescently labeled streptavidin was used to target the anti-DMPO probe biotin, which was elevated in septic brain, liver, and lungs compared to sham. Ex vivo DMPO adducts (qualitative) and oxidative products, including 4-hydroxynonenal and 3-nitrotyrosine (quantitative, p < 0.05 for both), were elevated in septic brains compared to shams. This is the first study that has reported on the detection of in vivo and in situ levels of free radicals in murine septic encephalopathy. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Towner, Rheal A.; Garteiser, Philippe; Smith, Nataliya; Saunders, Debra] Oklahoma Med Res Fdn, Adv Magnet Resonance Ctr, Oklahoma City, OK 73104 USA.
   [Bozza, Fernando; d'Avila, Joana C. P.; Magno, Flora] Inst Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-20001 Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biol Mol & Biotecnol, Lab Bioquim Resposta Estresse, Rio De Janeiro, RJ, Brazil.
   [Ehrenshaft, Marilyn; Mason, Ronald P.] NIEHS, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA.
   [Lupu, Florea; Silasi-Mansat, Robert] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
   [Ramirez, Dario C.; Gomez-Mejiba, Sandra E.] Natl Univ San Luis, CONICET, Inst Multidisciplinario Invest Biol San Luis, Lab Expt Med & Therapeut, RA-5700 San Luis, Argentina.
   [Castro Faria-Neto, Hugo C.] Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, RJ, Brazil.
RP Towner, RA (corresponding author), Oklahoma Med Res Fdn, Adv Magnet Resonance Ctr, 825 NE 13th St, Oklahoma City, OK 73104 USA.
EM Rheal-Towner@omrf.org
RI Bozza, Fernando A/A-2618-2013; Lupu, Florea/C-3162-2009; Garteiser,
   Philippe/P-5719-2017; Oliveira, Marcus/G-3158-2011; d'Avila,
   Joana/L-8970-2013; RAMIREZ, DARIO C/K-3312-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Lupu, Florea/0000-0003-1249-9278;
   Garteiser, Philippe/0000-0003-0157-8851; Oliveira,
   Marcus/0000-0002-9890-8425; d'Avila, Joana/0000-0002-2045-0813; RAMIREZ,
   DARIO C/0000-0001-6725-3326; GOMEZ MEJIBA, SANDRA/0000-0002-8515-0483;
   Silasi, Robert/0000-0001-9590-6160
FU Oklahoma Medical Research Foundation; National Institute of
   Environmental Health SciencesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS); CNPqNational Council for
   Scientific and Technological Development (CNPq); PAPESNational Council
   for Scientific and Technological Development (CNPq); FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [ZIAES050117, ZIAES050117, ZIAES050117, ZIAES050117,
   ZIAES050117, ZIAES050117, ZIAES050117, ZIAES050117, ZIAES050117,
   ZIAES050117] Funding Source: NIH RePORTER
FX Funding was obtained by the Oklahoma Medical Research Foundation
   (R.A.T.) and the National Institute of Environmental Health Sciences
   (R.P.M.). H.C.C.F.-N. and F.A.B. were supported by CNPq, PAPES, and
   FAPERJ. F.A.B., M.F.O., and H.C.C.F.-N. are research scholars from CNPq
   and FAPERJ.
CR Araujo CV, 2012, MICROVASC RES, V84, P218, DOI 10.1016/j.mvr.2012.05.006
   Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48
   Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044
   Bozza FA, 2010, J CEREBR BLOOD F MET, V30, P440, DOI 10.1038/jcbfm.2009.215
   Chatterjee S., 2013, BIOCH BIOPH IN PRESS
   Chatterjee S, 2009, J IMMUNOL, V183, P4055, DOI 10.4049/jimmunol.0900593
   Chatterjee S, 2009, FREE RADICAL BIO MED, V46, P454, DOI 10.1016/j.freeradbiomed.2008.10.046
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Dafni H, 2002, NMR BIOMED, V15, P120, DOI 10.1002/nbm.724
   De Souza P. C., 2013, BIOCH BIOPH IN PRESS
   Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X
   Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192
   Gavins FNE, 2012, FASEB J, V26, P4977, DOI 10.1096/fj.12-205971
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Haacke E. M., MAGNETIC RESONANCE I, P367
   He T, 2011, J CELL MOL MED, V15, P837, DOI 10.1111/j.1582-4934.2010.01091.x
   Hermanson G., 1996, BIOCONJUGATE TECHNIQ, P456
   Liu KJ, 1996, RES CHEM INTERMEDIAT, V22, P499, DOI 10.1163/156856796X00700
   Macdonald J, 2003, BRIT J ANAESTH, V90, P221, DOI 10.1093/bja/aeg034
   Mason RP, 2004, FREE RADICAL BIO MED, V36, P1214, DOI 10.1016/j.freeradbiomed.2004.02.077
   Massot P, 2012, CONTRAST MEDIA MOL I, V7, P45, DOI 10.1002/cmmi.464
   Neviere RR, 1999, AM J PHYSIOL-HEART C, V277, pH885
   Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x
   Ozan G, 2012, INFLAMMATION, V35, P665, DOI 10.1007/s10753-011-9359-8
   Sakaguchi S, 2002, EUR J PHARMACOL, V451, P309, DOI 10.1016/S0014-2999(02)02223-9
   Sakaguchi S, 2007, INT IMMUNOPHARMACOL, V7, P191, DOI 10.1016/j.intimp.2006.09.008
   Sakaguchi S, 2006, FEMS IMMUNOL MED MIC, V47, P167, DOI 10.1111/j.1574-695X.2006.00072.x
   Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com
   Semmler A, 2005, J CHEM NEUROANAT, V30, P144, DOI 10.1016/j.jchemneu.2005.07.003
   Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
   Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013
   Towner RA, 2008, J CELL MOL MED, V12, P174, DOI 10.1111/j.1582-4934.2008.00220.x
   Towner RA, 2010, TISSUE ENG PT A, V16, P357, DOI 10.1089/ten.TEA.2009.0233
   Towner RA, 2010, TISSUE ENG PT A, V16, P365, DOI [10.1089/ten.tea.2009.0234, 10.1089/ten.TEA.2009.0234]
   Towner RA, 2013, FREE RADICAL BIO MED, V63, P351, DOI 10.1016/j.freeradbiomed.2013.05.026
   Towner RA, 2012, DIABETES, V61, P2405, DOI 10.2337/db11-1540
   Towner RA, 2010, FREE RADICAL BIO MED, V48, P691, DOI 10.1016/j.freeradbiomed.2009.12.012
   Tsuge M, 2010, MICROBIOL IMMUNOL, V54, P417, DOI 10.1111/j.1348-0421.2010.00226.x
   Yokoo H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051539
   Zarkovic N, 1999, LIFE SCI, V65, P1901, DOI 10.1016/S0024-3205(99)00444-0
   Zhai ZL, 2012, FREE RADICAL BIO MED, V53, P172, DOI 10.1016/j.freeradbiomed.2012.04.023
   Zhan RZ, 1996, SHOCK, V6, P293, DOI 10.1097/00024382-199610000-00012
   Zhelev Z, 2013, EUR J CANCER, V49, P1467, DOI 10.1016/j.ejca.2012.10.026
NR 43
TC 16
Z9 16
U1 2
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD DEC
PY 2013
VL 65
BP 828
EP 837
DI 10.1016/j.freeradbiomed.2013.08.172
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 278DI
UT WOS:000328868900078
PM 23978375
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Lopes, JF
   Freitas, C
   Valls-de-Souza, R
   Oliveira, MF
   Bozza, MT
   Da Poian, AT
   Weyrich, AS
   Zimmerman, GA
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Lopes, Juliana F.
   Freitas, Carla
   Valls-de-Souza, Rogerio
   Oliveira, Marcus F.
   Bozza, Marcelo T.
   Da Poian, Andrea T.
   Weyrich, Andrew S.
   Zimmerman, Guy A.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI Platelets mediate increased endothelium permeability in dengue through
   NLRP3-inflammasome activation
SO BLOOD
LA English
DT Article
ID HEMORRHAGIC-FEVER; CELL-DEATH; VIRUS-INFECTIONS; SHOCK-SYNDROME;
   MICROPARTICLES; INFLAMMASOME; LIPOPOLYSACCHARIDE; SEVERITY; PROTEIN;
   IMMUNOPATHOGENESIS
AB Dengue is the most frequent hemorrhagic viral disease and re-emergent infection in the world. Although thrombocytopenia is characteristically observed in mild and severe forms of dengue, the role of platelet activation in dengue pathogenesis has not been fully elucidated. We hypothesize that platelets have major roles in inflammatory amplification and increased vascular permeability during severe forms of dengue. Here we investigate interleukin (IL)-1 beta synthesis, processing, and secretion in platelets during dengue virus (DV) infection and potential contribution of these events to endothelial permeability during infection. We observed increased expression of IL-1 beta in platelets and platelet-derived microparticles from patients with dengue or after platelet exposure to DV in vitro. We demonstrated that DV infection leads to assembly of nucleotide-binding domain leucine rich repeat containing protein (NLRP3) inflammasomes, activation of caspase-1, and caspase-1-dependent IL-1 beta secretion. Our findings also indicate that platelet-derived IL-1 beta is chiefly released in microparticles through mechanisms dependent on mitochondrial reactive oxygen species-triggered NLRP3 inflammasomes. Inflammasome activation and platelet shedding of IL-1 beta-rich microparticles correlated with signs of increased vascular permeability. Moreover, microparticles from DV-stimulated platelets induced enhanced permeability in vitro in an IL-1-dependent manner. Our findings provide new evidence that platelets contribute to increased vascular permeability in DV infection by inflammasome-dependent release of IL-1 beta.
C1 [Hottz, Eugenio D.; Lopes, Juliana F.; Freitas, Carla; Zimmerman, Guy A.; Bozza, Patricia T.] Inst Oswaldo Cruz, Lab Immunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Valls-de-Souza, Rogerio; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil.
   [Weyrich, Andrew S.; Zimmerman, Guy A.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [Weyrich, Andrew S.] Univ Utah, Program Mol Med, Salt Lake City, UT USA.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Ave Brasil 4365, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com; pbozza@ioc.fiocruz.br
RI Oliveira, Marcus/G-3158-2011; Bozza, Fernando A/A-2618-2013; Da Poian,
   Andrea T./V-1699-2019; Hottz, Eugenio D/I-9850-2014
OI Oliveira, Marcus/0000-0002-9890-8425; Bozza, Fernando
   A/0000-0003-4878-0256; Da Poian, Andrea/0000-0002-3969-704X; Weyrich,
   Andrew/0000-0001-9622-4647; Bozza, Marcelo/0000-0003-3683-7550; Bozza,
   Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de JaneiroCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Programa Estrategico de Apoio a Pesquisa em Saude/Fiocruz; Instituto
   Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem;
   Programa de Apoio a Nucleos de Excelencia Dengue; National Institute of
   Science and Technology in Dengue; National Institutes of Health,
   National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HL066277, HL091754,
   HL044525]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL091754,
   R01HL066277, R01HL091754, R01HL091754, R01HL066277, R01HL066277,
   R01HL066277, R37HL044525, R01HL044525, R01HL066277, R01HL066277,
   R37HL044525, R01HL044525, R01HL044525, R01HL044525, R37HL044525,
   R37HL044525, R01HL066277, R01HL044525, R37HL044525, R01HL066277,
   R01HL044525, R01HL044525, R01HL044525, R01HL044525, R37HL044525,
   R01HL044525, R37HL044525, R01HL044525, R37HL044525, R01HL066277,
   R37HL044525, R01HL066277, R01HL066277, R01HL044525, R01HL044525,
   R37HL044525, R01HL091754, R01HL044525, R01HL066277] Funding Source: NIH
   RePORTER
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Fundacao de Amparo a Pesquisa
   do Estado do Rio de Janeiro, Programa Estrategico de Apoio a Pesquisa em
   Saude/Fiocruz, Instituto Nacional de Ciencia e Tecnologia de Biologia
   Estrutural e Bioimagem, Programa de Apoio a Nucleos de Excelencia
   Dengue, and National Institute of Science and Technology in Dengue, and
   the National Institutes of Health, National Heart, Lung, and Blood
   Institute grants (HL066277, HL091754, and HL044525 to A. S. W. and
   G.A.Z).
CR Aggrey AA, 2013, J IMMUNOL, V190, P4685, DOI 10.4049/jimmunol.1202672
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Burdette D, 2012, J GEN VIROL, V93, P235, DOI 10.1099/vir.0.034033-0
   Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   DACHARYPRIGENT J, 1993, BLOOD, V81, P2554
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Falconar AKI, 2006, CLIN VACCINE IMMUNOL, V13, P1044, DOI 10.1128/CVI.00105-06
   HAMBURGER SA, 1990, BLOOD, V75, P550
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Houghton-Trivino N, 2010, BIOMEDICA, V30, P587
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   KAPLANSKI G, 1993, BLOOD, V81, P2492
   Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   Lamkanfi M, 2011, J IMMUNOL, V187, P597, DOI 10.4049/jimmunol.1100229
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mause SF, 2005, ARTERIOSCL THROM VAS, V25, P1512, DOI 10.1161/01.ATV.0000170133.43608.37
   MITRAKUL C, 1977, AM J TROP MED HYG, V26, P975, DOI 10.4269/ajtmh.1977.26.975
   Nasirudeen AMA, 2009, J MED VIROL, V81, P1069, DOI 10.1002/jmv.21486
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Schmidt AC, 2010, NEW ENGL J MED, V363, P484, DOI 10.1056/NEJMcibr1005904
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231
   Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3
   Shcherbina A, 1999, BLOOD, V93, P2128
   Shu PY, 2003, CLIN DIAGN LAB IMMUN, V10, P622, DOI 10.1128/CDLI.10.4.622-630.2003
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   Wang JG, 2011, BLOOD, V118, P2366, DOI 10.1182/blood-2011-01-330878
   WANG SG, 1995, VIROLOGY, V213, P254, DOI 10.1006/viro.1995.1567
   Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wu MF, 2013, BLOOD, V121, P95, DOI 10.1182/blood-2012-05-430090
   Yu CY, 2010, J VIROL, V84, P2421, DOI 10.1128/JVI.02174-09
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 50
TC 142
Z9 145
U1 1
U2 18
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 14
PY 2013
VL 122
IS 20
BP 3405
EP 3414
DI 10.1182/blood-2013-05-504449
PG 10
WC Hematology
SC Hematology
GA 261LM
UT WOS:000327666500010
PM 24009231
OA Green Published
DA 2020-12-01
ER

PT J
AU Azevedo, L
   Caruso, P
   Silva, UVA
   Torelly, A
   Silva, E
   Rezende, E
   Netto, JJ
   Piras, C
   Lobo, S
   Knibel, M
   Teles, IMM
   Lima, R
   Ferreira, B
   Friedman, G
   Rea-Neto, A
   Dal Pizzol, F
   Bozza, FA
   Sallnh, JIF
   Soares, M
AF Azevedo, L.
   Caruso, P.
   Silva, U. V. A.
   Torelly, A.
   Silva, E.
   Rezende, E.
   Netto, J. J.
   Piras, C.
   Lobo, S.
   Knibel, M.
   Teles, I. M. M.
   Lima, R.
   Ferreira, B.
   Friedman, G.
   Rea-Neto, A.
   Dal Pizzol, F.
   Bozza, F. A.
   Sallnh, J. I. F.
   Soares, M.
CA BRICNet
TI OUTCOMES OF PATIENTS WITH CANCER REQUIRING VENTILATORY SUPPORT: RESULTS
   FROM A PROSPECTIVE MULTICENTER STUDY
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT ESICM 26th Annual Congress
CY OCT 05-09, 2013
CL Paris, FRANCE
SP ESICM
C1 [Azevedo, L.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Azevedo, L.; Netto, J. J.; Sallnh, J. I. F.; Soares, M.] Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Caruso, P.] Hosp AC Camargo Fund Antonio Prudente, Sao Paulo, Brazil.
   [Silva, U. V. A.] Fundacao Pio XII Hosp Canc Barretos, Barretos, Brazil.
   [Torelly, A.; Friedman, G.] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil.
   [Silva, E.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Rezende, E.] Hosp Servidor Publ Estadual, Sao Paulo, Brazil.
   [Piras, C.] Vitoria Apart Hosp, Vitoria, Brazil.
   [Lobo, S.] Med Sch & Hosp Base, Sao Jose Do Rio Preto, Brazil.
   [Knibel, M.] Hosp Sao Lucas, Rio De Janeiro, Brazil.
   [Teles, I. M. M.] Hosp Portugues, Salvador, BA, Brazil.
   [Lima, R.] Hosp Samaritano, Rio De Janeiro, Brazil.
   [Ferreira, B.] Pasteur Hosp, Rio De Janeiro, Brazil.
   [Rea-Neto, A.] Univ Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, Brazil.
   [Dal Pizzol, F.] Univ Extremo Sul Catarinense, Criciuma, Brazil.
   [Bozza, F. A.] Fundacao Oswald Cruz, Rio De Janeiro, Brazil.
   [Bozza, F. A.; Sallnh, J. I. F.; Soares, M.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RI Azevedo, Luciano CP/H-2652-2012; Dal-Pizzol, Felipe/F-2756-2015;
   Friedman, Gilberto/F-7208-2015; Soares, Marcio/B-3083-2013; Bozza,
   Fernando A/A-2618-2013; Rea-Neto, Alvaro/AAR-7909-2020; V.A.Silva,
   Ulysses/AAZ-3336-2020; Friedman, Gilberto/F-7212-2015
OI Azevedo, Luciano CP/0000-0001-6759-3910; Dal-Pizzol,
   Felipe/0000-0003-3003-8977; Friedman, Gilberto/0000-0001-9369-2488;
   Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256; Rea-Neto, Alvaro/0000-0001-5524-0907; V.A.Silva,
   Ulysses/0000-0002-1284-2016; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD OCT
PY 2013
VL 39
SU 2
MA 0406
BP S327
EP S328
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA AP9WI
UT WOS:000342431600405
DA 2020-12-01
ER

PT J
AU Teixeira-da-Cunha, MGA
   Gomes, RN
   Roehrs, N
   Bozza, FA
   Prescott, SM
   Stafforini, D
   Zimmerman, GA
   Bozza, PT
   Castro-Faria-Neto, HC
AF Teixeira-da-Cunha, Mariana G. A.
   Gomes, Rachel N.
   Roehrs, Nathassia
   Bozza, Fernando A.
   Prescott, Stephen M.
   Stafforini, Diana
   Zimmerman, Guy A.
   Bozza, Patricia T.
   Castro-Faria-Neto, Hugo C.
TI Bacterial Clearance Is Improved in Septic Mice by Platelet-Activating
   Factor-Acetylhydrolase (PAF-AH) Administration
SO PLOS ONE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; RECEPTOR-DEFICIENT MICE;
   NITRIC-OXIDE PRODUCTION; MCP-1 PROTECTS MICE; ENDOTOXIC-SHOCK;
   CLINICAL-TRIAL; SEVERE SEPSIS; HOST-DEFENSE; LUNG INJURY; IN-VITRO
AB Current evidence indicates that dysregulation of the host inflammatory response to infectious agents is central to the mortality of patients with sepsis. Strategies to block inflammatory mediators such as PAF have been investigated as adjuvant therapies for sepsis. PAF-AH, the enzyme responsible for PAF degradation, showed positive results in pre-clinical studies and phase II clinical trials, but the results of a phase III study were disappointing. In this study, we investigated the potential protective mechanism of PAF-AH in sepsis using the murine model of cecal ligation and puncture (CLP). Treatment with rPAF-AH increased peritoneal fluid levels of the anti-inflammatory mediators MCP-1/CCL2 after CLP. The numbers of bacteria (CFU) in the peritoneal cavity were decreased in the rPAF-AH-treated group, indicating more efficient bacterial clearance after rPAF-AH treatment. Interestingly, we observed increased levels of nitric oxide (NO) after PAF-AH administration, and rPAF-AH treatment did not decrease CFU numbers either in iNOS-deficient mice or in CCR2-deficient mice. We concluded that administration of exogenous rPAF-AH reduced inflammatory injury, altered cytokine levels and favored bacterial clearance with a clear impact on mortality through modulation of MCP-1/CCL2 and NO levels in a clinically relevant sepsis model.
C1 [Prescott, Stephen M.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA.
   [Stafforini, Diana] Huntsman Canc Inst, Salt Lake City, UT USA.
   [Zimmerman, Guy A.] Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT USA.
EM rachelngomes@gmail.com
RI Bozza, Fernando A/A-2618-2013; Gomes, Rachel N/I-7643-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529
FU PAPES-FIOCRUZ; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992, P01CA073992,
   P01CA073992, P01CA073992, P01CA073992, P01CA073992] Funding Source: NIH
   RePORTER
FX This work was supported by PAPES-FIOCRUZ, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), and Fundacao de
   Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aliberti JCS, 1999, INFECT IMMUN, V67, P2810, DOI 10.1128/IAI.67.6.2810-2814.1999
   Angus DC, 2001, CRIT CARE MED, V29, pS109, DOI 10.1097/00003246-200107001-00035
   Benjamim CF, 2002, INFECT IMMUN, V70, P3602, DOI 10.1128/IAI.70.7.3602-3610.2002
   Biswas SK, 2001, NITRIC OXIDE-BIOL CH, V5, P566, DOI 10.1006/niox.2001.0370
   CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   CUNHA FQ, 1994, IMMUNOLOGY, V81, P211
   DePaolo RW, 2005, INFECT IMMUN, V73, P6514, DOI 10.1128/IAI.73.10.6514-6522.2005
   Fierro IM, 1999, J LEUKOCYTE BIOL, V65, P508
   Forslund T, 1997, BIOCHEM BIOPH RES CO, V233, P492, DOI 10.1006/bbrc.1997.6490
   Franchini A, 1995, ADV NEUROIMMUNOL, V5, P463, DOI 10.1016/0960-5428(95)00029-1
   GERRA G, 1995, INT CLIN PSYCHOPHARM, V10, P245, DOI 10.1097/00004850-199511000-00006
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Gomes RN, 2013, SHOCK, V39, P63, DOI 10.1097/SHK.0b013e31827802b5
   Guo HT, 2002, IMMUNOL LETT, V80, P21, DOI 10.1016/S0165-2478(01)00284-X
   Hauser B, 2004, SHOCK, V22, P588, DOI 10.1097/00024382-200412000-00016
   IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Kaplan SS, 1996, INFECT IMMUN, V64, P69, DOI 10.1128/IAI.64.1.69-76.1996
   Karasawa K, 2006, BBA-MOL CELL BIOL L, V1761, P1359, DOI 10.1016/j.bbalip.2006.06.017
   Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0
   MAKRISTATHIS A, 1993, INFECT IMMUN, V61, P1996, DOI 10.1128/IAI.61.5.1996-2002.1993
   MALAWISTA SE, 1992, J CLIN INVEST, V90, P631, DOI 10.1172/JCI115903
   Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Moreno SE, 2006, J IMMUNOL, V177, P1264, DOI 10.4049/jimmunol.177.2.1264
   MOZES T, 1991, J LIPID MEDIATOR, V4, P309
   NAKANO Y, 1994, INFECT IMMUN, V62, P377, DOI 10.1128/IAI.62.2.377-383.1994
   NARAHARA H, 1993, J CLIN ENDOCR METAB, V77, P1258, DOI 10.1210/jc.77.5.1258
   Neto HCCF, 2005, MEM I OSWALDO CRUZ, V100, P83, DOI 10.1590/S0074-02762005000900014
   Okuma T, 2006, INT J EXP PATHOL, V87, P475, DOI 10.1111/j.1365-2613.2006.00502.x
   Opal S, 2004, CRIT CARE MED, V32, P332, DOI 10.1097/01.CCM.0000108867.87890.6D
   Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419
   Reddy RC, 2001, IMMUNOL RES, V24, P273, DOI 10.1385/IR:24:3:273
   Rijneveld AW, 2004, J INFECT DIS, V189, P711, DOI 10.1086/381392
   Schuster DP, 2003, CRIT CARE MED, V31, P1612, DOI 10.1097/01.CCM.0000063267.79824.DB
   Souza DG, 2003, BRIT J PHARMACOL, V139, P733, DOI 10.1038/sj.bjp.0705296
   STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223
   TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0
   Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
NR 45
TC 15
Z9 15
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2013
VL 8
IS 9
AR e74567
DI 10.1371/journal.pone.0074567
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 242KO
UT WOS:000326240100111
PM 24069320
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU d'Avila, JC
   Carnevale, R
   Gomes, RN
   Reis, PA
   Garcia-Souza, LF
   Neto, HCCF
   Oliveira, MF
   Bozza, FA
AF d'Avila, Joana C.
   Carnevale, Renata
   Gomes, Rachel N.
   Reis, Patricia A.
   Garcia-Souza, Luiz F.
   Castro Faria Neto, Hugo C.
   Oliveira, Marcus F.
   Bozza, Fernando A.
TI Brain metabolic dysfunction in response to systemic inflammation and
   sepsis
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Meeting Abstract
CT 10th International Conference on Brain Energy Metabolism - Bioenergetics
   of Neurological Disease and Aging
CY APR 17-20, 2012
CL Pacific Grove, CA
SP NINDS, NIA, Int Soc Neurochemistry (ISN) Conf Comm, NCIRE, Vet Hlth Res Inst, Wiley Blackwell, Seahorse Bioscience
C1 [d'Avila, Joana C.; Carnevale, Renata; Gomes, Rachel N.; Reis, Patricia A.; Castro Faria Neto, Hugo C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Garcia-Souza, Luiz F.; Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, BR-21941 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, BR-21045900 Rio De Janeiro, RJ, Brazil.
RI Bozza, Fernando A/A-2618-2013; d'Avila, Joana/L-8970-2013
OI Bozza, Fernando A/0000-0003-4878-0256; d'Avila,
   Joana/0000-0002-2045-0813
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0360-4012
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD AUG
PY 2013
VL 91
IS 8
SI SI
BP 1100
EP 1101
PG 2
WC Neurosciences
SC Neurosciences & Neurology
GA 171MO
UT WOS:000320933700048
DA 2020-12-01
ER

PT J
AU Amancio, RT
   Japiassu, AM
   Gomes, RN
   Mesquita, EC
   Assis, EF
   Medeiros, DM
   Grinsztejn, B
   Bozza, PT
   Neto, HCCF
   Bozza, FA
AF Amancio, Rodrigo T.
   Japiassu, Andre M.
   Gomes, Rachel N.
   Mesquita, Emersom C.
   Assis, Edson F.
   Medeiros, Denise M.
   Grinsztejn, Beatriz
   Bozza, Patricia T.
   Castro-Faria Neto, Hugo C.
   Bozza, Fernando A.
TI The Innate Immune Response in HIV/AIDS Septic Shock Patients: A
   Comparative Study
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; C-REACTIVE
   PROTEIN; CRITICALLY-ILL PATIENTS; SEVERE SEPSIS; ORGAN DYSFUNCTION;
   INTENSIVE-CARE; UNITED-STATES; EPIDEMIOLOGY; OUTCOMES
AB Introduction: In recent years, the incidence of sepsis has increased in critically ill HIV/AIDS patients, and the presence of severe sepsis emerged as a major determinant of outcomes in this population. The inflammatory response and deregulated cytokine production play key roles in the pathophysiology of sepsis; however, these mechanisms have not been fully characterized in HIV/AIDS septic patients.
   Methods: We conducted a prospective cohort study that included HIV/AIDS and non-HIV patients with septic shock. We measured clinical parameters and biomarkers (C-reactive protein and cytokine levels) on the first day of septic shock and compared these parameters between HIV/AIDS and non-HIV patients.
   Results: We included 30 HIV/AIDS septic shock patients and 30 non-HIV septic shock patients. The HIV/AIDS patients presented low CD4 cell counts (72 [7-268] cells/mm(3)), and 17 (57%) patients were on HAART before hospital admission. Both groups were similar according to the acute severity scores and hospital mortality. The IL-6, IL-10 and G-CSF levels were associated with hospital mortality in the HIV/AIDS septic group; however, the CRP levels and the surrogates of innate immune activation (cytokines) were similar among HIV/AIDS and non-HIV septic patients. Age (odds ratio 1.05, CI 95% 1.02-1.09, p=0.002) and the IL-6 levels (odds ratio 1.00, CI 95% 1.00-1.01, p=0.05) were independent risk factors for hospital mortality.
   Conclusions: IL-6, IL-10 and G-CSF are biomarkers that can be used to predict prognosis and outcomes in HIV/AIDS septic patients. Although HIV/AIDS patients are immunocompromised, an innate immune response can be activated in these patients, which is similar to that in the non-HIV septic population. In addition, age and the IL-6 levels are independent risk factors for hospital mortality irrespective of HIV/AIDS disease.
C1 [Amancio, Rodrigo T.; Japiassu, Andre M.; Gomes, Rachel N.; Mesquita, Emersom C.; Medeiros, Denise M.; Bozza, Fernando A.] Inst Pesquisa Clin Evandro Chagas IPEC, Lab Med Intens, Rio De Janeiro, RJ, Brazil.
   [Grinsztejn, Beatriz] Inst Pesquisa Clin Evandro Chagas IPEC, Lab HIV, Rio De Janeiro, RJ, Brazil.
   [Assis, Edson F.; Bozza, Patricia T.; Castro-Faria Neto, Hugo C.] Fundacao Oswaldo Cruz FIOCRUZ, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Japiassu, Andre M.; Bozza, Fernando A.] Inst Or Pesquisa Ensino IDOR, Rio De Janeiro, RJ, Brazil.
RP Bozza, FA (corresponding author), Inst Pesquisa Clin Evandro Chagas IPEC, Lab Med Intens, Rio De Janeiro, RJ, Brazil.
EM fernando.bozza@ipec.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Gomes, Rachel N/I-7643-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529; Mesquita, Emersom/0000-0002-5132-3315
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); PAPES/FIOCRUZ
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) and PAPES/FIOCRUZ. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andaluz-Ojeda D, 2012, CYTOKINE, V57, P332, DOI 10.1016/j.cyto.2011.12.002
   Ballester JCA, 2008, INFECT CONT HOSP EP, V29, P630, DOI 10.1086/589583
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087
   BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Benito N, 2004, CLIN DIAGN LAB IMMUN, V11, P608, DOI 10.1128/CDLI.11.3.608-614.2004
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Blanco J, 2008, CRIT CARE, V12, DOI 10.1186/cc7157
   Boumendil A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034387
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   CIPOLLE MD, 1993, CRIT CARE CLIN, V9, P261
   Coquet I, 2010, CRIT CARE, V14, DOI 10.1186/cc9056
   Deeks SG, 2012, CURR OPIN IMMUNOL, V24, P501, DOI 10.1016/j.coi.2012.05.004
   Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
   Faix JD, 2013, CRIT REV CL LAB SCI, V50, P23, DOI 10.3109/10408363.2013.764490
   Gilstrap LG, 2012, CLIN CHEM, V58, P72, DOI 10.1373/clinchem.2011.165712
   GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401
   Greenberg JA, 2012, J CRIT CARE, V27, P51, DOI 10.1016/j.jcrc.2011.08.015
   Haddy RI, 2012, J AM BOARD FAM MED, V25, P318, DOI 10.3122/jabfm.2012.03.110106
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Jacob ST, 2009, PLOS ONE, V4, pA115, DOI 10.1371/journal.pone.0007782
   Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Rezende ELLF, 2010, BRAZ J INFECT DIS, V14, P558, DOI [10.1590/S1413-86702010000600003, 10.1016/S1413-8670(10)70112-4]
   Ledwaba L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024243
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Lucas S, 2012, CURR OPIN INFECT DIS, V25, P36, DOI 10.1097/QCO.0b013e32834ef5c4
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Mera S, 2011, APMIS, V119, P155, DOI 10.1111/j.1600-0463.2010.02705.x
   Mrus JM, 2005, CRIT CARE, V9, pR623, DOI 10.1186/cc3811
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16
   Povoa P, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-32
   Povoa P, 2011, CRIT CARE, V15, DOI 10.1186/cc10242
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Rosenberg AL, 2001, CRIT CARE MED, V29, P548, DOI 10.1097/00003246-200103000-00013
   Ross AC, 2009, CLIN INFECT DIS, V49, P1119, DOI 10.1086/605578
   Salluh JIF, 2011, CRIT CARE, V15, DOI 10.1186/cc10301
   Schleicher GK, 2005, EUR RESPIR J, V25, P688, DOI 10.1183/09031936.05.00067604
   Suratt BT, 2009, CRIT CARE MED, V37, P1322, DOI 10.1097/CCM.0b013e31819c14fa
   Thyrault M, 1997, INTENS CARE MED, V23, P1018, DOI 10.1007/s001340050451
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
NR 45
TC 15
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 11
PY 2013
VL 8
IS 7
AR e68730
DI 10.1371/journal.pone.0068730
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 188UA
UT WOS:000322218800042
PM 23874739
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rondina, MT
   Tolley, ND
   Schwertz, H
   Diaz-Ortiz, R
   Hunter-Mellado, R
   Bozza, FA
   DeVette, C
   Zimmerman, GA
   Washington, V
   Weyrich, AS
AF Rondina, M. T.
   Tolley, N. D.
   Schwertz, H.
   Diaz-Ortiz, R.
   Hunter-Mellado, R.
   Bozza, F. A.
   DeVette, C.
   Zimmerman, G. A.
   Washington, V
   Weyrich, A. S.
TI Influenza and dengue viruses upregulate interferon-induced transmembrane
   (IFITM) proteins in human platelets: novel immune sensing of viral
   pathogens
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Meeting Abstract
C1 [Rondina, M. T.; Tolley, N. D.; DeVette, C.; Zimmerman, G. A.; Weyrich, A. S.] Univ Utah, Salt Lake City, UT USA.
   [Schwertz, H.] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany.
   [Diaz-Ortiz, R.; Hunter-Mellado, R.; Washington, V] Univ Cent Caribe, San Juan, PR USA.
   [Bozza, F. A.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013; Schwertz, Hansjorg/Q-3305-2019
OI Bozza, Fernando A/0000-0003-4878-0256; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUL
PY 2013
VL 11
SU 2
SI SI
BP 188
EP 188
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA AB5MV
UT WOS:000331833601424
DA 2020-12-01
ER

PT J
AU Bozza, FA
   D'Avila, JC
   Ritter, C
   Sonneville, R
   Sharshar, T
   Dal-Pizzol, F
AF Bozza, Fernando A.
   D'Avila, Joana C.
   Ritter, Cristiane
   Sonneville, Romain
   Sharshar, Tarek
   Dal-Pizzol, Felipe
TI BIOENERGETICS, MITOCHONDRIAL DYSFUNCTION, AND OXIDATIVE STRESS IN THE
   PATHOPHYSIOLOGY OF SEPTIC ENCEPHALOPATHY
SO SHOCK
LA English
DT Article
DE Sepsis; infection; central nervous system; microglia; neuroinflammation;
   mitochondrial; energy
ID NITRIC-OXIDE SYNTHASE; TERM COGNITIVE IMPAIRMENT; CECAL LIGATION;
   RAT-BRAIN; RESPIRATORY-CHAIN; NADPH OXIDASE; PROINFLAMMATORY CYTOKINES;
   ENERGY-METABOLISM; PROTEIN-KINASE; SEVERE SEPSIS
AB Sepsis is a major cause of mortality and morbidity in intensive care units. Acute and long-term brain dysfunctions have been demonstrated both in experimental models and septic patients. Sepsis-associated encephalopathy is an early and frequent manifestation but is underdiagnosed, because of the absence of specific biomarkers and of confounding factors such as sedatives used in the intensive care unit. Sepsis-associated encephalopathy may have acute and long-term consequences including development of autonomic dysfunction, delirium, and cognitive impairment. The mechanisms of sepsis-associated encephalopathy involve mitochondrial and vascular dysfunctions, oxidative stress, neurotransmission disturbances, inflammation, and cell death. Here we review specific evidence that links bioenergetics, mitochondrial dysfunction, and oxidative stress in the setting of brain dysfunctions associated to sepsis.
C1 [Bozza, Fernando A.; D'Avila, Joana C.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; D'Avila, Joana C.] Inst Nacl Ciencia & Tecnol Biol Estrutural, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [D'Avila, Joana C.] Fundacao Oswaldo Cruz Fiocruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Ritter, Cristiane; Dal-Pizzol, Felipe] Univ Extremo Catarinense, Lab Fisiopatol Expt, Criciuma, SC, Brazil.
   [Ritter, Cristiane; Dal-Pizzol, Felipe] Univ Extremo Catarinense, Unidade Acad Ciencias Saude, Programa Posgrad Ciencias Saude, Inst Nacl Ciencia & Tecnol Translac Med, Criciuma, SC, Brazil.
   [Ritter, Cristiane; Dal-Pizzol, Felipe] Hosp Sao Jose, Intens Care Unit, Criciuma, SC, Brazil.
   [Sonneville, Romain; Sharshar, Tarek] Hop Raymond Poincare, Serv Reanimat Med, Garches, France.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz Fiocruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
EM fernando.bozza@ipec.fiocruz.br; piz@unesc.net
RI Dal-Pizzol, Felipe/F-2756-2015; Bozza, Fernando A/A-2618-2013;
   Sonneville, Romain/AAE-7039-2020; d'Avila, Joana/L-8970-2013
OI Dal-Pizzol, Felipe/0000-0003-3003-8977; Bozza, Fernando
   A/0000-0003-4878-0256; Sonneville, Romain/0000-0003-0245-309X; d'Avila,
   Joana/0000-0002-2045-0813
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Instituto Nacional de Ciencia e Tecnologia
   (INCT) em Biologia Estrutural e Bioimagem, e INCT em Translacional em
   Medicina, Brazil
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ), Instituto Nacional de
   Ciencia e Tecnologia (INCT) em Biologia Estrutural e Bioimagem, e INCT
   em Translacional em Medicina, Brazil.
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080
   Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035
   ARVIDSSON S, 1985, CIRC SHOCK, V16, P383
   Bal-Price A, 2001, J NEUROSCI, V21, P6480
   Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12
   Barichello T, 2005, CRIT CARE MED, V33, P221, DOI 10.1097/01.CCM.0000150741.12906.BD
   Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96
   Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48
   Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006
   Bozza FA, 2010, J CEREBR BLOOD F MET, V30, P440, DOI 10.1038/jcbfm.2009.215
   Brealey D, 2002, LANCET, V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557
   Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325
   Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178
   Cassol OJ, 2010, BRAIN RES, V1348, P128, DOI 10.1016/j.brainres.2010.06.023
   Changsirivathanathamrong D, 2011, CRIT CARE MED, V39, P2678
   Cheret C, 2008, J NEUROSCI, V28, P12039, DOI 10.1523/JNEUROSCI.3568-08.2008
   Chuang YC, 2002, J BIOMED SCI, V9, P542, DOI 10.1007/BF02254981
   CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2
   Comim CM, 2008, MITOCHONDRION, V8, P313, DOI 10.1016/j.mito.2008.07.002
   Comim CM, 2011, NEUROCHEM RES, V36, P304, DOI 10.1007/s11064-010-0320-2
   Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023
   Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002
   Czapski GA, 2004, POL J PHARMACOL, V56, P643
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Dare AJ, 2009, FREE RADICAL BIO MED, V47, P1517, DOI 10.1016/j.freeradbiomed.2009.08.019
   Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470
   Exline MC, 2008, FRONT BIOSCI-LANDMRK, V13, P5030
   FREUND HR, 1985, J SURG RES, V38, P267, DOI 10.1016/0022-4804(85)90037-X
   Gavillet M, 2008, GLIA, V56, P975, DOI 10.1002/glia.20671
   Godbout JP, 2004, J NEUROIMMUNOL, V149, P101, DOI 10.1016/j.jneuroim.2003.12.017
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Hamed SA, 2009, NEUROPEDIATRICS, V40, P66, DOI 10.1055/s-0029-1231054
   Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008
   Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Jackson JC, 2009, SOUTH MED J, V102, P1150, DOI 10.1097/SMJ.0b013e3181b6a592
   JEPPSSON B, 1981, AM J SURG, V141, P136, DOI 10.1016/0002-9610(81)90026-X
   Kheir-Eldin AA, 2001, INT J BIOCHEM CELL B, V33, P475, DOI 10.1016/S1357-2725(01)00032-2
   Kim EJ, 2002, J NEUROSCI RES, V70, P97, DOI 10.1002/jnr.10373
   Korcok J, 2002, J NEUROCHEM, V81, P185, DOI 10.1046/j.1471-4159.2002.00814.x
   Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619
   Marrif H, 1999, J NEUROSCI RES, V57, P255
   Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x
   Murray C, 2012, NEUROBIOL AGING, V33, P603, DOI 10.1016/j.neurobiolaging.2010.04.002
   Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49
   Ninkovic M., 2006, ACTA PHYSIOLOGICA HUNGARICA, V93, P315, DOI 10.1556/APhysiol.93.2006.4.7
   Ninkovic MB, 2009, GEN PHYSIOL BIOPHYS, V28, P243
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Polito A, 2011, CRIT CARE, V15, DOI 10.1186/cc10244
   Santiago APSA, 2008, BIOCHIMIE, V90, P1566, DOI 10.1016/j.biochi.2008.06.013
   Schlapbach LJ, 2011, PEDIATRICS, V128, pE348, DOI 10.1542/peds.2010-3338
   Schousboe A, 2011, J NEUROSCI RES, V89, P1926, DOI 10.1002/jnr.22746
   Sebai H, 2009, BRAIN INJURY, V23, P1089, DOI 10.3109/02699050903379370
   Semmler A, 2005, J CHEM NEUROANAT, V30, P144, DOI 10.1016/j.jchemneu.2005.07.003
   Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003
   Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4
   Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y
   Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001
   Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521
   Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008
   Sun HN, 2008, BIOL PHARM BULL, V31, P1711, DOI 10.1248/bpb.31.1711
   SZABO C, 2007, NOVART FDN SYMP, V280, P103
   SZABO C, 2007, NOVART FDN SYMP, V280, P160
   Szabo C, 2007, NOVART FDN SYMP, V280, P92
   Tsacopoulos M, 1996, J NEUROSCI, V16, P877
   van den Boogaard M, 2011, CRIT CARE, V15, DOI 10.1186/cc10598
   van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7
   van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2
   Voigt K, 2002, FREE RADICAL RES, V36, P735, DOI 10.1080/10715760290032557
   Weberpals M, 2009, J NEUROSCI, V29, P14177, DOI 10.1523/JNEUROSCI.3238-09.2009
   Willard LB, 2000, EXP BRAIN RES, V134, P58, DOI 10.1007/s002210000446
   Wilson JRA, 2012, CRIT CARE MED, V40, P835, DOI 10.1097/CCM.0b013e318236f62d
   Woo MS, 2008, J NEUROCHEM, V106, P770, DOI 10.1111/j.1471-4159.2008.05430.x
   Yoo BK, 2008, NEUROCHEM INT, V52, P1188, DOI 10.1016/j.neuint.2007.12.009
   Zhan RZ, 1996, SHOCK, V6, P293, DOI 10.1097/00024382-199610000-00012
NR 77
TC 64
Z9 68
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD MAY
PY 2013
VL 39
IS 7
SU 1
BP 10
EP 16
DI 10.1097/SHK.0b013e31828fade1
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 297JF
UT WOS:000330251000004
PM 23481496
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Oliveira, MF
   Nunes, PCG
   Nogueira, RMR
   Valls-De-Souza, R
   Da Poian, AT
   Weyrich, AS
   Zimmerman, GA
   Bozza, PT
   Bozza, FA
AF Hottz, E. D.
   Oliveira, M. F.
   Nunes, P. C. G.
   Nogueira, R. M. R.
   Valls-De-Souza, R.
   Da Poian, A. T.
   Weyrich, A. S.
   Zimmerman, G. A.
   Bozza, P. T.
   Bozza, F. A.
TI Dengue induces platelet activation, mitochondrial dysfunction and cell
   death through mechanisms that involve DC-SIGN and caspases
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE apoptosis; DC-SIGN; dengue; mitochondrial dysfunction; platelet
   activation; thrombocytopenia
ID VIRUS-INFECTION; EXPRESSION; APOPTOSIS; PATHWAYS; BINDING
AB Background Worldwide, dengue is the most prevalent human arbovirus disease. Dengue infection may cause a range of clinical manifestations from self-limiting febrile illness through to a life-threatening syndrome accompanied by both bleeding and shock. Thrombocytopenia is frequently observed in mild and severe disease; however, the mechanisms involved in DENV-induced platelet activation and thrombocytopenia are incompletely understood. Patients and methods Freshly isolated platelets from patients with dengue were evaluated for markers of activation, mitochondrial alteration and activation of cell death pathways. In parallel, we examined direct DENV-induced activation and apoptosis of platelets obtained from healthy subjects. Results We found that platelets from DENV-infected patients exhibited increased activation by comparison to control subjects. Moreover, platelets from DENV-infected patients exhibited classic signs of the intrinsic pathway of apoptosis that include increased surface phosphatidylserine exposure, mitochondrial depolarization and activation of caspase-9 and -3. Indeed, thrombocytopenia was shown to strongly associate with enhanced platelet activation and cell death in DENV-infected patients. Platelet activation, mitochondrial dysfunction and caspase-dependent phosphatidylserine exposure on platelets were also observed when platelets from healthy subjects were directly exposed to DENV in vitro. DENV-induced platelet activation was shown to occur through mechanisms largely dependent on DC-SIGN. Conclusions Together our results demonstrate that platelets from patients with dengue present signs of activation, mitochondrial dysfunction and activation of the apoptosis caspase cascade, which may contribute to the development of thrombocytopenia in patients with dengue. Our results also suggest the involvement of DC-SIGN as a critical receptor in DENV-dependent platelet activation.
C1 [Hottz, E. D.; Bozza, P. T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Immunofarmacol, Rio De Janeiro, Brazil.
   [Hottz, E. D.; Valls-De-Souza, R.; Bozza, F. A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Oliveira, M. F.; Da Poian, A. T.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Nunes, P. C. G.; Nogueira, R. M. R.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
   [Weyrich, A. S.] Univ Utah, Program Mol Med, Salt Lake City, UT USA.
   [Weyrich, A. S.; Zimmerman, G. A.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br; fernando.bozza@ipec.fiocruz.br
RI Da Poian, Andrea T./V-1699-2019; Oliveira, Marcus/G-3158-2011; Bozza,
   Fernando A/A-2618-2013; Hottz, Eugenio D/I-9850-2014
OI Oliveira, Marcus/0000-0002-9890-8425; Bozza, Fernando
   A/0000-0003-4878-0256; Bozza, Patricia/0000-0001-8349-9529; Weyrich,
   Andrew/0000-0001-9622-4647; Da Poian, Andrea/0000-0002-3969-704X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); PAPES/FIOCRUZ; INBEB; PRONEX Dengue;
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HL066277, HL091754,
   HL044525]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [U54HL112311,
   R01HL044525, U54HL112311, U54HL112311, U54HL112311, R37HL044525,
   U54HL112311, R01HL044525, R37HL044525, R01HL044525, U54HL112311,
   R01HL066277, R01HL044525, U54HL112311, U54HL112311, R01HL066277,
   U54HL112311, U54HL112311, U54HL112311, U54HL112311, R01HL044525,
   U54HL112311, U54HL112311, R01HL066277, R01HL066277, U54HL112311,
   R37HL044525, U54HL112311, R01HL066277, R01HL044525, U54HL112311,
   U54HL112311, R37HL044525, R01HL066277, R01HL066277, U54HL112311,
   U54HL112311, U54HL112311, U54HL112311, R01HL066277, R01HL044525,
   R01HL044525, R01HL091754, U54HL112311, R01HL091754, U54HL112311,
   R01HL066277, R01HL044525, U54HL112311, R01HL044525, U54HL112311,
   R01HL066277, U54HL112311, U54HL112311, U54HL112311, R37HL044525,
   R01HL091754, R01HL091754, U54HL112311, U54HL112311, U54HL112311,
   U54HL112311, U54HL112311, R01HL044525, U54HL112311, U54HL112311,
   U54HL112311, R01HL044525, R01HL044525, U54HL112311, R01HL044525,
   U54HL112311, R01HL066277, R37HL044525, U54HL112311, U54HL112311,
   R37HL044525, U54HL112311, R37HL044525, U54HL112311, U54HL112311,
   R01HL066277, R37HL044525, U54HL112311, R37HL044525] Funding Source: NIH
   RePORTER
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ), PAPES/FIOCRUZ, INBEB and
   PRONEX Dengue; and from the National Institutes of Health (HL066277,
   HL091754, and HL044525 awarded to A.S.W. and G.A.Z).
CR Alonzo MTG, 2012, J INFECT DIS, V205, P1321, DOI 10.1093/infdis/jis180
   Alves LR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021358
   Boukour S, 2006, J THROMB HAEMOST, V4, P426, DOI 10.1111/j.1538-7836.2006.01749.x
   Conceicao TM, 2010, J INFECTION, V60, P65, DOI 10.1016/j.jinf.2009.10.003
   Courageot MP, 2003, ADV VIRUS RES, V60, P157, DOI 10.1016/S0065-3527(03)60005-9
   El-Bacha T, 2007, BBA-MOL BASIS DIS, V1772, P1158, DOI 10.1016/j.bbadis.2007.08.003
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Falconar AKI, 2006, CLIN VACCINE IMMUNOL, V13, P1044, DOI 10.1128/CVI.00105-06
   Fitzgerald JR, 2006, MOL MICROBIOL, V59, P212, DOI 10.1111/j.1365-2958.2005.04922.x
   Ghosh K, 2008, J ELECTRON MICROSC, V57, P113, DOI 10.1093/jmicro/dfn007
   Honda S, 2009, AM J TROP MED HYG, V80, P841, DOI 10.4269/ajtmh.2009.80.841
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Jobe SM, 2008, BLOOD, V111, P1257, DOI 10.1182/blood-2007-05-092684
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Krishnamurti C, 2002, AM J TROP MED HYG, V66, P435, DOI 10.4269/ajtmh.2002.66.435
   LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992
   LARUSSA VF, 1995, BAILLIERE CLIN HAEM, V8, P249, DOI 10.1016/S0950-3536(05)80240-9
   Leytin V, 2006, J THROMB HAEMOST, V4, P2656, DOI 10.1111/j.1538-7836.2006.02200.x
   Leytin V, 2008, BRIT J HAEMATOL, V142, P494, DOI 10.1111/j.1365-2141.2008.07209.x
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Lopez JJ, 2008, J THROMB HAEMOST, V6, P1780, DOI 10.1111/j.1538-7836.2008.03111.x
   Martínez Torres Eric, 2008, Estud. av., V22, P33, DOI 10.1590/S0103-40142008000300004
   Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037
   MITRAKUL C, 1977, AM J TROP MED HYG, V26, P975, DOI 10.4269/ajtmh.1977.26.975
   Mourao MPG, 2007, PLATELETS, V18, P605, DOI 10.1080/09537100701426604
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   Paul BZS, 2003, J THROMB HAEMOST, V1, P814, DOI 10.1046/j.1538-7836.2003.00099.x
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Schmidt AC, 2010, NEW ENGL J MED, V363, P484, DOI 10.1056/NEJMcibr1005904
   Srichaikul T, 2000, BEST PRACT RES CL HA, V13, P261, DOI 10.1053/beha.2000.0073
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Tsai JJ, 2011, J INNATE IMMUN, V3, P530, DOI 10.1159/000322904
   Verhoeven AJ, 2005, TRANSFUSION, V45, P82, DOI 10.1111/j.1537-2995.2005.04023.x
   Wahala WMPB, 2011, VIRUSES-BASEL, V3, P2374, DOI 10.3390/v3122374
   WANG SG, 1995, VIROLOGY, V213, P254, DOI 10.1006/viro.1995.1567
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Zhang JL, 2007, BIOCHEM BIOPH RES CO, V356, P763, DOI 10.1016/j.bbrc.2007.03.051
NR 39
TC 94
Z9 98
U1 3
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD MAY
PY 2013
VL 11
IS 5
BP 951
EP 962
DI 10.1111/jth.12178
PG 12
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 145JQ
UT WOS:000319011900018
PM 23433144
OA Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Teixeira-Cunha, MGA
   Figueiredo, RT
   Almeida, PE
   Alves, SC
   Bozza, PT
   Bozza, FA
   Bozza, MT
   Zimmerman, GA
   Castro-Faria-Neto, HC
AF Gomes, Rachel N.
   Teixeira-Cunha, Mariana G. A.
   Figueiredo, Rodrigo T.
   Almeida, Patricia E.
   Alves, Silvio C.
   Bozza, Patricia T.
   Bozza, Fernando A.
   Bozza, Marcelo T.
   Zimmerman, Guy A.
   Castro-Faria-Neto, Hugo C.
TI BACTERIAL CLEARANCE IN SEPTIC MICE IS MODULATED BY MCP-1/CCL2 AND NITRIC
   OXIDE
SO SHOCK
LA English
DT Article
DE Chemokines; nitric oxide; bacterial infection; phagocytosis
ID HOST-DEFENSE; SYNTHASE INHIBITOR; CHEMOKINES; SEPSIS; PROTEIN-1; ROLES;
   RECRUITMENT; MECHANISMS; MORTALITY; DISEASE
AB Bacterial clearance is one of the most important beneficial consequences of the innate immune response. Chemokines are important mediators controlling leukocyte trafficking and activation, whereas reactive oxygen and nitrogen species are effectors in bacterial killing. In the present work, we used in vivo and in vitro models of infections to study the role of monocyte chemoattractant protein 1 (MCP-1)/CCL2 and nitric oxide (NO) in the bacterial clearance in sepsis. Our results show that MCP-1/CCL2 and NO levels are increased in the peritoneal cavity of mice 6 h after sepsis induced by cecal ligation and puncture. Pretreatment with anti-MCP-1/CCL2 monoclonal antibodies increased the number of colony-forming units (CFUs) recovered in the peritoneal lavage fluid. Moreover, CFU counts were increased in the peritoneal fluid of CCR2(-/-) mice subjected to cecal ligation and puncture. In vitro stimulation of peritoneal macrophages with recombinant MCP-1/CCL2 reduced CFU counts in the supematant after challenge with Escherichia coli. Conversely, treatment with anti-MCP-1/CCL2 increased CFU counts under the same experimental condition. Stimulation of cultured macrophages with MCP-1/CCL2 and interferon had a synergistic effect on NO production. Macrophages from CCL2(-/-) mice showed a consistent decrease in NO production when compared with wild-type controls after stimulation with LPS + interferon. Finally, we showed incubation of macrophages with E. coli, and the ERK inhibitor U0126 increased CFU numbers and decreased intracellular levels of NO. In conclusion, we demonstrated for the first time that MCP-1/CCL2 has a crucial role in the clearance of bacteria by mechanisms involving increased expression of inducible NO synthase and production of NO by ERK signaling pathways.
C1 [Gomes, Rachel N.; Teixeira-Cunha, Mariana G. A.; Almeida, Patricia E.; Alves, Silvio C.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Gomes, Rachel N.; Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Evandro Chagas, Lab Integrado Med Intens, BR-21045900 Rio De Janeiro, Brazil.
   [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio de Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Lab Inflamacao & Imunidade, Rio de Janeiro, Brazil.
   [Zimmerman, Guy A.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
RP Castro-Faria-Neto, HC (corresponding author), Fiocruz MS, Dept Fisiol & Farmacodinam, IOC, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM hcastro@ioc.fiocruz.br
RI ; Figueiredo, Rodrigo/F-5176-2016
OI Bozza, Fernando Augusto/0000-0003-4878-0256; Almeida, Patricia Elaine
   de/0000-0002-9081-8601; Figueiredo, Rodrigo/0000-0002-7551-8782; Bozza,
   Patricia/0000-0001-8349-9529; Bozza, Marcelo/0000-0003-3683-7550
FU PAPES-FIOCRUZ; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); National Institutes of
   Health/National Heart, Lung, and Blood InstituteUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [SR37WLO44525]; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525, R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525] Funding Source: NIH RePORTER
FX This work was supported by PAPES-FIOCRUZ, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), and Fundacao de
   Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil). The funding
   agencies had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. Dr. Zimmerman's
   research activities are in part supported by National Institutes of
   Health/National Heart, Lung, and Blood Institute award SR37WLO44525.
CR Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Balamayooran G, 2011, INFECT IMMUN, V79, P2567, DOI 10.1128/IAI.00067-11
   Beck PL, 2004, AM J PHYSIOL-GASTR L, V286, pG137, DOI 10.1152/ajpgi.00309.2003
   Biswas SK, 2001, NITRIC OXIDE-BIOL CH, V5, P566, DOI 10.1006/niox.2001.0370
   BOSSINK AWJ, 1995, BLOOD, V86, P3841, DOI 10.1182/blood.V86.10.3841.bloodjournal86103841
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Cross AS, 2003, ANN INTERN MED, V138, P502, DOI 10.7326/0003-4819-138-6-200303180-00016
   Forslund T, 1997, BIOCHEM BIOPH RES CO, V233, P492, DOI 10.1006/bbrc.1997.6490
   Franchini A, 1995, ADV NEUROIMMUNOL, V5, P463, DOI 10.1016/0960-5428(95)00029-1
   Gaieski DF, 2010, CRIT CARE MED, V38, P1045, DOI 10.1097/CCM.0b013e3181cc4824
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Hauser B, 2004, SHOCK, V22, P588, DOI 10.1097/00024382-200412000-00016
   Jia T, 2008, J IMMUNOL, V180, P6846, DOI 10.4049/jimmunol.180.10.6846
   Kaufmann SHE, 1995, CIBA F SYMP, V195, P239
   Kilbourn RG, 1997, SHOCK, V7, P235, DOI 10.1097/00024382-199704000-00001
   Liew FY, 1995, CIBA F SYMP, V195, P234
   Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0
   Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   MOILANEN E, 1995, ANN MED, V27, P359, DOI 10.3109/07853899509002589
   MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x
   NAKANO Y, 1994, INFECT IMMUN, V62, P377, DOI 10.1128/IAI.62.2.377-383.1994
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Siddiqui Shahla, 2009, J Ayub Med Coll Abbottabad, V21, P106
   SPAIN DA, 1994, J TRAUMA, V36, P720, DOI 10.1097/00005373-199405000-00021
   Tsai WC, 1997, INFECT IMMUN, V65, P1870, DOI 10.1128/IAI.65.5.1870-1875.1997
   Vromen A, 1996, SHOCK, V6, P248, DOI 10.1097/00024382-199610000-00004
NR 36
TC 39
Z9 41
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JAN
PY 2013
VL 39
IS 1
BP 63
EP 69
DI 10.1097/SHK.0b013e31827802b5
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 063CB
UT WOS:000312972500010
PM 23247123
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Reis, PA
   Estato, V
   da Silva, TI
   d'Avila, JC
   Siqueira, LD
   Assis, EF
   Bozza, PT
   Bozza, FA
   Tibirica, EV
   Zimmerman, GA
   Castro-Faria-Neto, HC
AF Reis, Patricia A.
   Estato, Vanessa
   da Silva, Tathiany I.
   d'Avila, Joana C.
   Siqueira, Luciana D.
   Assis, Edson F.
   Bozza, Patricia T.
   Bozza, Fernando A.
   Tibirica, Eduardo V.
   Zimmerman, Guy A.
   Castro-Faria-Neto, Hugo C.
TI Statins Decrease Neuroinflammation and Prevent Cognitive Impairment
   after Cerebral Malaria
SO PLOS PATHOGENS
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1;
   IN-VIVO; CEREBROSPINAL-FLUID; MALAWIAN CHILDREN; SEPSIS; ATORVASTATIN;
   PATHOGENESIS; DYSFUNCTION
AB Cerebral malaria (CM) is the most severe manifestation of Plasmodium falciparum infection in children and non-immune adults. Previous work has documented a persistent cognitive impairment in children who survive an episode of CM that is mimicked in animal models of the disease. Potential therapeutic interventions for this complication have not been investigated, and are urgently needed. HMG-CoA reductase inhibitors (statins) are widely prescribed for cardiovascular diseases. In addition to their effects on the inhibition of cholesterol synthesis, statins have pleiotropic immunomodulatory activities. Here we tested if statins would prevent cognitive impairment in a murine model of cerebral malaria. Six days after infection with Plasmodium berghei ANKA (PbA) mice displayed clear signs of CM and were treated with chloroquine, or chloroquine and lovastatin. Intravital examination of pial vessels of infected animals demonstrated a decrease in functional capillary density and an increase in rolling and adhesion of leukocytes to inflamed endothelium that were reversed by treatment with lovastatin. In addition, oedema, ICAM-1, and CD11b mRNA levels were reduced in lovastatin-treated PbA-infected mice brains. Moreover, HMOX-1 mRNA levels are enhanced in lovastatin-treated healthy and infected brains. Oxidative stress and key inflammatory chemokines and cytokines were reduced to non-infected control levels in animals treated with lovastatin. Fifteen days post-infection cognitive dysfunction was detected by a battery of cognition tests in animals rescued from CM by chloroquine treatment. In contrast, it was absent in animals treated with lovastatin and chloroquine. The outcome was similar in experimental bacterial sepsis, suggesting that statins have neuroprotective effects in severe infectious syndromes in addition to CM. Statin treatment prevents neuroinflammation and blood brain barrier dysfunction in experimental CM and related conditions that are associated with cognitive sequelae, and may be a valuable adjuvant therapeutic agent for prevention of cognitive impairment in patients surviving an episode of CM.
C1 [Reis, Patricia A.; da Silva, Tathiany I.; d'Avila, Joana C.; Siqueira, Luciana D.; Assis, Edson F.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Estato, Vanessa; Tibirica, Eduardo V.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Invest Cardiovasc, Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil.
   [Zimmerman, Guy A.] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA.
RP Reis, PA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
EM reispa@gmail.com; reispa@gmail.com
RI Estato, Vanessa/AAJ-9060-2020; d'Avila, Joana/L-8970-2013; Bozza,
   Fernando A/A-2618-2013
OI d'Avila, Joana/0000-0002-2045-0813; Bozza, Fernando
   A/0000-0003-4878-0256; Bozza, Patricia/0000-0001-8349-9529
FU CNPq (National Counsel of Technological and Scientific
   Development)National Council for Scientific and Technological
   Development (CNPq); Faperj (Fundacao Carlos Chagas de Amparo a Pesquisa
   do Estado do Rio de Janeiro)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); Pronex (Programa de
   Apoio a Nucleos de Excelencia); NIH/NINDSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS) [RO3
   NS04512]; NIHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R37 HL044525];
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525, R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525] Funding Source: NIH RePORTER
FX Financial support was provided by CNPq (National Counsel of
   Technological and Scientific Development), Faperj (Fundacao Carlos
   Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro), Pronex
   (Programa de Apoio a Nucleos de Excelencia), NIH/NINDS RO3 NS04512 and
   NIHS R37 HL044525. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ali F, 2009, J BIOL CHEM, V284, P18882, DOI 10.1074/jbc.M109.009886
   Araujo CV, 2012, MICROVASC RES, V84, P218, DOI 10.1016/j.mvr.2012.05.006
   Armah H, 2005, ANN TROP MED PARASIT, V99, P629, DOI 10.1179/136485905X51508
   Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12
   Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96
   Bienvenu AL, 2008, ANTIMICROB AGENTS CH, V52, P4203, DOI 10.1128/AAC.00513-08
   Boivin MJ, 2007, PEDIATRICS, V119, pE360, DOI 10.1542/peds.2006-2027
   Brown H, 1999, NEUROPATH APPL NEURO, V25, P331
   Brown H, 2001, AM J TROP MED HYG, V64, P207, DOI 10.4269/ajtmh.2001.64.207
   Bu DX, 2011, CURR OPIN LIPIDOL, V22, P165, DOI 10.1097/MOL.0b013e3283453e41
   Carter JA, 2006, DEV MED CHILD NEUROL, V48, P51, DOI 10.1017/S0012162206000107
   Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893
   Carvalho LJM, 2010, TRENDS PARASITOL, V26, P271, DOI 10.1016/j.pt.2010.03.001
   Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141
   Cordoliani YS, 1998, AM J NEURORADIOL, V19, P871
   Craig AG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002401
   de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715
   Dobbie M, 2000, AM J TROP MED HYG, V62, P284, DOI 10.4269/ajtmh.2000.62.284
   Dorovini-Zis K, 2011, AM J PATHOL, V178, P2146, DOI 10.1016/j.ajpath.2011.01.016
   DRAPER HH, 1990, METHOD ENZYMOL, V186, P421
   Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2
   Faille D, 2009, THROMB HAEMOSTASIS, V102, P1093, DOI 10.1160/TH09-05-0337
   Golenser J, 2006, INT J PARASITOL, V36, P583, DOI 10.1016/j.ijpara.2006.02.009
   Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839
   Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje
   Hsu M, 2006, BIOCHEM BIOPH RES CO, V343, P738, DOI 10.1016/j.bbrc.2006.03.036
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Hunt NH, 2007, NAT MED, V13, P667, DOI 10.1038/nm0607-667
   Hunt NH, 2010, TRENDS PARASITOL, V26, P272, DOI 10.1016/j.pt.2010.03.006
   IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709
   John CC, 2008, AM J TROP MED HYG, V78, P198, DOI 10.4269/ajtmh.2008.78.198
   Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785
   Kouroumichakis I, 2011, EUR J INTERN MED, V22, P125, DOI 10.1016/j.ejim.2010.12.004
   Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x
   Langhorne J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-23
   LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   LOOAREESUWAN S, 1995, CLIN INFECT DIS, V21, P300, DOI 10.1093/clinids/21.2.300
   Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001
   Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288
   Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913
   Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813
   McGown CC, 2010, BRIT J ANAESTH, V104, P183, DOI 10.1093/bja/aep361
   MILLAN JM, 1993, AM J NEURORADIOL, V14, P493
   Morandi A, 2011, CHEST, V140, P580, DOI 10.1378/chest.10-3065
   Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   Nie CQ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000369
   Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Papadopoulos G, 2002, EUR J ANAESTH, V19, P152, DOI 10.1017/S0265021502250267
   Patankar TF, 2002, RADIOLOGY, V224, P811, DOI 10.1148/radiol.2243010588
   Paul R, 2007, EXP NEUROL, V203, P158, DOI 10.1016/j.expneurol.2006.08.003
   Penet MF, 2007, J BIOL CHEM, V282, P14505, DOI 10.1074/jbc.M608035200
   Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005
   Pino P, 2005, THROMB HAEMOSTASIS, V94, P336, DOI 10.1160/TH05-05-0354
   PUHL H, 1994, METHOD ENZYMOL, V233, P425
   Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963
   Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Sabino B, 2008, J CARDIOVASC PHARM, V51, P402, DOI 10.1097/FJC.0b013e3181673bc5
   Sacanella E, 2011, CRIT CARE, V15, DOI 10.1186/cc10121
   Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
   Souraud JB, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-13
   Stocker R, 2006, CIRCULATION, V114, P2178, DOI 10.1161/CIRCULATIONAHA.105.598698
   Taoufiq Z, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-52
   Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   Terblanche M, 2007, LANCET INFECT DIS, V7, P358, DOI 10.1016/S1473-3099(07)70111-1
   van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002
   van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2
   WILLIMANN K, 1995, J EXP MED, V182, P643, DOI 10.1084/jem.182.3.643
   Wurtz N, 2010, J ANTIMICROB CHEMOTH, V65, P1387, DOI 10.1093/jac/dkq173
   Yadava A, 1996, P NATL ACAD SCI USA, V93, P4595, DOI 10.1073/pnas.93.10.4595
   Yoshimoto T, 1998, J IMMUNOL, V160, P5500
   Zimmerman GA, 2010, EXPERT REV ANTI-INFE, V8, P1209, DOI [10.1586/eri.10.117, 10.1586/ERI.10.117]
NR 78
TC 62
Z9 64
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2012
VL 8
IS 12
AR e1003099
DI 10.1371/journal.ppat.1003099
PG 13
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 062GJ
UT WOS:000312907100046
PM 23300448
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Evangelista, L
   Cervino, AR
   Sanco, R
   Memo, L
   Burei, M
   Michieletto, S
   Saibene, T
   Valpione, S
   Bozza, F
   Ghiotto, C
AF Evangelista, L.
   Cervino, A. R.
   Sanco, R.
   Memo, L.
   Burei, M.
   Michieletto, S.
   Saibene, T.
   Valpione, S.
   Bozza, F.
   Ghiotto, C.
TI The "old" and "current" nuclear medicine imaging in locally advanced
   breast cancer patient evaluation: 99mTc-MIBI mammoscintigraphy (MMS) and
   fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed
   tomography (CT)
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT 25th Annual Congress of the European-Association-of-Nuclear-Medicine
   (EANM)
CY OCT 27-31, 2012
CL Milan, ITALY
SP European Assoc Nucl Med (EANM)
C1 [Evangelista, L.; Cervino, A. R.; Sanco, R.; Memo, L.; Burei, M.] Ist Oncol Veneto, Nucl Med Unit, Padua, Italy.
   [Michieletto, S.; Saibene, T.; Bozza, F.] Ist Oncol Veneto, Surg Oncol Unit, Padua, Italy.
   [Valpione, S.; Ghiotto, C.] Ist Oncol Veneto, Oncol Unit 2, Padua, Italy.
RI Valpione, Sara/C-4051-2014; Bozza, Fernando A/A-2618-2013
OI Valpione, Sara/0000-0002-1699-2548; Bozza, Fernando
   A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2012
VL 39
SU 2
MA OP643
BP S284
EP S284
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 019GW
UT WOS:000309726600464
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Bozza, FA
AF Japiassu, Andre Miguel
   Bozza, Fernando A.
TI The many facets of procalcitonin in the critically ill population
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID BLOOD-STREAM INFECTION; SEPSIS; PREDICTION; BIOMARKERS; DIAGNOSIS
C1 [Japiassu, Andre Miguel; Bozza, Fernando A.] Ctr Hosp, Intens Care Unit, Inst Pesquisa, Clin Evandro Chagas,Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Inst Or Pesquisa & Ensino, Rio De Janeiro, Brazil.
RP Japiassu, AM (corresponding author), Ctr Hosp, Intens Care Unit, Inst Pesquisa, Clin Evandro Chagas,Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Abraham E, 2007, CRIT CARE MED, V35, P2408, DOI 10.1097/01.CCM.0000282072.56245.91
   Aouifi A, 2000, CRIT CARE MED, V28, P3171, DOI 10.1097/00003246-200009000-00008
   Charles PE, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-163
   Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC
   Cinel I, 2009, CRIT CARE MED, V37, P291, DOI 10.1097/CCM.0b013e31819267fb
   Clec'h C, 2004, CRIT CARE MED, V32, P1166, DOI 10.1097/01.CCM.0000126263.00551.06
   Coelho LM, 2012, CRIT CARE, V16, DOI 10.1186/cc11291
   Gerlach H, 2011, CRIT CARE CLIN, V27, P215, DOI 10.1016/j.ccc.2010.12.007
   Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396, DOI 10.1164/ajrccm.164.3.2009052
   Liappis AP, 2011, INFLAMM RES, V60, P203, DOI 10.1007/s00011-010-0255-8
   Peters RPH, 2006, CLIN MICROBIOL INFEC, V12, P1207, DOI 10.1111/j.1469-0691.2006.01556.x
   Povoa P, 2006, CRIT CARE, V10, DOI 10.1186/cc4892
   Rau B, 2000, INTENS CARE MED, V26, pS159, DOI 10.1007/BF02900730
   Reinhart K, 2011, CRIT CARE CLIN, V27, P253, DOI 10.1016/j.ccc.2011.01.002
   Reynolds SC, 2012, CRIT CARE MED, V40, P2781, DOI 10.1097/CCM.0b013e31825b89cc
NR 15
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD OCT
PY 2012
VL 40
IS 10
BP 2903
EP 2905
DI 10.1097/CCM.0b013e3182631e56
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA 007XB
UT WOS:000308920600025
PM 22986656
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Reis, P
   Alexandre, PC
   Pitombo, MM
   Castro-Faria-Neto, HC
AF Bozza, F. A.
   Reis, P.
   Alexandre, P. C.
   Pitombo, M. M.
   Castro-Faria-Neto, H. C.
TI STATINS PROTECTS COGNITIVE IMPAIRMENT IN ANIMAL MODEL OF SEPSIS
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Bozza, F. A.] Fundacao Oswaldo Cruz, ICU, Evandro Chagas Inst, Rio De Janeiro, Brazil.
   [Bozza, F. A.; Reis, P.; Alexandre, P. C.; Pitombo, M. M.; Castro-Faria-Neto, H. C.] Fundacao Oswaldo Cruz, Imunopharmacol Lab, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD OCT
PY 2012
VL 38
SU 1
MA 0442
BP S125
EP S125
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JP
UT WOS:000209083000443
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Teixeira-Cunha, MGA
   Figueiredo, RT
   Almeida, PE
   Alves, SC
   Bozza, FA
   Bozza, PT
   Zimmerman, GA
   Bozza, MT
   Castro-Faria-Neto, HC
AF Gomes, R. N.
   Teixeira-Cunha, M. G. A.
   Figueiredo, R. T.
   Almeida, P. E.
   Alves, S. C.
   Bozza, F. A.
   Bozza, P. T.
   Zimmerman, G. A.
   Bozza, M. T.
   Castro-Faria-Neto, H. C.
TI BACTERIAL CLEARANCE IN SEPTIC MICE IS MODULATED BY MCP-1/CCL2 AND NITRIC
   OXIDE
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Gomes, R. N.] Inst Pesquisa Evandro Chagas, Rio De Janeiro, Brazil.
   [Gomes, R. N.; Teixeira-Cunha, M. G. A.; Almeida, P. E.; Alves, S. C.; Bozza, P. T.; Castro-Faria-Neto, H. C.] Inst Oswaldo Cruz FIOCRUZ, Rio De Janeiro, Brazil.
   [Figueiredo, R. T.] Inst Ciencias Biomed UFRJ, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Fiocruz MS, Inst Pesquisa Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Zimmerman, G. A.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   [Bozza, M. T.] Univ Fed Rio de Janeiro, Lab Inflamacao & Imunidade, Inst Microbiol, Rio de Janeiro, Brazil.
RI Gomes, Rachel N/I-7643-2013; Figueiredo, Rodrigo T./F-5176-2016; Bozza,
   Fernando A/A-2618-2013
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Bozza, Fernando
   A/0000-0003-4878-0256
CR Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD OCT
PY 2012
VL 38
SU 1
MA 0172
BP S52
EP S52
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JP
UT WOS:000209083000173
DA 2020-12-01
ER

PT J
AU Rigby, C
   Oliveira, MF
   Neto, HCCF
   Bozza, PT
   Bozza, F
AF Rigby, C.
   Oliveira, M. F.
   Faria Neto, H. C. C.
   Bozza, P. T.
   Bozza, F.
TI ANALYSIS OF CYTOKINE PROFILE, HEME METABOLISM AND OXIDATIVE STRESS AFTER
   HEMORRHAGIC STROKE
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Rigby, C.; Bozza, F.] Fiocruz MS, IDOR, IPEC, BR-21045900 Rio De Janeiro, Brazil.
   [Oliveira, M. F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio de Janeiro, Brazil.
   [Faria Neto, H. C. C.; Bozza, P. T.] Fiocruz MS, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD OCT
PY 2012
VL 38
SU 1
MA 0389
BP S109
EP S109
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JP
UT WOS:000209083000390
DA 2020-12-01
ER

PT J
AU Zollinger, L
   Rodrigues, R
   Bozza, F
   Hoffman, J
   Morton, K
AF Zollinger, Lauren
   Rodrigues, Rosana
   Bozza, Fernando
   Hoffman, John
   Morton, Kathryn
TI Imaging acute endotoxin-induced lung injury in a rat model
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Meeting Abstract
C1 [Zollinger, Lauren; Hoffman, John; Morton, Kathryn] Univ Utah, Radiol, Salt Lake City, UT USA.
   [Rodrigues, Rosana] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
   [Bozza, Fernando] Natl Inst Sci & Technol Struct Biol & Bioimaging, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
FU Molecular Imaging Progam; Huntsman Cancer Institut
FX Molecular Imaging Progam, Huntsman Cancer Institut
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD MAY 1
PY 2012
VL 53
SU 1
MA 603
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA VF8FX
UT WOS:000443680201230
DA 2020-12-01
ER

PT J
AU Serafim, RB
   Dutra, MF
   Saddy, F
   Tura, B
   de Castro, JEC
   Villarinho, LC
   Santos, MD
   Bozza, FA
   Rocco, JR
AF Serafim, Rodrigo Bernardo
   Dutra, Maximiliano F.
   Saddy, Felipe
   Tura, Bernardo
   Couto de Castro, Jose Eduardo
   Villarinho, Luciana C.
   Santos, Maria da Gloria
   Bozza, Fernando Augusto
   Rocco, Jose Rodolfo
TI Delirium in postoperative nonventilated intensive care patients: risk
   factors and outcomes
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Delirium; Postoperative; Surgery; Confusion assessment method
AB Background: Delirium features can vary greatly depending on the postoperative population studied; however, most studies focus only on high-risk patients. Describing the impact of delirium and risk factors in mixed populations can help in the development of preventive actions.
   Methods: The occurrence of delirium was evaluated prospectively in 465 consecutive nonventilated postoperative patients admitted to a surgical intensive care unit (SICU) using the confusion assessment method (CAM). Patients with and without delirium were compared. A multiple logistic regression was performed to identify the main risk factors for delirium in the first 24 h of admission to the SICU and the main predictors of outcomes.
   Results: Delirium was diagnosed in 43 (9.2%) individuals and was more frequent on the second and third days of admission. The presence of delirium resulted in longer lengths of SICU and hospital stays [6 days (3-13) vs. 2 days (1-3), p < 0.001 and 26 days (12-39) vs. 6 days (3-13), p < 0.001, respectively], as well as higher hospital and SICU mortality rates [16.3% vs. 4.0%, p = 0.004 and 6.5% vs. 1.7%, p = 0.042, respectively]. The risk factors for delirium were age (odds ratio (OR), 1.04 [1.02-1.07]), Acute Physiologic Score (APS; OR, 1.11 [1.04-1.2]), emergency surgery (OR, 8.05 [3.58-18.06]), the use of benzodiazepines (OR, 2.28 [1.04-5.00]), and trauma (OR, 6.16 [4.1-6.5]).
   Conclusions: Delirium negatively impacts postoperative nonventilated patients. Risk factors can be used to detect high-risk patients in a mixed population of SICU patients.
C1 [Serafim, Rodrigo Bernardo; Saddy, Felipe] Copa DOr Hosp, Ventilatory Care Unit, Rio De Janeiro, Brazil.
   [Serafim, Rodrigo Bernardo; Tura, Bernardo; Bozza, Fernando Augusto] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Serafim, Rodrigo Bernardo; Rocco, Jose Rodolfo] Univ Fed Rio de Janeiro, Dept Internal Med, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Serafim, Rodrigo Bernardo; Rocco, Jose Rodolfo] Univ Fed Rio de Janeiro, Postgrad Program, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Dutra, Maximiliano F.; Couto de Castro, Jose Eduardo; Villarinho, Luciana C.; Santos, Maria da Gloria] Copa DOr Hosp, Surg Intens Care Unit, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, ICU, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
RP Serafim, RB (corresponding author), Copa DOr Hosp, Ventilatory Care Unit, Rio De Janeiro, Brazil.
EM rodrigobserafim@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Aldemir M, 2001, CRIT CARE, V5, P265, DOI 10.1186/cc1044
   Bekker Alex Y, 2003, Best Pract Res Clin Anaesthesiol, V17, P259, DOI 10.1016/S1521-6896(03)00005-3
   Dasgupta M, 2006, J AM GERIATR SOC, V54, P1578, DOI 10.1111/j.1532-5415.2006.00893.x
   DYER CB, 1995, ARCH INTERN MED, V155, P461, DOI 10.1001/archinte.155.5.461
   Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   ERGINA PL, 1993, WORLD J SURG, V17, P192, DOI 10.1007/BF01658926
   Fabbri RMA, 2001, ARQ NEURO-PSIQUIAT, V59, P175, DOI 10.1590/S0004-282X2001000200004
   Gabriel EA, 2007, EUR J CARDIO-THORAC, V31, P406, DOI 10.1016/j.ejcts.2006.11.053
   Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1
   Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901
   INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941
   Inouye SK, 1998, CLIN GERIATR MED, V14, P745
   Larsen KA, 2010, PSYCHOSOMATICS, V51, P409, DOI 10.1176/appi.psy.51.5.409
   Marcantonio E, 2002, J AM GERIATR SOC, V50, P850, DOI 10.1046/j.1532-5415.2002.50210.x
   MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134
   Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x
   Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7
   Mason SE, 2010, J ALZHEIMERS DIS, V22, pS67, DOI 10.3233/JAD-2010-101086
   McNicoll L, 2005, J AM GERIATR SOC, V53, P495, DOI 10.1111/j.1532-5415.2005.53171.x
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608
   Rudolph JL, 2009, CIRCULATION, V119, P229, DOI 10.1161/CIRCULATIONAHA.108.795260
   Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333
   Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729
   Young J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3704
NR 28
TC 41
Z9 46
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PY 2012
VL 2
AR 51
DI 10.1186/2110-5820-2-51
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA V35JY
UT WOS:000209147100051
PM 23272945
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Rodrigues, RS
   Marchiori, E
   Bozza, FA
   Pitrowsky, MT
   Velasco, E
   Soares, M
   Salluh, JIF
AF Rodrigues, Rosana Souza
   Marchiori, Edson
   Bozza, Fernando A.
   Pitrowsky, Melissa Tassano
   Velasco, Eduardo
   Soares, Marcio
   Salluh, Jorge I. F.
TI Chest computed tomography findings in severe influenza pneumonia
   occurring in neutropenic cancer patients
SO CLINICS
LA English
DT Article
DE H1N1; Viral pneumonia; Neutropenia; Cancer; Computed tomography
ID VIRUS-ASSOCIATED PNEUMONIA; RESOLUTION CT FINDINGS; H1N1 INFLUENZA;
   INFECTION; DISEASE; RADIOGRAPHY
AB OBJECTIVE: To describe the chest computed tomography findings for severe influenza H1N1 infection in a series of hospitalized neutropenic cancer patients.
   METHODS: We performed a retrospective systematic analysis of chest computed tomography scans for eight hospitalized patients with fever, neutropenia, and confirmed diagnoses of influenza H1N1. The clinical data had been prospectively collected.
   RESULTS: Six of eight patients (75%) developed respiratory failure and required intensive care. Prolonged H1N1 shedding was observed in the three mechanically ventilated patients, and overall hospital mortality in our series was 25%. The most frequent computed tomography findings were ground-glass opacity (all patients), consolidation (7/8 cases), and airspace nodules (6/8 cases) that were frequently moderate or severe. Other parenchymal findings were not common. Five patients had features of pneumonia, two had computed tomography findings compatible with bronchitis and/or bronchiolitis, and one had tomographic signs of chronicity.
   CONCLUSION: In this series of neutropenic patients with severe influenza H1N1 infection, chest computed tomography demonstrated mainly moderate or severe parenchymatous disease, but bronchiolitis was not a common feature. These findings associated with febrile neutropenia should elicit a diagnosis of severe viral infection.
C1 [Rodrigues, Rosana Souza; Marchiori, Edson] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Rodrigues, Rosana Souza; Bozza, Fernando A.; Soares, Marcio; Salluh, Jorge I. F.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Pitrowsky, Melissa Tassano; Soares, Marcio; Salluh, Jorge I. F.] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
   [Pitrowsky, Melissa Tassano; Soares, Marcio; Salluh, Jorge I. F.] Inst Nacl Canc, Postgrad Program, Rio De Janeiro, Brazil.
   [Velasco, Eduardo] Inst Nacl Canc, Dept Infect Dis, Rio De Janeiro, Brazil.
RP Rodrigues, RS (corresponding author), Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
EM jorgesalluh@gmail.com
RI Bozza, Fernando A/A-2618-2013; dantas, vicente c souza/L-2648-2013;
   Rodrigues, Rosana/N-9866-2013; Salluh, Jorge IF/F-6779-2012; Marchiori,
   Edson/C-1205-2013; Soares, Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Salluh, Jorge/0000-0002-8164-1453;
   Marchiori, Edson/0000-0001-8797-7380
CR Abbo L, 2010, BRIT J RADIOL, V83, P645, DOI 10.1259/bjr/53692814
   Agarwal PP, 2009, AM J ROENTGENOL, V193, P1488, DOI 10.2214/AJR.09.3599
   Aviram G, 2010, RADIOLOGY, V255, P252, DOI 10.1148/radiol.10092240
   BLYTH CC, 2010, EURO SURVEILL, V15
   *CDCP, INT GUID CAS DEF BE
   Elicker BM, 2010, EMERG RADIOL, V17, P299, DOI 10.1007/s10140-010-0859-x
   Ellis M, 2008, ANN NY ACAD SCI, V1138, P329, DOI 10.1196/annals.1414.035
   Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Heussel CP, 2004, EUR RADIOL, V14, P256, DOI 10.1007/s00330-003-1985-6
   Influenza Team, 2010, EUROSURVEILLANCE, V15, P19753
   Karadeli E, 2011, DIAGN INTERV RADIOL, V17, P216, DOI 10.4261/1305-3825.DIR.3337-10.1
   KIM EA, 2002, RADIOGRAPHICS, V22
   Li P, 2011, EUR J RADIOL, V80, pE146, DOI 10.1016/j.ejrad.2010.05.029
   Marchiori E, 2011, EUR J RADIOL, V80, pE500, DOI 10.1016/j.ejrad.2010.10.003
   Marchiori E, 2011, EUR J RADIOL, V80, P573, DOI 10.1016/j.ejrad.2010.10.004
   Marchiori E, 2011, AM J ROENTGENOL, V196, pW723, DOI 10.2214/AJR.10.5109
   Marchiori E, 2010, AM J ROENTGENOL, V195, pW317, DOI 10.2214/AJR.10.4651
   Marchiori E, 2010, KOREAN J RADIOL, V11, P587, DOI 10.3348/kjr.2010.11.5.587
   Marchiori E, 2010, EUR J RADIOL, V74, P93, DOI 10.1016/j.ejrad.2009.11.005
   Marchiori E, 2010, BRIT J RADIOL, V83, P179, DOI 10.1259/bjr/93404758
   Oikonomou A, 2003, AM J ROENTGENOL, V181, P507, DOI 10.2214/ajr.181.2.1810507
   Oliveira W, 2009, EUROSURVEILLANCE, V14
   Serra MC, 2008, EUR RESPIR J, V31, P618, DOI 10.1183/09031936.00073807
   Shiley KT, 2010, J THORAC IMAG, V25, P68, DOI 10.1097/RTI.0b013e3181b0ba8b
   Souza TML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014158
   Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497
   Tate MD, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-57
   Zemans RL, 2009, AM J RESP CELL MOL, V40, P519, DOI 10.1165/rcmb.2008-0348TR
NR 29
TC 10
Z9 12
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PY 2012
VL 67
IS 4
BP 313
EP 318
DI 10.6061/clinics/2012(04)03
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 931EV
UT WOS:000303199300003
PM 22522755
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Coelho, LM
   Salluh, JIF
   Soares, M
   Bozza, FA
   Verdeal, JCR
   Castro-Faria-Neto, HC
   Silva, JRLE
   Bozza, PT
   Povoa, P
AF Coelho, Luis M.
   Salluh, Jorge I. F.
   Soares, Marcio
   Bozza, Fernando A.
   Verdeal, Juan Carlos R.
   Castro-Faria-Neto, Hugo C.
   Lapa e Silva, Jose Roberto
   Bozza, Patricia T.
   Povoa, Pedro
TI Patterns of c-reactive protein RATIO response in severe
   community-acquired pneumonia: a cohort study
SO CRITICAL CARE
LA English
DT Article
ID VENTILATOR-ASSOCIATED PNEUMONIA; ORGAN FAILURE; MANAGEMENT; RESOLUTION;
   INFECTION; PREDICTOR; THERAPY; ADULTS; SCORE
AB Introduction: Community-acquired pneumonia (CAP) requiring intensive care unit (ICU) admission remains a severe medical condition, presenting ICU mortality rates reaching 30%. The aim of this study was to assess the value of different patterns of C-reactive protein (CRP)-ratio response to antibiotic therapy in patients with severe CAP requiring ICU admission as an early maker of outcome.
   Methods: In total, 191 patients with severe CAP were prospectively included and CRP was sampled every other day from D1 to D7 of antibiotic prescription. CRP-ratio was calculated in relation to D1 CRP concentration. Patients were classified according to an individual pattern of CRP-ratio response with the following criteria: fast response when D5 CRP was less than or equal to 0.4 of D1 CRP concentration; slow response - when D5 CRP was > 0.4 and D7 less than or equal to 0.8 of D1 CRP concentration; nonresponse - when D7 CRP was > 0.8 of D1 CRP concentration. Comparison between ICU survivors and non-survivors was performed.
   Results: CRP-ratio from D1 to D7 decreased faster in survivors than in non-survivors (p = 0.01). The ability of CRP-ratio by D5 to predict ICU outcome assessed by the area under the ROC curve was 0.73 (95% Confidence Interval, 0.64 - 0.82). By D5, a CRP concentration above 0.5 of the initial level was a marker of poor outcome (sensitivity 0.81, specificity 0.58, positive likelihood ratio 1.93, negative likelihood ratio 0.33). The time-dependent analysis of CRP-ratio of the three patterns (fast response n = 66; slow response n = 81; nonresponse n = 44) was significantly different between groups (p < 0.001). The ICU mortality rate was considerably different according to the patterns of CRP-ratio response: fast response 4.8%, slow response 17.3% and nonresponse 36.4% (p < 0.001).
   Conclusions: In severe CAP, sequential evaluation of CRP-ratio was useful in the early identification of patients with poor outcome. The evaluation of CRP-ratio pattern of response to antibiotics during the first week of therapy was useful in the recognition of the individual clinical evolution.
C1 [Coelho, Luis M.; Povoa, Pedro] Hosp Sao Francisco Xavier, Ctr Hosp Lisboa Ocidental, Polyvalent Intens Care Unit, P-1449005 Lisbon, Portugal.
   [Coelho, Luis M.; Povoa, Pedro] Univ Nova Lisboa, Fac Med Sci, CEDOC, P-1169056 Lisbon, Portugal.
   [Salluh, Jorge I. F.; Soares, Marcio] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Soares, Marcio] Inst Nacl Canc, Postgrad Program, BR-20230014 Rio De Janeiro, RJ, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Verdeal, Juan Carlos R.] Hosp Barra DOr, Intens Care Unit, BR-22775002 Rio De Janeiro, RJ, Brazil.
   [Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, BR-21040360 Rio De Janeiro, RJ, Brazil.
   [Lapa e Silva, Jose Roberto] Univ Fed Rio de Janeiro, Pulm Dis Dept, BR-21941970 Rio De Janeiro, RJ, Brazil.
RP Coelho, LM (corresponding author), Hosp Sao Francisco Xavier, Ctr Hosp Lisboa Ocidental, Polyvalent Intens Care Unit, Estr Forte Alto Duque, P-1449005 Lisbon, Portugal.
EM luismiguelcoelho16@gmail.com
RI Soares, Marcio/B-3083-2013; dantas, vicente c souza/L-2648-2013; Bozza,
   Fernando A/A-2618-2013; Lapa e Silva, Jose R./AAS-4793-2020
OI Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256; Lapa e Silva, Jose R./0000-0003-3116-0253; Povoa,
   Pedro/0000-0002-7069-7304; Salluh, Jorge/0000-0002-8164-1453; Bozza,
   Patricia/0000-0001-8349-9529
CR Almirall J, 2000, EUR RESPIR J, V15, P757, DOI 10.1034/j.1399-3003.2000.15d21.x
   Bruns AHW, 2008, EUR RESPIR J, V32, P726, DOI 10.1183/09031936.00003608
   Chalmers JD, 2008, AM J MED, V121, P219, DOI 10.1016/j.amjmed.2007.10.033
   COX ML, 1986, AGE AGEING, V15, P257, DOI 10.1093/ageing/15.5.257
   Eisenhut M, 2008, CRIT CARE, V12, DOI 10.1186/cc6204
   Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lisboa T, 2008, CRIT CARE MED, V36, P166, DOI 10.1097/01.CCM.0000297886.32564.CF
   Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043
   Luna CM, 2003, CRIT CARE MED, V31, P676, DOI 10.1097/01.CCM.0000055380.86458.1E
   Moreno MS, 2010, J INFECTION, V61, P205, DOI 10.1016/j.jinf.2010.06.005
   Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010
   Povas P, 2005, CLIN INFECT DIS, V40, P1855, DOI 10.1086/430382
   Povoa P, 1998, INTENS CARE MED, V24, P1052, DOI 10.1007/s001340050715
   Povoa P, 2005, EUR RESPIR J, V25, P804, DOI 10.1183/09031936.05.00071704
   Povoa P, 2008, CURR OPIN INFECT DIS, V21, P157, DOI 10.1097/QCO.0b013e3282f47c32
   Povoa P, 2011, CRIT CARE, V15, DOI 10.1186/cc10313
   Povoa P, 2011, CRIT CARE, V15, DOI 10.1186/cc10242
   Restrepo MI, 2008, CHEST, V133, P610, DOI 10.1378/chest.07-1456
   Seligman R, 2006, CRIT CARE, V10, DOI 10.1186/cc5036
   VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wunderink RG, 2011, AM J RESP CRIT CARE, V183, P1561, DOI 10.1164/rccm.201007-1167OC
NR 24
TC 48
Z9 50
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2012
VL 16
IS 2
AR R53
DI 10.1186/cc11291
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 066CF
UT WOS:000313196800019
PM 22449513
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Rabello, LSCF
   Rosolem, MM
   Soares, M
   Bozza, FA
   Verdeal, JCR
   Mello, GW
   Neto, HCCF
   Silva, JRLE
   Bozza, PT
AF Salluh, Jorge I. F.
   Rabello, Ligia S. C. F.
   Rosolem, Maira M.
   Soares, Marcio
   Bozza, Fernando A.
   Verdeal, Juan Carlos R.
   Mello, Gustavo W.
   Castro Faria Neto, Hugo C.
   Lapa e Silva, Jose Roberto
   Bozza, Patricia T.
TI The impact of coagulation parameters on the outcomes of patients with
   severe community-acquired pneumonia requiring intensive care unit
   admission
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE D-Dimer; Coagulation; Community-acquired pneumonia; Sepsis; Outcomes
ID FACTOR PATHWAY INHIBITOR; SEVERE SEPSIS; DISEASE SEVERITY;
   CLINICAL-TRIALS; ORGAN FAILURE; LOW-RISK; BIOMARKERS; MARKERS; SYSTEM;
   SCORES
AB Introduction: Coagulation abnormalities are frequent in patients with severe infections. However, the predictive value of D-dimer and of the presence of associated coagulation derangements in severe community-acquired pneumonia (CAP) remains to be thoroughly evaluated. The aim of this study was to investigate the predictive value of coagulation parameters in patients with severe CAP admitted to the intensive care unit.
   Methods: D-Dimer, antithrombin, International Society of Thrombosis and Hemostasis score, clinical variables, Sequential Organ Failure Assessment (SOFA), The Acute Physiology and Chronic Health Evaluation II (APACHE II) and the CURB-65 score were measured in the first 24 hours. Results are shown as median (25%-75% interquartile range). The main outcome measure was hospital mortality.
   Results: Ninety patients with severe CAP admitted to the intensive care unit were evaluated. Overall hospital mortality was 15.5%. D-Dimer levels in nonsurvivors were higher than those in survivors. In the univariate analysis, D-dimer, SOFA, and APACHE II scores were predictors of death. The discriminative ability of D-dimer (area under receiver operating curve = 0.75 [95% confidence interval, 0.64-0.83]; best cutoff for D-dimer was 1798 ng/mL) for in-hospital mortality was comparable with APACHE II and SOFA and better than C-reactive protein. Moreover, the addition of D-dimer to APACHE II or SOFA score increased the discriminative ability of both scores (area under the receiver operating curve = 0.82 [0.72-0.89] and 0.84 [0.75-0.91], respectively).
   Conclusions: D-Dimer levels are good predictors of outcome in severe CAP and may augment the predictive ability of scoring systems as APACHE II and SOFA. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Salluh, Jorge I. F.] Inst Nacl Canc, Ctr Tratamento Intens, Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Rabello, Ligia S. C. F.; Rosolem, Maira M.; Soares, Marcio] Inst Nacl Canc, Postgrad Program, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Castro Faria Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, BR-21040360 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, BR-21040360 Rio De Janeiro, Brazil.
   [Verdeal, Juan Carlos R.; Mello, Gustavo W.] Hosp Barra Dor, Crit Care Dept, Intens Care Unit, BR-22775002 Rio De Janeiro, Brazil.
   [Lapa e Silva, Jose Roberto] Univ Fed Rio de Janeiro, Dept Pulm Dis, BR-21941913 Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Inst Nacl Canc, Ctr Tratamento Intens, Intens Care Unit, 10 Andar,Praca Cruz Vermelha 23, BR-20230130 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br; ligiarabello@yahoo.com.br;
   mairarosalem@gmail.com; marciosoaresms@yahoo.com.br;
   bozza.fernando@gmail.com; jverdeal@gmail.com;
   gustavowmello@yahoo.com.br; hcastro@ioc.fiocruz.br;
   jrlapa.ntg@terra.com.br; pbozza@gmail.com
RI Bozza, Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013; Salluh, Jorge
   IF/F-6779-2012; Lapa e Silva, Jose R./AAS-4793-2020; dantas, vicente c
   souza/L-2648-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Lapa e Silva, Jose R./0000-0003-3116-0253;
   Salluh, Jorge/0000-0002-8164-1453; Bozza, Patricia/0000-0001-8349-9529
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq); FAPERJ (Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); PRONEX; CNPqNational Council for
   Scientific and Technological Development (CNPq); PRONEX (Programa de
   Apoio a Nucleos de Excelencia)
FX This work was supported in part by scholarships from CNPq (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico), FAPERJ (Fundacao
   de Amparo a Pesquisa do Estado do Rio de Janeiro), and PRONEX. Financial
   support was provided by CNPq and PRONEX (Programa de Apoio a Nucleos de
   Excelencia).
CR Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238
   Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935
   Bakhtiari K, 2004, CRIT CARE MED, V32, P2416, DOI 10.1097/01.CCM.0000147769.07699.E3
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bozza FA, 2005, MEM I OSWALDO CRUZ, V100, P217, DOI 10.1590/S0074-02762005000900037
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Buising KL, 2006, THORAX, V61, P419, DOI 10.1136/thx.2005.051326
   Coelho L, 2007, CRIT CARE, V11, DOI 10.1186/cc6105
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Laterre PF, 2009, CRIT CARE, V13, DOI 10.1186/cc7747
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A
   Marshall John C, 2006, Curr Infect Dis Rep, V8, P351, DOI 10.1007/s11908-006-0045-1
   Marshall JC, 2009, CRIT CARE MED, V37, P2290, DOI 10.1097/CCM.0b013e3181a02afc
   Milbrandt EB, 2009, MOL MED, V15, P438, DOI 10.2119/molmed.2009.00091
   Mira JP, 2008, CRIT CARE, V12, DOI 10.1186/cc7028
   Niederman MS, 2007, CHEST, V131, P1205, DOI 10.1378/chest.06-1994
   Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010
   Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59
   Povoa P, 2008, CURR OPIN INFECT DIS, V21, P157, DOI 10.1097/QCO.0b013e3282f47c32
   Querol-Ribelles JM, 2004, CHEST, V126, P1087, DOI 10.1378/chest.126.4.1087
   Rello J, 2007, INTENS CARE MED, V33, P2043, DOI 10.1007/s00134-007-0896-4
   Rodriguez A, 2009, INTENS CARE MED, V35, P430, DOI 10.1007/s00134-008-1363-6
   Salluh JIF, 2008, CRIT CARE MED, V36, P2192, DOI 10.1097/CCM.0b013e31817c0cd8
   Salluh JIF, 2010, CRIT CARE MED, V38, P1749, DOI 10.1097/CCM.0b013e3181e941f6
   Shilon Y, 2003, BLOOD COAGUL FIBRIN, V14, P745, DOI 10.1097/00001721-200312000-00009
   Vieira SRR, 1999, AM J RESP CRIT CARE, V159, P1612, DOI 10.1164/ajrccm.159.5.9805112
   Vincent JL, 2010, CRIT CARE MED, V38, P283, DOI 10.1097/CCM.0b013e3181b785a2
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
NR 32
TC 19
Z9 27
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
J9 J CRIT CARE
JI J. Crit. Care
PD OCT
PY 2011
VL 26
IS 5
BP 496
EP 501
DI 10.1016/j.jcrc.2011.02.001
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA 834NP
UT WOS:000295968800012
PM 21454038
DA 2020-12-01
ER

PT J
AU Amancio, RT
   Japiassu, AM
   Gomes, RN
   Mesquita, E
   Medeiros, DM
   Castro-Faria-Neto, HC
   Bozza, FA
AF Amancio, R. T.
   Japiassu, A. M.
   Gomes, R. N.
   Mesquita, E.
   Medeiros, D. M.
   Castro-Faria-Neto, H. C.
   Bozza, F. A.
TI MCP-1/CCL2 PREDICT MORTALITY IN HIV SEPTIC PATIENTS IN THE INTENSIVE
   CARE UNIT
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Amancio, R. T.; Japiassu, A. M.; Gomes, R. N.; Mesquita, E.; Medeiros, D. M.; Bozza, F. A.] Inst Pesquisa Chnica Evandro Chagas, ICU, Rio De Janeiro, Brazil.
   [Gomes, R. N.; Castro-Faria-Neto, H. C.] Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2011
VL 37
SU 1
MA 0963
BP S246
EP S246
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JN
UT WOS:000209082801186
DA 2020-12-01
ER

PT J
AU d'Avila, JC
   Carnevale, R
   Reis, PA
   Garcia-Souza, LF
   Castro-Faria-Neto, HC
   Oliveira, MF
   Bozza, FA
AF d'Avila, J. C.
   Carnevale, R.
   Reis, P. A.
   Garcia-Souza, L. F.
   Castro-Faria-Neto, H. C.
   Oliveira, M. F.
   Bozza, F. A.
TI BRAIN METABOLIC ADAPTATION IN RESPONSE TO SEPSIS
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [d'Avila, J. C.; Carnevale, R.; Reis, P. A.; Castro-Faria-Neto, H. C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Garcia-Souza, L. F.; Oliveira, M. F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Lab Bioquim Redox, Rio de Janeiro, Brazil.
   [Bozza, F. A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, ICU, BR-21045900 Rio De Janeiro, Brazil.
   [Bozza, F. A.] Inst DOr Pesquisa & Ensino IDOr, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2011
VL 37
SU 1
MA 1008
BP S257
EP S257
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JN
UT WOS:000209082801231
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Azambuja, P
   Garcia-Souza, LF
   Hottz, ED
   Castro-Faria-Neto, HC
   Oliveira, MF
   Bozza, FA
AF Japiassu, A. M.
   Azambuja, P.
   Garcia-Souza, L. F.
   Hottz, E. D.
   Castro-Faria-Neto, H. C.
   Oliveira, M. F.
   Bozza, F. A.
TI HYDROCORTISONE AFFECTS MITOCHONDRIAL RESPIRATION IN SEPTIC SHOCK
   PATIENTS
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Japiassu, A. M.; Bozza, F. A.] Fiocruz MS, Inst Pesquisa Clin & Evandro Chagas, ICU, BR-21045900 Rio De Janeiro, Brazil.
   [Japiassu, A. M.; Bozza, F. A.] Inst DOr Pesquisa & Ensino IDOr, Rio De Janeiro, Brazil.
   [Azambuja, P.; Hottz, E. D.; Castro-Faria-Neto, H. C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Garcia-Souza, L. F.; Oliveira, M. F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Lab Bioquim Redox, Rio de Janeiro, Brazil.
RI de Azambuja Penna, Patricia/AAA-3763-2019; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2011
VL 37
SU 1
MA 0134
BP S39
EP S39
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V34JN
UT WOS:000209082800135
DA 2020-12-01
ER

PT J
AU Allonso, D
   Rosa, MD
   Coelho, DR
   da Costa, SM
   Nogueira, RMR
   Bozza, FA
   Dos Santos, FB
   Alves, AMD
   Mohana-Borges, R
AF Allonso, Diego
   Rosa, Marcela da Silva
   Coelho, Diego Rodrigues
   da Costa, Simone Morais
   Ribeiro Nogueira, Rita Maria
   Bozza, Fernando Augusto
   Dos Santos, Flavia Barreto
   de Barcelos Alves, Ada Maria
   Mohana-Borges, Ronaldo
TI Polyclonal antibodies against properly folded Dengue virus NS1 protein
   expressed in E-coli enable sensitive and early dengue diagnosis
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Dengue virus; NS1 protein; Dengue diagnosis; E. coli
ID NONSTRUCTURAL GLYCOPROTEIN NS1; SECONDARY STRUCTURE ANALYSES; ANTIGEN
   CAPTURE IMMUNOASSAY; LINKED-IMMUNOSORBENT-ASSAY; MONOCLONAL-ANTIBODIES;
   SIGNAL SEQUENCE; DNA VACCINE; TYPE-1; INFECTIONS; CELLS
AB The non-structural 1 (NS1) protein plays an important role in dengue diagnosis because it has been detected as a soluble serum antigen in both primary and secondary infections. The NS1 protein was expressed in Escherichia coli cells, and the efficiency of four different refolding protocols was tested. All of the protocols generated dimeric NS1 in a conformation similar to that of the protein expressed by eukaryotic cells. A polyclonal antibody produced from the properly folded E. coli recombinant NS1 (rNS1) protein proved to be a useful tool for the diagnosis of Dengue virus because it detected 100% of the Dengue virus 2 (DENV2) in infected patients' sera and 60% of the DENV IgM-positive sera not detected by commercial NS1-based diagnostic kits. These data suggest a high-efficiency method for correctly folding rNS1 that maintains its structural and immunogenic properties. In addition, a detection method using the polyclonal antibody against correctly folded rNS1 seemed to be more sensitive and efficient for NS1 detection in serum, highlighting its usefulness for developing a high-sensitivity diagnostic kit. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Allonso, Diego; Rosa, Marcela da Silva; Coelho, Diego Rodrigues; Mohana-Borges, Ronaldo] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Genom Estruct, BR-21941590 Rio De Janeiro, Brazil.
   [da Costa, Simone Morais; de Barcelos Alves, Ada Maria] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biotecnol & Fisiol Infeccoes Virais, Rio De Janeiro, Brazil.
   [Ribeiro Nogueira, Rita Maria; Dos Santos, Flavia Barreto] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil.
   [Bozza, Fernando Augusto] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Unidade Terapia Intens, Rio De Janeiro, Brazil.
RP Mohana-Borges, R (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Genom Estruct, Edificio Ctr Ciencias Saude,Bloco C,Sala 36 Sub S, BR-21941902 Rio de Janeiro, Brazil.
EM mohana@biof.ufrj.br
RI Bozza, Fernando A/A-2618-2013; Allonso, Diego/Y-3446-2018; Borges,
   Ronaldo S Mohana/C-5575-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Allonso,
   Diego/0000-0002-1410-480X; Mohana Borges, Ronaldo/0000-0002-1796-475X
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); IMBEBB; FINEP (GENOPROT Dengue)Ciencia
   Tecnologia e Inovacao (FINEP); National Institutes of Science and
   Technology in Structural Biology and Bioimaging (INCT-INBEB);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
FX This work was supported by the following funding agencies: CNPq, FAPERJ,
   IMBEBB, and FINEP (GENOPROT Dengue), the National Institutes of Science
   and Technology in Structural Biology and Bioimaging (INCT-INBEB). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. We thank M.Sc.
   Iamara Andrade for her help with fluorescence microscopy and Ana
   Carolina Fonseca-Guimaraes for her technical assistance. Diego Allonso
   holds a Ph.D. fellowship from Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES). We would also like to thank the Genomic
   Platform for DNA sequencing of PDTIS/FIOCRUZ.
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Costa SM, 2006, VACCINE, V24, P4562, DOI 10.1016/j.vaccine.2005.08.022
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   Das D, 2009, PROTEIN EXPRES PURIF, V66, P66, DOI 10.1016/j.pep.2009.02.003
   Dos Santos FB, 2004, AM J TROP MED HYG, V71, P144, DOI 10.4269/ajtmh.2004.71.144
   Dos Santos FB, 2007, CLIN VACCINE IMMUNOL, V14, P641, DOI 10.1128/CVI.00474-06
   Falconar AKI, 1997, ARCH VIROL, V142, P897, DOI 10.1007/s007050050127
   FALCONAR AKI, 1991, J GEN VIROL, V72, P961, DOI 10.1099/0022-1317-72-4-961
   FALGOUT B, 1989, J VIROL, V63, P1852, DOI 10.1128/JVI.63.5.1852-1860.1989
   FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995
   Flamand M, 1999, J VIROL, V73, P6104, DOI 10.1128/JVI.73.7.6104-6110.1999
   Kao CL, 2001, J CLIN MICROBIOL, V39, P3672, DOI 10.1128/JCM.39.10.3672-3677.2001
   Lemes EMB, 2005, J CLIN VIROL, V32, P305, DOI 10.1016/j.jcv.2004.08.015
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   MASON PW, 1990, J GEN VIROL, V71, P2107, DOI 10.1099/0022-1317-71-9-2107
   Melo MN, 2009, J MOL BIOL, V392, P736, DOI 10.1016/j.jmb.2009.07.035
   PRYOR MJ, 1994, J GEN VIROL, V75, P1183, DOI 10.1099/0022-1317-75-5-1183
   PRYOR MJ, 1993, VIROLOGY, V194, P769, DOI 10.1006/viro.1993.1318
   Qiu LW, 2009, CLIN VACCINE IMMUNOL, V16, P88, DOI 10.1128/CVI.00212-08
   Lima MDQ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000738
   Ramirez AH, 2009, DIAGN MICR INFEC DIS, V65, P247, DOI 10.1016/j.diagmicrobio.2009.07.022
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   SMITH GW, 1985, J GEN VIROL, V66, P559, DOI 10.1099/0022-1317-66-3-559
   Wallis TP, 2004, J BIOL CHEM, V279, P20729, DOI 10.1074/jbc.M312907200
   Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4
   WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   Xu H, 2006, J CLIN MICROBIOL, V44, P2872, DOI 10.1128/JCM.00777-06
   ZHAO B, 1987, J VIROL, V61, P4019, DOI 10.1128/JVI.61.12.4019-4022.1987
   Zhou JM, 2006, VIRUS GENES, V33, P27, DOI 10.1007/s11262-005-0036-6
NR 34
TC 16
Z9 17
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUL
PY 2011
VL 175
IS 1
BP 109
EP 116
DI 10.1016/j.jviromet.2011.04.029
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 791LG
UT WOS:000292666100016
PM 21569796
OA Green Published
DA 2020-12-01
ER

PT J
AU Gomes, RN
   da Cunha, MT
   Figueiredo, RT
   Caetano, S
   Bozza, FA
   Zimmerman, GA
   Bozza, PT
   Bozza, MT
   Castro-Faria-Neto, HC
AF Gomes, R. N.
   da Cunha, M. T.
   Figueiredo, R. T.
   Caetano, S.
   Bozza, F. A.
   Zimmerman, G. A.
   Bozza, P. T.
   Bozza, M. T.
   Castro-Faria-Neto, H. C.
TI INVOLVEMENT OF CCL2 AND NITRIC OXIDE ON BACTERIAL CLEARANCE IN SEPTIC
   MICE
SO INFLAMMATION RESEARCH
LA English
DT Meeting Abstract
CT 10th World Congress on Inflammation
CY JUN 25-29, 2011
CL Paris, FRANCE
SP Int Assoc Inflammation Soc, Grp Res & Study Mediators Inflammat
C1 [Gomes, R. N.; da Cunha, M. T.; Caetano, S.; Bozza, P. T.; Castro-Faria-Neto, H. C.] IOC FIOCRUZ, Oswaldo Cruz Fdn, Lab Immunopharmacol, Rio De Janeiro, Brazil.
   [Figueiredo, R. T.; Bozza, M. T.] Univ Fed Rio de Janeiro, Lab Inflammat & Immun, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Oswaldo Cruz Fdn IPEC FIOCRUZ, Lab Integrated Intens Care Med, Rio De Janeiro, Brazil.
   [Zimmerman, G. A.] Univ Utah, Salt Lake City, UT USA.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1023-3830
J9 INFLAMM RES
JI Inflamm. Res.
PD JUN
PY 2011
VL 60
SU 1
BP 165
EP 165
PG 1
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 774CM
UT WOS:000291358900448
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Santiago, APSA
   d'Avila, JDP
   Garcia-Souza, LF
   Galina, A
   Faria-Neto, HCC
   Bozza, FA
   Oliveira, MF
AF Japiassu, Andre M.
   Santiago, Ana Paula S. A.
   d'Avila, Joana da Costa P.
   Garcia-Souza, Luiz F.
   Galina, Antonio
   Faria-Neto, Hugo C. Castro
   Bozza, Fernando A.
   Oliveira, Marcus F.
TI Bioenergetic failure of human peripheral blood monocytes in patients
   with septic shock is mediated by reduced F1F0 adenosine-5 '-triphosphate
   synthase activity
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE sepsis; immune system; mitochondria; organ dysfunction; metabolism;
   oxygen consumption
ID CRITICALLY ILL PATIENTS; SEVERE HUMAN SEPSIS; MITOCHONDRIAL DYSFUNCTION;
   OXYGEN-CONSUMPTION; MONONUCLEAR-CELLS; ORGAN DYSFUNCTION;
   SKELETAL-MUSCLE; ENDOTOXEMIA; METABOLISM; GUIDELINES
AB Objective: Increasing evidence points to the role of mitochondrial dysfunction in the pathogenesis of sepsis. Previous data indicate that mitochondrial function is affected in monocytes from septic patients, but the underlying mechanisms and the impact of these changes on the patients' outcome are unknown. We aimed to determine the mechanisms involved in mitochondrial dysfunction in peripheral blood mononuclear cells from patients with septic shock.
   Design: A cohort of patients with septic shock to study peripheral blood mononuclear cell mitochondrial respiration by high-resolution respirometry analyses and to compare with cells from control subjects.
   Setting: Three intensive care units and an academic research laboratory.
   Subjects: Twenty patients with septic shock and a control group composed of 18 postoperative patients without sepsis or shock.
   Interventions: Ex vivo measurements of mitochondrial oxygen consumption were carried out in digitonin-permeabilized peripheral blood mononuclear cells from 20 patients with septic shock taken during the first 48 hrs after intensive care unit admission as well as in peripheral blood mononuclear cells from control subjects. Clinical parameters such as hospital outcome and sepsis severity were also analyzed and the relationship between these parameters and the oxygen consumption pattern was investigated.
   Measurements and Main Results: We observed a significant reduction in the respiration specifically associated with adenosine-5'-triphosphate synthesis (state 3) compared with the control group (5.60 vs. 9.89 nmol O-2/min/10(7) cells, respectively, p < .01). Reduction of state 3 respiration in patients with septic shock was seen with increased prevalence of organ failure (r = -0.46, p = .005). Nonsurviving patients with septic shock presented significantly lower adenosine diphosphate-stimulated respiration when compared with the control group (4.56 vs. 10.27 nmol O-2/min/10(7) cells, respectively; p < .004). Finally, the presence of the functional F1F0 adenosine-5'-triphosphate synthase complex (0.51 vs. 1.00 ng oligo/mL/10(6) cells, p = .02), but not the adenine nucleotide translocator, was significantly lower in patients with septic shock compared with control cells.
   Conclusion: Mitochondrial dysfunction is present in immune cells from patients with septic shock and is characterized as a reduced respiration associated to adenosine-5'-triphosphate synthesis. The molecular basis of this phenotype involve a reduction of F1F0 adenosine-5'-triphosphate synthase activity, which may contribute to the energetic failure found in sepsis. (Crit Care Med 2011; 39:1056-1063)
C1 [Japiassu, Andre M.; Bozza, Fernando A.] Oswaldo Cruz Fdn Fiocruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
   [Japiassu, Andre M.] Casa Saude Sao Jose, Intens Care Unit, Rio De Janeiro, Brazil.
   [Japiassu, Andre M.; Bozza, Fernando A.] Univ Fed Rio de Janeiro, DOr Inst Res & Educ, Rio De Janeiro, Brazil.
   [Santiago, Ana Paula S. A.; d'Avila, Joana da Costa P.; Garcia-Souza, Luiz F.; Bozza, Fernando A.; Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Lab Inflamacao & Metab, Inst Nacl Ciencia & Tecnol Biol Estrutural, Rio De Janeiro, Brazil.
   [Galina, Antonio] Univ Fed Rio de Janeiro, Lab Bioenerget & Fisiol Mitocondrial, Inst Bioquim Med, Programa Bioquim Biofis Celular, Rio De Janeiro, Brazil.
   [Faria-Neto, Hugo C. Castro] Fiocruz MS, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Santiago, Ana Paula S. A.; d'Avila, Joana da Costa P.; Garcia-Souza, Luiz F.; Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Lab Bioquim Redox, Programa Biol Mol & Biotecnol, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Oswaldo Cruz Fdn Fiocruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com; maroli@bioqmed.ufrj.br
RI Galina, Antonio/A-9292-2008; d'Avila, Joana/L-8970-2013; Bozza, Fernando
   A/A-2618-2013; Oliveira, Marcus/G-3158-2011
OI d'Avila, Joana/0000-0002-2045-0813; Bozza, Fernando
   A/0000-0003-4878-0256; Oliveira, Marcus/0000-0002-9890-8425; Garcia e
   Souza, Luiz Felipe/0000-0003-1474-5428
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); FAPERJ, CNPq, through Institutos Nacionais
   de Ciencia e TecnologiaNational Council for Scientific and Technological
   Development (CNPq)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ)
FX This work was supported by grants from FAPERJ, CNPq, through Institutos
   Nacionais de Ciencia e Tecnologia 2008. The funders had no role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. Drs. Galina, Castro Faria-Neto, Bozza,
   and Oliveira are research scholars from CNPq. Drs. Bozza and Oliveira
   are recipients of the JCNE scholarship from FAPERJ.
CR Adrie C, 2001, AM J RESP CRIT CARE, V164, P389, DOI 10.1164/ajrccm.164.3.2009088
   ALLAN EH, 1983, BIOCHIM BIOPHYS ACTA, V725, P71, DOI 10.1016/0005-2728(83)90225-6
   Banerjee R, 2009, BBA-MOL BASIS DIS, V1792, P651, DOI 10.1016/j.bbadis.2008.11.007
   Belikova I, 2007, CRIT CARE MED, V35, P2702, DOI 10.1097/01.CCM.0000295593.25106.C4
   BOEKSTEGERS P, 1991, INFECTION, V19, P317, DOI 10.1007/BF01645355
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Brealey D, 2002, LANCET, V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Callahan LA, 2005, AM J RESP CRIT CARE, V172, P861, DOI 10.1164/rccm.200410-1344OC
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Carre JE, 2008, BBA-BIOENERGETICS, V1777, P763, DOI 10.1016/j.bbabio.2008.04.024
   Comim CM, 2008, MITOCHONDRION, V8, P313, DOI 10.1016/j.mito.2008.07.002
   Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023
   Crouser ED, 2002, CRIT CARE MED, V30, P2722, DOI 10.1097/00003246-200212000-00017
   Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z
   Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058
   Dyson A, 2007, AM J PHYSIOL-HEART C, V293, pH526, DOI 10.1152/ajpheart.00052.2007
   Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412
   Exline MC, 2008, FRONT BIOSCI-LANDMRK, V13, P5030
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Fink MP, 2001, CRIT CARE CLIN, V17, P219, DOI 10.1016/S0749-0704(05)70161-5
   Fujita C, 2009, J STEROID BIOCHEM, V117, P50, DOI 10.1016/j.jsbmb.2009.07.002
   GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601
   HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404
   Haynes V, 2010, AM J PHYSIOL-ENDOC M, V298, pE978, DOI 10.1152/ajpendo.00739.2009
   HODGIN UG, 1965, AM J MED, V39, P952, DOI 10.1016/0002-9343(65)90118-X
   Kantrow SP, 2000, FREE RADICAL BIO MED, V28, P251, DOI 10.1016/S0891-5849(99)00238-5
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   LIPPE G, 1991, BIOCHEM BIOPH RES CO, V181, P764, DOI 10.1016/0006-291X(91)91256-C
   Lunemann JD, 2001, BIOSCIENCE REP, V21, P627, DOI 10.1023/A:1014768909442
   Nicholls DG, 2002, BIOENERGETICS, V3, P82
   Regueira T, 2008, CRIT CARE, V12, DOI 10.1186/cc6956
   Reynolds CM, 2009, FREE RADICAL BIO MED, V46, P564, DOI 10.1016/j.freeradbiomed.2008.11.007
   Rosser DM, 1998, INTENS CARE MED, V24, P725, DOI 10.1007/s001340050651
   Rosser DM, 1996, AM J PHYSIOL-HEART C, V271, pH891
   Sair M, 2001, CRIT CARE MED, V29, P1343, DOI 10.1097/00003246-200107000-00008
   Simon N, 1998, FEBS LETT, V435, P25, DOI 10.1016/S0014-5793(98)01033-3
   SIMS NR, 1986, J NEUROCHEM, V47, P496
   Singer M, 2007, CRIT CARE MED, V35, pS441, DOI 10.1097/01.CCM.0000278049.48333.78
   Trzcionka M, 2008, J EXP BIOL, V211, P1911, DOI 10.1242/jeb.016519
   VANDERMEER TJ, 1995, CRIT CARE MED, V23, P1217, DOI 10.1097/00003246-199507000-00011
   Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896
NR 43
TC 78
Z9 79
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAY
PY 2011
VL 39
IS 5
BP 1056
EP 1063
DI 10.1097/CCM.0b013e31820eda5c
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 752CX
UT WOS:000289667000018
PM 21336129
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Soares, M
   Coelho, LM
   Bozza, FA
   Verdeal, JCR
   Castro-Faria-Neto, HC
   Silva, JRLE
   Bozza, PT
   Povoa, P
AF Salluh, Jorge I. F.
   Soares, Marcio
   Coelho, Luis M.
   Bozza, Fernando A.
   Verdeal, Juan Carlos R.
   Castro-Faria-Neto, Hugo C.
   Lapa e Silva, Jose Roberto
   Bozza, Patrcia T.
   Povoa, Pedro
TI Impact of systemic corticosteroids on the clinical course and outcomes
   of patients with severe community-acquired pneumonia: A cohort study
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Community-acquired pneumonia; Corticosteroids; C-reactive protein;
   Mechanical ventilation; Multiple organ failure; Severe sepsis
ID C-REACTIVE PROTEIN; PROPENSITY SCORES; ORGAN FAILURE; GUIDELINES;
   DISEASE; HYDROCORTISONE; DEFINITIONS; MANAGEMENT; EFFICACY; STEROIDS
AB Introduction: Our aim was to evaluate the impact of corticosteroids on clinical course and outcomes of patients with severe community-acquired pneumonia (CAP) requiring invasive mechanical ventilation.
   Methods: This was a cohort study of patients with severe CAP from 2 intensive care units in tertiary hospitals in Brazil and Portugal.
   Results: A total of 111 patients were included (median age, 69 years; 56% men; 34% hospital mortality). Corticosteroids were prescribed in 61 (55%) patients. Main indications for their use were bronchospasm (52.5%) and septic shock (36%). Mortality rate of patients treated with and without corticosteroids was comparable (29.5% vs 32%, P = .837). No significant differences were observed on clinical course from day 1 to day 7 as assessed by the Sequential Organ Failure Assessment score (P = .95). Furthermore, C-reactive protein declined similarly in both groups (P = .147). In a multivariate analysis, mortality was associated with older age and higher Acute Physiology and Chronic Health Evaluation II score.
   Conclusions: In patients with severe CAP requiring invasive mechanical ventilation, adjunctive therapy with corticosteroids did not influence intensive care unit and hospital mortality. In addition, no changes were observed on weaning from vasopressors, on recovery from organ failure/dysfunction as assessed by the Sequential Organ Failure Assessment score, as well as on C-reactive protein course. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Salluh, Jorge I. F.] Inst Nacl Canc INCA, Ctr Tratamento Intens, Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Soares, Marcio] Inst Nacl Canc INCA, Postgrad Program, BR-20230130 Rio De Janeiro, Brazil.
   [Coelho, Luis M.; Povoa, Pedro] Univ Nova Lisboa, Polyvalent Intens Care Unit, Hosp Sao Francisco Xavier, Ctr Hosp Lisboa Ocidental,CEDOC,Fac Med Sci, P-20230130 Lisbon, Portugal.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Verdeal, Juan Carlos R.] Hosp Barra Dor, Intens Care Unit, Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, Hugo C.; Bozza, Patrcia T.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Lapa e Silva, Jose Roberto] Univ Fed Rio de Janeiro, Dept Pulm Dis, Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Inst Nacl Canc INCA, Ctr Tratamento Intens, Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br; marciosoaresms@yahoo.com.br;
   luismiguelcoelho16@gmail.com; fernando.bozza@ipec.fiocruz.br;
   jverdeal@gmail.com; hcastro@ioc.fiocruz.br; jrlapa.ntg@terra.com.br;
   pbozza@ioc.fiocruz.br; povoap@netcabo.pt
RI Soares, Marcio/B-3083-2013; Salluh, Jorge IF/F-6779-2012; Lapa e Silva,
   Jose R./AAS-4793-2020; Bozza, Fernando A/A-2618-2013; dantas, vicente c
   souza/L-2648-2013
OI Soares, Marcio/0000-0003-2503-6088; Lapa e Silva, Jose
   R./0000-0003-3116-0253; Bozza, Fernando A/0000-0003-4878-0256; Povoa,
   Pedro/0000-0002-7069-7304; Bozza, Patricia/0000-0001-8349-9529; Salluh,
   Jorge/0000-0002-8164-1453
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); PRONEX-MCT
FX MS receives an individual research grant from CNPq. Financial support
   was provided by FAPERJ, CNPq, and PRONEX-MCT.
CR Annane D, 2008, EUR RESPIR J, V31, P1150, DOI 10.1183/09031936.00040908
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Coelho L, 2007, CRIT CARE, V11, DOI 10.1186/cc6105
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   Garcia-Vidal C, 2007, EUR RESPIR J, V30, P951, DOI 10.1183/09031936.00027607
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Japiassu AM, 2009, MEM I OSWALDO CRUZ, V104, P531, DOI 10.1590/S0074-02762009000400001
   Joffe MM, 1999, AM J EPIDEMIOL, V150, P327
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   MARIK P, 1993, CHEST, V104, P389, DOI 10.1378/chest.104.2.389
   Mikami K, 2007, LUNG, V185, P249, DOI 10.1007/s00408-007-9020-3
   Mira JP, 2008, CRIT CARE, V12, DOI 10.1186/cc7028
   Niederman MS, 2007, CHEST, V131, P1205, DOI 10.1378/chest.06-1994
   Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010
   Perren A, 2008, INFECTION, V36, P163, DOI 10.1007/s15010-007-7206-5
   Povas P, 2005, CLIN INFECT DIS, V40, P1855, DOI 10.1086/430382
   Povoa P, 2005, EUR RESPIR J, V25, P804, DOI 10.1183/09031936.05.00071704
   Rodriguez A, 2007, CRIT CARE MED, V35, P1493, DOI 10.1097/01.CCM.0000266755.75844.05
   Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064
   Salluh JIF, 2008, CRIT CARE, V12, DOI 10.1186/cc6922
   Salluh JIF, 2008, CHEST, V134, P947, DOI 10.1378/chest.08-1382
   Sibila O, 2008, EUR RESPIR J, V32, P259, DOI 10.1183/09031936.00154107
   Snijders D, 2010, AM J RESP CRIT CARE, V181, P975, DOI 10.1164/rccm.200905-0808OC
   VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336
   Vincent JL, 2006, CHEST, V129, P1061, DOI 10.1378/chest.129.4.1061
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
NR 31
TC 37
Z9 42
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
EI 1557-8615
J9 J CRIT CARE
JI J. Crit. Care
PD APR
PY 2011
VL 26
IS 2
BP 193
EP 200
DI 10.1016/j.jcrc.2010.07.014
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 754WG
UT WOS:000289887800016
PM 20889284
DA 2020-12-01
ER

PT J
AU Souza, TML
   Salluh, JIF
   Bozza, FA
   Mesquita, M
   Soares, M
   Motta, FC
   Pitrowsky, MT
   Oliveira, MD
   Mishin, VP
   Gubareva, LV
   Whitney, A
   Rocco, SA
   Goncalves, VMC
   Marques, VP
   Velasco, E
   Siqueira, MM
AF Souza, Thiago Moreno L.
   Salluh, Jorge I. F.
   Bozza, Fernando A.
   Mesquita, Milene
   soares, Marcio
   Motta, Fernando C.
   Pitrowsky, Melissa Tassano
   Oliveira, Maria de Lourdes
   Mishin, Vasiliy P.
   Gubareva, Larissa V.
   Whitney, Anne
   Rocco, Sandra Amaral
   Goncalves, Vania Maria C.
   Marques, Venceslaine Prado
   Velasco, Eduardo
   Siqueira, Marilda M.
TI H1N1pdm Influenza Infection in Hospitalized Cancer Patients: Clinical
   Evolution and Viral Analysis
SO PLOS ONE
LA English
DT Article
ID CRITICALLY-ILL PATIENTS; A H1N1; OSELTAMIVIR TREATMENT; VIRUS-INFECTION;
   A(H1N1); MANAGEMENT; PNEUMONIA; MORTALITY; LOAD
AB Background: The novel influenza A pandemic virus (H1N1pdm) caused considerable morbidity and mortality worldwide in 2009. The aim of the present study was to evaluate the clinical course, duration of viral shedding, H1N1pdm evolution and emergence of antiviral resistance in hospitalized cancer patients with severe H1N1pdm infections during the winter of 2009 in Brazil.
   Methods: We performed a prospective single-center cohort study in a cancer center in Rio de Janeiro, Brazil. Hospitalized patients with cancer and a confirmed diagnosis of influenza A H1N1pdm were evaluated. The main outcome measures in this study were in-hospital mortality, duration of viral shedding, viral persistence and both functional and molecular analyses of H1N1pdm susceptibility to oseltamivir.
   Results: A total of 44 hospitalized patients with suspected influenza-like illness were screened. A total of 24 had diagnosed H1N1pdm infections. The overall hospital mortality in our cohort was 21%. Thirteen (54%) patients required intensive care. The median age of the studied cohort was 14.5 years (3-69 years). Eighteen (75%) patients had received chemotherapy in the previous month, and 14 were neutropenic at the onset of influenza. A total of 10 patients were evaluated for their duration of viral shedding, and 5 (50%) displayed prolonged viral shedding (median 23, range = 11-63 days); however, this was not associated with the emergence of a resistant H1N1pdm virus. Viral evolution was observed in sequentially collected samples.
   Conclusions: Prolonged influenza A H1N1pdm shedding was observed in cancer patients. However, oseltamivir resistance was not detected. Taken together, our data suggest that severely ill cancer patients may constitute a pandemic virus reservoir with major implications for viral propagation.
C1 [Souza, Thiago Moreno L.; Motta, Fernando C.; Oliveira, Maria de Lourdes; Siqueira, Marilda M.] Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Sarampo, BR-21045900 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; soares, Marcio; Pitrowsky, Melissa Tassano] Hosp Canc I INCA, Intens Care Unit, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisas Evandro Chagas, Intens Care Unit, BR-21045900 Rio De Janeiro, Brazil.
   [Rocco, Sandra Amaral] Hosp Canc I INCA, Pediat Intens Care Unit, Rio De Janeiro, Brazil.
   [Goncalves, Vania Maria C.; Marques, Venceslaine Prado; Velasco, Eduardo] Hosp Canc I INCA, Infect Control Comm, Rio De Janeiro, Brazil.
   [Goncalves, Vania Maria C.; Marques, Venceslaine Prado; Velasco, Eduardo] Hosp Canc I INCA, Dept Infect Dis, Rio De Janeiro, Brazil.
   [Mishin, Vasiliy P.; Gubareva, Larissa V.; Whitney, Anne] Ctr Dis Control, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Souza, TML (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Virus Resp & Sarampo, BR-21045900 Rio De Janeiro, Brazil.
EM tmoreno@ioc.fiocruz.br; mmsiq@ioc.fiocruz.br
RI dantas, vicente c souza/L-2648-2013; Salluh, Jorge IF/F-6779-2012; DE
   LOURDES A OLIVEIRA, MARIA/H-2474-2018; Souza, Thiago Moreno
   L./G-2900-2012; Bozza, Fernando A/A-2618-2013; Soares,
   Marcio/B-3083-2013
OI Souza, Thiago Moreno L./0000-0003-2212-3899; Bozza, Fernando
   A/0000-0003-4878-0256; Soares, Marcio/0000-0003-2503-6088; Salluh,
   Jorge/0000-0002-8164-1453
FU Instituto Nacional de Cancer; Instituto Oswaldo Cruz/Fiocruz; Brazilian
   Ministry of Health/Decit; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ);
   FAPERJ/SESDEC/CNPqNational Council for Scientific and Technological
   Development (CNPq)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ) [E-26/110.778/2010]; IOC/Fiocruz;
   Fiocruz
FX The work was supported by Instituto Nacional de Cancer
   (www.inca.gov.br), Instituto Oswaldo Cruz/Fiocruz (www.ioc.fiocruz.br)
   and Brazilian Ministry of Health/Decit
   (http://dtr2001.saude.gov.br/sctie/decit/index.htm). Dr. Soares, Dr.
   Bozza and Dr. Siqueira were supported in part by individual research
   grants from CNPq (www.cnpq.br). Dr. Souza used, in part, individual
   research grants from FAPERJ (www.faperj.br). FAPERJ/SESDEC/CNPq provided
   the grant #E-26/110.778/2010 (PPSUS-DECIT/SCTIE/MS). Thanks are also due
   to IOC/Fiocruz for providing MM a PhD fellowship. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.; We are indebted to the Instituto
   Nacional de Cancer, Fiocruz, FAPERJ and CNPq for their support. The
   authors thank Marc-Alain Widdowson (CDC/CCID/NCIRD) for critical review
   of the manuscript. Alicia Fry (CDC Atlanta epidemiology intelligence
   officer) was also extremely helpful in discussions on virus shedding.
CR Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb
   Baz M, 2006, CLIN INFECT DIS, V43, P1555, DOI 10.1086/508777
   Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612
   Casper C, 2010, BLOOD, V115, P1331, DOI 10.1182/blood-2009-11-255455
   Cowling BJ, 2010, NEW ENGL J MED, V362, P2175, DOI 10.1056/NEJMoa0911530
   Cunha BA, 2010, J HOSP INFECT, V74, P278, DOI 10.1016/j.jhin.2009.08.024
   De Serres G, 2010, EMERG INFECT DIS, V16, P783, DOI 10.3201/eid1605.091894
   Deyde VM, 2010, ANTIMICROB AGENTS CH, V54, P1102, DOI 10.1128/AAC.01417-09
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   Englund J., 2009, Morbidity and Mortality Weekly Report, V58, P893
   Fleury H, 2009, EUROSURVEILLANCE, V14, P14
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Hajjar LA, 2010, ANN ONCOL, V21, P2333, DOI 10.1093/annonc/mdq254
   Hayden FG, 2004, J INFECT DIS, V189, P440, DOI 10.1086/381128
   HIEN TT, 2010, PLOS MED, V0007
   Ison MG, 2006, J INFECT DIS, V193, P760, DOI 10.1086/500465
   Kidd IM, 2009, LANCET, V374, P1036, DOI 10.1016/S0140-6736(09)61528-2
   Kobayashi Shinichi, 2008, Journal of Infection and Chemotherapy, V14, P308, DOI 10.1007/s10156-008-0615-2
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
   Lapinsky SE, 2010, CRIT CARE MED, V38, pE52, DOI 10.1097/CCM.0b013e3181c85d5f
   Li IW, 2010, CHEST, V137, P759, DOI 10.1378/chest.09-3072
   Ling LM, 2010, CLIN INFECT DIS, V50, P963, DOI 10.1086/651083
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   McMinn P, 1999, CLIN INFECT DIS, V29, P456, DOI 10.1086/520243
   Melidou A, 2010, VIRUS RES, V151, P192, DOI 10.1016/j.virusres.2010.05.005
   *MIN SAUD, 2009, PROT MAN CLIN VIG EP
   *MIN SAUD, 2009, DIR ENFR PAND INF H1
   *MIN SAUD INF EP, INFL PAND H1N1 2009
   Mora M, 2010, EMERG INFECT DIS, V16, P1175, DOI 10.3201/eid1607.091339
   Munster VJ, 2009, SCIENCE, V325, P481, DOI 10.1126/science.1177127
   Nichols WG, 2004, CLIN INFECT DIS, V39, P1300, DOI 10.1086/425004
   Redelman-Sidi G, 2010, J INFECTION, V60, P257, DOI 10.1016/j.jinf.2010.01.009
   Rouphael NG, 2007, LANCET INFECT DIS, V7, P814, DOI 10.1016/S1473-3099(07)70290-6
   Seiter K, 2010, J CLIN ONCOL, V28, pE27, DOI 10.1200/JCO.2009.25.8889
   Seville MTA, 2010, TRANSPLANTATION, V90, P571, DOI 10.1097/TP.0b013e3181e86af0
   Shen J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007789
   Soares M, 2010, CRIT CARE MED, V38, P9, DOI 10.1097/CCM.0b013e3181c0349e
   Takiyama A, 2010, JPN J INFECT DIS, V63, P72
   To KKW, 2010, J MED VIROL, V82, P1, DOI 10.1002/jmv.21664
   Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481
   *WHO, 2009, PROT VIR SEQ
   *WHO, 2009, WEEKLY EPIDEM RECORD
   Witkop CT, 2010, AM J PREV MED, V38, P121, DOI 10.1016/j.amepre.2009.10.005
   World Health Organization, 2009, CDC PROT REALT RTPCR
   World Health Organization (WHO), 2009, HUM INF PAND H1N1 20
NR 46
TC 26
Z9 26
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2010
VL 5
IS 11
AR e14158
DI 10.1371/journal.pone.0014158
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 687DK
UT WOS:000284755100036
PM 21152402
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Larsen, R
   Gozzelino, R
   Jeney, V
   Tokaji, L
   Bozza, FA
   Japiassu, AM
   Bonaparte, D
   Cavalcante, MM
   Chora, A
   Ferreira, A
   Marguti, I
   Cardoso, S
   Sepulveda, N
   Smith, A
   Soares, MP
AF Larsen, Rasmus
   Gozzelino, Raffaella
   Jeney, Viktoria
   Tokaji, Laszlo
   Bozza, Fernando A.
   Japiassu, Andre M.
   Bonaparte, Dolores
   Cavalcante, Moises Marinho
   Chora, Angelo
   Ferreira, Ana
   Marguti, Ivo
   Cardoso, Slvia
   Sepulveda, Nuno
   Smith, Ann
   Soares, Miguel P.
TI A Central Role for Free Heme in the Pathogenesis of Severe Sepsis
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID APPROVED RECOMMENDATION 1985; CATALYTIC CONCENTRATION; IFCC METHODS;
   CELL-DEATH; 2-OXOGLUTARATE AMINOTRANSFERASE; INFECTIOUS-DISEASES; SEVERE
   MALARIA; SEPTIC SHOCK; OXYGENASE-1; HEMOPEXIN
AB Low-grade polymicrobial infection induced by cecal ligation and puncture is lethal in heme oxygenase-1-deficient mice (Hmox1(-/-)), but not in wild-type (Hmox1(+/+)) mice. Here we demonstrate that the protective effect of this heme-catabolizing enzyme relies on its ability to prevent tissue damage caused by the circulating free heme released from hemoglobin during infection. Heme administration after low-grade infection in mice promoted tissue damage and severe sepsis. Free heme contributed to the pathogenesis of severe sepsis irrespective of pathogen load, revealing that it compromised host tolerance to infection. Development of lethal forms of severe sepsis after high-grade infection was associated with reduced serum concentrations of the heme sequestering protein hemopexin (HPX), whereas HPX administration after high-grade infection prevented tissue damage and lethality. Finally, the lethal outcome of septic shock in patients was also associated with reduced HPX serum concentrations. We propose that targeting free heme by HPX might be used therapeutically to treat severe sepsis.
C1 [Larsen, Rasmus; Gozzelino, Raffaella; Jeney, Viktoria; Tokaji, Laszlo; Bonaparte, Dolores; Cavalcante, Moises Marinho; Chora, Angelo; Ferreira, Ana; Marguti, Ivo; Cardoso, Slvia; Sepulveda, Nuno; Soares, Miguel P.] Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal.
   [Bozza, Fernando A.; Japiassu, Andre M.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, BR-21040900 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Japiassu, Andre M.] DOr Inst Res & Educ, BR-22281100 Rio De Janeiro, Brazil.
   [Sepulveda, Nuno] Univ Lisbon, Ctr Stat & Applicat, P-1749016 Lisbon, Portugal.
   [Smith, Ann] Univ Missouri, Div Mol Biol & Biochem, Kansas City, MO 64110 USA.
RP Soares, MP (corresponding author), Inst Gulbenkian Ciencias, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.
EM mpsoares@igc.gulbenkian.pt
RI Sepulveda, Nuno/S-9936-2019; Jeney, Viktoria/AAF-5355-2019; Jeney,
   Viktoria/A-6779-2011; Gozzelino, Raffaella/E-8147-2017; Larsen,
   Rasmus/I-9204-2012; Bozza, Fernando A/A-2618-2013; Gozzelino,
   Raffaella/J-4524-2013
OI Gozzelino, Raffaella/0000-0002-1195-8527; Bozza, Fernando
   A/0000-0003-4878-0256; Gozzelino, Raffaella/0000-0002-1195-8527;
   Sepulveda, Nuno/0000-0002-8542-1706; Soares, Miguel/0000-0002-9314-4833;
   Ferreira Chora, Angelo/0000-0002-7941-7196; Ferreira,
   Ana/0000-0002-9171-6068; Cardoso, Silvia/0000-0003-4639-698X
FU Fundacao para a Ciencia e Tecnologia (Portugal)Portuguese Foundation for
   Science and Technology [SFRH/BPD/25436/2005, PTDC/BIO/70815/2006,
   SFRH/BPD/44256/2008, SFRH/BD/11816/2003, SFRH/BD/3106/2000,
   SFRH/BPD/21707/2005, PTDC/SAU MII/71140/2006, SFHR/BD/33218/2007]; Linde
   Healthcare; European CommunityEuropean Community (EC)
   [LSH-2005-1.2.5-1]; Marie CurieEuropean Union (EU)
   [FP7-PEOPLE-2007-2-1-IEF]; University of Missouri at Kansas City, MO,
   USA; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); FAPERJ, BrazilCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX This work was supported by Fundacao para a Ciencia e Tecnologia
   (Portugal) grants SFRH/BPD/25436/2005 and PTDC/BIO/70815/2006 (to R.L.);
   SFRH/BPD/44256/2008 (to R.G.); SFRH/BD/11816/2003 (to L.T.);
   SFRH/BD/3106/2000 (to A.C.); SFRH/BPD/21707/2005 and PTDC/SAU
   MII/71140/2006 (to A.F.); SFHR/BD/33218/2007 (to I.M.);
   POCTI/SAU-MNO/56066/2004, POCTI/BIA-BCM/56829/2004,
   PTDC/BIA-BCM/101311/2008, and PTDC/SAU-FCF/100762/2008 (to M.P.S.); as
   well as GEMI Fund Linde Healthcare (to M.P.S.), the European Community,
   Sixth Framework grant LSH-2005-1.2.5-1 (to M.P.S.), and Marie Curie
   FP7-PEOPLE-2007-2-1-IEF, GASMALARIA (to V.J.). A.S. is supported by
   research incentive funds from the University of Missouri at Kansas City,
   MO, USA. F.A.B. is a research scholar supported by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico and FAPERJ, Brazil.
CR BERGMEYER HU, 1986, J CLIN CHEM CLIN BIO, V24, P497
   BERGMEYER HU, 1986, J CLIN CHEM CLIN BIO, V24, P481
   Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bullen J, 2000, MICROBES INFECT, V2, P409, DOI 10.1016/S1286-4579(00)00326-9
   CHOU AC, 1981, J CLIN INVEST, V68, P672, DOI 10.1172/JCI110302
   Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Eskew JD, 1999, J BIOL CHEM, V274, P638, DOI 10.1074/jbc.274.2.638
   Fenton H. J. H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Goncalves LA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-169
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Griess J. P., 1864, PHIL T R SOC LOND, V154, P667, DOI 10.1039/JS8651800268
   GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861
   HORDER M, 1991, EUR J CLIN CHEM CLIN, V29, P435
   Li RC, 2009, J CEREBR BLOOD F MET, V29, P953, DOI 10.1038/jcbfm.2009.19
   Liang XY, 2009, J LEUKOCYTE BIOL, V86, P229, DOI 10.1189/jlb.1208742
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   McDaid J, 2005, FASEB J, V19, P458, DOI 10.1096/fj.04-2217fje
   MCMASTERS KM, 1993, J SURG RES, V54, P426, DOI 10.1006/jsre.1993.1067
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Medzhitov R, 2009, P NATL ACAD SCI USA, V106, P15525, DOI 10.1073/pnas.0908451106
   Moreno R, 1999, INTENS CARE MED, V25, P686, DOI 10.1007/s001340050931
   Nielsen MJ, 2009, BLOOD, V114, P764, DOI 10.1182/blood-2009-01-198309
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Raberg L, 2007, SCIENCE, V318, P812, DOI 10.1126/science.1148526
   Read AF, 2008, PLOS BIOL, V6, P2638, DOI 10.1371/journal.pbio.1000004
   Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456
   Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185
   SCHAFER JF, 1971, ANNU REV PHYTOPATHOL, V9, P235, DOI 10.1146/annurev.py.09.090171.001315
   Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Silva G, 2006, J IMMUNOL, V177, P1894, DOI 10.4049/jimmunol.177.3.1894
   Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344
   SMITH A, 1978, BIOCHEM BIOPH RES CO, V84, P151, DOI 10.1016/0006-291X(78)90276-0
   Soares MP, 2009, TRENDS MOL MED, V15, P50, DOI 10.1016/j.molmed.2008.12.004
   Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553
   Takaki S, 2010, INTENS CARE MED, V36, P42, DOI 10.1007/s00134-009-1575-4
   Takamiya R, 2009, AM J RESP CELL MOL, V41, P129, DOI 10.1165/rcmb.2008-0331OC
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   Tolosano E, 2010, ANTIOXID REDOX SIGN, V12, P305, DOI 10.1089/ars.2009.2787
   Tracz MJ, 2007, KIDNEY INT, V72, P1073, DOI 10.1038/sj.ki.5002471
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
   Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015
   Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163
NR 50
TC 261
Z9 266
U1 3
U2 33
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 29
PY 2010
VL 2
IS 51
AR 51ra71
DI 10.1126/scitranslmed.3001118
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 735SS
UT WOS:000288438400004
PM 20881280
DA 2020-12-01
ER

PT J
AU Bergamini, BC
   Medeiros, D
   Bozza, F
   Giannella-Neto, A
   Carvalho, AR
AF Bergamini, B. C.
   Medeiros, D.
   Bozza, F.
   Giannella-Neto, A.
   Carvalho, A. R.
TI COMPARISON OF TWO STRATEGIES TO SET POSITIVE END-EXPIRATORY PRESSURE
   DURING A DECREMENTAL TRIAL
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY OCT 09-13, 2010
CL Barcelona, SPAIN
SP European Soc Intens Care Med
C1 [Bergamini, B. C.; Giannella-Neto, A.] Univ Fed Rio de Janeiro, Biomed Engn Program, Rio De Janeiro, Brazil.
   [Medeiros, D.; Bozza, F.] Evandro Chagas Clin Res Inst, Oswaldo Cruz Fdn, Rio De Janeiro, Brazil.
   [Carvalho, A. R.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013; Carvalho, Alysson/AAF-1022-2019
OI Bozza, Fernando A/0000-0003-4878-0256; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2010
VL 36
SU 2
MA 0521
BP S216
EP S216
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 648GS
UT WOS:000281679500522
DA 2020-12-01
ER

PT J
AU Gomes, RN
   da Cunha, MT
   Figueiredo, RT
   Roehrs, NE
   Alves, SC
   Bozza, FA
   Zimmerman, G
   Bozza, M
   Bozza, P
   Castro-Faria-Neto, HC
AF Gomes, R. N.
   da Cunha, M. T.
   Figueiredo, R. T.
   Roehrs, N. E.
   Alves, S. C.
   Bozza, F. A.
   Zimmerman, G.
   Bozza, M.
   Bozza, P.
   Castro-Faria-Neto, H. C.
TI PAF-AH IMPROVED BACTERIAL CLEARANCE IN SEPSIS MODEL: SIGNALING INVOLVING
   MCP-1/CCL2 AND NITRIC OXIDE PRODUCTION
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY OCT 09-13, 2010
CL Barcelona, SPAIN
SP European Soc Intens Care Med
C1 [Gomes, R. N.; da Cunha, M. T.; Roehrs, N. E.; Alves, S. C.; Bozza, P.; Castro-Faria-Neto, H. C.] Oswaldo Cruz Fdn IOC FIOCRUZ, Immunopharmacol Lab, Rio De Janeiro, Brazil.
   [Figueiredo, R. T.; Bozza, M.] Univ Fed Rio de Janeiro, Imun & Inflammat Lab, Rio De Janeiro, Brazil.
   [Bozza, F. A.] IPEC FIOCRUZ, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2010
VL 36
SU 2
MA 0336
BP S169
EP S169
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 648GS
UT WOS:000281679500337
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Gomes, RN
   Assis, EF
   Carnevale, RC
   Bozza, PT
   Castro-Faria-Neto, HC
   Bozza, FA
AF Japiassu, A. M.
   Gomes, R. N.
   Assis, E. F.
   Carnevale, R. C.
   Bozza, P. T.
   Castro-Faria-Neto, H. C.
   Bozza, F. A.
TI KINETICS OF INFLAMMATORY BIOMARKERS AND PROGNOSIS IN SEPTIC SHOCK
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY OCT 09-13, 2010
CL Barcelona, SPAIN
SP European Soc Intens Care Med
C1 [Japiassu, A. M.; Bozza, F. A.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Japiassu, A. M.] Casa de Saude Sao Jose, Rio De Janeiro, Brazil.
   [Gomes, R. N.; Assis, E. F.; Carnevale, R. C.; Bozza, P. T.; Castro-Faria-Neto, H. C.] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Inst Ensino & Pesquisa Or, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2010
VL 36
SU 2
MA 0905
BP S312
EP S312
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 648GS
UT WOS:000281679500906
DA 2020-12-01
ER

PT J
AU Oliveira, M
   Carnevale, R
   Reis, P
   Castro-Faria-Neto, H
   Bozza, F
AF Oliveira, M.
   Carnevale, R.
   Reis, P.
   Castro-Faria-Neto, H.
   Bozza, F.
TI CHANGES IN THE BRAIN INFLAMMATORY AND METABOLIC PARAMETERS IN A
   POLYMICROBIAL SEPSIS RODENT MODEL
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY OCT 09-13, 2010
CL Barcelona, SPAIN
SP European Soc Intens Care Med
C1 [Oliveira, M.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Carnevale, R.; Reis, P.; Castro-Faria-Neto, H.; Bozza, F.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2010
VL 36
SU 2
MA 1306
BP S413
EP S413
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 648GS
UT WOS:000281679501351
DA 2020-12-01
ER

PT J
AU Rabello, L
   Rosolem, M
   Salluh, J
   Soares, M
   Bozza, F
   Verdeal, JC
   Mello, G
   Castro-Faria-Neto, H
   Silva, JRLE
   Bozza, P
AF Rabello, L.
   Rosolem, M.
   Salluh, J.
   Soares, M.
   Bozza, F.
   Verdeal, J. C.
   Mello, G.
   Castro-Faria-Neto, H.
   Lapa e Silva, J. R.
   Bozza, P.
TI THE IMPACT OF COAGULATION PARAMETERS ON THE OUTCOMES OF PATIENTS WITH
   SEVERE COMMUNITY-ACQUIRED PNEUMONIA REQUIRING ICU ADMISSION
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY OCT 09-13, 2010
CL Barcelona, SPAIN
SP European Soc Intens Care Med
C1 [Rabello, L.; Rosolem, M.; Salluh, J.; Soares, M.] Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Bozza, F.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Verdeal, J. C.; Mello, G.] Hosp Barra DOr, Rio De Janeiro, Brazil.
   [Lapa e Silva, J. R.] Univ Fed Rio de Janeiro, Dept Pulm Dis, Rio De Janeiro, Brazil.
   [Bozza, P.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, BR-21045900 Rio De Janeiro, Brazil.
RI Salluh, Jorge IF/F-6779-2012; Soares, Marcio/B-3083-2013; Bozza,
   Fernando A/A-2618-2013; Lapa e Silva, Jose R./AAS-4793-2020; dantas,
   vicente c souza/L-2648-2013
OI Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256; Lapa e Silva, Jose R./0000-0003-3116-0253; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2010
VL 36
SU 2
MA 1023
BP S343
EP S343
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 648GS
UT WOS:000281679501069
DA 2020-12-01
ER

PT J
AU Turon, R
   Shinotsuka, CR
   Kurtz, P
   Amaral, MCR
   Japiassu, AM
   Bozza, FA
AF Turon, R.
   Shinotsuka, C. R.
   Kurtz, P.
   Amaral, M. C. R.
   Japiassu, A. M.
   Bozza, F. A.
TI PREDICTIVE FACTORS OF HOSPITAL MORTALITY FOR NEUROLOGICAL CRITICALLY ILL
   PATIENTS
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY OCT 09-13, 2010
CL Barcelona, SPAIN
SP European Soc Intens Care Med
C1 [Turon, R.] Hosp Clin Niteroi, Rio De Janeiro, Brazil.
   [Shinotsuka, C. R.] Hosp Copa DOr, Intens Care Unit, Rio De Janeiro, Brazil.
   [Kurtz, P.; Amaral, M. C. R.; Japiassu, A. M.] Casa de Saude Sao Jose, Rio De Janeiro, Brazil.
   [Japiassu, A. M.; Bozza, F. A.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Inst DOr Pesquisa & Ensino, Rio De Janeiro, Brazil.
RI Shinotsuka, Cassia Righy/H-9181-2013; Bozza, Fernando A/A-2618-2013
OI Shinotsuka, Cassia Righy/0000-0002-9206-9552; Bozza, Fernando
   A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2010
VL 36
SU 2
MA 1316
BP S416
EP S416
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 648GS
UT WOS:000281679501361
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Shinotsuka, CR
   Soares, M
   Bozza, FA
   Silva, JRLE
   Tura, BR
   Bozza, PT
   Vidal, CG
AF Salluh, Jorge I. F.
   Shinotsuka, Cassia Righy
   Soares, Marcio
   Bozza, Fernando A.
   Roberto Lapa e Silva, Jose
   Tura, Bernardo Rangel
   Bozza, Patricia T.
   Garcia Vidal, Carolina
TI Cortisol levels and adrenal response in severe community-acquired
   pneumonia: A systematic review of the literature
SO JOURNAL OF CRITICAL CARE
LA English
DT Review
DE Adrenal failure; Community-acquired pneumonia; Corticosteroids;
   Cortisol; Sepsis
ID CRITICALLY-ILL PATIENTS; SEPTIC SHOCK; CORTICOSTEROID INSUFFICIENCY;
   MOLECULAR ACTIONS; DISEASE SEVERITY; SEVERE SEPSIS; MORTALITY;
   HYDROCORTISONE; CORTICOTROPIN; DIAGNOSIS
AB Objectives: Our aim was to review the literature on the prevalence and impact of critical-illness related corticosteroid insufficiency (CIRCI) on the outcomes of patients with severe community-acquired pneumonia (CAP).
   Methods: We reviewed Cochrane, Medline, and CINAHL databases (through July 2008) to identify studies evaluating the adrenal function in severe CAP. Main data collected were prevalence of CIRCI and its mortality.
   Results: We screened 152 articles and identified 7 valid studies. Evaluation of adrenal function varied, and most studies used baseline total cortisol levels. The prevalence of CIRCI in severe CAP ranged from 0% to 48%. Among 533 patients, 56 (10.7%) had cortisol levels of 10 mu g/dL or less and 121 patients (21.2%) had cortisol levels of 15 mu g/dL or less. In a raw analysis, there was no significant difference in mortality when patients with cortisol levels less than 10 mu g/dL (8.6 vs 15.5%; P = .55) or less than 15 mu g/dL (12.4 vs 16%; P = .38) were compared with those with cortisol above these levels. In the meta-analysis, relative risk for mortality were 0.81 (confidence interval, 0.39-1.7; P = .59; chi(2) = 1.04) for cortisol levels less than 10 mu g/dL and relative risk was 0.67 (confidence interval, 0.4-1.14; P = .84; chi(2) = 1.4) for cortisol levels less than 15 mu g/dL.
   Conclusions: A significant proportion of patients with severe CAP fulfilled criteria for CIRCI. However, CIRCI does not seem to affect the outcomes. Noteworthy, the presence of elevated cortisol levels is associated with increased mortality and may be useful as a prognostic marker in patients with severe CAP. (c) 2010 Elsevier Inc. All rights reserved.
C1 [Salluh, Jorge I. F.; Shinotsuka, Cassia Righy; Soares, Marcio] Inst Nacl Canc, Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Shinotsuka, Cassia Righy; Soares, Marcio] Inst Nacl Canc, Postgrad Program, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Immunopharmacol Lab, BR-21040900 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Tura, Bernardo Rangel] Fundacao Oswaldo Cruz, Evandro Chagas Inst, ICU, BR-21040900 Rio De Janeiro, Brazil.
   [Roberto Lapa e Silva, Jose] Univ Fed Rio de Janeiro, Dept Pulm Dis, BR-21941913 Rio De Janeiro, Brazil.
   [Garcia Vidal, Carolina] Hosp Univ Bellvitge, Infect Dis Serv, Barcelona 08907, Spain.
RP Salluh, JIF (corresponding author), Ctr Tratamento Intens, Inst Nacl Canc INCA, 10 Andar, BR-20230130 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI Bozza, Fernando A/A-2618-2013; vidal, carolina garcia/A-7290-2012;
   Shinotsuka, Cassia Righy/H-9181-2013; dantas, vicente c
   souza/L-2648-2013; Soares, Marcio/B-3083-2013; Salluh, Jorge
   IF/F-6779-2012; Lapa e Silva, Jose R./AAS-4793-2020
OI Bozza, Fernando A/0000-0003-4878-0256; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552; Soares, Marcio/0000-0003-2503-6088; Lapa e
   Silva, Jose R./0000-0003-3116-0253; Bozza, Patricia/0000-0001-8349-9529;
   Salluh, Jorge/0000-0002-8164-1453; Garcia-Vidal,
   Carolina/0000-0002-8915-0683
CR Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Annane D, 2006, AM J RESP CRIT CARE, V174, P1319, DOI 10.1164/rccm.200509-1369OC
   Beishuizen Albertus, 2004, Curr Opin Crit Care, V10, P461, DOI 10.1097/01.ccx.0000142748.40422.c8
   BOUACHOUR G, 1995, INTENS CARE MED, V21, P57, DOI 10.1007/BF02425155
   Brivet FG, 2008, INTENS CARE MED, V34, P975, DOI 10.1007/s00134-007-0982-7
   *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P535
   Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC
   Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529
   de Jong MFC, 2007, CRIT CARE, V11, DOI 10.1186/cc5928
   de Jong MFC, 2007, CRIT CARE MED, V35, P1896, DOI 10.1097/01.CCM.0000275387.51629.ED
   de Jong MFC, 2007, CLIN ENDOCRINOL, V66, P732, DOI 10.1111/j.1365-2265.2007.02814.x
   FELDMAN C, 1989, S AFR MED J, V76, P593
   Salluh JIF, 2006, ARCH SURG-CHICAGO, V141, P945, DOI 10.1001/archsurg.141.9.945-a
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Garcia-Vidal C, 2008, EUR RESPIR J, V32, P733, DOI 10.1183/09031936.00128107
   Goodman S, 2005, INTENS CARE MED, V31, P1362, DOI 10.1007/s00134-005-2770-6
   Gotoh S, 2008, EUR RESPIR J, V31, P1268, DOI 10.1183/09031936.00135607
   Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266
   Japiassu AM, 2009, MEM I OSWALDO CRUZ, V104, P531, DOI 10.1590/S0074-02762009000400001
   Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba
   Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022
   Mikami K, 2007, LUNG, V185, P249, DOI 10.1007/s00408-007-9020-3
   Niederman MS, 2007, CHEST, V131, P1205, DOI 10.1378/chest.06-1994
   Prigent H, 2004, CRIT CARE, V8, P243, DOI 10.1186/cc2878
   REICHLIN S, 1993, NEW ENGL J MED, V329, P1246
   Riche FC, 2007, INTENS CARE MED, V33, P1761, DOI 10.1007/s00134-007-0770-4
   ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7
   Salluh J, 2006, INTENS CARE MED, V32, P595, DOI 10.1007/s00134-005-0046-9
   Salluh JIF, 2008, CRIT CARE, V12, DOI 10.1186/cc6922
   Salluh JIF, 2008, CHEST, V134, P947, DOI 10.1378/chest.08-1382
   Salluh Jorge Ibrain Figueira, 2006, Rev. bras. ter. intensiva, V18, P7, DOI 10.1590/S0103-507X2006000100002
   Sam S, 2004, CLIN ENDOCRINOL, V60, P29, DOI 10.1111/j.1365-2265.2004.01923.x
   SCHEIN RMH, 1990, CRIT CARE MED, V18, P259, DOI 10.1097/00003246-199003000-00002
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
NR 35
TC 23
Z9 27
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
J9 J CRIT CARE
JI J. Crit. Care
PD SEP
PY 2010
VL 25
IS 3
AR 541.e1
DI 10.1016/j.jcrc.2010.03.004
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 674FI
UT WOS:000283719800031
PM 20627449
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Carnevale, R
   Japiassu, AM
   Castro-Faria-Neto, HC
   Angus, DC
   Salluh, JIF
AF Bozza, Fernando A.
   Carnevale, Renata
   Japiassu, Andre Miguel
   Castro-Faria-Neto, Hugo Caire
   Angus, Derek C.
   Salluh, Jorge I. F.
TI EARLY FLUID RESUSCITATION IN SEPSIS: EVIDENCE AND PERSPECTIVES
SO SHOCK
LA English
DT Article
DE Sepsis; Surviving Sepsis Campaign; hemodynamic optimization; shock;
   fluid replacement; early goal-directed therapy
ID GOAL-DIRECTED THERAPY; CRITICALLY ILL PATIENTS; SEPTIC SHOCK; OXYGEN
   DELIVERY; EMERGENCY-DEPARTMENT; CAMPAIGN GUIDELINES; MANAGEMENT;
   MULTICENTER; PATTERNS; CARE
AB Hemodynamic instability plays a major role in the pathogenesis of systemic inflammation, tissue hypoxia, and multiple organ dysfunction in sepsis. Aggressive fluid replacement is one of the key interventions for the hemodynamic support in severe sepsis. In this scenario, the ability to restore the imbalance between tissue oxygen demand and supply, the heterogeneity in microcirculation, and endothelial dysfunction in the early stages of sepsis are associated with reduced mortality. In 2001, a single-center randomized controlled trial showed impressive reductions in hospital mortality when patients presenting to the emergency department with severe sepsis were treated with an aggressive protocol of fluids, blood transfusion, and inotropes aiming to improve tissue perfusion. However, external validation of this trial remains to be carried out. To date, there is no unequivocal evidence that such strategy is both universally feasible and effective. In the present article, we review the current evidence and comment on the future perspectives on early fluid resuscitation in severe sepsis.
C1 [Bozza, Fernando A.; Japiassu, Andre Miguel] Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Intens Care Unit, BR-21040360 Rio De Janeiro, Brazil.
   [Carnevale, Renata; Castro-Faria-Neto, Hugo Caire] Fundacao Oswaldo Cruz, Immunopharmacol Lab, IOC, BR-21040360 Rio De Janeiro, Brazil.
   [Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.
   [Salluh, Jorge I. F.] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Intens Care Unit, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI dantas, vicente c souza/L-2648-2013; Salluh, Jorge IF/F-6779-2012;
   Bozza, Fernando A/A-2618-2013; Angus, Derek C/E-9671-2012
OI Bozza, Fernando A/0000-0003-4878-0256; Salluh, Jorge/0000-0002-8164-1453
CR Awad S, 2008, CLIN NUTR, V27, P179, DOI 10.1016/j.clnu.2008.01.008
   Baskett TF, 2002, RESUSCITATION, V55, P231, DOI 10.1016/S0300-9572(02)00294-0
   BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779
   Boyd O, 1996, New Horiz, V4, P453
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Dorresteijn MJ, 2005, J ENDOTOXIN RES, V11, P287, DOI 10.1179/096805105X58715
   Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294
   GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601
   HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404
   Ho BCH, 2006, CRIT CARE, V10, DOI 10.1186/cc4918
   Huang DT, 2007, CRIT CARE MED, V35, P2090, DOI 10.1097/01.CCM.0000281636.82971.92
   Jones AE, 2008, CRIT CARE MED, V36, P2734, DOI 10.1097/CCM.0b013e318186f839
   Jones AE, 2007, CHEST, V132, P425, DOI 10.1378/chest.07-0234
   Latta T, 1832, LANCET, V18, P370, DOI 10.1016/S0140-6736(02)94630-1
   Latta T, 1832, LANCET, V19, P208
   MacGillivray N, 2006, J ROY COLL PHYS EDIN, V36, P80
   MACLEAN LD, 1967, ANN SURG, V166, P543, DOI 10.1097/00000658-196710000-00004
   O'Shaughnessy W. B., 1831, LANCET, V17, P366, DOI DOI 10.1016/S0140-6736(02)94163-2
   Peake SL, 2009, RESUSCITATION, V80, P811, DOI 10.1016/j.resuscitation.2009.03.008
   Perel A, 2008, CRIT CARE, V12, DOI 10.1186/cc6979
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Rivers EP, 2008, CURR OPIN ANESTHESIO, V21, P128, DOI 10.1097/ACO.0b013e3282f4db7a
   Rivers EP, 2007, CRIT CARE MED, V35, P2016, DOI 10.1097/01.CCM.0000281637.08984.6E
   RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724
   RUSSELL JA, 1994, AM J RESP CRIT CARE, V149, P533, DOI 10.1164/ajrccm.149.2.8306058
   SHIRES G T, 1964, Int Anesthesiol Clin, V2, P435, DOI 10.1097/00004311-196402000-00016
   SHOEMAKER WC, 1993, CHEST, V104, P1529, DOI 10.1378/chest.104.5.1529
   SHOEMAKER WC, 1986, CRIT CARE MED, V14, P1032, DOI 10.1097/00003246-198612000-00008
   Singer M, 2004, LANCET, V364, P545, DOI 10.1016/S0140-6736(04)16815-3
   SWAN HJC, 1970, NEW ENGL J MED, V283, P447, DOI 10.1056/NEJM197008272830902
   Trzeciak S, 2006, CHEST, V129, P225, DOI 10.1378/chest.129.2.225
   van Beest PA, 2008, CRIT CARE, V12, DOI 10.1186/cc6811
   Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
NR 36
TC 13
Z9 15
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD SEP
PY 2010
VL 34
SU 1
BP 40
EP 43
DI 10.1097/SHK.0b013e3181e7e668
PG 4
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 640GW
UT WOS:000281038500007
PM 20714265
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Reis, PA
   Comim, CM
   Hermani, F
   Silva, B
   Barichello, T
   Portella, AC
   Gomes, FCA
   Sab, IM
   Frutuoso, VS
   Oliveira, MF
   Bozza, PT
   Bozza, FA
   Dal-Pizzol, F
   Zimmerman, GA
   Quevedo, J
   Castro-Faria-Neto, HC
AF Reis, Patricia A.
   Comim, Clarissa M.
   Hermani, Fernanda
   Silva, Bruno
   Barichello, Tatiana
   Portella, Aline C.
   Gomes, Flavia C. A.
   Sab, Ive M.
   Frutuoso, Valber S.
   Oliveira, Marcus F.
   Bozza, Patricia T.
   Bozza, Fernando A.
   Dal-Pizzol, Felipe
   Zimmerman, Guy A.
   Quevedo, Joao
   Castro-Faria-Neto, Hugo C.
TI Cognitive Dysfunction Is Sustained after Rescue Therapy in Experimental
   Cerebral Malaria, and Is Reduced by Additive Antioxidant Therapy
SO PLOS PATHOGENS
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; PLASMODIUM-YOELII 17XL; CD8(+) T-CELLS;
   OXIDATIVE STRESS; ENDOTHELIAL-CELLS; INFECTED ERYTHROCYTES; OBJECT
   RECOGNITION; PREFRONTAL CORTEX; N-ACETYLCYSTEINE; MEMORY FORMATION
AB Neurological impairments are frequently detected in children surviving cerebral malaria (CM), the most severe neurological complication of infection with Plasmodium falciparum. The pathophysiology and therapy of long lasting cognitive deficits in malaria patients after treatment of the parasitic disease is a critical area of investigation. In the present study we used several models of experimental malaria with differential features to investigate persistent cognitive damage after rescue treatment. Infection of C57BL/6 and Swiss (SW) mice with Plasmodium berghei ANKA (PbA) or a lethal strain of Plasmodium yoelii XL (PyXL), respectively, resulted in documented CM and sustained persistent cognitive damage detected by a battery of behavioral tests after cure of the acute parasitic disease with chloroquine therapy. Strikingly, cognitive impairment was still present 30 days after the initial infection. In contrast, BALB/c mice infected with PbA, C57BL6 infected with Plasmodium chabaudi chabaudi and SW infected with non lethal Plasmodium yoelii NXL (PyNXL) did not develop signs of CM, were cured of the acute parasitic infection by chloroquine, and showed no persistent cognitive impairment. Reactive oxygen species have been reported to mediate neurological injury in CM. Increased production of malondialdehyde (MDA) and conjugated dienes was detected in the brains of PbA-infected C57BL/6 mice with CM, indicating high oxidative stress. Treatment of PbA-infected C57BL/6 mice with additive antioxidants together with chloroquine at the first signs of CM prevented the development of persistent cognitive damage. These studies provide new insights into the natural history of cognitive dysfunction after rescue therapy for CM that may have clinical relevance, and may also be relevant to cerebral sequelae of sepsis and other disorders.
C1 [Reis, Patricia A.; Sab, Ive M.; Frutuoso, Valber S.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Comim, Clarissa M.; Hermani, Fernanda; Silva, Bruno; Barichello, Tatiana; Quevedo, Joao] Univ Extremo Catarinense, Lab Neurociencias, Criciuma, Brazil.
   [Comim, Clarissa M.; Hermani, Fernanda; Silva, Bruno; Barichello, Tatiana; Quevedo, Joao] Univ Extremo Catarinense, Inst Nacl Ciencia & Tecnol Translac Med, Criciuma, Brazil.
   [Portella, Aline C.; Gomes, Flavia C. A.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Dal-Pizzol, Felipe] Univ Extremo Catarinense, Lab Fisiopatol Expt, Criciuma, Brazil.
   [Zimmerman, Guy A.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [Zimmerman, Guy A.] Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.
RP Reis, PA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
EM hugocfneto@gmail.com
RI Barichello, Tatiana/E-2725-2013; Comim, Clarissa M/C-4365-2014;
   Oliveira, Marcus/G-3158-2011; Neurociencia, Inct/I-1011-2013;
   Dal-Pizzol, Felipe/F-2756-2015; de Quevedo, Joao Luciano/N-1407-2019;
   Bozza, Fernando A/A-2618-2013; Comim, Clarissa M/S-9007-2019; de
   Quevedo, Joao Luciano/E-5491-2013; Gomes, Flavia/C-5383-2013
OI Oliveira, Marcus/0000-0002-9890-8425; Dal-Pizzol,
   Felipe/0000-0003-3003-8977; de Quevedo, Joao
   Luciano/0000-0003-3114-6611; Bozza, Fernando A/0000-0003-4878-0256;
   Comim, Clarissa M/0000-0003-4991-042X; de Quevedo, Joao
   Luciano/0000-0003-3114-6611; Gomes, Flavia/0000-0003-2966-0638;
   Barichello, Tatiana/0000-0001-7776-8454; Bozza,
   Patricia/0000-0001-8349-9529
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); PRONEX; PAPESNational Council for
   Scientific and Technological Development (CNPq); NIH/NINDSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [RO3 NS04512]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL044525,
   R37HL044525, R37HL044525, R37HL044525, R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525, R37HL044525] Funding Source: NIH
   RePORTER
FX The present work was supported by CNPq (www.cnpq.br), FAPERJ
   (www.faperj.br), PRONEX
   (www.cnpq.br/programasespeciais/pronex/index.htm), PAPES
   (www.castelo.fiocruz.br/vppdt1/papes.php) and NIH/NINDS (RO3 NS04512).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X
   Barichello T, 2005, CRIT CARE MED, V33, P221, DOI 10.1097/01.CCM.0000150741.12906.BD
   Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96
   Becker K, 2004, INT J PARASITOL, V34, P163, DOI 10.1016/j.ijpara.2003.09.011
   Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369
   Bermpohl D, 2005, J CLIN INVEST, V115, P1607, DOI 10.1172/JCI23223
   Boivin MJ, 2007, PEDIATRICS, V119, pE360, DOI 10.1542/peds.2006-2027
   Budson AE, 2005, NEW ENGL J MED, V352, P692, DOI 10.1056/NEJMra041071
   Carter JA, 2006, DEV MED CHILD NEUROL, V48, P51, DOI 10.1017/S0012162206000107
   Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893
   CORDEIRO RSB, 1984, EXPERIENTIA, V40, P301, DOI 10.1007/BF01947593
   De Flora S, 1991, AM J MED S3C, V91, P122
   DEKOSSODO S, 1993, J IMMUNOL, V151, P4811
   Desruisseaux MS, 2008, J INFECT DIS, V197, P1621, DOI 10.1086/587908
   DRAPER HH, 1990, METHOD ENZYMOL, V186, P421
   Dugbartey AT, 1998, AM J TROP MED HYG, V59, P393, DOI 10.4269/ajtmh.1998.59.393
   Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103
   ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X
   Faille D, 2009, THROMB HAEMOSTASIS, V102, P1093, DOI 10.1160/TH09-05-0337
   Favre N, 1999, PARASITOLOGY, V118, P135, DOI 10.1017/S0031182098003606
   Glickstein M, 2008, CORTEX, V44, P914, DOI 10.1016/j.cortex.2008.04.001
   Golenser J, 2006, INT J PARASITOL, V36, P583, DOI 10.1016/j.ijpara.2006.02.009
   Halliwell B, 2007, BIOCHEM SOC T, V35, P1147, DOI 10.1042/BST0351147
   HALLIWELL B, 1987, FASEB J, V1, P358
   HALLIWELL B, 1989, FREE RADICAL BIO MED, V7, P645, DOI 10.1016/0891-5849(89)90145-7
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Heidbreder CA, 2003, NEUROSCI BIOBEHAV R, V27, P555, DOI 10.1016/j.neubiorev.2003.09.003
   Holding PA, 1999, T ROY SOC TROP MED H, V93, P529, DOI 10.1016/S0035-9203(99)90368-1
   Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869
   Hunt NH, 2006, INT J PARASITOL, V36, P569, DOI 10.1016/j.ijpara.2006.02.016
   Izquierdo I, 1998, NATURE, V393, P635, DOI 10.1038/31371
   Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799
   IZQUIERDO I, 1995, NEUROBIOL LEARN MEM, V63, P19, DOI 10.1006/nlme.1995.1002
   Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8
   John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709
   Laatu S, 2003, ACTA NEUROL SCAND, V108, P82, DOI 10.1034/j.1600-0404.2003.00097.x
   Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x
   Li C, 2001, MED MICROBIOL IMMUN, V189, P115, DOI 10.1007/s430-001-8017-8
   Martins YC, 2009, NEUROIMMUNOMODULAT, V16, P134, DOI 10.1159/000180268
   Mogensen J, 2005, BRAIN RES BULL, V65, P41, DOI 10.1016/j.brainresbull.2004.11.010
   Mohanty S, 2006, INDIAN J MED RES, V124, P245
   Mu DZ, 2005, EXP NEUROL, V195, P407, DOI 10.1016/j.expneurol.2005.06.001
   Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57
   Nahrevanian H, 2001, PARASITE IMMUNOL, V23, P491, DOI 10.1046/j.1365-3024.2001.00406.x
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005
   Pino P, 2003, ANN NY ACAD SCI, V1010, P582, DOI 10.1196/annals.1299.109
   Potter SM, 2005, INFECT IMMUN, V73, P4941, DOI 10.1128/IAI.73.8.4941-4947.2005
   Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003
   PUHL H, 1994, METHOD ENZYMOL, V233, P425
   Quevedo J, 1999, LEARN MEMORY, V6, P600, DOI 10.1101/lm.6.6.600
   Randall LM, 2008, INFECT IMMUN, V76, P3312, DOI 10.1128/IAI.01475-07
   Ritter C, 2004, CRIT CARE MED, V32, P342, DOI 10.1097/01.CCM.0000109454.13145.CA
   Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551
   Rosa RM, 2003, NEUROSCI LETT, V341, P217, DOI 10.1016/S0304-3940(03)00187-3
   Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050
   Sanni LA, 1999, J INFECT DIS, V179, P217, DOI 10.1086/314552
   Sarfo BY, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-63
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Schroder N, 2003, SYNAPSE, V49, P89, DOI 10.1002/syn.10210
   Shear HL, 1998, AM J TROP MED HYG, V59, P852, DOI 10.4269/ajtmh.1998.59.852
   SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849
   Taoufiq Z, 2006, MOL BIOCHEM PARASIT, V150, P166, DOI 10.1016/j.molbiopara.2006.07.008
   Teixeira LK, 2005, J IMMUNOL, V175, P5931, DOI 10.4049/jimmunol.175.9.5931
   Tuon L, 2008, INTENS CARE MED, V34, P1724, DOI 10.1007/s00134-008-1129-1
   Tuon L, 2008, CRIT CARE, V12, DOI 10.1186/cc7103
   vanHensbroek MB, 1997, J PEDIATR-US, V131, P125, DOI 10.1016/S0022-3476(97)70135-5
   Vianna MRM, 2000, LEARN MEMORY, V7, P333, DOI 10.1101/lm.34600
   Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011
NR 69
TC 74
Z9 79
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2010
VL 6
IS 6
AR e1000963
DI 10.1371/journal.ppat.1000963
PG 16
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 624GX
UT WOS:000279806300036
PM 20585569
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Salluh, JIF
AF Bozza, Fernando A.
   Salluh, Jorge I. F.
TI An urban perspective on sepsis in developing countries
SO LANCET INFECTIOUS DISEASES
LA English
DT Letter
ID VENTILATOR-ASSOCIATED PNEUMONIA; SURVIVING SEPSIS; INTENSIVE-CARE;
   SEPTIC SHOCK; INFECTIONS; CAMPAIGN
C1 [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI dantas, vicente c souza/L-2648-2013; Bozza, Fernando A/A-2618-2013;
   Salluh, Jorge IF/F-6779-2012
OI Bozza, Fernando A/0000-0003-4878-0256; Salluh, Jorge/0000-0002-8164-1453
CR Arabi Y, 2008, INT J INFECT DIS, V12, P505, DOI 10.1016/j.ijid.2008.02.010
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Becker JU, 2009, LANCET INFECT DIS, V9, P577, DOI 10.1016/S1473-3099(09)70135-5
   BOZZA FA, SHOCK IN PRESS
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294
   Ho BCH, 2006, CRIT CARE, V10, DOI 10.1186/cc4918
   Jones AE, 2008, CRIT CARE MED, V36, P2734, DOI 10.1097/CCM.0b013e318186f839
   Montgomery MR, 2008, SCIENCE, V319, P761, DOI 10.1126/science.1153012
   Morrow BM, 2009, J PAEDIATR CHILD H, V45, P104, DOI 10.1111/j.1440-1754.2008.01437.x
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   Rezende E, 2008, CLINICS, V63, P457, DOI 10.1590/S1807-59322008000400008
   Rosenthal VD, 2006, ANN INTERN MED, V145, P582, DOI 10.7326/0003-4819-145-8-200610170-00007
   Salluh JIF, 2008, SHOCK, V30, P70, DOI 10.1097/SHK.0b013e318181ad60
   Simchen E, 2007, CRIT CARE MED, V35, P449, DOI 10.1097/01.CCM.0000253407.89594.15
NR 15
TC 13
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAY
PY 2010
VL 10
IS 5
BP 290
EP 291
DI 10.1016/S1473-3099(10)70074-8
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 595HA
UT WOS:000277600100002
PM 20417408
DA 2020-12-01
ER

PT J
AU London, NR
   Zhu, WQ
   Bozza, FA
   Smith, MCP
   Greif, DM
   Sorensen, LK
   Chen, LM
   Kaminoh, Y
   Chan, AC
   Passi, SF
   Day, CW
   Barnard, DL
   Zimmerman, GA
   Krasnow, MA
   Li, DY
AF London, Nyall R.
   Zhu, Weiquan
   Bozza, Fernando A.
   Smith, Matthew C. P.
   Greif, Daniel M.
   Sorensen, Lise K.
   Chen, Luming
   Kaminoh, Yuuki
   Chan, Aubrey C.
   Passi, Samuel F.
   Day, Craig W.
   Barnard, Dale L.
   Zimmerman, Guy A.
   Krasnow, Mark A.
   Li, Dean Y.
TI Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm
   in Sepsis and Influenza
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID ACUTE LUNG INJURY; VASCULAR ENDOTHELIAL CADHERIN; VE-CADHERIN;
   PUBLIC-HEALTH; TYROSINE PHOSPHORYLATION; DEPENDENT ENDOCYTOSIS; MAGIC
   ROUNDABOUT; HEPARAN-SULFATE; CECAL LIGATION; PROTEIN
AB The innate immune system provides a first line of defense against invading pathogens by releasing multiple inflammatory cytokines, such as interleukin-1 beta and tumor necrosis factor-alpha, which directly combat the infectious agent and recruit additional immune responses. This exuberant cytokine release paradoxically injures the host by triggering leakage from capillaries, tissue edema, organ failure, and shock. Current medical therapies target individual pathogens with antimicrobial agents or directly either blunt or boost the host's immune system. We explored a third approach: activating with the soluble ligand Slit an endothelium-specific, Robo4-dependent signaling pathway that strengthens the vascular barrier, diminishing deleterious aspects of the host's response to the pathogen-induced cytokine storm. This approach reduced vascular permeability in the lung and other organs and increased survival in animal models of bacterial endotoxin exposure, polymicrobial sepsis, and H5N1 influenza. Thus, enhancing the resilience of the host vascular system to the host's innate immune response may provide a therapeutic strategy for treating multiple infectious agents.
C1 [London, Nyall R.; Zhu, Weiquan; Smith, Matthew C. P.; Sorensen, Lise K.; Chen, Luming; Kaminoh, Yuuki; Chan, Aubrey C.; Passi, Samuel F.; Li, Dean Y.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
   [London, Nyall R.; Zhu, Weiquan; Smith, Matthew C. P.; Sorensen, Lise K.; Chen, Luming; Kaminoh, Yuuki; Chan, Aubrey C.; Passi, Samuel F.; Zimmerman, Guy A.; Li, Dean Y.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [London, Nyall R.; Zhu, Weiquan; Smith, Matthew C. P.; Sorensen, Lise K.; Chen, Luming; Kaminoh, Yuuki; Chan, Aubrey C.; Passi, Samuel F.; Li, Dean Y.] Univ Utah, Program Mol Med, Salt Lake City, UT 84112 USA.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, BR-21045900 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Greif, Daniel M.; Krasnow, Mark A.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.
   [Greif, Daniel M.; Krasnow, Mark A.] Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.
   [Greif, Daniel M.] Stanford Univ, Dept Med, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA.
   [Day, Craig W.; Barnard, Dale L.] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
RP Li, DY (corresponding author), Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
EM dean.li@u2m2.utah.edu
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Chan, Aubrey/0000-0002-9191-2173;
   Chen, Luming/0000-0003-0852-5752
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI); National
   Institute of Allergy and Infectious Diseases (NIAID)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID);
   Rocky Mountain Regional Center of Excellence in Biodefense and Emerging
   Infectious Disease; Juvenile Diabetes Research FoundationJuvenile
   Diabetes Research Foundation; HA and Edna Benning Foundation; American
   Asthma Foundation; National Center for Research Resources Public Health
   ServicesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [UL1-RR025764]; Department of DefenseUnited States
   Department of Defense; Burroughs Wellcome FoundationBurroughs Wellcome
   Fund; American Heart AssociationAmerican Heart Association; Ruth L.
   Kirschstein National Research Service AwardUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [NO1-AI-15435]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [5R37 HL44525-20]; Sarnoff Cardiovascular Research Foundation Scholar
   Award; NIH-NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [K08]; Pulmonary Hypertension Association;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   Brazil)National Council for Scientific and Technological Development
   (CNPq);  [T32-GM007464]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Center for Research Resources (NCRR)
   [UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764,
   UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764,
   UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764,
   UL1RR025764, UL1RR025764, UL1RR025764, UL1RR025764] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL068873,
   R01HL065648, R01HL068873, R01HL084516, R37HL044525, R01HL065648,
   R37HL044525, R01HL065648, R01HL084516, R01HL065648, R01HL077671,
   R01HL084516, R01HL084516, R37HL044525, R01HL068873, R01HL077671,
   R01HL084516, R01HL065648, R01HL077671, R37HL044525, R01HL077671,
   R01HL077671, R01HL077671, R37HL044525, R01HL068873, R37HL044525,
   R01HL077671, R01HL077671, R37HL044525, R01HL065648, R01HL068873,
   R01HL077671, R01HL084516, R37HL044525, R01HL065648, R37HL044525,
   R01HL084516, R37HL044525, R01HL068873, R01HL065648, R01HL065648,
   R01HL084516, R01HL077671, R01HL068873, R01HL077671, R01HL077671,
   R01HL068873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [N01AI015435] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [T32GM007464, T32GM007464, T32GM007464, T32GM007464,
   T32GM007464, T32GM007464, T32GM007464, T32GM007464, T32GM007464,
   T32GM007464, T32GM007464, T32GM007464, T32GM007464, T32GM007464,
   T32GM007464, T32GM007464, T32GM007464, T32GM007464, T32GM007464,
   T32GM007464, T32GM007464, T32GM007464, T32GM007464, T32GM007464,
   T32GM007464, T32GM007464, T32GM007464, T32GM007464, T32GM007464,
   T32GM007464, T32GM007464, T32GM007464, T32GM007464, T32GM007464] Funding
   Source: NIH RePORTER
FX Funding: National Heart, Lung, and Blood Institute (NHLBI); National
   Institute of Allergy and Infectious Diseases (NIAID); Rocky Mountain
   Regional Center of Excellence in Biodefense and Emerging Infectious
   Disease; Juvenile Diabetes Research Foundation; HA and Edna Benning
   Foundation; American Asthma Foundation; National Center for Research
   Resources Public Health Services research grant UL1-RR025764; and
   Department of Defense. D.Y.L. is a Burroughs Wellcome Foundation
   Clinical Scientist in Translational Research and an Established
   Investigator of the American Heart Association. N.R.L., M. C. P. S., and
   A. C. C. were supported, respectively, by the Ruth L. Kirschstein
   National Research Service Award, T-32 Hematology Training Grant, and
   training grant T32-GM007464. This work was also supported by NIAID
   contract NO1-AI-15435 (C. W. D. and D. L. B.); a NIH Merit Award 5R37
   HL44525-20 (G. A. Z.); and the Sarnoff Cardiovascular Research
   Foundation Scholar Award, NIH-NHLBI (K08), and the Pulmonary
   Hypertension Association (D. M. G.). F. A. B. is a research scholar
   supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil). Author contributions: N.R.L., W. Z., and
   D.Y.L. were responsible for project conceptualization, experimental
   design, and data analysis. N.R.L., G. A. Z., and D.Y.L. were responsible
   for manuscript preparation. N.R.L., W. Z., and F. A. B. were responsible
   for performing all experiments or coordinating experimental design and
   work of others. M. C. P. S., D. M. G., L. K. S., L. C., Y.K., A. C. C.,
   and S. F. P. performed necessary experiments for the manuscript or in
   response to reviewers. C. W. D., D. L. B., G. A. Z, and M. A. K.
   provided important expertise, reagents, technical personnel and advice.
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Abraham E, 2001, CRIT CARE MED, V29, P503, DOI 10.1097/00003246-200103000-00006
   Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887
   Angelini DJ, 2006, AM J PHYSIOL-LUNG C, V291, pL1232, DOI 10.1152/ajplung.00109.2006
   Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105
   Bossi P, 2006, CELL MOL LIFE SCI, V63, P2196, DOI 10.1007/s00018-006-6308-z
   Chedotal A, 2007, ADV EXP MED BIOL, V621, P65, DOI 10.1007/978-0-387-76715-4_5
   COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458
   Coltel N, 2004, CURR NEUROVASC RES, V1, P91, DOI 10.2174/1567202043480116
   Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679
   CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019
   Crum NF, 2005, MEDICINE, V84, P291, DOI 10.1097/01.md.0000180044.19285.9a
   de Jong JC, 2000, J INFECTION, V40, P218, DOI 10.1053/jinf.2000.0652
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897
   Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S
   Ferreira AM, 2005, MICROCIRCULATION, V12, P563, DOI 10.1080/10739680500253493
   Gampel A, 2006, BLOOD, V108, P2624, DOI 10.1182/blood-2005-12-007484
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Grieshammer U, 2004, DEV CELL, V6, P709, DOI 10.1016/S1534-5807(04)00108-X
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hackett CJ, 2003, J ALLERGY CLIN IMMUN, V112, P686, DOI 10.1016/S0091-6749(03)02025-6
   Hohenester E, 2006, BIOCHEM SOC T, V34, P418, DOI 10.1042/BST0340418
   Hsieh YC, 2006, J FORMOS MED ASSOC, V105, P1, DOI 10.1016/S0929-6646(09)60102-9
   Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482
   Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e
   Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745
   Jones CA, 2008, NAT MED, V14, P448, DOI 10.1038/nm1742
   Jones CA, 2009, NAT CELL BIOL, V11, P1325, DOI 10.1038/ncb1976
   Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495
   Layne SP, 2009, SCIENCE, V323, P1560, DOI 10.1126/science.323.5921.1560
   London NR, 2009, ANGIOGENESIS, V12, P149, DOI 10.1007/s10456-009-9130-z
   Matute-Bello G, 2008, AM J PHYSIOL-LUNG C, V295, pL379, DOI 10.1152/ajplung.00010.2008
   Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269
   Metzger RJ, 2008, NATURE, V453, P745, DOI 10.1038/nature07005
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   Morens DM, 2008, JAMA-J AM MED ASSOC, V299, P214, DOI 10.1001/jama.2007.31-a
   Morse SS, 2006, SCIENCE, V314, P929, DOI 10.1126/science.1135823
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Park KW, 2003, DEV BIOL, V261, P251, DOI 10.1016/S0012-1606(03)00258-6
   Perdue ML, 2005, AVIAN DIS, V49, P317, DOI 10.1637/7390-060305R.1
   Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200
   Qureshi ST, 2003, GENES IMMUN, V4, P87, DOI 10.1038/sj.gene.6363937
   Sabatier C, 2004, CELL, V117, P157, DOI 10.1016/S0092-8674(04)00303-4
   SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T
   Sepkowitz KA, 2009, NEW ENGL J MED, V361, P120, DOI 10.1056/NEJMp0902373
   Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250
   Sheldon H, 2009, FASEB J, V23, P513, DOI 10.1096/fj.07-098269
   Sidwell RW, 2005, ANTIVIR RES, V68, P10, DOI 10.1016/j.antiviral.2005.06.003
   Steigemann P, 2004, CURR BIOL, V14, P225, DOI 10.1016/j.cub.2004.01.006
   Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje
   Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014
   Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001
   VILLA P, 1995, CLIN DIAGN LAB IMMUN, V2, P549, DOI 10.1128/CDLI.2.5.549-553.1995
   Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098
   Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440
   ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232
NR 62
TC 208
Z9 223
U1 4
U2 28
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAR 17
PY 2010
VL 2
IS 23
AR 23ra19
DI 10.1126/scitranslmed.3000678
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 591ME
UT WOS:000277304000004
PM 20375003
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Garteiser, P
   Oliveira, MF
   Doblas, S
   Cranford, R
   Saunders, D
   Jones, I
   Towner, RA
   Castro-Faria-Neto, HC
AF Bozza, Fernando A.
   Garteiser, Philippe
   Oliveira, Marcus F.
   Doblas, Sabrina
   Cranford, Rebecca
   Saunders, Debra
   Jones, Inna
   Towner, Rheal A.
   Castro-Faria-Neto, Hugo C.
TI Sepsis-associated encephalopathy: a magnetic resonance imaging and
   spectroscopy study
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Article
DE inflammation; infection; central nervous system; blood-brain barrier;
   delirium
ID BLOOD-BRAIN-BARRIER; MECHANICALLY VENTILATED PATIENTS; NITRIC-OXIDE
   SYNTHASE; SEPTIC SHOCK; IN-VIVO; INFLAMMATORY RESPONSE; CEREBRAL
   MALARIA; CECAL LIGATION; EDEMA; DYSFUNCTION
AB Brain dysfunction is frequently observed in sepsis as a consequence of changes in cerebral structure and metabolism, resulting in worse outcome and reduced life-quality of surviving patients. However, the mechanisms of sepsis-associated encephalopathy development and a better characterization of this syndrome in vivo are lacking. Here, we used magnetic resonance imaging (MRI) techniques to assess brain morphology and metabolism in a murine sepsis model (cecal ligation and puncture, CLP). Sham-operated and CLP mice were subjected to a complete MRI session at baseline, 6 and 24 h after surgery. Accumulation of vasogenic edematic fluid at the base of the brain was observed in T-2-weighted image at 6 and 24 h after CLP. Also, the water apparent diffusion coefficients in both hippocampus and cortex were decreased, suggesting a cytotoxic edema in brains of nonsurvival septic animals. Moreover, the N-acetylaspartate/choline ratio was reduced in brains of septic mice, indicating neuronal damage. In conclusion, noninvasive assessment by MRI allowed the identification of new aspects of brain damage in sepsis, including cytotoxic and vasogenic edema as well as neuronal damage. These findings highlight the potential applications of MRI techniques for the diagnostic and therapeutic studies in sepsis. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 440-448; doi: 10.1038/jcbfm.2009.215; published online 21 October 2009
C1 [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, BR-21040900 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.; Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Lab Inflamacao & Metab, Inst Nacl Ciencia & Tecnol Biol Estrutural & Bioi, Rio De Janeiro, Brazil.
   [Garteiser, Philippe; Doblas, Sabrina; Cranford, Rebecca; Saunders, Debra; Jones, Inna; Towner, Rheal A.] Oklahoma Med Res Fdn, Adv Magnet Resonance Ctr, Oklahoma City, OK 73104 USA.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Programa Biol Mol & Biotecnol, Lab Bioquim Redox, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, Hugo C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, Av Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI Oliveira, Marcus/G-3158-2011; Bozza, Fernando A/A-2618-2013; Garteiser,
   Philippe/P-5719-2017
OI Oliveira, Marcus/0000-0002-9890-8425; Bozza, Fernando
   A/0000-0003-4878-0256; Garteiser, Philippe/0000-0003-0157-8851; Doblas,
   Sabrina/0000-0002-5194-3872
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq, Brazil)National Council for Scientific and Technological
   Development (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); Fundacao
   Oswaldo Cruz
FX FAB, MFO, and HCCFN are research scholars from CNPq.; Supported in part
   by grants from Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil) and Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil), and Fundacao
   Oswaldo Cruz.
CR Anda T, 1997, NEUROL RES, V19, P369, DOI 10.1080/01616412.1997.11758599
   Barichello T, 2005, CRIT CARE MED, V33, P1671, DOI 10.1097/01.CCM.0000170192.54682.C1
   BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X
   Blankenberg FG, 1997, BLOOD, V89, P3778, DOI 10.1182/blood.V89.10.3778.3778_3778_3786
   Bogdanski R, 2000, ANESTHESIOLOGY, V93, P793, DOI 10.1097/00000542-200009000-00029
   Chan JYH, 2007, MOL PHARMACOL, V71, P1129, DOI 10.1124/mol.106.031161
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x
   EIS M, 1995, MAGN RESON MED, V34, P835, DOI 10.1002/mrm.1910340608
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Flierl MA, 2009, CRIT CARE, V13, DOI 10.1186/cc7710
   Franklin K.B.J., 1997, MOUSE BRAIN STEREOTA
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613
   Hinkelbein J, 2007, CURR NEUROVASC RES, V4, P39, DOI 10.2174/156720207779940671
   HUYNH HK, 1993, AM J PATHOL, V142, P1265
   JEPPSSON B, 1981, AM J SURG, V141, P136, DOI 10.1016/0002-9610(81)90026-X
   Kadoi Y, 2004, ANESTH ANALG, V99, P212, DOI 10.1213/01.ANE.0000118111.94913.22
   Kafa IM, 2007, NEUROPATHOLOGY, V27, P213, DOI 10.1111/j.1440-1789.2007.00757.x
   Kokubo Y, 2002, BRAIN RES, V947, P1, DOI 10.1016/S0006-8993(02)02899-8
   Lackner P, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-116
   Lin SM, 2008, J CRIT CARE, V23, P372, DOI 10.1016/j.jcrc.2006.09.001
   Messaris E, 2004, CRIT CARE MED, V32, P1764, DOI 10.1097/01.CCM.0000135744.30137.B4
   Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003
   Orihuela CJ, 2006, INFECT IMMUN, V74, P3783, DOI 10.1128/IAI.00022-06
   Papadopoulos MC, 1999, CLIN SCI, V96, P461, DOI 10.1042/CS19980327
   Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057
   Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005
   Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895
   Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004
   Rosengarten B, 2008, INFLAMM RES, V57, P479, DOI 10.1007/s00011-008-8042-5
   Ross B, 2001, ANAT RECORD, V265, P54, DOI 10.1002/ar.1058
   Server A, 2009, ACTA RADIOL, V50, P682, DOI 10.1080/02841850902933123
   Sharshar T, 2004, BRAIN PATHOL, V14, P21, DOI 10.1111/j.1750-3639.2004.tb00494.x
   Sharshar T, 2003, LANCET, V362, P1799, DOI 10.1016/S0140-6736(03)14899-4
   Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y
   Siami S, 2008, CRIT CARE CLIN, V24, P67, DOI 10.1016/j.ccc.2007.10.001
   Sibtain NA, 2007, CLIN RADIOL, V62, P109, DOI 10.1016/j.crad.2006.09.012
   SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001
   STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690
   Testylier G, 2007, TOXICOL APPL PHARM, V220, P125, DOI 10.1016/j.taap.2007.01.013
   Towner RA, 2008, J CELL MOL MED, V12, P174, DOI 10.1111/j.1582-4934.2008.00220.x
   Pancoto JAT, 2008, AUTON NEUROSCI-BASIC, V138, P57, DOI 10.1016/j.autneu.2007.10.006
   Vuori K, 2004, RADIOLOGY, V230, P703, DOI 10.1148/radiol.2303021804
   Walker PM, 2004, J NEUROL SCI, V220, P23, DOI 10.1016/j.jns.2004.01.012
NR 45
TC 47
Z9 52
U1 0
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD FEB
PY 2010
VL 30
IS 2
BP 440
EP 448
DI 10.1038/jcbfm.2009.215
PG 9
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA 551TS
UT WOS:000274233800019
PM 19844239
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Amancio, RT
   Mesquita, EC
   Medeiros, DM
   Bernal, HB
   Nunes, EP
   Luz, PM
   Grinsztejn, B
   Bozza, FA
AF Japiassu, Andre M.
   Amancio, Rodrigo T.
   Mesquita, Emerson C.
   Medeiros, Denise M.
   Bernal, Helena B.
   Nunes, Estevao P.
   Luz, Paula M.
   Grinsztejn, Beatriz
   Bozza, Fernando A.
TI Sepsis is a major determinant of outcome in critically ill HIV/AIDS
   patients
SO CRITICAL CARE
LA English
DT Article
ID HIV-INFECTED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; RIO-DE-JANEIRO;
   INTENSIVE-CARE; SEPTIC SHOCK; UNITED-STATES; SURVIVING SEPSIS; ORGAN
   FAILURE; SAPS-II; EPIDEMIOLOGY
AB Introduction: New challenges have arisen for the management of critically ill HIV/AIDS patients. Severe sepsis has emerged as a common cause of intensive care unit (ICU) admission for those living with HIV/AIDS. Contrastingly, HIV/AIDS patients have been systematically excluded from sepsis studies, limiting the understanding of the impact of sepsis in this population. We prospectively followed up critically ill HIV/AIDS patients to evaluate the main risk factors for hospital mortality and the impact of severe sepsis on the short-and long-term survival.
   Methods: All consecutive HIV-infected patients admitted to the ICU of an infectious diseases research center, from June 2006 to May 2008, were included. Severity of illness, time since AIDS diagnosis, CD4 cell count, antiretroviral treatment, incidence of severe sepsis, and organ dysfunctions were registered. The 28-day, hospital, and 6-month outcomes were obtained for all patients. Cox proportional hazards regression analysis measured the effect of potential factors on 28-day and 6-month mortality.
   Results: During the 2-year study period, 88 HIV/AIDS critically ill patients were admitted to the ICU. Seventy percent of patients had opportunist infections, median CD4 count was 75 cells/mm(3), and 45% were receiving antiretroviral therapy. Location on a ward before ICU admission, cardiovascular and respiratory dysfunctions on the first day after admission, and the presence of severe sepsis/septic shock were associated with reduced 28-day and 6-month survival on a univariate analysis. After a multivariate analysis, severe sepsis determined the highest hazard ratio (HR) for 28-day (adjusted HR, 3.13; 95% CI, 1.21-8.07) and 6-month (adjusted HR, 3.35; 95% CI, 1.42-7.86) mortality. Severe sepsis occurred in 44 (50%) patients, mainly because of lower respiratory tract infections. The survival of septic and nonseptic patients was significantly different at 28-day and 6-month follow-up times (log-rank and Peto test, P < 0.001).
   Conclusions: Severe sepsis has emerged as a major cause of admission and mortality for hospitalized HIV/AIDS patients, significantly affecting short-and longer-term survival of critically ill HIV/AIDS patients.
C1 [Japiassu, Andre M.; Amancio, Rodrigo T.; Mesquita, Emerson C.; Medeiros, Denise M.; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Intens Care Unit, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
   [Bernal, Helena B.; Nunes, Estevao P.; Luz, Paula M.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, HIV AIDS Res Ctr, Inst Pesquisa Clin Evandro Chagas, BR-21040360 Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Intens Care Unit, Inst Pesquisa Clin Evandro Chagas, Av Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Mesquita,
   Emersom/0000-0002-5132-3315; Luz, Paula/0000-0001-9746-719X
CR Afessa B, 2000, CHEST, V118, P138, DOI 10.1378/chest.118.1.138
   Ballester JCA, 2008, INFECT CONT HOSP EP, V29, P630, DOI 10.1086/589583
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087
   Arthur G, 2001, CLIN INFECT DIS, V33, P248, DOI 10.1086/321820
   Beale R, 2009, INFECTION, V37, P222, DOI 10.1007/s15010-008-8203-z
   Becker JU, 2009, LANCET INFECT DIS, V9, P577, DOI 10.1016/S1473-3099(09)70135-5
   Blanco J, 2008, CRIT CARE, V12, DOI 10.1186/cc7157
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bozza FA, 2010, LANCET INFECT DIS, V10, P290, DOI 10.1016/S1473-3099(10)70074-8
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4
   Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7
   Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P308
   Cheng AC, 2008, PLOS MED, V5, P1173, DOI 10.1371/journal.pmed.0050175
   Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7
   Davaro Raul E, 2007, J Intensive Care Med, V22, P73, DOI 10.1177/0885066606297964
   Davis JL, 2008, THORAX, V63, P988, DOI 10.1136/thx.2008.095786
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Grinsztejn B, 1997, ARCH INTERN MED, V157, P2359, DOI 10.1001/archinte.157.20.2359
   Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494
   Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
   Hung CC, 1998, J FORMOS MED ASSOC, V97, P690
   Khouli Hassan, 2005, J Intensive Care Med, V20, P327
   Khwannimit B, 2009, EPIDEMIOL INFECT, V137, P1333, DOI 10.1017/S0950268809002027
   Le Gall JR, 2005, CRIT CARE, V9, pR645, DOI 10.1186/cc3821
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Morris A, 2002, AM J RESP CRIT CARE, V166, P262, DOI 10.1164/rccm.2111025
   Mrus JM, 2005, CRIT CARE, V9, pR623, DOI 10.1186/cc3811
   Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
   Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531
   Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5
   Palacios R, 2006, HIV MED, V7, P193, DOI 10.1111/j.1468-1293.2006.00353.x
   Petrosillo N, 2003, INFECTION, V31, P28, DOI 10.1007/s15010-003-8227-3
   Powell K, 2009, CHEST, V135, P11, DOI 10.1378/chest.08-0980
   Rosen MJ, 2006, CRIT CARE MED, V34, pS245, DOI 10.1097/01.CCM.0000232491.15369.AB
   Rosenberg AL, 2001, CRIT CARE MED, V29, P548, DOI 10.1097/00003246-200103000-00013
   Sales Júnior João Andrade L., 2006, Rev. bras. ter. intensiva, V18, P9, DOI 10.1590/S0103-507X2006000100003
   Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892
   Soares M, 2007, INTENS CARE MED, V33, P1014, DOI 10.1007/s00134-007-0623-1
   Schmaltz CAS, 2009, JAIDS-J ACQ IMM DEF, V52, P623, DOI 10.1097/QAI.0b013e3181b31e56
   Thyrault M, 1997, INTENS CARE MED, V23, P1018, DOI 10.1007/s001340050451
   Tumbarello M, 2000, J ACQ IMMUN DEF SYND, V23, P145
   *UNAIDS WHO, AIDS EP UPD 2009
   Vidal F, 1999, EUR J CLIN MICROBIOL, V18, P473, DOI 10.1007/s100960050326
   Vincent B, 2004, INTENS CARE MED, V30, P859, DOI 10.1007/s00134-004-2158-z
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Waddell RD, 2001, AIDS, V15, P55, DOI 10.1097/00002030-200101050-00009
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 51
TC 57
Z9 58
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2010
VL 14
IS 4
AR R152
DI 10.1186/cc9221
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 680JJ
UT WOS:000284227900027
PM 20698966
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Soares, M
   Caruso, P
   Silva, E
   Teles, JMM
   Lobo, SMA
   Friedman, G
   Dal Pizzol, F
   Mello, PVC
   Bozza, FA
   Silva, UVA
   Torelly, AP
   Knibel, MF
   Rezende, E
   Netto, JJ
   Piras, C
   Castro, A
   Ferreira, BS
   Rea-Neto, A
   Olmeda, PB
   Salluh, JIF
AF Soares, Marcio
   Caruso, Pedro
   Silva, Eliezer
   Teles, Jose M. M.
   Lobo, Suzana M. A.
   Friedman, Gilberto
   Dal Pizzol, Felipe
   Mello, Patricia V. C.
   Bozza, Fernando A.
   Silva, Ulisses V. A.
   Torelly, Andre P.
   Knibel, Marcos F.
   Rezende, Ederlon
   Netto, Jose J.
   Piras, Claudio
   Castro, Aline
   Ferreira, Bruno S.
   Rea-Neto, Alvaro
   Olmeda, Patricia B.
   Salluh, Jorge I. F.
CA BRICNet
TI Characteristics and outcomes of patients with cancer requiring admission
   to intensive care units: A prospective multicenter study
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE cancer; intensive care unit; mortality; multicenter study; outcome
ID CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATORY SUPPORT; HOSPITAL
   MORTALITY; ACUTE PHYSIOLOGY; SEPTIC SHOCK; SEPSIS; IMPACT; MALIGNANCIES;
   SURVIVAL; SCORE
AB Objective: To evaluate the characteristics and outcomes of patients with cancer admitted to several intensive care units. Knowledge on patients with cancer requiring intensive care is mostly restricted to single-center studies.
   Design: Prospective, multicenter, cohort study.
   Setting: Intensive care units from 28 hospitals in Brazil.
   Patients: A total of 717 consecutive patients included over a 2-mo period.
   Interventions: None.
   Measurements and Main Results: There were 667 (93%) patients with solid tumors and 50 (7%) patients had hematologic malignancies. The main reasons for intensive care unit admission were postoperative care (57%), sepsis (15%), and respiratory failure (10%). Overall hospital mortality rate was 30% and was higher in patients admitted because of medical complications (58%) than in emergency (37%) and scheduled (11%) surgical patients (p < .001). Adjusting for covariates other than the type of admission, the number of hospital days before intensive care unit admission (odds ratio [OR], 1.18; 95% confidence interval [CI], 1.01-1.37), higher Sequential Organ Failure Assessment scores (OR, 1.25; 95% CI, 1.17-1.34), poor performance status (OR, 3.40; 95% CI, 2.19-5.26), the need for mechanical ventilation (OR, 2.42; 95% CI, 1.51-3.87), and active underlying malignancy in recurrence or progression (OR, 2.42; 95% CI, 1.51-3.87) were associated with increased hospital mortality in multivariate analysis.
   Conclusions: This large multicenter study reports encouraging survival rates for patients with cancer requiring intensive care. In these patients, mortality was mostly dependent on the severity of organ failures, performance status, and need for mechanical ventilation rather than cancer-related characteristics, such as the type of malignancy or the presence of neutropenia. (Crit Care Med 2010; 38:9-15)
C1 [Soares, Marcio; Olmeda, Patricia B.; Salluh, Jorge I. F.] Hosp Canc I, ICU, Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Caruso, Pedro] Hosp AC Camargo Fund Antonio Prudente, ICU, Sao Paulo, Brazil.
   [Silva, Eliezer] Hosp Israelita Albert Einstein, ICU, Sao Paulo, Brazil.
   [Teles, Jose M. M.] Hosp Portugues, ICU, Salvador, BA, Brazil.
   [Lobo, Suzana M. A.] Sch Med, Dept Internal Med, Div Crit Care Med, Sao Jose Do Rio Preto, Brazil.
   Hosp Base, Sao Jose Do Rio Preto, Brazil.
   [Friedman, Gilberto] Univ Fed Rio Grande do Sul, ICU, Porto Alegre, RS, Brazil.
   [Dal Pizzol, Felipe] Univ Extermo Sul Catarinense, Unidad Acad Ciencias Saude, Programa Posgrad Ciencias Saude, Lab Fisiopatol Expt, Criciuma, Brazil.
   [Mello, Patricia V. C.] Univ Estadual Piaui, ICU, Teresina, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisas Evandro Chagas, ICU, Rio De Janeiro, Brazil.
   [Silva, Ulisses V. A.] Fundacao Pio XII, Hosp Canc Barretos, ICU, Barretos, Brazil.
   [Knibel, Marcos F.] Hosp Sao Lucas, Rio De Janeiro, Brazil.
   [Rezende, Ederlon] Hosp Serv Publ Estadual, ICU, Sao Paulo, Brazil.
   [Netto, Jose J.] Hosp Canc II, Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   [Piras, Claudio] Vitoria Apart Hosp, ICU, Vitoria, Brazil.
   [Castro, Aline] Hosp Samaritano, ICU, Rio De Janeiro, Brazil.
   [Ferreira, Bruno S.] Pasteur Hosp, Rio De Janeiro, Brazil.
   [Rea-Neto, Alvaro] Univ Fed Parana, Hosp Clin, ICU, BR-80060000 Curitiba, Parana, Brazil.
   [Friedman, Gilberto; Torelly, Andre P.] Santa Casa Misericordia Porto Alegre, ICU, Porto Alegre, RS, Brazil.
RP Soares, M (corresponding author), Hosp Canc I, ICU, Inst Nacl Canc, Rio De Janeiro, Brazil.
EM marciosoaresms@yahoo.com.br
RI V.A.Silva, Ulysses/AAZ-3336-2020; Rea-Neto, Alvaro/AAR-7909-2020;
   dantas, vicente c souza/L-2648-2013; Caruso, Pedro/B-6054-2016; Dal
   Pizzol, Felipe/F-2756-2015
OI V.A.Silva, Ulysses/0000-0002-1284-2016; Rea-Neto,
   Alvaro/0000-0001-5524-0907; Caruso, Pedro/0000-0002-1051-8458; Soares,
   Marcio/0000-0003-2503-6088; Dal Pizzol, Felipe/0000-0003-3003-8977;
   Salluh, Jorge/0000-0002-8164-1453; Bozza, Fernando
   Augusto/0000-0003-4878-0256
FU Instituto Nacional de Cancer; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This study was supported, in part, by Instituto Nacional de Cancer.; Dr.
   Soares and Dr. Bozza are supported, in part, by individual research
   grants from CNPq. The remaining authors have not disclosed any potential
   conflicts of interest.
CR Azoulay E, 2001, CRIT CARE MED, V29, P519, DOI 10.1097/00003246-200103000-00009
   Azoulay E, 2000, INTENS CARE MED, V26, P1817, DOI 10.1007/s001340051350
   Benoit DD, 2003, CRIT CARE MED, V31, P104, DOI 10.1097/00003246-200301000-00017
   Darmon M, 2005, CRIT CARE MED, V33, P2488, DOI 10.1097/01.CCM.0000181728.13354.0A
   Groeger JS, 1998, J CLIN ONCOL, V16, P761, DOI 10.1200/JCO.1998.16.2.761
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Kress JP, 1999, AM J RESP CRIT CARE, V160, P1957, DOI 10.1164/ajrccm.160.6.9812055
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Maschmeyer G, 2003, EUR J CANCER, V39, P783, DOI 10.1016/S0959-8049(03)00004-2
   Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5
   Pene F, 2008, CRIT CARE MED, V36, P690, DOI 10.1097/CCM.0B013E318165314B
   PICCIRILLO JF, 2001, ADULT COMORBIDITY EV
   Schellongowski P, 2004, INTENS CARE MED, V30, P430, DOI 10.1007/s00134-003-2043-1
   Soares M, 2005, CRIT CARE MED, V33, P520, DOI 10.1097/01.ccm.0000155783.46747.04
   Soares M, 2006, CRIT CARE MED, V34, P715, DOI 10.1097/01.CCM.0000201883.05900.3F
   Soares M, 2005, INTENS CARE MED, V31, P408, DOI 10.1007/s00134-005-2554-z
   Soares M, 2007, INTENS CARE MED, V33, P1014, DOI 10.1007/s00134-007-0623-1
   Soares M, 2006, J CLIN ONCOL, V24, P4003, DOI 10.1200/JCO.2006.05.7869
   Staudinger T, 2000, CRIT CARE MED, V28, P1322, DOI 10.1097/00003246-200005000-00011
   Taccone FS, 2009, CRIT CARE, V13, DOI 10.1186/cc7713
   Thiery G, 2005, J CLIN ONCOL, V23, P4406, DOI 10.1200/JCO.2005.01.487
   Vandijck DM, 2008, INTENS CARE MED, V34, P847, DOI 10.1007/s00134-008-1002-2
   Vieira JM, 2007, CRIT CARE MED, V35, P184, DOI 10.1097/01.CCM.0000249828.81705.65
   Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0
   Zubrod C.G, 1960, J CHRON DIS, V11, P7, DOI DOI 10.1016/0021-9681(60)90137-5
NR 29
TC 186
Z9 198
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JAN
PY 2010
VL 38
IS 1
BP 9
EP 15
DI 10.1097/CCM.0b013e3181c0349e
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 539AE
UT WOS:000273224800003
PM 19829101
DA 2020-12-01
ER

PT J
AU Rodrigues, RS
   Carvalho, AR
   Morton, KA
   Bozza, FA
AF Rodrigues, Rosana S.
   Carvalho, Alysson R.
   Morton, Kathryn A.
   Bozza, Fernando A.
TI (18)-F-fluorodeoxyglucose positron emission tomography/computed
   tomography study in acute lung injury/acute respiratory distress
   syndrome
SO CRITICAL CARE MEDICINE
LA English
DT Letter
C1 [Rodrigues, Rosana S.] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
   [Carvalho, Alysson R.] Univ Fed Rio de Janeiro, Lab Respirat Physiol, Rio De Janeiro, Brazil.
   [Morton, Kathryn A.] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA.
RP Rodrigues, RS (corresponding author), Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
RI Carvalho, Alysson/AAF-1022-2019; Rodrigues, Rosana/N-9866-2013; Bozza,
   Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Carvalho,
   Alysson/0000-0003-2708-7735
CR Bellani G, 2009, CRIT CARE MED, V37, P2216, DOI 10.1097/CCM.0b013e3181aab31f
   de Abreu MG, 2008, CRIT CARE MED, V36, P818, DOI 10.1097/01.CCM.0000299736.55039.3A
   Jacene HA, 2004, CLIN NUCL MED, V29, P786, DOI 10.1097/00003072-200412000-00002
   Musch G, 2004, ANESTHESIOLOGY, V100, P323, DOI 10.1097/00000542-200402000-00022
   Rodrigues RS, 2008, INTENS CARE MED, V34, P2273, DOI 10.1007/s00134-008-1220-7
NR 5
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JAN
PY 2010
VL 38
IS 1
BP 347
EP 348
DI 10.1097/CCM.0b013e3181bfe7de
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 539AE
UT WOS:000273224800083
PM 20023508
DA 2020-12-01
ER

PT J
AU Assuncao-Miranda, I
   Amaral, FA
   Bozza, FA
   Fagundes, CT
   Sousa, LP
   Souza, DG
   Pacheco, P
   Barbosa-Lima, G
   Gomes, RN
   Bozza, PT
   Da Poian, AT
   Teixeira, MM
   Bozza, MT
AF Assuncao-Miranda, Iranaia
   Amaral, Flavio A.
   Bozza, Fernando A.
   Fagundes, Caio T.
   Sousa, Lirlandia P.
   Souza, Danielle G.
   Pacheco, Patricia
   Barbosa-Lima, Giselle
   Gomes, Rachel N.
   Bozza, Patricia T.
   Da Poian, Andrea T.
   Teixeira, Mauro M.
   Bozza, Marcelo T.
TI Contribution of macrophage migration inhibitory factor to the
   pathogenesis of dengue virus infection
SO FASEB JOURNAL
LA English
DT Article
DE MIF; cytokine; lipid droplets; inflammation; hemorrhagic fever; sepsis
ID FACTOR MIF; HEMORRHAGIC-FEVER; JAPANESE ENCEPHALITIS; CHEMOKINE
   RECEPTORS; DISEASE SEVERITY; INNATE IMMUNITY; REGULATORY ROLE;
   SHOCK-SYNDROME; SEPTIC SHOCK; SERUM-LEVELS
AB Dengue fever is an emerging viral disease transmitted by arthropods to humans in tropical countries. Dengue hemorrhagic fever (DHF) is escalating in frequency and mortality rates. Here we studied the involvement of macrophage migration inhibitory factor (MIF) in dengue virus (DENV) infection and its pathogenesis. Patients with DHF had elevated plasma concentrations of MIF. Both leukocytes from these patients and macrophages from healthy donors infected in vitro with DENV showed a substantial amount of MIF within lipid droplets. The secretion of MIF by macrophages and hepatocytes required a productive infection and occurred without an increase in gene transcription or cell death, thus indicating active secretion from preformed stocks. In vivo infection of wildtype and mif-deficient (Mif(-/-)) mice demonstrated a role of MIF in dengue pathogenesis. Clinical disease was less severe in Mif(-/-) mice, and they exhibited a significant delay in lethality, lower viremia, and lower viral load in the spleen than wild-type mice. This reduction in all parameters of severity on DENV infection in Mif(-/-) mice correlated with reduced proinflammatory cytokine concentrations. These results demonstrated the contribution of MIF to the pathogenesis of dengue and pointed to a possible beneficial role of neutralizing MIF as an adjunctive therapeutic approach to treat the severe forms of the disease.-Assuncao-Miranda, I., Amaral, F. A., Bozza, F. A., Fagundes, C. T., Sousa, L. P., Souza, D. G., Pacheco, P., Barbosa-Lima, G., Gomes, R. N., Bozza, P. T., Da Poian, A. T., Teixeira, M. M., Bozza, M. T. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J. 24, 218-228 (2010). www.fasebj.org
C1 [Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Assuncao-Miranda, Iranaia; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Programa Biol Estrutural, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Assuncao-Miranda, Iranaia; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
   [Amaral, Flavio A.; Fagundes, Caio T.; Souza, Danielle G.] Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
   [Pacheco, Patricia; Barbosa-Lima, Giselle; Gomes, Rachel N.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP Teixeira, MM (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Ave Antonio Carlos,6627 Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM mmtex@icb.ufmg.br; mtbozza@gmail.com
RI Da Poian, Andrea T./V-1699-2019; Gomes, Rachel N/I-7643-2013; Fagundes,
   Caio/AAK-9336-2020; Teixeira, Mauro M/A-4587-2008; Bozza, Fernando
   A/A-2618-2013; Amaral, Flavio/D-5489-2014; souza, danielle/D-3378-2014;
   Amaral, Flavio Almeida/C-3768-2018
OI Fagundes, Caio/0000-0002-6747-5233; Teixeira, Mauro
   M/0000-0002-6944-3008; Bozza, Fernando A/0000-0003-4878-0256; Amaral,
   Flavio/0000-0002-1695-0612; Amaral, Flavio Almeida/0000-0002-1695-0612;
   Bozza, Marcelo/0000-0003-3683-7550; Bozza, Patricia/0000-0001-8349-9529;
   Da Poian, Andrea/0000-0002-3969-704X
FU Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq;
   Brazil)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ; Brazil)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); National Institute of Science and
   Technology in Dengue (INCT-Dengue; Brazil)
FX This work was supported by Conselho de Desenvolvimento Cientifico e
   Tecnologico (CNPq;Brazil), Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ; Brazil), and National Institute of Science and
   Technology in Dengue (INCT-Dengue; Brazil).
CR Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011
   Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218
   Armstrong ME, 2008, J IMMUNOL, V180, P7125, DOI 10.4049/jimmunol.180.11.7125
   Arndt U, 2002, J VIROL, V76, P9298, DOI 10.1128/JVI.76.18.9298-9306.2002
   Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Bacher M, 2002, VIROLOGY, V299, P32, DOI 10.1006/viro.2002.1464
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   BOZZA PT, 2009, BIOCHIM BIOPHYS ACTA, V1791, P40
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   El-Bacha T, 2007, BBA-MOL BASIS DIS, V1772, P1158, DOI 10.1016/j.bbadis.2007.08.003
   Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1
   Flores M, 2008, FASEB J, V22, P3661, DOI 10.1096/fj.08-111666
   Frascaroli G, 2009, J IMMUNOL, V182, P477, DOI 10.4049/jimmunol.182.1.477
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guzman MG, 2008, T ROY SOC TROP MED H, V102, P522, DOI 10.1016/j.trstmh.2008.03.001
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Kimura K, 2006, CLIN VACCINE IMMUNOL, V13, P415, DOI 10.1128/CVI.13.3.415-419.2006
   Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699
   La Braga E, 2001, MEM I OSWALDO CRUZ, V96, P229, DOI 10.1590/S0074-02762001000200015
   Leng L, 2005, CRIT CARE MED, V33, pS475, DOI 10.1097/01.CCM.0000191278.04636.D8
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398
   Merk M, 2009, J IMMUNOL, V182, P6896, DOI 10.4049/jimmunol.0803710
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Paiva CN, 2009, J LEUKOCYTE BIOL, V85, P855, DOI 10.1189/jlb.0108009
   Pan American Health Organization, 2007, NUMB REP CAS DENG DE
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001
   Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020
   Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106
   Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4
   Sprong T, 2007, SHOCK, V27, P482, DOI 10.1097/01.shk.0000246898.65692.34
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Suzuki T, 2000, BBA-GENE STRUCT EXPR, V1517, P100, DOI 10.1016/S0167-4781(00)00262-1
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   *WHO, 2002, 117 WHO
   Zhang Wei, 2002, Hepatobiliary Pancreat Dis Int, V1, P577
NR 62
TC 89
Z9 90
U1 0
U2 11
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2010
VL 24
IS 1
BP 218
EP 228
DI 10.1096/fj.09-139469
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 539DL
UT WOS:000273233600023
PM 19776337
DA 2020-12-01
ER

PT J
AU Wang, LM
   Becker, JS
   Wu, Q
   Oliveira, MF
   Bozza, FA
   Schwager, AL
   Hoffman, JM
   Morton, KA
AF Wang, Li-Ming
   Becker, J. Sabine
   Wu, Qi
   Oliveira, Marcus F.
   Bozza, Fernando A.
   Schwager, Andrea L.
   Hoffman, John M.
   Morton, Kathryn A.
TI Bioimaging of copper alterations in the aging mouse brain by
   autoradiography, laser ablation inductively coupled plasma mass
   spectrometry and immunohistochemistry
SO METALLOMICS
LA English
DT Article
ID ALZHEIMERS; NEURONS; ZINC; AGE
AB Copper may play an important role in the brain in aging and neurodegenerative diseases. We compare the active Cu uptake, Cu-containing enzyme levels, and total Cu distribution in the brains of young and aging mice. Cu-67 was administered intravenously to 2, 7-9, and 14 month old mice. Active uptake of Cu-67 in the brain was measured at 24 h by digital phosphor autoradiography. Cerebral superoxide dismutase-1 (SOD-1) and cytochrome-C oxidase subunit-1 (CCO-1) levels were analyzed by immunohistochemistry. The total Cu distribution in brain section was determined by imaging laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). In aging mice, active Cu-67 uptake and SOD-1 levels were significantly decreased in the brain, whereas blood Cu-67 and CCO-1 levels were similar for all mice, irrespective of age. Paradoxically, global Cu cerebral content was increased in aged mice, suggesting that regulation of active Cu uptake by the brain may be linked to total Cu levels in an attempt to maintain Cu homeostasis. However, focal areas of both decreased Cu uptake and Cu content were noted in the striatum and ventral cortex in aging mice. These focal areas of Cu deficit correspond to the regions of greatest reduction in SOD-1 in the aged mice. In aging, dysregulated Cu homeostasis may result in decreased SOD-1 levels, which may contribute to oxidative vulnerability of the aging brain. This study illustrates the importance of a multi-modality approach in studying the biodistribution and homeostasis of Cu in the brain.
C1 [Becker, J. Sabine] Res Ctr Juelich, Cent Div Analyt Chem, D-52425 Julich, Germany.
   [Wang, Li-Ming; Wu, Qi; Hoffman, John M.; Morton, Kathryn A.] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Nacl Biol Estrutural Bioimagem INBEB, Lab Bioquim Redox, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.; Bozza, Fernando A.] Univ Fed Rio de Janeiro, Lab Associado Inflamacao & Metab, INBEB, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Univ Fed Rio de Janeiro, Inst Pesquisa Clin Evandro Chagas, Fundacao Oswaldo Cruz, INBEB, Rio De Janeiro, Brazil.
   [Schwager, Andrea L.] Univ Utah, Grad Program Neurosci, Salt Lake City, UT USA.
   [Hoffman, John M.] Univ Utah, Dept Neurol, Salt Lake City, UT USA.
RP Becker, JS (corresponding author), Res Ctr Juelich, Cent Div Analyt Chem, D-52425 Julich, Germany.
EM s.becker@fz-juelich.de
RI Bozza, Fernando A/A-2618-2013; Oliveira, Marcus/G-3158-2011
OI Bozza, Fernando A/0000-0003-4878-0256; Oliveira,
   Marcus/0000-0002-9890-8425
FU NIBIB/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Biomedical
   Imaging & Bioengineering (NIBIB) [EB 005728]; CNPq through Institutos
   Nacionais de Ciencia e Tecnologia; FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); ICGEB;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Biomedical Imaging & Bioengineering
   (NIBIB) [R21EB005728, R21EB005728] Funding Source: NIH RePORTER
FX Supported by grants from the NIBIB/NIH (EB 005728) and CNPq (through
   Institutos Nacionais de Ciencia e Tecnologia 2008), FAPERJ (MFO and FAB
   through Jovens Cientistas do Nosso Estado and Edital de Apoio a Grupos
   Emergentes de Pesquisa do Rio de Janeiro) and ICGEB. MFO and FAB are
   research scholars from CNPq.
CR Becker J.S., 2007, INORGANIC MASS SPECT
   Becker JS, 2010, METALLOMICS, V2, P104, DOI 10.1039/b916722f
   Becker JS, 2010, MASS SPECTROM REV, V29, P156, DOI 10.1002/mas.20239
   Becker JS, 2009, CHEM SOC REV, V38, P1969, DOI 10.1039/b618635c
   Bush AI, 2008, NEUROTHERAPEUTICS, V5, P421, DOI 10.1016/j.nurt.2008.05.001
   Choi BS, 2009, BRAIN RES, V1248, P14, DOI 10.1016/j.brainres.2008.10.056
   GUPTA A, 1991, GERONTOLOGY, V37, P305, DOI 10.1159/000213277
   Horning MS, 2001, J NEUROPHYSIOL, V86, P1652
   Kaler SG, 1998, AM J CLIN NUTR, V67, p1029S, DOI 10.1093/ajcn/67.5.1029S
   Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640
   KOZMA M, 1981, ACTA HISTOCHEM, V69, P12, DOI 10.1016/S0065-1281(81)80003-7
   Liu GJ, 2006, J STRUCT BIOL, V155, P45, DOI 10.1016/j.jsb.2005.12.011
   MASSIE HR, 1979, MECH AGEING DEV, V10, P93, DOI 10.1016/0047-6374(79)90073-3
   Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004
   Schlief ML, 2006, MOL NEUROBIOL, V33, P81, DOI 10.1385/MN:33:2:81
   Sigel A, 2006, NEURODEGENERATIVE DI
   SU J, 2008, TALANTA, V76, P1183
   SU J, 2007, J ANAL ATOM SPECTROM, V22, P63
   Treiber C, 2004, J BIOL CHEM, V279, P51958, DOI 10.1074/jbc.M407410200
   Zatta P, 2007, BRAIN RES REV, V54, P19, DOI 10.1016/j.brainresrev.2006.10.001
NR 20
TC 39
Z9 41
U1 2
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1756-5901
EI 1756-591X
J9 METALLOMICS
JI Metallomics
PY 2010
VL 2
IS 5
BP 348
EP 353
DI 10.1039/c003875j
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 594UI
UT WOS:000277564000006
PM 21072380
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Dal-Pizzol, F
   Mello, PVC
   Friedman, G
   Silva, E
   Teles, JMM
   Lobo, SMA
   Bozza, FA
   Soares, M
AF Salluh, Jorge I. F.
   Dal-Pizzol, Felipe
   Mello, Patricia V. C.
   Friedman, Gilberto
   Silva, Eliezer
   Teles, Jose Mario M.
   Lobo, Suzana M. A.
   Bozza, Fernando A.
   Soares, Marcio
CA BRICNet
TI Delirium recognition and sedation practices in critically ill patients:
   A survey on the attitudes of 1015 Brazilian critical care physicians
SO JOURNAL OF CRITICAL CARE
LA English
DT Article
DE Delirium; Sedation; Mechanical ventilation; Critically ill patients;
   Acute brain dysfunction
ID MECHANICALLY VENTILATED PATIENTS; NEUROMUSCULAR BLOCKING-AGENTS;
   POSTTRAUMATIC-STRESS-DISORDER; UNIT PATIENTS; CRITICAL ILLNESS;
   NATIONAL-SURVEY; RISK-FACTORS; ANALGESICS; SYMPTOMS; BRAIN
AB Purpose: The aim of the study was to characterize the practices of Brazilian ICU physicians toward sedation and delirium.
   Materials and Methods: A cross-sectional survey was conducted among a convenience sample of critical care physicians between April and June 2008.
   Results: One thousand fifteen critical care physicians responded. Sedation scoring systems were used by 893 (88.3%) of the respondents. The Ramsay and Richmond Agitation-Sedation Scale were used by 81.9% and 6.8% of the respondents, respectively. Most respondents did not discuss sedation targets (62.8%) or practice daily sedative interruption (68.3%) in most patients. More than half of the respondents (52.7%) used a sedation protocol, and the most used sedatives were midazolam (97.8%), fentanyl (91.5%), and propofol (55%). A significant rate of the respondents (42.7%) estimated that more than 25% of patients under mechanical ventilation have delirium, but 53.5% occasionally assessed patients for delirium. Thirteen percent used specific delirium scales, with the Confusion Assessment Method for intensive care unit (ICU) being the most applied. Delirium was often treated with haloperidol (88.1%); however, atypical antipsychotics (36.3%) and benzodiazepines (42.3%) were also used.
   Conclusions: Despite the recent advances in knowledge of sedation and delirium, most of them are still not translated into clinical practice. Significant variation in practice is observed among ICU physicians and represents a potential target for future research and educational interventions. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Salluh, Jorge I. F.] Hosp Canc I, Inst Nacl Canc, INCA, Ctr Tratamento Intens,Med Surg Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
   [Dal-Pizzol, Felipe] Univ Extremo Catarinense, Unidade Acad Ciencias Saude, Programa Posgrad Ciencias Saude, Lab Fisiopatol Expt, BR-20230130 Criciuma, Brazil.
   [Mello, Patricia V. C.] Univ Estadual Piaui, Intens Care Unit, Teresina, Brazil.
   [Friedman, Gilberto] Univ Fed Ciencias Saude Porto Alegre, Curso Med, Dept Med Interna, BR-20230130 Porto Alegre, RS, Brazil.
   [Silva, Eliezer] Univ Sao Paulo, BR-20230130 Sao Paulo, Brazil.
   [Teles, Jose Mario M.] Hosp Portugues, Intens Care Unit, BR-20230130 Salvador, BA, Brazil.
   [Lobo, Suzana M. A.] Sch Med, Dept Internal Med, Div Crit Care Med, BR-20230130 Sao Paulo, Brazil.
   [Lobo, Suzana M. A.] Hosp Base, BR-20230130 Sao Paulo, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Hosp Canc I, Inst Nacl Canc, INCA, Ctr Tratamento Intens,Med Surg Intens Care Unit, 10 Andar,Pca Cruz Vermelha 23, BR-20230130 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI Salluh, Jorge IF/F-6779-2012; Bozza, Fernando A/A-2618-2013; Soares,
   Marcio/B-3083-2013; Friedman, Gilberto/F-7208-2015; dantas, vicente c
   souza/L-2648-2013; Friedman, Gilberto/F-7212-2015; Dal-Pizzol,
   Felipe/F-2756-2015
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Friedman, Gilberto/0000-0001-9369-2488;
   Dal-Pizzol, Felipe/0000-0003-3003-8977; Salluh,
   Jorge/0000-0002-8164-1453
CR Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12
   Cheung CZ, 2008, INTENS CARE MED, V34, P437, DOI 10.1007/s00134-007-0947-x
   Christensen BV, 1999, INTENS CARE MED, V25, P186, DOI 10.1007/s001340050814
   d'Avila JC, 2008, CRIT CARE MED, V36, P1925, DOI 10.1097/CCM.0b013e3181760c4b
   Devlin JW, 2007, CRIT CARE MED, V35, P2721, DOI 10.1097/01.CCM.0000292011.93074.82
   Ely EW, 2007, CRIT CARE MED, V35, P112, DOI 10.1097/01.CCM.0000251925.18961.CA
   Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
   Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC
   Girard TD, 2007, CRIT CARE, V11, DOI 10.1186/cc5708
   Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707
   Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020
   Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002
   Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC
   Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1
   Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92
   Morandi A, 2008, INTENSIVE CARE MED
   Ouimet S, 2007, INTENS CARE MED, V33, P1007, DOI 10.1007/s00134-007-0618-y
   Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8
   Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005
   Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d
   Pandharipande P, 2007, INTENS CARE MED, V33, P1726, DOI 10.1007/s00134-007-0687-y
   Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644
   Patel RP, 2009, CRIT CARE MED, V37, P825, DOI 10.1097/CCM.0b013e31819b8608
   Reschreiter H, 2008, CRIT CARE, V12, DOI 10.1186/cc7141
   Weinert CR, 2003, AM J RESP CRIT CARE, V167, P1304, DOI 10.1164/rccm.200205-478OC
NR 25
TC 45
Z9 58
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0883-9441
J9 J CRIT CARE
JI J. Crit. Care
PD DEC
PY 2009
VL 24
IS 4
BP 556
EP 562
DI 10.1016/j.jcrc.2009.04.004
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 527XJ
UT WOS:000272404200014
PM 19577412
DA 2020-12-01
ER

PT J
AU Albuquerque, LM
   Trugilho, MRO
   Chapeaurouge, A
   Jurgilas, PB
   Bozza, PT
   Bozza, FA
   Perales, J
   Neves-Ferreira, AGC
AF Albuquerque, Lidiane M.
   Trugilho, Monique R. O.
   Chapeaurouge, Alex
   Jurgilas, Patricia B.
   Bozza, Patricia T.
   Bozza, Fernando A.
   Perales, Jonas
   Neves-Ferreira, Ana G. C.
TI Two-Dimensional Difference Gel Electrophoresis (DiGE) Analysis of
   Plasmas from Dengue Fever Patients
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE dengue fever; plasma; proteome; DIGE
ID D-BINDING PROTEIN; HEMORRHAGIC-FEVER; PROTEOMIC ANALYSIS; SHOCK
   SYNDROME; ALPHA-1-ACID GLYCOPROTEIN; BIOMARKER DISCOVERY;
   MASS-SPECTROMETRY; GENE-EXPRESSION; VIRUS-INFECTION; HEPG2 CELLS
AB Dengue fever is the world's most important arthropod-born viral disease affecting humans. To contribute to a better understanding of its pathogenesis, this study aims to identify proteins differentially expressed in plasmas from severe dengue fever patients relative to healthy donors, The use of 2-D Fluorescence Difference Gel Electrophoresis to analyze plasmas depleted of six high-abundance proteins (albumin, IgG, antitrypsin, IgA, transferrin and haptoglobin) allowed for the detection of 73 differentially expressed protein spots (n = 13, p < 0.01), of which 37 could be identified by mass spectrometry. These 37 spots comprised a total of 14 proteins, as follows: 7 had increased expression in plasmas from dengue fever patients (C1 inhibitor, alpha 1-antichymotrypsin, vitamin D-binding protein, fibrinogen gamma-chain, alpha 1-acid glycoprotein, apolipoprotein J and complement component C3c), while 7 others had decreased expression in the same samples (alpha-2 macroglobulin, prothrombin, histidine-rich glycoprotein, apolipoproteins A-IV and A-I, transthyretin and complement component C3b). The possible involvement of these proteins in the inflammatory process triggered by dengue virus infection and in the repair mechanisms of vascular damage occurring in this pathology is discussed in this study.
C1 [Albuquerque, Lidiane M.; Trugilho, Monique R. O.; Chapeaurouge, Alex; Jurgilas, Patricia B.; Perales, Jonas; Neves-Ferreira, Ana G. C.] Fiocruz MS, Lab Toxinol, BR-21040900 Rio De Janeiro, Brazil.
   [Bozza, Patricia T.] Fiocruz MS, Lab Imunofarmacol, BR-21040900 Rio De Janeiro, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21040900 Rio De Janeiro, Brazil.
   [Trugilho, Monique R. O.; Chapeaurouge, Alex; Jurgilas, Patricia B.; Perales, Jonas; Neves-Ferreira, Ana G. C.] Rede Prote Rio de Janeiro, Rio De Janeiro, Brazil.
RP Neves-Ferreira, AGC (corresponding author), Fiocruz MS, Lab Toxinol, Av Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM anag@ioc.fiocruz.br
RI Bozza, Fernando A/A-2618-2013; Neves-Ferreira, Ana Gisele C./N-3596-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Neves-Ferreira, Ana Gisele
   C./0000-0002-7863-9512; Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientffico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Rede Proteomica do Rio de Janeiro/Fundacao Carlos Chagas Filho
   de Amparo A Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Fundacao Oswaldo Cruz/PDTIS, Brazil
FX This study was supported by grants from Conselho Nacional de
   Desenvolvimento Cientffico e Tecnologico (CNPq), Rede Proteomica do Rio
   de Janeiro/Fundacao Carlos Chagas Filho de Amparo A Pesquisa do Estado
   do Rio de Janeiro (FAPERJ) and Fundacao Oswaldo Cruz/PDTIS, Brazil. The
   authors thank Simone de Amorim Chermont, from Laboratorio de
   Toxinologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil
   (IOC), for technical assistance, and Bruno Eschenazi, Heloisa Maria
   Nogueira Diniz and Genilton Jose Vieira from Servico de Producao e
   Tratamento de Imagens-IOC, for preparing high resolution figures for
   publication. We are grateful to Dr. Claire F. Kubelka, from Laboratorio
   de Imunologia Viral and Dr. Rita M. R. Nogueira, from Laboratorio de
   Flavivirus, IOC, for conducting dengue serological testing.
CR Alban A, 2003, PROTEOMICS, V3, P36, DOI 10.1002/pmic.200390006
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   ANTON ARS, 2006, PESQ BRAS ODONTOPED, V6, P295
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   Blank M, 2008, CLIN REV ALLERG IMMU, V34, P307, DOI 10.1007/s12016-007-8058-6
   BORISH L, 1992, INFLAMMATION, V16, P471, DOI 10.1007/BF00918973
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6
   Brown JH, 2000, P NATL ACAD SCI USA, V97, P85, DOI 10.1073/pnas.97.1.85
   Calero M, 1999, BIOCHEM J, V344, P375, DOI 10.1042/0264-6021:3440375
   Carvalho PC, 2008, J PROTEOMICS, V71, P486, DOI 10.1016/j.jprot.2008.06.015
   Chromy BA, 2004, J PROTEOME RES, V3, P1120, DOI 10.1021/pr049921p
   Corzett TH, 2006, J PROTEOME RES, V5, P2611, DOI 10.1021/pr060100p
   Davis AE, 2007, IMMUNOBIOLOGY, V212, P313, DOI 10.1016/j.imbio.2006.10.003
   de Kruif MD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000215
   DEBOER JP, 1993, INFECT IMMUN, V61, P5035, DOI 10.1128/IAI.61.12.5035-5043.1993
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Farrell DH, 2004, CURR OPIN HEMATOL, V11, P151, DOI 10.1097/01.moh.0000131440.02397.a4
   Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9
   French K, 2008, BIOCHEMISTRY-US, V47, P1176, DOI 10.1021/bi701976f
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Gomme PT, 2004, TRENDS BIOTECHNOL, V22, P340, DOI 10.1016/j.tibtech.2004.05.001
   Good DM, 2007, J PROTEOME RES, V6, P4549, DOI 10.1021/pr070529w
   Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   Hjerno Karin, 2007, Methods Mol Biol, V367, P61
   Honsawek S, 2007, J INFECTION, V54, P225, DOI 10.1016/j.jinf.2006.06.002
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   Jiang Zhenyou, 2007, J Infect, V55, pe23, DOI 10.1016/j.jinf.2007.04.351
   Johnson AM, 2007, CLIN CHEM LAB MED, V45, P419, DOI 10.1515/CCLM.2007.051
   Kim SS, 2007, J PROTEOME RES, V6, P180, DOI 10.1021/pr060323f
   Kurane I, 2007, COMP IMMUNOL MICROB, V30, P329, DOI 10.1016/j.cimid.2007.05.010
   LaBaer J, 2005, J PROTEOME RES, V4, P1053, DOI 10.1021/pr0501259
   Lescuyer P, 2007, J PROTEOME RES, V6, P3371, DOI 10.1021/pr0702060
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Liu LY, 2007, CANCER SCI, V98, P1617, DOI 10.1111/j.1349-7006.2007.00576.x
   Loke H, 2002, AM J TROP MED HYG, V67, P102, DOI 10.4269/ajtmh.2002.67.102
   Manolov T, 2008, J IMMUNOL METHODS, V333, P180, DOI 10.1016/j.jim.2007.12.012
   Marouga R, 2005, ANAL BIOANAL CHEM, V382, P669, DOI 10.1007/s00216-005-3126-3
   Matsumoto K, 2007, BIOL PHARM BULL, V30, P1226, DOI 10.1248/bpb.30.1226
   Medzihradszky KF, 2005, METHOD ENZYMOL, V402, P209, DOI 10.1016/S0076-6879(05)02007-0
   Mestriner FLAC, 2007, P NATL ACAD SCI USA, V104, P19595, DOI 10.1073/pnas.0709681104
   Miagostovich Mariz P., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P149, DOI 10.1590/S0036-46651993000200006
   Miagostovich MP, 1997, MEM I OSWALDO CRUZ, V92, P595, DOI 10.1590/S0074-02761997000500006
   *MIN SAUD, 2008, SECR VIG SAN BRASLL
   Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Navarro MA, 2005, CYTOKINE, V31, P52, DOI 10.1016/j.cyto.2005.03.002
   Navarro-Sanchez E, 2005, ARCH MED RES, V36, P425, DOI 10.1016/j.arcmed.2005.04.007
   Nielsen EW, 2007, MOL IMMUNOL, V44, P1819, DOI 10.1016/j.molimm.2006.10.003
   Omenn GS, 2005, PROTEOMICS, V5, P3226, DOI 10.1002/pmic.200500358
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Pattanakitsakul S, 2007, J PROTEOME RES, V6, P4592, DOI 10.1021/pr070366b
   Petrak J, 2008, PROTEOMICS, V8, P1744, DOI 10.1002/pmic.200700919
   Rabilloud T., 2000, PROTEOME RES 2 DIMEN, P107, DOI DOI 10.1007/978-3-642-57105-3_5
   Recalde D, 2004, ARTERIOSCL THROM VAS, V24, P756, DOI 10.1161/01.ATV.0000119353.03690.22
   Righetti PG, 2005, CLIN CHIM ACTA, V357, P123, DOI 10.1016/j.cccn.2005.03.018
   Rydengard V, 2007, FEBS J, V274, P377, DOI 10.1111/j.1742-4658.2006.05586.x
   Seneviratne SL, 2006, T ROY SOC TROP MED H, V100, P608, DOI 10.1016/j.trstmh.2005.10.007
   Setiati TE, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-22
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Singhi S, 2007, J PEDIAT-BRAZIL, V83, pS22, DOI 10.1590/S0021-75572007000300004
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Speeckaert M, 2006, CLIN CHIM ACTA, V372, P33, DOI 10.1016/j.cca.2006.03.011
   Speicher K D, 2000, J Biomol Tech, V11, P74
   Stead DA, 2006, MOL CELL PROTEOMICS, V5, P1205, DOI 10.1074/mcp.M500426-MCP200
   STONE KL, 1993, PRACTICAL GUIDE PROT, P43
   Tannu NS, 2006, NAT PROTOC, V1, P1732, DOI 10.1038/nprot.2006.256
   Thayan R, 2009, T ROY SOC TROP MED H, V103, P413, DOI 10.1016/j.trstmh.2008.12.018
   Tsuchida-Straeten N, 2005, J THROMB HAEMOST, V3, P865, DOI 10.1111/j.1538-7836.2005.01238.x
   Ubol S, 2008, J INFECT DIS, V197, P1459, DOI 10.1086/587699
   Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133
   Van Lenten BJ, 2001, CIRCULATION, V103, P2283
   Wan J, 2006, PROTEOMICS, V6, P2886, DOI 10.1002/pmic.200500638
   Wang ZY, 2007, J MOL BIOL, V371, P323, DOI 10.1016/j.jmb.2007.05.049
   White IR, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-33
   Wijte D, 2006, J PROTEOME RES, V5, P2033, DOI 10.1021/pr060076f
   Wills BA, 2002, CLIN INFECT DIS, V35, P277, DOI 10.1086/341410
   Zolg W, 2006, MOL CELL PROTEOMICS, V5, P1720, DOI 10.1074/mcp.R600001-MCP200
   Zolotarjova N, 2005, PROTEOMICS, V5, P3304, DOI 10.1002/pmic.200402021
NR 82
TC 35
Z9 36
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD DEC
PY 2009
VL 8
IS 12
BP 5431
EP 5441
DI 10.1021/pr900236f
PG 11
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 527AV
UT WOS:000272339100003
PM 19845402
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Medeiros, DM
   Bernal, H
   Mesquita, EC
   Amancio, RT
   Japiassu, AM
AF Bozza, F. A.
   Medeiros, D. M.
   Bernal, H.
   Mesquita, E. C.
   Amancio, R. T.
   Japiassu, A. M.
TI LOOKING AT PIRO FACTORS FOR AIDS PATIENTS WITH SEPTIC SHOCK
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 22nd Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 11-14, 2009
CL Vienna, AUSTRIA
SP European Soc Intens Gare Med
C1 [Bozza, F. A.; Medeiros, D. M.; Bernal, H.; Mesquita, E. C.; Amancio, R. T.; Japiassu, A. M.] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2009
VL 35
MA 0321
BP 85
EP 85
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 482QA
UT WOS:000268902600322
DA 2020-12-01
ER

PT J
AU Rotman, V
   Bozza, FA
   Carvalho, A
   Rodrigues, R
   Carvalho, CRR
AF Rotman, V.
   Bozza, F. A.
   Carvalho, A.
   Rodrigues, R.
   Carvalho, C. R. R.
TI EFFECTS OF OPEN LUNG APPROACH FOLLOWING ARDSNET VENTILATORY STRATEGY IN
   PATIENTS WITH EARLY ALI/ARDS
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 22nd Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 11-14, 2009
CL Vienna, AUSTRIA
SP European Soc Intens Gare Med
C1 [Rotman, V.] Hosp Copa D Or, Rio De Janeiro, Brazil.
   [Bozza, F. A.] IPEC, Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Carvalho, A.] Univ Fed Rio de Janeiro, Inst Biofis, Rio De Janeiro, Brazil.
   [Carvalho, C. R. R.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Rodrigues, Rosana/N-9866-2013; Bozza, Fernando A/A-2618-2013; Carvalho,
   Alysson/AAF-1022-2019; rotman, vivian/AAF-9140-2020
OI Bozza, Fernando A/0000-0003-4878-0256; 
CR Grasso S, 2002, ANESTHESIOLOGY, V96, P795, DOI 10.1097/00000542-200204000-00005
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2009
VL 35
MA 0875
BP 226
EP 226
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 482QA
UT WOS:000268902600876
DA 2020-12-01
ER

PT J
AU Soares, M
   Caruso, P
   Silva, E
   Telles, JM
   Lobo, SM
   Friedman, G
   Mello, P
   dal Pizzol, F
   Bozza, FA
   Silva, U
   Salluh, J
AF Soares, M.
   Caruso, P.
   Silva, E.
   Telles, J. M.
   Lobo, S. M.
   Friedman, G.
   Mello, P.
   dal Pizzol, F.
   Bozza, F. A.
   Silva, U.
   Salluh, J.
CA BRICNet
TI CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CANCER REQUIRING ADMISSION
   TO INTENSIVE CARE UNITS: A PROSPECTIVE MULTICENTER STUDY
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 22nd Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 11-14, 2009
CL Vienna, AUSTRIA
SP European Soc Intens Gare Med
C1 [Soares, M.; Salluh, J.] ICU, Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Soares, M.; Caruso, P.; Silva, E.; Telles, J. M.; Lobo, S. M.; Friedman, G.; Mello, P.; dal Pizzol, F.; Bozza, F. A.; Silva, U.; Salluh, J.] BRICNet, Rio De Janeiro, Brazil.
RI Dal-Pizzol, Felipe/F-2756-2015; Salluh, Jorge IF/F-6779-2012; Bozza,
   Fernando A/A-2618-2013; V.A.Silva, Ulysses/AAZ-3336-2020; Caruso,
   Pedro/B-6054-2016; dantas, vicente c souza/L-2648-2013; Soares,
   Marcio/B-3083-2013; Friedman, Gilberto/F-7212-2015; Friedman,
   Gilberto/F-7208-2015
OI Dal-Pizzol, Felipe/0000-0003-3003-8977; Bozza, Fernando
   A/0000-0003-4878-0256; V.A.Silva, Ulysses/0000-0002-1284-2016; Caruso,
   Pedro/0000-0002-1051-8458; Soares, Marcio/0000-0003-2503-6088; Friedman,
   Gilberto/0000-0001-9369-2488; Salluh, Jorge/0000-0002-8164-1453
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2009
VL 35
MA 1137
BP 292
EP 292
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 482QA
UT WOS:000268902601138
DA 2020-12-01
ER

PT J
AU Rodrigues, RS
   Bozza, FA
   Christian, PE
   Hoffman, JM
   Butterfield, RI
   Christensen, CR
   Heilbrun, M
   Wiggins, RH
   Hunt, JP
   Bentz, BG
   Hitchcock, YJ
   Morton, KA
AF Rodrigues, Rosana S.
   Bozza, Fernando A.
   Christian, Paul E.
   Hoffman, John M.
   Butterfield, Regan I.
   Christensen, Carl R.
   Heilbrun, Marta
   Wiggins, Richard H., III
   Hunt, Jason P.
   Bentz, Brandon G.
   Hitchcock, Ying J.
   Morton, Kathryn A.
TI Comparison of Whole-Body PET/CT, Dedicated High-Resolution Head and Neck
   PET/CT, and Contrast-Enhanced CT in Preoperative Staging of Clinically
   M0 Squamous Cell Carcinoma of the Head and Neck
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE positron emission tomography; computed tomography; head and neck cancer;
   squamous cell carcinoma; tumor staging
ID POSITRON-EMISSION-TOMOGRAPHY; FDG-PET/CT; COMPUTED-TOMOGRAPHY;
   DIAGNOSTIC-ACCURACY; IMAGING MODALITIES; F-18-FDG PET; ORAL-CAVITY;
   CANCER; IMPACT; TUMORS
AB The purpose of this study was to compare optimized whole-body (WB) and dedicated high-resolution contrast-enhanced PET/CT protocols and contrast enhanced CT in the preoperative staging of primary squamous cell carcinoma of the head and neck. Methods: A total of 44 patients with clinically M0 squamous cell carcinoma of the head and neck underwent primary tumor resection and neck dissection within 6 wk of diagnostic imaging. Imaging consisted of a standard WB PET/CT protocol without intravenous contrast enhancement, followed by a high-resolution dedicated head and neck (HN) PET/CT protocol, which included diagnostic-quality contrast-enhanced CT (CECT). Imaging results were compared with histopathology. A 5-point scale was used to designate primary tumor localization and the presence of lymph node metastasis on a per-patient and per-level basis. For cervical nodes, receiver-operating-characteristic curves were generated to determine the differences in performance between the WB and HN PET/CT protocols and CECT. Sensitivity, specificity, positive and negative predictive values, and accuracy were calculated for primary tumor and cervical nodes. Results: No statistical difference was observed between WB and HN PET/CT protocols, both of which significantly outperformed CECT, in the evaluation of the primary tumor. The performance of the HN PET/CT protocol was superior to that of the WB PET/CT in the detection of cervical node metastases, achieving statistical significance on a per-level basis and approaching significance on a per-patient basis, with the greatest advantage in the detection of small positive lymph nodes (<15 mm). No significant difference was observed between the WB PET/CT protocol and CECT in nodal staging, either on a per-patient or on a per-level basis. Conclusion: The primary advantage of the dedicated HN PET/CT protocol over the WB protocol or CECT in the staging of head and neck cancer is in the detection of small lymph node metastases.
C1 [Hoffman, John M.; Christensen, Carl R.; Heilbrun, Marta; Wiggins, Richard H., III; Morton, Kathryn A.] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA.
   [Rodrigues, Rosana S.] Univ Fed Rio de Janeiro, Biomaging INBEB, Rio De Janeiro, Brazil.
   [Rodrigues, Rosana S.] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Natl Inst Sci & Technol Struct Biol, Rio De Janeiro, Brazil.
   [Christian, Paul E.; Butterfield, Regan I.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84132 USA.
   [Hunt, Jason P.; Bentz, Brandon G.] Univ Utah, Dept Surg, Div Otolaryngol Head & Neck Surg, Salt Lake City, UT 84132 USA.
   [Hitchcock, Ying J.] Univ Utah, Dept Radiat Oncol, Salt Lake City, UT 84132 USA.
RP Morton, KA (corresponding author), Univ Utah, Dept Radiol, 1A71 SOM,50 N Med Dr, Salt Lake City, UT 84132 USA.
EM kathryn.morton@hsc.utah.edu
RI Heilbrun, Marta/AAZ-4640-2020; Bozza, Fernando A/A-2618-2013; Rodrigues,
   Rosana/N-9866-2013
OI Bozza, Fernando A/0000-0003-4878-0256; 
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Pesquisa (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX This work was supported in part by a Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES) fellowship and a Conselho Nacional de
   Pesquisa (CNPq) fellowship.
CR Aassar OS, 1999, RADIOLOGY, V210, P177, DOI 10.1148/radiology.210.1.r99ja48177
   Agarwal V, 2008, OTOLARYNG CLIN N AM, V41, P23, DOI 10.1016/j.otc.2007.10.005
   Branstetter BF, 2005, RADIOLOGY, V235, P580, DOI 10.1148/radiol.2352040134
   de Bondt RBJ, 2007, EUR J RADIOL, V64, P266, DOI 10.1016/j.ejrad.2007.02.037
   Di Martino E, 2000, ARCH OTOLARYNGOL, V126, P1457, DOI 10.1001/archotol.126.12.1457
   Ekberg T, 2007, ACTA OTO-LARYNGOL, V127, P186, DOI 10.1080/00016480600801407
   Fleming AJ, 2007, LARYNGOSCOPE, V117, P1173, DOI 10.1097/MLG.0b013e31805d017b
   Goerres GW, 2003, ORAL ONCOL, V39, P547, DOI 10.1016/S1368-8375(03)00016-2
   Goerres GW, 2004, ARCH OTOLARYNGOL, V130, P105, DOI 10.1001/archotol.130.1.105
   Gordin A, 2006, LARYNGOSCOPE, V116, P273, DOI 10.1097/01.mlg.0000197930.93582.32
   Gordin A, 2007, OTOLARYNG HEAD NECK, V137, P130, DOI 10.1016/j.otohns.2007.02.001
   Goshen E, 2005, INT J ORAL MAX SURG, V34, P386, DOI 10.1016/j.ijom.2004.08.007
   Hain SF, 2005, BRIT J ORAL MAX SURG, V43, P1, DOI 10.1016/j.bjoms.2004.09.006
   Hustinx R, 1999, EUR J NUCL MED, V26, P1345, DOI 10.1007/s002590050593
   Ishimori T, 2005, J NUCL MED, V46, P752
   Kim SY, 2007, ANN ONCOL, V18, P1698, DOI 10.1093/annonc/mdm270
   Kitagawa Y, 2002, ORAL SURG ORAL MED O, V93, P202, DOI 10.1067/moe.2002.121386
   Lan XL, 2008, CLIN RADIOL, V63, P756, DOI 10.1016/j.crad.2008.01.003
   McCollum AD, 2004, HEAD NECK-J SCI SPEC, V26, P890, DOI 10.1002/hed.20080
   Nabili V, 2007, AM J OTOLARYNG, V28, P153, DOI 10.1016/j.amjoto.2006.08.001
   Ng SH, 2005, J NUCL MED, V46, P1136
   Schoder H, 2004, RADIOLOGY, V231, P65, DOI 10.1148/radiol.2311030271
   Schwartz DL, 2004, ARCH OTOLARYNGOL, V130, P1361, DOI 10.1001/archotol.130.12.1361
   Scott AM, 2008, J NUCL MED, V49, P1593, DOI 10.2967/jnumed.108.053660
   Sigg MB, 2003, J ORAL MAXIL SURG, V61, P1022, DOI 10.1016/S0278-2391(03)00314-8
   Veit-Haibach P, 2007, EUR J NUCL MED MOL I, V34, P1953, DOI 10.1007/s00259-007-0564-5
   Yamamoto Y, 2007, RADIOLOGY, V244, P263, DOI 10.1148/radiol.2433060043
   Zhuang HM, 2001, J NUCL MED, V42, P1412
   Zytoon AA, 2008, CLIN RADIOL, V63, P1213, DOI 10.1016/j.crad.2008.03.014
NR 29
TC 64
Z9 64
U1 0
U2 4
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD AUG
PY 2009
VL 50
IS 8
BP 1205
EP 1213
DI 10.2967/jnumed.109.062075
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 529VX
UT WOS:000272548100008
PM 19617339
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Salluh, JIF
   Bozza, PT
   Bozza, FA
   Castro-Faria-Neto, HC
AF Japiassu, Andre M.
   Salluh, Jorge I. F.
   Bozza, Patricia T.
   Bozza, Fernando A.
   Castro-Faria-Neto, Hugo C.
TI Revisiting steroid treatment for septic shock: molecular actions and
   clinical effects - A review
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Review
DE sepsis; septic shock; glucocorticoids; therapeutics; bacterial
   infections
ID RESPIRATORY-DISTRESS-SYNDROME; COMMUNITY-ACQUIRED PNEUMONIA; ACUTE LUNG
   INJURY; INDUCED LEUCINE-ZIPPER; FACTOR-KAPPA-B; MEMBRANE
   GLUCOCORTICOID-RECEPTORS; RELATIVE ADRENAL INSUFFICIENCY; SENSITIVE
   POTASSIUM CHANNELS; HIGH-DOSE METHYLPREDNISOLONE; RANDOMIZED
   CONTROLLED-TRIAL
AB Corticosteroids are widely used to treat a diversity of pathological conditions including allergic, autoimmune and some infectious diseases. These drugs have complex mechanisms of action involving both genomic and non-genomic mechanisms and interfere with different signal transduction pathways in the cell. The use of corticosteroids to treat critically ill patients with acute respiratory distress syndrome and severe infections, such as sepsis and pneumonia, is still a matter of intense debate in the scientific and medical community with evidence both for and against its use in these patients. Here, we review the basic molecular mechanisms important for corticosteroid action as well as current evidence for their use, or not, in septic patients. We also present an analysis of the reasons why this is still such a controversial point in the literature.
C1 [Japiassu, Andre M.; Salluh, Jorge I. F.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Inst Pesquisa Clin Evandro Chagas Fiocruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Japiassu, Andre M.; Bozza, Fernando A.] Inst Pesquisa Clin Evandro Chagas Fiocruz, Unidade Terapia Intens, BR-21045900 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.] Inst Nacl Cancer, Unidade Terapia Intens, Rio De Janeiro, Brazil.
   [Japiassu, Andre M.] Casa Saude Sao Jose, Unidade Terapia Intens, Rio De Janeiro, Brazil.
RP Castro-Faria-Neto, HC (corresponding author), Inst Pesquisa Clin Evandro Chagas Fiocruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM hcastro@ioc.fiocruz.br
RI dantas, vicente c souza/L-2648-2013; Salluh, Jorge IF/F-6779-2012;
   Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529; Salluh, Jorge/0000-0002-8164-1453
CR Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935
   Abraham SM, 2006, BIOCHEM SOC T, V34, P1018, DOI 10.1042/BST0341018
   Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347
   Almawi WY, 2002, J LEUKOCYTE BIOL, V71, P9
   Annane D, 2006, CRIT CARE MED, V34, P22, DOI 10.1097/01.CCM.0000194723.78632.62
   Annane D, 2004, BRIT MED J, V329, P480, DOI 10.1136/bmj.38181.482222.55
   Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Annane D, 2006, AM J RESP CRIT CARE, V174, P1319, DOI 10.1164/rccm.200509-1369OC
   Annane D, 2008, CRIT CARE, V12, DOI 10.1186/cc6940
   [Anonymous], 1962, T ASSOC AM PHYSICIAN, V75, P198
   Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743
   Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557
   Bartholome B, 2004, FASEB J, V18, P70, DOI 10.1096/fj.03-0328com
   Bellissant E, 2000, CLIN PHARMACOL THER, V68, P293, DOI 10.1067/mcp.2000.109354
   BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538
   Bianca RDD, 2003, BRIT J PHARMACOL, V140, P91, DOI 10.1038/sj.bjp.0705406
   Bladh LG, 2005, MOL PHARMACOL, V67, P815, DOI 10.1124/mol.104.005801
   Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010
   Bollaert PE, 2003, SHOCK, V19, P13, DOI 10.1097/00024382-200301000-00003
   BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101
   BONE RC, 1987, CHEST, V92, P1032, DOI 10.1378/chest.92.6.1032
   BONE RC, 1992, CHEST, V101, P594, DOI 10.1378/chest.101.3.594
   Bornstein SR, 2004, P NATL ACAD SCI USA, V101, P16695, DOI 10.1073/pnas.0407550101
   Bornstein SR, 2004, HORM METAB RES, V36, P470, DOI 10.1055/s-2004-825750
   Bozza FA, 2005, MEM I OSWALDO CRUZ, V100, P217, DOI 10.1590/S0074-02762005000900037
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Brem AS, 1999, MOL GENET METAB, V67, P53, DOI 10.1006/mgme.1999.2812
   Briegel J, 1999, CRIT CARE MED, V27, P723, DOI 10.1097/00003246-199904000-00025
   Briel M, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-101
   Brooks B, 1934, ANN SURG, V100, P728, DOI 10.1097/00000658-193410000-00014
   Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590
   Buttgereit F, 2004, ARTHRITIS RHEUM-US, V50, P3408, DOI 10.1002/art.20583
   Buttgereit F, 2002, STEROIDS, V67, P529, DOI 10.1016/S0039-128X(01)00171-4
   Buttgereit F, 2005, SCAND J RHEUMATOL, V34, P14, DOI 10.1080/03009740510017706
   Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351
   Calfee CS, 2007, CHEST, V131, P913, DOI 10.1378/chest.06-1743
   Chawla K, 2000, JAMA-J AM MED ASSOC, V284, P309
   Chen SJ, 1999, N-S ARCH PHARMACOL, V359, P493, DOI 10.1007/PL00005381
   Chen WW, 2006, MOL ENDOCRINOL, V20, P560, DOI 10.1210/me.2005-0318
   Cheng AC, 2008, PLOS MED, V5, P1173, DOI 10.1371/journal.pmed.0050175
   Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124
   Chesnutt AN, 1997, CHEST, V111, P652, DOI 10.1378/chest.111.3.652
   Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103
   Chinenov Y, 2007, MOL CELL ENDOCRINOL, V275, P30, DOI 10.1016/j.mce.2007.04.014
   Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272
   Czaika G, 2000, MUSCLE NERVE, V23, P967
   D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2
   Dallman MF, 2005, FRONT NEUROENDOCRIN, V26, P103, DOI 10.1016/j.yfrne.2005.08.001
   de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334
   de Jong MFC, 2007, CRIT CARE MED, V35, P1896, DOI 10.1097/01.CCM.0000275387.51629.ED
   Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920
   Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z
   Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358
   Dostert A, 2004, CURR PHARM DESIGN, V10, P2807
   Eddleston J, 2007, J ALLERGY CLIN IMMUN, V119, P115, DOI 10.1016/j.jaci.2006.08.027
   Elsouri N, 2006, J CRIT CARE, V21, P73, DOI 10.1016/j.jcrc.2005.09.055
   ETIENNE A, 1986, PHARMACOL RES COMMUN, V18, P71, DOI 10.1016/0031-6989(86)90040-8
   Feige JN, 2007, TRENDS CELL BIOL, V17, P292, DOI 10.1016/j.tcb.2007.04.001
   Fernandes ABS, 2005, BRAZ J MED BIOL RES, V38, P147, DOI 10.1590/S0100-879X2005000200003
   Salluh JIF, 2006, ARCH SURG-CHICAGO, V141, P945, DOI 10.1001/archsurg.141.9.945-a
   Friderichsen C, 1918, JB KINDERHEILKD, V87, P109
   Furst R, 2007, FASEB J, V21, P74, DOI 10.1096/fj.06-6752com
   Gametchu B, 1999, STEROIDS, V64, P107, DOI 10.1016/S0039-128X(98)00097-X
   Goodman S, 2005, INTENS CARE MED, V31, P1362, DOI 10.1007/s00134-005-2770-6
   Gotoh S, 2008, EUR RESPIR J, V31, P1268, DOI 10.1183/09031936.00135607
   Grad W, 2007, MOL CELL ENDOCRINOL, V275, P2, DOI 10.1016/j.mce.2007.05.018
   GREGORY PB, 1976, NEW ENGL J MED, V294, P681, DOI 10.1056/NEJM197603252941301
   Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525
   Guzman JA, 2007, J CRIT CARE, V22, P319, DOI 10.1016/j.jcrc.2007.05.003
   Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473
   HAHN EO, 1951, J CLIN INVEST, V30, P274, DOI 10.1172/JCI102441
   HALUSHKA PV, 1985, CRIT CARE MED, V13, P451, DOI 10.1097/00003246-198506000-00001
   Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266
   Hartman FA, 1930, SCIENCE, V72, P76, DOI 10.1126/science.72.1855.76
   Hausmann MJ, 2000, KIDNEY INT, V57, P476, DOI 10.1046/j.1523-1755.2000.t01-1-00867.x
   HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x
   HINSHAW LB, 1979, SURG GYNECOL OBSTET, V149, P545
   HINSHAW LB, 1980, J SURG RES, V28, P151, DOI 10.1016/0022-4804(80)90158-4
   Hirasawa N, 1998, J IMMUNOL, V161, P4939
   Ho JT, 2006, J CLIN ENDOCR METAB, V91, P105, DOI 10.1210/jc.2005-0265
   HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203
   Homma T, 2004, AM J RESP CELL MOL, V31, P463, DOI 10.1165/rcmb.2004-0161OC
   JAHN JP, 1954, J PEDIATR-US, V44, P640, DOI 10.1016/S0022-3476(54)80005-9
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC
   KOSAKA H, 1992, BIOCHEM BIOPH RES CO, V184, P1119, DOI 10.1016/0006-291X(92)90708-S
   LANDRY DW, 1992, J CLIN INVEST, V89, P2071, DOI 10.1172/JCI115820
   LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502
   Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860
   Leite JHP, 2008, CRIT CARE MED, V36, P2621, DOI 10.1097/CCM.0b013e3181847b43
   LIU G, 1993, EUR J BIOCHEM, V218, P679, DOI 10.1111/j.1432-1033.1993.tb18422.x
   Liu SB, 2000, SHOCK, V14, P361, DOI 10.1097/00024382-200014030-00021
   Liu Y, 2001, INFECT IMMUN, V69, P2788, DOI 10.1128/IAI.69.5.2788-2796.2001
   Loisa P, 2007, CRIT CARE, V11, DOI 10.1186/cc5696
   Lowenberg M, 2005, BLOOD, V106, P1703, DOI 10.1182/blood-2004-12-4790
   LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62
   Manglik S, 2003, CRIT CARE MED, V31, P1668, DOI 10.1097/01.CCM.0000063447.37342.A9
   Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299
   Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba
   Marik PE, 2005, CRIT CARE MED, V33, P1254, DOI 10.1097/01.CCM.0000164541.12106.57
   Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022
   Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A
   Mason HL, 1936, J BIOL CHEM, V114, P613
   McGee S, 2008, ARCH INTERN MED, V168, P1034, DOI 10.1001/archinte.168.10.1034
   Meduri GU, 2008, INTENS CARE MED, V34, P61, DOI 10.1007/s00134-007-0933-3
   Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100
   Meduri GU, 2005, NEUROIMMUNOMODULAT, V12, P321, DOI 10.1159/000091126
   Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159
   MELBY JC, 1958, J CLIN INVEST, V37, P1791, DOI 10.1172/JCI103772
   Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200
   Morel J, 2006, INTENS CARE MED, V32, P1184, DOI 10.1007/s00134-006-0233-3
   Murphy Joseph F., 1993, Journal of Burn Care and Rehabilitation, V14, P155, DOI 10.1097/00004630-199303000-00005
   NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031
   Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029
   Palacios EH, 2004, ONCOGENE, V23, P7990, DOI 10.1038/sj.onc.1208074
   Pariante CM, 1999, ENDOCRINOLOGY, V140, P4359, DOI 10.1210/en.140.9.4359
   PEDUZZI P, 1987, NEW ENGL J MED, V317, P659
   Peter JV, 2008, BMJ-BRIT MED J, V336, P1006, DOI 10.1136/bmj.39537.939039.BE
   Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9
   Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6
   Reily MM, 2006, EMBO J, V25, P108, DOI 10.1038/sj.emboj.7600919
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Rocco PRM, 2003, AM J RESP CRIT CARE, V168, P677, DOI 10.1164/rccm.200302-256OC
   Rogatsky I, 2006, TISSUE ANTIGENS, V68, P1, DOI 10.1111/j.1399-0039.2006.00599.x
   Rogatsky I, 2003, P NATL ACAD SCI USA, V100, P13845, DOI 10.1073/pnas.2336092100
   Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071
   Rozkova D, 2006, CLIN IMMUNOL, V120, P260, DOI 10.1016/j.clim.2006.04.567
   Salgado DR, 2008, ACTA ANAESTH SCAND, V52, P36, DOI 10.1111/j.1399-6576.2007.01492.x
   Salgado LR, 2006, EUR J ENDOCRINOL, V155, P725, DOI 10.1530/eje.1.02278
   Salluh J, 2006, INTENS CARE MED, V32, P595, DOI 10.1007/s00134-005-0046-9
   Salluh JIF, 2008, CRIT CARE, V12, DOI 10.1186/cc6922
   Salluh JIF, 2008, CHEST, V134, P947, DOI 10.1378/chest.08-1382
   Santos FB, 2006, J APPL PHYSIOL, V100, P98, DOI 10.1152/japplphysiol.00395.2005
   SARETT LH, 1948, J AM CHEM SOC, V70, P1454, DOI 10.1021/ja01184a047
   Schaecke H, 2007, MOL CELL ENDOCRINOL, V275, P109, DOI 10.1016/j.mce.2007.05.014
   SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283
   SCHUMER W, 1976, ANN SURG, V184, P333, DOI 10.1097/00000658-197609000-00011
   Sevransky JE, 2008, CHEST, V134, P534, DOI 10.1378/chest.08-0309
   Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200
   Sibila O, 2008, EUR RESPIR J, V32, P259, DOI 10.1183/09031936.00154107
   SMEDEGARD G, 1989, AM J PATHOL, V135, P489
   SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4
   Sorrentino R, 1999, BRIT J PHARMACOL, V127, P1447, DOI 10.1038/sj.bjp.0702666
   Sotto A, 2002, J ANTIMICROB CHEMOTH, V50, P569, DOI 10.1093/jac/dkf167
   Spies CM, 2006, ANN RHEUM DIS, V65, P1139, DOI 10.1136/ard.2005.048272
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801
   Stahn C, 2007, MOL CELL ENDOCRINOL, V275, P71, DOI 10.1016/j.mce.2007.05.019
   STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869
   Steinberg KP, 2006, NEW ENGL J MED, V354, P1671
   Swingle WW, 1933, SCIENCE, V77, P58, DOI 10.1126/science.77.1985.58
   Terluk MR, 2000, N-S ARCH PHARMACOL, V361, P477, DOI 10.1007/s002100000216
   THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B
   Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com
   Tryc AB, 2006, J RHEUMATOL, V33, P2249
   Tsai MH, 2006, HEPATOLOGY, V43, P673, DOI 10.1002/hep.21101
   Vakharia K, 2005, ENDOCRINOLOGY, V146, P1398, DOI 10.1210/en.2004-0882
   van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2
   Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101
   Wang XX, 2008, LIFE SCI, V83, P671, DOI 10.1016/j.lfs.2008.09.003
   WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601
   Weber-Carstens S, 2007, INTENS CARE MED, V33, P730, DOI 10.1007/s00134-007-0540-3
   Widmer IE, 2005, J CLIN ENDOCR METAB, V90, P4579, DOI 10.1210/jc.2005-0354
   Wikstrom AC, 2003, J ENDOCRINOL, V178, P331, DOI 10.1677/joe.0.1780331
   Xu Jianming, 2002, Rev Endocr Metab Disord, V3, P185, DOI 10.1023/A:1020016208071
   Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116
   Yildiz O, 2002, CRIT CARE, V6, P251, DOI 10.1186/cc1498
   Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675
   Zacharowski K, 2006, P NATL ACAD SCI USA, V103, P6392, DOI 10.1073/pnas.0601527103
   Zimmerman JJ, 2007, PEDIATR CRIT CARE ME, V8, P530, DOI 10.1097/01.PCC.0000288710.11834.E6
NR 176
TC 8
Z9 11
U1 0
U2 9
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUL
PY 2009
VL 104
IS 4
BP 531
EP 548
DI 10.1590/S0074-02762009000400001
PG 18
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 489ZU
UT WOS:000269466900001
PM 19722073
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Maracaja-Neto, LF
   Vercosa, N
   Roncally, AC
   Giannella, A
   Bozza, FA
   Lessa, MA
AF Maracaja-Neto, L. F.
   Vercosa, N.
   Roncally, A. C.
   Giannella, A.
   Bozza, F. A.
   Lessa, M. A.
TI Beneficial effects of high positive end-expiratory pressure in lung
   respiratory mechanics during laparoscopic surgery
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article
ID BLOOD-GAS CHANGES; CARBON-DIOXIDE; GYNECOLOGICAL LAPAROSCOPY; ESOPHAGEAL
   BALLOON; GENERAL-ANESTHESIA; AIRWAY PRESSURE; CHOLECYSTECTOMY;
   PNEUMOPERITONEUM; ATELECTASIS; PARALYSIS
AB The effect of neuromuscular blockade (NMB) and positive end-expiratory pressure (PEEP) on the elastic properties of the respiratory system during pneumoperitoneum (PnP) remains a controversial subject. The main objective of the present study was to evaluate the effects of NMB and PEEP on respiratory mechanics.
   We performed a dynamic analysis of respiratory mechanics in patients subjected to PnP. Twenty-one patients underwent cholecystectomy videolaparoscopy and total intravenous anesthesia. The respiratory system resistance (R-RS), pulmonary elastance (E-P), chest wall elastance (E-CW), and respiratory system elastance (E-RS) were computed via the least squares fit technique using an equation describing the motion of the respiratory system, which uses primary signs such as airway pressure, tidal volume, air flow, and esophageal pressures. Measurements were taken after tracheal intubation, PnP, NMB, establishment of PEEP (10 cmH(2)O), and PEEP withdrawal [zero end-expiratory pressure (ZEEP)].
   PnP significantly increased E-RS by 27%; both E-P and E-CW increased 21.3 and 64.1%, respectively (P < 0.001). NMB did not alter the respiratory mechanic properties. Setting PEEP reduced E-RS by 8.6% (P < 0.05), with a reduction of 10.9% in E-P (P < 0.01) and a significant decline of 15.7% in R-RS (P < 0.05). These transitory changes in elastance disappeared after ZEEP.
   We concluded that the 10 cmH(2)O of PEEP attenuates the effects of PnP in respiratory mechanics, lowering R-RS, E-P, and E-RS. These effects may be useful in the ventilatory approach for patients experiencing a non-physiological increase in IAP owing to PnP in laparoscopic procedures.
C1 [Lessa, M. A.] Fiocruz MS, Inst Oswaldo Cruz, Lab Cardiovasc Invest, BR-21045900 Rio De Janeiro, Brazil.
   [Maracaja-Neto, L. F.; Vercosa, N.] Univ Fed Rio de Janeiro, Anesthesiol Serv, Rio De Janeiro, Brazil.
   [Roncally, A. C.; Giannella, A.] Univ Fed Rio de Janeiro, Lab Pulm Engineer, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Fiocruz MS, Evandro Chagas Inst, Intens Care Unit, BR-21045900 Rio De Janeiro, Brazil.
RP Lessa, MA (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Cardiovasc Invest, Av Brasil 4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM malessa@ioc.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Carvalho,
   Alysson/0000-0003-2708-7735
CR Andersson LE, 2005, ANESTHESIOLOGY, V102, P293, DOI 10.1097/00000542-200502000-00009
   BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788
   BRUNNER JX, 1985, CRIT CARE MED, V13, P675, DOI 10.1097/00003246-198508000-00014
   Bures E, 1996, ACTA ANAESTH SCAND, V40, P566, DOI 10.1111/j.1399-6576.1996.tb04489.x
   Carry PY, 1998, ANESTH ANALG, V87, P1393, DOI 10.1097/00000539-199812000-00035
   Chassard D, 1996, ANN FR ANESTH, V15, P1013, DOI 10.1016/S0750-7658(96)89470-6
   Chassard D, 1996, ANESTH ANALG, V82, P525, DOI 10.1097/00000539-199603000-00017
   COLLINS KM, 1984, ANAESTHESIA, V39, P819, DOI 10.1111/j.1365-2044.1984.tb06534.x
   Cunningham AJ, 2001, CLIN ANESTH, P1051
   Duggan M, 2005, ANESTHESIOLOGY, V102, P838, DOI 10.1097/00000542-200504000-00021
   Fahy BG, 1996, ANESTH ANALG, V82, P501, DOI 10.1097/00000539-199603000-00013
   GABBOTT DA, 1992, ANAESTHESIA, V47, P587, DOI 10.1111/j.1365-2044.1992.tb02329.x
   GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209
   Grasso S, 2004, CRIT CARE MED, V32, P1018, DOI 10.1097/01.CCM.0000120059.94009.AD
   HANLEY ES, 1992, SURG CLIN N AM, V72, P1013
   Hedenstierna G, 2005, INTENS CARE MED, V31, P1327, DOI 10.1007/s00134-005-2761-7
   HIGGS BD, 1983, ANESTHESIOLOGY, V59, P340, DOI 10.1097/00000542-198310000-00012
   HIRVONEN EA, 1995, ANESTH ANALG, V80, P961, DOI 10.1097/00000539-199505000-00018
   HODGSON C, 1970, ANAESTHESIA, V25, P382, DOI 10.1111/j.1365-2044.1970.tb00226.x
   IOTTI GA, 1995, INTENS CARE MED, V21, P406, DOI 10.1007/BF01707409
   JORIS J, 1992, BRIT J ANAESTH, V69, P341, DOI 10.1093/bja/69.4.341
   Kim JH, 2007, ACTA ANAESTH SCAND, V51, P235, DOI 10.1111/j.1399-6576.2006.01208.x
   Klopfenstein CE, 2008, ACTA ANAESTH SCAND, V52, P700, DOI 10.1111/j.1399-6576.2007.01568.x
   Magnusson L, 2003, BRIT J ANAESTH, V91, P61, DOI 10.1093/bja/aeg085
   MEAD J, 1953, J APPL PHYSIOL, V5, P779
   Meininger D, 2005, ACTA ANAESTH SCAND, V49, P778, DOI 10.1111/j.1399-6576.2005.00713.x
   MOTEW M, 1973, AM J OBSTET GYNECOL, V115, P1002, DOI 10.1016/0002-9378(73)90683-2
   Nguyen NT, 2005, ANN SURG, V241, P219, DOI 10.1097/01.sla.0000151791.93571.70
   Nguyen NT, 2004, SURG ENDOSC, V18, P64, DOI 10.1007/s00464-002-8786-x
   OIKKONEN M, 1995, CAN J ANAESTH, V42, P495, DOI 10.1007/BF03011687
   Pelosi P, 1999, ANESTHESIOLOGY, V91, P1221, DOI 10.1097/00000542-199911000-00011
   PUTENSEN C, 1994, CRIT CARE MED, V22, P1976
   Rizzotti L, 2002, RESP MED, V96, P268, DOI 10.1053/rmed.2001.1264
   Rothen HU, 1998, BRIT J ANAESTH, V81, P681, DOI 10.1093/bja/81.5.681
   Salihoglu Z, 2003, EUR J ANAESTH, V20, P658, DOI 10.1097/00003643-200308000-00012
   Sandbu R, 2001, SURG ENDOSC-ULTRAS, V15, P1478, DOI 10.1007/s00464-001-9002-0
   Schibler Andreas, 2002, Pediatr Crit Care Med, V3, P124, DOI 10.1097/00130478-200204000-00006
   SENGUPTA P, 1987, EUR J ANAESTH, V4, P93
   Takahata O, 2007, ACTA ANAESTH SCAND, V51, P687, DOI 10.1111/j.1399-6576.2007.01311.x
   VALTA P, 1992, CHEST, V102, P227, DOI 10.1378/chest.102.1.227
   Vassiliou MP, 2003, HEPATO-GASTROENTEROL, V50, P934
   Wahba RWM, 1996, CAN J ANAESTH, V43, P77, DOI 10.1007/BF03015963
   Williams MT, 2003, ANAESTHESIA, V58, P574, DOI 10.1046/j.1365-2044.2003.03150.x
NR 43
TC 43
Z9 47
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD FEB
PY 2009
VL 53
IS 2
BP 210
EP 217
DI 10.1111/j.1399-6576.2008.01826.x
PG 8
WC Anesthesiology
SC Anesthesiology
GA 395HM
UT WOS:000262515200009
PM 19175578
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Shah, AM
   Weyrich, AS
   Zimmerman, GA
AF Bozza, Fernando A.
   Shah, Amrapali M.
   Weyrich, Andrew S.
   Zimmerman, Guy A.
TI Amicus or Adversary Platelets in Lung Biology, Acute Injury, and
   Inflammation
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Review
DE platelets; inflammation; thrombosis; lung injury
ID RESPIRATORY-DISTRESS-SYNDROME; NEUTROPHIL EXTRACELLULAR TRAPS; ACTIVATED
   HUMAN PLATELETS; TISSUE FACTOR EXPRESSION; HUMAN ENDOTHELIAL-CELLS;
   PULMONARY-EDEMA FLUID; NECROSIS-FACTOR-ALPHA; SPHINGOSINE 1-PHOSPHATE;
   DENDRITIC CELLS; P-SELECTIN
AB Platelets are the chief effector cells in hemostasis and have additional major functions in inflammation, vascular integrity, and tissue repair. Platelets and the lungs have interrelated activities. Previous studies provide evidence that platelets contribute to pulmonary vascular barrier function and are required for defense against pulmonary hemorrhage, and that the lungs can influence platelet number and distribution. There is also evidence that platelets contribute to pathologic syndromes of pulmonary inflammation and thrombosis. Thus, platelets have an "amicus or adversary" relationship with the lung. Recent observations and discoveries have established new paradigms relevant to influences of platelets on lung cell and molecular biology. These new findings are in a variety of areas including thrombopoieis, nontraditional activities of platelets, new synthetic capabilities and mechanisms of post-translational gene expression, interactions of platelets with endothelial cells and contributions to alveolar capillary barrier permeability, interactions of platelets with myeloid leukocytes, and platelet involvement in stem cell signaling and vascular repair. These issues are considered in a translational approach, with an emphasis on acute lung injury and the acute respiratory distress syndrome.
C1 [Bozza, Fernando A.; Shah, Amrapali M.; Weyrich, Andrew S.; Zimmerman, Guy A.] Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.
   [Bozza, Fernando A.] Fudacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Shah, Amrapali M.; Weyrich, Andrew S.; Zimmerman, Guy A.] Univ Utah, Dept Internal Med, Div Resp & Crit Care Med, Salt Lake City, UT 84112 USA.
RP Zimmerman, GA (corresponding author), Univ Utah, Program Human Mol Biol & Genet, 15 N 2030 E,Room 4220, Salt Lake City, UT 84112 USA.
EM guy.zimmerman@hmbg.utah.edu
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Weyrich,
   Andrew/0000-0001-9622-4647
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [RO1 HL091754, RO1
   AG031065, RO1 HL 066277, R37 HL44525]; American Heart
   AssociationAmerican Heart Association; Conselho Nacional de
   Desenvolvimento Cientifico e Technologico of the Ministry for Science
   and Technology of Brazil; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL066277, R37HL044525, R37HL044525, R01HL066277,
   R37HL044525, R01HL066277, R01HL066277, R01HL066277, R37HL044525,
   R01HL066277, R01HL091754, R01HL066277, R37HL044525, R37HL044525,
   R01HL066277, R01HL066277, R01HL066277, R37HL044525, R01HL066277,
   R37HL044525, R01HL066277, R37HL044525, R37HL044525, R01HL091754,
   R01HL091754, R01HL091754] Funding Source: NIH RePORTER
FX This work was supported by grants from the National Institutes of Health
   (RO1 HL091754; RO1 AG031065; RO1 HL 066277; R37 HL44525) to A.S.W. and
   G.A.Z., an Established Investigator Award from the American Heart
   Association to A.S.W., and an award from the Conselho Nacional de
   Desenvolvimento Cientifico e Technologico of the Ministry for Science
   and Technology of Brazil to F.A.B.
CR Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279
   Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
   Aird WC, 2003, MAYO CLIN PROC, V78, P869, DOI 10.4065/78.7.869
   Andonegui G, 2005, BLOOD, V106, P2417, DOI 10.1182/blood-2005-03-0916
   Aslam R, 2006, BLOOD, V107, P637, DOI 10.1182/blood-2005-06-2202
   AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470
   BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
   Barazzone C, 1996, AM J RESP CELL MOL, V15, P107, DOI 10.1165/ajrcmb.15.1.8679214
   Beiter K, 2006, CURR BIOL, V16, P401, DOI 10.1016/j.cub.2006.01.056
   Bergmeier W, 2007, PLATELETS, 2ND EDITION, P713, DOI 10.1016/B978-012369367-9/50801-6
   Bhattacharya J, 2004, AM J RESP CRIT CARE, V170, P928, DOI 10.1164/rccm.2408008
   BIERMAN HR, 1955, AM J SURG, V89, P130, DOI 10.1016/0002-9610(55)90515-8
   BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2
   Bonnans C, 2007, AM J RESP CELL MOL, V36, P201, DOI 10.1165/rcmb.2006-0269TR
   Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342
   BREDENBERG CE, 1980, SURGERY, V87, P59
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   CHOI ES, 1995, BLOOD, V85, P402
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Cognasse F, 2005, IMMUNOL CELL BIOL, V83, P196, DOI 10.1111/j.1440-1711.2005.01314.x
   COHEN AB, 1993, AM J PHYSIOL, V264, pL490
   Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336
   Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014
   de Boer HC, 2006, ARTERIOSCL THROM VAS, V26, P1653, DOI 10.1161/01.ATV.0000222982.55731.f1
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   DIEZ FL, 1989, J CLIN INVEST, V83, P1733, DOI 10.1172/JCI114074
   Dixon DA, 2006, J CLIN INVEST, V116, P2727, DOI 10.1172/JC127209
   Downey GP, 1999, CHEST, V116, p46S, DOI 10.1378/chest.116.suppl_1.46S-a
   Eichhorn ME, 2002, J VASC RES, V39, P330, DOI 10.1159/000065545
   Elstad M R, 1995, Curr Opin Hematol, V2, P47
   Evangelista V, 2007, BLOOD, V109, P2461, DOI 10.1182/blood-2006-06-029082
   Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985
   FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123
   Gawaz M, 2005, J CLIN INVEST, V115, P3378, DOI 10.1172/JCI27196
   Geddis AE, 2007, SCIENCE, V317, P1689, DOI 10.1126/science.1148946
   Geiser T, 2001, AM J RESP CRIT CARE, V163, P1384, DOI 10.1164/ajrccm.163.6.2006131
   GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582
   Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855
   Hagihara M, 2004, J IMMUNOL, V172, P5297, DOI 10.4049/jimmunol.172.9.5297
   Hartwig J, 2003, J THROMB HAEMOST, V1, P1580, DOI 10.1046/j.1538-7836.2003.00331.x
   HAYNES JB, 1980, AM REV RESPIR DIS, V122, P841
   Healy AM, 2006, CIRCULATION, V113, P2278, DOI 10.1161/CIRCULATIONAHA.105.607333
   HEFFNER J, 1997, LUNG SCI FDN
   HEFFNER JE, 1987, AM REV RESPIR DIS, V135, P482
   HEFFNER JE, 1991, LUNG SCI FDN, P617
   Herd C.M., 1995, IMMUNOPHARMACOLOGY P, P1
   Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750
   Hilf N, 2002, BLOOD, V99, P3676, DOI 10.1182/blood.V99.10.3676
   HILL JD, 1976, J THORAC CARDIOV SUR, V71, P64
   IDELL S, 1989, CHEST, V96, P1125, DOI 10.1378/chest.96.5.1125
   ISSEKUTZ AC, 1983, LAB INVEST, V49, P716
   Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400
   Junt T, 2007, SCIENCE, V317, P1767, DOI 10.1126/science.1146304
   Kissel K, 2006, TRANSFUSION, V46, P818, DOI 10.1111/j.1537-2995.2006.00802.x
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Krump-Konvalinkova V, 2005, ARTERIOSCL THROM VAS, V25, P546, DOI 10.1161/01.ATV.0000154360.36106.d9
   Kuebler WM, 2006, J CLIN INVEST, V116, P3106, DOI 10.1172/JCI30664
   Langer HF, 2007, ARTERIOSCL THROM VAS, V27, P1463, DOI 10.1161/ATVBAHA.107.141515
   Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X
   Li GL, 2003, J IMMUNOL, V171, P669, DOI 10.4049/jimmunol.171.2.669
   Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058
   Lindemann SW, 2005, TRENDS CARDIOVAS MED, V15, P9, DOI 10.1016/j.tcm.2004.10.004
   Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322
   Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238
   Looney MR, 2004, CHEST, V126, P249, DOI 10.1378/chest.126.1.249
   Mackman N, 2007, ARTERIOSCL THROM VAS, V27, P1687, DOI 10.1161/ATVBAHA.107.141911
   MAGUIRE PB, 2007, ENDOTHELIAL BIOMEDIC, P587
   Mandal RV, 2007, EXP MOL PATHOL, V83, P327, DOI 10.1016/j.yexmp.2007.08.005
   Martin TR, 1999, CHEST, V116, p2S, DOI 10.1378/chest.116.suppl_1.2S
   Martinez ML, 2007, ENDOTHELIAL BIOMEDIC, P1178
   Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Michelson AD, 2001, CIRCULATION, V104, P1533, DOI 10.1161/hc3801.095588
   Mirlashari MR, 2002, PLATELETS, V13, P91, DOI 10.1080/09537100220122448
   Morel O, 2006, ARTERIOSCL THROM VAS, V26, P2594, DOI 10.1161/01.ATV.0000246775.14471.26
   Nieswandt B, 1999, BLOOD, V94, P684, DOI 10.1182/blood.V94.2.684
   O'Sullivan BP, 2006, AM J RESP CRIT CARE, V173, P483, DOI 10.1164/rccm.200508-1243PP
   Olman MA, 2004, J IMMUNOL, V172, P2668, DOI 10.4049/jimmunol.172.4.2668
   Palucka KA, 1998, J IMMUNOL, V160, P4587
   Panes O, 2007, BLOOD, V109, P5242, DOI 10.1182/blood-2006-06-030619
   PARISE LV, 2006, WILLIAMS HEMATOLOGY, P1597
   Patel SR, 2005, J CLIN INVEST, V115, P3348, DOI 10.1172/JCI26891
   PEACOCK AJ, 2002, INTERACTIONS BLOOD P, P187
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC
   Prescott SM, 2005, J THROMB HAEMOST, V3, P2571, DOI 10.1111/j.1538-7836.2005.01659.x
   Ravid K, 2006, BLOOD, V108, P2139, DOI 10.1182/blood-2006-07-035238
   Roux J, 2005, J BIOL CHEM, V280, P18579, DOI 10.1074/jbc.M410561200
   Savage B, 2007, PLATELETS, 2ND EDITION, P359, DOI 10.1016/B978-012369367-9/50780-1
   SCHNEIDER RC, 1980, AM REV RESPIR DIS, V122, P445
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Shi QZ, 2006, J CLIN INVEST, V116, P1974, DOI 10.1172/JCI28416
   Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x
   SNAPPER JR, 1984, J CLIN INVEST, V74, P1782, DOI 10.1172/JCI111597
   Steiner S, 2003, ARTERIOSCL THROM VAS, V23, P1697, DOI 10.1161/01.ATV.0000087035.46547.89
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Stellos K, 2008, PHARMACOL REP, V60, P101
   Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI200113416
   Tomashefski JF, 2000, CLIN CHEST MED, V21, P435, DOI 10.1016/S0272-5231(05)70158-1
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   TOMASHEFSKI JF, 2003, ACUTE RESP DISTRESS, V179, P75
   Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177
   TVEDTEN HW, 1985, AM J PATHOL, V119, P92
   Tweardy DJ, 2006, SHOCK, V26, P386, DOI 10.1097/01.shk.0000227907.56060.2b
   Urban C, 2007, NAT MED, V13, P403, DOI 10.1038/nm0407-403
   Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Ware LB, 2006, AM J PHYSIOL-LUNG C, V291, pL307, DOI 10.1152/ajplung.00157.2006
   Weyrich AS, 2007, BLOOD, V109, P1975, DOI 10.1182/blood-2006-08-042192
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Weyrich AS, 1998, P NATL ACAD SCI USA, V95, P5556, DOI 10.1073/pnas.95.10.5556
   Weyrich AS, 2004, TRENDS IMMUNOL, V25, P489, DOI 10.1016/j.it.2004.07.003
   Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x
   White KE, 2008, J IMMUNOL, V180, P637, DOI 10.4049/jimmunol.180.1.637
   Xiao DW, 2006, PLATELETS, V17, P347, DOI 10.1080/09537100600745120
   Yatomi Y, 2000, BLOOD, V96, P3431
   Yeaman MR, 2007, PLATELETS, 2ND EDITION, P727, DOI 10.1016/B978-012369367-9/50802-8
   Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499
   Zhao LJ, 2002, BLOOD, V100, P3233, DOI 10.1182/blood-2002-01-0252
   ZIMMERMAN GA, 1984, AM REV RESPIR DIS, V129, P798, DOI 10.1164/arrd.1984.129.5.798
   ZIMMERMAN GA, 1997, LUNG SCI FDN, P289
   Zimmerman GA, 2003, ACUTE RESP DISTRESS, V179, P245
   Zimmerman GA, 2008, ARTERIOSCL THROM VAS, V28, pS17, DOI 10.1161/ATVBAHA.107.160218
   Zucker-Franklin D, 2000, AM J PATHOL, V157, P69, DOI 10.1016/S0002-9440(10)64518-X
NR 129
TC 90
Z9 98
U1 0
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD FEB
PY 2009
VL 40
IS 2
BP 123
EP 134
DI 10.1165/rcmb.2008-0241TR
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 400ML
UT WOS:000262872200001
PM 18723438
OA Green Published
DA 2020-12-01
ER

PT J
AU Coelho, L
   Povoa, P
   Soares, M
   Bozza, F
   Verdeal, J
   Castro-Faria-Neto, H
   Silva, JLE
   Bozza, P
   Salluh, J
AF Coelho, L.
   Povoa, P.
   Soares, M.
   Bozza, F.
   Verdeal, J.
   Castro-Faria-Neto, H.
   Lapa e Silva, J.
   Bozza, P.
   Salluh, J.
TI Patterns of C-Reactive Protein Response to Antibiotic Therapy in Severe
   Community-Acquired Pneumonia Patients: A Cohort Study
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Coelho, L.; Povoa, P.] Hosp Sao Francisco Xavier, CHLO, UCIM, Lisbon, Portugal.
   [Soares, M.; Salluh, J.] Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   [Bozza, F.] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Verdeal, J.] Hosp Barra Dor, ICU, Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, H.; Bozza, P.] Fiocruz MS, IPEC, ICU, BR-21045900 Rio De Janeiro, Brazil.
   [Lapa e Silva, J.] Univ Fed Rio de Janeiro, Dept Pneumol, Rio de Janeiro, Brazil.
EM luismiguelcoelho16@gmail.com
RI Bozza, Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013; dantas,
   vicente c souza/L-2648-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A1720
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733100720
DA 2020-12-01
ER

PT J
AU Povoa, PR
   Soares, M
   Coelho, LM
   Bozza, FA
   Verdeal, JR
   Castro-Faria-Neto, HC
   Silva, JL
   Bozza, PT
   Salluh, JI
AF Povoa, P. R.
   Soares, M.
   Coelho, L. M.
   Bozza, F. A.
   Verdeal, J. R.
   Castro-Faria-Neto, H. C.
   Silva, J. L.
   Bozza, P. T.
   Salluh, J. I.
TI C-Reactive Protein as an Early Marker of Severe Community-Acquired
   Pneumonia Resolution
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Povoa, P. R.; Coelho, L. M.] Hosp Sao Francisco Xavier, UCIM, CHLO, Lisbon, Portugal.
   [Soares, M.; Salluh, J. I.] Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Verdeal, J. R.] Hosp Barra Dor, ICU, Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, H. C.; Bozza, P. T.] Fiocruz MS, ICU, IPEC, BR-21045900 Rio De Janeiro, Brazil.
   [Silva, J. L.] Univ Fed Rio de Janeiro, Dept Pneumol, Rio de Janeiro, Brazil.
EM povoap@netcabo.pt
RI dantas, vicente c souza/L-2648-2013; Soares, Marcio/B-3083-2013; Bozza,
   Fernando A/A-2618-2013
OI Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A6113
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733105704
DA 2020-12-01
ER

PT J
AU Salluh, JI
   Soares, M
   Coelho, LM
   Bozza, FA
   Verdeal, JC
   Castro-Faria-Neto, HC
   Silva, JL
   Bozza, PT
   Povoa, PR
AF Salluh, J. I.
   Soares, M.
   Coelho, L. M.
   Bozza, F. A.
   Verdeal, J. C.
   Castro-Faria-Neto, H. C.
   Silva, J. L.
   Bozza, P. T.
   Povoa, P. R.
TI Impact of Systemic Corticosteroids on the Outcome of Patients with
   Severe Community-Acquired Pneumonia: A Cohort Study
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Salluh, J. I.; Soares, M.] Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   [Coelho, L. M.; Povoa, P. R.] Hosp Sao Francisco Xavier, CHLO, UCIM, Lisbon, Portugal.
   [Bozza, F. A.] Fiocruz MS, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Verdeal, J. C.] Hosp Barra Dor, ICU, Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, H. C.; Bozza, P. T.] Fiocruz MS, IPEC, ICU, BR-21045900 Rio De Janeiro, Brazil.
   [Silva, J. L.] Univ Fed Rio de Janeiro, Dept Pneumol, Rio de Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI dantas, vicente c souza/L-2648-2013; Bozza, Fernando A/A-2618-2013;
   Soares, Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Salluh, Jorge/0000-0002-8164-1453
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A1716
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733100716
DA 2020-12-01
ER

PT J
AU Salluh, J
   Soares, M
   Dal Pizzol, F
   Mello, PV
   Friedman, G
   Bozza, FA
   Lobo, S
   Silva, E
   Teles, JM
AF Salluh, Jorge
   Soares, Marcio
   Dal Pizzol, Felipe
   Mello, Patricia V.
   Friedman, Gilberto
   Bozza, Fernando A.
   Lobo, Suzana
   Silva, Eliezer
   Teles, Jose M.
TI DELIRIUM RECOGNITION AND SEDATION PRACTICES IN CRITICALLY ILL PATIENTS:
   A SURVEY ON THE ATTITUDES OF 1015 CRITICAL CARE PHYSICIANS.
SO CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT 38th Critical Care Congress of the Society-of-Critical-Care-Medicine
CY JAN 31-FEB 04, 2009
CL Nashville, TN
SP Soc Crit Care Med
C1 [Salluh, Jorge; Soares, Marcio] INCA MS, ICU, Rio De Janeiro, Brazil.
   [Dal Pizzol, Felipe] Univ Extremo Sul Catarinense, PPG, Criciuma, Brazil.
   [Mello, Patricia V.] Univ Estadual Piaui, ICU, Teresina, Brazil.
   [Friedman, Gilberto] Univ Fed Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
   [Silva, Eliezer] USP, ICU, S Lo Paulo, Brazil.
   [Teles, Jose M.] Hosp Portugues, ICU, Salvador, BA, Brazil.
   [Bozza, Fernando A.] IPEC FioCruz, ICU, Rio De Janeiro, Brazil.
   [Lobo, Suzana] FAMERP, S Lo Jos Do Rio Preto, Brazil.
RI dantas, vicente c souza/L-2648-2013; Friedman, Gilberto/F-7212-2015;
   Salluh, Jorge IF/F-6779-2012; Dal-Pizzol, Felipe/F-2756-2015; Bozza,
   Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013; Friedman,
   Gilberto/F-7208-2015
OI Dal-Pizzol, Felipe/0000-0003-3003-8977; Bozza, Fernando
   A/0000-0003-4878-0256; Soares, Marcio/0000-0003-2503-6088; Friedman,
   Gilberto/0000-0001-9369-2488
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD DEC
PY 2008
VL 36
IS 12
SU S
MA 495
BP A124
EP A124
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 376WM
UT WOS:000261213700460
DA 2020-12-01
ER

PT J
AU Rodrigues, RS
   Miller, PR
   Bozza, FA
   Marchiori, E
   Zimmerman, GA
   Hoffman, JM
   Morton, KA
AF Rodrigues, R. S.
   Miller, P. R.
   Bozza, F. A.
   Marchiori, E.
   Zimmerman, G. A.
   Hoffman, J. M.
   Morton, K. A.
TI FDG-PET in patients at risk for acute respiratory distress syndrome: a
   preliminary report
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Acute respiratory distress syndrome; Adult respiratory distress
   syndrome; Postitron emission tomography; Fluordeoxyglucose; Acute lung
   injury
ID ACUTE LUNG INJURY; STANDARDIZED UPTAKE VALUES; QUALITY-OF-LIFE; ARDS;
   TOMOGRAPHY; F-18-FDG; KINETICS
AB Objective: To compare the pattern of lung uptake of 18F-fluorodeoxyglucose (FDG) by positron emission tomography (PET) imaging in patients with lung contusion that developed or did not progress to acute respiratory distress syndrome (ARDS).
   Design: Prospective, observational study.
   Setting: Trauma Center (academic urban hospital).
   Patients and interventions: Eight patients with blunt thoracic trauma and pulmonary contusion, confirmed by computed tomography (CT) on admission, underwent repeat CT and FDG-PET (on the same day) 24-72 h after admission.
   Results: No subjects met the criteria for ARDS at the time of the PET and second CT. Four subjects subsequently developed ARDS 1-3 days after the PET scan; the other four did not develop the syndrome. Three of the four subjects who subsequently developed ARDS showed diffuse FDG uptake throughout the entire lungs, while those who did not develop ARDS showed significant FDG uptake only in areas of focal lung opacity (non or poorly aerated lung units) on CT. FDG uptake in normally aerated lung regions was higher for those who subsequently developed ARDS than those who did not, approaching statistical significance. The normally aerated tissue: liver ratio was significantly higher in subjects who developed ARDS than in those who did not (P = 0.029).
   Conclusion: In this small series of patients with thoracic trauma, diffuse lung uptake of FDG was detected by PET imaging 1-3 days prior to clinically determined ARDS.
C1 [Morton, K. A.] Univ Utah, Hosp & Clin, Salt Lake City, UT 84132 USA.
   [Rodrigues, R. S.; Marchiori, E.] Univ Fed Rio de Janeiro, Dept Radiol, Rio De Janeiro, Brazil.
   [Miller, P. R.] Wake Forest Univ, Dept Surg, Winston Salem, NC 27109 USA.
   [Bozza, F. A.] Fundacao Oswaldo Cruz, IPEC, Rio De Janeiro, Brazil.
   [Marchiori, E.] Univ Fed Fluminense, Dept Radiol, Rio De Janeiro, Brazil.
   [Zimmerman, G. A.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84132 USA.
   [Zimmerman, G. A.] Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA.
   [Hoffman, J. M.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84132 USA.
   [Morton, K. A.] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA.
RP Morton, KA (corresponding author), Univ Utah, Hosp & Clin, 30 North 1900 East,Room 1A71, Salt Lake City, UT 84132 USA.
EM kathryn.Morton@hsc.utah.edu
RI Bozza, Fernando A/A-2618-2013; Rodrigues, Rosana/N-9866-2013; Marchiori,
   Edson/C-1205-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Marchiori,
   Edson/0000-0001-8797-7380
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL044525, R01HL044525,
   R01HL044525, R01HL044525, R01HL044525, R01HL044525, R01HL044525,
   R01HL044525, R01HL044525, R01HL044525, R01HL044525, R01HL044525,
   R01HL044525, R01HL044525] Funding Source: NIH RePORTER; NHLBI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL044525] Funding Source: Medline
CR BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   Chen DL, 2006, MOL PHARMACEUT, V3, P488, DOI 10.1021/mp060050w
   Chen DL, 2006, J APPL PHYSIOL, V100, P1602, DOI 10.1152/japplphysiol.01429.2005
   Chen DL, 2004, AM J PHYSIOL-LUNG C, V286, pL834, DOI 10.1152/ajplung.00339.2003
   Dowdy DW, 2006, INTENS CARE MED, V32, P1115, DOI 10.1007/s00134-006-0217-3
   Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121
   Jacene HA, 2004, CLIN NUCL MED, V29, P786, DOI 10.1097/00003072-200412000-00002
   Maggiore SM, 2006, INTENS CARE MED, V32, P1683, DOI 10.1007/s00134-006-0345-9
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS
   Miller PR, 2001, J TRAUMA, V51, P223, DOI 10.1097/00005373-200108000-00003
   Musch G, 2007, ANESTHESIOLOGY, V106, P723, DOI 10.1097/01.anes.0000264748.86145.ac
   Paik JY, 2004, J NUCL MED, V45, P124
   Paquet N, 2004, J NUCL MED, V45, P784
   Richard JC, 2006, INTENS CARE MED, V32, P1889, DOI 10.1007/s00134-006-0331-2
   Schroeder T, 2008, ACAD RADIOL, V15, P763, DOI 10.1016/j.acra.2007.12.016
   Schuster DP, 2007, AM J RESP CRIT CARE, V176, P224, DOI 10.1164/rccm.200703-462PP
   Schuster DP, 2002, INTENS CARE MED, V28, P1246, DOI 10.1007/s00134-002-1414-3
   Westerterp M, 2007, EUR J NUCL MED MOL I, V34, P392, DOI 10.1007/s00259-006-0224-1
   Zimmerman GA, 2003, ACUTE RESP DISTRESS, V179, P245
NR 20
TC 48
Z9 51
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD DEC
PY 2008
VL 34
IS 12
BP 2273
EP 2278
DI 10.1007/s00134-008-1220-7
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA 374SA
UT WOS:000261062800022
PM 18682917
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Bozza, FA
   Soares, M
   Verdeal, JCR
   Castro-Faria-Neto, HC
   Silva, JRLE
   Bozza, PT
AF Salluh, Jorge I. F.
   Bozza, Fernando A.
   Soares, Marcio
   Verdeal, Juann Carlos R.
   Castro-Faria-Neto, Hugo C.
   Silva, Jose Roberto Lapa e
   Bozza, Patricia T.
TI Adrenal Response in Severe Community-Acquired Pneumonia Impact on
   Outcomes and Disease Severity
SO CHEST
LA English
DT Article; Proceedings Paper
CT 21st Annual Meeting of the European-Society-of-Intensive-Care-Medicine
CY SEP 21-24, 2008
CL Lisbon, PORTUGAL
SP European Soc Inten Care Med
DE adrenal insufficency; community-acquired pneumonia; cortisol; critical
   illness-related corticosteroid insufficiency; severe sepsis
ID CRITICALLY-ILL PATIENTS; SEPTIC SHOCK; CORTISOL-LEVELS; ORGAN FAILURE;
   CORTICOSTEROID INSUFFICIENCY; LEVELS CORRELATE; SEPSIS; HYDROCORTISONE;
   VALIDATION; MARKERS
AB Background: High cortisol levels are frequent in patients with severe infections. However, the predictive value of total cortisol and of the presence of critical illness-related corticosteroid insufficiency (CIRCI) in severe community-acquired pneumonia (CAP) remains to be thoroughly evaluated. The aim of this study was to investigate the predictive value of adrenal response in patients with severe CAP admitted to the ICU.
   Methods: Baseline and postcorticotropin cortisol levels C-reactive protein (CRP), d-dimer, clinical variables, sequential organ failure assessment (SOFA), APACHE (acute physiology and chronic health evaluation) 11, and CURB-65 (confusion, urea nitrogen, respiratory rate, BP, age >= 65 years) scores were measured in the first 24 h. Results are shown as median (interquartile range [IQR]). The major outcome measure was hospital mortality.
   Results: Seventy-two patients with severe CAP admitted to the ICU were evaluated. Baseline cortisol levels were 18.1 mu g/dL (IQR, 14.4 to 26.7 mu g/dL), and the difference between baseline and postcorticotropin cortisol after 250 mu g of corticotropin was 19 mu g/dL (IQR, 12.8 to 27 mu g/dL). Baseline cortisol levels presented positive correlations with scores of disease severity, including CURB-65, APACHE 11, and SOFA (p < 0.05). Cortisol levels in nonsurvivors were higher than in survivors. CIRCI was diagnosed in 29 patients (40.8%). In univariate analysis, baseline cortisol, CURB-65, and APACHE 11 were predictors of death. The discriminative ability of baseline cortisol (area under receiver operating characteristic curve, 0.77; 95% confidence interval, 0.65 to 0.90; best cutoff for cortisol, 25.7 mu g/dL) for in-hospital mortality was better than APACHE II, CURB-65, SOFA, d-dimer, or CRP.
   Conclusions: Baseline cortisol levels are better predictors of severity and outcome in severe CAP than postcorticotropin cortisol or routinely measured laboratory parameters or scores as APACHE 11, SOFA, and CURB-65. (CHEST 2008; 134:947-954)
C1 [Salluh, Jorge I. F.] Inst Nacl Canc, Ctr Tratamento Intens, Intens Care Unit, BR-20930130 Rio De Janeiro, Brazil.
   [Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Inst Oswaldo Cruz, Lab Immunopharmacol, Fiocruz, Brazil.
   [Bozza, Patricia T.] Inst Pesquisa Clin Evandro Chagas, Fiocruz, Brazil.
   [Verdeal, Juann Carlos R.] Hosp Barra Dor, Intens Care Unit, Rio De Janeiro, Brazil.
   [Silva, Jose Roberto Lapa e] Univ Fed Rio de Janeiro, Dept Pulm Dis, Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Inst Nacl Canc, Ctr Tratamento Intens, Intens Care Unit, 10 Andar,Cruz Vernelha 23, BR-20930130 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI Soares, Marcio/B-3083-2013; dantas, vicente c souza/L-2648-2013; Bozza,
   Fernando A/A-2618-2013; Salluh, Jorge IF/F-6779-2012; Lapa e Silva, Jose
   R./AAS-4793-2020
OI Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256; Lapa e Silva, Jose R./0000-0003-3116-0253;
   Salluh, Jorge/0000-0002-8164-1453; Bozza, Patricia/0000-0001-8349-9529
CR Alberti C, 2005, AM J RESP CRIT CARE, V171, P461, DOI 10.1164/rccm.200403-324OC
   Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Bakhtiari K, 2004, CRIT CARE MED, V32, P2416, DOI 10.1097/01.CCM.0000147769.07699.E3
   BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bozza FA, 2005, MEM I OSWALDO CRUZ, V100, P217, DOI 10.1590/S0074-02762005000900037
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Buising KL, 2006, THORAX, V61, P419, DOI 10.1136/thx.2005.051326
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529
   de Jong MFC, 2007, CRIT CARE, V11, DOI 10.1186/cc5928
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   GOTOH S, 2008, EUR RESP J
   Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043
   Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba
   Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A
   Marshall John C, 2006, Curr Infect Dis Rep, V8, P351, DOI 10.1007/s11908-006-0045-1
   Niederman MS, 2007, CHEST, V131, P1205, DOI 10.1378/chest.06-1994
   Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010
   Povoa P, 2008, CURR OPIN INFECT DIS, V21, P157, DOI 10.1097/QCO.0b013e3282f47c32
   Querol-Ribelles JM, 2004, CHEST, V126, P1087, DOI 10.1378/chest.126.4.1087
   Rello J, 2007, INTENS CARE MED, V33, P2043, DOI 10.1007/s00134-007-0896-4
   Restrepo MI, 2008, CHEST, V133, P828, DOI 10.1378/chest.07-2887
   Riche FC, 2007, INTENS CARE MED, V33, P1761, DOI 10.1007/s00134-007-0770-4
   Salluh J, 2006, INTENS CARE MED, V32, P595, DOI 10.1007/s00134-005-0046-9
   Salluh JIF, 2008, CRIT CARE, V12, DOI 10.1186/cc6922
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
NR 36
TC 38
Z9 43
U1 0
U2 1
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD NOV
PY 2008
VL 134
IS 5
BP 947
EP 954
DI 10.1378/chest.08-1382
PG 8
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 372RF
UT WOS:000260918500011
PM 18753464
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Zimmerman, GA
AF Bozza, Fernando A.
   Zimmerman, Guy A.
TI Promises, promises: N-terminal proB-type natriuretic peptide as a
   biomarker in acute lung injury
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE acute respiratory distress syndrome; biomarkers; N-terminal proB-type
   natriuretic peptide; natriuretic peptides; outcome; stratification
ID RESPIRATORY-DISTRESS-SYNDROME; SEPSIS; HYPOXIA
C1 [Bozza, Fernando A.] Fiocruz MS, Inst Pesquisas Clin Evandro Chagas, Intens Care Unit, BR-21045900 Rio De Janeiro, Brazil.
   [Zimmerman, Guy A.] Univ Utah, Dept Internal Med, Program Human Mol Biol & Genet, Div Resp & Crit Care Med, Salt Lake City, UT 84112 USA.
RP Bozza, FA (corresponding author), Fiocruz MS, Inst Pesquisas Clin Evandro Chagas, Intens Care Unit, BR-21045900 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
CR Bajwa EK, 2008, CRIT CARE MED, V36, P2322, DOI 10.1097/CCM.0b013e318181040d
   Bajwa EK, 2007, CRIT CARE MED, V35, P2484, DOI 10.1097/01.CCM.0000281852.36573.22
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Girard TD, 2007, CRIT CARE MED, V35, P2638, DOI 10.1097/01.CCM.0000288097.81989.D3
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Ma KK, 2004, J MOL CELL CARDIOL, V36, P505, DOI 10.1016/j.yjmcc.2004.01.001
   Martinez-Rumayor A, 2008, AM J CARDIOL, V101, p3A, DOI 10.1016/j.amjcard.2007.11.012
   Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305
   Pettila V, 2002, CRIT CARE MED, V30, P271, DOI 10.1097/00003246-200202000-00001
   Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976
   Sun JZ, 2000, AM J PHYSIOL-LUNG C, V279, pL511
   Weidemann A, 2008, BIOCHEM J, V409, P233, DOI 10.1042/BJ20070629
   ZIMMERMAN GA, 1982, AM J MED, V73, P25, DOI 10.1016/0002-9343(82)90920-2
NR 13
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD AUG
PY 2008
VL 36
IS 8
BP 2461
EP 2462
DI 10.1097/CCM.0b013e31818112eb
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA 335DN
UT WOS:000258271100044
PM 18664803
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Cruz, OG
   Zagne, SM
   Azeredo, EL
   Nogueira, RMR
   Assis, EF
   Bozza, PT
   Kubelka, CF
AF Bozza, Fernando A.
   Cruz, Oswaldo G.
   Zagne, Sonia Mo
   Azeredo, Elzinandes L.
   Nogueira, Rita M. R.
   Assis, Edson F.
   Bozza, Patricia T.
   Kubelka, Claire F.
TI Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma
   as predictive factors for severity
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; C VIRUS-INFECTION; HEMORRHAGIC-FEVER; DISEASE
   SEVERITY; ADHESION MOLECULES; SHOCK-SYNDROME; NK CELLS; IMMUNE
   ACTIVATION; SERUM-LEVELS; T-CELLS
AB Background: Dengue virus pathogenesis is not yet fully understood and the identification of patients at high risk for developing severe disease forms is still a great challenge in dengue patient care. During the present study, we evaluated prospectively the potential of cytokines present in plasma from patients with dengue in stratifying disease severity.
   Methods: Seventeen-cytokine multiplex fluorescent microbead immunoassay was used for the simultaneous detection in 59 dengue patients. GLM models using bimodal or Gaussian family were determined in order to associate cytokines with clinical manifestations and laboratory diagnosis.
   Results: IL-1 beta, IFN-gamma, IL-4, IL-6, IL-13, IL-7 and GM-CSF were significantly increased in patients with severe clinical manifestations ( severe dengue) when compared to mild disease forms ( mild dengue). In contrast, increased MIP-1 beta levels were observed in patients with mild dengue. MIP-1 beta was also associated with CD56+NK cell circulating rates. IL-1 beta, IL-8, TNF-alpha and MCP-1 were associated with marked thrombocytopenia. Increased MCP-1 and GM-CSF levels correlated with hypotension. Moreover, MIP-1 beta and IFN-gamma were independently associated with both dengue severity and disease outcome.
   Conclusion: Our data demonstrated that the use of a multiple cytokine assay platform was suitable for identifying distinct cytokine profiles associated with the dengue clinical manifestations and severity. MIP-beta is indicated for the first time as a good prognostic marker in contrast to IFN-gamma that was associated with disease severity.
C1 [Azeredo, Elzinandes L.; Kubelka, Claire F.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunol Viral, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa, Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Cruz, Oswaldo G.] Fundacao Oswaldo Cruz, Programa Computacao Cient, Rio De Janeiro, Brazil.
   [Zagne, Sonia Mo] Univ Fed Fluminense, Hosp Univ Antonio Pedro, Niteroi, RJ, Brazil.
   [Nogueira, Rita M. R.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Flavivirus, Rio de Janeiro, Brazil.
   [Assis, Edson F.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio de Janeiro, Brazil.
RP Kubelka, CF (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunol Viral, Rio De Janeiro, Brazil.
EM fernando.bozza@ipec.fiocruz.br; oswaldo@fiocruz.br;
   sonia_maris@yahoo.com.br; elzinandes@ioc.fiocruz.br;
   rita@ioc.fiocruz.br; edassis@ioc.fiocruz.br; pbozza@ioc.fiocruz.br;
   claire@ioc.fiocruz.br
RI Kubelka, Claire F/C-5558-2009; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529
CR [Anonymous], R LANG ENV STAT COMP
   Avila-Aguero ML, 2004, CYTOKINE, V27, P173, DOI 10.1016/j.cyto.2004.05.007
   Azeredo EL, 2006, CLIN EXP IMMUNOL, V143, P345, DOI 10.1111/j.1365-2249.2006.02996.x
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Balmaseda A, 2005, AM J TROP MED HYG, V73, P1059, DOI 10.4269/ajtmh.2005.73.1059
   BERNASCONI S, 1995, INT J CANCER, V60, P300, DOI 10.1002/ijc.2910600304
   Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807
   Bigger CB, 2004, J VIROL, V78, P13779, DOI 10.1128/JVI.78.24.13779-13792.2004
   Bouros Demosthenes, 2004, BMC Pulm Med, V4, P6, DOI 10.1186/1471-2466-4-6
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   *BRAZ HLTH MIN, 2007, SECR VIG SAUD DENG I
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Dorner BG, 2004, J IMMUNOL, V172, P3119, DOI 10.4049/jimmunol.172.5.3119
   Fink J, 2006, REV MED VIROL, V16, P263, DOI 10.1002/rmv.507
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   Hutchinson KL, 2001, J MED VIROL, V65, P561, DOI 10.1002/jmv.2073
   KURANE I, 1993, AM J TROP MED HYG, V48, P222, DOI 10.4269/ajtmh.1993.48.222
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   La Braga E, 2001, MEM I OSWALDO CRUZ, V96, P229, DOI 10.1590/S0074-02762001000200015
   Laur F, 1998, T ROY SOC TROP MED H, V92, P654, DOI 10.1016/S0035-9203(98)90800-8
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Loetscher P, 1996, J IMMUNOL, V156, P322
   Mabalirajan U, 2005, AM J TROP MED HYG, V72, P783, DOI 10.4269/ajtmh.2005.72.783
   Mangada MM, 2005, J IMMUNOL, V175, P2676, DOI 10.4049/jimmunol.175.4.2676
   Mangada MM, 2002, J INFECT DIS, V185, P1697, DOI 10.1086/340822
   Marty AM, 2006, CLIN LAB MED, V26, P345, DOI 10.1016/j.cll.2006.05.001
   Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X
   Miagostovich Mariz P., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P149, DOI 10.1590/S0036-46651993000200006
   Miagostovich MP, 1999, J CLIN VIROL, V14, P183, DOI 10.1016/S1386-6532(99)00059-1
   Miagostovich MP, 1997, MEM I OSWALDO CRUZ, V92, P595, DOI 10.1590/S0074-02761997000500006
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Phuong CXT, 2004, AM J TROP MED HYG, V70, P172, DOI 10.4269/ajtmh.2004.70.172
   Pinto LA, 2005, VACCINE, V23, P3555, DOI 10.1016/j.vaccine.2005.01.146
   Shivbalan So., 2004, Indian Journal of Pediatrics, V71, P33, DOI 10.1007/BF02725653
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Spain-Santana TA, 2001, J MED VIROL, V65, P324, DOI 10.1002/jmv.2037
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   TAUB DD, 1995, J IMMUNOL, V155, P3877
   VITARANA T, 1991, Ceylon Medical Journal, V36, P63
   *WHO, 2002, DENG DENG HEM FEV
   Wilder-Smith A, 2005, NEW ENGL J MED, V353, P924, DOI 10.1056/NEJMra041927
   World Health Organization, 1997, DENG HEM FEV DIAGN T
   Wright H, 2005, DIGEST DIS SCI, V50, P1793, DOI 10.1007/s10620-005-2940-y
NR 55
TC 216
Z9 219
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 25
PY 2008
VL 8
AR 86
DI 10.1186/1471-2334-8-86
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 329NE
UT WOS:000257873500001
PM 18578883
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU d'Avila, JC
   Santiago, APSA
   Amancio, RT
   Galina, A
   Oliveira, MF
   Bozza, FA
AF d'Avila, Joana da Costa
   Santiago, Ana Paula S. A.
   Amancio, Rodrigo T.
   Galina, Antonio
   Oliveira, Marcus F.
   Bozza, Fernando A.
TI Sepsis induces brain mitochondrial dysfunction
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE energy metabolism; MODS; mitochondria; sepsis; brain; oxidative stress
ID NITRIC-OXIDE; ORGAN DYSFUNCTION; OXIDATIVE STRESS; CECAL LIGATION;
   SEPTIC SHOCK; RAT-BRAIN; REDUCTASE-ACTIVITY; HYDROGEN-PEROXIDE; CRITICAL
   ILLNESS; SKELETAL-MUSCLE
AB Objective: Mitochondrial dysfunctions have been associated with the pathogenesis of sepsis. A systematic survey of mitochondrial function in brain tissues during sepsis is lacking. In the present work, we investigate brain mitochondrial function in a septic mouse model.
   Design: Prospective animal study.
   Setting: University research laboratory.
   Subjects: Male Swiss mice, aged 6-8 wks.
   Interventions: Mice were subjected to cecal ligation and perforation (sepsis group) with saline resuscitation or to sham operation (control group).
   Measurements and Main Results. Oxygen consumption was measured polarographically in an oximeter. Brain homogenates from septic animals presented higher oxygen consumption in the absence of adenosine 5'-diphosphate (state 4) compared with control animals. The increase in state 4 respiration in animals in the cecal ligation and perforation group resulted in a drastic decrease in both respiratory control and adenosine 5'-diphosphate/oxygen ratios, indicating a reduction in the oxidative phosphorylation efficiency. Septic animals presented a significant increase in the recovery time of mitochondrial membrane potential on adenosine 5'-diphosphate addition compared with control animals, suggesting a proton leak through the inner mitochondrial membrane. The septic group presented a general reduction in the content of cytochromes. Moreover, the activity of cytochrome c oxidase was specifically and significantly decreased in the brain during sepsis. Hydrogen peroxide generation by brain mitochondria from septic mice did not respond to substrates of electron transport chain or to adenosine 5'-diphosphate, showing that mitochondrial function may be compromised in a critical level in the brain during sepsis.
   Conclusions. The mitochondrial dysfunctions demonstrated here indicate that uncoupling of oxidative phosphorylation takes place in the brain of septic mice, compromising tissue bioenergetic efficiency.
C1 [d'Avila, Joana da Costa; Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Lab Bioquim Redox, Programa Biol Mol & Biotecnol, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Santiago, Ana Paula S. A.; Galina, Antonio] Univ Fed Rio de Janeiro, Lab Bioenerget Adaptat, Programa Biofis & Bioquim Celular, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Amancio, Rodrigo T.; Bozza, Fernando A.] Inst Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-20001 Rio De Janeiro, Brazil.
   [Amancio, Rodrigo T.; Bozza, Fernando A.] Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil.
RP d'Avila, JC (corresponding author), Univ Fed Rio de Janeiro, Lab Bioquim Redox, Programa Biol Mol & Biotecnol, Inst Bioquim Med, Cidade Univ, Rio De Janeiro, Brazil.
EM maroli@bioqmed.ufrj.br; fbozza@hucff.ufrj.br
RI Oliveira, Marcus/G-3158-2011; Bozza, Fernando A/A-2618-2013; Galina,
   Antonio/A-9292-2008; d'Avila, Joana/L-8970-2013
OI Oliveira, Marcus/0000-0002-9890-8425; Bozza, Fernando
   A/0000-0003-4878-0256; d'Avila, Joana/0000-0002-2045-0813
CR Adrie C, 2001, AM J RESP CRIT CARE, V164, P389, DOI 10.1164/ajrccm.164.3.2009088
   AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6
   BAKER CC, 1983, SURGERY, V94, P331
   Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12
   Barichello T, 2005, CRIT CARE MED, V33, P221, DOI 10.1097/01.CCM.0000150741.12906.BD
   Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0
   Boczkowski J, 1999, FASEB J, V13, P1637
   Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7
   BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707
   Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003
   Brealey D, 2002, LANCET, V360, P219, DOI 10.1016/S0140-6736(02)09459-X
   Callahan LA, 2005, AM J RESP CRIT CARE, V172, P861, DOI 10.1164/rccm.200410-1344OC
   Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178
   CHANCE B, 1955, J BIOL CHEM, V217, P383
   Chuang YC, 2002, J BIOMED SCI, V9, P542, DOI 10.1007/BF02254981
   Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631
   Crouser ED, 2004, MITOCHONDRION, V4, P729, DOI 10.1016/j.mito.2004.07.023
   Crouser ED, 2002, CRIT CARE MED, V30, P276, DOI 10.1097/00003246-200202000-00002
   D'Amico G, 2006, J CELL SCI, V119, P2291, DOI 10.1242/jcs.02914
   Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2
   Echtay KS, 2003, EMBO J, V22, P4103, DOI 10.1093/emboj/cdg412
   Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a
   Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470
   Fink MP, 2002, INTENS CARE MED, V28, P369, DOI 10.1007/s00134-001-1205-2
   Fink MP, 2001, CRIT CARE CLIN, V17, P219, DOI 10.1016/S0749-0704(05)70161-5
   GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601
   Gegg ME, 2003, J NEUROCHEM, V86, P228, DOI 10.1046/j.1471-4159.2003.01821.x
   Gnaiger E, 1998, J EXP BIOL, V201, P1129
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Hayes MA, 1997, CRIT CARE MED, V25, P926, DOI 10.1097/00003246-199706000-00007
   Kadoi Y, 2004, ANESTH ANALG, V99, P212, DOI 10.1213/01.ANE.0000118111.94913.22
   Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X
   LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Milbrandt EB, 2006, CRIT CARE, V10, DOI 10.1186/cc5078
   Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x
   Navarro A, 2004, AM J PHYSIOL-REG I, V287, pR1244, DOI 10.1152/ajpregu.00226.2004
   Nicholls D. G., 2002, BIOENERGETICS, V3
   Porta F, 2006, CRIT CARE, V10, DOI 10.1186/cc5013
   Porta F, 2006, J ENDOTOXIN RES, V12, P358, DOI 10.1179/096805106X153952
   Protti A, 2006, CRIT CARE, V10, DOI 10.1186/cc5014
   Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   SCHUMER W, 1970, ANN SURG, V171, P875, DOI 10.1097/00000658-197006010-00008
   Sharp DJ, 2004, CEREB CORTEX, V14, P1, DOI 10.1093/cercor/bhg086
   SIMS NR, 1986, J NEUROCHEM, V47, P496
   SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x
   SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001
   Sun XY, 2003, AM J PHYSIOL-ENDOC M, V285, pE512, DOI 10.1152/ajpendo.00446.2002
   Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4
   Vianna RCS, 2004, SHOCK, V21, P115, DOI 10.1097/01.shk.0000111828.07309.26
   Votyakova TV, 2004, ARCH BIOCHEM BIOPHYS, V431, P138, DOI 10.1016/j.abb.2004.07.025
NR 55
TC 96
Z9 104
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUN
PY 2008
VL 36
IS 6
BP 1925
EP 1932
DI 10.1097/CCM.0b013e3181760c4b
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 310EZ
UT WOS:000256513000032
PM 18496362
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Weyrich, AS
AF Bozza, Fernando A.
   Weyrich, Andrew S.
TI Mitochondria push platelets past their prime
SO BLOOD
LA English
DT Editorial Material
C1 [Bozza, Fernando A.; Weyrich, Andrew S.] Univ Utah, Fundacao Oswaldo Cruz, Salt Lake City, UT 84112 USA.
RP Bozza, FA (corresponding author), Univ Utah, Fundacao Oswaldo Cruz, Salt Lake City, UT 84112 USA.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Weyrich,
   Andrew/0000-0001-9622-4647
CR Leytin V, 2006, J THROMB HAEMOST, V4, P2656, DOI 10.1111/j.1538-7836.2006.02200.x
   Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037
   Remenyi G, 2005, ARTERIOSCL THROM VAS, V25, P467, DOI 10.1161/01.ATV.0000152726.49229.bf
   Verhoeven AJ, 2005, TRANSFUSION, V45, P82, DOI 10.1111/j.1537-2995.2005.04023.x
NR 4
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 1
PY 2008
VL 111
IS 5
BP 2496
EP 2497
DI 10.1182/blood-2007-12-126193
PG 2
WC Hematology
SC Hematology
GA 269SX
UT WOS:000253671600002
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Povoa, P
   Soares, M
   Castro-Faria-Neto, HC
   Bozza, FA
   Bozza, PT
AF Salluh, Jorge I. F.
   Povoa, Pedro
   Soares, Marcio
   Castro-Faria-Neto, Hugo C.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI The role of corticosteroids in severe community-acquired pneumonia: a
   systematic review
SO CRITICAL CARE
LA English
DT Article
ID C-REACTIVE PROTEIN; LOW-DOSE HYDROCORTISONE; SEPTIC SHOCK;
   METHYLPREDNISOLONE TREATMENT; INFLAMMATORY RESPONSE; DIRECTED THERAPY;
   CORTISOL-LEVELS; SEVERE SEPSIS; RECOMMENDATIONS; MANAGEMENT
AB Introduction The purpose of this review was to evaluate the impact of corticosteroids on the outcomes of patients with severe community-acquired pneumonia (CAP).
   Methods We performed a systematic MEDLINE, Cochrane database, and CINAHL search (1966 to November 2007) identify full-text publications that evaluated the use of corticosteroids in CAP.
   Results An initial literature search yielded 109 articles, and 105 studies were excluded after the first analysis. We found four studies eligible for analysis. On the basis of their results, the use of corticosteroids as adjunctive therapy in severe CAP should be categorized as a weak recommendation (two studies) and a strong recommendation (two studies) with either low-or moderate-quality evidence. However, no evidence of adverse outcomes or harm is present in the evaluated studies.
   Conclusion According to the GRADE system, available studies not support the recommendation of corticosteroids as a standard of care for patients with severe CAP. Further randomized controlled trials with this aim should enroll a larger number of severely ill patients. However, in patients needing corticosteroids, it may be reasonable to conclude that corticosteroid administration is safe in patients with severe infections receiving antimicrobial therapy.
C1 [Salluh, Jorge I. F.; Soares, Marcio] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Soares, Marcio] Praca Cruz Vermelha, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo Cruz, Immunopharmacol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Povoa, Pedro] Ctr Hosp Lisboa Ocidental, Hosp Sao Francisco Xavier, Med Intens Care Unit, P-1449005 Lisbon, Portugal.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI Bozza, Fernando A/A-2618-2013; Soares, Marcio/B-3083-2013; dantas,
   vicente c souza/L-2648-2013; Salluh, Jorge IF/F-6779-2012
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Povoa, Pedro/0000-0002-7069-7304; Bozza,
   Patricia/0000-0001-8349-9529
CR Annane D, 2006, CRIT CARE MED, V34, P22, DOI 10.1097/01.CCM.0000194723.78632.62
   Annane D, 2004, BRIT MED J, V329, P480, DOI 10.1136/bmj.38181.482222.55
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Bauer TT, 2001, EUR RESPIR J, V17, P274, DOI 10.1183/09031936.01.17202740
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010
   BONE RC, 1987, CHEST, V92, P1032, DOI 10.1378/chest.92.6.1032
   Bozza FA, 2005, MEM I OSWALDO CRUZ, V100, P217, DOI 10.1590/S0074-02762005000900037
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Briel M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006150
   Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC
   Coelho L, 2007, CRIT CARE, V11, DOI 10.1186/cc6105
   Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC
   Ewig S, 1998, AM J RESP CRIT CARE, V158, P1102, DOI 10.1164/ajrccm.158.4.9803114
   Fernandez-Serrano S, 2003, CLIN DIAGN LAB IMMUN, V10, P813, DOI 10.1128/CDLI.10.5.813-820.2003
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Garcia-Vidal C, 2007, EUR RESPIR J, V30, P951, DOI 10.1183/09031936.00027607
   Hambach L, 2002, HAEMATOLOGICA, V87, P643
   HARRISON BDW, 1987, J ROY COLL PHYS LOND, V21, P267
   Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC
   Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   MARIK P, 1993, CHEST, V104, P389, DOI 10.1378/chest.104.2.389
   Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba
   Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084
   Meduri GU, 2002, AM J RESP CRIT CARE, V165, P983, DOI 10.1164/ajrccm.165.7.2106014
   Mikami K, 2007, LUNG, V185, P249, DOI 10.1007/s00408-007-9020-3
   Monton C, 1999, EUR RESPIR J, V14, P218, DOI 10.1034/j.1399-3003.1999.14a37.x
   Niederman MS, 2007, CHEST, V131, P1205, DOI 10.1378/chest.06-1994
   Oppert M, 2005, CRIT CARE MED, V33, P2457, DOI 10.1097/01.CCM.0000186370.78639.23
   Perren A, 2008, INFECTION, V36, P163, DOI 10.1007/s15010-007-7206-5
   Povoa P, 2005, EUR RESPIR J, V25, P804, DOI 10.1183/09031936.05.00071704
   Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307
   Salluh J, 2006, INTENS CARE MED, V32, P595, DOI 10.1007/s00134-005-0046-9
   Schunemann HJ, 2006, AM J RESP CRIT CARE, V174, P605, DOI 10.1164/rccm.200602-197ST
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   Woodhead M, 2006, CRIT CARE, V10, DOI 10.1186/cc4927
NR 37
TC 51
Z9 58
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2008
VL 12
IS 3
AR R76
DI 10.1186/cc6922
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA 326CK
UT WOS:000257635300015
PM 18547407
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Povoa, P
   Soares, M
   Castro-Faria-Neto, HC
   Bozza, FA
   Bozza, PT
AF Salluh, Jorge I. F.
   Povoa, Pedro
   Soares, Marcio
   Castro-Faria-Neto, Hugo C.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI The role of corticosteroids in severe community-acquired pneumonia: a
   systematic review (vol 12, pg R76, 2008)
SO CRITICAL CARE
LA English
DT Correction
C1 [Salluh, Jorge I. F.; Soares, Marcio] Inst Nacl Canc, Intens Care Unit, BR-20230130 Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo, Immunopharmacol Lab, BR-21045900 Rio De Janeiro, Brazil.
   [Povoa, Pedro] Hosp Sao Francisco Xavier, Ctr Hosp Lisboa Ocident, Med Intens Care Unit, P-1449005 Lisbon, Portugal.
   [Bozza, Fernando A.] Fundacao Oswaldo, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Inst Nacl Canc, Intens Care Unit, Praca Cruz Vermelha 23,10 Andar Ctr, BR-20230130 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI dantas, vicente c souza/L-2648-2013; Soares, Marcio/B-3083-2013; Salluh,
   Jorge IF/F-6779-2012; Bozza, Fernando A/A-2618-2013
OI Soares, Marcio/0000-0003-2503-6088; Bozza, Fernando
   A/0000-0003-4878-0256; Povoa, Pedro/0000-0002-7069-7304; Bozza,
   Patricia/0000-0001-8349-9529
CR Salluh JIF, 2008, CRIT CARE, V12, DOI 10.1186/cc6922
NR 1
TC 0
Z9 0
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1466-609X
J9 CRIT CARE
JI Crit. Care
PY 2008
VL 12
IS 6
AR 434
DI 10.1186/cc7107
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 415QK
UT WOS:000263949200049
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Salluh, JIF
   Bozza, PT
   Bozza, FA
AF Salluh, Jorge I. F.
   Bozza, Patricia T.
   Bozza, Fernando A.
TI Surviving sepsis campaign: A critical reappraisal
SO SHOCK
LA English
DT Article; Proceedings Paper
CT 4th International Sepsis Symposium
CY MAY, 2007
CL Sao Paulo, BRAZIL
SP Brazilian Shock Soc, Latin Amer Sepsis Inst
DE sepsis; surviving sepsis campaign; severe infections; guidelines;
   multiorgan failure
ID INTENSIVE INSULIN THERAPY; SEPTIC SHOCK; GUIDELINES; HYDROCORTISONE;
   MANAGEMENT; EFFICACY; SAFETY
AB In 2002, the declaration of Barcelona launched a worldwide campaign that proposed to decrease in sepsis-related mortality by the introduction of evidence-based medicine into the management of sepsis. This paved the way for the publication of a wide selection of recommendations entitled the Surviving Sepsis Campaign (SSC) Guidelines. Whereas most of the medical community received the guidelines with enthusiasm, dissonant voices were made public just after its publication, and in recent years, the SSC guidelines were a source of intense debate, resulting in a recent revision of the guidelines. In the midst of a large controversy, it is evident that a critical reappraisal of the SSC guidelines is timely. In our opinion, whereas many relevant aspects of the SSC guidelines have been discussed, there are three major limitations that deserve a closer look, and they are sepsis as a public health issue, the weight of the evidence behind the recommendations, and the absence of recommendations related to the prevention of sepsis. In conclusion, although we recognize that the SSC is a valuable initiative, many of its present aspects must be revised to provide a clear message for clinicians taking care of sepsis patients at bedside. New guidelines should be based on solid evidence, have no interference from the pharmaceutical or medical equipment industry, and should have a stronger preventive and public health approach.
C1 [Salluh, Jorge I. F.] Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
   [Salluh, Jorge I. F.; Bozza, Patricia T.] IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
RP Salluh, JIF (corresponding author), Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br
RI Bozza, Fernando A/A-2618-2013; Salluh, Jorge IF/F-6779-2012; dantas,
   vicente c souza/L-2648-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Salluh,
   Jorge/0000-0002-8164-1453; Bozza, Patricia/0000-0001-8349-9529
CR Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238
   Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935
   Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862
   Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001
   Bertolini G, 2007, INTENS CARE MED, V33, P426, DOI 10.1007/s00134-007-0554-x
   Bozza FA, 2005, MEM I OSWALDO CRUZ, V100, P217, DOI 10.1590/S0074-02762005000900037
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   BRUNBUISSON C, 1994, ARCH INTERN MED, V154, P2484
   Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716
   Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   DePriest JL, 2004, CRIT CARE MED, V32, P1626, DOI 10.1097/01.CCM.0000130833.92258.B9
   Eichacker PQ, 2006, NEW ENGL J MED, V355, P1640, DOI 10.1056/NEJMp068197
   Fletcher SJ, 2006, ANAESTHESIA, V61, P313, DOI 10.1111/j.1365-2044.2006.04531.x
   Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9
   Landucci D, 2004, CRIT CARE MED, V32, P1598, DOI 10.1097/01.CCM.0000130834.99548.D9
   Lin SM, 2006, SHOCK, V26, P551, DOI 10.1097/01.shk.0000232271.09440.8f
   Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203
   Nadel S, 2007, LANCET, V369, P836, DOI 10.1016/S0140-6736(07)60411-5
   Pocock SJ, 2005, JAMA-J AM MED ASSOC, V294, P2228, DOI 10.1001/jama.294.17.2228
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   Remick DG, 2005, SHOCK, V24, P7, DOI 10.1097/01.shk.0000191384.34066.85
   SALLUH JI, 2008, CRIT CARE MED, V1, P1
   Salluh Jorge I. F., 2006, Rev. bras. ter. intensiva, V18, P328, DOI 10.1590/S0103-507X2006000400002
   Schultz MJ, 2008, INTENS CARE MED, V34, P779, DOI 10.1007/s00134-008-1027-6
   Simchen E, 2007, CRIT CARE MED, V35, P449, DOI 10.1097/01.CCM.0000253407.89594.15
   Singer Mervyn, 2006, Crit Care Resusc, V8, P244
   Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366
   Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   Vanhorebeek Ilse, 2006, Endocr Pract, V12 Suppl 3, P14
   Vlahakes GJ, 2006, NEW ENGL J MED, V354, P413, DOI 10.1056/NEJMe058272
   Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869
NR 35
TC 8
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PY 2008
VL 30
SU 1
BP 70
EP 72
DI 10.1097/SHK.0b013e318181ad60
PG 3
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 351JM
UT WOS:000259420600014
PM 18704005
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Gomes, M
   Cunha, M
   Torres, D
   Bozza, FA
   Zimmerman, GA
   Prescott, SM
   Bozza, PT
   Castro-Faria, HC
AF Gomes, Rachel N.
   Gomes, Michelle
   Cunha, Mariana
   Torres, Daianne
   Bozza, Fernando A.
   Zimmerman, Guy A.
   Prescott, Stephen M.
   Bozza, Patricia T.
   Castro-Faria-Neto, Hugo C.
TI Bacterial clearance and mortality are improved by platelet-activating
   factor acetylhydrolase (PAF-AH) administration: Involvement of
   MCP-I/CCL2
SO SHOCK
LA English
DT Meeting Abstract
CT 6th Congress of the International-Federation-of-Shock-Societies/31st
   Annual Conference of the Shock-Society
CY JUN 28-JUL 02, 2008
CL Cologne, GERMANY
SP Int Federat Shock Soc, Shock Soc
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PY 2008
VL 29
SU 1
MA P223
BP 74
EP 75
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 308SE
UT WOS:000256409500241
DA 2020-12-01
ER

PT J
AU Japiassu, A
   d'Avila, J
   Carnevale, R
   Galina, A
   Castro-Faria-Neto, H
   Oliveira, M
   Bozza, F
AF Japiassu, Andre
   d'Avila, Joana
   Carnevale, Renata
   Galina, Antonio
   Castro-Faria-Neto, Hugo
   Oliveira, Marcus
   Bozza, Fernando
TI Sepsis affect mitochondrial oxygen consumption associated to ATP
   synthesis in human peripheral blood monocytes by modifying ADP
   metabolism
SO SHOCK
LA English
DT Meeting Abstract
CT 6th Congress of the International-Federation-of-Shock-Societies/31st
   Annual Conference of the Shock-Society/7th Int Conf Complexity in Acute
   Illness
CY JUN 28-JUL 02, 2008
CL Cologne, GERMANY
SP Int Federat Shock Soc, Shock Soc
C1 IOC, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   IPEC, Intens Care Unit, Rio De Janeiro, Brazil.
   UFRJ, Inst Bioquim Med, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013; Galina, Antonio/A-9292-2008
OI Bozza, Fernando A/0000-0003-4878-0256; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PY 2008
VL 29
SU 1
MA P327
BP 104
EP 104
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 308SE
UT WOS:000256409500343
DA 2020-12-01
ER

PT J
AU Japiassu, A
   Amancio, R
   Carnevale, R
   Gomes, R
   Bastos, M
   Bozza, F
   Bozza, P
   Castro-Faria-Neto, H
AF Japiassu, Andre
   Amancio, Rodrigo
   Carnevale, Renata
   Gomes, Rachel
   Bastos, Michele
   Bozza, Fernando
   Bozza, Patricia
   Castro-Faria-Neto, Hugo
TI A novel sepsis model in mice using clinical parameters
SO SHOCK
LA English
DT Meeting Abstract
CT 6th Congress of the International-Federation-of-Shock-Societies/31st
   Annual Conference of the Shock-Society/7th Int Conf Complexity in Acute
   Illness
CY JUN 28-JUL 02, 2008
CL Cologne, GERMANY
SP Int Federat Shock Soc, Shock Soc
C1 [Japiassu, Andre; Amancio, Rodrigo; Carnevale, Renata; Gomes, Rachel; Bastos, Michele; Bozza, Fernando; Bozza, Patricia; Castro-Faria-Neto, Hugo] Fiocruz MS, IOC, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PY 2008
VL 29
SU 1
MA P328
BP 104
EP 105
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 308SE
UT WOS:000256409500344
DA 2020-12-01
ER

PT J
AU Salluh, JI
   Pino, AV
   Silva, AR
   Gomes, RN
   Souza, HS
   Silva, JRLE
   Jandre, FC
   Giannella, A
   Zimmerman, GA
   Stafforini, DM
   Prescott, SM
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, FA
AF Salluh, Jorge I.
   Pino, Alexandre V.
   Silva, Adriana R.
   Gomes, Rachel N.
   Souza, Heitor S.
   Silva, Jose Roberto Lapa e
   Jandre, Frederico C.
   Giannella-Neto, Antonio
   Zimmerman, Guy A.
   Stafforini, Diana M.
   Prescott, Stephen M.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
   Bozza, Fernando A.
TI Lung production of platelet-activating factor acetylhydrolase in oleic
   acid-induced acute lung injury
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
ID BRONCHOALVEOLAR LAVAGE FLUID; PROTEINS; MEDIATOR; PAF
AB Platelet-activating factor (PAF) is a proinflammatory mediator that plays a central role in acute lung injury (ALI). PAF-acetylhydrolases (PAF-AHs) terminate PAF's signals and regulate inflammation. In this study, we describe the kinetics of plasma and bronchoalveolar lavage (BAL) PAF-AH in the early phase of ALI. Six pigs with oleic acid induced ALI and two healthy controls were studied. Plasma and BAL samples were collected every 2h and immunohistochemical analysis of PAF-AH was performed in lung tissues. PAF-AH activity in BAL was increased at the end of the experiment (BAL PAF-AH Time 0 = 0.001 +/- 0.001 nmol/ml/min/g vs Time 6 = 0.031 +/- 0.018 nmol/ml/min/g, p = 0.04) while plasma activity was not altered. We observed increased PAF-AH staining of macrophages and epithelial cells in the lungs of animals with ALI but not in healthy controls. Our data suggest that increases in PAF-AH levels are, in part, a result of alveolar production. PAF-AH may represent a modulatory strategy to counteract the excessive pro-inflammatory effects of PAF and PAF-like lipids in lung inflammation. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Fundacao Oswaldo Cruz, IOC, Dept Physiol & Pharmacodynam, Immunopharmacol Lab, BR-21045900 Rio De Janeiro, Brazil.
   Inst Nacl Canc, Intens Care Unit, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Dept Biomed Engn, Pulm Engn Lab, BR-21945 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Multidisciplinary Lab, Rio De Janeiro, Brazil.
   Univ Utah, Dept Internal Med, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, ICU, BR-21045900 Rio De Janeiro, Brazil.
RP Salluh, JI (corresponding author), Fundacao Oswaldo Cruz, IOC, Dept Physiol & Pharmacodynam, Immunopharmacol Lab, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM jorgesalluh@yahoo.com.br; fbozza@ipec.fiocruz.br
RI Gomes, Rachel N/I-7643-2013; Bozza, Fernando A/A-2618-2013; de Souza,
   Heitor Siffert Pereira/G-3297-2012; Silva, Adriana/C-5931-2014; Salluh,
   Jorge IF/F-6779-2012; dantas, vicente c souza/L-2648-2013; Silva,
   Adriana Ribeiro/U-7811-2019; Lapa e Silva, Jose R./AAS-4793-2020
OI Bozza, Fernando A/0000-0003-4878-0256; de Souza, Heitor Siffert
   Pereira/0000-0002-3647-7324; Silva, Adriana/0000-0002-5137-4251; Silva,
   Adriana Ribeiro/0000-0002-5137-4251; Lapa e Silva, Jose
   R./0000-0003-3116-0253; Bozza, Patricia/0000-0001-8349-9529; Salluh,
   Jorge/0000-0002-8164-1453; Pino, Alexandre/0000-0001-5074-6562
CR Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   BYRNE K, 1991, J SURG RES, V50, P111, DOI 10.1016/0022-4804(91)90232-B
   CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980
   Claus RA, 2005, CRIT CARE MED, V33, P1416, DOI 10.1097/01.CCM.0000165807.26485.ED
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Grissom CK, 2003, CRIT CARE MED, V31, P770, DOI 10.1097/01.CCM.0000053647.82608.29
   Jandre FC, 2004, IEEE T BIO-MED ENG, V51, P823, DOI 10.1109/TBME.2004.826678
   Jehle R, 2001, BBA-MOL CELL BIOL L, V1532, P60, DOI 10.1016/S1388-1981(01)00112-3
   Karagiorga G, 2006, INTENS CARE MED, V32, P116, DOI 10.1007/s00134-005-2868-x
   Kollef MH, 1998, CHEST, V113, P412, DOI 10.1378/chest.113.2.412
   Louis NA, 2005, PROSTAG LEUKOTR ESS, V73, P197, DOI 10.1016/j.plefa.2005.05.006
   MATSUMOTO K, 1992, CLIN EXP PHARMACOL P, V19, P509, DOI 10.1111/j.1440-1681.1992.tb00497.x
   Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727
   Nakos G, 1997, AM J RESP CRIT CARE, V155, P945, DOI 10.1164/ajrccm.155.3.9117030
   Nakos G, 2005, CRIT CARE MED, V33, P772, DOI 10.1097/01.CCM.0000158519.80090.74
   Nakos G, 2004, CRIT CARE MED, V32, P1434, DOI 10.1097/01.CCM.0000124879.21782.3A
   Nakos G, 1998, INTENS CARE MED, V24, P296, DOI 10.1007/s001340050571
   Nakos G, 2003, INTENS CARE MED, V29, P555, DOI 10.1007/s00134-003-1680-8
   Neto HCCF, 2005, MEM I OSWALDO CRUZ, V100, P83, DOI 10.1590/S0074-02762005000900014
   Opal S, 2004, CRIT CARE MED, V32, P332, DOI 10.1097/01.CCM.0000108867.87890.6D
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682
   Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693
   Triggiani M, 1997, AM J RESP CRIT CARE, V156, P94, DOI 10.1164/ajrccm.156.1.9608084
   Zhou ZH, 2005, AM J RESP CRIT CARE, V172, P344, DOI 10.1164/rccm.200503-343OC
   Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020
   Zimmerman GA, 2005, CRIT CARE MED, V33, P1462, DOI 10.1097/01.CCM.0000166719.65161.D3
NR 27
TC 9
Z9 10
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD JUL
PY 2007
VL 77
IS 1
BP 1
EP 8
DI 10.1016/j.plefa.2007.04.001
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA 211TF
UT WOS:000249545500001
PM 17629689
DA 2020-12-01
ER

PT J
AU Azambuja, P
   Bozza, F
   Graca-Souza, A
   Gomes, R
   Neto, HCF
AF Azambuja, P.
   Bozza, F.
   Graca-Souza, A.
   Gomes, R.
   Neto, H. Castro Faria
TI Biliverdin protects mice against lethal sepsis
SO SHOCK
LA English
DT Meeting Abstract
CT 30th Annual Conference of the Shock-Society
CY JUN 09-12, 2007
CL Baltimore, MD
SP Shock Soc
C1 Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD JUN
PY 2007
VL 27
SU 1
BP 80
EP 80
PG 1
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 173PT
UT WOS:000246885700251
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Salluh, JI
   Japiassu, AM
   Soares, M
   Assis, EF
   Gomes, RN
   Bozza, MT
   Castro-Faria-Neto, HC
   Bozza, PT
AF Bozza, Fernando A.
   Salluh, Jorge I.
   Japiassu, Andre M.
   Soares, Marcio
   Assis, Edson F.
   Gomes, Rachel N.
   Bozza, Marcelo T.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
TI Cytokine profiles as markers of disease severity in sepsis: a multiplex
   analysis
SO CRITICAL CARE
LA English
DT Article
ID MCP-1 PROTECTS MICE; ORGAN FAILURE; SEPTIC SHOCK; SYSTEM; DEFINITIONS;
   GUIDELINES; PROTEIN-1; ASSAYS; SCORE
AB Introduction The current shortage of accurate and readily available, validated biomarkers of disease severity in sepsis is an important limitation when attempting to stratify patients into homogeneous groups, in order to study pathogenesis or develop therapeutic interventions. The aim of the present study was to determine the cytokine profile in plasma of patients with severe sepsis by using a multiplex system for simultaneous detection of 17 cytokines.
   Methods This was a prospective cohort study conducted in four tertiary hospitals. A total of 60 patients with a recent diagnosis of severe sepsis were included. Plasma samples were collected for measurement of cytokine concentrations. A multiplex analysis was performed to evaluate levels of 17 cytokines ( IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, interferon-gamma, granulocyte colony-stimulating factor [ G-CSF], granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein [ MCP]-1, macrophage inflammatory protein-1 and tumour necrosis factor-alpha). Cytokine concentrations were related to the presence of severe sepsis or septic shock, the severity and evolution of organ failure, and early and late mortality.
   Results Concentrations of IL-1 beta, IL-6, IL-7, IL-8, IL-10, IL-13, interferon-gamma, MCP-1 and tumour necrosis factor-alpha were significantly higher in septic shock patients than in those with severe sepsis. Cytokine concentrations were associated with severity and evolution of organ dysfunction. With regard to the severity of organ dysfunction on day 1, IL-8 and MCP-1 exhibited the best correlation with Sequential Organ Failure Assessment score. In addition, IL-6, IL-8 and G-CSF concentrations during the first 24 hours were predictive of worsening organ dysfunction or failure of organ dysfunction to improve on day three. In terms of predicting mortality, the cytokines IL-1 beta, IL-4, IL-6, IL-8, MCP-1 and G-CSF had good accuracy for predicting early mortality (< 48 hours), and IL-8 and MCP-1 had the best accuracy for predicting mortality at 28 days. In multivariate analysis, only MCP-1 was independently associated with prognosis.
   Conclusion In this exploratory analysis we demonstrated that use of a multiple cytokine assay platform allowed identification of distinct cytokine profiles associated with sepsis severity, evolution of organ failure and death.
C1 Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Frago Filho, ICU, Rio De Janeiro, Brazil.
   Hosp Barra Or, ICU, BR-22775001 Rio De Janeiro, Brazil.
   Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   Hosp Quinta Or, ICU, BR-20941150 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, Av Brasil 4365, Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Gomes, Rachel N/I-7643-2013; dantas, vicente c souza/L-2648-2013;
   Salluh, Jorge IF/F-6779-2012; Bozza, Fernando A/A-2618-2013; Soares,
   Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Bozza, Patricia/0000-0001-8349-9529; Salluh,
   Jorge/0000-0002-8164-1453; Bozza, Marcelo/0000-0003-3683-7550
CR BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   BOSSINK AWJ, 1995, BLOOD, V86, P3841, DOI 10.1182/blood.V86.10.3841.bloodjournal86103841
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Brueckmann M, 2003, THROMB HAEMOSTASIS, V89, P149
   Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Gerlach H, 2003, CRIT CARE, V7, P256, DOI 10.1186/cc2195
   Gibot S, 2004, ANN INTERN MED, V141, P9, DOI 10.7326/0003-4819-141-1-200407060-00009
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Knight PR, 2004, SHOCK, V21, P26, DOI 10.1097/01.shk.0000101668.49265.19
   Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.0000182798.39709.84
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A
   Marshall John C, 2006, Curr Infect Dis Rep, V8, P351, DOI 10.1007/s11908-006-0045-1
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59
   Oliver KG, 1998, CLIN CHEM, V44, P2057
   Prabhakar U, 2002, J IMMUNOL METHODS, V260, P207, DOI 10.1016/S0022-1759(01)00543-9
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   Sennikov SV, 2003, J IMMUNOL METHODS, V275, P81, DOI 10.1016/S0022-1759(03)00007-3
   Simon L, 2004, CLIN INFECT DIS, V39, P206, DOI 10.1086/421997
   Tam SW, 2002, J IMMUNOL METHODS, V261, P157, DOI 10.1016/S0022-1759(01)00572-5
   Tjardes T, 2002, SHOCK, V17, P1, DOI 10.1097/00024382-200201000-00001
   Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007
   Vermont CL, 2006, CRIT CARE, V10, DOI 10.1186/cc4836
   Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022-1759(00)00238-6
   Vincent JL, 2006, AM J RESP CRIT CARE, V173, P256, DOI 10.1164/rccm.200510-1604OE
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 38
TC 423
Z9 457
U1 0
U2 49
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1466-609X
J9 CRIT CARE
JI Crit. Care
PY 2007
VL 11
IS 2
AR R49
DI 10.1186/cc5783
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 185OV
UT WOS:000247721200019
PM 17448250
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Carvalho, ARS
   Jandre, FC
   Pino, AV
   Bozza, FA
   Salluh, J
   Rodrigues, R
   Ascoli, FO
   Giannella-Neto, A
AF Carvalho, Alysson Roncally S.
   Jandre, Frederico C.
   Pino, Alexandre V.
   Bozza, Fernando A.
   Salluh, Jorge
   Rodrigues, Rosana
   Ascoli, Fabio O.
   Giannella-Neto, Antonio
TI Represents the best compromise between mechanical stress and lung
   aeration in oleic acid induced lung injury
SO CRITICAL CARE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE;
   COMPUTED-TOMOGRAPHY; PROTECTIVE VENTILATION; RECRUITMENT; COLLAPSE;
   ARDS; DYNAMICS; PATTERNS; MODEL
AB Introduction Protective ventilatory strategies have been applied to prevent ventilator-induced lung injury in patients with acute lung injury (ALI). However, adjustment of positive end-expiratory pressure (PEEP) to avoid alveolar de-recruitment and hyperinflation remains difficult. An alternative is to set the PEEP based on minimizing respiratory system elastance (Ers) by titrating PEEP. In the present study we evaluate the distribution of lung aeration (assessed using computed tomography scanning) and the behaviour of Ers in a porcine model of ALI, during a descending PEEP titration manoeuvre with a protective low tidal volume.
   Methods PEEP titration (from 26 to 0 cmH(2)O, with a tidal volume of 6 to 7 ml/kg) was performed, following a recruitment manoeuvre. At each PEEP, helical computed tomography scans of juxta-diaphragmatic parts of the lower lobes were obtained during end-expiratory and end-inspiratory pauses in six piglets with ALI induced by oleic acid. The distribution of the lung compartments (hyperinflated, normally aerated, poorly aerated and non-aerated areas) was determined and the Ers was estimated on a breath-by-breath basis from the equation of motion of the respiratory system using the least-squares method.
   Results Progressive reduction in PEEP from 26 cmH(2)O to the PEEP at which the minimum Ers was observed improved poorly aerated areas, with a proportional reduction in hyperinflated areas. Also, the distribution of normally aerated areas remained steady over this interval, with no changes in non-aerated areas. The PEEP at which minimal Ers occurred corresponded to the greatest amount of normally aerated areas, with lesser hyperinflated, and poorly and non-aerated areas. Levels of PEEP below that at which minimal Ers was observed increased poorly and non-aerated areas, with concomitant reductions in normally inflated and hyperinflated areas.
   Conclusion The PEEP at which minimal Ers occurred, obtained by descending PEEP titration with a protective low tidal volume, corresponded to the greatest amount of normally aerated areas, with lesser collapsed and hyperinflated areas. The institution of high levels of PEEP reduced poorly aerated areas but enlarged hyperinflated ones. Reduction in PEEP consistently enhanced poorly or non-aerated areas as well as tidal re-aeration. Hence, monitoring respiratory mechanics during a PEEP titration procedure may be a useful adjunct to optimize lung aeration.
C1 Univ Fed Rio de Janeiro, COPPE, Biomed Engn Program, BR-21941914 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   IOC, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   ICU, Natl Inst Canc 1, BR-20230130 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Radiodiagnost Serv, BR-21941913 Rio De Janeiro, Brazil.
RP Giannella, A (corresponding author), Univ Fed Rio de Janeiro, COPPE, Biomed Engn Program, Av Horacio Mecedo,CT Bloco H-327,2030, BR-21941914 Rio De Janeiro, Brazil.
EM agn@peb.ufrj.br
RI Bozza, Fernando A/A-2618-2013; Salluh, Jorge IF/F-6779-2012; dantas,
   vicente c souza/L-2648-2013; Carvalho, Alysson/AAF-1022-2019; Rodrigues,
   Rosana/N-9866-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Carvalho,
   Alysson/0000-0003-2708-7735; Salluh, Jorge/0000-0002-8164-1453; Pino,
   Alexandre/0000-0001-5074-6562
CR Bernard GR, 2005, AM J RESP CRIT CARE, V172, P798, DOI 10.1164/rccm.200504-663OE
   Bugedo G, 2003, INTENS CARE MED, V29, P218, DOI 10.1007/s00134-002-1618-6
   Carvalho ARS, 2006, CRIT CARE, V10, DOI 10.1186/cc5030
   CARVALHO ARS, 2005, ANN 9 WORLD FED SOC, P146
   de Abreu MG, 2006, ANESTHESIOLOGY, V104, P278, DOI 10.1097/00000542-200602000-00013
   dos Santos CC, 2006, ANNU REV PHYSIOL, V68, P585, DOI 10.1146/annurev.physiol.68.072304.113443
   dos Santos CC, 2004, CRIT CARE, V8, P145, DOI 10.1186/cc2849
   Dries DJ, 2002, CRIT CARE MED, V30, P1159, DOI 10.1097/00003246-200205000-00036
   Dueck R, 2006, CURR OPIN ANESTHESIO, V19, P650, DOI 10.1097/ACO.0b013e328011015d
   Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052
   Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121
   Hickling KC, 2001, AM J RESP CRIT CARE, V163, P69, DOI 10.1164/ajrccm.163.1.9905084
   Karmrodt J, 2006, BRIT J ANAESTH, V97, P883, DOI 10.1093/bja/ael275
   LASSEN HCA, 1953, LANCET, V264, P37
   Marini JJ, 2004, CRIT CARE MED, V32, P250, DOI 10.1097/01.CCM.0000104946.66723.A8
   Neumann P, 1998, AM J RESP CRIT CARE, V158, P1636, DOI 10.1164/ajrccm.158.5.9711095
   Neumann P, 1998, J APPL PHYSIOL, V85, P1533
   Pesenti A, 2001, INTENS CARE MED, V27, P631, DOI 10.1007/s001340100877
   Puybasset L, 2000, INTENS CARE MED, V26, P1215, DOI 10.1007/s001340051340
   Richard JC, 2004, CRIT CARE, V8, P163, DOI 10.1186/cc2391
   Roth H, 2004, ACTA ANAESTH SCAND, V48, P851, DOI 10.1111/j.1399-6576.2004.00430.x
   Rouby JJ, 2005, CRIT CARE, V9, P465, DOI 10.1186/cc3763
   Rouby JJ, 2004, AM J RESP CRIT CARE, V170, P1039, DOI 10.1164/rccm.2409001
   Rouby JJ, 2004, ANESTHESIOLOGY, V101, P228, DOI 10.1097/00000542-200407000-00033
   Rouby JJ, 2002, AM J RESP CRIT CARE, V165, P1182, DOI 10.1164/ajrccm.165.8.2105122
   Routly JJ, 2003, CRIT CARE MED, V31, pS285, DOI 10.1097/01.CCM.0000057905.74813.BC
   Rylander C, 2004, ANESTH ANALG, V98, P782
   SCHOENE RB, 1984, J APPL PHYSIOL, V56, P472
   SCHUSTER DP, 1994, AM J RESP CRIT CARE, V149, P245, DOI 10.1164/ajrccm.149.1.8111590
   SCHUSTER DP, 1995, PEDIATR PULM, P104
   Suarez-Sipmann F, 2006, CRIT CARE MED
   Suh GY, 2003, J KOREAN MED SCI, V18, P349, DOI 10.3346/jkms.2003.18.3.349
   SUTER PM, 1975, NEW ENGL J MED, V292, P284, DOI 10.1056/NEJM197502062920604
   SUTER PM, 1978, CHEST, V73, P158, DOI 10.1378/chest.73.2.158
   Takeuchi M, 2002, ANESTHESIOLOGY, V97, P682, DOI 10.1097/00000542-200209000-00023
   Terragni PP, 2003, EUR RESPIR J, V22, p15S, DOI 10.1183/09031936.03.00420303
   Treggiari MM, 2002, CRIT CARE MED, V30, P1747, DOI 10.1097/00003246-200208000-00012
   Vieira SRR, 1998, AM J RESP CRIT CARE, V158, P1571, DOI 10.1164/ajrccm.158.5.9802101
   Ward NS, 2002, CRIT CARE MED, V30, P963, DOI 10.1097/00003246-200205000-00002
NR 39
TC 66
Z9 71
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2007
VL 11
IS 4
AR R86
DI 10.1186/cc6093
PG 13
WC Critical Care Medicine
SC General & Internal Medicine
GA 224TJ
UT WOS:000250469000015
PM 17688701
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU d'Avila, JCP
   Santiago, APS
   Amancio, R
   Galina, A
   de Oliveira, MF
   Bozza, FA
AF d'Avila, Joana C. P.
   Santiago, Ana Paula S.
   Amancio, Rodrigo
   Galina, Antonio
   de Oliveira, Marcus Fernondes
   Bozza, Fernando Augusto
TI Sepsis induces brain mitochondrial dysfunction
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Meeting Abstract
CT 14th Annual Meeting of the Society-for-Free-Radical-Biology-and-Medicine
CY NOV 14-18, 2007
CL Washington, DC
SP Soc Free Rad Biol & Med
C1 [d'Avila, Joana C. P.; Santiago, Ana Paula S.; Galina, Antonio; de Oliveira, Marcus Fernondes] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Amancio, Rodrigo; Bozza, Fernando Augusto] Fiocruz MS, Rio De Janeiro, Brazil.
RI Galina, Antonio/A-9292-2008; Bozza, Fernando A/A-2618-2013; d'Avila,
   Joana/L-8970-2013
OI Bozza, Fernando A/0000-0003-4878-0256; d'Avila,
   Joana/0000-0002-2045-0813
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PY 2007
VL 43
SU 1
BP S137
EP S137
PG 1
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 229WC
UT WOS:000250835900365
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Figueiredo, RT
   Bozza, FA
   Pacheco, P
   Amancio, RT
   Laranjeira, AP
   Castro-Faria, HC
   Bozza, PT
   Bozza, MT
AF Gomes, Rachel N.
   Figueiredo, Rodrigo T.
   Bozza, Fernando A.
   Pacheco, Patricia
   Amancio, Rodrigo T.
   Laranjeira, Andrea P.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
   Bozza, Marcelo T.
TI Increased susceptibility to septic and endotoxic shock in monocyte
   chemoattractant protein 1/CC chemokine ligand 2-deficient mice
   correlates with reduced interleukin 10 and enhanced macrophage migration
   inhibitory factor production
SO SHOCK
LA English
DT Article
DE MCP-1; CCL2; CLP; endotoxin; sepsis; cytokines
ID INFLAMMATORY RESPONSE SYNDROME; LETHAL ENDOTOXEMIA; HOST-DEFENSE; MURINE
   MODEL; CHEMOTACTIC PROTEIN-1; BACTERIAL-INFECTION; ACTIVATING-FACTOR;
   SEPSIS; MCP-1; PERITONITIS
AB The chemokine monocyte chemoattractant protein 1/CC chemokine ligand 2 (MCP-1/CCL2) is a potent chemoattractant of mononuclear cells and a regulatory mediator involved in a variety of inflammatory diseases. In the present study, we demonstrate that mcp-1/ccl2-deficient mice are more susceptible to systemic inflammatory response syndrome induced by lipopolysaccharide and to polymicrobial sepsis induced by cecum ligation and puncture (CLP) when compared with wild-type mice. Interestingly, in the CLP model, mcp-1/ccl2 deficient mice efficiently cleared the bacteria despite an impaired recruitment of leukocytes, especially mononuclear cells. The increased lethality rate in these models correlates with an impaired production of interleukin (IL) 10 in vivo. Furthermore, macrophages from mcp-1/ccl2-deficient mice activated with lipopolysaccharide also produced lower amounts of IL-10 and similar tumor necrosis factor compared with wild-type mice. We observed a drastic increase in the amounts of macrophage migration inhibitory factor at 6 and 24 h after CLP in mcp-1/ccl2-deficient mice. These results indicate that endogenous MCP-1/CCL2 positively regulates IL-10 but negatively controls macrophage migration inhibitory factor during peritoneal sepsis, thus suggesting an important immunomodulatory role for MCP-1/CCL2 in controlling the balance between proinflammatory and anti-inflammatory factors in sepsis.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941590 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, LATEB, BR-21045900 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Ctr Tratamento Intens, BR-21045900 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Av Brigadeiro Trompowsky S-N CCS Bloco I, BR-21941590 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br; mbozza@micro.ufrj.br
RI Figueiredo, Rodrigo T./F-5176-2016; Bozza, Fernando A/A-2618-2013;
   Gomes, Rachel N/I-7643-2013
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Bozza, Fernando
   A/0000-0003-4878-0256; Bozza, Patricia/0000-0001-8349-9529
CR Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398
   BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   BOSSINK AWJ, 1995, BLOOD, V86, P3841, DOI 10.1182/blood.V86.10.3841.bloodjournal86103841
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Chensue SW, 1996, J IMMUNOL, V157, P4602
   Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0
   ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
   Feterowski C, 2004, EUR J IMMUNOL, V34, P3664, DOI 10.1002/eji.200425294
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c
   GREENBERGER MJ, 1995, J IMMUNOL, V155, P722
   Held KS, 2004, VIROLOGY, V329, P251, DOI 10.1016/j.virol.2004.09.006
   Hokeness KL, 2005, J IMMUNOL, V174, P1549, DOI 10.4049/jimmunol.174.3.1549
   JANSEN PM, 1995, J INFECT DIS, V171, P1640, DOI 10.1093/infdis/171.6.1640
   LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Matsukawa A, 2000, EXP MOL PATHOL, V68, P77, DOI 10.1006/exmp.1999.2296
   NAKANO Y, 1994, INFECT IMMUN, V62, P377, DOI 10.1128/IAI.62.2.377-383.1994
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Penido C, 2003, J IMMUNOL, V171, P6788, DOI 10.4049/jimmunol.171.12.6788
   Raghavendran K, 2005, AM J PHYSIOL-LUNG C, V289, pL134, DOI 10.1152/ajplung.00390.2004
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
   Sewnath ME, 2001, J IMMUNOL, V166, P6323, DOI 10.4049/jimmunol.166.10.6323
   Speyer CL, 2004, AM J PATHOL, V165, P2187, DOI 10.1016/S0002-9440(10)63268-3
   Steinhauser ME, 1999, J IMMUNOL, V162, P392
   STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365
   Tsuda Y, 2004, J LEUKOCYTE BIOL, V76, P368, DOI 10.1189/jlb.1203645
   Vianna RCS, 2004, SHOCK, V21, P115, DOI 10.1097/01.shk.0000111828.07309.26
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
NR 39
TC 37
Z9 39
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD NOV
PY 2006
VL 26
IS 5
BP 457
EP 463
DI 10.1097/01.shk.0000228801.56223.92
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 104BU
UT WOS:000241931700005
PM 17047515
DA 2020-12-01
ER

PT J
AU Albuquerque, LM
   Trugilho, MRO
   Neves-Ferreira, AGC
   Valente, RH
   Jurgilas, PB
   Chermont, SA
   Chapeaurouge, A
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, F
   Perales, J
AF Albuquerque, L. M.
   Trugilho, M. R. O.
   Neves-Ferreira, A. G. C.
   Valente, R. H.
   Jurgilas, P. B.
   Chermont, S. A.
   Chapeaurouge, A.
   Castro-Faria-Neto, H. C.
   Bozza, P. T.
   Bozza, F.
   Perales, J.
TI Comparative proteomic analysis of plasmas from patients with dengue
   hemorrhagic fever and from healthy donors
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Meeting Abstract
C1 IOC Fiocruz, Rio De Janeiro, Brazil.
RI PERALES, JOSE C./AAC-3156-2019; Bozza, Fernando A/A-2618-2013; PERALES,
   JOSE C. C/D-5586-2012; Neves-Ferreira, Ana Gisele C./N-3596-2013
OI PERALES, JOSE C./0000-0001-7363-2226; Bozza, Fernando
   A/0000-0003-4878-0256; PERALES, JOSE C. C/0000-0001-7363-2226;
   Neves-Ferreira, Ana Gisele C./0000-0002-7863-9512
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD OCT
PY 2006
VL 5
IS 10
SU S
MA 1221
BP S331
EP S331
PG 1
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 098FM
UT WOS:000241506401336
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Bozza, FA
   Amancio, RT
   Japiassu, AM
   Vianna, RCS
   Larangeira, AP
   Gouvea, JM
   Bastos, MS
   Zimmerman, GA
   Stafforini, DM
   Prescott, SM
   Bozza, PT
   Castro-Faria-Neto, HC
AF Gomes, Rachel N.
   Bozza, Fernando A.
   Amancio, Rodrigo T.
   Japiassu, Andre M.
   Vianna, Rosa C. S.
   Larangeira, Andra P.
   Gouvea, Juliana M.
   Bastos, Marcela S.
   Zimmerman, Guy A.
   Stafforini, Diana M.
   Prescott, Stephen M.
   Bozza, Patricia T.
   Castro-Faria-Neto, Hugo C.
TI Exogenous platelet-activating factor acetylhydrolase reduces mortality
   in mice with systemic inflammatory response syndrome and sepsis
SO SHOCK
LA English
DT Article
DE sepsis; PAF; PAF-AH; cytokines; SIRS
ID RESPIRATORY-DISTRESS-SYNDROME; MIGRATION INHIBITORY FACTOR; MCP-1
   PROTECTS MICE; CLINICAL-TRIAL; SEPTIC SHOCK; RECEPTOR ANTAGONIST;
   DOUBLE-BLIND; ILL PATIENTS; IN-VIVO; MULTICENTER
AB Current evidence indicates that dysregulation of the host inflammatory response to infectious agents is central to the mortality of patients with sepsis and in those with systemic inflammatory response syndrome. Strategies to block inflammatory mediators, often with complicated outcomes, are currently being investigated as new adjuvant therapies for sepsis. Here, we determined if administration of recombinant platelet-activating factor (rPAF)-acetylhydrolase (rPAF-AH), an enzyme that inactivates PAF and PAF-like lipids, protects mice from inflammatory injury and death after administration of lipopolysaccharide (LIPS) or cecal ligation and puncture (CLP). Administration of rPAF-AH increased plasma PAF-AH activity and reduced mortality in both models. Treatment with rPAF-AH increased peritoneal fluid levels of monocyte chemoattractant protein 1/CCL-2 and decreased interleukin 6 and macrophage migration inhibitory factor levels after LPS administration or CLP. Administration of a broad-spectrum antibiotic together with rPAF-AH was more protective than single treatment with either of these agents. The combined treatment was associated with reduced interleukin 6 levels in mice subjected to CLP. We observed acute decreases in plasma PAF-AH activity in mice subjected to CLP or challenged with LPS and in human patients with sepsis. We conclude that alterations in the endogenous PAF-AH contribute to the pathophysiology of sepsis and that administration of exogenous rPAF-AH reduces inflammatory injury and mortality in models relevant to the clinical syndrome. Variations in endogenous PAF-AH activity may potentially account for variable responses to exogenous rPAF-AH in previous clinical trials. Serial measurements of plasma PAF-AH activity in murine models demonstrate dynamic regulation of the endogenous enzyme. potentially explaining the variations in human subjects.
C1 Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Ctr Tratamento Intens, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, LATEB, Rio De Janeiro, Brazil.
   Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT USA.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
RP Castro-Faria-Neto, HC (corresponding author), Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM hcastro@ioc.fiocruz.br
RI Gomes, Rachel N/I-7643-2013; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [R03TW005531, R03TW005531, R03TW005531]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153, P50HL050153, P50HL050153, P50HL050153, P50HL050153,
   P50HL050153] Funding Source: NIH RePORTER; FIC NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH Fogarty International Center (FIC) [TW5531] Funding Source:
   Medline; NHLBI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [HL 50153] Funding Source: Medline
CR Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012
   CAPLAN MS, 1990, J PEDIATR-US, V117, pS47, DOI 10.1016/S0022-3476(05)81130-8
   CASTROFARIANETO HC, 1989, THROMB HAEMOSTASIS, V62, P1107
   CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980
   Claus RA, 2005, CRIT CARE MED, V33, P1416, DOI 10.1097/01.CCM.0000165807.26485.ED
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005
   DIEZ FL, 1989, J CLIN INVEST, V83, P1733, DOI 10.1172/JCI114074
   GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z
   GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009
   Grissom CK, 2003, CRIT CARE MED, V31, P770, DOI 10.1097/01.CCM.0000053647.82608.29
   Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0
   HACK CE, 1989, BLOOD, V74, P1704
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e
   IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x
   KruseElliott KT, 1996, SHOCK, V5, P265, DOI 10.1097/00024382-199604000-00006
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395
   Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Memon RA, 1999, AM J PHYSIOL-REG I, V277, pR94
   NARAHARA H, 1993, J CLIN ENDOCR METAB, V77, P1258, DOI 10.1210/jc.77.5.1258
   Opal S, 2004, CRIT CARE MED, V32, P332, DOI 10.1097/01.CCM.0000108867.87890.6D
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Remick DG, 2005, SHOCK, V24, P7, DOI 10.1097/01.shk.0000191384.34066.85
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Schuster DP, 2003, CRIT CARE MED, V31, P1612, DOI 10.1097/01.CCM.0000063267.79824.DB
   Stafforini DM, 1999, J CLIN INVEST, V103, P989, DOI 10.1172/JCI5574
   Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018
   Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693
   TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124
   TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0
   TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481
   van der Poll T, 2001, Lancet Infect Dis, V1, P165, DOI 10.1016/S1473-3099(01)00093-7
   Vianna RCS, 2004, SHOCK, V21, P115, DOI 10.1097/01.shk.0000111828.07309.26
   WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2
   Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
NR 43
TC 53
Z9 57
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUL
PY 2006
VL 26
IS 1
BP 41
EP 49
DI 10.1097/01.shk.0000209562.00070.1a
PG 9
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 055HZ
UT WOS:000238442200009
PM 16783197
DA 2020-12-01
ER

PT J
AU de Abreu, MG
   Quelhas, AD
   Spieth, P
   Brauer, G
   Knels, L
   Kasper, M
   Pino, AV
   Bleyl, JU
   Hubler, M
   Bozza, F
   Salluh, J
   Kuhlisch, E
   Giannella-Neto, A
   Koch, T
AF de Abreu, MG
   Quelhas, AD
   Spieth, P
   Brauer, G
   Knels, L
   Kasper, M
   Pino, AV
   Bleyl, JU
   Hubler, M
   Bozza, F
   Salluh, J
   Kuhlisch, E
   Giannella-Neto, A
   Koch, T
TI Comparative effects of vaporized perfluorohexane and partial liquid
   ventilation in oleic acid-induced lung injury
SO ANESTHESIOLOGY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; GAS-EXCHANGE;
   PULMONARY-FUNCTION; MECHANICAL VENTILATION; IMPROVES OXYGENATION;
   PERFLUOROCARBON; MODEL; PERFLUBRON; ANIMALS
AB Background: It is currently not known whether vaporized perfluorohexane is superior to partial liquid ventilation (PLV) for therapy of acute lung injury. in this study, the authors compared the effects of both therapies in oleic acid-induced lung injury.
   Methods: Lung injury was induced in 30 anesthetized and mechanically ventilated pigs by means of central venous infusion of oleic acid. Animals were assigned to one of the following groups: (1) control or gas ventilation (GV), (2) 2.5% perfluorohexane vapor, (3) 5% perfluorohexane vapor, (4) 10% perfluorohexane vapor, or (5) PLV with perfluorooctane (30 ml/kg). Two hours after randomization, lungs were recruited and positive end-expiratory pressure was adjusted to obtain minimal elastance. Ventilation was continued during 4 additional hours, when animals were killed for lung histologic examination.
   Results: Gas exchange and elastance were comparable among vaporized perfluorohexane, PLV, and GV before the open lung approach was used and improved in a similar fashion in all groups after positive end-expiratory pressure was adjusted to optimal elastance (P < 0.05). A similar behavior was observed in functional residual capacity (FRC) in animals treated with vaporized perfluorohexane and GV. Lung resistance improved after recruitment (P < 0.05), but values were higher in the 10% perfluorohexane and PLV groups as compared with GV (P < 0.05). Interestingly, positive end-expiratory pressure values required to obtain minimal elastance were lower with 5% perfluorohexane than with PLV and Gv (P < 0.05). In addition, diffuse alveolar damage was significantly lower in the 5% and 10% perfluorohexane vapor groups as compared with PLV and GV (P < 0.05).
   Conclusions: Although the use of 5% vaporized perfluorohexane permitted the authors to reduce pressures needed to stabilize the lungs and was associated with better histologic findings than were PLV and GV, none of these perfluorocarbon therapies improved gas exchange or lung mechanics as compared with GV.
C1 Tech Univ Dresden, Univ Clin Carl Gustav Carus, Clin Anesthesiol & Intens Care Med, D-01307 Dresden, Germany.
   Tech Univ Dresden, Fac Med, Inst Biometr & Informat, D-01307 Dresden, Germany.
   Tech Univ Dresden, Fac Med, Inst Anat, D-01307 Dresden, Germany.
RP de Abreu, MG (corresponding author), Tech Univ Dresden, Univ Clin Carl Gustav Carus, Clin Anesthesiol & Intens Care Med, Fetscherstr 74, D-01307 Dresden, Germany.
EM mgabreu@aol.com
RI Spieth, Peter/C-2928-2011; dantas, vicente c souza/L-2648-2013; Bozza,
   Fernando A/A-2618-2013; Salluh, Jorge IF/F-6779-2012
OI Bozza, Fernando A/0000-0003-4878-0256; Salluh,
   Jorge/0000-0002-8164-1453; Pino, Alexandre/0000-0001-5074-6562
CR AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744
   Avanzolini G, 1997, ANN BIOMED ENG, V25, P154, DOI 10.1007/BF02738546
   Bleyl JU, 1999, ANESTHESIOLOGY, V91, P461, DOI 10.1097/00000542-199908000-00021
   Bleyl JU, 2002, CRIT CARE MED, V30, P1340, DOI 10.1097/00003246-200206000-00034
   BLEYL JU, 2002, AM J RESP CRIT CARE, V162, pA46
   Broccard AF, 1997, CRIT CARE MED, V25, P16, DOI 10.1097/00003246-199701000-00007
   BRUNNER JX, 1985, J APPL PHYSIOL, V59, P1008
   Cox PN, 1997, AM J RESP CRIT CARE, V156, P992, DOI 10.1164/ajrccm.156.3.9608049
   CROWDER GA, 1967, J CHEM ENG DATA, V12, P481, DOI 10.1021/je60035a005
   CURTIS SE, 1993, J APPL PHYSIOL, V75, P2696
   Davies MW, 2002, CRIT CARE MED, V30, P1123, DOI 10.1097/00003246-200205000-00027
   de Abreu MG, 2005, ANESTHESIOLOGY, V102, P597, DOI 10.1097/00000542-200503000-00019
   de Anda GFV, 2001, EUR RESPIR J, V18, P93, DOI 10.1183/09031936.01.00019901
   de Anda GFV, 1999, INTENS CARE MED, V25, P990, DOI 10.1007/s001340050994
   Dreyfuss D, 1999, AM J RESP CRIT CARE, V159, P1752, DOI 10.1164/ajrccm.159.6.9805018
   EAST TD, 1988, J CLIN MONITOR, V4, P91, DOI 10.1007/BF01641808
   Fitzpatrick JC, 1997, J PEDIATR SURG, V32, P192, DOI 10.1016/S0022-3468(97)90177-9
   Fujino Y, 2000, AM J RESP CRIT CARE, V162, P650, DOI 10.1164/ajrccm.162.2.9909036
   Gauger PG, 1998, J APPL PHYSIOL, V84, P1566
   Greenspan JS, 2000, SEMIN PERINATOL, V24, P396, DOI 10.1053/sper.2000.20092
   Harris RS, 2002, J APPL PHYSIOL, V92, P297
   Hernan LJ, 1996, CRIT CARE MED, V24, P475, DOI 10.1097/00003246-199603000-00018
   Hickling KC, 2001, AM J RESP CRIT CARE, V163, P69, DOI 10.1164/ajrccm.163.1.9905084
   Hirschl RB, 2002, AM J RESP CRIT CARE, V165, P781, DOI 10.1164/ajrccm.165.6.2003052
   HIRSCHL RB, 1995, CHEST, V108, P500, DOI 10.1378/chest.108.2.500
   Hubler M, 2001, ANESTHESIOLOGY, V95, P1414
   *I LAB AN RES COMM, 1996, GUID CAR US LAB AN
   Kaisers U, 2003, BRIT J ANAESTH, V91, P143, DOI 10.1093/bja/aeg147
   Kandler MA, 2001, AM J RESP CRIT CARE, V164, P31, DOI 10.1164/ajrccm.164.1.2010049
   KATZENSTEIN ALA, 1980, AM J SURG PATHOL, V4, P223, DOI 10.1097/00000478-198006000-00002
   Kemming GI, 2005, ANESTHESIOLOGY, V103, P585, DOI 10.1097/00000542-200509000-00022
   Koch T, 2001, ANESTHESIOLOGY, V94, P101, DOI 10.1097/00000542-200101000-00020
   LANTERI CJ, 1994, PEDIATR PULM, V17, P56, DOI 10.1002/ppul.1950170110
   Martynowicz MA, 2001, J APPL PHYSIOL, V90, P1744
   Papo MC, 1996, CRIT CARE MED, V24, P466, DOI 10.1097/00003246-199603000-00017
   Ragaller M, 2000, ANAESTHESIST, V49, P291, DOI 10.1007/s001010050831
   Reickert CA, 2001, CHEST, V119, P515, DOI 10.1378/chest.119.2.515
   Schmalisch G, 2003, CRIT CARE MED, V31, P1435, DOI 10.1097/01.CCM.0000063041.94690.76
   Tooley R, 1996, CRIT CARE MED, V24, P268, DOI 10.1097/00003246-199602000-00015
   TURNER MJ, 1989, J APPL PHYSIOL, V67, P472
   TUTUNCU AS, 1993, AM REV RESPIR DIS, V148, P785
   Van der Kloot TE, 2000, AM J RESP CRIT CARE, V161, P1485, DOI 10.1164/ajrccm.161.5.9809014
   van Eeden SF, 2000, AM J RESP CELL MOL, V22, P441, DOI 10.1165/ajrcmb.22.4.3717
   van Kaam AH, 2003, PEDIATR RES, V53, P245, DOI 10.1203/01.PDR.0000047520.44168.22
   Woods CM, 2000, AM J PHYSIOL-LUNG C, V278, pL1008
   YEH MP, 1982, J APPL PHYSIOL, V53, P280
NR 46
TC 28
Z9 28
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB
PY 2006
VL 104
IS 2
BP 278
EP 289
DI 10.1097/00000542-200602000-00013
PG 12
WC Anesthesiology
SC Anesthesiology
GA 007QX
UT WOS:000234985500011
PM 16436847
DA 2020-12-01
ER

PT J
AU Carvalho, ARS
   Jandre, FC
   Pino, AV
   Bozza, FA
   Salluh, JI
   Rodrigues, RS
   Soares, JHN
   Giannella-Neto, A
AF Carvalho, Alysson Roncally S.
   Jandre, Frederico C.
   Pino, Alexandre V.
   Bozza, Fernando A.
   Salluh, Jorge I.
   Rodrigues, Rosana S.
   Soares, Joao H. N.
   Giannella-Neto, Antonio
TI Effects of descending positive end-expiratory pressure on lung mechanics
   and aeration in healthy anaesthetized piglets
SO CRITICAL CARE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; COMPUTED-TOMOGRAPHY; ATELECTASIS
   FORMATION; GENERAL-ANESTHESIA; VENTILATION; PARALYSIS; VOLUME; GAS
AB Introduction Atelectasis and distal airway closure are common clinical entities of general anaesthesia. These two phenomena are expected to reduce the ventilation of dependent lung regions and represent major causes of arterial oxygenation impairment in anaesthetic conditions. The behaviour of the elastance of the respiratory system (E-rs), as well as the lung aeration assessed by computed tomography (CT) scan, was evaluated during a descendent positive end-expiratory pressure ( PEEP) titration. This work sought to evaluate the potential usefulness of Ers monitoring to set the PEEP in order to prevent tidal recruitment and hyperinflation of healthy lungs under general anaesthesia.
   Methods PEEP titration ( from 16 to 0 cmH(2)O, tidal volume of 8 ml/kg) was performed, and at each PEEP, CT scans were obtained during end-expiratory and end-inspiratory pauses in six healthy, anaesthetized and paralyzed piglets. The distribution of lung aeration was determined and the tidal re-aeration was calculated as the difference between end-expiratory and end-inspiratory poorly aerated and normally aerated areas. Similarly, tidal hyperinflation was obtained as the difference between end-inspiratory and end-expiratory hyperinflated areas. E-rs was estimated from the equation of motion of the respiratory system during all PEEP titration with the least-squares method.
   Results Hyperinflated areas decreased from PEEP 16 to 0 cmH(2)O ( ranges decreased from 24 - 62% to 1 - 7% at end-expiratory pauses and from 44 - 73% to 4 - 17% at end-inspiratory pauses) whereas normally aerated areas increased ( from 30 - 66% to 72 - 83% at end-expiratory pauses and from 19 - 48% to 73 - 77% at end-inspiratory pauses). From 16 to 8 cmH(2)O, E-rs decreased with a corresponding reduction in tidal hyperinflation. A flat minimum of Ers was observed from 8 to 4 cmH(2)O. For PEEP below 4 cmH(2)O, Ers increased in association with a rise in tidal re-aeration and a flat maximum of the normally aerated areas.
   Conclusion In healthy piglets under a descending PEEP protocol, the PEEP at minimum Ers presented a compromise between maximizing normally aerated areas and minimizing tidal re-aeration and hyperinflation. High levels of PEEP, greater than 8 cmH(2)O, reduced tidal re-aeration but increased hyperinflation with a concomitant decrease in normally aerated areas.
C1 Univ Fed Rio de Janeiro, COPPE, Biomed Engn Program, BR-21945970 Rio De Janeiro, Brazil.
   Univ Catolica Pelotas, Dept Elect Engn, BR-96010000 Pelotas, RS, Brazil.
   Univ Fed Rio de Janeiro, ICU, Celmentino Fraga Filho Hosp, BR-21950900 Rio De Janeiro, Brazil.
   ICU, Natl Inst Canc 1, BR-20230130 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Clementino Fraga Filho Hosp, Radiodiagnost Serv, BR-21950900 Rio De Janeiro, Brazil.
   UNIGRANRIO, Sch Vet Med, BR-25071200 Duque De Caxias, RJ, Brazil.
RP Giannella, A (corresponding author), Univ Fed Rio de Janeiro, COPPE, Biomed Engn Program, POB 68510, BR-21945970 Rio De Janeiro, Brazil.
EM agn@peb.ufrj.br
RI Salluh, Jorge IF/F-6779-2012; Soares, Joao/AAD-7928-2019; Carvalho,
   Alysson/AAF-1022-2019; Rodrigues, Rosana/N-9866-2013; dantas, vicente c
   souza/L-2648-2013; Bozza, Fernando A/A-2618-2013; Soares, Joao Henrique
   Neves/G-8519-2016
OI Bozza, Fernando A/0000-0003-4878-0256; Pino,
   Alexandre/0000-0001-5074-6562; Soares, Joao Henrique
   Neves/0000-0001-9044-3208; Salluh, Jorge/0000-0002-8164-1453
CR BRISMAR B, 1985, ANESTHESIOLOGY, V62, P422, DOI 10.1097/00000542-198504000-00009
   David M, 2005, CHEST, V128, P3757, DOI 10.1378/chest.128.5.3757
   De Robertis E, 2001, EUR RESPIR J, V17, P703, DOI 10.1183/09031936.01.17407030
   FROESE AB, 1974, ANESTHESIOLOGY, V41, P242, DOI 10.1097/00000542-197409000-00006
   Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121
   Hedenstierna G, 2005, INTENS CARE MED, V31, P1327, DOI 10.1007/s00134-005-2761-7
   Hedenstierna G, 2000, J CLIN MONITOR COMP, V16, P329, DOI 10.1023/A:1011491231934
   Jandre FC, 2004, IEEE T BIO-MED ENG, V51, P823, DOI 10.1109/TBME.2004.826678
   KLINGSTEDT C, 1990, ACTA ANAESTH SCAND, V34, P421, DOI 10.1111/j.1399-6576.1990.tb03117.x
   Malbouisson LM, 2001, AM J RESP CRIT CARE, V163, P1444, DOI 10.1164/ajrccm.163.6.2005001
   Puybasset L, 2000, INTENS CARE MED, V26, P857, DOI 10.1007/s001340051274
   Puybasset L, 1998, AM J RESP CRIT CARE, V158, P1644, DOI 10.1164/ajrccm.158.5.9802003
   Reber A, 1996, BRIT J ANAESTH, V76, P760
   Reber A, 1998, ANAESTHESIA, V53, P1054, DOI 10.1046/j.1365-2044.1998.00569.x
   Rothen HU, 1998, BRIT J ANAESTH, V81, P681, DOI 10.1093/bja/81.5.681
   Rouby JJ, 2004, ANESTHESIOLOGY, V101, P228, DOI 10.1097/00000542-200407000-00033
   Rouby JJ, 2003, EUR RESPIR J, V22, p27S, DOI 10.1183/09031936.03.00420503
   Rouby JJ, 2002, AM J RESP CRIT CARE, V165, P1182, DOI 10.1164/ajrccm.165.8.2105122
   SUTER PM, 1978, CHEST, V73, P158, DOI 10.1378/chest.73.2.158
   Vieira SRR, 2005, CRIT CARE MED, V33, P741, DOI 10.1097/01.CCM.0000155786.53015.E7
   Vieira SRR, 1998, AM J RESP CRIT CARE, V158, P1571, DOI 10.1164/ajrccm.158.5.9802101
   Ward NS, 2002, CRIT CARE MED, V30, P963, DOI 10.1097/00003246-200205000-00002
NR 22
TC 35
Z9 36
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PY 2006
VL 10
IS 4
AR R122
DI 10.1186/cc5030
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 185LK
UT WOS:000247712300025
PM 16925814
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Bozza, PT
   Neto, HCCF
AF Bozza, FA
   Bozza, PT
   Neto, HCCF
TI Beyond sepsis pathophysiology with cytokines: what is their value as
   biornarkers for disease severity?
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT International Symposium on Nitric Oxide, Cytokines and Inflammation
CY JUN 06-09, 2004
CL Rio de Janeiro, BRAZIL
SP Oswaldo Cruz Fdn, Univ Calgary, Univ Calif Los Angeles, Brazilian Soc Pharmacol & Expt Therapeut, Canadian Assoc Gastroenterol
DE sepsis; biomarkers; cytokines; stratification
ID MIGRATION-INHIBITORY FACTOR; CRITICAL MEDIATOR; REGULATORY ROLE; SEPTIC
   SHOCK; MACROPHAGE; PROCALCITONIN; MARKERS; SYSTEM; MIF
AB Sepsis is a major challenge in medicine. It is a common and frequently fatal infectious condition. The incidence continues to increase, with unacceptably high mortality rates, despite the use of specific antibiotics, aggressive operative intervention, nutritional support, and anti-inflammatory therapies. Typically, septic patients exhibit a high degree of heterogeneity due to variables such as age, weight, gender the presence of secondary disease, the state of the immune system, and the severity of the infection. We are at urgent need for biomarkers and reliable measurements that can be applied to risk stratification of septic patients and that would easily identify those patients at the highest risk of a poor outcome. Such markers would be of fundamental importance to decision making for early intervention therapy or for the design of septic clinical trials. In the present work, we will review current biomarkers for sepsis severity and especially the use of cytokines as biomarkers with important pathophysiological role.
C1 Inst Oswaldo Cruz Fiocruz, Lab Imunofarmacol, Dept Fisiol & Farmacodinam, BR-21040900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Unidade Terapia Intens, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
RP Neto, HCCF (corresponding author), Inst Oswaldo Cruz Fiocruz, Lab Imunofarmacol, Dept Fisiol & Farmacodinam, Av Brasil 4365, BR-21040900 Rio De Janeiro, Brazil.
EM hcastro@ioc.fiocruz.br
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529
CR Abbate Antonio, 2003, Semin Vasc Med, V3, P375
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Bacher M, 1997, AM J PATHOL, V150, P235
   Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Calandra T, 1996, J INFLAMM, V47, P39
   CHALFIN DB, 1993, JAMA-J AM MED ASSOC, V269, P249, DOI 10.1001/jama.269.2.249
   Clec'h C, 2004, CRIT CARE MED, V32, P1166, DOI 10.1097/01.CCM.0000126263.00551.06
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320
   Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818
   Gattas DJ, 2003, J CRIT CARE, V18, P52, DOI 10.1053/jcrc.2003.YJCRC11
   Glauser MP, 2000, CRIT CARE MED, V28, pS4, DOI 10.1097/00003246-200009001-00002
   Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214
   Hengst Joan M, 2003, Adv Neonatal Care, V3, P3, DOI 10.1053/adnc.2003.50010
   Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006
   Kox WJ, 2000, INTENS CARE MED, V26, pS124, DOI 10.1007/s001340051129
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022
   Libby P, 2004, CIRCULATION, V109, P1, DOI 10.1161/01.CIR.0000129499.33411.59
   Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A
   MENDONCA HTF, 2004, SHOCK, V22, P533
   PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338
   PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565
   Polderman KH, 2004, LANCET, V363, P1721, DOI 10.1016/S0140-6736(04)16259-4
   *PX D, 1946, B I NATL HYG, V1, P70
   Rau B, 2004, LANGENBECK ARCH SURG, V389, P134, DOI 10.1007/s00423-004-0463-1
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Riedemann NC, 2003, EXPERT OPIN BIOL TH, V3, P339, DOI 10.1517/14712598.3.2.339
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Simon L, 2004, CLIN INFECT DIS, V39, P206, DOI 10.1086/421997
   Tanaka H, 1996, J TRAUMA, V40, P718, DOI 10.1097/00005373-199605000-00006
   Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003
   Vincent JL, 2003, INTENS CARE MED, V29, pS74
   Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307
NR 41
TC 27
Z9 32
U1 0
U2 0
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAR
PY 2005
VL 100
SU 1
BP 217
EP 221
DI 10.1590/S0074-02762005000900037
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 918RE
UT WOS:000228564500037
PM 15962126
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU de Mendonca, HTF
   Gomes, RV
   Campos, LAD
   Tura, B
   Nunes, EM
   Gomes, R
   Bozza, F
   Bozza, PT
   Castro-Faria-Neto, HC
AF de Mendonca, HTF
   Gomes, RV
   Campos, LAD
   Tura, B
   Nunes, EM
   Gomes, R
   Bozza, F
   Bozza, PT
   Castro-Faria-Neto, HC
TI Circulating levels of macrophage migration inhibitory factor are
   associated with mild pulmonary dysfunction after cardiopulmonary bypass
SO SHOCK
LA English
DT Article
DE acute lung injury; cardiac surgery; macrophage migration inhibitory
   factor; steroids
ID COMPLEMENT ACTIVATION; CYTOKINE; MIF; INTERLEUKIN-1; INFLAMMATION;
   GENERATION; RESPONSES; STEROIDS; HORMONE; RELEASE
AB Macrophage migration inhibitory factor (MIF) is a central mediator of inflammatory response and acute lung injury that is secreted in response to corticosteroids. A rise in systemic MIF levels was described after cardiac surgery in steroid-treated patients. This study aimed to investigate the circulating levels of MIF and the possible relationship of this cytokine to pulmonary dysfunction after cardiopulmonary bypass (CPB). We included 74 patients without previous organ dysfunction undergoing elective coronary artery bypass surgery (CABS). The same team performed all CABS via a standard technique adding methylprednisolone (15 mg/kg) to the CPB priming solution (Group MP, n = 37). In the remaining patients (Group NS, n = 37), methylprednisolone was withdrawn from the CPB priming. MIF, C-reactive protein (CRP), and total C3 were assayed in peripheral blood sampled immediately before anesthesia induction and 3, 6, and 24 h post-CPB. Preoperative risk scores and peri- and postoperative variables were documented. Postoperative kinetics of MIF and C3 were similar for both groups. Levels of CRP 24 h post-CPB were higher in Group MP (P = 0.003). Higher MIF levels were detected 6 h post-CPB, and returned to preoperative levels 24 h after CPB. MIF levels 6 h post-CPB were inversely related to the postoperative PaO2/FiO(2) ratio (P = 0.0021) and were directly related to the duration of mechanical ventilation (P = 0.014). Perioperative use of methylprednisolone did not modify the MIF response to CPB, but it was related to an enhanced acute phase response. Higher circulating MIF levels 6 h post-CPB were associated with worse postoperative pulmonary short-course outcome.
C1 Fundacao Oswaldo Cruz, Dept Physiol & Pharmacodynam, Lab Immunopharmacol, BR-21045900 Rio De Janeiro, RJ, Brazil.
   Procardiaco Hosp, Surg Intens Care Unit, Rio De Janeiro, RJ, Brazil.
RP de Mendonca, HTF (corresponding author), Fundacao Oswaldo Cruz, Dept Physiol & Pharmacodynam, Lab Immunopharmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM imunobiologia@procardiaco.com.br
RI Gomes, Rachel N/I-7643-2013; Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529
CR ADAMS DH, 2001, TXB CARDIOVASCULAR M, P2069
   Andersen L W, 1989, J Cardiothorac Anesth, V3, P544, DOI 10.1016/0888-6296(89)90150-6
   Annane D, 2003, SHOCK, V20, P197, DOI 10.1097/01.shk.0000079423.72656.2f
   BAUMANN H, 1987, J IMMUNOL, V139, P4122
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   BORALESSA H, 1986, ANAESTHESIA, V41, P11, DOI 10.1111/j.1365-2044.1986.tb12696.x
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Bucala R, 1996, FASEB J, V10, P1607
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   CAVAROCCHI NC, 1986, J THORAC CARDIOV SUR, V91, P252
   Chaney MA, 2002, CHEST, V121, P921, DOI 10.1378/chest.121.3.921
   Chang WN, 1998, IEEE T POWER SYST, V13, P27, DOI 10.1109/59.651609
   CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901
   Cremer J, 1996, ANN THORAC SURG, V61, P1714, DOI 10.1016/0003-4975(96)00055-0
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   Donnelly SC, 1999, CHEST, V116, p111S, DOI 10.1378/chest.116.suppl_1.111S
   ELGEBALY SA, 1994, ANN THORAC SURG, V57, P391, DOI 10.1016/0003-4975(94)91003-0
   ENGELMAN RM, 1995, ANN THORAC SURG, V60, P801, DOI 10.1016/0003-4975(95)00211-3
   Gando S, 2000, SURG TODAY, V30, P689, DOI 10.1007/s005950050041
   Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818
   Golej J, 2003, SHOCK, V20, P110, DOI 10.1097/01.shk.0000075571.93053.2c
   Gulielmos V, 2000, EUR J CARDIO-THORAC, V18, P594, DOI 10.1016/S1010-7940(00)00553-4
   Isidori AM, 2002, J CLIN ENDOCR METAB, V87, P1834, DOI 10.1210/jc.87.4.1834
   Kabir K, 2002, SHOCK, V17, P300, DOI 10.1097/00024382-200204000-00010
   Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022
   MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007
   NISHIMURA T, 1995, ELECTRON COMM JPN 3, V78, P1, DOI 10.1002/ecjc.4430780101
   POLLOCK EMM, 1988, BRIT J ANAESTH, V60, P536, DOI 10.1093/bja/60.5.536
   Price JA, 1999, CHEST, V115, p130S, DOI 10.1378/chest.115.suppl_2.130S
   REPLOGLE RL, 1966, CIRCULATION, V33, pI86, DOI 10.1161/01.CIR.33.4S1.I-86
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Takala A, 2002, SHOCK, V17, P252, DOI 10.1097/00024382-200204000-00002
   TOLEDOPEREYRA LH, 1980, AM SURGEON, V46, P155
   Wan S, 1997, ANN THORAC SURG, V63, P269
   YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101
NR 39
TC 25
Z9 25
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD DEC
PY 2004
VL 22
IS 6
BP 533
EP 537
DI 10.1097/01.shk.0000142817.84070.df
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 873TN
UT WOS:000225304100006
PM 15545824
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Gomes, RN
   Japiassu, AM
   Soares, M
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
AF Bozza, FA
   Gomes, RN
   Japiassu, AM
   Soares, M
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
TI Macrophage migration inhibitory factor levels correlate with fatal
   outcome in sepsis
SO SHOCK
LA English
DT Article
DE sepsis; MIF; IL-6; cytokine; mortality; markers
ID RESPIRATORY-DISTRESS-SYNDROME; SEPTIC SHOCK; FACTOR MIF; CRITICAL
   MEDIATOR; REGULATORY ROLE; PLASMA-LEVELS; INTERLEUKIN-6; ACTIVATION;
   CYTOKINE; SEVERITY
AB Macrophage migration inhibitory factor (MIF) is a cytokine playing a critical role in the pathophysiology of experimental sepsis. The purpose of this study was to determine the levels of MIF and to compare those to interleukin-6 (IL-6) levels in predicting mortality among critically ill patients with sepsis. The levels of MIF and IL-6 were measured in 25 patients with septic shock, 17 patients with sepsis, and 11 healthy volunteers. The median plasma concentrations of MIF and IL-6 were significantly higher in patients with septic shock and in patients with sepsis than in healthy controls. MIF levels were significantly different between survivors and nonsurvivors, as were IL-6 levels. Discriminatory power in predicting mortality, as assessed by the areas under receiver operating characteristic curves (AUROC), was 0.793 for MIF and 0.680 for IL-6. Finally, high plasma levels of MIF (>1100 pg/mL) had a sensitivity of 100% and a specificity of 64% to identify the patients who eventually would evolve to a fatal outcome. Thus, our data suggest that an elevated MIF level in recently diagnosed septic patients appears to be an early indicator of poor outcome and a potential entry criterion for future studies with therapeutic intervention aiming at MIF neutralization.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Grafa Filho, ICU, BR-21941590 Rio De Janeiro, Brazil.
   Hosp Espanol, ICU, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Av Brigadeiro Trompowsky,S-N CCS Bloco 1,Ilha Fun, BR-21941590 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Bozza, Fernando A/A-2618-2013; Gomes, Rachel N/I-7643-2013; Soares,
   Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Bozza, Patricia/0000-0001-8349-9529
CR Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Bacher M, 1997, AM J PATHOL, V150, P235
   Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004
   Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811
   Bergmann M, 2003, SHOCK, V20, P575, DOI 10.1097/01.shk.0000095934.86703.83
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A
   Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001
   DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320
   Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC
   Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818
   GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296
   HERRIOTT MJ, 1993, J IMMUNOL, V150, P4524
   Joshi PC, 2000, RES COMMUN MOL PATH, V107, P13
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022
   Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5
   Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086
   Opal SM, 2003, SHOCK, V20, P295, DOI 10.1097/01.shk.0000084343.58020.57
   Pettila V, 2002, INTENS CARE MED, V28, P1220, DOI 10.1007/s00134-002-1416-1
   Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004
   Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Turnbull IR, 2004, SHOCK, V21, P121, DOI 10.1097/01.shk.0000108399.56565.e7
   Vianna RCS, 2004, SHOCK, V21, P115, DOI 10.1097/01.shk.0000111828.07309.26
   Vincent JL, 2002, CLIN INFECT DIS, V34, P1084, DOI 10.1086/339549
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Yang SL, 2001, AM J PHYSIOL-GASTR L, V281, pG1014
NR 39
TC 123
Z9 135
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD OCT
PY 2004
VL 22
IS 4
BP 309
EP 313
DI 10.1097/01.shk.0000140305.01641.c8
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 859LF
UT WOS:000224264300002
PM 15377884
DA 2020-12-01
ER

PT J
AU Vianna, RCS
   Gomes, RN
   Bozza, FA
   Amancio, RT
   Bozza, PT
   David, CMN
   Castro-Faria-Neto, HC
AF Vianna, RCS
   Gomes, RN
   Bozza, FA
   Amancio, RT
   Bozza, PT
   David, CMN
   Castro-Faria-Neto, HC
TI Antibiotic treatment in a murine model of sepsis: Impact on cytokines
   and endotoxin release
SO SHOCK
LA English
DT Article
DE inflammation; LPS; mortality; treatment; cecal ligation and puncture;
   peritonitis
ID TUMOR-NECROSIS-FACTOR; GRAM-NEGATIVE BACTERIA; MENINGOCOCCAL DISEASE;
   INFLAMMATORY RESPONSE; SEPTIC SHOCK; SERUM; INTERLEUKIN-6; PLASMA;
   CEFTAZIDIME; ASSOCIATION
AB Experimental and clinical studies in sepsis indicate that antibiotic therapy may induce the release of endotoxin (LPS) from the outer membrane of gram-negative bacteria and therefore may affect the physiologic response and survival. The aim of this study was to evaluate if antibiotics commonly used to treat secondary peritonitis are capable of changing survival rates, proinflammatory and anti-inflammatory cytokine concentrations, and the release of endotoxin in a murine model of sepsis. Sepsis was induced by cecal ligation and puncture (CLP) in Swiss mice using an 18-gauge needle. The animals received injections of saline solution or imipenem or a combination of ciprofloxacin plus clindamycin every 8 h for 3 days. Antibiotic treatment induced an increase in survival rate and decreased plasma and peritoneal fluid levels of TNF-alpha and IL-6 at 6 and 24 h after CLP as compared with saline-treated animals. Antibiotic-treated animals also showed an early (6 h) decrease and a late (24 h) increase in IL-10 concentration in the peritoneal fluid. LPS concentrations were elevated in all groups, but imipenem-treated animals showed higher levels (2.2 EU/mL) than ciprofloxacin plus clindamycin (1.3 EU/mL) and saline-treated (1.5 EU/mL) groups. We conclude that antibiotic-induced endotoxin release is not a major determinant in the inflammatory response and prognosis in murine models of sepsis.
C1 Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Intens Care Unit, Rio De Janeiro, Brazil.
RP Castro-Faria-Neto, HC (corresponding author), Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM hcastro@ioc.fiocruz.br
OI Bozza, Patricia/0000-0001-8349-9529; Bozza, Fernando
   Augusto/0000-0003-4878-0256
CR Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   BRUMBRUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968
   BUCKLIN SE, 1994, EUR J CLIN MICROBIOL, V13, P43, DOI 10.1007/BF02390684
   Casey LC, 1997, CRIT CARE MED, V25, P1270, DOI 10.1097/00003246-199708000-00008
   CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001
   CHAUDRY IH, 1979, SURGERY, V85, P205
   COHEN LF, 1980, AM J MED, V68, P486, DOI 10.1016/0002-9343(80)90286-7
   Coopersmith CM, 2003, SHOCK, V19, P408, DOI 10.1097/01.shk.0000054370.24363.ee
   DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001
   Ebong S, 1999, INFECT IMMUN, V67, P6603
   ENG RHK, 1993, DIAGN MICR INFEC DIS, V16, P185, DOI 10.1016/0732-8893(93)90109-K
   FONG Y, 1990, CLIN IMMUNOL IMMUNOP, V55, P157, DOI 10.1016/0090-1229(90)90094-7
   HACK CE, 1989, BLOOD, V74, P1704
   Holzheimer RG, 1998, INFECTION, V26, P77, DOI 10.1007/BF02767765
   HOLZHEIMER RG, 1995, ARCH SURG-CHICAGO, V130, P1314
   HOPKIN BD, 1985, LANCET, V2, P549
   JACKSON JJ, 1992, J INFECT DIS, V165, P1033, DOI 10.1093/infdis/165.6.1033
   LEHMANN AK, 1995, INFECT IMMUN, V63, P2109, DOI 10.1128/IAI.63.6.2109-2112.1995
   Lepper PM, 2002, INTENS CARE MED, V28, P824, DOI 10.1007/s00134-002-1330-6
   LUNDBLAD R, 1995, SHOCK, V3, P455
   MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007
   MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540
   Morrison DC, 1996, SCAND J INFECT DIS, P3
   Newcomb D, 1998, SHOCK, V10, P110, DOI 10.1097/00024382-199808000-00005
   Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002
   Opal SM, 2000, CURR OPIN INFECT DIS, V13, P221, DOI 10.1097/00001432-200006000-00004
   PRINS JM, 1995, INFECT IMMUN, V63, P2236, DOI 10.1128/IAI.63.6.2236-2242.1995
   PRINS JM, 1995, J INFECT DIS, V172, P886, DOI 10.1093/infdis/172.3.886
   PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211
   Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004
   Rios-Santos F, 2003, SHOCK, V19, P61, DOI 10.1097/00024382-200301000-00012
   Rosman C, 1996, EUR SURG RES, V28, P351, DOI 10.1159/000129476
   Simpson AJH, 2000, J INFECT DIS, V181, P1014, DOI 10.1086/315306
   Song GY, 1999, SURGERY, V126, P378, DOI 10.1016/S0039-6060(99)70180-7
   Standiford TJ, 1997, J INVEST MED, V45, P335
   van der Poll T, 1999, INFECT DIS CLIN N AM, V13, P413, DOI 10.1016/S0891-5520(05)70083-0
   WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333
   WAAGE A, 1987, LANCET, V1, P355
NR 38
TC 71
Z9 79
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD FEB
PY 2004
VL 21
IS 2
BP 115
EP 120
DI 10.1097/01.shk.0000111828.07309.26
PG 6
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 766TU
UT WOS:000188392300004
PM 14752283
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Bozza, FA
   Amancio, RT
   Japiassu, AM
   Larangeira, AP
   Bastos, MS
   Zimmerman, GA
   Stafforini, D
   Prescott, SM
   Bozza, PT
   Castro-Faria-Neto, HC
AF Gomes, RN
   Bozza, FA
   Amancio, RT
   Japiassu, AM
   Larangeira, AP
   Bastos, MS
   Zimmerman, GA
   Stafforini, D
   Prescott, SM
   Bozza, PT
   Castro-Faria-Neto, HC
TI Administration of recombinant human PAF acetylhydrolase protects mice
   against lethal sepsis
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 16th Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 05-08, 2003
CL AMSTERDAM, NETHERLANDS
SP European Soc Intens Care Med
C1 Fiocruz MS, IOC, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   UFRJ, Hosp Clementino Fraga Filho, ICU, Rio De Janeiro, Brazil.
   Fiocruz MS, LATEB, BR-21045900 Rio De Janeiro, Brazil.
   Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT USA.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2003
VL 29
MA 326
BP S87
EP S87
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 728ZC
UT WOS:000185745400327
DA 2020-12-01
ER

PT J
AU Japiassu, AM
   Pinto, JE
   Bozza, FA
   Koatz, VL
   David, CM
AF Japiassu, AM
   Pinto, JE
   Bozza, FA
   Koatz, VL
   David, CM
TI Administration of policlonal immunoglobulins in septic shock: Effects on
   cytokines kinetics and sofa
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 16th Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 05-08, 2003
CL AMSTERDAM, NETHERLANDS
SP European Soc Intens Care Med
C1 Fed Univ Rio De Janeiro, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2003
VL 29
MA 88
BP S27
EP S27
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 728ZC
UT WOS:000185745400089
DA 2020-12-01
ER

PT J
AU Mendonca, HF
   Campos, LA
   Gomes, RV
   Fagundes, FES
   Nunes, EM
   Gomes, R
   Bozza, F
   Bozza, PR
   Castro-Faria-Neto, HC
AF Mendonca, HF
   Campos, LA
   Gomes, RV
   Fagundes, FES
   Nunes, EM
   Gomes, R
   Bozza, F
   Bozza, PR
   Castro-Faria-Neto, HC
TI Correlation between inflammatory response and pulmonary dysfunction
   after cardiac surgery
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 16th Annual Congress of the European-Society-of-Intensive-Care-Medicine
CY OCT 05-08, 2003
CL AMSTERDAM, NETHERLANDS
SP European Soc Intens Care Med
C1 Pro Cardiaco Hosp, Surg Intens Care Unit, Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, Lab Immunopharmacol, BR-20001 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2003
VL 29
MA 445
BP S117
EP S117
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 728ZC
UT WOS:000185745400446
DA 2020-12-01
ER

PT J
AU Pacheco, P
   Bozza, FA
   Gomes, RN
   Bozza, M
   Weller, PF
   Castro-Faria-Neto, HC
   Bozza, PT
AF Pacheco, P
   Bozza, FA
   Gomes, RN
   Bozza, M
   Weller, PF
   Castro-Faria-Neto, HC
   Bozza, PT
TI Lipopolysaccharide-induced leukocyte lipid body formation in vivo:
   Innate immunity elicited intracellular loci involved in eicosanoid
   metabolism
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID PLATELET-ACTIVATING-FACTOR; NECROSIS-FACTOR-ALPHA; GRAM-NEGATIVE
   BACTERIA; ARACHIDONIC-ACID; IN-VIVO; NEUTROPHIL ACCUMULATION; ALVEOLAR
   MACROPHAGES; INFLAMMATORY CELLS; PHOSPHOLIPASE A(2); HUMAN EOSINOPHILS
AB Lipid bodies are rapidly inducible, specialized cytoplasmic domains for eicosanoid-forming enzyme localization, which we hypothesize to have specific roles in enhanced inflammatory mediator production during pathological conditions, including sepsis. However, little is known about the origins, composition, or functions of lipid bodies in vivo. We show that lipid body numbers were increased in leukocytes from septic patients in comparison with healthy subjects. Analogously, the intrathoracic administration of LPS into mice induced a dose- and time-dependent increase in lipid body numbers. Pretreatment with anti-CD14 or anti-CD11b/CD18 mAb drastically inhibited LPS-induced lipid body formation. Moreover, LPS failed to form lipid bodies in C3H/HeJ (TLR4 mutated) mice, demonstrating a requisite role for LPS receptors in lipid body formation. LPS-induced lipid body formation was also inhibited by the platelet-activating factor-receptor antagonists, suggesting a role for endogenous platelet-activating factor. The eicosanoid-forming enzymes, 5-lipoxygenase and cyclooxygenase-2, were immunolocalized within experimentally induced (LPS in mice) or naturally occurring (septic patients) lipid bodies. The proinflammatory cytokine involved in the pathogenesis of sepsis, TNF-alpha, was also shown to colocalize within lipid bodies. Prior stimulation of leukocytes to form lipid bodies enhanced the capacity of leukocytes to produce leukotriene B-4 and PGE(2). In conclusion, our studies indicate that lipid bodies formed after LPS stimulation and sepsis are sites for eicosanoid-forming enzymes and cytokine localization and may develop and function as structurally distinct, intracellular sites for paracrine eicosanoid synthesis during inflammatory conditions.
C1 Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Fdn Oswaldo Cruz, Rio De Janeiro, Brazil.
   Hosp Univ Clementino Fraga Filho, Ctr Terapia Intens, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Rio De Janeiro, Brazil.
   Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Harvard Thorndike Labs, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.
RP Bozza, PT (corresponding author), Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Fdn Oswaldo Cruz, Ave Brasil 4365, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013; Gomes, Rachel N/I-7643-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Bozza,
   Patricia/0000-0001-8349-9529
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI022571, R01AI022571, R01AI022571, R01AI022571, R01AI022571,
   R01AI022571, R01AI022571, R01AI022571, R01AI022571, R01AI022571,
   R01AI022571, R01AI022571, R01AI022571, R01AI022571, R01AI022571,
   R01AI022571, R01AI022571, R01AI022571, R01AI022571, R01AI022571,
   R01AI022571, R01AI022571, R01AI022571, R01AI022571, R01AI022571] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI22571] Funding
   Source: Medline
CR Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675
   APTE RN, 1977, J IMMUNOL, V119, P1898
   BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8
   Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   Bartemes KR, 1999, J IMMUNOL, V162, P2982
   BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252
   BEIL WJ, 1995, J LEUKOCYTE BIOL, V58, P284
   BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   BOZZA PT, 1994, EUR J PHARM-ENVIRON, V270, P143, DOI 10.1016/0926-6917(94)90056-6
   BOZZA PT, 1993, EUR J PHARM-ENVIRON, V248, P41, DOI 10.1016/0926-6917(93)90023-J
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091
   Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   BOZZA PT, 2002, IN PRESS PROSTAGLAND
   Bulger EM, 2000, CRIT CARE MED, V28, pN27, DOI 10.1097/00003246-200004001-00004
   Calabrese C, 2000, ALLERGY, V55, P27, DOI 10.1034/j.1398-9995.2000.00504.x
   CHANG SW, 1987, J CLIN INVEST, V79, P1498, DOI 10.1172/JCI112980
   COIMBRA A, 1971, J HISTOCHEM CYTOCHEM, V19, P551, DOI 10.1177/19.9.551
   COLDITZ IG, 1984, J IMMUNOL, V133, P2169
   Dennis EA, 2000, AM J RESP CRIT CARE, V161, pS32, DOI 10.1164/ajrccm.161.supplement_1.ltta-7
   DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Gilmour RS, 2001, EXP BIOL MED, V226, P1
   GUSTAFSONSVARD C, 1993, SCAND J GASTROENTERO, V28, P323, DOI 10.3109/00365529309090250
   Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   HUBBARD NE, 1993, J LEUKOCYTE BIOL, V54, P105
   IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x
   INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473
   JAYADEV S, 1994, J BIOL CHEM, V269, P5757
   Johnson MM, 1999, AM J RESP CELL MOL, V21, P253, DOI 10.1165/ajrcmb.21.2.3489
   KOPANIAK MM, 1980, AM J PATHOL, V98, P485
   KUNKEL SL, 1988, J BIOL CHEM, V263, P5380
   Leturcq DJ, 1996, J CLIN INVEST, V98, P1533, DOI 10.1172/JCI118945
   Lin WW, 1997, EUR J PHARMACOL, V321, P121, DOI 10.1016/S0014-2999(96)00930-2
   Mathiak G, 1997, SHOCK, V7, P391, DOI 10.1097/00024382-199706000-00001
   Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506
   MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902
   Mukaida N, 1996, J LEUKOCYTE BIOL, V59, P145
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547
   Penido C, 1997, J IMMUNOL, V159, P853
   Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   RENZ H, 1988, J IMMUNOL, V141, P2388
   ROSENSTREICH DL, 1978, J IMMUNOL, V121, P1664
   ROUZER CA, 1988, J BIOL CHEM, V263, P10980
   RYLANDER R, 1987, AM REV RESPIR DIS, V135, P83
   Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157
   SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347
   Surette ME, 1998, FASEB J, V12, P1521
   TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181
   Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1
   Vogel SN, 1999, J IMMUNOL, V162, P5666
   Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161
   WELLER PF, 1991, AM J PATHOL, V138, P141
   WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889
   WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935
   WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876
   Yu WG, 1998, AM J PATHOL, V152, P759
   Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085
NR 67
TC 100
Z9 102
U1 0
U2 13
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2002
VL 169
IS 11
BP 6498
EP 6506
DI 10.4049/jimmunol.169.11.6498
PG 9
WC Immunology
SC Immunology
GA 619LX
UT WOS:000179478400052
PM 12444160
OA Bronze
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Gomes, RN
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
AF Bozza, FA
   Gomes, RN
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
TI Macrophage migration inhibitory factor (MIF) a new marker of severity in
   sepsis?
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 15th Annual Congress on European-Society-of-Internsive-Care-Medicine
CY SEP 29-OCT 02, 2002
CL BARCELONA, SPAIN
SP European Soc Interns Care Med
C1 Hosp Espanhol, Ctr Terapia Intens, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Univ Hosp, BR-21941 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, DFF, BR-20001 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2002
VL 28
SU 1
MA 368
BP S97
EP S97
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 599QD
UT WOS:000178345900367
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Bozza, FA
   Larangeira, A
   Figueiredo, RT
   Amancio, RT
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
AF Gomes, RN
   Bozza, FA
   Larangeira, A
   Figueiredo, RT
   Amancio, RT
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
TI A role for monocyte chemoattractant protein-1 in CLP-induced sepsis in
   mice.
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 15th Annual Congress on European-Society-of-Internsive-Care-Medicine
CY SEP 29-OCT 02, 2002
CL BARCELONA, SPAIN
SP European Soc Interns Care Med
C1 Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, DFF, BR-20001 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Univ Hosp, BR-21941 Rio De Janeiro, Brazil.
   Hosp Espanhol, Ctr Terapia Intens, BR-21941 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2002
VL 28
SU 1
MA 238
BP S64
EP S64
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 599QD
UT WOS:000178345900238
DA 2020-12-01
ER

PT J
AU Pacheco, P
   Bozza, FA
   Bozza, MT
   Gomes, RN
   Weller, PF
   Castro-Faria-Neto, HC
   Bozza, PT
AF Pacheco, P
   Bozza, FA
   Bozza, MT
   Gomes, RN
   Weller, PF
   Castro-Faria-Neto, HC
   Bozza, PT
TI Lipopolysaccharide induced leukocyte lipid body formation in vivo:
   Innate immunity elicited intracel
SO INTENSIVE CARE MEDICINE
LA English
DT Meeting Abstract
CT 15th Annual Congress on European-Society-of-Internsive-Care-Medicine
CY SEP 29-OCT 02, 2002
CL BARCELONA, SPAIN
SP European Soc Interns Care Med
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0342-4642
J9 INTENS CARE MED
JI Intensive Care Med.
PD SEP
PY 2002
VL 28
SU 1
MA 50
BP S17
EP S17
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 599QD
UT WOS:000178345900051
DA 2020-12-01
ER

PT J
AU Mendonca, HTF
   Neto, HCCF
   Fagundes, F
   Nunes, E
   Bozza, F
   Gomes, R
   Gomes, R
AF Mendonca, HTF
   Neto, HCCF
   Fagundes, F
   Nunes, E
   Bozza, F
   Gomes, R
   Gomes, R
TI Postoperative organ dysfunction is related to macrophage migration
   inhibitory factor (MIF) blood levels in patients submitted to coronary
   artery bypass surgery (CABS)
SO CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 Procardiaco Hosp, Rio De Janeiro, Brazil.
   Oswaldo Cruz Fdn, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD DEC
PY 2001
VL 29
IS 12
SU S
MA 188
BP A61
EP A61
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 505PJ
UT WOS:000172920900188
DA 2020-12-01
ER

PT J
AU Filho, HTFM
   Castro-Faria-Neto, H
   Novaes, R
   Bozza, F
   Bozza, P
   Gomes, RV
   Campos, LAA
AF Filho, HTFM
   Castro-Faria-Neto, H
   Novaes, R
   Bozza, F
   Bozza, P
   Gomes, RV
   Campos, LAA
TI Macrophage migration inhibitory factor(MIF),C-reactive protein(CRP) and
   C3a serum levels following coronary artery bypass graft surgery(CABG)
SO CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 Procardiaco Hosp, Rio De Janeiro, Brazil.
   FIOCRUZ, BR-21045900 Rio De Janeiro, Brazil.
   Fed Univ Rio De Janeiro, Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD DEC
PY 2000
VL 28
IS 12
SU S
MA 387
BP A137
EP A137
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA 388ZD
UT WOS:000166212200388
DA 2020-12-01
ER

PT J
AU Suarez-Kurtz, G
   Bozza, FA
   Vicente, FL
   Ponte, CG
   Struchiner, CJ
AF Suarez-Kurtz, G
   Bozza, FA
   Vicente, FL
   Ponte, CG
   Struchiner, CJ
TI Limited-sampling strategy models for itraconazole and
   hydroxy-itraconazole based on data from a bioequivalence study
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PHARMACOKINETICS; FOOD; VOLUNTEERS
AB The extensive interindividual variability in oral bioavailability of itraconazole prompted an assessment of the bioequivalence of two formulations marketed in Brazil, namely, Sporanox (reference) and Traconal (test). Eighteen healthy volunteers received single 200-mg oral doses of each formulation at 2-week intervals in a randomized, crossover protocol. The concentrations of itraconazole and hydroxy-itraconazole in plasma were measured by high-performance liquid chromatography, and the datum points (n = 396) were subsequently used to develop limited-sampling strategy models for estimation of the areas under the curve (AUCs) for both compounds. The 90% confidence intervals for individual percent ratios (test/reference formulations) of the maximum concentration of drug in serum, the AUC from 0 to 48 h and the AUC from time zero to infinity (AUC(0-infinity)) for itraconazole and hydoro-itraconazole were below the range of 80 to 125%, suggesting that these formulations are not bioequivalent. Linear regression analysis of the AUC(0-infinity) against time and a "jackknife'' validation procedure revealed that models based on three sampling times accurately predict (R-2, > 0.98; bias, <3%; precision, 3 to 7%) the AUC(0-infinity) for each of the four formulation-compound pairs tested. Increasing the number of sampling points to more than three adds little to the accuracy of the estimates of AUC(0-infinity). The three-point models developed for the reference formulation were validated retrospectively and were found to predict within 2% the AUC(0-infinity) reported in previous studies performed under similar protocols, In conclusion, the data in this study indicate (i) that the tested formulations are not bioequivalent when single doses are compared and (ii) that limited-sampling strategy models based on three points predict accurately the AUC(0-infinity)s for itraconazole and hydroxy-itraconazole and could be a valuable tool in pharmacokinetic and bioequivalence studies of single oral doses of itraconazole.
C1 Inst Nacl Canc, Coordenacao Pesquisa, Programa Farmacol, BR-20130230 Rio De Janeiro, Brazil.
   Santa Casa Misericordia, Unidade Farmacol, Rio De Janeiro, Brazil.
RP Suarez-Kurtz, G (corresponding author), Inst Nacl Canc, Coordenacao Pesquisa, Programa Farmacol, Praca da Cruz Vermelha 23-4, BR-20130230 Rio De Janeiro, Brazil.
EM kurtz@inca.org.br
RI Bozza, Fernando A/A-2618-2013; Struchiner, Claudio J/M-9360-2013;
   Suarez-Kurtz, Guilherme/J-6648-2012; Suarez-Kurtz, Guilherme/P-4620-2019
OI Bozza, Fernando A/0000-0003-4878-0256; Struchiner, Claudio
   J/0000-0003-2114-847X; Suarez-Kurtz, Guilherme/0000-0002-1115-8319;
   Suarez-Kurtz, Guilherme/0000-0002-1115-8319
CR BARONE JA, 1993, ANTIMICROB AGENTS CH, V37, P778, DOI 10.1128/AAC.37.4.778
   BRADFORD CR, 1991, J ANTIMICROB CHEMOTH, V28, P555, DOI 10.1093/jac/28.4.555
   DARGENIO DZ, 1997, ADAPT 2 USERS GUIDE
   Food and Drug Administration, 1993, PHARMACOPEIAL FORUM, V19, P6501
   FURNIVAL GM, 1974, TECHNOMETRICS, V16, P499, DOI 10.2307/1267601
   HARDIN TC, 1988, ANTIMICROB AGENTS CH, V32, P1310, DOI 10.1128/AAC.32.9.1310
   Haria M, 1996, DRUGS, V51, P585, DOI 10.2165/00003495-199651040-00006
   HAUSCHKE D, 1990, INT J CLIN PHARM TH, V28, P72
   HEYKANTS J, 1989, MYCOSES, V32, P67, DOI 10.1111/j.1439-0507.1989.tb02296.x
   Ingram D., 1984, MATH METHODS MED 1
   Jodrell DI, 1996, CANCER CHEMOTH PHARM, V37, P356, DOI 10.1007/s002800050397
   Lange D, 1997, J CLIN PHARMACOL, V37, P535, DOI 10.1002/j.1552-4604.1997.tb04332.x
   LIM SG, 1993, ALIMENT PHARM THERAP, V7, P317, DOI 10.1111/j.1365-2036.1993.tb00103.x
   *MATHS, 1997, SPLUS 4 GUID STAT
   Meyboom RHB, 1997, NEW ZEAL MED J, V110, P300
   PILLANS P, 1993, NEW ZEAL MED J, V106, P436
   SCHAFERKORTING M, 1990, J AM ACAD DERMATOL, V22, P211, DOI 10.1016/0190-9622(90)70026-E
   SMITH D, 1992, J PHARM PHARMACOL, V44, P618, DOI 10.1111/j.2042-7158.1992.tb05478.x
   VandeVelde VJS, 1996, PHARMACOTHERAPY, V16, P424
   VANPEER A, 1989, EUR J CLIN PHARMACOL, V36, P423, DOI 10.1007/BF00558308
   WOESTENBORGHS R, 1987, J CHROMATOGR-BIOMED, V413, P332, DOI 10.1016/0378-4347(87)80249-9
   ZIMMERMANN T, 1994, EUR J CLIN PHARMACOL, V46, P147, DOI 10.1007/BF00199879
NR 22
TC 19
Z9 19
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 1999
VL 43
IS 1
BP 134
EP 140
DI 10.1128/AAC.43.1.134
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 163UD
UT WOS:000078424000023
PM 9869578
OA Bronze
DA 2020-12-01
ER

PT J
AU Suarez-Kurtz, G
   Ponte, CG
   Vicente, FL
   Bozza, FA
   Struchiner, CJ
AF Suarez-Kurtz, G
   Ponte, CG
   Vicente, FL
   Bozza, FA
   Struchiner, CJ
TI Limited-sampling strategy models for itraconazole and
   hydroxy-itraconazole using data from a bioequivalence study
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Meeting Abstract
C1 Inst Nacl Canc, BR-20230130 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.
RI Bozza, Fernando A/A-2618-2013; Struchiner, Claudio/M-9360-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Struchiner,
   Claudio/0000-0003-2114-847X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0028-1298
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PY 1998
VL 358
IS 1
SU 2
MA P4742
BP R466
EP R466
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 107KW
UT WOS:000075207800363
DA 2020-12-01
ER

PT J
AU Suarez-Kurtz, G
   Ponte, CG
   Vicente, FL
   Bozza, FA
   Struchiner, CJ
AF Suarez-Kurtz, G
   Ponte, CG
   Vicente, FL
   Bozza, FA
   Struchiner, CJ
TI Limited-sampling strategy models for itraconazole and
   hydroxy-itraconazole using data from a bioequivalence study
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Meeting Abstract
C1 Inst Nacl Canc, BR-20230130 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.
RI Struchiner, Claudio J/M-9360-2013; Suarez-Kurtz, Guilherme/P-4620-2019;
   Bozza, Fernando A/A-2618-2013
OI Struchiner, Claudio J/0000-0003-2114-847X; Suarez-Kurtz,
   Guilherme/0000-0002-1115-8319; Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0028-1298
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PY 1998
VL 358
IS 1
SU 2
MA P4735
BP R464
EP R464
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 107KW
UT WOS:000075207800356
DA 2020-12-01
ER

PT S
AU LOCATIHEILBRON, E
   MAISONBLANCHE, P
   BOZZA, F
   DEJODE, P
   COUMEL, P
AF LOCATIHEILBRON, E
   MAISONBLANCHE, P
   BOZZA, F
   DEJODE, P
   COUMEL, P
BE Murray, A
TI PROBABILITY OF VENTRICULAR ARRHYTHMIAS FOLLOWING STEREOTYPED SHORT-LONG
   SEQUENCES - A COMPUTERIZED ANALYSIS OF DIGITIZED DYNAMIC ECG RECORDINGS
SO COMPUTERS IN CARDIOLOGY 1993, PROCEEDINGS
SE COMPUTERS IN CARDIOLOGY
LA English
DT Proceedings Paper
CT 20th Annual Meeting of Computers in Cardiology
CY SEP 05-08, 1993
CL LONDON, ENGLAND
SP AMERSHAM INT, CAMBRIDGE ELECTR DESIGN LTD, DIAGNOST SONAR LTD, DIASON SONATRON LTD, DUPONT PHARMA UK LTD, ELSCINT LTD, GRANTA BOOK EXHIBIT, HEWLETT PACKARD HEALTHCARE GRP, MARQUETTE ELECTR LTD, NUCL DIAGNOST LTD, OAKFIELD INSTRUMENTS LTD, REYNOLDS MED LTD, SCIMED INC, SHIMADZU UK LTD, SILICON GRAPH LTD, SMITH KLINE BEECHAM PHARM LTD, WISEPRESS LTD
C1 UNIV DEGLI STUDI,IST CLIN MED 2,MILAN,ITALY.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I E E E, COMPUTER SOC PRESS
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, LOS ALAMITOS, CA 90720
SN 0276-6574
BN 0-8186-5470-8
J9 COMPUT CARDIOL
PY 1993
BP 883
EP 886
PG 4
WC Cardiac & Cardiovascular Systems; Computer Science, Interdisciplinary
   Applications; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Computer Science; Engineering
GA BA39W
UT WOS:A1993BA39W00222
DA 2020-12-01
ER

PT B
AU FAYN, J
   HAMIDI, S
   MAISONBLANCHE, P
   BOZZA, F
   RUBEL, P
   COUMEL, P
AF FAYN, J
   HAMIDI, S
   MAISONBLANCHE, P
   BOZZA, F
   RUBEL, P
   COUMEL, P
GP IEEE
TI QUANTITATIVE ASSESSMENT OF CHANGES IN THE REPOLARIZATION PHASE IN HOLTER
   RECORDINGS USING CAVIAR
SO COMPUTERS IN CARDIOLOGY 1992 : PROCEEDINGS
LA English
DT Proceedings Paper
CT CONF ON COMPUTERS IN CARDIOLOGY
CY OCT 11-14, 1992
CL DURHAM, NC
SP DUKE UNIV, ELI LILLY, GLAXO, HEWLETT PACKARD, IEEE, ENGN MED & BIOL SOC, MAROUETTE ELECTR, MEDTRON, MORTARA INSTRUMENT, NIH, ORTIVUS MED LAB
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 6
Z9 6
U1 0
U2 0
PU I E E E, COMPUTER SOC PRESS
PI LOS ALAMITOS
PA LOS ALAMITOS
BN 0-8186-3550-9
J9 COMPUT CARDIOL
PY 1992
BP 175
EP 178
PG 4
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA BX78F
UT WOS:A1992BX78F00045
DA 2020-12-01
ER

EF